1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	5	attr	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	administration	administration	NN	_	6	dep	_	_
6	decreased	decrease	VBD	_	1	acl	_	_
7	the	the	DT	_	9	det	_	_
8	mean	mean	JJ	_	9	attr	_	_
9	AUC	auc	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	total	total	NN	_	9	ppmod	_	_
12	drug3	drug0	IN	_	14	case	_	_
13	approximately	approximately	RB	_	14	adv	_	_
14	55	0	CD	_	9	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	.	.	.	_	1	p	_	_

1	The	the	DT	_	4	det	_	_
2	incremental	incremental	JJ	_	4	attr	_	_
3	LDL-C	ldl-c	NN	_	4	com	_	_
4	reduction	reduction	NN	_	13	dep	_	_
5	due	due	JJ	_	4	attr	_	_
6	to	to	TO	_	7	aux	_	_
7	adding	add	VBG	_	5	ppmod	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	to	to	TO	_	10	aux	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	reduced	reduce	VBN	_	0	root	_	_
14	by	by	IN	_	16	case	_	_
15	this	this	DT	_	16	det	_	_
16	interaction	interaction	NN	_	13	ppmod	_	_
17	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	safety	safety	NN	_	15	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	effectiveness	effectiveness	NN	_	4	conj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NNS	_	4	ppmod	_	_
9	administered	administer	VBN	_	8	acl	_	_
10	with	with	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	have	have	VBP	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	established	establish	VBN	_	1	acl	_	_
16	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	cholesterol	cholesterol	NN	_	5	com	_	_
5	excretion	excretion	NN	_	3	obj	_	_
6	into	into	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	bile	bile	NN	_	3	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	leading	lead	VBG	_	3	comp	_	_
11	to	to	TO	_	12	aux	_	_
12	cholelithiasis	cholelithiasis	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	preclinical	preclinical	JJ	_	4	attr	_	_
4	study	study	NN	_	9	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	dogs	dog	NNS	_	4	ppmod	_	_
7	,	,	,	_	9	p	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	increased	increase	VBD	_	0	root	_	_
10	cholesterol	cholesterol	NN	_	9	obj	_	_
11	in	in	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	gallbladder	gallbladder	NN	_	14	com	_	_
14	bile	bile	NN	_	9	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	Co-administration	co-administration	NN	_	8	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	is	be	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	recommended	recommend	VBN	_	0	root	_	_
9	until	until	IN	_	14	mark	_	_
10	use	use	NN	_	14	dep	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	is	be	VBZ	_	14	aux	_	_
14	studied	study	VBN	_	8	comp	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	6	attr	_	_
6	study	study	NN	_	11	ppmod	_	_
7	,	,	,	_	11	p	_	_
8	concomitant	concomitant	JJ	_	10	attr	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	administration	administration	NN	_	11	dep	_	_
11	increased	increase	VBD	_	1	acl	_	_
12	total	total	NN	_	14	com	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	11	obj	_	_
15	approximately	approximately	RB	_	16	com	_	_
16	1.5-fold	0-fold	RB	_	11	adv	_	_
17	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	6	attr	_	_
6	study	study	NN	_	11	ppmod	_	_
7	,	,	,	_	11	p	_	_
8	concomitant	concomitant	JJ	_	10	attr	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	administration	administration	NN	_	11	dep	_	_
11	increased	increase	VBD	_	1	acl	_	_
12	total	total	NN	_	14	com	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	11	obj	_	_
15	approximately	approximately	RB	_	16	com	_	_
16	1.7-fold	0-fold	RB	_	11	adv	_	_
17	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	No	no	DT	_	7	det	_	_
4	clinically	clinically	RB	_	5	adv	_	_
5	significant	significant	JJ	_	7	attr	_	_
6	pharmacokinetic	pharmacokinetic	JJ	_	7	attr	_	_
7	interactions	interaction	NNS	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	seen	see	VBN	_	1	acl	_	_
10	when	when	WRB	_	13	adv	_	_
11	drug2	drug0	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	co-administered	co-administered	VBN	_	9	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug6	drug0	NN	_	15	conj	_	_
22	,	,	,	_	21	p	_	_
23	or	or	CC	_	21	cc	_	_
24	drug7	drug0	NN	_	15	conj	_	_
25	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	6	det	_	_
4	total	total	JJ	_	6	attr	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	level	level	NN	_	7	dep	_	_
7	increased	increase	VBD	_	1	acl	_	_
8	12-fold	0-fold	RB	_	7	adv	_	_
9	in	in	IN	_	13	case	_	_
10	one	#crd#	CD	_	13	num	_	_
11	renal	renal	JJ	_	13	attr	_	_
12	transplant	transplant	NN	_	13	com	_	_
13	patient	patient	NN	_	7	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	multiple	multiple	JJ	_	16	attr	_	_
16	medications	medication	NNS	_	14	obj	_	_
17	,	,	,	_	16	p	_	_
18	including	include	VBG	_	19	adv	_	_
19	drug3	drug0	NN	_	16	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	11	dep	_	_
2	who	who	WP	_	3	dep	_	_
3	take	take	VBP	_	1	relcl	_	_
4	both	both	CC	_	5	cc	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	should	should	MD	_	11	modal	_	_
9	be	be	VB	_	11	aux	_	_
10	carefully	carefully	RB	_	11	adv	_	_
11	monitored	monitor	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Carcinogenesis	carcinogenesis	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	Mutagenesis	mutagenesis	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	Impairment	impairment	NN	_	1	appo	_	_
6	of	of	IN	_	7	case	_	_
7	Fertility	fertility	NN	_	5	ppmod	_	_
8	A	a	DT	_	12	det	_	_
9	104-week	0-week	JJ	_	12	attr	_	_
10	dietary	dietary	JJ	_	12	attr	_	_
11	carcinogenicity	carcinogenicity	NN	_	12	com	_	_
12	study	study	NN	_	16	dep	_	_
13	with	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	was	be	VBD	_	16	aux	_	_
16	conducted	conduct	VBN	_	5	acl	_	_
17	in	in	IN	_	18	case	_	_
18	rats	rat	NNS	_	16	ppmod	_	_
19	at	at	IN	_	20	case	_	_
20	doses	dose	NNS	_	16	ppmod	_	_
21	up	up	RB	_	23	adv	_	_
22	to	to	TO	_	23	attr	_	_
23	1500	0	CD	_	24	num	_	_
24	mg/kg/day	mg/kg/day	NN	_	20	appo	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	males	male	NNS	_	24	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	and	and	CC	_	24	cc	_	_
29	500	0	CD	_	30	num	_	_
30	mg/kg/day	mg/kg/day	NN	_	24	conj	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	females	female	NNS	_	30	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	(	-lrb-	-LRB-	_	36	p	_	_
35	~20	~0	CD	_	36	num	_	_
36	times	time	NNS	_	30	prn	_	_
37	the	the	DT	_	39	det	_	_
38	human	human	JJ	_	39	attr	_	_
39	exposure	exposure	NN	_	36	appo	_	_
40	at	at	IN	_	42	case	_	_
41	10	0	CD	_	42	num	_	_
42	mg	mg	NN	_	39	ppmod	_	_
43	daily	daily	RB	_	42	adv	_	_
44	based	base	VBN	_	42	acl	_	_
45	on	on	IN	_	46	case	_	_
46	AUC0-24hr	auc0hr	NN	_	44	ppmod	_	_
47	for	for	IN	_	49	case	_	_
48	total	total	JJ	_	49	attr	_	_
49	drug2	drug0	NN	_	46	ppmod	_	_
50	)	-rrb-	-RRB-	_	36	p	_	_
51	.	.	.	_	1	p	_	_

1	A	a	DT	_	5	det	_	_
2	104-week	0-week	JJ	_	5	attr	_	_
3	dietary	dietary	JJ	_	5	attr	_	_
4	carcinogenicity	carcinogenicity	NN	_	5	com	_	_
5	study	study	NN	_	10	dep	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	was	be	VBD	_	10	aux	_	_
9	also	also	RB	_	10	adv	_	_
10	conducted	conduct	VBN	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	mice	mouse	NNS	_	10	ppmod	_	_
13	at	at	IN	_	14	case	_	_
14	doses	dose	NNS	_	10	ppmod	_	_
15	up	up	RB	_	17	adv	_	_
16	to	to	TO	_	17	attr	_	_
17	500	0	CD	_	18	num	_	_
18	mg/kg/day	mg/kg/day	NN	_	14	attr	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	>150	>0	CD	_	21	num	_	_
21	times	time	NNS	_	10	prn	_	_
22	the	the	DT	_	24	det	_	_
23	human	human	JJ	_	24	attr	_	_
24	exposure	exposure	NN	_	21	appo	_	_
25	at	at	IN	_	27	case	_	_
26	10	0	CD	_	27	num	_	_
27	mg	mg	NN	_	24	ppmod	_	_
28	daily	daily	RB	_	27	adv	_	_
29	based	base	VBN	_	27	acl	_	_
30	on	on	IN	_	31	case	_	_
31	AUC0-24hr	auc0hr	NN	_	29	ppmod	_	_
32	for	for	IN	_	34	case	_	_
33	total	total	JJ	_	34	attr	_	_
34	drug2	drug0	NN	_	24	ppmod	_	_
35	)	-rrb-	-RRB-	_	21	p	_	_
36	.	.	.	_	10	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	6	det	_	_
4	statistically	statistically	RB	_	5	adv	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	increases	increase	NNS	_	2	obj	_	_
7	in	in	IN	_	9	case	_	_
8	tumor	tumor	NN	_	9	com	_	_
9	incidences	incidence	NNS	_	6	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	drug-treated	drug-treated	JJ	_	12	attr	_	_
12	rats	rat	NNS	_	6	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	mice	mouse	NNS	_	12	conj	_	_
15	.	.	.	_	2	p	_	_

1	No	no	DT	_	2	det	_	_
2	evidence	evidence	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	mutagenicity	mutagenicity	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	6	adv	_	_
9	in	in	IN	_	16	case	_	_
10	a	a	DT	_	16	det	_	_
11	microbial	microbial	JJ	_	16	attr	_	_
12	mutagenicity	mutagenicity	NN	_	16	attr	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	Ames	ames	NN	_	16	attr	_	_
15	)	-rrb-	-RRB-	_	16	p	_	_
16	test	test	NN	_	6	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	Salmonella	salmonella	FW	_	19	attr	_	_
19	typhimurium	typhimurium	FW	_	23	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	Escherichia	escherichia	FW	_	22	attr	_	_
22	coli	coli	FW	_	19	conj	_	_
23	with	with	IN	_	6	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	without	without	IN	_	27	case	_	_
26	metabolic	metabolic	JJ	_	27	attr	_	_
27	activation	activation	NN	_	23	conj	_	_
28	.	.	.	_	6	p	_	_

1	No	no	DT	_	2	det	_	_
2	evidence	evidence	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	clastogenicity	clastogenicity	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	6	adv	_	_
9	in	in	IN	_	13	case	_	_
10	a	a	DT	_	12	det	_	_
11	chromosomal	chromosomal	JJ	_	12	attr	_	_
12	aberration	aberration	NN	_	13	com	_	_
13	assay	assay	NN	_	6	ppmod	_	_
14	in	in	IN	_	18	case	_	_
15	human	human	JJ	_	18	attr	_	_
16	peripheral	peripheral	JJ	_	18	attr	_	_
17	blood	blood	NN	_	18	com	_	_
18	lymphocytes	lymphocyte	NNS	_	13	ppmod	_	_
19	with	with	IN	_	13	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	without	without	IN	_	23	case	_	_
22	metabolic	metabolic	JJ	_	23	attr	_	_
23	activation	activation	NN	_	19	conj	_	_
24	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	there	there	EX	_	5	dep	_	_
5	was	be	VBD	_	0	root	_	_
6	no	no	DT	_	7	det	_	_
7	evidence	evidence	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	genotoxicity	genotoxicity	NN	_	7	ppmod	_	_
10	in	in	IN	_	16	case	_	_
11	the	the	DT	_	16	det	_	_
12	in	in	FW	_	13	adv	_	_
13	vivo	vivo	FW	_	16	attr	_	_
14	mouse	mouse	NN	_	16	com	_	_
15	micronucleus	micronucleus	NN	_	16	com	_	_
16	test	test	NN	_	5	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	In	in	IN	_	7	case	_	_
2	oral	oral	JJ	_	7	attr	_	_
3	(	-lrb-	-LRB-	_	7	p	_	_
4	gavage	gavage	NN	_	7	attr	_	_
5	)	-rrb-	-RRB-	_	7	p	_	_
6	fertility	fertility	NN	_	7	com	_	_
7	studies	study	NNS	_	15	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	conducted	conduct	VBN	_	7	acl	_	_
11	in	in	IN	_	12	case	_	_
12	rats	rat	NNS	_	10	ppmod	_	_
13	,	,	,	_	15	p	_	_
14	there	there	EX	_	15	dep	_	_
15	was	be	VBD	_	0	root	_	_
16	no	no	DT	_	17	det	_	_
17	evidence	evidence	NN	_	15	obj	_	_
18	of	of	IN	_	20	case	_	_
19	reproductive	reproductive	JJ	_	20	attr	_	_
20	toxicity	toxicity	NN	_	17	ppmod	_	_
21	at	at	IN	_	22	case	_	_
22	doses	dose	NNS	_	15	ppmod	_	_
23	up	up	RB	_	25	adv	_	_
24	to	to	TO	_	25	attr	_	_
25	1000	0	CD	_	26	num	_	_
26	mg/kg/day	mg/kg/day	NN	_	22	appo	_	_
27	in	in	IN	_	31	case	_	_
28	male	male	JJ	_	31	attr	_	_
29	or	or	CC	_	28	cc	_	_
30	female	female	JJ	_	28	conj	_	_
31	rats	rat	NNS	_	26	ppmod	_	_
32	(	-lrb-	-LRB-	_	34	p	_	_
33	~7	~0	CD	_	34	num	_	_
34	times	time	NNS	_	31	prn	_	_
35	the	the	DT	_	37	det	_	_
36	human	human	JJ	_	37	attr	_	_
37	exposure	exposure	NN	_	34	appo	_	_
38	at	at	IN	_	40	case	_	_
39	10	0	CD	_	40	num	_	_
40	mg	mg	NN	_	37	ppmod	_	_
41	daily	daily	RB	_	40	adv	_	_
42	based	base	VBN	_	40	acl	_	_
43	on	on	IN	_	44	case	_	_
44	AUC0-24hr	auc0hr	NN	_	42	ppmod	_	_
45	for	for	IN	_	47	case	_	_
46	total	total	JJ	_	47	attr	_	_
47	drug2	drug0	NN	_	37	ppmod	_	_
48	)	-rrb-	-RRB-	_	34	p	_	_
49	.	.	.	_	15	p	_	_

1	Pregnancy	pregnancy	NN	_	3	com	_	_
2	Pregnancy	pregnancy	NN	_	3	com	_	_
3	Category	category	NN	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	C	c	LS	_	7	meta	_	_
6	There	there	EX	_	7	dep	_	_
7	are	be	VBP	_	3	acl	_	_
8	no	no	DT	_	12	det	_	_
9	adequate	adequate	JJ	_	12	attr	_	_
10	and	and	CC	_	9	cc	_	_
11	well-controlled	well-controlled	JJ	_	9	conj	_	_
12	studies	study	NNS	_	7	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	pregnant	pregnant	JJ	_	17	attr	_	_
17	women	woman	NNS	_	12	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	during	during	IN	_	6	case	_	_
6	pregnancy	pregnancy	NN	_	4	ppmod	_	_
7	only	only	RB	_	12	adv	_	_
8	if	if	IN	_	12	mark	_	_
9	the	the	DT	_	11	det	_	_
10	potential	potential	JJ	_	11	attr	_	_
11	benefit	benefit	NN	_	12	dep	_	_
12	justifies	justify	VBZ	_	4	comp	_	_
13	the	the	DT	_	14	det	_	_
14	risk	risk	NN	_	12	obj	_	_
15	to	to	TO	_	17	aux	_	_
16	the	the	DT	_	17	det	_	_
17	fetus	fetus	NN	_	14	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	In	in	IN	_	8	case	_	_
2	oral	oral	JJ	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	gavage	gavage	NN	_	8	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	embryo-fetal	embryo-fetal	JJ	_	8	attr	_	_
7	development	development	NN	_	8	com	_	_
8	studies	study	NNS	_	20	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	conducted	conduct	VBN	_	8	acl	_	_
12	in	in	IN	_	13	case	_	_
13	rats	rat	NNS	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	rabbits	rabbit	NNS	_	13	conj	_	_
16	during	during	IN	_	17	case	_	_
17	organogenesis	organogenesis	NN	_	11	ppmod	_	_
18	,	,	,	_	20	p	_	_
19	there	there	EX	_	20	dep	_	_
20	was	be	VBD	_	0	root	_	_
21	no	no	DT	_	22	det	_	_
22	evidence	evidence	NN	_	20	obj	_	_
23	of	of	IN	_	25	case	_	_
24	embryolethal	embryolethal	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	22	ppmod	_	_
26	at	at	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	doses	dose	NNS	_	25	ppmod	_	_
29	tested	test	VBN	_	28	acl	_	_
30	(	-lrb-	-LRB-	_	36	p	_	_
31	250	0	CD	_	35	num	_	_
32	,	,	,	_	35	p	_	_
33	500	0	CD	_	35	num	_	_
34	,	,	,	_	35	p	_	_
35	1000	0	CD	_	36	num	_	_
36	mg/kg/day	mg/kg/day	NN	_	28	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	.	.	.	_	20	p	_	_

1	In	in	IN	_	2	case	_	_
2	rats	rat	NNS	_	27	ppmod	_	_
3	,	,	,	_	27	p	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	incidences	incidence	NNS	_	27	dep	_	_
6	of	of	IN	_	10	case	_	_
7	common	common	JJ	_	10	attr	_	_
8	fetal	fetal	JJ	_	10	attr	_	_
9	skeletal	skeletal	JJ	_	10	attr	_	_
10	findings	finding	NNS	_	5	ppmod	_	_
11	(	-lrb-	-LRB-	_	24	p	_	_
12	extra	extra	JJ	_	13	attr	_	_
13	pair	pair	NN	_	24	dep	_	_
14	of	of	IN	_	16	case	_	_
15	thoracic	thoracic	JJ	_	16	attr	_	_
16	ribs	rib	NNS	_	13	ppmod	_	_
17	,	,	,	_	13	p	_	_
18	unossified	unossified	JJ	_	21	attr	_	_
19	cervical	cervical	JJ	_	21	attr	_	_
20	vertebral	vertebral	NN	_	21	com	_	_
21	centra	centra	NN	_	13	appo	_	_
22	,	,	,	_	24	p	_	_
23	shortened	shorten	VBD	_	24	attr	_	_
24	ribs	rib	NNS	_	10	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	were	be	VBD	_	27	aux	_	_
27	observed	observe	VBN	_	0	root	_	_
28	at	at	IN	_	30	case	_	_
29	1000	0	CD	_	30	num	_	_
30	mg/kg/day	mg/kg/day	NN	_	27	ppmod	_	_
31	(	-lrb-	-LRB-	_	33	p	_	_
32	~10	~0	CD	_	33	num	_	_
33	times	time	NNS	_	27	prn	_	_
34	the	the	DT	_	36	det	_	_
35	human	human	JJ	_	36	attr	_	_
36	exposure	exposure	NN	_	33	appo	_	_
37	at	at	IN	_	39	case	_	_
38	10	0	CD	_	39	num	_	_
39	mg	mg	NN	_	36	ppmod	_	_
40	daily	daily	RB	_	39	adv	_	_
41	based	base	VBN	_	39	acl	_	_
42	on	on	IN	_	43	case	_	_
43	AUC0-24hr	auc0hr	NN	_	41	ppmod	_	_
44	for	for	IN	_	46	case	_	_
45	total	total	JJ	_	46	attr	_	_
46	drug1	drug0	NN	_	36	ppmod	_	_
47	)	-rrb-	-RRB-	_	33	p	_	_
48	.	.	.	_	27	p	_	_

1	In	in	IN	_	2	case	_	_
2	rabbits	rabbit	NNS	_	15	ppmod	_	_
3	treated	treat	VBN	_	2	acl	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	15	p	_	_
7	an	an	DT	_	9	det	_	_
8	increased	increase	VBN	_	9	attr	_	_
9	incidence	incidence	NN	_	15	dep	_	_
10	of	of	IN	_	13	case	_	_
11	extra	extra	JJ	_	13	attr	_	_
12	thoracic	thoracic	JJ	_	13	attr	_	_
13	ribs	rib	NNS	_	9	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	observed	observe	VBN	_	0	root	_	_
16	at	at	IN	_	18	case	_	_
17	1000	0	CD	_	18	num	_	_
18	mg/kg/day	mg/kg/day	NN	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	150	0	CD	_	21	num	_	_
21	times	time	NNS	_	15	prn	_	_
22	the	the	DT	_	24	det	_	_
23	human	human	JJ	_	24	attr	_	_
24	exposure	exposure	NN	_	21	appo	_	_
25	at	at	IN	_	27	case	_	_
26	10	0	CD	_	27	num	_	_
27	mg	mg	NN	_	24	ppmod	_	_
28	daily	daily	RB	_	27	adv	_	_
29	based	base	VBN	_	27	acl	_	_
30	on	on	IN	_	31	case	_	_
31	AUC0-24hr	auc0hr	NN	_	29	ppmod	_	_
32	for	for	IN	_	34	case	_	_
33	total	total	JJ	_	34	attr	_	_
34	drug2	drug0	NN	_	24	ppmod	_	_
35	)	-rrb-	-RRB-	_	21	p	_	_
36	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	crossed	cross	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	placenta	placenta	NN	_	2	obj	_	_
5	when	when	WRB	_	10	adv	_	_
6	pregnant	pregnant	JJ	_	7	attr	_	_
7	rats	rat	NNS	_	10	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	rabbits	rabbit	NNS	_	7	conj	_	_
10	were	be	VBD	_	2	comp	_	_
11	given	given	IN	_	14	case	_	_
12	multiple	multiple	JJ	_	14	attr	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	doses	dose	NNS	_	10	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	Multiple	multiple	JJ	_	3	attr	_	_
2	dose	dose	NN	_	3	com	_	_
3	studies	study	NNS	_	20	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	given	give	VBN	_	5	acl	_	_
7	in	in	IN	_	8	case	_	_
8	combination	combination	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug3	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	in	in	IN	_	15	case	_	_
15	rats	rat	NNS	_	10	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	rabbits	rabbit	NNS	_	15	conj	_	_
18	during	during	IN	_	19	case	_	_
19	organogenesis	organogenesis	NN	_	6	ppmod	_	_
20	result	result	VBP	_	0	root	_	_
21	in	in	IN	_	23	case	_	_
22	higher	high	JJR	_	23	attr	_	_
23	drug4	drug0	NN	_	20	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	statin	statin	NN	_	26	com	_	_
26	exposures	exposure	NNS	_	23	conj	_	_
27	.	.	.	_	20	p	_	_

1	Reproductive	reproductive	JJ	_	2	attr	_	_
2	findings	finding	NNS	_	3	dep	_	_
3	occur	occur	VBP	_	0	root	_	_
4	at	at	IN	_	6	case	_	_
5	lower	low	JJR	_	6	attr	_	_
6	doses	dose	NNS	_	3	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	combination	combination	NN	_	9	com	_	_
9	therapy	therapy	NN	_	3	ppmod	_	_
10	compared	compare	VBD	_	9	acl	_	_
11	to	to	TO	_	12	aux	_	_
12	monotherapy	monotherapy	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	All	all	DT	_	2	det	_	_
2	drug1	drug0	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	contraindicated	contraindicate	VBN	_	0	root	_	_
5	in	in	IN	_	9	case	_	_
6	pregnant	pregnant	JJ	_	9	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	nursing	nursing	JJ	_	6	conj	_	_
9	women	woman	NNS	_	4	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	administered	administer	VBN	_	15	advcl	_	_
5	with	with	IN	_	7	case	_	_
6	an	an	DT	_	7	det	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	woman	woman	NN	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	childbearing	childbearing	JJ	_	13	attr	_	_
13	potential	potential	NN	_	10	ppmod	_	_
14	,	,	,	_	15	p	_	_
15	refer	refer	VBP	_	0	root	_	_
16	to	to	TO	_	19	aux	_	_
17	the	the	DT	_	19	det	_	_
18	pregnancy	pregnancy	NN	_	19	com	_	_
19	category	category	NN	_	15	ppmod	_	_
20	and	and	CC	_	15	cc	_	_
21	package	package	VBP	_	15	conj	_	_
22	labeling	labeling	NN	_	21	obj	_	_
23	for	for	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	.	.	.	_	15	p	_	_

1	Labor	labor	NN	_	15	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	Delivery	delivery	NN	_	5	attr	_	_
4	The	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	1	conj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	on	on	IN	_	9	case	_	_
9	labor	labor	NN	_	5	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	delivery	delivery	NN	_	9	conj	_	_
12	in	in	IN	_	14	case	_	_
13	pregnant	pregnant	JJ	_	14	attr	_	_
14	women	woman	NNS	_	9	ppmod	_	_
15	are	be	VBP	_	0	root	_	_
16	unknown	unknown	JJ	_	15	dep	_	_
17	.	.	.	_	15	p	_	_

1	Nursing	nurse	VBG	_	14	advcl	_	_
2	Mothers	mother	NNS	_	1	obj	_	_
3	In	in	IN	_	5	case	_	_
4	rat	rat	NN	_	5	com	_	_
5	studies	study	NNS	_	2	ppmod	_	_
6	,	,	,	_	14	p	_	_
7	exposure	exposure	NN	_	14	dep	_	_
8	to	to	TO	_	10	aux	_	_
9	total	total	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	nursing	nursing	NN	_	13	com	_	_
13	pups	pup	NNS	_	7	ppmod	_	_
14	was	be	VBD	_	0	root	_	_
15	up	up	RB	_	17	adv	_	_
16	to	to	TO	_	17	aux	_	_
17	half	half	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	that	that	DT	_	17	ppmod	_	_
20	observed	observe	VBN	_	19	acl	_	_
21	in	in	IN	_	23	case	_	_
22	maternal	maternal	JJ	_	23	attr	_	_
23	plasma	plasma	NN	_	20	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	whether	whether	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	excreted	excrete	VBN	_	4	comp	_	_
9	into	into	IN	_	12	case	_	_
10	human	human	JJ	_	12	attr	_	_
11	breast	breast	NN	_	12	com	_	_
12	milk	milk	NN	_	8	ppmod	_	_
13	;	;	:	_	4	p	_	_

1	therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	nursing	nursing	JJ	_	10	attr	_	_
10	mothers	mother	NNS	_	7	ppmod	_	_
11	unless	unless	IN	_	15	mark	_	_
12	the	the	DT	_	14	det	_	_
13	potential	potential	JJ	_	14	attr	_	_
14	benefit	benefit	NN	_	15	dep	_	_
15	justifies	justify	VBZ	_	7	comp	_	_
16	the	the	DT	_	18	det	_	_
17	potential	potential	JJ	_	18	attr	_	_
18	risk	risk	NN	_	15	obj	_	_
19	to	to	TO	_	21	aux	_	_
20	the	the	DT	_	21	det	_	_
21	infant	infant	NN	_	18	ppmod	_	_
22	.	.	.	_	7	p	_	_

1	Pediatric	pediatric	JJ	_	2	attr	_	_
2	Use	use	NN	_	0	root	_	_
3	The	the	DT	_	4	det	_	_
4	pharmacokinetics	pharmacokinetics	NNS	_	17	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	adolescents	adolescent	NNS	_	4	ppmod	_	_
9	(	-lrb-	-LRB-	_	13	p	_	_
10	10	0	CD	_	13	num	_	_
11	to	to	TO	_	10	cc	_	_
12	18	0	CD	_	10	conj	_	_
13	years	year	NNS	_	8	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	shown	show	VBN	_	2	acl	_	_
18	to	to	TO	_	19	aux	_	_
19	be	be	VB	_	17	comp	_	_
20	similar	similar	JJ	_	19	dep	_	_
21	to	to	TO	_	22	aux	_	_
22	that	that	DT	_	20	ppmod	_	_
23	in	in	IN	_	24	case	_	_
24	adults	adult	NNS	_	22	ppmod	_	_
25	.	.	.	_	2	p	_	_

1	Treatment	treatment	NN	_	9	dep	_	_
2	experience	experience	VBP	_	1	acl	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	pediatric	pediatric	JJ	_	8	attr	_	_
8	population	population	NN	_	2	ppmod	_	_
9	is	be	VBZ	_	0	root	_	_
10	limited	limited	JJ	_	9	dep	_	_
11	to	to	TO	_	13	aux	_	_
12	4	0	CD	_	13	num	_	_
13	patients	patient	NNS	_	10	ppmod	_	_
14	(	-lrb-	-LRB-	_	18	p	_	_
15	9	0	CD	_	18	num	_	_
16	to	to	TO	_	15	cc	_	_
17	17	0	CD	_	15	conj	_	_
18	years	year	NNS	_	13	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	sitosterolemia	sitosterolemia	NN	_	23	com	_	_
23	study	study	NN	_	13	ppmod	_	_
24	and	and	CC	_	13	cc	_	_
25	5	0	CD	_	26	num	_	_
26	patients	patient	NNS	_	13	conj	_	_
27	(	-lrb-	-LRB-	_	31	p	_	_
28	11	0	CD	_	31	num	_	_
29	to	to	TO	_	28	cc	_	_
30	17	0	CD	_	28	conj	_	_
31	years	year	NNS	_	26	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	in	in	IN	_	36	case	_	_
34	the	the	DT	_	36	det	_	_
35	HoFH	hofh	NN	_	36	com	_	_
36	study	study	NN	_	26	ppmod	_	_
37	.	.	.	_	9	p	_	_

1	Treatment	treatment	NN	_	14	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	children	child	NNS	_	1	ppmod	_	_
6	(	-lrb-	-LRB-	_	10	p	_	_
7	&lt	&lt	NN	_	10	attr	_	_
8	;	;	:	_	10	p	_	_
9	10	0	CD	_	10	num	_	_
10	years	year	NNS	_	5	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	is	be	VBZ	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	recommended	recommend	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Geriatric	geriatric	JJ	_	2	attr	_	_
2	Use	use	NN	_	14	dep	_	_
3	Of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	patients	patient	NNS	_	2	ppmod	_	_
6	who	who	WP	_	7	dep	_	_
7	received	receive	VBD	_	5	relcl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	in	in	IN	_	11	case	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	studies	study	NNS	_	8	ppmod	_	_
12	,	,	,	_	5	p	_	_
13	948	0	CD	_	5	appo	_	_
14	were	be	VBD	_	0	root	_	_
15	65	0	CD	_	14	obj	_	_
16	and	and	CC	_	15	cc	_	_
17	older	old	JJR	_	15	conj	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	this	this	DT	_	20	dep	_	_
20	included	include	VBD	_	14	prn	_	_
21	206	0	CD	_	20	obj	_	_
22	who	who	WP	_	23	dep	_	_
23	were	be	VBD	_	21	relcl	_	_
24	75	0	CD	_	23	obj	_	_
25	and	and	CC	_	24	cc	_	_
26	older	old	JJR	_	24	conj	_	_
27	)	-rrb-	-RRB-	_	20	p	_	_
28	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	effectiveness	effectiveness	NN	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	safety	safety	NN	_	2	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	were	be	VBD	_	0	root	_	_
8	similar	similar	JJ	_	7	dep	_	_
9	between	between	IN	_	11	case	_	_
10	these	these	DT	_	11	det	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	younger	young	JJR	_	14	attr	_	_
14	subjects	subject	NNS	_	11	conj	_	_
15	.	.	.	_	7	p	_	_

1	Greater	great	JJR	_	2	attr	_	_
2	sensitivity	sensitivity	NN	_	9	dep	_	_
3	of	of	IN	_	6	case	_	_
4	some	some	DT	_	6	det	_	_
5	older	old	JJR	_	6	attr	_	_
6	individuals	individual	NNS	_	2	ppmod	_	_
7	cannot	cannot	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	ruled	rule	VBN	_	0	root	_	_
10	out	out	RP	_	9	prt	_	_
11	.	.	.	_	9	p	_	_

1	Interaction	interaction	NN	_	22	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	:	:	:	_	22	p	_	_
5	Although	although	IN	_	7	mark	_	_
6	drug2	drug0	NN	_	7	dep	_	_
7	does	do	VBZ	_	22	advcl	_	_
8	not	not	RB	_	7	neg	_	_
9	itself	itself	PRP	_	7	obj	_	_
10	cause	cause	VBP	_	9	acl	_	_
11	orthostatic	orthostatic	JJ	_	12	attr	_	_
12	hypotension	hypotension	NN	_	10	obj	_	_
13	,	,	,	_	22	p	_	_
14	its	its	PRP$	_	15	poss	_	_
15	administration	administration	NN	_	22	dep	_	_
16	to	to	TO	_	17	aux	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	already	already	RB	_	19	adv	_	_
19	receiving	receive	VBG	_	17	acl	_	_
20	drug3	drug0	NN	_	19	obj	_	_
21	can	can	MD	_	22	modal	_	_
22	result	result	VB	_	0	root	_	_
23	in	in	IN	_	26	case	_	_
24	profound	profound	JJ	_	26	attr	_	_
25	orthostatic	orthostatic	JJ	_	26	attr	_	_
26	effects	effect	NNS	_	22	ppmod	_	_
27	.	.	.	_	22	p	_	_

1	If	if	IN	_	8	mark	_	_
2	at	at	IN	_	5	case	_	_
3	all	all	DT	_	5	det	_	_
4	possible	possible	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	8	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	discontinued	discontinue	VBN	_	13	advcl	_	_
9	well	well	RB	_	8	adv	_	_
10	before	before	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	is	be	VBZ	_	13	aux	_	_
13	begun	begin	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Where	where	WRB	_	3	adv	_	_
2	this	this	DT	_	3	dep	_	_
3	is	be	VBZ	_	11	advcl	_	_
4	not	not	RB	_	3	neg	_	_
5	possible	possible	JJ	_	3	dep	_	_
6	,	,	,	_	11	p	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	therapy	therapy	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	started	start	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	hospital	hospital	NN	_	11	ppmod	_	_
15	and	and	CC	_	11	cc	_	_
16	the	the	DT	_	17	det	_	_
17	patient	patient	NN	_	20	dep	_	_
18	should	should	MD	_	20	modal	_	_
19	remain	remain	VB	_	20	aux	_	_
20	institutionalized	institutionalize	VBN	_	11	conj	_	_
21	until	until	IN	_	25	mark	_	_
22	severe	severe	JJ	_	24	attr	_	_
23	orthostatic	orthostatic	JJ	_	24	attr	_	_
24	effects	effect	NNS	_	25	dep	_	_
25	are	be	VBP	_	20	comp	_	_
26	no	no	RB	_	27	com	_	_
27	longer	long	RBR	_	25	neg	_	_
28	present	present	JJ	_	25	dep	_	_
29	or	or	CC	_	25	cc	_	_
30	the	the	DT	_	31	det	_	_
31	patient	patient	NN	_	33	dep	_	_
32	has	have	VBZ	_	33	aux	_	_
33	learned	learn	VBN	_	25	conj	_	_
34	to	to	TO	_	35	aux	_	_
35	avoid	avoid	VB	_	33	comp	_	_
36	activities	activity	NNS	_	35	obj	_	_
37	that	that	WDT	_	38	dep	_	_
38	provoke	provoke	VBP	_	36	relcl	_	_
39	them	them	PRP	_	38	obj	_	_
40	.	.	.	_	11	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	21	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	which	which	WDT	_	10	ppmod	_	_
6	34	0	CD	_	8	num	_	_
7	different	different	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	10	dep	_	_
9	were	be	VBD	_	10	aux	_	_
10	tested	test	VBN	_	3	relcl	_	_
11	,	,	,	_	21	p	_	_
12	therapeutically	therapeutically	RB	_	13	adv	_	_
13	relevant	relevant	JJ	_	14	attr	_	_
14	concentrations	concentration	NNS	_	21	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug3	drug0	NN	_	16	conj	_	_
21	displaced	displace	VBD	_	0	root	_	_
22	protein-bound	protein-bound	JJ	_	23	attr	_	_
23	drug4	drug0	NN	_	21	obj	_	_
24	in	in	IN	_	27	case	_	_
25	fresh	fresh	JJ	_	27	attr	_	_
26	human	human	JJ	_	27	attr	_	_
27	serum	serum	NN	_	21	ppmod	_	_
28	to	to	TO	_	33	aux	_	_
29	a	a	DT	_	33	det	_	_
30	small	small	JJ	_	33	attr	_	_
31	but	but	CC	_	30	cc	_	_
32	significant	significant	JJ	_	30	conj	_	_
33	extent	extent	NN	_	21	ppmod	_	_
34	.	.	.	_	21	p	_	_

1	Because	because	IN	_	6	case	_	_
2	of	of	IN	_	6	case	_	_
3	the	the	DT	_	6	det	_	_
4	extremely	extremely	RB	_	5	adv	_	_
5	high	high	JJ	_	6	attr	_	_
6	binding	binding	NN	_	19	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	to	to	TO	_	11	aux	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	proteins	protein	NNS	_	6	ppmod	_	_
12	,	,	,	_	19	p	_	_
13	these	these	DT	_	15	det	_	_
14	small	small	JJ	_	15	attr	_	_
15	decreases	decrease	NNS	_	19	dep	_	_
16	in	in	IN	_	17	case	_	_
17	binding	binding	NN	_	15	ppmod	_	_
18	could	could	MD	_	19	modal	_	_
19	cause	cause	VB	_	0	root	_	_
20	substantial	substantial	JJ	_	21	attr	_	_
21	increases	increase	NNS	_	19	obj	_	_
22	in	in	IN	_	25	case	_	_
23	free	free	JJ	_	25	attr	_	_
24	drug	drug	NN	_	25	com	_	_
25	levels	level	NNS	_	21	ppmod	_	_
26	in	in	IN	_	27	case	_	_
27	plasma	plasma	NN	_	25	ppmod	_	_
28	which	which	WDT	_	30	dep	_	_
29	could	could	MD	_	30	modal	_	_
30	result	result	VB	_	27	relcl	_	_
31	in	in	IN	_	32	case	_	_
32	potentiation	potentiation	NN	_	30	ppmod	_	_
33	of	of	IN	_	35	case	_	_
34	drug	drug	NN	_	35	com	_	_
35	toxicity	toxicity	NN	_	32	ppmod	_	_
36	.	.	.	_	19	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	administering	administer	VBG	_	6	ppmod	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	injection	injection	NN	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	to	to	TO	_	15	aux	_	_
15	patients	patient	NNS	_	8	ppmod	_	_
16	receiving	receive	VBG	_	15	acl	_	_
17	these	these	DT	_	19	det	_	_
18	other	other	JJ	_	19	attr	_	_
19	agents	agent	NNS	_	16	obj	_	_
20	.	.	.	_	6	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	change	change	NN	_	2	obj	_	_
5	in	in	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	kinetics	kinetics	NNS	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	when	when	WRB	_	12	adv	_	_
12	coadministered	coadministered	VBN	_	2	comp	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	However	however	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	the	the	DT	_	5	det	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	clearance	clearance	NN	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	was	be	VBD	_	10	aux	_	_
9	slightly	slightly	RB	_	10	adv	_	_
10	increased	increase	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	An	an	DT	_	2	det	_	_
2	increase	increase	NN	_	9	dep	_	_
3	in	in	IN	_	5	case	_	_
4	intracellular	intracellular	JJ	_	5	attr	_	_
5	levels	level	NNS	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	in	in	FW	_	11	adv	_	_
11	vitro	vitro	FW	_	9	adv	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	presence	presence	NN	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	antagonize	antagonize	VBP	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	uricosuric	uricosuric	JJ	_	5	attr	_	_
5	action	action	NN	_	2	obj	_	_
6	of	of	IN	_	8	case	_	_
7	.	.	.	_	8	p	_	_
8	drugs	drug	NNS	_	5	ppmod	_	_
9	used	use	VBN	_	8	acl	_	_
10	to	to	TO	_	11	aux	_	_
11	treat	treat	VB	_	9	comp	_	_
12	gout	gout	NN	_	11	obj	_	_
13	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	AND	and	CC	_	1	cc	_	_
3	OTHER	other	JJ	_	4	attr	_	_
4	drug2	drug0	NNS	_	1	conj	_	_
5	WILL	will	MD	_	6	modal	_	_
6	BE	be	VB	_	0	root	_	_
7	ADDITIVE	additive	JJ	_	6	dep	_	_
8	TO	to	TO	_	9	aux	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	AND	and	CC	_	6	cc	_	_
11	MAY	may	MD	_	12	modal	_	_
12	INCREASE	increase	VB	_	6	conj	_	_
13	PLASMA	plasma	NN	_	14	com	_	_
14	CONCENTRATIONS	concentration	NNS	_	12	obj	_	_
15	OF	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	TO	to	TO	_	19	aux	_	_
18	TOXIC	toxic	JJ	_	19	attr	_	_
19	LEVELS	level	NNS	_	12	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	Drugs	drug	NNS	_	9	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	foods	food	NNS	_	1	conj	_	_
4	that	that	WDT	_	5	dep	_	_
5	raise	raise	VBP	_	1	relcl	_	_
6	urine	urine	NN	_	7	com	_	_
7	pH	ph	NN	_	5	obj	_	_
8	will	will	MD	_	9	modal	_	_
9	increase	increase	VB	_	0	root	_	_
10	renal	renal	JJ	_	11	attr	_	_
11	clearance	clearance	NN	_	9	obj	_	_
12	and	and	CC	_	11	cc	_	_
13	urinary	urinary	JJ	_	14	attr	_	_
14	excretion	excretion	NN	_	11	conj	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	11	ppmod	_	_
17	,	,	,	_	9	p	_	_
18	thus	thus	RB	_	19	adv	_	_
19	lowering	lower	VBG	_	9	comp	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	levels	level	NNS	_	19	obj	_	_
22	;	;	:	_	9	p	_	_

1	acidifying	acidify	VBG	_	2	attr	_	_
2	drugs	drug	NNS	_	6	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	foods	food	NNS	_	2	conj	_	_
5	will	will	MD	_	6	modal	_	_
6	decrease	decrease	VB	_	0	root	_	_
7	urinary	urinary	JJ	_	8	attr	_	_
8	excretion	excretion	NN	_	6	obj	_	_
9	and	and	CC	_	6	cc	_	_
10	increase	increase	VB	_	6	conj	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	levels	level	NNS	_	10	obj	_	_
13	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	given	give	VBN	_	1	acl	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	predispose	predispose	VB	_	0	root	_	_
8	to	to	TO	_	10	aux	_	_
9	systemic	systemic	JJ	_	10	attr	_	_
10	bleeding	bleeding	JJ	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hypoglycemic	hypoglycemic	JJ	_	6	attr	_	_
6	effect	effect	NN	_	3	obj	_	_
7	of	of	IN	_	9	case	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	sulfonylurea	sulfonylurea	NN	_	13	com	_	_
13	class	class	NN	_	9	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	competes	compete	VBZ	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	number	number	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drugs	drug	NNS	_	5	ppmod	_	_
8	for	for	IN	_	11	case	_	_
9	protein	protein	NN	_	11	com	_	_
10	binding	binding	NN	_	11	com	_	_
11	sites	site	NNS	_	2	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	notably	notably	RB	_	11	adv	_	_
14	drug2	drug0	NN	_	11	appo	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	14	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug6	drug0	NN	_	14	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug7	drug0	NN	_	14	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug8	drug0	NN	_	14	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug9	drug0	NN	_	14	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug10	drug0	NN	_	14	conj	_	_
31	,	,	,	_	30	p	_	_
32	and	and	CC	_	30	cc	_	_
33	possibly	possibly	RB	_	34	adv	_	_
34	drug11	drug0	NN	_	14	conj	_	_
35	.	.	.	_	2	p	_	_

1	Drug/	drug/	VBG	_	6	advcl	_	_
2	Laboratory	laboratory	NN	_	4	com	_	_
3	Test	test	NN	_	4	com	_	_
4	Interactions	interaction	NNS	_	1	obj	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	competes	compete	VBZ	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	thyroid	thyroid	NN	_	9	com	_	_
9	hormone	hormone	NN	_	6	ppmod	_	_
10	for	for	IN	_	11	case	_	_
11	binding	bind	VBG	_	6	ppmod	_	_
12	to	to	TO	_	14	aux	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	proteins	protein	NNS	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	which	which	WDT	_	19	dep	_	_
17	may	may	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	reflected	reflect	VBN	_	14	relcl	_	_
20	in	in	IN	_	25	case	_	_
21	a	a	DT	_	25	det	_	_
22	depressed	depressed	JJ	_	25	attr	_	_
23	plasma	plasma	NN	_	25	com	_	_
24	T4	t0	NN	_	25	com	_	_
25	value	value	NN	_	19	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	some	some	DT	_	28	det	_	_
28	patients	patient	NNS	_	25	ppmod	_	_
29	;	;	:	_	6	p	_	_

1	thyroid	thyroid	NN	_	2	com	_	_
2	function	function	NN	_	6	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	basal	basal	JJ	_	5	attr	_	_
5	metabolism	metabolism	NN	_	2	conj	_	_
6	are	be	VBP	_	0	root	_	_
7	unaffected	unaffected	JJ	_	6	dep	_	_
8	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	elderly	elderly	JJ	_	3	attr	_	_
3	patients	patient	NNS	_	21	ppmod	_	_
4	concurrently	concurrently	RB	_	5	adv	_	_
5	receiving	receive	VBG	_	3	acl	_	_
6	certain	certain	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	5	obj	_	_
8	,	,	,	_	3	p	_	_
9	primarily	primarily	RB	_	10	adv	_	_
10	drug2	drug0	NN	_	3	appo	_	_
11	,	,	,	_	21	p	_	_
12	an	an	DT	_	14	det	_	_
13	increased	increase	VBN	_	14	attr	_	_
14	incidence	incidence	NN	_	21	dep	_	_
15	of	of	IN	_	16	case	_	_
16	thrombopenia	thrombopenia	NN	_	14	ppmod	_	_
17	with	with	IN	_	18	case	_	_
18	purpura	purpura	NN	_	14	ppmod	_	_
19	has	have	VBZ	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	reported	report	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	that	that	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	prolong	prolong	VB	_	4	comp	_	_
9	the	the	DT	_	11	det	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	time	time	NN	_	8	obj	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	8	ppmod	_	_
14	who	who	WP	_	16	dep	_	_
15	are	be	VBP	_	16	aux	_	_
16	receiving	receive	VBG	_	13	relcl	_	_
17	the	the	DT	_	19	det	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	drug3	drug0	NN	_	16	obj	_	_
20	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	kept	keep	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	mind	mind	NN	_	5	ppmod	_	_
8	when	when	WRB	_	11	adv	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	given	give	VBN	_	5	comp	_	_
12	to	to	TO	_	13	aux	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	already	already	RB	_	13	adv	_	_
15	on	on	IN	_	17	case	_	_
16	anticoagulant	anticoagulant	JJ	_	17	attr	_	_
17	therapy	therapy	NN	_	11	ppmod	_	_
18	,	,	,	_	5	p	_	_
19	and	and	CC	_	5	cc	_	_
20	the	the	DT	_	22	det	_	_
21	coagulation	coagulation	NN	_	22	com	_	_
22	time	time	NN	_	25	dep	_	_
23	should	should	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	reassessed	reassess	VBN	_	5	conj	_	_
26	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	inhibit	inhibit	VBP	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hepatic	hepatic	JJ	_	6	attr	_	_
6	metabolism	metabolism	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	At	at	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	1.6-g	0-g	JJ	_	4	attr	_	_
4	dose	dose	NN	_	7	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	produced	produce	VBD	_	0	root	_	_
8	a	a	DT	_	12	det	_	_
9	slight	slight	JJ	_	12	attr	_	_
10	but	but	CC	_	9	cc	_	_
11	significant	significant	JJ	_	9	conj	_	_
12	increase	increase	NN	_	7	obj	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	half-life	half-life	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	but	but	CC	_	7	cc	_	_
19	did	do	VBD	_	21	aux	_	_
20	not	not	RB	_	21	neg	_	_
21	produce	produce	VB	_	7	conj	_	_
22	a	a	DT	_	24	det	_	_
23	corresponding	corresponding	JJ	_	24	attr	_	_
24	decrease	decrease	NN	_	21	obj	_	_
25	in	in	IN	_	29	case	_	_
26	the	the	DT	_	29	det	_	_
27	metabolic	metabolic	JJ	_	29	attr	_	_
28	clearance	clearance	NN	_	29	com	_	_
29	rate	rate	NN	_	24	ppmod	_	_
30	.	.	.	_	7	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	administering	administer	VBG	_	9	advcl	_	_
3	these	these	DT	_	4	det	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	concurrently	concurrently	RB	_	2	adv	_	_
6	,	,	,	_	9	p	_	_
7	one	#crd#	PRP	_	9	dep	_	_
8	should	should	MD	_	9	modal	_	_
9	be	be	VB	_	0	root	_	_
10	alert	alert	JJ	_	9	dep	_	_
11	for	for	IN	_	15	case	_	_
12	possible	possible	JJ	_	15	attr	_	_
13	excessive	excessive	JJ	_	15	attr	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	effect	effect	NN	_	10	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	can	can	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	displace	displace	VB	_	0	root	_	_
5	drug2	drug0	NN	_	4	obj	_	_
6	from	from	IN	_	9	case	_	_
7	plasma	plasma	NN	_	9	attr	_	_
8	protein-binding	protein-binding	JJ	_	9	attr	_	_
9	sites	site	NNS	_	4	ppmod	_	_
10	,	,	,	_	4	p	_	_
11	thus	thus	RB	_	12	adv	_	_
12	increasing	increase	VBG	_	4	comp	_	_
13	free	free	JJ	_	15	attr	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	12	obj	_	_
16	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	presence	presence	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	interfere	interfere	VB	_	0	root	_	_
7	with	with	IN	_	13	case	_	_
8	the	the	DT	_	13	det	_	_
9	Jaff	jaff	NN	_	13	com	_	_
10	alkaline	alkaline	NN	_	13	com	_	_
11	picrate	picrate	NN	_	13	com	_	_
12	reaction	reaction	NN	_	13	com	_	_
13	assay	assay	NN	_	6	ppmod	_	_
14	for	for	IN	_	15	case	_	_
15	creatinine	creatinine	NN	_	13	ppmod	_	_
16	,	,	,	_	6	p	_	_
17	resulting	result	VBG	_	6	comp	_	_
18	in	in	IN	_	19	case	_	_
19	overestimations	overestimation	NNS	_	17	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	about	about	RB	_	22	adv	_	_
22	10	0	CD	_	19	ppmod	_	_
23	%	%	NN	_	22	meta	_	_
24	in	in	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	range	range	NN	_	17	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	normal	normal	JJ	_	29	attr	_	_
29	values	value	NNS	_	26	ppmod	_	_
30	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	listed	list	VBN	_	3	acl	_	_
5	below	below	IN	_	4	case	_	_
6	are	be	VBP	_	0	root	_	_
7	potentially	potentially	RB	_	9	adv	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	important	important	JJ	_	6	dep	_	_
10	.	.	.	_	6	p	_	_

1	Mutual	mutual	JJ	_	2	attr	_	_
2	inhibition	inhibition	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	metabolism	metabolism	NN	_	2	ppmod	_	_
5	occurs	occur	VBZ	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	concurrent	concurrent	JJ	_	8	attr	_	_
8	use	use	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	;	;	:	_	5	p	_	_

1	therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	it	it	PRP	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	possible	possible	JJ	_	4	dep	_	_
6	that	that	IN	_	18	mark	_	_
7	adverse	adverse	JJ	_	8	attr	_	_
8	events	event	NNS	_	18	dep	_	_
9	associated	associate	VBN	_	8	acl	_	_
10	with	with	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	individual	individual	JJ	_	13	attr	_	_
13	use	use	NN	_	9	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	either	either	DT	_	16	det	_	_
16	drug	drug	NN	_	13	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	4	comp	_	_
19	more	more	JJR	_	20	attr	_	_
20	apt	apt	NNS	_	22	dep	_	_
21	to	to	TO	_	22	aux	_	_
22	occur	occur	VB	_	18	comp	_	_
23	.	.	.	_	4	p	_	_

1	convulsions	convulsion	NNS	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	concurrent	concurrent	JJ	_	7	attr	_	_
7	use	use	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	.	.	.	_	4	p	_	_

1	Drugs	drug	NNS	_	15	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	induce	induce	VBP	_	1	relcl	_	_
4	hepatic	hepatic	JJ	_	5	attr	_	_
5	enzymes	enzyme	NNS	_	3	obj	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug3	drug0	NN	_	8	conj	_	_
14	may	may	MD	_	15	modal	_	_
15	increase	increase	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	clearance	clearance	NN	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug4	drug0	NNS	_	17	ppmod	_	_
20	and	and	CC	_	15	cc	_	_
21	may	may	MD	_	23	modal	_	_
22	require	require	VB	_	23	aux	_	_
23	increased	increase	VBN	_	15	conj	_	_
24	in	in	IN	_	26	case	_	_
25	drug5	drug0	NN	_	26	com	_	_
26	dose	dose	NN	_	23	ppmod	_	_
27	to	to	TO	_	28	aux	_	_
28	achieve	achieve	VB	_	23	comp	_	_
29	the	the	DT	_	31	det	_	_
30	desired	desired	JJ	_	31	attr	_	_
31	response	response	NN	_	28	obj	_	_
32	.	.	.	_	15	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	such	such	JJ	_	4	adv	_	_
3	as	as	IN	_	4	case	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	inhibit	inhibit	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	metabolism	metabolism	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	8	cc	_	_
14	thus	thus	RB	_	15	adv	_	_
15	decrease	decrease	VB	_	8	conj	_	_
16	its	its	PRP$	_	17	poss	_	_
17	clearance	clearance	NN	_	15	obj	_	_
18	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	the	the	DT	_	4	det	_	_
4	dose	dose	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	titrated	titrate	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	avoid	avoid	VB	_	9	comp	_	_
12	steroid	steroid	NN	_	13	com	_	_
13	toxicity	toxicity	NN	_	11	obj	_	_
14	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	clearance	clearance	NN	_	3	obj	_	_
6	of	of	IN	_	10	case	_	_
7	chronic	chronic	JJ	_	10	attr	_	_
8	high	high	JJ	_	10	attr	_	_
9	dose	dose	NN	_	10	com	_	_
10	drug2	drug0	NN	_	5	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	This	this	DT	_	3	dep	_	_
2	could	could	MD	_	3	modal	_	_
3	lead	lead	VB	_	0	root	_	_
4	to	to	TO	_	8	aux	_	_
5	decreased	decrease	VBN	_	8	attr	_	_
6	drug1	drug0	NN	_	8	com	_	_
7	serum	serum	NN	_	8	com	_	_
8	levels	level	NNS	_	3	ppmod	_	_
9	or	or	CC	_	3	cc	_	_
10	increase	increase	VBP	_	3	conj	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	toxicity	toxicity	NN	_	12	ppmod	_	_
16	when	when	WRB	_	19	adv	_	_
17	drug3	drug0	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	withdrawn	withdraw	VBN	_	10	comp	_	_
20	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	cautiously	cautiously	RB	_	4	adv	_	_
6	in	in	IN	_	7	case	_	_
7	conjunction	conjunction	NN	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	suffering	suffer	VBG	_	11	acl	_	_
13	from	from	IN	_	14	case	_	_
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	12	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug2	drug0	NNS	_	2	ppmod	_	_
8	is	be	VBZ	_	0	root	_	_
9	variable	variable	NN	_	8	obj	_	_
10	.	.	.	_	8	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	reports	report	NNS	_	2	obj	_	_
4	of	of	IN	_	5	case	_	_
5	enhanced	enhance	VBN	_	3	ppmod	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	5	cc	_	_
8	as	as	IN	_	7	com	_	_
9	diminished	diminish	VBN	_	10	attr	_	_
10	effects	effect	NNS	_	5	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	when	when	WRB	_	14	adv	_	_
14	given	give	VBN	_	2	comp	_	_
15	concurrently	concurrently	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	coagulation	coagulation	NN	_	4	com	_	_
4	indices	index	NNS	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	monitored	monitor	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	maintain	maintain	VB	_	7	comp	_	_
10	the	the	DT	_	13	det	_	_
11	desired	desired	JJ	_	13	attr	_	_
12	anticoagulant	anticoagulant	JJ	_	13	attr	_	_
13	effect	effect	NN	_	9	obj	_	_
14	.	.	.	_	7	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	generally	generally	RB	_	10	adv	_	_
7	should	should	MD	_	10	modal	_	_
8	not	not	RB	_	10	neg	_	_
9	be	be	VB	_	10	aux	_	_
10	treated	treat	VBN	_	0	root	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	action	action	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	potentiated	potentiate	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	anesthesia	anesthesia	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	9	appo	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	.	.	.	_	7	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	24	ppmod	_	_
4	,	,	,	_	24	p	_	_
5	the	the	DT	_	7	det	_	_
6	concurrent	concurrent	JJ	_	7	attr	_	_
7	administration	administration	NN	_	24	dep	_	_
8	of	of	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	inhaler	inhaler	NN	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	other	other	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	11	conj	_	_
15	commonly	commonly	RB	_	16	adv	_	_
16	used	use	VBN	_	14	acl	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	treatment	treatment	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	asthma	asthma	NN	_	19	ppmod	_	_
22	was	be	VBD	_	24	aux	_	_
23	not	not	RB	_	24	neg	_	_
24	associated	associate	VBN	_	0	root	_	_
25	with	with	IN	_	29	case	_	_
26	any	any	DT	_	29	det	_	_
27	unusual	unusual	JJ	_	29	attr	_	_
28	adverse	adverse	JJ	_	29	attr	_	_
29	events	event	NNS	_	24	ppmod	_	_
30	.	.	.	_	24	p	_	_

1	However	however	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	drug1	drug0	NN	_	14	dep	_	_
4	,	,	,	_	3	p	_	_
5	a	a	DT	_	7	det	_	_
6	potent	potent	JJ	_	7	attr	_	_
7	inhibitor	inhibitor	NN	_	3	appo	_	_
8	of	of	IN	_	11	case	_	_
9	cytochrome	cytochrome	NN	_	11	com	_	_
10	P450	p0	NN	_	11	com	_	_
11	3A4	0a0	NN	_	7	ppmod	_	_
12	,	,	,	_	3	p	_	_
13	may	may	MD	_	14	modal	_	_
14	increase	increase	VB	_	0	root	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	levels	level	NNS	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	during	during	IN	_	21	case	_	_
20	concomitant	concomitant	JJ	_	21	attr	_	_
21	dosing	dosing	NN	_	14	ppmod	_	_
22	.	.	.	_	14	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	13	dep	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	conj	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	performed	performed	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Drugs	drug	NNS	_	6	dep	_	_
2	such	such	JJ	_	4	adv	_	_
3	as	as	IN	_	4	case	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	potentiate	potentiate	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	release	release	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	neutrophils	neutrophil	NNS	_	8	ppmod	_	_
11	;	;	:	_	6	p	_	_

1	patients	patient	NNS	_	10	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	should	should	MD	_	10	modal	_	_
7	have	have	VB	_	10	lv	_	_
8	more	more	RBR	_	9	adv	_	_
9	frequent	frequent	JJ	_	10	attr	_	_
10	monitoring	monitoring	NN	_	0	root	_	_
11	of	of	IN	_	13	case	_	_
12	neutrophil	neutrophil	NN	_	13	com	_	_
13	counts	count	NNS	_	10	ppmod	_	_
14	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	increase	increase	VB	_	0	root	_	_
5	sensitivity	sensitivity	NN	_	4	obj	_	_
6	to	to	TO	_	8	aux	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug3	drug0	NN	_	5	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	Dosage	dosage	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	have	have	VB	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	be	be	VB	_	9	aux	_	_
9	decreased	decrease	VBN	_	6	comp	_	_
10	in	in	IN	_	13	mark	_	_
11	order	order	NN	_	13	dep	_	_
12	to	to	TO	_	13	aux	_	_
13	maintain	maintain	VB	_	9	comp	_	_
14	desired	desired	JJ	_	16	attr	_	_
15	prothrombin	prothrombin	NN	_	16	com	_	_
16	time	time	NN	_	13	obj	_	_
17	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	oral	oral	JJ	_	5	attr	_	_
4	anticoagulant	anticoagulant	NN	_	5	com	_	_
5	therapy	therapy	NN	_	2	obj	_	_
6	require	require	VBP	_	0	root	_	_
7	close	close	JJ	_	8	attr	_	_
8	monitoring	monitoring	NN	_	6	obj	_	_
9	,	,	,	_	6	p	_	_
10	especially	especially	RB	_	11	com	_	_
11	when	when	WRB	_	14	adv	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	are	be	VBP	_	14	aux	_	_
14	started	start	VBN	_	6	comp	_	_
15	or	or	CC	_	14	cc	_	_
16	stopped	stop	VBN	_	14	conj	_	_
17	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	5	det	_	_
4	multidose	multidose	JJ	_	5	attr	_	_
5	study	study	NN	_	25	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	5	p	_	_
9	given	give	VBN	_	5	acl	_	_
10	as	as	IN	_	15	case	_	_
11	5	0	CD	_	14	num	_	_
12	or	or	CC	_	11	cc	_	_
13	10	0	CD	_	11	conj	_	_
14	mg	mg	NN	_	15	com	_	_
15	BID	bid	NN	_	9	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	15	0	CD	_	19	num	_	_
18	healthy	healthy	JJ	_	19	attr	_	_
19	subjects	subject	NNS	_	9	ppmod	_	_
20	concurrently	concurrently	RB	_	21	adv	_	_
21	treated	treat	VBN	_	19	acl	_	_
22	with	with	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	,	,	,	_	5	p	_	_
25	resulted	result	VBD	_	1	acl	_	_
26	in	in	IN	_	29	case	_	_
27	a	a	DT	_	29	det	_	_
28	mean	mean	JJ	_	29	attr	_	_
29	increase	increase	NN	_	25	ppmod	_	_
30	in	in	IN	_	32	case	_	_
31	drug4	drug0	NN	_	32	com	_	_
32	half-life	half-life	NN	_	29	ppmod	_	_
33	from	from	IN	_	37	case	_	_
34	26	0	CD	_	37	num	_	_
35	to	to	TO	_	34	cc	_	_
36	48	0	CD	_	34	conj	_	_
37	hours	hour	NNS	_	32	ppmod	_	_
38	and	and	CC	_	32	cc	_	_
39	AUC	auc	NN	_	32	conj	_	_
40	from	from	IN	_	46	case	_	_
41	4.55	0	CD	_	46	num	_	_
42	to	to	TO	_	41	cc	_	_
43	12.08	0	CD	_	41	conj	_	_
44	ng	ng	NN	_	46	com	_	_
45	*	*	NN	_	46	com	_	_
46	hr/mL	hr/ml	NN	_	39	ppmod	_	_
47	:	:	:	_	1	p	_	_
48	similar	similar	JJ	_	49	attr	_	_
49	increases	increase	NNS	_	57	dep	_	_
50	in	in	IN	_	52	case	_	_
51	drug5	drug0	NN	_	52	com	_	_
52	half-life	half-life	NN	_	49	ppmod	_	_
53	and	and	CC	_	52	cc	_	_
54	AUC	auc	NN	_	52	conj	_	_
55	were	be	VBD	_	57	aux	_	_
56	also	also	RB	_	57	adv	_	_
57	detected	detect	VBN	_	1	acl	_	_
58	.	.	.	_	1	p	_	_

1	Microscopic	microscopic	JJ	_	2	attr	_	_
2	hematuria	hematuria	NN	_	14	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	9/15	0	CD	_	2	num	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	and	and	CC	_	2	cc	_	_
7	gingival	gingival	JJ	_	8	attr	_	_
8	bleeding	bleeding	JJ	_	2	conj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	1/15	0	NN	_	8	num	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	were	be	VBD	_	14	aux	_	_
13	also	also	RB	_	14	adv	_	_
14	observed	observe	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	A	a	DT	_	3	det	_	_
2	5.5-fold	0-fold	RB	_	3	adv	_	_
3	decrease	decrease	NN	_	25	dep	_	_
4	in	in	IN	_	8	case	_	_
5	the	the	DT	_	8	det	_	_
6	mean	mean	JJ	_	8	attr	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	dose	dose	NN	_	3	ppmod	_	_
9	from	from	IN	_	14	case	_	_
10	6.13	0	CD	_	14	num	_	_
11	mg/day	mg/day	NN	_	14	attr	_	_
12	to	to	TO	_	14	attr	_	_
13	1.13	0	CD	_	14	num	_	_
14	mg/day	mg/day	NN	_	8	ppmod	_	_
15	(	-lrb-	-LRB-	_	19	p	_	_
16	approximately	approximately	RB	_	17	adv	_	_
17	80-85	0	CD	_	19	num	_	_
18	%	%	NN	_	17	meta	_	_
19	reduction	reduction	NN	_	14	prn	_	_
20	of	of	IN	_	22	case	_	_
21	drug2	drug0	NN	_	22	com	_	_
22	dose	dose	NN	_	19	ppmod	_	_
23	)	-rrb-	-RRB-	_	19	p	_	_
24	,	,	,	_	3	p	_	_
25	was	be	VBD	_	0	root	_	_
26	necessary	necessary	JJ	_	25	dep	_	_
27	to	to	TO	_	28	aux	_	_
28	maintain	maintain	VB	_	26	comp	_	_
29	a	a	DT	_	31	det	_	_
30	target	target	NN	_	31	com	_	_
31	INR	inr	NN	_	28	obj	_	_
32	of	of	IN	_	33	case	_	_
33	1.5	0	CD	_	31	ppmod	_	_
34	.	.	.	_	25	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	initiated	initiate	VBN	_	25	advcl	_	_
6	in	in	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	already	already	RB	_	10	adv	_	_
10	receiving	receive	VBG	_	8	acl	_	_
11	treatment	treatment	NN	_	10	obj	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	25	p	_	_
15	the	the	DT	_	16	det	_	_
16	INR	inr	NN	_	25	dep	_	_
17	or	or	CC	_	16	cc	_	_
18	prothrombin	prothrombin	NN	_	19	com	_	_
19	time	time	NN	_	16	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	PT	pt	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	should	should	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	monitored	monitor	VBN	_	0	root	_	_
26	closely	closely	RB	_	25	adv	_	_
27	and	and	CC	_	25	cc	_	_
28	the	the	DT	_	29	det	_	_
29	dose	dose	NN	_	44	dep	_	_
30	of	of	IN	_	31	case	_	_
31	drug3	drug0	NN	_	29	ppmod	_	_
32	adjusted	adjust	VBN	_	31	acl	_	_
33	as	as	IN	_	34	case	_	_
34	necessary	necessary	JJ	_	32	ppmod	_	_
35	until	until	IN	_	39	case	_	_
36	a	a	DT	_	39	det	_	_
37	stable	stable	JJ	_	39	attr	_	_
38	target	target	NN	_	39	com	_	_
39	INR	inr	NN	_	34	ppmod	_	_
40	or	or	CC	_	39	cc	_	_
41	PT	pt	NN	_	39	conj	_	_
42	has	have	VBZ	_	44	aux	_	_
43	been	be	VBN	_	44	aux	_	_
44	achieved	achieve	VBN	_	25	conj	_	_
45	.	.	.	_	25	p	_	_

1	Furthermore	furthermore	RB	_	26	adv	_	_
2	,	,	,	_	26	p	_	_
3	in	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	26	ppmod	_	_
5	receiving	receive	VBG	_	4	acl	_	_
6	both	both	DT	_	7	det	_	_
7	drugs	drug	NNS	_	5	obj	_	_
8	,	,	,	_	26	p	_	_
9	careful	careful	JJ	_	10	attr	_	_
10	monitoring	monitoring	NN	_	26	dep	_	_
11	of	of	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	INR	inr	NN	_	10	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	PT	pt	NN	_	13	conj	_	_
16	,	,	,	_	10	p	_	_
17	and	and	CC	_	10	cc	_	_
18	adjustment	adjustment	NN	_	10	conj	_	_
19	of	of	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	drug1	drug0	NN	_	22	com	_	_
22	dosage	dosage	NN	_	18	ppmod	_	_
23	if	if	IN	_	24	mark	_	_
24	indicated	indicate	VBN	_	22	acl	_	_
25	are	be	VBP	_	26	aux	_	_
26	recommended	recommend	VBN	_	0	root	_	_
27	when	when	WRB	_	32	adv	_	_
28	the	the	DT	_	30	det	_	_
29	drug2	drug0	NN	_	30	com	_	_
30	dose	dose	NN	_	32	dep	_	_
31	is	be	VBZ	_	32	aux	_	_
32	changed	change	VBN	_	26	comp	_	_
33	or	or	CC	_	32	cc	_	_
34	discontinued	discontinue	VBN	_	32	conj	_	_
35	.	.	.	_	26	p	_	_

1	Patients	patient	NNS	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	be	be	VB	_	5	aux	_	_
4	closely	closely	RB	_	5	adv	_	_
5	monitored	monitor	VBN	_	0	root	_	_
6	for	for	IN	_	7	case	_	_
7	signs	sign	NNS	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	symptoms	symptom	NNS	_	7	conj	_	_
10	of	of	IN	_	12	case	_	_
11	occult	occult	JJ	_	12	attr	_	_
12	bleeding	bleeding	JJ	_	7	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	Oral	oral	JJ	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	inhibit	inhibit	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	metabolism	metabolism	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	oral	oral	JJ	_	10	attr	_	_
10	drug3	drug0	NN	_	7	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	16	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	In	in	IN	_	5	case	_	_
5	patients	patient	NNS	_	1	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	edema	edema	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	concomitant	concomitant	JJ	_	10	attr	_	_
10	administration	administration	NN	_	7	appo	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	may	may	MD	_	16	modal	_	_
16	increase	increase	VB	_	0	root	_	_
17	the	the	DT	_	18	det	_	_
18	edema	edema	NN	_	16	obj	_	_
19	.	.	.	_	16	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	test	test	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	drug1	drug0	NN	_	3	attr	_	_
5	may	may	MD	_	6	modal	_	_
6	decrease	decrease	VB	_	0	root	_	_
7	levels	level	NNS	_	6	obj	_	_
8	of	of	IN	_	10	case	_	_
9	thyroxine-binding	thyroxine-binding	JJ	_	10	attr	_	_
10	globulin	globulin	NN	_	7	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	resulting	result	VBG	_	6	comp	_	_
13	in	in	IN	_	18	case	_	_
14	decreased	decrease	VBN	_	18	attr	_	_
15	total	total	JJ	_	18	attr	_	_
16	T4	t0	NN	_	18	com	_	_
17	serum	serum	NN	_	18	com	_	_
18	levels	level	NNS	_	12	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	increased	increase	VBN	_	22	attr	_	_
21	resin	resin	NN	_	22	com	_	_
22	uptake	uptake	NN	_	18	conj	_	_
23	of	of	IN	_	24	case	_	_
24	T3	t0	NN	_	22	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	T4	t0	NN	_	24	conj	_	_
27	.	.	.	_	6	p	_	_

1	Free	free	JJ	_	4	attr	_	_
2	thyroid	thyroid	NN	_	4	com	_	_
3	hormone	hormone	NN	_	4	com	_	_
4	levels	level	NNS	_	5	dep	_	_
5	remain	remain	VBP	_	0	root	_	_
6	unchanged	unchanged	JJ	_	5	dep	_	_
7	.	.	.	_	5	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	13	ppmod	_	_
3	,	,	,	_	13	p	_	_
4	a	a	DT	_	5	det	_	_
5	decrease	decrease	NN	_	13	dep	_	_
6	in	in	IN	_	7	case	_	_
7	PBI	pbi	NN	_	5	ppmod	_	_
8	and	and	CC	_	5	cc	_	_
9	radioactive	radioactive	JJ	_	11	attr	_	_
10	iodine	iodine	NN	_	11	com	_	_
11	uptake	uptake	NN	_	5	conj	_	_
12	may	may	MD	_	13	modal	_	_
13	occur	occur	VB	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	The	the	DT	_	3	det	_	_
2	following	follow	VBG	_	3	attr	_	_
3	agents	agent	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	certain	certain	JJ	_	7	attr	_	_
7	actions	action	NNS	_	5	obj	_	_
8	or	or	CC	_	7	cc	_	_
9	side	side	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	7	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	7	ppmod	_	_
13	:	:	:	_	7	p	_	_
14	drug2	drug0	NN	_	7	appo	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	e.g.	e.g.	FW	_	20	ppmod	_	_
19	,	,	,	_	20	p	_	_
20	drug4	drug0	NNS	_	16	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	16	p	_	_
23	drug5	drug0	NN	_	14	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug6	drug0	NN	_	14	conj	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	e.g.	e.g.	FW	_	29	ppmod	_	_
28	,	,	,	_	29	p	_	_
29	drug7	drug0	NN	_	25	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	,	,	,	_	25	p	_	_
32	drug8	drug0	NN	_	14	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug9	drug0	NN	_	14	conj	_	_
35	,	,	,	_	34	p	_	_
36	drug10	drug0	CD	_	14	conj	_	_
37	(	-lrb-	-LRB-	_	40	p	_	_
38	e.g.	e.g.	FW	_	40	ppmod	_	_
39	,	,	,	_	40	p	_	_
40	drug11	drug0	CD	_	36	num	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	,	,	,	_	36	p	_	_
43	drug12	drug0	CD	_	36	appo	_	_
44	and	and	CC	_	43	cc	_	_
45	drug13	drug0	CD	_	43	conj	_	_
46	,	,	,	_	36	p	_	_
47	drug14	drug0	CD	_	36	appo	_	_
48	,	,	,	_	36	p	_	_
49	drug15	drug0	CD	_	36	appo	_	_
50	,	,	,	_	36	p	_	_
51	and	and	CC	_	36	cc	_	_
52	other	other	JJ	_	53	attr	_	_
53	drugs	drug	NNS	_	14	conj	_	_
54	having	have	VBG	_	56	lv	_	_
55	anticholinergic	anticholinergic	JJ	_	56	attr	_	_
56	activity	activity	NN	_	53	acl	_	_
57	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	antagonize	antagonize	VBP	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	in	in	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	presence	presence	NN	_	1	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	increased	increase	VBN	_	8	attr	_	_
7	intraocular	intraocular	JJ	_	8	attr	_	_
8	pressure	pressure	NN	_	4	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	be	be	VB	_	0	root	_	_
11	hazardous	hazardous	JJ	_	10	dep	_	_
12	when	when	WRB	_	13	adv	_	_
13	taken	take	VBN	_	10	comp	_	_
14	concurrently	concurrently	RB	_	13	adv	_	_
15	with	with	IN	_	16	case	_	_
16	agents	agent	NNS	_	13	ppmod	_	_
17	such	such	JJ	_	19	adv	_	_
18	as	as	IN	_	19	case	_	_
19	drug2	drug0	NN	_	16	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	affect	affect	VB	_	0	root	_	_
4	gastrointestinal	gastrointestinal	JJ	_	5	attr	_	_
5	absorption	absorption	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	various	various	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	such	such	JJ	_	15	adv	_	_
11	as	as	IN	_	15	case	_	_
12	slowly	slowly	RB	_	13	adv	_	_
13	dissolving	dissolve	VBG	_	15	attr	_	_
14	dosage	dosage	NN	_	15	com	_	_
15	forms	form	NNS	_	8	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	;	;	:	_	3	p	_	_

1	increased	increase	VBN	_	4	attr	_	_
2	serum	serum	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	result	result	VB	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	antagonize	antagonize	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drugs	drug	NNS	_	5	ppmod	_	_
8	that	that	WDT	_	9	dep	_	_
9	alter	alter	VBP	_	7	relcl	_	_
10	gastrointestinal	gastrointestinal	JJ	_	11	attr	_	_
11	motility	motility	NN	_	9	obj	_	_
12	,	,	,	_	7	p	_	_
13	such	such	JJ	_	15	adv	_	_
14	as	as	IN	_	15	case	_	_
15	drug2	drug0	NN	_	7	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	interfere	interfere	VB	_	18	advcl	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	absorption	absorption	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	18	p	_	_
11	simultaneous	simultaneous	JJ	_	12	attr	_	_
12	use	use	NN	_	18	dep	_	_
13	of	of	IN	_	15	case	_	_
14	these	these	DT	_	15	det	_	_
15	drugs	drug	NNS	_	12	ppmod	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	avoided	avoid	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	The	the	DT	_	3	det	_	_
2	inhibiting	inhibiting	NN	_	3	com	_	_
3	effects	effect	NNS	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	on	on	IN	_	10	case	_	_
7	gastric	gastric	JJ	_	10	attr	_	_
8	hydrochloric	hydrochloric	JJ	_	10	attr	_	_
9	acid	acid	NN	_	10	com	_	_
10	secretion	secretion	NN	_	3	ppmod	_	_
11	are	be	VBP	_	12	aux	_	_
12	antagonized	antagonize	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	agents	agent	NNS	_	12	ppmod	_	_
15	used	use	VBN	_	14	acl	_	_
16	to	to	TO	_	17	aux	_	_
17	treat	treat	VB	_	15	comp	_	_
18	achlorhydria	achlorhydria	NN	_	17	obj	_	_
19	and	and	CC	_	14	cc	_	_
20	those	those	DT	_	14	conj	_	_
21	used	use	VBN	_	20	acl	_	_
22	to	to	TO	_	23	aux	_	_
23	test	test	VB	_	21	comp	_	_
24	gastric	gastric	JJ	_	25	attr	_	_
25	secretion	secretion	NN	_	23	obj	_	_
26	.	.	.	_	12	p	_	_

1	Since	since	IN	_	7	mark	_	_
2	drug1	drug0	NN	_	7	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug2	drug0	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	may	may	MD	_	7	modal	_	_
7	interact	interact	VB	_	21	advcl	_	_
8	with	with	IN	_	11	case	_	_
9	concurrently	concurrently	RB	_	10	adv	_	_
10	administered	administer	VBN	_	11	attr	_	_
11	drug3	drug0	NN	_	7	ppmod	_	_
12	,	,	,	_	21	p	_	_
13	periodic	periodic	JJ	_	16	attr	_	_
14	serum	serum	NN	_	16	com	_	_
15	level	level	NN	_	16	com	_	_
16	determinations	determination	NNS	_	21	dep	_	_
17	of	of	IN	_	19	case	_	_
18	these	these	DT	_	19	det	_	_
19	drugs	drug	NNS	_	16	ppmod	_	_
20	may	may	MD	_	21	modal	_	_
21	be	be	VB	_	0	root	_	_
22	necessary	necessary	JJ	_	21	dep	_	_
23	(	-lrb-	-LRB-	_	25	p	_	_
24	eg	eg	JJ	_	25	attr	_	_
25	drug4	drug0	NNS	_	22	prn	_	_
26	may	may	MD	_	27	modal	_	_
27	increase	increase	VB	_	25	acl	_	_
28	the	the	DT	_	30	det	_	_
29	plasma	plasma	NN	_	30	com	_	_
30	concentrations	concentration	NNS	_	27	obj	_	_
31	of	of	IN	_	32	case	_	_
32	drug5	drug0	NN	_	30	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	drug6	drug0	NN	_	32	conj	_	_
35	)	-rrb-	-RRB-	_	25	p	_	_
36	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	13	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	probably	probably	RB	_	4	com	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug3	drug0	NNS	_	3	conj	_	_
8	given	give	VBN	_	3	acl	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug4	drug0	NN	_	8	ppmod	_	_
12	can	can	MD	_	13	modal	_	_
13	cause	cause	VB	_	1	acl	_	_
14	unusually	unusually	RB	_	15	adv	_	_
15	large	large	JJ	_	18	attr	_	_
16	or	or	CC	_	15	cc	_	_
17	prolonged	prolonged	JJ	_	15	conj	_	_
18	losses	loss	NNS	_	13	obj	_	_
19	of	of	IN	_	20	case	_	_
20	fluid	fluid	NN	_	18	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	electrolytes	electrolyte	NNS	_	20	conj	_	_
23	.	.	.	_	1	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	When	when	WRB	_	8	adv	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	Tablets	tablet	NNS	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	used	use	VBN	_	16	advcl	_	_
9	with	with	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug3	drug0	NN	_	8	ppmod	_	_
12	,	,	,	_	16	p	_	_
13	care	care	NN	_	16	dep	_	_
14	must	must	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	taken	take	VBN	_	2	acl	_	_
17	,	,	,	_	16	p	_	_
18	especially	especially	RB	_	21	adv	_	_
19	during	during	IN	_	21	case	_	_
20	initial	initial	JJ	_	21	attr	_	_
21	therapy	therapy	NN	_	16	ppmod	_	_
22	.	.	.	_	2	p	_	_

1	Dosage	dosage	NN	_	2	com	_	_
2	adjustments	adjustment	NNS	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	necessary	necessary	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	:	:	:	_	1	p	_	_
8	The	the	DT	_	10	det	_	_
9	hypotensive	hypotensive	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	16	dep	_	_
11	of	of	IN	_	13	case	_	_
12	these	these	DT	_	13	det	_	_
13	drugs	drug	NNS	_	10	ppmod	_	_
14	may	may	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	potentiated	potentiate	VBN	_	1	acl	_	_
17	by	by	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	volume	volume	NN	_	20	com	_	_
20	contraction	contraction	NN	_	16	ppmod	_	_
21	that	that	WDT	_	24	dep	_	_
22	may	may	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	associated	associate	VBN	_	20	relcl	_	_
25	with	with	IN	_	27	case	_	_
26	drug4	drug0	NN	_	27	com	_	_
27	therapy	therapy	NN	_	24	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	-induced	-induced	JJ	_	5	attr	_	_
5	hypokalemia	hypokalemia	NN	_	1	appo	_	_
6	can	can	MD	_	7	modal	_	_
7	increase	increase	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	sensitivity	sensitivity	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	myocardium	myocardium	NN	_	9	ppmod	_	_
13	to	to	TO	_	14	aux	_	_
14	drug3	drug0	NN	_	9	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	Serious	serious	JJ	_	2	attr	_	_
2	arrhythmias	arrhythmia	NNS	_	4	dep	_	_
3	can	can	MD	_	4	modal	_	_
4	result	result	VB	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	May	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	1	acl	_	_
7	the	the	DT	_	8	det	_	_
8	risk	risk	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	hypokalemia	hypokalemia	NN	_	8	ppmod	_	_
11	and	and	CC	_	6	cc	_	_
12	increase	increase	VB	_	6	conj	_	_
13	salt	salt	NN	_	12	obj	_	_
14	and	and	CC	_	13	cc	_	_
15	water	water	NN	_	16	com	_	_
16	retention	retention	NN	_	13	conj	_	_
17	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	attr	_	_
2	:	:	:	_	5	p	_	_
3	Serum	serum	NN	_	5	com	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	levels	level	NNS	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	increase	increase	VB	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	-induced	-induced	JJ	_	5	attr	_	_
5	hypokalemia	hypokalemia	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	enhance	enhance	VB	_	23	advcl	_	_
8	neuromuscular	neuromuscular	NN	_	10	com	_	_
9	blocking	blocking	NN	_	10	com	_	_
10	effects	effect	NNS	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	such	such	JJ	_	7	prn	_	_
15	as	as	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	)	-rrb-	-RRB-	_	14	p	_	_
18	the	the	DT	_	21	det	_	_
19	most	most	RBS	_	20	adv	_	_
20	serious	serious	JJ	_	21	attr	_	_
21	effect	effect	NN	_	23	dep	_	_
22	would	would	MD	_	23	modal	_	_
23	be	be	VB	_	1	acl	_	_
24	respiratory	respiratory	JJ	_	25	attr	_	_
25	depression	depression	NN	_	23	obj	_	_
26	which	which	WDT	_	28	dep	_	_
27	could	could	MD	_	28	modal	_	_
28	proceed	proceed	VB	_	25	relcl	_	_
29	to	to	TO	_	30	aux	_	_
30	apnea	apnea	NN	_	28	ppmod	_	_
31	.	.	.	_	1	p	_	_

1	Accordingly	accordingly	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	be	be	VB	_	0	root	_	_
6	advisable	advisable	JJ	_	5	dep	_	_
7	to	to	TO	_	10	aux	_	_
8	discontinue	discontinue	NN	_	10	com	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	Tablets	tablet	NNS	_	6	ppmod	_	_
11	three	#crd#	CD	_	12	num	_	_
12	days	day	NNS	_	10	appo	_	_
13	before	before	IN	_	15	case	_	_
14	elective	elective	JJ	_	15	attr	_	_
15	surgery	surgery	NN	_	12	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	Other	other	JJ	_	4	attr	_	_
4	drug2	drug0	NNS	_	1	conj	_	_
5	:	:	:	_	4	p	_	_
6	May	may	MD	_	7	modal	_	_
7	decrease	decrease	VB	_	0	root	_	_
8	the	the	DT	_	10	det	_	_
9	antihypertensive	antihypertensive	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	7	obj	_	_
11	of	of	IN	_	13	case	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	Tablets	tablet	NNS	_	10	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	decrease	decrease	VB	_	1	acl	_	_
6	arterial	arterial	JJ	_	7	attr	_	_
7	responsiveness	responsiveness	NN	_	5	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	5	p	_	_
11	but	but	CC	_	5	cc	_	_
12	this	this	DT	_	13	det	_	_
13	diminution	diminution	NN	_	14	dep	_	_
14	is	be	VBZ	_	5	conj	_	_
15	not	not	RB	_	14	neg	_	_
16	sufficient	sufficient	JJ	_	14	dep	_	_
17	to	to	TO	_	18	aux	_	_
18	preclude	preclude	VB	_	16	comp	_	_
19	effectiveness	effectiveness	NN	_	18	obj	_	_
20	of	of	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	pressor	pressor	JJ	_	23	attr	_	_
23	agent	agent	NN	_	19	ppmod	_	_
24	for	for	IN	_	26	case	_	_
25	therapeutic	therapeutic	JJ	_	26	attr	_	_
26	use	use	NN	_	23	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	Efficacy	efficacy	NN	_	1	appo	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	decreased	decrease	VBN	_	0	root	_	_
7	due	due	JJ	_	11	adv	_	_
8	to	to	TO	_	11	aux	_	_
9	urinary	urinary	JJ	_	11	attr	_	_
10	alkalizing	alkalizing	JJ	_	11	attr	_	_
11	effect	effect	NN	_	6	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	as	as	RB	_	6	com	_	_
6	well	well	RB	_	3	cc	_	_
7	as	as	IN	_	6	com	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug3	drug0	NN	_	1	conj	_	_
10	,	,	,	_	9	p	_	_
11	may	may	MD	_	12	modal	_	_
12	affect	affect	VB	_	0	root	_	_
13	the	the	DT	_	15	det	_	_
14	hypoprothrombinemic	hypoprothrombinemic	JJ	_	15	attr	_	_
15	response	response	NN	_	12	obj	_	_
16	to	to	TO	_	17	aux	_	_
17	drug4	drug0	NN	_	15	ppmod	_	_
18	;	;	:	_	12	p	_	_

1	dosage	dosage	NN	_	2	com	_	_
2	adjustments	adjustment	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	necessary	necessary	JJ	_	4	dep	_	_
6	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	resulted	result	VBD	_	0	root	_	_
7	in	in	IN	_	11	case	_	_
8	increased	increase	VBN	_	11	attr	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	6	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	57	0	CD	_	11	num	_	_
14	%	%	NN	_	13	meta	_	_
15	)	-rrb-	-RRB-	_	13	p	_	_
16	,	,	,	_	11	p	_	_
17	increased	increase	VBN	_	21	attr	_	_
18	plasma	plasma	NN	_	21	com	_	_
19	bismuth	bismuth	NN	_	21	com	_	_
20	trough	trough	NN	_	21	com	_	_
21	concentrations	concentration	NNS	_	11	conj	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	48	0	CD	_	21	num	_	_
24	%	%	NN	_	23	meta	_	_
25	)	-rrb-	-RRB-	_	23	p	_	_
26	,	,	,	_	21	p	_	_
27	and	and	CC	_	21	cc	_	_
28	increased	increase	VBN	_	31	attr	_	_
29	drug4	drug0	NN	_	31	com	_	_
30	plasma	plasma	NN	_	31	com	_	_
31	concentrations	concentration	NNS	_	11	conj	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	31	0	CD	_	31	num	_	_
34	%	%	NN	_	33	meta	_	_
35	)	-rrb-	-RRB-	_	33	p	_	_
36	.	.	.	_	6	p	_	_

1	Coadministration	coadministration	NN	_	4	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	results	result	VBZ	_	0	root	_	_
5	in	in	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	slight	slight	JJ	_	8	attr	_	_
8	decrease	decrease	NN	_	4	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	rate	rate	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	absorption	absorption	NN	_	11	ppmod	_	_
15	that	that	WDT	_	16	dep	_	_
16	is	be	VBZ	_	8	relcl	_	_
17	clinically	clinically	RB	_	18	adv	_	_
18	unimportant	unimportant	JJ	_	16	dep	_	_
19	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	12	dep	_	_
2	with	with	IN	_	5	case	_	_
3	a	a	DT	_	5	det	_	_
4	high	high	JJ	_	5	attr	_	_
5	dose	dose	NN	_	1	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	170	0	CD	_	10	num	_	_
10	mEq	meq	NN	_	5	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	results	result	VBZ	_	0	root	_	_
13	in	in	IN	_	17	case	_	_
14	a	a	DT	_	17	det	_	_
15	28	0	CD	_	17	num	_	_
16	%	%	NN	_	15	meta	_	_
17	decrease	decrease	NN	_	12	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	12	cc	_	_
24	may	may	MD	_	25	modal	_	_
25	decrease	decrease	VB	_	12	conj	_	_
26	plasma	plasma	NN	_	27	com	_	_
27	concentrations	concentration	NNS	_	25	obj	_	_
28	of	of	IN	_	29	case	_	_
29	bismuth	bismuth	NN	_	27	ppmod	_	_
30	from	from	IN	_	31	case	_	_
31	drug3	drug0	NN	_	25	ppmod	_	_
32	.	.	.	_	12	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	clinically	clinically	RB	_	5	adv	_	_
5	insignificant	insignificant	JJ	_	3	dep	_	_
6	.	.	.	_	3	p	_	_

1	For	for	IN	_	2	case	_	_
2	information	information	NN	_	10	ppmod	_	_
3	on	on	IN	_	5	case	_	_
4	drug	drug	NN	_	5	com	_	_
5	interactions	interaction	NNS	_	2	ppmod	_	_
6	associated	associate	VBN	_	5	acl	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	10	p	_	_
10	refer	refer	VBP	_	0	root	_	_
11	to	to	TO	_	15	aux	_	_
12	the	the	DT	_	15	det	_	_
13	drug2	drug0	NN	_	15	com	_	_
14	package	package	NN	_	15	com	_	_
15	insert	insert	NN	_	10	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	other	other	JJ	_	12	attr	_	_
11	local	local	JJ	_	12	attr	_	_
12	drug2	drug0	NNS	_	9	obj	_	_
13	or	or	CC	_	12	cc	_	_
14	agents	agent	NNS	_	12	conj	_	_
15	structurally	structurally	RB	_	16	adv	_	_
16	related	related	JJ	_	12	attr	_	_
17	to	to	TO	_	18	aux	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	4	p	_	_
20	since	since	IN	_	27	mark	_	_
21	the	the	DT	_	23	det	_	_
22	toxic	toxic	JJ	_	23	attr	_	_
23	effects	effect	NNS	_	27	dep	_	_
24	of	of	IN	_	26	case	_	_
25	these	these	DT	_	26	det	_	_
26	drugs	drug	NNS	_	23	ppmod	_	_
27	are	be	VBP	_	4	comp	_	_
28	additive	additive	JJ	_	27	dep	_	_
29	.	.	.	_	4	p	_	_

1	Cytochrome	cytochrome	NN	_	2	com	_	_
2	P4501A2	p0a0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	involved	involve	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	formation	formation	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	the	the	DT	_	13	det	_	_
12	major	major	JJ	_	13	attr	_	_
13	metabolite	metabolite	NN	_	9	appo	_	_
14	.	.	.	_	4	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vivo	vivo	FW	_	10	adv	_	_
3	,	,	,	_	10	p	_	_
4	the	the	DT	_	6	det	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	clearance	clearance	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	reduced	reduce	VBN	_	0	root	_	_
11	by	by	IN	_	12	case	_	_
12	70	0	CD	_	10	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	during	during	IN	_	15	case	_	_
15	coadministration	coadministration	NN	_	10	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	25	0	CD	_	20	num	_	_
20	mg	mg	NN	_	17	prn	_	_
21	bid	bid	JJ	_	20	attr	_	_
22	for	for	IN	_	24	case	_	_
23	2	0	CD	_	24	num	_	_
24	days	day	NNS	_	21	ppmod	_	_
25	)	-rrb-	-RRB-	_	20	p	_	_
26	,	,	,	_	17	p	_	_
27	a	a	DT	_	32	det	_	_
28	selective	selective	JJ	_	32	attr	_	_
29	and	and	CC	_	28	cc	_	_
30	potent	potent	JJ	_	28	conj	_	_
31	CYP1A2	cyp0a0	NN	_	32	com	_	_
32	inhibitor	inhibitor	NN	_	17	appo	_	_
33	.	.	.	_	10	p	_	_

1	Thus	thus	RB	_	20	adv	_	_
2	strong	strong	JJ	_	3	attr	_	_
3	inhibitors	inhibitor	NNS	_	20	dep	_	_
4	of	of	IN	_	6	case	_	_
5	cytochrome	cytochrome	NN	_	6	com	_	_
6	P4501A2	p0a0	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	such	such	JJ	_	10	adv	_	_
9	as	as	IN	_	10	case	_	_
10	drug1	drug0	NN	_	3	ppmod	_	_
11	,	,	,	_	3	p	_	_
12	given	give	VBN	_	3	acl	_	_
13	concomitantly	concomitantly	RB	_	12	adv	_	_
14	during	during	IN	_	15	case	_	_
15	administration	administration	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	3	p	_	_
19	can	can	MD	_	20	modal	_	_
20	interact	interact	VB	_	0	root	_	_
21	with	with	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	leading	lead	VBG	_	22	acl	_	_
24	to	to	TO	_	28	aux	_	_
25	increased	increase	VBN	_	28	attr	_	_
26	drug4	drug0	NN	_	28	com	_	_
27	plasma	plasma	NN	_	28	com	_	_
28	levels	level	NNS	_	23	ppmod	_	_
29	.	.	.	_	20	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	9	adv	_	_
6	CYP1A2	cyp0a0	NN	_	7	com	_	_
7	inhibitors	inhibitor	NNS	_	9	dep	_	_
8	are	be	VBP	_	9	aux	_	_
9	coadministered	coadministered	VBN	_	4	comp	_	_
10	.	.	.	_	4	p	_	_

1	Possible	possible	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	21	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	known	know	VBN	_	4	acl	_	_
6	to	to	TO	_	8	aux	_	_
7	be	be	VB	_	8	aux	_	_
8	metabolized	metabolize	VBN	_	5	comp	_	_
9	by	by	IN	_	10	case	_	_
10	CYP1A2	cyp0a0	NN	_	8	ppmod	_	_
11	via	via	IN	_	13	case	_	_
12	competitive	competitive	JJ	_	13	attr	_	_
13	inhibition	inhibition	NN	_	8	ppmod	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	drug1	drug0	NN	_	13	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	may	may	MD	_	21	modal	_	_
20	also	also	RB	_	21	adv	_	_
21	occur	occur	VB	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	Coadministration	coadministration	NN	_	28	dep	_	_
2	of	of	IN	_	7	case	_	_
3	a	a	DT	_	7	det	_	_
4	selective	selective	JJ	_	7	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	potent	potent	JJ	_	4	conj	_	_
7	inhibitor	inhibitor	NN	_	1	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	CYP3A4	cyp0a0	NN	_	7	ppmod	_	_
10	,	,	,	_	7	p	_	_
11	drug1	drug0	NN	_	7	appo	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	100	0	CD	_	14	num	_	_
14	mg	mg	NN	_	15	com	_	_
15	bid	bid	NN	_	11	prn	_	_
16	for	for	IN	_	18	case	_	_
17	2	0	CD	_	18	num	_	_
18	days	day	NNS	_	15	ppmod	_	_
19	with	with	IN	_	21	case	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	infusion	infusion	NN	_	15	ppmod	_	_
22	administered	administer	VBN	_	21	acl	_	_
23	1	0	CD	_	24	num	_	_
24	hour	hour	NN	_	26	dat	_	_
25	after	after	IN	_	26	case	_	_
26	drug3	drug0	NN	_	22	ppmod	_	_
27	)	-rrb-	-RRB-	_	15	p	_	_
28	caused	cause	VBD	_	0	root	_	_
29	a	a	DT	_	32	det	_	_
30	15	0	CD	_	32	num	_	_
31	%	%	NN	_	30	meta	_	_
32	reduction	reduction	NN	_	28	obj	_	_
33	in	in	IN	_	36	case	_	_
34	in-vivo	in-vivo	JJ	_	36	attr	_	_
35	plasma	plasma	NN	_	36	com	_	_
36	clearance	clearance	NN	_	32	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug4	drug0	NN	_	36	ppmod	_	_
39	.	.	.	_	28	p	_	_

1	Additives	additive	NNS	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	be	be	VB	_	0	root	_	_
4	incompatible	incompatible	JJ	_	3	dep	_	_
5	;	;	:	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	are	be	VBP	_	0	root	_	_
5	incompatible	incompatible	JJ	_	4	dep	_	_
6	with	with	IN	_	8	case	_	_
7	drug3	drug0	NN	_	8	com	_	_
8	solution	solution	NN	_	5	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	addition	addition	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	to	to	TO	_	7	aux	_	_
6	parenteral	parenteral	JJ	_	7	attr	_	_
7	solutions	solution	NNS	_	2	ppmod	_	_
8	containing	contain	VBG	_	7	acl	_	_
9	drug2	drug0	NN	_	8	obj	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	avoided	avoid	VBN	_	0	root	_	_
13	,	,	,	_	12	p	_	_
14	except	except	IN	_	20	case	_	_
15	where	where	WRB	_	20	adv	_	_
16	compatibility	compatibility	NN	_	20	dep	_	_
17	has	have	VBZ	_	20	aux	_	_
18	been	be	VBN	_	20	aux	_	_
19	previously	previously	RB	_	20	adv	_	_
20	established	establish	VBN	_	12	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	Precipitation	precipitation	NN	_	5	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	haze	haze	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	result	result	VB	_	0	root	_	_
6	from	from	IN	_	9	case	_	_
7	sodium	sodium	NN	_	9	com	_	_
8	bicarbonate-calcium	bicarbonate-calcium	NN	_	9	com	_	_
9	admixtures	admixture	NNS	_	5	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	NOTE	note	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Do	do	VBP	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	use	use	VB	_	1	acl	_	_
6	the	the	DT	_	7	det	_	_
7	injection	injection	NN	_	5	obj	_	_
8	if	if	IN	_	10	mark	_	_
9	it	it	PRP	_	10	dep	_	_
10	contains	contain	VBZ	_	5	comp	_	_
11	precipitate	precipitate	NN	_	10	obj	_	_
12	.	.	.	_	1	p	_	_

1	Additives	additive	NNS	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	be	be	VB	_	0	root	_	_
4	incompatible	incompatible	JJ	_	3	dep	_	_
5	.	.	.	_	3	p	_	_

1	Consult	consult	VB	_	0	root	_	_
2	with	with	IN	_	3	case	_	_
3	pharmacist	pharmacist	NN	_	1	ppmod	_	_
4	,	,	,	_	1	p	_	_
5	if	if	IN	_	6	mark	_	_
6	available	available	JJ	_	1	comp	_	_
7	.	.	.	_	1	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	introducing	introduce	VBG	_	5	advcl	_	_
3	additives	additive	NNS	_	2	obj	_	_
4	,	,	,	_	5	p	_	_
5	use	use	VBP	_	0	root	_	_
6	aseptic	aseptic	JJ	_	7	attr	_	_
7	technique	technique	NN	_	5	obj	_	_
8	,	,	,	_	7	p	_	_
9	mix	mix	NN	_	7	appo	_	_
10	thoroughly	thoroughly	RB	_	5	adv	_	_
11	and	and	CC	_	5	cc	_	_
12	do	do	VBP	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	store	store	VB	_	5	conj	_	_
15	.	.	.	_	5	p	_	_

1	Drug-Drug	drug-drug	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	Effect	effect	NN	_	2	appo	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug2	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	Metabolism	metabolism	NN	_	3	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	Other	other	JJ	_	14	attr	_	_
14	Drugs	drug	NNS	_	11	ppmod	_	_
15	:	:	:	_	2	p	_	_
16	drug3	drug0	NN	_	19	dep	_	_
17	is	be	VBZ	_	19	aux	_	_
18	primarily	primarily	RB	_	19	adv	_	_
19	metabolized	metabolize	VBN	_	2	acl	_	_
20	through	through	IN	_	21	case	_	_
21	hydrolysis	hydrolysis	NN	_	19	ppmod	_	_
22	by	by	IN	_	23	case	_	_
23	esterases	esterases	NNS	_	21	ppmod	_	_
24	.	.	.	_	2	p	_	_

1	Minimal	minimal	JJ	_	2	attr	_	_
2	metabolism	metabolism	NN	_	3	dep	_	_
3	occurs	occur	VBZ	_	0	root	_	_
4	via	via	IN	_	9	case	_	_
5	the	the	DT	_	9	det	_	_
6	major	major	JJ	_	9	attr	_	_
7	cytochrome	cytochrome	NN	_	9	com	_	_
8	P450	p0	NN	_	9	com	_	_
9	isoenzymes	isoenzymes	NNS	_	3	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	Based	base	VBN	_	5	adv	_	_
2	on	on	IN	_	5	case	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	studies	study	NNS	_	20	ppmod	_	_
6	,	,	,	_	20	p	_	_
7	no	no	DT	_	10	det	_	_
8	pharmacokinetic	pharmacokinetic	JJ	_	10	attr	_	_
9	drug	drug	NN	_	10	com	_	_
10	interactions	interaction	NNS	_	20	dep	_	_
11	with	with	IN	_	12	case	_	_
12	drugs	drug	NNS	_	10	ppmod	_	_
13	metabolized	metabolize	VBN	_	12	acl	_	_
14	by	by	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	following	following	JJ	_	18	attr	_	_
17	isoenzyme	isoenzyme	NN	_	18	com	_	_
18	systems	system	NNS	_	13	ppmod	_	_
19	are	be	VBP	_	20	aux	_	_
20	expected	expect	VBN	_	0	root	_	_
21	:	:	:	_	20	p	_	_
22	CYP1A2	cyp0a0	NN	_	20	dep	_	_
23	,	,	,	_	22	p	_	_
24	CYP2D6	cyp0d0	NN	_	22	conj	_	_
25	,	,	,	_	24	p	_	_
26	CYP3A4/5	cyp0a0	NN	_	22	conj	_	_
27	,	,	,	_	26	p	_	_
28	CYP2E1	cyp0e0	NN	_	22	conj	_	_
29	,	,	,	_	28	p	_	_
30	CYP2C9	cyp0c0	NN	_	22	conj	_	_
31	,	,	,	_	30	p	_	_
32	CYP2C8	cyp0c0	NN	_	22	conj	_	_
33	,	,	,	_	32	p	_	_
34	or	or	CC	_	32	cc	_	_
35	CYP2C19	cyp0c0	NN	_	22	conj	_	_
36	.	.	.	_	20	p	_	_

1	No	no	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	7	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	drug5	drug0	NN	_	7	conj	_	_
17	in	in	IN	_	18	case	_	_
18	studies	study	NNS	_	5	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	healthy	healthy	JJ	_	21	attr	_	_
21	volunteers	volunteer	NNS	_	18	ppmod	_	_
22	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	elevation	elevation	NN	_	11	dep	_	_
3	of	of	IN	_	5	case	_	_
4	prothrombin	prothrombin	NN	_	5	com	_	_
5	time	time	NN	_	2	ppmod	_	_
6	induced	induce	VBN	_	2	acl	_	_
7	by	by	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	is	be	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	affected	affect	VBN	_	0	root	_	_
12	by	by	IN	_	13	case	_	_
13	administration	administration	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	11	p	_	_

1	Effect	effect	NN	_	20	dep	_	_
2	of	of	IN	_	4	case	_	_
3	Other	other	JJ	_	4	attr	_	_
4	Drugs	drug	NNS	_	1	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	Metabolism	metabolism	NN	_	1	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	:	:	:	_	9	p	_	_
11	Drugs	drug	NNS	_	9	appo	_	_
12	that	that	WDT	_	13	dep	_	_
13	induce	induce	VBP	_	11	relcl	_	_
14	or	or	CC	_	13	cc	_	_
15	inhibit	inhibit	VBP	_	13	conj	_	_
16	CYP450	cyp0	NN	_	17	com	_	_
17	metabolism	metabolism	NN	_	15	obj	_	_
18	are	be	VBP	_	20	aux	_	_
19	not	not	RB	_	20	neg	_	_
20	expected	expect	VBN	_	0	root	_	_
21	to	to	TO	_	22	aux	_	_
22	alter	alter	VB	_	20	comp	_	_
23	the	the	DT	_	24	det	_	_
24	metabolism	metabolism	NN	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	20	p	_	_

1	Single	single	JJ	_	4	attr	_	_
2	dose	dose	NN	_	4	attr	_	_
3	pharmacokinetic	pharmacokinetic	JJ	_	4	attr	_	_
4	studies	study	NNS	_	5	dep	_	_
5	demonstrated	demonstrate	VBD	_	0	root	_	_
6	that	that	IN	_	14	mark	_	_
7	the	the	DT	_	8	det	_	_
8	metabolism	metabolism	NN	_	14	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	is	be	VBZ	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	significantly	significantly	RB	_	14	adv	_	_
14	affected	affect	VBN	_	5	comp	_	_
15	by	by	IN	_	17	case	_	_
16	concurrent	concurrent	JJ	_	17	attr	_	_
17	administration	administration	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug4	drug0	NN	_	19	conj	_	_
24	,	,	,	_	23	p	_	_
25	or	or	CC	_	23	cc	_	_
26	drug5	drug0	NN	_	19	conj	_	_
27	.	.	.	_	5	p	_	_

1	Population	population	NN	_	3	com	_	_
2	PK	pk	NN	_	3	com	_	_
3	analysis	analysis	NN	_	10	dep	_	_
4	with	with	IN	_	6	case	_	_
5	a	a	DT	_	6	det	_	_
6	database	database	NN	_	3	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	625	0	CD	_	9	num	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	showed	show	VBD	_	0	root	_	_
11	that	that	IN	_	18	mark	_	_
12	the	the	DT	_	13	det	_	_
13	pharmacokinetics	pharmacokinetics	NNS	_	18	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	were	be	VBD	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	influenced	influence	VBN	_	10	comp	_	_
19	by	by	IN	_	22	case	_	_
20	commonly	commonly	RB	_	21	adv	_	_
21	prescribed	prescribe	VBN	_	22	attr	_	_
22	medications	medication	NNS	_	18	ppmod	_	_
23	such	such	JJ	_	25	adv	_	_
24	as	as	IN	_	25	case	_	_
25	drug2	drug0	NN	_	22	ppmod	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	n=77	n=0	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	,	,	,	_	25	p	_	_
30	drug3	drug0	NN	_	25	appo	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	n=72	n=0	NN	_	25	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	,	,	,	_	25	p	_	_
35	drug4	drug0	NN	_	25	conj	_	_
36	(	-lrb-	-LRB-	_	35	p	_	_
37	n=75	n=0	CD	_	35	num	_	_
38	)	-rrb-	-RRB-	_	35	p	_	_
39	,	,	,	_	35	p	_	_
40	drug5	drug0	NN	_	25	conj	_	_
41	(	-lrb-	-LRB-	_	42	p	_	_
42	n=21	n=0	NN	_	40	prn	_	_
43	)	-rrb-	-RRB-	_	42	p	_	_
44	,	,	,	_	40	p	_	_
45	drug6	drug0	NN	_	25	conj	_	_
46	(	-lrb-	-LRB-	_	45	p	_	_
47	n=79	n=0	CD	_	45	num	_	_
48	)	-rrb-	-RRB-	_	45	p	_	_
49	,	,	,	_	45	p	_	_
50	drug7	drug0	NN	_	25	conj	_	_
51	(	-lrb-	-LRB-	_	50	p	_	_
52	n=70	n=0	CD	_	50	num	_	_
53	)	-rrb-	-RRB-	_	50	p	_	_
54	,	,	,	_	50	p	_	_
55	drug8	drug0	NN	_	25	conj	_	_
56	(	-lrb-	-LRB-	_	57	p	_	_
57	n=177	n=0	NN	_	55	prn	_	_
58	)	-rrb-	-RRB-	_	57	p	_	_
59	,	,	,	_	55	p	_	_
60	drug9	drug0	NN	_	25	conj	_	_
61	(	-lrb-	-LRB-	_	62	p	_	_
62	n=35	n=0	NN	_	60	prn	_	_
63	)	-rrb-	-RRB-	_	62	p	_	_
64	,	,	,	_	60	p	_	_
65	and	and	CC	_	60	cc	_	_
66	drug10	drug0	NN	_	25	conj	_	_
67	(	-lrb-	-LRB-	_	68	p	_	_
68	n=15	n=0	NN	_	66	prn	_	_
69	)	-rrb-	-RRB-	_	68	p	_	_
70	.	.	.	_	10	p	_	_

1	Use	use	NN	_	13	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	:	:	:	_	13	p	_	_
5	Because	because	IN	_	8	case	_	_
6	of	of	IN	_	8	case	_	_
7	their	their	PRP$	_	8	poss	_	_
8	mechanism	mechanism	NN	_	13	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	action	action	NN	_	8	ppmod	_	_
11	,	,	,	_	13	p	_	_
12	drug2	drug0	NNS	_	13	dep	_	_
13	have	have	VBP	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	potential	potential	NN	_	13	obj	_	_
16	to	to	TO	_	17	aux	_	_
17	interfere	interfere	VB	_	15	acl	_	_
18	with	with	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	activity	activity	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	13	p	_	_

1	Use	use	NN	_	13	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	Other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	3	conj	_	_
7	:	:	:	_	13	p	_	_
8	A	a	DT	_	10	det	_	_
9	synergistic	synergistic	JJ	_	10	attr	_	_
10	effect	effect	NN	_	13	dep	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	expected	expect	VBN	_	0	root	_	_
14	when	when	WRB	_	17	adv	_	_
15	drug3	drug0	NN	_	17	dep	_	_
16	are	be	VBP	_	17	aux	_	_
17	given	give	VBN	_	13	comp	_	_
18	concurrently	concurrently	RB	_	17	adv	_	_
19	with	with	IN	_	20	case	_	_
20	drug4	drug0	NN	_	17	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	similar	similar	JJ	_	23	attr	_	_
23	drug5	drug0	NN	_	20	conj	_	_
24	or	or	CC	_	23	cc	_	_
25	drug6	drug0	NNS	_	20	conj	_	_
26	such	such	JJ	_	28	adv	_	_
27	as	as	IN	_	28	case	_	_
28	drug7	drug0	NN	_	25	ppmod	_	_
29	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Reports	report	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug2	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	diminish	diminish	VB	_	3	comp	_	_
8	the	the	DT	_	10	det	_	_
9	antihypertensive	antihypertensive	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	given	give	VBN	_	6	lv	_	_
6	consideration	consideration	NN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	concomitantly	concomitantly	RB	_	6	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	6	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	15	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	1000	0	CD	_	9	num	_	_
9	mg	mg	NN	_	10	com	_	_
10	TID	tid	NN	_	6	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	to	to	TO	_	14	aux	_	_
13	healthy	healthy	JJ	_	14	attr	_	_
14	volunteers	volunteer	NNS	_	4	ppmod	_	_
15	tended	tend	VBD	_	1	acl	_	_
16	to	to	TO	_	17	aux	_	_
17	increase	increase	VB	_	15	comp	_	_
18	the	the	DT	_	19	det	_	_
19	AUC	auc	NN	_	17	obj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	10	0	CD	_	19	num	_	_
22	%	%	NN	_	21	meta	_	_
23	)	-rrb-	-RRB-	_	21	p	_	_
24	and	and	CC	_	19	cc	_	_
25	Cmax	cmax	NN	_	19	conj	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	24	0	CD	_	25	num	_	_
28	%	%	NN	_	27	meta	_	_
29	)	-rrb-	-RRB-	_	27	p	_	_
30	of	of	IN	_	31	case	_	_
31	drug3	drug0	NN	_	19	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	interaction	interaction	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	known	know	VBN	_	0	root	_	_
10	;	;	:	_	9	p	_	_

1	however	however	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	as	as	IN	_	6	case	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	17	ppmod	_	_
7	,	,	,	_	17	p	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	17	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	is	be	VBZ	_	17	aux	_	_
15	not	not	RB	_	17	neg	_	_
16	generally	generally	RB	_	17	adv	_	_
17	recommended	recommend	VBN	_	0	root	_	_
18	because	because	IN	_	21	case	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	potential	potential	NN	_	17	ppmod	_	_
22	for	for	IN	_	25	case	_	_
23	increased	increase	VBN	_	25	attr	_	_
24	adverse	adverse	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	21	ppmod	_	_
26	.	.	.	_	17	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	low-dose	low-dose	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	result	result	VB	_	0	root	_	_
10	in	in	IN	_	13	case	_	_
11	an	an	DT	_	13	det	_	_
12	increased	increase	VBN	_	13	attr	_	_
13	rate	rate	NN	_	9	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	GI	gi	NN	_	16	com	_	_
16	ulceration	ulceration	NN	_	13	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	other	other	JJ	_	19	attr	_	_
19	complications	complication	NNS	_	16	conj	_	_
20	,	,	,	_	9	p	_	_
21	compared	compare	VBN	_	9	comp	_	_
22	to	to	TO	_	23	aux	_	_
23	use	use	NN	_	21	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	alone	alone	RB	_	25	adv	_	_
27	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	is	be	VBZ	_	5	aux	_	_
3	not	not	RB	_	5	neg	_	_
4	a	a	DT	_	5	det	_	_
5	substitute	substitute	VB	_	0	root	_	_
6	for	for	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	for	for	IN	_	10	case	_	_
9	cardiovascular	cardiovascular	JJ	_	10	attr	_	_
10	prophylaxis	prophylaxis	NN	_	5	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Pretreatment	pretreatment	NN	_	10	dep	_	_
4	for	for	IN	_	6	case	_	_
5	four	#crd#	CD	_	6	num	_	_
6	days	day	NNS	_	3	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	3	ppmod	_	_
9	significantly	significantly	RB	_	10	adv	_	_
10	increased	increase	VBD	_	1	acl	_	_
11	the	the	DT	_	12	det	_	_
12	clearance	clearance	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	by	by	IN	_	16	case	_	_
16	50	0	CD	_	12	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	dep	_	_
2	resulted	result	VBD	_	0	root	_	_
3	in	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	decrease	decrease	NN	_	2	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	t1/2	t0	NN	_	5	ppmod	_	_
8	,	,	,	_	11	p	_	_
9	from	from	IN	_	11	case	_	_
10	19.2	0	CD	_	11	num	_	_
11	hours	hour	NNS	_	7	prn	_	_
12	to	to	TO	_	14	aux	_	_
13	12.5	0	CD	_	14	num	_	_
14	hours	hour	NNS	_	11	ppmod	_	_
15	,	,	,	_	11	p	_	_
16	and	and	CC	_	5	cc	_	_
17	a	a	DT	_	20	det	_	_
18	35	0	CD	_	20	num	_	_
19	%	%	NN	_	20	meta	_	_
20	reduction	reduction	NN	_	5	conj	_	_
21	in	in	IN	_	22	case	_	_
22	AUC	auc	NN	_	20	ppmod	_	_
23	.	.	.	_	2	p	_	_

1	This	this	DT	_	2	dep	_	_
2	suggests	suggest	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	existence	existence	NN	_	2	obj	_	_
5	of	of	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	recirculation	recirculation	NN	_	8	com	_	_
8	pathway	pathway	NN	_	4	ppmod	_	_
9	for	for	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	gastrointestinal	gastrointestinal	JJ	_	14	attr	_	_
14	tract	tract	NN	_	4	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	relevance	relevance	NN	_	10	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	interaction	interaction	NN	_	3	ppmod	_	_
7	has	have	VBZ	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	established	establish	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	12	dep	_	_
5	of	of	IN	_	7	case	_	_
6	200	0	CD	_	7	num	_	_
7	mg	mg	NN	_	4	ppmod	_	_
8	drug2	drug0	JJ	_	7	attr	_	_
9	QID	qid	JJ	_	7	attr	_	_
10	did	do	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	alter	alter	VB	_	1	acl	_	_
13	the	the	DT	_	15	det	_	_
14	single-dose	single-dose	JJ	_	15	attr	_	_
15	pharmacokinetics	pharmacokinetics	NNS	_	12	obj	_	_
16	of	of	IN	_	19	case	_	_
17	30	0	CD	_	18	num	_	_
18	mg	mg	NN	_	19	com	_	_
19	drug3	drug0	NN	_	15	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	15	0	CD	_	5	num	_	_
5	mg	mg	NN	_	1	appo	_	_
6	once	once	RB	_	7	adv	_	_
7	daily	daily	JJ	_	5	attr	_	_
8	for	for	IN	_	10	case	_	_
9	7	0	CD	_	10	num	_	_
10	days	day	NNS	_	7	ppmod	_	_
11	did	do	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	alter	alter	VB	_	0	root	_	_
14	the	the	DT	_	17	det	_	_
15	plasma	plasma	NN	_	17	com	_	_
16	concentration	concentration	NN	_	17	com	_	_
17	profile	profile	NN	_	13	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	after	after	IN	_	22	case	_	_
21	b-acetyldigoxin	b-acetyldigoxin	JJ	_	22	attr	_	_
22	administration	administration	NN	_	13	ppmod	_	_
23	for	for	IN	_	25	case	_	_
24	7	0	CD	_	25	num	_	_
25	days	day	NNS	_	22	ppmod	_	_
26	at	at	IN	_	28	case	_	_
27	clinical	clinical	JJ	_	28	attr	_	_
28	doses	dose	NNS	_	25	ppmod	_	_
29	.	.	.	_	13	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	testing	testing	NN	_	4	dep	_	_
4	found	find	VBD	_	0	root	_	_
5	no	no	DT	_	9	det	_	_
6	protein	protein	NN	_	9	com	_	_
7	binding	binding	NN	_	9	com	_	_
8	drug	drug	NN	_	9	com	_	_
9	interaction	interaction	NN	_	4	obj	_	_
10	between	between	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	13	dep	_	_
5	,	,	,	_	4	p	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	4	cc	_	_
8	as	as	IN	_	7	com	_	_
9	post-marketing	post-marketing	JJ	_	10	attr	_	_
10	observations	observation	NNS	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	have	have	VBP	_	13	aux	_	_
13	shown	show	VBN	_	1	acl	_	_
14	that	that	IN	_	17	mark	_	_
15	drug2	drug0	NN	_	17	dep	_	_
16	can	can	MD	_	17	modal	_	_
17	reduce	reduce	VB	_	13	comp	_	_
18	the	the	DT	_	20	det	_	_
19	natriuretic	natriuretic	JJ	_	20	attr	_	_
20	effect	effect	NN	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	in	in	IN	_	27	case	_	_
26	some	some	DT	_	27	det	_	_
27	patients	patient	NNS	_	20	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	Studies	study	NNS	_	9	dep	_	_
2	with	with	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	agents	agent	NNS	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NNS	_	4	conj	_	_
7	have	have	VBP	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	demonstrated	demonstrate	VBN	_	0	root	_	_
10	a	a	DT	_	11	det	_	_
11	reduction	reduction	NN	_	9	obj	_	_
12	in	in	IN	_	14	case	_	_
13	natriuretic	natriuretic	JJ	_	14	attr	_	_
14	effect	effect	NN	_	11	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	single	single	JJ	_	7	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	multiple	multiple	JJ	_	3	conj	_	_
6	dose	dose	NN	_	7	com	_	_
7	pharmacodynamics	pharmacodynamics	NNS	_	12	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	7	conj	_	_
10	are	be	VBP	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	affected	affect	VBN	_	1	acl	_	_
13	by	by	IN	_	15	case	_	_
14	multiple	multiple	JJ	_	15	attr	_	_
15	doses	dose	NNS	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	Nevertheless	nevertheless	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	during	during	IN	_	5	case	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	therapy	therapy	NN	_	14	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	14	p	_	_
11	patients	patient	NNS	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	observed	observe	VBN	_	0	root	_	_
15	closely	closely	RB	_	14	adv	_	_
16	for	for	IN	_	17	case	_	_
17	signs	sign	NNS	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	declining	decline	VBG	_	17	ppmod	_	_
20	renal	renal	JJ	_	21	attr	_	_
21	function	function	NN	_	19	obj	_	_
22	,	,	,	_	19	p	_	_
23	as	as	RB	_	24	com	_	_
24	well	well	RB	_	19	cc	_	_
25	as	as	IN	_	24	com	_	_
26	to	to	TO	_	27	aux	_	_
27	assure	assure	VB	_	19	conj	_	_
28	diuretic	diuretic	JJ	_	29	attr	_	_
29	efficacy	efficacy	NN	_	27	obj	_	_
30	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	trials	trial	NNS	_	9	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	drug2	drug0	NNS	_	9	dep	_	_
8	have	have	VBP	_	9	aux	_	_
9	produced	produce	VBN	_	1	acl	_	_
10	an	an	DT	_	11	det	_	_
11	elevation	elevation	NN	_	9	obj	_	_
12	of	of	IN	_	15	case	_	_
13	plasma	plasma	NN	_	15	com	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	levels	level	NNS	_	11	ppmod	_	_
16	and	and	CC	_	11	cc	_	_
17	a	a	DT	_	18	det	_	_
18	reduction	reduction	NN	_	11	conj	_	_
19	in	in	IN	_	22	case	_	_
20	renal	renal	JJ	_	22	attr	_	_
21	drug4	drug0	NN	_	22	com	_	_
22	clearance	clearance	NN	_	18	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	16	ppmod	_	_
4	conducted	conduct	VBN	_	3	acl	_	_
5	in	in	IN	_	7	case	_	_
6	healthy	healthy	JJ	_	7	attr	_	_
7	subjects	subject	NNS	_	4	ppmod	_	_
8	,	,	,	_	16	p	_	_
9	mean	mean	NN	_	12	com	_	_
10	pre-dose	pre-dose	NN	_	12	com	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	concentration	concentration	NN	_	16	dep	_	_
13	and	and	CC	_	12	cc	_	_
14	AUC	auc	NN	_	12	conj	_	_
15	were	be	VBD	_	16	aux	_	_
16	increased	increase	VBN	_	0	root	_	_
17	by	by	IN	_	18	case	_	_
18	21	0	CD	_	16	ppmod	_	_
19	%	%	NN	_	18	meta	_	_
20	in	in	IN	_	21	case	_	_
21	subjects	subject	NNS	_	16	ppmod	_	_
22	receiving	receive	VBG	_	21	acl	_	_
23	drug2	drug0	NN	_	24	com	_	_
24	doses	dose	NNS	_	22	obj	_	_
25	ranging	range	VBG	_	24	acl	_	_
26	from	from	IN	_	27	case	_	_
27	804	0	CD	_	25	ppmod	_	_
28	to	to	TO	_	31	aux	_	_
29	1072	0	CD	_	30	num	_	_
30	mg	mg	NN	_	31	com	_	_
31	BID	bid	NN	_	25	ppmod	_	_
32	with	with	IN	_	36	case	_	_
33	drug3	drug0	NN	_	36	attr	_	_
34	15	0	CD	_	35	num	_	_
35	mg	mg	NN	_	36	com	_	_
36	QD	qd	NN	_	22	ppmod	_	_
37	as	as	IN	_	38	mark	_	_
38	compared	compare	VBN	_	36	acl	_	_
39	to	to	TO	_	40	aux	_	_
40	subjects	subject	NNS	_	38	ppmod	_	_
41	receiving	receive	VBG	_	40	acl	_	_
42	drug4	drug0	NN	_	41	obj	_	_
43	alone	alone	RB	_	42	adv	_	_
44	.	.	.	_	16	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	by	by	IN	_	13	case	_	_
13	drug1	drug0	NN	_	7	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	Patients	patient	NNS	_	8	dep	_	_
2	on	on	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	treatment	treatment	NN	_	1	ppmod	_	_
5	should	should	MD	_	8	modal	_	_
6	be	be	VB	_	8	aux	_	_
7	closely	closely	RB	_	8	adv	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	when	when	WRB	_	12	adv	_	_
10	drug2	drug0	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	introduced	introduce	VBN	_	8	comp	_	_
13	or	or	CC	_	12	cc	_	_
14	withdrawn	withdraw	VBN	_	12	conj	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	4	det	_	_
4	study	study	NN	_	13	dep	_	_
5	in	in	IN	_	12	case	_	_
6	13	0	CD	_	8	num	_	_
7	rheumatoid	rheumatoid	JJ	_	8	attr	_	_
8	arthritis	arthritis	NN	_	12	attr	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	RA	ra	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	patients	patient	NNS	_	4	ppmod	_	_
13	evaluated	evaluate	VBD	_	1	acl	_	_
14	the	the	DT	_	15	det	_	_
15	effects	effect	NNS	_	13	obj	_	_
16	of	of	IN	_	18	case	_	_
17	multiple	multiple	JJ	_	18	attr	_	_
18	doses	dose	NNS	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	on	on	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	pharmacokinetics	pharmacokinetics	NNS	_	15	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	taken	take	VBN	_	23	acl	_	_
27	once	once	RB	_	28	com	_	_
28	weekly	weekly	RB	_	26	adv	_	_
29	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	have	have	VB	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	significant	significant	JJ	_	7	attr	_	_
7	effect	effect	NN	_	4	obj	_	_
8	on	on	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	4	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	single	single	JJ	_	13	attr	_	_
13	doses	dose	NNS	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	7	adv	_	_
3	,	,	,	_	7	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	did	do	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	displace	displace	VB	_	0	root	_	_
8	drug2	drug0	NN	_	7	obj	_	_
9	from	from	IN	_	14	case	_	_
10	its	its	PRP$	_	14	poss	_	_
11	human	human	JJ	_	14	attr	_	_
12	serum	serum	NN	_	14	com	_	_
13	binding	binding	NN	_	14	com	_	_
14	sites	site	NNS	_	7	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Anticoagulant	anticoagulant	NN	_	4	com	_	_
4	activity	activity	NN	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	monitored	monitor	VBN	_	1	acl	_	_
8	,	,	,	_	7	p	_	_
9	particularly	particularly	RB	_	14	adv	_	_
10	in	in	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	first	#ord#	JJ	_	14	attr	_	_
13	few	few	JJ	_	14	attr	_	_
14	days	day	NNS	_	7	ppmod	_	_
15	after	after	IN	_	16	case	_	_
16	initiating	initiate	VBG	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	changing	change	VBG	_	16	conj	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	therapy	therapy	NN	_	18	obj	_	_
21	in	in	IN	_	22	case	_	_
22	patients	patient	NNS	_	20	ppmod	_	_
23	receiving	receive	VBG	_	22	acl	_	_
24	drug3	drug0	JJ	_	27	attr	_	_
25	or	or	CC	_	24	cc	_	_
26	similar	similar	JJ	_	24	conj	_	_
27	agents	agent	NNS	_	23	obj	_	_
28	,	,	,	_	7	p	_	_
29	since	since	IN	_	32	mark	_	_
30	these	these	DT	_	31	det	_	_
31	patients	patient	NNS	_	32	dep	_	_
32	are	be	VBP	_	7	comp	_	_
33	at	at	IN	_	36	case	_	_
34	an	an	DT	_	36	det	_	_
35	increased	increase	VBN	_	36	attr	_	_
36	risk	risk	NN	_	32	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	bleeding	bleeding	JJ	_	36	ppmod	_	_
39	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	anticoagulant	anticoagulant	JJ	_	8	attr	_	_
8	effect	effect	NN	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	was	be	VBD	_	12	aux	_	_
12	studied	study	VBN	_	0	root	_	_
13	in	in	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	group	group	NN	_	12	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	healthy	healthy	JJ	_	18	attr	_	_
18	subjects	subject	NNS	_	15	ppmod	_	_
19	receiving	receive	VBG	_	18	acl	_	_
20	daily	daily	JJ	_	21	attr	_	_
21	doses	dose	NNS	_	19	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	that	that	WDT	_	25	dep	_	_
25	produced	produce	VBD	_	21	relcl	_	_
26	an	an	DT	_	27	det	_	_
27	INR	inr	NN	_	25	obj	_	_
28	(	-lrb-	-LRB-	_	31	p	_	_
29	International	international	NNP	_	31	attr	_	_
30	Normalized	normalize	VBN	_	31	attr	_	_
31	Ratio	ratio	NN	_	27	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	between	between	IN	_	34	case	_	_
34	1.2	0	CD	_	27	ppmod	_	_
35	and	and	CC	_	34	cc	_	_
36	1.8	0	CD	_	34	conj	_	_
37	.	.	.	_	12	p	_	_

1	In	in	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	subjects	subject	NNS	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	alter	alter	VB	_	0	root	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	8	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	the	the	DT	_	15	det	_	_
13	average	average	JJ	_	15	attr	_	_
14	anticoagulant	anticoagulant	NN	_	15	com	_	_
15	effect	effect	NN	_	10	conj	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	as	as	IN	_	19	mark	_	_
19	determined	determine	VBN	_	8	comp	_	_
20	by	by	IN	_	22	case	_	_
21	prothrombin	prothrombin	NN	_	22	com	_	_
22	time	time	NN	_	19	ppmod	_	_
23	.	.	.	_	8	p	_	_

1	However	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	one	#crd#	CD	_	4	num	_	_
4	subject	subject	NN	_	5	dep	_	_
5	showed	show	VBD	_	0	root	_	_
6	an	an	DT	_	7	det	_	_
7	increase	increase	NN	_	5	obj	_	_
8	in	in	IN	_	9	case	_	_
9	INR	inr	NNS	_	7	ppmod	_	_
10	from	from	IN	_	13	case	_	_
11	1.5	0	CD	_	13	num	_	_
12	to	to	TO	_	13	attr	_	_
13	2.1	0	CD	_	9	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	administering	administer	VBG	_	4	comp	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	since	since	IN	_	15	mark	_	_
11	patients	patient	NNS	_	15	dep	_	_
12	on	on	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	may	may	MD	_	15	modal	_	_
15	experience	experience	VBP	_	6	comp	_	_
16	changes	change	NNS	_	15	obj	_	_
17	in	in	IN	_	18	case	_	_
18	INR	inr	NN	_	16	ppmod	_	_
19	and	and	CC	_	16	cc	_	_
20	an	an	DT	_	22	det	_	_
21	increased	increase	VBN	_	22	attr	_	_
22	risk	risk	NN	_	16	conj	_	_
23	of	of	IN	_	25	case	_	_
24	bleeding	bleeding	JJ	_	25	attr	_	_
25	complications	complication	NNS	_	22	ppmod	_	_
26	when	when	WRB	_	31	adv	_	_
27	a	a	DT	_	29	det	_	_
28	new	new	JJ	_	29	attr	_	_
29	medication	medication	NN	_	31	dep	_	_
30	is	be	VBZ	_	31	aux	_	_
31	introduced	introduce	VBN	_	15	comp	_	_
32	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	inhibit	inhibit	VBP	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hepatic	hepatic	JJ	_	6	attr	_	_
6	metabolism	metabolism	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	,	,	,	_	1	p	_	_
3	given	give	VBN	_	1	acl	_	_
4	at	at	IN	_	8	case	_	_
5	a	a	DT	_	8	det	_	_
6	common	common	JJ	_	8	attr	_	_
7	clinical	clinical	JJ	_	8	attr	_	_
8	dosage	dosage	NN	_	3	ppmod	_	_
9	,	,	,	_	1	p	_	_
10	increased	increase	VBD	_	0	root	_	_
11	the	the	DT	_	13	det	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	half-life	half-life	NN	_	10	obj	_	_
14	by	by	IN	_	15	case	_	_
15	51	0	CD	_	10	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	and	and	CC	_	10	cc	_	_
18	decreased	decrease	VBD	_	10	conj	_	_
19	the	the	DT	_	23	det	_	_
20	drug3	drug0	NN	_	23	attr	_	_
21	metabolic	metabolic	JJ	_	23	attr	_	_
22	clearance	clearance	NN	_	23	com	_	_
23	rate	rate	NN	_	18	obj	_	_
24	by	by	IN	_	25	case	_	_
25	30	0	CD	_	18	ppmod	_	_
26	%	%	NN	_	25	meta	_	_
27	.	.	.	_	10	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	administering	administer	VBG	_	9	advcl	_	_
3	these	these	DT	_	4	det	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	concurrently	concurrently	RB	_	2	adv	_	_
6	,	,	,	_	9	p	_	_
7	one	#crd#	PRP	_	9	dep	_	_
8	should	should	MD	_	9	modal	_	_
9	be	be	VB	_	0	root	_	_
10	alert	alert	JJ	_	9	dep	_	_
11	for	for	IN	_	15	case	_	_
12	possible	possible	JJ	_	15	attr	_	_
13	excessive	excessive	JJ	_	15	attr	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	effect	effect	NN	_	10	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	Excessive	excessive	JJ	_	3	attr	_	_
2	glucocorticoid	glucocorticoid	NN	_	3	com	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	will	will	MD	_	5	modal	_	_
5	inhibit	inhibit	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	growth-promoting	growth-promoting	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	with	with	IN	_	4	case	_	_
3	ACTH	acth	NN	_	4	com	_	_
4	deficiency	deficiency	NN	_	1	ppmod	_	_
5	should	should	MD	_	6	modal	_	_
6	have	have	VB	_	0	root	_	_
7	their	their	PRP$	_	10	poss	_	_
8	drug1	drug0	JJ	_	10	attr	_	_
9	-replacement	-replacement	JJ	_	10	attr	_	_
10	dose	dose	NN	_	6	obj	_	_
11	carefully	carefully	RB	_	12	adv	_	_
12	adjusted	adjust	VBN	_	10	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	avoid	avoid	VB	_	12	comp	_	_
15	an	an	DT	_	17	det	_	_
16	inhibitory	inhibitory	JJ	_	17	attr	_	_
17	effect	effect	NN	_	14	obj	_	_
18	on	on	IN	_	19	case	_	_
19	growth	growth	NN	_	17	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	17	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	2	ppmod	_	_
7	with	with	IN	_	10	case	_	_
8	chronic	chronic	JJ	_	10	attr	_	_
9	renal	renal	JJ	_	10	attr	_	_
10	insufficiency	insufficiency	NN	_	6	ppmod	_	_
11	receiving	receive	VBG	_	6	acl	_	_
12	glucocorticoid	glucocorticoid	NN	_	13	com	_	_
13	therapy	therapy	NN	_	11	obj	_	_
14	has	have	VBZ	_	17	aux	_	_
15	not	not	RB	_	17	neg	_	_
16	been	be	VBN	_	17	aux	_	_
17	evaluated	evaluate	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	Concomitant	concomitant	JJ	_	3	attr	_	_
2	glucocorticoid	glucocorticoid	NN	_	3	com	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	inhibit	inhibit	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	growth-promoting	growth-promoting	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	If	if	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	replacement	replacement	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	required	require	VBN	_	13	advcl	_	_
6	,	,	,	_	13	p	_	_
7	the	the	DT	_	9	det	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	dose	dose	NN	_	13	dep	_	_
10	should	should	MD	_	13	modal	_	_
11	be	be	VB	_	13	aux	_	_
12	carefully	carefully	RB	_	13	adv	_	_
13	adjusted	adjust	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	in	in	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	controlled	controlled	JJ	_	8	attr	_	_
8	studies	study	NNS	_	2	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	drug1	drug0	NN	_	12	com	_	_
11	s	s	NN	_	12	com	_	_
12	interaction	interaction	NN	_	8	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drugs	drug	NNS	_	12	ppmod	_	_
15	commonly	commonly	RB	_	16	adv	_	_
16	used	use	VBN	_	14	acl	_	_
17	in	in	IN	_	21	case	_	_
18	chronic	chronic	JJ	_	20	attr	_	_
19	renal	renal	JJ	_	20	attr	_	_
20	insufficiency	insufficiency	NN	_	21	com	_	_
21	patients	patient	NNS	_	16	ppmod	_	_
22	.	.	.	_	2	p	_	_

1	Limited	limited	JJ	_	3	attr	_	_
2	published	publish	VBN	_	3	attr	_	_
3	data	datum	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	treatment	treatment	NN	_	8	dep	_	_
8	increases	increase	VBZ	_	4	comp	_	_
9	cytochrome	cytochrome	NN	_	10	com	_	_
10	P450	p0	NN	_	8	obj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	CP450	cp0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	mediated	mediate	VBN	_	10	acl	_	_
15	drug2	drug0	IN	_	16	case	_	_
16	clearance	clearance	NN	_	14	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	man	man	NN	_	16	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	administration	administration	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	alter	alter	VB	_	3	comp	_	_
9	the	the	DT	_	10	det	_	_
10	clearance	clearance	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	compounds	compound	NNS	_	10	ppmod	_	_
13	known	know	VBN	_	12	acl	_	_
14	to	to	TO	_	16	aux	_	_
15	be	be	VB	_	16	aux	_	_
16	metabolized	metabolize	VBN	_	13	comp	_	_
17	by	by	IN	_	20	case	_	_
18	CP450	cp0	NN	_	20	com	_	_
19	liver	liver	NN	_	20	com	_	_
20	enzymes	enzyme	NNS	_	16	ppmod	_	_
21	(	-lrb-	-LRB-	_	30	p	_	_
22	e.g.	e.g.	FW	_	24	adv	_	_
23	,	,	,	_	24	p	_	_
24	drug2	drug0	NN	_	30	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	drug3	drug0	NN	_	24	appo	_	_
27	,	,	,	_	24	p	_	_
28	drug4	drug0	NN	_	24	appo	_	_
29	,	,	,	_	30	p	_	_
30	drug5	drug0	NNS	_	20	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	.	.	.	_	3	p	_	_

1	Careful	careful	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	advisable	advisable	JJ	_	3	dep	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	administered	administer	VBN	_	3	comp	_	_
9	in	in	IN	_	10	case	_	_
10	combination	combination	NN	_	8	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	10	ppmod	_	_
14	known	know	VBN	_	13	acl	_	_
15	to	to	TO	_	17	aux	_	_
16	be	be	VB	_	17	aux	_	_
17	metabolized	metabolize	VBN	_	14	comp	_	_
18	by	by	IN	_	21	case	_	_
19	CP450	cp0	NN	_	21	com	_	_
20	liver	liver	NN	_	21	com	_	_
21	enzymes	enzyme	NNS	_	17	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	other	other	JJ	_	7	attr	_	_
6	addictive	addictive	JJ	_	7	attr	_	_
7	medications	medication	NNS	_	3	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	in	in	IN	_	10	case	_	_
10	that	that	WDT	_	13	ppmod	_	_
11	it	it	PRP	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	increase	increase	VB	_	7	relcl	_	_
14	the	the	DT	_	15	det	_	_
15	likelyhood	likelyhood	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	addiction	addiction	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	abuse	abuse	NN	_	17	conj	_	_
20	.	.	.	_	3	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug2	drug0	NNS	_	4	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	increase	increase	VB	_	0	root	_	_
10	the	the	DT	_	13	det	_	_
11	CNS	cns	NN	_	13	com	_	_
12	depressant	depressant	NN	_	13	com	_	_
13	effects	effect	NNS	_	9	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	or	or	CC	_	13	cc	_	_
17	these	these	DT	_	19	det	_	_
18	other	other	JJ	_	19	attr	_	_
19	medications	medication	NNS	_	13	conj	_	_
20	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effectiveness	effectiveness	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	certain	certain	JJ	_	11	attr	_	_
11	drug3	drug0	NN	_	8	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	8	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug5	drug0	NN	_	8	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug6	drug0	NN	_	8	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug7	drug0	NN	_	8	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	drug8	drug0	NN	_	8	conj	_	_
23	.	.	.	_	3	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	when	when	WRB	_	5	adv	_	_
5	administering	administer	VBG	_	3	comp	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	with	with	IN	_	8	case	_	_
8	compounds	compound	NNS	_	5	ppmod	_	_
9	that	that	WDT	_	11	dep	_	_
10	are	be	VBP	_	11	aux	_	_
11	metabolized/eliminated	metabolized/eliminated	VBN	_	8	relcl	_	_
12	predominantly	predominantly	RB	_	11	adv	_	_
13	by	by	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	UGT1A1	ugt0a0	NN	_	16	com	_	_
16	pathway	pathway	NN	_	11	ppmod	_	_
17	(	-lrb-	-LRB-	_	19	p	_	_
18	e.g.	e.g.	FW	_	19	ppmod	_	_
19	drug2	drug0	NNS	_	16	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	.	.	.	_	3	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	5	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	resulted	result	VBD	_	0	root	_	_
6	in	in	IN	_	10	case	_	_
7	a	a	DT	_	10	det	_	_
8	21	0	CD	_	10	num	_	_
9	%	%	NN	_	8	meta	_	_
10	increase	increase	NN	_	5	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	AUC	auc	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	when	when	WRB	_	5	adv	_	_
5	administering	administer	VBG	_	3	comp	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibits	inhibit	VBZ	_	0	root	_	_
3	CYP2B6	cyp0b0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	CYP2C8	cyp0c0	NN	_	3	conj	_	_
6	in	in	FW	_	7	adv	_	_
7	vitro	vitro	FW	_	2	adv	_	_
8	with	with	IN	_	10	case	_	_
9	Ki	ki	NN	_	10	com	_	_
10	values	value	NNS	_	2	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	6	0	CD	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	1-2	0	CD	_	12	conj	_	_
15	?	?	.	_	12	p	_	_
16	M	m	NN	_	12	appo	_	_
17	,	,	,	_	10	p	_	_
18	respectively	respectively	RB	_	10	adv	_	_
19	.	.	.	_	2	p	_	_

1	Systemic	systemic	JJ	_	2	attr	_	_
2	exposure	exposure	NN	_	10	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	substrates	substrate	NNS	_	2	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	CYP2B6	cyp0b0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	CYP2C8	cyp0c0	NN	_	6	conj	_	_
9	is	be	VBZ	_	10	aux	_	_
10	expected	expect	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	increase	increase	VB	_	10	comp	_	_
13	when	when	WRB	_	14	adv	_	_
14	co-administered	co-administered	VBN	_	12	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	10	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	when	when	WRB	_	5	adv	_	_
5	administering	administer	VBG	_	3	comp	_	_
6	substrates	substrate	NNS	_	5	obj	_	_
7	of	of	IN	_	8	case	_	_
8	CYP2B6	cyp0b0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	CYP2C8	cyp0c0	NN	_	8	conj	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	5	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	administered	administer	VBN	_	9	advcl	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	drug2	drug0	NN	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	enhance	enhance	VB	_	0	root	_	_
10	or	or	CC	_	9	cc	_	_
11	precipitate	precipitate	VB	_	9	conj	_	_
12	bradycardia	bradycardia	NN	_	11	obj	_	_
13	,	,	,	_	12	p	_	_
14	A.V.	a.v.	NNP	_	12	appo	_	_

1	block	block	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	arrhythmia	arrhythmia	NN	_	1	conj	_	_
4	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	23	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	that	that	WDT	_	6	dep	_	_
6	stimulate	stimulate	VBP	_	4	relcl	_	_
7	alpha-adrenergic	alpha-adrenergic	JJ	_	8	attr	_	_
8	receptors	receptor	NNS	_	6	obj	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	e.g.	e.g.	FW	_	12	adv	_	_
11	,	,	,	_	12	p	_	_
12	drug1	drug0	NN	_	8	prn	_	_
13	,	,	,	_	12	p	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	12	conj	_	_
19	or	or	CC	_	18	cc	_	_
20	drug5	drug0	NN	_	12	conj	_	_
21	)	-rrb-	-RRB-	_	12	p	_	_
22	may	may	MD	_	23	modal	_	_
23	enhance	enhance	VB	_	37	advcl	_	_
24	or	or	CC	_	23	cc	_	_
25	potentiate	potentiate	VB	_	23	conj	_	_
26	the	the	DT	_	28	det	_	_
27	pressor	pressor	NN	_	28	com	_	_
28	effects	effect	NNS	_	25	obj	_	_
29	of	of	IN	_	30	case	_	_
30	drug6	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	23	p	_	_
32	Therefore	therefore	RB	_	37	adv	_	_
33	,	,	,	_	37	p	_	_
34	caution	caution	NN	_	37	dep	_	_
35	should	should	MD	_	37	modal	_	_
36	be	be	VB	_	37	aux	_	_
37	used	use	VBN	_	0	root	_	_
38	when	when	WRB	_	41	adv	_	_
39	drug7	drug0	NN	_	41	dep	_	_
40	is	be	VBZ	_	41	aux	_	_
41	administered	administer	VBN	_	37	comp	_	_
42	concomitantly	concomitantly	RB	_	41	adv	_	_
43	with	with	IN	_	44	case	_	_
44	agents	agent	NNS	_	41	ppmod	_	_
45	that	that	WDT	_	46	dep	_	_
46	cause	cause	VBP	_	44	relcl	_	_
47	vasoconstriction	vasoconstriction	NN	_	46	obj	_	_
48	.	.	.	_	37	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	concomitantly	concomitantly	RB	_	8	adv	_	_
8	treated	treat	VBN	_	6	acl	_	_
9	with	with	IN	_	12	case	_	_
10	salt-retaining	salt-retaining	JJ	_	12	attr	_	_
11	steroid	steroid	NN	_	12	com	_	_
12	therapy	therapy	NN	_	8	ppmod	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	i.e.	i.e.	FW	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	drug2	drug0	NNS	_	12	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	4	p	_	_
19	with	with	IN	_	4	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	without	without	IN	_	23	case	_	_
22	salt	salt	NN	_	23	com	_	_
23	supplementation	supplementation	NN	_	19	conj	_	_
24	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	potential	potential	NN	_	9	dep	_	_
3	for	for	IN	_	5	case	_	_
4	supine	supine	JJ	_	5	attr	_	_
5	hypertension	hypertension	NN	_	2	ppmod	_	_
6	should	should	MD	_	9	modal	_	_
7	be	be	VB	_	9	aux	_	_
8	carefully	carefully	RB	_	9	adv	_	_
9	monitored	monitor	VBN	_	0	root	_	_
10	in	in	IN	_	12	case	_	_
11	these	these	DT	_	12	det	_	_
12	patients	patient	NNS	_	9	ppmod	_	_
13	and	and	CC	_	9	cc	_	_
14	may	may	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	minimized	minimize	VBN	_	9	conj	_	_
17	by	by	IN	_	19	case	_	_
18	either	either	CC	_	19	cc	_	_
19	reducing	reduce	VBG	_	16	ppmod	_	_
20	the	the	DT	_	21	det	_	_
21	dose	dose	NN	_	19	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	or	or	CC	_	19	cc	_	_
25	decreasing	decrease	VBG	_	19	conj	_	_
26	the	the	DT	_	28	det	_	_
27	salt	salt	NN	_	28	com	_	_
28	intake	intake	NN	_	25	obj	_	_
29	prior	prior	JJ	_	28	attr	_	_
30	to	to	TO	_	31	aux	_	_
31	initiation	initiation	NN	_	29	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	treatment	treatment	NN	_	31	ppmod	_	_
34	with	with	IN	_	33	case	_	_
35	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	15	dep	_	_
2	.	.	.	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	drug3	drug0	NN	_	1	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug5	drug0	NN	_	7	conj	_	_
13	,	,	,	_	1	p	_	_
14	can	can	MD	_	15	modal	_	_
15	antagonize	antagonize	VB	_	27	comp	_	_
16	the	the	DT	_	17	det	_	_
17	effects	effect	NNS	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug6	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	15	p	_	_
21	Potential	potential	NN	_	15	dep	_	_
22	for	for	IN	_	24	case	_	_
23	Drug	drug	NN	_	24	com	_	_
24	Interactions	interaction	NNS	_	21	ppmod	_	_
25	:	:	:	_	27	p	_	_
26	It	it	PRP	_	27	dep	_	_
27	appears	appear	VBZ	_	0	root	_	_
28	possible	possible	JJ	_	27	dep	_	_
29	,	,	,	_	27	p	_	_
30	although	although	IN	_	32	mark	_	_
31	there	there	EX	_	32	dep	_	_
32	is	be	VBZ	_	27	comp	_	_
33	no	no	DT	_	36	det	_	_
34	supporting	support	VBG	_	36	attr	_	_
35	experimental	experimental	JJ	_	36	attr	_	_
36	evidence	evidence	NN	_	32	obj	_	_
37	,	,	,	_	32	p	_	_
38	that	that	IN	_	49	mark	_	_
39	the	the	DT	_	42	det	_	_
40	high	high	JJ	_	42	attr	_	_
41	renal	renal	JJ	_	42	attr	_	_
42	clearance	clearance	NN	_	49	dep	_	_
43	of	of	IN	_	44	case	_	_
44	drug7	drug0	NN	_	42	ppmod	_	_
45	(	-lrb-	-LRB-	_	47	p	_	_
46	a	a	DT	_	47	det	_	_
47	base	base	NN	_	44	prn	_	_
48	)	-rrb-	-RRB-	_	47	p	_	_
49	is	be	VBZ	_	32	comp	_	_
50	due	due	JJ	_	49	dep	_	_
51	to	to	TO	_	54	aux	_	_
52	active	active	JJ	_	54	attr	_	_
53	tubular	tubular	JJ	_	54	attr	_	_
54	secretion	secretion	NN	_	50	ppmod	_	_
55	by	by	IN	_	58	case	_	_
56	the	the	DT	_	58	det	_	_
57	base-secreting	base-secreting	JJ	_	58	attr	_	_
58	system	system	NN	_	54	ppmod	_	_
59	also	also	RB	_	60	adv	_	_
60	responsible	responsible	JJ	_	58	attr	_	_
61	for	for	IN	_	63	case	_	_
62	the	the	DT	_	63	det	_	_
63	secretion	secretion	NN	_	60	ppmod	_	_
64	of	of	IN	_	66	case	_	_
65	such	such	JJ	_	66	attr	_	_
66	drugs	drug	NNS	_	63	ppmod	_	_
67	as	as	IN	_	68	case	_	_
68	drug8	drug0	NN	_	66	ppmod	_	_
69	,	,	,	_	63	p	_	_
70	drug9	drug0	NN	_	63	conj	_	_
71	,	,	,	_	70	p	_	_
72	drug10	drug0	NN	_	63	conj	_	_
73	,	,	,	_	72	p	_	_
74	drug11	drug0	NN	_	63	conj	_	_
75	,	,	,	_	74	p	_	_
76	drug12	drug0	NN	_	63	conj	_	_
77	,	,	,	_	76	p	_	_
78	drug13	drug0	NN	_	63	conj	_	_
79	,	,	,	_	78	p	_	_
80	and	and	CC	_	78	cc	_	_
81	drug14	drug0	NN	_	63	conj	_	_
82	.	.	.	_	27	p	_	_

1	Thus	thus	RB	_	4	adv	_	_
2	there	there	EX	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	a	a	DT	_	6	det	_	_
6	potential	potential	NN	_	4	obj	_	_
7	for	for	IN	_	9	case	_	_
8	drug-drug	drug-drug	JJ	_	9	attr	_	_
9	interactions	interaction	NNS	_	6	ppmod	_	_
10	with	with	IN	_	12	case	_	_
11	these	these	DT	_	12	det	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	enhance	enhance	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	sedative	sedative	JJ	_	9	attr	_	_
9	activity	activity	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug4	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	drug5	drug0	NN	_	11	conj	_	_
19	.	.	.	_	4	p	_	_

1	Peripheral	peripheral	JJ	_	2	attr	_	_
2	Neuropathy	neuropathy	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Medications	medication	NNS	_	14	dep	_	_
5	known	know	VBN	_	4	acl	_	_
6	to	to	TO	_	8	aux	_	_
7	be	be	VB	_	8	aux	_	_
8	associated	associate	VBN	_	5	comp	_	_
9	with	with	IN	_	11	case	_	_
10	peripheral	peripheral	JJ	_	11	attr	_	_
11	neuropathy	neuropathy	NN	_	8	ppmod	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	used	use	VBN	_	2	acl	_	_
15	with	with	IN	_	16	case	_	_
16	caution	caution	NN	_	14	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	patients	patient	NNS	_	14	ppmod	_	_
19	receiving	receive	VBG	_	18	acl	_	_
20	drug1	drug0	NN	_	19	obj	_	_
21	.	.	.	_	2	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	In	in	IN	_	7	case	_	_
5	10	0	CD	_	7	num	_	_
6	healthy	healthy	JJ	_	7	attr	_	_
7	women	woman	NNS	_	33	ppmod	_	_
8	,	,	,	_	33	p	_	_
9	the	the	DT	_	11	det	_	_
10	pharmacokinetic	pharmacokinetic	JJ	_	11	attr	_	_
11	profiles	profile	NNS	_	33	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	following	follow	VBG	_	17	adv	_	_
17	administration	administration	NN	_	13	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	single	single	JJ	_	21	attr	_	_
21	dose	dose	NN	_	17	ppmod	_	_
22	containing	contain	VBG	_	21	acl	_	_
23	1.0	0	CD	_	24	num	_	_
24	mg	mg	NN	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	drug4	drug0	NN	_	24	ppmod	_	_
27	and	and	CC	_	24	cc	_	_
28	75	0	CD	_	29	num	_	_
29	g	g	NN	_	24	conj	_	_
30	of	of	IN	_	31	case	_	_
31	drug5	drug0	NN	_	29	ppmod	_	_
32	were	be	VBD	_	33	aux	_	_
33	studied	study	VBN	_	2	acl	_	_
34	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	were	be	VBD	_	0	root	_	_
4	similar	similar	JJ	_	3	dep	_	_
5	with	with	IN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	without	without	IN	_	8	case	_	_
8	coadministration	coadministration	NN	_	5	conj	_	_
9	of	of	IN	_	12	case	_	_
10	drug1	drug0	NN	_	12	attr	_	_
11	200	0	CD	_	12	num	_	_
12	mg/day	mg/day	NN	_	8	ppmod	_	_
13	to	to	TO	_	15	aux	_	_
14	steady-state	steady-state	JJ	_	15	attr	_	_
15	levels	level	NNS	_	8	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Important	important	JJ	_	5	attr	_	_
2	Non-	non-	NN	_	5	com	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	Drug	drug	NN	_	5	com	_	_
5	Interactions	interaction	NNS	_	0	root	_	_
6	Drugs	drug	NNS	_	5	appo	_	_
7	That	that	IN	_	8	mark	_	_
8	Interfere	interfere	VBP	_	6	acl	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	:	:	:	_	5	p	_	_
12	Concomitant	concomitant	JJ	_	13	attr	_	_
13	use	use	NN	_	5	appo	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug6	drug0	NN	_	15	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug7	drug0	NN	_	15	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug8	drug0	NN	_	15	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug9	drug0	NN	_	15	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug10	drug0	NN	_	15	conj	_	_
30	,	,	,	_	29	p	_	_
31	or	or	CC	_	29	cc	_	_
32	certain	certain	JJ	_	34	attr	_	_
33	herbal	herbal	JJ	_	34	attr	_	_
34	supplements	supplement	NNS	_	15	conj	_	_
35	such	such	JJ	_	37	adv	_	_
36	as	as	IN	_	37	case	_	_
37	St.	st.	NN	_	34	ppmod	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug2	drug0	NN	_	1	ppmod	_	_
4	may	may	MD	_	5	modal	_	_
5	reduce	reduce	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	effectiveness	effectiveness	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	contraception	contraception	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	up	up	RB	_	14	adv	_	_
13	to	to	TO	_	14	attr	_	_
14	one	#crd#	CD	_	15	num	_	_
15	month	month	NN	_	10	conj	_	_
16	after	after	IN	_	17	case	_	_
17	discontinuation	discontinuation	NN	_	10	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	these	these	DT	_	21	det	_	_
20	concomitant	concomitant	JJ	_	21	attr	_	_
21	therapies	therapy	NNS	_	17	ppmod	_	_
22	.	.	.	_	5	p	_	_

1	Therefore	therefore	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	women	woman	NNS	_	14	dep	_	_
4	requiring	require	VBG	_	3	acl	_	_
5	treatment	treatment	NN	_	4	obj	_	_
6	with	with	IN	_	7	case	_	_
7	one	#crd#	CD	_	5	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	more	more	JJR	_	7	conj	_	_
10	of	of	IN	_	12	case	_	_
11	these	these	DT	_	12	det	_	_
12	drugs	drug	NNS	_	7	ppmod	_	_
13	must	must	MD	_	14	modal	_	_
14	use	use	VB	_	0	root	_	_
15	two	#crd#	CD	_	21	num	_	_
16	OTHER	other	JJ	_	21	attr	_	_
17	effective	effective	JJ	_	21	attr	_	_
18	or	or	CC	_	17	cc	_	_
19	highly	highly	RB	_	20	adv	_	_
20	effective	effective	JJ	_	17	conj	_	_
21	methods	method	NNS	_	14	obj	_	_
22	of	of	IN	_	23	case	_	_
23	contraception	contraception	NN	_	21	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	abstain	abstain	NN	_	23	conj	_	_
26	from	from	IN	_	29	case	_	_
27	heterosexual	heterosexual	JJ	_	29	attr	_	_
28	sexual	sexual	JJ	_	29	attr	_	_
29	contact	contact	NN	_	14	ppmod	_	_
30	while	while	IN	_	31	mark	_	_
31	taking	take	VBG	_	14	comp	_	_
32	drug1	drug0	NN	_	31	obj	_	_
33	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	and	and	CC	_	9	cc	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug4	drug0	NN	_	7	conj	_	_
13	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	increase	increase	VBP	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	reduce	reduce	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	antihypertensive	antihypertensive	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	8	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug5	drug0	NN	_	8	conj	_	_
15	.	.	.	_	3	p	_	_

1	Interactions	interaction	NNS	_	11	dep	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	3	conj	_	_
7	have	have	VBP	_	11	aux	_	_
8	not	not	RB	_	11	neg	_	_
9	been	be	VBN	_	11	aux	_	_
10	fully	fully	RB	_	11	adv	_	_
11	evaluated	evaluate	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Drugs	drug	NNS	_	19	dep	_	_
2	which	which	WDT	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	potentiate	potentiate	VB	_	1	relcl	_	_
5	the	the	DT	_	7	det	_	_
6	myeloproliferative	myeloproliferative	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	1	p	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	drug2	drug0	NN	_	1	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	1	p	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	used	use	VBN	_	0	root	_	_
20	with	with	IN	_	21	case	_	_
21	caution	caution	NN	_	19	ppmod	_	_
22	.	.	.	_	19	p	_	_

1	The	the	DT	_	4	det	_	_
2	in	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	4	attr	_	_
4	binding	binding	NN	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	to	to	TO	_	10	aux	_	_
8	human	human	JJ	_	10	attr	_	_
9	plasma	plasma	NN	_	10	com	_	_
10	proteins	protein	NNS	_	4	ppmod	_	_
11	is	be	VBZ	_	12	aux	_	_
12	unaffected	unaffected	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	12	p	_	_
16	and	and	CC	_	12	cc	_	_
17	drug3	drug0	NN	_	20	dep	_	_
18	does	do	VBZ	_	20	aux	_	_
19	not	not	RB	_	20	neg	_	_
20	alter	alter	VB	_	12	conj	_	_
21	the	the	DT	_	23	det	_	_
22	prothrombin	prothrombin	NN	_	23	com	_	_
23	time	time	NN	_	20	obj	_	_
24	of	of	IN	_	26	case	_	_
25	normal	normal	JJ	_	26	attr	_	_
26	volunteers	volunteer	NNS	_	23	ppmod	_	_
27	.	.	.	_	12	p	_	_

1	However	however	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	increased	increase	VBN	_	5	attr	_	_
4	prothrombin	prothrombin	NN	_	5	com	_	_
5	time	time	NN	_	10	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	bleeding	bleeding	JJ	_	5	conj	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	on	on	IN	_	15	case	_	_
14	concomitant	concomitant	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	JJ	_	18	attr	_	_
18	therapy	therapy	NN	_	15	conj	_	_
19	.	.	.	_	10	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	exercised	exercise	VBN	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	administering	administer	VBG	_	6	comp	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	to	to	TO	_	11	aux	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	on	on	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	In	in	IN	_	4	case	_	_
2	adult	adult	JJ	_	4	attr	_	_
3	diabetic	diabetic	JJ	_	4	attr	_	_
4	patients	patient	NNS	_	13	ppmod	_	_
5	under	under	IN	_	6	case	_	_
6	treatment	treatment	NN	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	either	either	CC	_	9	cc	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	there	there	EX	_	13	dep	_	_
13	is	be	VBZ	_	0	root	_	_
14	no	no	DT	_	15	det	_	_
15	change	change	NN	_	13	obj	_	_
16	in	in	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	clinical	clinical	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	15	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	either	either	CC	_	22	cc	_	_
22	drug3	drug0	NN	_	19	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	the	the	DT	_	25	det	_	_
25	drug4	drug0	NN	_	22	conj	_	_
26	.	.	.	_	13	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	if	if	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	administered	administer	VBN	_	4	comp	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	1	conj	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	reduce	reduce	VB	_	7	comp	_	_
10	the	the	DT	_	12	det	_	_
11	tubular	tubular	JJ	_	12	attr	_	_
12	secretion	secretion	NN	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	18	case	_	_
16	an	an	DT	_	18	det	_	_
17	animal	animal	JJ	_	18	attr	_	_
18	model	model	NN	_	9	ppmod	_	_
19	,	,	,	_	9	p	_	_
20	possibly	possibly	RB	_	21	adv	_	_
21	enhancing	enhance	VBG	_	9	comp	_	_
22	the	the	DT	_	23	det	_	_
23	toxicity	toxicity	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	7	p	_	_

1	Laboratory	laboratory	NN	_	2	com	_	_
2	Tests	test	NNS	_	18	dep	_	_
3	Because	because	IN	_	11	mark	_	_
4	serious	serious	JJ	_	7	attr	_	_
5	GI	gi	NN	_	7	com	_	_
6	tract	tract	NN	_	7	com	_	_
7	ulceration	ulceration	NN	_	11	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	bleeding	bleeding	JJ	_	7	conj	_	_
10	can	can	MD	_	11	modal	_	_
11	occur	occur	VB	_	18	advcl	_	_
12	without	without	IN	_	14	case	_	_
13	warning	warning	JJ	_	14	attr	_	_
14	symptoms	symptom	NNS	_	11	ppmod	_	_
15	,	,	,	_	18	p	_	_
16	physicians	physician	NNS	_	18	dep	_	_
17	should	should	MD	_	18	modal	_	_
18	follow	follow	VBP	_	0	root	_	_
19	chronically	chronically	RB	_	20	adv	_	_
20	treated	treat	VBN	_	21	attr	_	_
21	patients	patient	NNS	_	18	obj	_	_
22	for	for	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	signs	sign	NNS	_	21	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	symptoms	symptom	NNS	_	24	conj	_	_
27	of	of	IN	_	28	case	_	_
28	ulceration	ulceration	NN	_	24	ppmod	_	_
29	and	and	CC	_	28	cc	_	_
30	bleeding	bleeding	JJ	_	28	conj	_	_
31	and	and	CC	_	18	cc	_	_
32	should	should	MD	_	33	modal	_	_
33	inform	inform	VB	_	18	conj	_	_
34	them	them	PRP	_	33	obj	_	_
35	of	of	IN	_	37	case	_	_
36	the	the	DT	_	37	det	_	_
37	importance	importance	NN	_	33	ppmod	_	_
38	of	of	IN	_	40	case	_	_
39	this	this	DT	_	40	det	_	_
40	follow-up	follow-up	NN	_	37	ppmod	_	_
41	.	.	.	_	18	p	_	_

1	An	an	DT	_	2	det	_	_
2	inhibitor	inhibitor	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	CYP2C8	cyp0c0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	such	such	JJ	_	4	prn	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	)	-rrb-	-RRB-	_	6	p	_	_
10	may	may	MD	_	11	modal	_	_
11	increase	increase	VB	_	0	root	_	_
12	the	the	DT	_	13	det	_	_
13	AUC	auc	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	11	cc	_	_
17	an	an	DT	_	18	det	_	_
18	inducer	inducer	NN	_	27	dep	_	_
19	of	of	IN	_	20	case	_	_
20	CYP2C8	cyp0c0	NN	_	18	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	such	such	JJ	_	20	prn	_	_
23	as	as	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	may	may	MD	_	27	modal	_	_
27	decrease	decrease	VB	_	11	conj	_	_
28	the	the	DT	_	29	det	_	_
29	AUC	auc	NN	_	27	obj	_	_
30	of	of	IN	_	31	case	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	.	.	.	_	11	p	_	_

1	Therefore	therefore	RB	_	26	adv	_	_
2	,	,	,	_	26	p	_	_
3	if	if	IN	_	12	mark	_	_
4	an	an	DT	_	5	det	_	_
5	inhibitor	inhibitor	NN	_	12	dep	_	_
6	or	or	CC	_	5	cc	_	_
7	an	an	DT	_	8	det	_	_
8	inducer	inducer	NN	_	5	conj	_	_
9	of	of	IN	_	10	case	_	_
10	CYP2C8	cyp0c0	NN	_	8	ppmod	_	_
11	is	be	VBZ	_	12	aux	_	_
12	started	start	VBN	_	26	advcl	_	_
13	or	or	CC	_	12	cc	_	_
14	stopped	stop	VBN	_	12	conj	_	_
15	during	during	IN	_	16	case	_	_
16	treatment	treatment	NN	_	14	ppmod	_	_
17	with	with	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	26	p	_	_
20	changes	change	NNS	_	26	dep	_	_
21	in	in	IN	_	23	case	_	_
22	diabetes	diabetes	NN	_	23	com	_	_
23	treatment	treatment	NN	_	20	ppmod	_	_
24	may	may	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	needed	need	VBN	_	0	root	_	_
27	based	base	VBN	_	30	adv	_	_
28	upon	upon	IN	_	30	case	_	_
29	clinical	clinical	JJ	_	30	attr	_	_
30	response	response	NN	_	26	ppmod	_	_
31	.	.	.	_	26	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	properties	property	NNS	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	altered	alter	VBN	_	0	root	_	_
8	by	by	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	addition	addition	NN	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	either	either	CC	_	13	cc	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	or	or	CC	_	10	cc	_	_
17	the	the	DT	_	18	det	_	_
18	combination	combination	NN	_	10	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug4	drug0	NN	_	18	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug5	drug0	NN	_	20	conj	_	_
23	.	.	.	_	7	p	_	_

1	No	no	DT	_	4	det	_	_
2	clinically	clinically	RB	_	3	adv	_	_
3	significant	significant	JJ	_	4	attr	_	_
4	changes	change	NNS	_	11	dep	_	_
5	to	to	TO	_	6	aux	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	6	conj	_	_
10	were	be	VBD	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	following	follow	VBG	_	14	adv	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	administration	administration	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
8	properties	property	NNS	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreases	decrease	VBZ	_	18	advcl	_	_
3	the	the	DT	_	4	det	_	_
4	elimination	elimination	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NNS	_	4	ppmod	_	_
7	causing	cause	VBG	_	6	acl	_	_
8	an	an	DT	_	9	det	_	_
9	increase	increase	NN	_	7	obj	_	_
10	in	in	IN	_	12	case	_	_
11	overall	overall	JJ	_	12	attr	_	_
12	exposure	exposure	NN	_	9	ppmod	_	_
13	.	.	.	_	2	p	_	_
14	The	the	DT	_	15	det	_	_
15	addition	addition	NN	_	18	dep	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	has	have	VBZ	_	0	root	_	_
19	no	no	DT	_	22	det	_	_
20	clinically	clinically	RB	_	21	adv	_	_
21	significant	significant	JJ	_	22	attr	_	_
22	effect	effect	NN	_	18	obj	_	_
23	on	on	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	pharmacokinetic	pharmacokinetic	JJ	_	26	attr	_	_
26	properties	property	NNS	_	18	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug4	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	18	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	38	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	11	0	CD	_	7	num	_	_
6	HIV-infected	hiv-infected	JJ	_	7	attr	_	_
7	patients	patient	NNS	_	3	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	drug1	drug0	NN	_	11	com	_	_
10	-maintenance	-maintenance	NN	_	11	com	_	_
11	therapy	therapy	NN	_	8	obj	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	40	0	CD	_	14	num	_	_
14	mg	mg	NN	_	11	prn	_	_
15	and	and	CC	_	14	cc	_	_
16	90	0	CD	_	17	num	_	_
17	mg	mg	NN	_	14	conj	_	_
18	daily	daily	RB	_	14	adv	_	_
19	)	-rrb-	-RRB-	_	14	p	_	_
20	with	with	IN	_	22	case	_	_
21	600	0	CD	_	22	num	_	_
22	mg	mg	NN	_	8	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	twice	twice	RB	_	26	com	_	_
26	daily	daily	RB	_	22	adv	_	_
27	(	-lrb-	-LRB-	_	32	p	_	_
28	twice	twice	RB	_	32	adv	_	_
29	the	the	DT	_	32	det	_	_
30	currently	currently	RB	_	31	adv	_	_
31	recommended	recommend	VBN	_	32	attr	_	_
32	dose	dose	NN	_	22	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	,	,	,	_	38	p	_	_
35	oral	oral	JJ	_	37	attr	_	_
36	drug3	drug0	NN	_	37	com	_	_
37	clearance	clearance	NN	_	38	dep	_	_
38	increased	increase	VBD	_	0	root	_	_
39	22	0	CD	_	38	obj	_	_
40	%	%	NN	_	39	meta	_	_
41	(	-lrb-	-LRB-	_	44	p	_	_
42	90	0	CD	_	44	num	_	_
43	%	%	NN	_	44	meta	_	_
44	CI	ci	NN	_	39	prn	_	_
45	6	0	CD	_	44	num	_	_
46	%	%	NN	_	44	meta	_	_
47	to	to	TO	_	44	attr	_	_
48	42	0	CD	_	44	num	_	_
49	%	%	NN	_	44	meta	_	_
50	)	-rrb-	-RRB-	_	44	p	_	_
51	.	.	.	_	38	p	_	_

1	This	this	DT	_	2	det	_	_
2	alteration	alteration	NN	_	5	dep	_	_
3	will	will	MD	_	5	modal	_	_
4	not	not	RB	_	5	neg	_	_
5	result	result	VB	_	0	root	_	_
6	in	in	IN	_	10	case	_	_
7	a	a	DT	_	10	det	_	_
8	drug1	drug0	JJ	_	10	attr	_	_
9	dose	dose	NN	_	10	com	_	_
10	modification	modification	NN	_	5	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	majority	majority	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	;	;	:	_	5	p	_	_

1	however	however	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	an	an	DT	_	6	det	_	_
4	increased	increase	VBN	_	6	attr	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	dose	dose	NN	_	9	dep	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	required	require	VBN	_	0	root	_	_
10	in	in	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	small	small	JJ	_	13	attr	_	_
13	number	number	NN	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	concomitantly	concomitantly	RB	_	6	adv	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	drug3	drug0	NN	_	12	com	_	_
12	USP	usp	NN	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	because	because	IN	_	17	mark	_	_
15	they	they	PRP	_	17	dep	_	_
16	may	may	MD	_	17	modal	_	_
17	have	have	VB	_	6	comp	_	_
18	additive	additive	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	17	obj	_	_
20	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	being	be	VBG	_	10	aux	_	_
10	treated	treat	VBN	_	8	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	4	p	_	_
16	since	since	IN	_	27	mark	_	_
17	the	the	DT	_	18	det	_	_
18	action	action	NN	_	27	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug4	drug0	NN	_	18	ppmod	_	_
21	on	on	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	vascular	vascular	JJ	_	24	attr	_	_
24	system	system	NN	_	18	ppmod	_	_
25	may	may	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	potentiated	potentiate	VBN	_	4	comp	_	_
28	.	.	.	_	4	p	_	_

1	A	a	DT	_	2	det	_	_
2	study	study	NN	_	6	dep	_	_
3	published	publish	VBN	_	2	acl	_	_
4	in	in	IN	_	5	case	_	_
5	2002	0	NN	_	3	ppmod	_	_
6	found	find	VBD	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	causes	cause	VBZ	_	6	comp	_	_
10	a	a	DT	_	13	det	_	_
11	statistically	statistically	RB	_	12	adv	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	increase	increase	NN	_	9	obj	_	_
14	in	in	IN	_	16	case	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	clearance	clearance	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	1984	0	NN	_	13	ppmod	_	_
3	,	,	,	_	13	p	_	_
4	Drs	drs	NNS	_	13	dep	_	_
5	Rimmer	rimmer	NNP	_	4	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	Richens	richens	NNP	_	5	conj	_	_
8	at	at	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	University	university	NNP	_	4	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	Wales	wales	NN	_	10	ppmod	_	_
13	reported	report	VBD	_	0	root	_	_
14	that	that	IN	_	19	mark	_	_
15	administering	administer	VBG	_	19	advcl	_	_
16	drug1	drug0	NN	_	15	obj	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	15	ppmod	_	_
19	lowered	lower	VBD	_	13	comp	_	_
20	the	the	DT	_	23	det	_	_
21	serum	serum	NN	_	23	com	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	concentration	concentration	NN	_	19	obj	_	_
24	in	in	IN	_	25	case	_	_
25	patients	patient	NNS	_	19	ppmod	_	_
26	with	with	IN	_	28	case	_	_
27	treatment-resistant	treatment-resistant	JJ	_	28	attr	_	_
28	epilepsy	epilepsy	NN	_	25	ppmod	_	_
29	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	concentration	concentration	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	falls	fall	VBZ	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	23	0	CD	_	5	ppmod	_	_
8	%	%	NN	_	7	meta	_	_
9	within	within	IN	_	11	case	_	_
10	five	#crd#	CD	_	11	num	_	_
11	weeks	week	NNS	_	5	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	according	accord	VBG	_	11	acl	_	_
14	to	to	TO	_	16	aux	_	_
15	an	an	DT	_	16	det	_	_
16	experiment	experiment	NN	_	13	ppmod	_	_
17	published	publish	VBN	_	16	acl	_	_
18	in	in	IN	_	19	case	_	_
19	1989	0	CD	_	17	ppmod	_	_
20	by	by	IN	_	24	case	_	_
21	the	the	DT	_	24	det	_	_
22	same	same	JJ	_	24	attr	_	_
23	two	#crd#	CD	_	24	num	_	_
24	scientists	scientist	NNS	_	17	ppmod	_	_
25	that	that	WDT	_	26	dep	_	_
26	tried	try	VBD	_	24	relcl	_	_
27	and	and	CC	_	26	cc	_	_
28	failed	fail	VBD	_	26	conj	_	_
29	to	to	TO	_	30	aux	_	_
30	elucidate	elucidate	VB	_	28	comp	_	_
31	the	the	DT	_	32	det	_	_
32	mechanism	mechanism	NN	_	30	obj	_	_
33	behind	behind	VBP	_	32	acl	_	_
34	this	this	DT	_	35	det	_	_
35	interaction	interaction	NN	_	33	obj	_	_
36	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	sedative	sedative	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	including	include	VBG	_	10	adv	_	_
10	drug3	drug0	NN	_	6	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug5	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug6	drug0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug7	drug0	NN	_	10	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	drug8	drug0	NN	_	10	conj	_	_
22	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	2	p	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug2	drug0	NN	_	2	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	enhanced	enhance	VBN	_	0	root	_	_
14	by	by	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	administration	administration	NN	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug4	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	effect	effect	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	metabolism	metabolism	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drugs	drug	NNS	_	5	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	liver	liver	NN	_	5	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	Interactions	interaction	NNS	_	11	dep	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	3	conj	_	_
7	have	have	VBP	_	11	aux	_	_
8	not	not	RB	_	11	neg	_	_
9	been	be	VBN	_	11	aux	_	_
10	fully	fully	RB	_	11	adv	_	_
11	evaluated	evaluate	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	administering	administer	VBG	_	4	comp	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	therapy	therapy	NN	_	6	obj	_	_
9	in	in	IN	_	10	case	_	_
10	combination	combination	NN	_	6	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	mixed	mix	VBN	_	0	root	_	_
6	with	with	IN	_	9	case	_	_
7	any	any	DT	_	9	det	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug	drug	NN	_	5	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	8	case	_	_
6	other	other	JJ	_	8	attr	_	_
7	cardioactive	cardioactive	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	2	ppmod	_	_
9	has	have	VBZ	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	studied	study	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	In	in	IN	_	4	case	_	_
2	addition	addition	NN	_	4	advnp	_	_
3	to	to	TO	_	4	aux	_	_
4	bleeding	bleeding	JJ	_	27	ppmod	_	_
5	associated	associate	VBN	_	4	acl	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	27	p	_	_
11	drugs	drug	NNS	_	27	dep	_	_
12	that	that	WDT	_	13	dep	_	_
13	alter	alter	VBP	_	11	relcl	_	_
14	platelet	platelet	NN	_	15	com	_	_
15	function	function	NN	_	13	obj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	such	such	JJ	_	13	prn	_	_
18	as	as	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug5	drug0	NN	_	19	conj	_	_
25	)	-rrb-	-RRB-	_	17	p	_	_
26	may	may	MD	_	27	modal	_	_
27	increase	increase	VBP	_	0	root	_	_
28	the	the	DT	_	29	det	_	_
29	risk	risk	NN	_	27	obj	_	_
30	of	of	IN	_	31	case	_	_
31	bleeding	bleeding	JJ	_	29	ppmod	_	_
32	if	if	IN	_	33	mark	_	_
33	administered	administer	VBN	_	29	acl	_	_
34	prior	prior	RB	_	33	adv	_	_
35	to	to	TO	_	34	ppmod	_	_
36	or	or	CC	_	34	cc	_	_
37	after	after	IN	_	39	case	_	_
38	drug6	drug0	NN	_	39	com	_	_
39	therapy	therapy	NN	_	34	conj	_	_
40	.	.	.	_	27	p	_	_

1	The	the	DT	_	2	det	_	_
2	occurrence	occurrence	NN	_	17	dep	_	_
3	of	of	IN	_	4	case	_	_
4	stupor	stupor	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	muscular	muscular	JJ	_	7	attr	_	_
7	rigidity	rigidity	NN	_	4	conj	_	_
8	,	,	,	_	7	p	_	_
9	severe	severe	JJ	_	10	attr	_	_
10	agitation	agitation	NN	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	elevated	elevated	JJ	_	14	attr	_	_
14	temperature	temperature	NN	_	4	conj	_	_
15	has	have	VBZ	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	reported	report	VBN	_	0	root	_	_
18	in	in	IN	_	20	case	_	_
19	some	some	DT	_	20	det	_	_
20	patients	patient	NNS	_	17	ppmod	_	_
21	receiving	receive	VBG	_	20	acl	_	_
22	the	the	DT	_	23	det	_	_
23	combination	combination	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug1	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug2	drug0	NN	_	25	conj	_	_
28	.	.	.	_	17	p	_	_

1	Symptoms	symptom	NNS	_	3	dep	_	_
2	usually	usually	RB	_	3	adv	_	_
3	resolve	resolve	VBP	_	0	root	_	_
4	over	over	IN	_	5	case	_	_
5	days	day	NNS	_	3	ppmod	_	_
6	when	when	WRB	_	10	adv	_	_
7	the	the	DT	_	8	det	_	_
8	combination	combination	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	discontinued	discontinue	VBN	_	3	comp	_	_
11	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	typical	typical	JJ	_	2	dep	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	interaction	interaction	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	.	.	.	_	2	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	serious	serious	JJ	_	3	attr	_	_
3	reactions	reaction	NNS	_	16	dep	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	including	include	VBG	_	7	adv	_	_
6	severe	severe	JJ	_	7	attr	_	_
7	agitation	agitation	NN	_	3	prn	_	_
8	,	,	,	_	7	p	_	_
9	hallucinations	hallucination	NNS	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	death	death	NN	_	7	conj	_	_
13	)	-rrb-	-RRB-	_	7	p	_	_
14	have	have	VBP	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	reported	report	VBN	_	0	root	_	_
17	in	in	IN	_	18	case	_	_
18	patients	patient	NNS	_	16	ppmod	_	_
19	receiving	receive	VBG	_	18	acl	_	_
20	this	this	DT	_	21	det	_	_
21	combination	combination	NN	_	19	obj	_	_
22	.	.	.	_	16	p	_	_

1	Severe	severe	JJ	_	2	attr	_	_
2	toxicity	toxicity	NN	_	6	dep	_	_
3	has	have	VBZ	_	6	aux	_	_
4	also	also	RB	_	6	adv	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	the	the	DT	_	11	det	_	_
11	combination	combination	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	and	and	CC	_	13	cc	_	_
17	drug3	drug0	NN	_	13	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	drug4	drug0	NN	_	17	conj	_	_
20	.	.	.	_	6	p	_	_

1	One	#crd#	CD	_	2	num	_	_
2	case	case	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	hypertensive	hypertensive	NN	_	5	com	_	_
5	crisis	crisis	NN	_	2	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	patient	patient	NN	_	8	ppmod	_	_
12	taking	take	VBG	_	11	acl	_	_
13	the	the	DT	_	15	det	_	_
14	recommended	recommend	VBN	_	15	attr	_	_
15	doses	dose	NNS	_	12	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	15	cc	_	_
19	a	a	DT	_	20	det	_	_
20	drug2	drug0	NN	_	15	conj	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug3	drug0	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	.	.	.	_	8	p	_	_

1	When	when	WRB	_	6	adv	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	are	be	VBP	_	6	aux	_	_
6	used	use	VBN	_	28	advcl	_	_
7	together	together	RB	_	6	adv	_	_
8	,	,	,	_	28	p	_	_
9	the	the	DT	_	10	det	_	_
10	signs	sign	NNS	_	28	dep	_	_
11	of	of	IN	_	12	case	_	_
12	atropinization	atropinization	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	flushing	flushing	NN	_	12	prn	_	_
15	,	,	,	_	14	p	_	_
16	mydriasis	mydriasis	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	tachycardia	tachycardia	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	dryness	dryness	NN	_	14	conj	_	_
21	of	of	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	mouth	mouth	NN	_	20	ppmod	_	_
24	and	and	CC	_	20	cc	_	_
25	nose	nose	NN	_	14	conj	_	_
26	)	-rrb-	-RRB-	_	14	p	_	_
27	may	may	MD	_	28	modal	_	_
28	occur	occur	VB	_	0	root	_	_
29	earlier	early	RBR	_	28	adv	_	_
30	than	than	IN	_	33	mark	_	_
31	might	might	MD	_	33	modal	_	_
32	be	be	VB	_	33	aux	_	_
33	expected	expect	VBN	_	29	comp	_	_
34	when	when	WRB	_	37	adv	_	_
35	drug3	drug0	NN	_	37	dep	_	_
36	is	be	VBZ	_	37	aux	_	_
37	used	use	VBN	_	33	comp	_	_
38	alone	alone	RB	_	37	adv	_	_
39	.	.	.	_	28	p	_	_

1	This	this	DT	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	especially	especially	RB	_	4	adv	_	_
4	true	true	JJ	_	2	dep	_	_
5	if	if	IN	_	12	mark	_	_
6	the	the	DT	_	8	det	_	_
7	total	total	JJ	_	8	attr	_	_
8	dose	dose	NN	_	12	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	has	have	VBZ	_	12	aux	_	_
12	been	be	VBN	_	2	comp	_	_
13	large	large	JJ	_	12	dep	_	_
14	and	and	CC	_	12	cc	_	_
15	the	the	DT	_	16	det	_	_
16	administration	administration	NN	_	21	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	has	have	VBZ	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	delayed	delay	VBN	_	12	conj	_	_
22	.	.	.	_	2	p	_	_

1	2	0	CD	_	6	num	_	_
2	-	-	CC	_	1	cc	_	_
3	4	0	CD	_	1	conj	_	_
4	The	the	DT	_	6	det	_	_
5	following	follow	VBG	_	6	attr	_	_
6	precautions	precaution	NNS	_	9	dep	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	kept	keep	VBN	_	42	advcl	_	_
10	in	in	IN	_	11	case	_	_
11	mind	mind	NN	_	9	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	treatment	treatment	NN	_	9	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	anticholinesterase	anticholinesterase	NN	_	17	com	_	_
17	poisoning	poisoning	NN	_	14	ppmod	_	_
18	,	,	,	_	9	p	_	_
19	although	although	IN	_	23	mark	_	_
20	they	they	PRP	_	23	dep	_	_
21	do	do	VBP	_	23	aux	_	_
22	not	not	RB	_	23	neg	_	_
23	bear	bear	VB	_	9	comp	_	_
24	directly	directly	RB	_	23	adv	_	_
25	on	on	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	use	use	NN	_	23	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug1	drug0	NN	_	27	ppmod	_	_
30	:	:	:	_	42	p	_	_
31	since	since	IN	_	34	mark	_	_
32	drug2	drug0	NNS	_	34	dep	_	_
33	are	be	VBP	_	34	aux	_	_
34	potentiated	potentiate	VBN	_	42	advcl	_	_
35	by	by	IN	_	37	case	_	_
36	the	the	DT	_	37	det	_	_
37	drug3	drug0	NN	_	34	ppmod	_	_
38	,	,	,	_	42	p	_	_
39	they	they	PRP	_	42	dep	_	_
40	should	should	MD	_	42	modal	_	_
41	be	be	VB	_	42	aux	_	_
42	used	use	VBN	_	0	root	_	_
43	cautiously	cautiously	RB	_	42	adv	_	_
44	in	in	IN	_	46	case	_	_
45	the	the	DT	_	46	det	_	_
46	treatment	treatment	NN	_	42	ppmod	_	_
47	of	of	IN	_	48	case	_	_
48	convulsions	convulsion	NNS	_	46	ppmod	_	_
49	;	;	:	_	42	p	_	_

1	drug1	drug0	NN	_	15	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	1	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug5	drug0	NN	_	1	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug6	drug0	NN	_	1	conj	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	avoided	avoid	VBN	_	0	root	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	with	with	IN	_	20	case	_	_
19	organophosphate	organophosphate	JJ	_	20	attr	_	_
20	poisoning	poisoning	NN	_	17	ppmod	_	_
21	.	.	.	_	15	p	_	_

1	No	no	DT	_	4	det	_	_
2	drug-drug	drug-drug	JJ	_	4	attr	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	conducted	conduct	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	administered	administer	VBN	_	1	acl	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	decrease	decrease	VBP	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	serum	serum	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	8	p	_	_

1	Laboratory	laboratory	NN	_	2	com	_	_
2	Tests	test	NNS	_	7	dep	_	_
3	The	the	DT	_	4	det	_	_
4	pathologist	pathologist	NN	_	2	attr	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	advised	advise	VBN	_	0	root	_	_
8	of	of	IN	_	10	case	_	_
9	progestin	progestin	NN	_	10	com	_	_
10	therapy	therapy	NN	_	7	ppmod	_	_
11	when	when	WRB	_	15	adv	_	_
12	relevant	relevant	JJ	_	13	attr	_	_
13	specimens	specimen	NNS	_	15	dep	_	_
14	are	be	VBP	_	15	aux	_	_
15	submitted	submit	VBN	_	7	comp	_	_
16	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	physician	physician	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	informed	inform	VBN	_	33	advcl	_	_
6	that	that	IN	_	19	mark	_	_
7	certain	certain	JJ	_	8	attr	_	_
8	endocrine	endocrine	NN	_	19	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	liver	liver	NN	_	12	com	_	_
11	function	function	NN	_	12	com	_	_
12	tests	test	NNS	_	8	conj	_	_
13	,	,	,	_	8	p	_	_
14	and	and	CC	_	8	cc	_	_
15	blood	blood	NN	_	16	com	_	_
16	components	component	NNS	_	8	conj	_	_
17	may	may	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	affected	affect	VBN	_	5	comp	_	_
20	by	by	IN	_	22	case	_	_
21	progestin	progestin	NN	_	22	com	_	_
22	therapy	therapy	NN	_	19	ppmod	_	_
23	:	:	:	_	33	p	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	a	a	LS	_	33	meta	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	Plasma	plasma	NN	_	33	dep	_	_
28	and	and	CC	_	27	cc	_	_
29	urinary	urinary	JJ	_	31	attr	_	_
30	steroid	steroid	NN	_	31	com	_	_
31	levels	level	NNS	_	27	conj	_	_
32	are	be	VBP	_	33	aux	_	_
33	decreased	decrease	VBN	_	0	root	_	_
34	(	-lrb-	-LRB-	_	37	p	_	_
35	e.g.	e.g.	FW	_	37	ppmod	_	_
36	,	,	,	_	37	p	_	_
37	progesterone	progesterone	NN	_	33	prn	_	_
38	,	,	,	_	37	p	_	_
39	estradiol	estradiol	NN	_	37	appo	_	_
40	,	,	,	_	37	p	_	_
41	pregnanediol	pregnanediol	NN	_	37	appo	_	_
42	,	,	,	_	37	p	_	_
43	testosterone	testosterone	NN	_	37	appo	_	_
44	,	,	,	_	37	p	_	_
45	cortisol	cortisol	NN	_	37	appo	_	_
46	)	-rrb-	-RRB-	_	37	p	_	_
47	.	.	.	_	33	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	b	b	LS	_	10	meta	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	Plasma	plasma	NN	_	10	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	urinary	urinary	JJ	_	8	attr	_	_
7	gonadotropin	gonadotropin	NN	_	8	com	_	_
8	levels	level	NNS	_	4	conj	_	_
9	are	be	VBP	_	10	aux	_	_
10	decreased	decrease	VBN	_	0	root	_	_
11	(	-lrb-	-LRB-	_	16	p	_	_
12	e.g.	e.g.	FW	_	14	adv	_	_
13	,	,	,	_	14	p	_	_
14	LH	lh	NN	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	FSH	fsh	NN	_	10	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	.	.	.	_	10	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	c	c	LS	_	5	meta	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	SHBG	shbg	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	7	dep	_	_
6	are	be	VBP	_	7	aux	_	_
7	decreased	decrease	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	(	-lrb-	-LRB-	_	5	p	_	_
2	d	d	NN	_	5	attr	_	_
3	)	-rrb-	-RRB-	_	5	p	_	_
4	T3-uptake	t0-uptake	JJ	_	5	attr	_	_
5	values	value	NNS	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	decrease	decrease	VB	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	e	e	NN	_	4	prn	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	There	there	EX	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	be	be	VB	_	0	root	_	_
7	small	small	JJ	_	8	attr	_	_
8	changes	change	NNS	_	6	obj	_	_
9	in	in	IN	_	11	case	_	_
10	coagulation	coagulation	NN	_	11	com	_	_
11	factors	factor	NNS	_	8	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	(	-lrb-	-LRB-	_	4	p	_	_
2	f	f	NN	_	4	attr	_	_
3	)	-rrb-	-RRB-	_	4	p	_	_
4	Sulfobromophthalein	sulfobromophthalein	NN	_	13	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	other	other	JJ	_	10	attr	_	_
7	liver	liver	NN	_	10	com	_	_
8	function	function	NN	_	10	com	_	_
9	test	test	NN	_	10	com	_	_
10	values	value	NNS	_	4	conj	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	increased	increase	VBN	_	0	root	_	_
14	slightly	slightly	RB	_	13	adv	_	_
15	.	.	.	_	13	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	g	g	NN	_	4	prn	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	There	there	EX	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	be	be	VB	_	0	root	_	_
7	small	small	JJ	_	8	attr	_	_
8	changes	change	NNS	_	6	obj	_	_
9	in	in	IN	_	11	case	_	_
10	lipid	lipid	NN	_	11	com	_	_
11	profiles	profile	NNS	_	8	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	30	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	30	p	_	_
7	patients	patient	NNS	_	30	dep	_	_
8	taking	take	VBG	_	7	acl	_	_
9	drug2	drug0	NN	_	8	obj	_	_
10	concomitantly	concomitantly	RB	_	12	adv	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	7	ppmod	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	drug4	drug0	NN	_	16	dep	_	_
15	,	,	,	_	16	p	_	_
16	Genentech	genentech	NNP	_	12	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	12	p	_	_
19	drug5	drug0	NN	_	12	conj	_	_
20	,	,	,	_	19	p	_	_
21	inhaled	inhaled	JJ	_	22	attr	_	_
22	drug6	drug0	NN	_	12	conj	_	_
23	,	,	,	_	22	p	_	_
24	other	other	JJ	_	25	attr	_	_
25	drug7	drug0	NN	_	12	conj	_	_
26	,	,	,	_	25	p	_	_
27	or	or	CC	_	25	cc	_	_
28	parenteral	parenteral	JJ	_	29	attr	_	_
29	drug8	drug0	NN	_	12	conj	_	_
30	demonstrated	demonstrate	VBD	_	0	root	_	_
31	adverse	adverse	JJ	_	30	dep	_	_
32	experience	experience	VBP	_	31	comp	_	_
33	profiles	profile	NNS	_	32	obj	_	_
34	similar	similar	JJ	_	33	attr	_	_
35	to	to	TO	_	38	aux	_	_
36	the	the	DT	_	38	det	_	_
37	study	study	NN	_	38	com	_	_
38	population	population	NN	_	34	ppmod	_	_
39	as	as	IN	_	41	case	_	_
40	a	a	DT	_	41	det	_	_
41	whole	whole	JJ	_	32	ppmod	_	_
42	.	.	.	_	30	p	_	_

1	Concurrent	concurrent	JJ	_	4	attr	_	_
2	and/or	and/or	CC	_	1	cc	_	_
3	sequential	sequential	JJ	_	1	conj	_	_
4	use	use	NN	_	17	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	4	ppmod	_	_
10	with	with	IN	_	14	case	_	_
11	neurotoxic	neurotoxic	JJ	_	14	attr	_	_
12	or	or	CC	_	11	cc	_	_
13	ototoxic	ototoxic	JJ	_	11	conj	_	_
14	potential	potential	NN	_	9	ppmod	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	avoided	avoid	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	Some	some	DT	_	2	det	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	can	can	MD	_	4	modal	_	_
4	enhance	enhance	VB	_	0	root	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	toxicity	toxicity	NN	_	4	obj	_	_
7	by	by	IN	_	8	case	_	_
8	altering	alter	VBG	_	4	ppmod	_	_
9	drug3	drug0	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	8	obj	_	_
11	in	in	IN	_	12	case	_	_
12	serum	serum	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	tissue	tissue	NN	_	12	conj	_	_
15	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	administered	administer	VBN	_	0	root	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	drug5	drug0	NN	_	8	conj	_	_
16	.	.	.	_	5	p	_	_

1	DRUG	drug	NN	_	2	com	_	_
2	INTERACTIONS	interaction	NNS	_	17	dep	_	_
3	There	there	EX	_	4	dep	_	_
4	are	be	VBP	_	2	acl	_	_
5	no	no	DT	_	8	det	_	_
6	known	known	JJ	_	8	attr	_	_
7	drug/drug	drug/drug	NN	_	8	com	_	_
8	interactions	interaction	NNS	_	4	obj	_	_
9	with	with	IN	_	12	case	_	_
10	oral	oral	JJ	_	12	attr	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	Vaccinations	vaccinations	NN	_	8	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	8	ppmod	_	_
15	are	be	VBP	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	recommended	recommend	VBN	_	28	advcl	_	_
18	in	in	IN	_	20	case	_	_
19	immunocompromised	immunocompromised	JJ	_	20	attr	_	_
20	individuals	individual	NNS	_	17	ppmod	_	_
21	drug3	drug0	NN	_	28	dep	_	_
22	together	together	RB	_	26	adv	_	_
23	with	with	IN	_	26	case	_	_
24	high-dose	high-dose	JJ	_	26	attr	_	_
25	intravenous	intravenous	JJ	_	26	attr	_	_
26	drug4	drug0	NN	_	21	ppmod	_	_
27	has	have	VBZ	_	28	aux	_	_
28	caused	cause	VBN	_	0	root	_	_
29	deaths	death	NNS	_	28	obj	_	_
30	in	in	IN	_	31	case	_	_
31	children	child	NNS	_	29	ppmod	_	_
32	due	due	JJ	_	31	attr	_	_
33	to	to	TO	_	35	aux	_	_
34	haemorrhagic	haemorrhagic	JJ	_	35	attr	_	_
35	enterocolitis	enterocolitis	NN	_	32	ppmod	_	_
36	.	.	.	_	28	p	_	_

1	Impaired	impaired	JJ	_	3	attr	_	_
2	renal	renal	JJ	_	3	attr	_	_
3	function	function	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	described	describe	VBN	_	0	root	_	_
7	in	in	IN	_	11	case	_	_
8	bone	bone	NN	_	9	com	_	_
9	marrow	marrow	NN	_	11	com	_	_
10	transplant	transplant	NN	_	11	com	_	_
11	patients	patient	NNS	_	6	ppmod	_	_
12	who	who	WP	_	14	dep	_	_
13	were	be	VBD	_	14	aux	_	_
14	conditioned	condition	VBN	_	11	advcl	_	_
15	with	with	IN	_	18	case	_	_
16	high-dose	high-dose	JJ	_	18	attr	_	_
17	intravenous	intravenous	JJ	_	18	attr	_	_
18	drug1	drug0	NN	_	14	ppmod	_	_
19	and	and	CC	_	14	cc	_	_
20	who	who	WP	_	22	dep	_	_
21	subsequently	subsequently	RB	_	22	adv	_	_
22	received	receive	VBD	_	14	conj	_	_
23	drug2	drug0	NN	_	22	obj	_	_
24	to	to	TO	_	25	aux	_	_
25	prevent	prevent	VB	_	22	comp	_	_
26	graft-versus-host	graft-versus-host	JJ	_	27	attr	_	_
27	disease	disease	NN	_	25	obj	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	because	because	IN	_	14	case	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	possibility	possibility	NN	_	9	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	conduction	conduction	NN	_	17	com	_	_
17	disturbances	disturbance	NNS	_	14	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Drugs	drug	NNS	_	11	dep	_	_
2	with	with	IN	_	4	case	_	_
3	parasympathomimetic	parasympathomimetic	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	1	ppmod	_	_
5	administered	administer	VBN	_	4	acl	_	_
6	concurrently	concurrently	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	would	would	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	expected	expect	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	result	result	VB	_	11	comp	_	_
14	in	in	IN	_	17	case	_	_
15	additive	additive	JJ	_	17	attr	_	_
16	pharmacologic	pharmacologic	JJ	_	17	attr	_	_
17	effects	effect	NNS	_	13	ppmod	_	_
18	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	might	might	MD	_	3	modal	_	_
3	antagonize	antagonize	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	anticholinergic	anticholinergic	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drugs	drug	NNS	_	6	ppmod	_	_
9	used	use	VBN	_	8	acl	_	_
10	concomitantly	concomitantly	RB	_	9	adv	_	_
11	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	considered	consider	VBN	_	0	root	_	_
6	when	when	IN	_	8	case	_	_
7	anticholinergic	anticholinergic	JJ	_	8	attr	_	_
8	properties	property	NNS	_	5	ppmod	_	_
9	may	may	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	contributing	contribute	VBG	_	8	acl	_	_
12	to	to	TO	_	15	aux	_	_
13	the	the	DT	_	15	det	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	effect	effect	NN	_	11	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	concomitant	concomitant	JJ	_	18	attr	_	_
18	medication	medication	NN	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	25	p	_	_
20	e.g.	e.g.	FW	_	22	adv	_	_
21	,	,	,	_	22	p	_	_
22	drug1	drug0	NN	_	25	ppmod	_	_
23	,	,	,	_	25	p	_	_
24	inhaled	inhaled	JJ	_	25	attr	_	_
25	drug2	drug0	NNS	_	18	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	.	.	.	_	5	p	_	_

1	While	while	IN	_	9	mark	_	_
2	no	no	DT	_	6	det	_	_
3	formal	formal	JJ	_	6	attr	_	_
4	drug	drug	NN	_	6	com	_	_
5	interaction	interaction	NN	_	6	com	_	_
6	studies	study	NNS	_	9	dep	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	performed	performed	VBN	_	16	advcl	_	_
10	,	,	,	_	16	p	_	_
11	the	the	DT	_	14	det	_	_
12	following	following	JJ	_	14	attr	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	16	dep	_	_
15	were	be	VBD	_	16	aux	_	_
16	used	use	VBN	_	0	root	_	_
17	in	in	IN	_	20	case	_	_
18	at	at	IN	_	20	case	_	_
19	least	least	JJS	_	20	attr	_	_
20	10	0	CD	_	16	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	of	of	IN	_	23	case	_	_
23	patients	patient	NNS	_	20	ppmod	_	_
24	in	in	IN	_	25	case	_	_
25	either	either	DT	_	23	ppmod	_	_
26	or	or	CC	_	20	cc	_	_
27	both	both	DT	_	29	det	_	_
28	Sj	sj	NN	_	29	com	_	_
29	grens	grens	NNS	_	31	com	_	_
30	efficacy	efficacy	NN	_	31	com	_	_
31	studies	study	NNS	_	20	conj	_	_
32	:	:	:	_	31	p	_	_
33	drug1	drug0	NN	_	20	conj	_	_
34	,	,	,	_	33	p	_	_
35	artificial	artificial	JJ	_	36	attr	_	_
36	tears	tear	NNS	_	20	conj	_	_
37	,	,	,	_	36	p	_	_
38	drug2	drug0	NN	_	20	conj	_	_
39	,	,	,	_	38	p	_	_
40	drug3	drug0	NN	_	20	conj	_	_
41	,	,	,	_	40	p	_	_
42	drug4	drug0	NN	_	20	conj	_	_
43	,	,	,	_	42	p	_	_
44	drug5	drug0	NN	_	20	conj	_	_
45	,	,	,	_	44	p	_	_
46	drug6	drug0	NN	_	20	conj	_	_
47	,	,	,	_	46	p	_	_
48	drug7	drug0	NN	_	20	conj	_	_
49	,	,	,	_	48	p	_	_
50	drug8	drug0	NN	_	20	conj	_	_
51	,	,	,	_	50	p	_	_
52	drug9	drug0	NN	_	20	conj	_	_
53	,	,	,	_	52	p	_	_
54	drug10	drug0	CD	_	20	conj	_	_
55	,	,	,	_	54	p	_	_
56	drug11	drug0	NN	_	20	conj	_	_
57	,	,	,	_	56	p	_	_
58	drug12	drug0	CD	_	20	conj	_	_
59	,	,	,	_	58	p	_	_
60	and	and	CC	_	58	cc	_	_
61	drug13	drug0	NN	_	20	conj	_	_
62	.	.	.	_	16	p	_	_

1	The	the	DT	_	4	det	_	_
2	induction	induction	NN	_	4	com	_	_
3	dose	dose	NN	_	4	com	_	_
4	requirements	requirement	NNS	_	11	dep	_	_
5	of	of	IN	_	8	case	_	_
6	drug1	drug0	NN	_	8	attr	_	_
7	Injectable	injectable	JJ	_	8	attr	_	_
8	Emulsion	emulsion	NN	_	4	ppmod	_	_
9	may	may	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	reduced	reduce	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	with	with	IN	_	18	case	_	_
15	intramuscular	intramuscular	JJ	_	18	attr	_	_
16	or	or	CC	_	15	cc	_	_
17	intravenous	intravenous	JJ	_	15	conj	_	_
18	premedication	premedication	NN	_	13	ppmod	_	_
19	,	,	,	_	11	p	_	_
20	particularly	particularly	RB	_	11	adv	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	11	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	eg	eg	NN	_	22	prn	_	_
25	,	,	,	_	24	p	_	_
26	drug3	drug0	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug4	drug0	NN	_	24	conj	_	_
29	,	,	,	_	28	p	_	_
30	and	and	CC	_	28	cc	_	_
31	drug5	drug0	NN	_	24	conj	_	_
32	,	,	,	_	31	p	_	_
33	etc	etc	NN	_	24	conj	_	_
34	.	.	.	_	33	p	_	_
35	)	-rrb-	-RRB-	_	24	p	_	_

1	and	and	CC	_	2	cc	_	_
2	combinations	combination	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	eg	eg	NN	_	2	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	drug4	drug0	NN	_	8	appo	_	_
13	,	,	,	_	8	p	_	_
14	drug5	drug0	NN	_	8	appo	_	_
15	,	,	,	_	8	p	_	_
16	drug6	drug0	NN	_	8	appo	_	_
17	,	,	,	_	8	p	_	_
18	etc	etc	NN	_	8	appo	_	_
19	.	.	.	_	8	p	_	_
20	)	-rrb-	-RRB-	_	8	p	_	_
21	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	increase	increase	VB	_	0	root	_	_
5	the	the	DT	_	9	det	_	_
6	anesthetic	anesthetic	JJ	_	9	attr	_	_
7	or	or	CC	_	6	cc	_	_
8	sedative	sedative	JJ	_	6	conj	_	_
9	effects	effect	NNS	_	4	obj	_	_
10	of	of	IN	_	13	case	_	_
11	drug1	drug0	JJ	_	13	attr	_	_
12	Injectable	injectable	JJ	_	13	attr	_	_
13	Emulsion	emulsion	NN	_	9	ppmod	_	_
14	and	and	CC	_	4	cc	_	_
15	may	may	MD	_	17	modal	_	_
16	also	also	RB	_	17	adv	_	_
17	result	result	VB	_	4	conj	_	_
18	in	in	IN	_	21	case	_	_
19	more	more	RBR	_	20	adv	_	_
20	pronounced	pronounced	JJ	_	21	attr	_	_
21	decreases	decrease	NNS	_	17	ppmod	_	_
22	in	in	IN	_	30	case	_	_
23	systolic	systolic	JJ	_	30	attr	_	_
24	,	,	,	_	23	p	_	_
25	diastolic	diastolic	JJ	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	mean	mean	NN	_	29	advnp	_	_
29	arterial	arterial	JJ	_	23	conj	_	_
30	pressures	pressure	NNS	_	21	ppmod	_	_
31	and	and	CC	_	30	cc	_	_
32	cardiac	cardiac	JJ	_	33	attr	_	_
33	output	output	NN	_	30	conj	_	_
34	.	.	.	_	4	p	_	_

1	During	during	IN	_	2	case	_	_
2	maintenance	maintenance	NN	_	17	ppmod	_	_
3	of	of	IN	_	4	case	_	_
4	anesthesia	anesthesia	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	sedation	sedation	NN	_	4	conj	_	_
7	,	,	,	_	17	p	_	_
8	the	the	DT	_	9	det	_	_
9	rate	rate	NN	_	17	dep	_	_
10	of	of	IN	_	14	case	_	_
11	drug1	drug0	JJ	_	14	attr	_	_
12	Injectable	injectable	JJ	_	14	attr	_	_
13	Emulsion	emulsion	NN	_	14	com	_	_
14	administration	administration	NN	_	9	ppmod	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	adjusted	adjust	VBN	_	0	root	_	_
18	according	accord	VBG	_	22	adv	_	_
19	to	to	TO	_	22	aux	_	_
20	the	the	DT	_	22	det	_	_
21	desired	desired	JJ	_	22	attr	_	_
22	level	level	NN	_	17	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	anesthesia	anesthesia	NN	_	22	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	sedation	sedation	NN	_	24	conj	_	_
27	and	and	CC	_	17	cc	_	_
28	may	may	MD	_	30	modal	_	_
29	be	be	VB	_	30	aux	_	_
30	reduced	reduce	VBN	_	17	conj	_	_
31	in	in	IN	_	36	case	_	_
32	the	the	DT	_	36	det	_	_
33	presence	presence	NN	_	36	advnp	_	_
34	of	of	IN	_	36	case	_	_
35	supplemental	supplemental	JJ	_	36	attr	_	_
36	drug2	drug0	NNS	_	30	ppmod	_	_
37	(	-lrb-	-LRB-	_	38	p	_	_
38	eg	eg	NN	_	36	prn	_	_
39	,	,	,	_	38	p	_	_
40	drug3	drug0	NN	_	38	conj	_	_
41	or	or	CC	_	40	cc	_	_
42	drug4	drug0	NN	_	38	conj	_	_
43	)	-rrb-	-RRB-	_	38	p	_	_
44	.	.	.	_	17	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	administration	administration	NN	_	28	dep	_	_
4	of	of	IN	_	7	case	_	_
5	potent	potent	JJ	_	7	attr	_	_
6	inhalational	inhalational	JJ	_	7	attr	_	_
7	agents	agent	NNS	_	3	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	eg	eg	NN	_	7	prn	_	_
10	,	,	,	_	9	p	_	_
11	drug1	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug2	drug0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug3	drug0	NN	_	9	conj	_	_
17	)	-rrb-	-RRB-	_	9	p	_	_
18	during	during	IN	_	19	case	_	_
19	maintenance	maintenance	NN	_	3	ppmod	_	_
20	with	with	IN	_	23	case	_	_
21	drug4	drug0	NN	_	23	attr	_	_
22	Injectable	injectable	JJ	_	23	attr	_	_
23	Emulsion	emulsion	NN	_	19	ppmod	_	_
24	has	have	VBZ	_	28	aux	_	_
25	not	not	RB	_	28	neg	_	_
26	been	be	VBN	_	28	aux	_	_
27	extensively	extensively	RB	_	28	adv	_	_
28	evaluated	evaluate	VBN	_	0	root	_	_
29	.	.	.	_	28	p	_	_

1	These	these	DT	_	3	det	_	_
2	inhalational	inhalational	JJ	_	3	attr	_	_
3	agents	agent	NNS	_	7	dep	_	_
4	can	can	MD	_	7	modal	_	_
5	also	also	RB	_	7	adv	_	_
6	be	be	VB	_	7	aux	_	_
7	expected	expect	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	increase	increase	VB	_	7	comp	_	_
10	the	the	DT	_	16	det	_	_
11	anesthetic	anesthetic	JJ	_	16	attr	_	_
12	or	or	CC	_	13	cc	_	_
13	sedative	sedative	JJ	_	16	attr	_	_
14	and	and	CC	_	13	cc	_	_
15	cardiorespiratory	cardiorespiratory	JJ	_	13	conj	_	_
16	effects	effect	NNS	_	9	obj	_	_
17	of	of	IN	_	20	case	_	_
18	drug1	drug0	JJ	_	20	attr	_	_
19	Injectable	injectable	JJ	_	20	attr	_	_
20	Emulsion	emulsion	NN	_	16	ppmod	_	_
21	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	Injectable	injectable	JJ	_	3	attr	_	_
3	Emulsion	emulsion	NN	_	6	dep	_	_
4	does	do	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	cause	cause	VB	_	0	root	_	_
7	a	a	DT	_	10	det	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	change	change	NN	_	6	obj	_	_
11	in	in	IN	_	12	case	_	_
12	onset	onset	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	intensity	intensity	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	duration	duration	NN	_	12	conj	_	_
18	of	of	IN	_	19	case	_	_
19	action	action	NN	_	12	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	the	the	DT	_	24	det	_	_
22	commonly	commonly	RB	_	23	adv	_	_
23	used	use	VBN	_	24	attr	_	_
24	drug2	drug0	NN	_	19	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	eg	eg	NN	_	24	prn	_	_
27	,	,	,	_	26	p	_	_
28	drug3	drug0	NN	_	26	conj	_	_
29	and	and	CC	_	28	cc	_	_
30	drug4	drug0	NN	_	26	conj	_	_
31	)	-rrb-	-RRB-	_	26	p	_	_
32	.	.	.	_	6	p	_	_

1	No	no	DT	_	4	det	_	_
2	significant	significant	JJ	_	4	attr	_	_
3	adverse	adverse	JJ	_	4	attr	_	_
4	interactions	interaction	NNS	_	34	dep	_	_
5	with	with	IN	_	8	case	_	_
6	commonly	commonly	RB	_	7	adv	_	_
7	used	use	VBN	_	8	attr	_	_
8	premedications	premedications	NNS	_	4	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drugs	drug	NNS	_	8	conj	_	_
11	used	use	VBN	_	10	acl	_	_
12	during	during	IN	_	13	case	_	_
13	anesthesia	anesthesia	NN	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	sedation	sedation	NN	_	13	conj	_	_
16	(	-lrb-	-LRB-	_	10	p	_	_
17	including	include	VBG	_	19	adv	_	_
18	a	a	DT	_	19	det	_	_
19	range	range	NN	_	10	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	inhalational	inhalational	JJ	_	24	attr	_	_
24	agents	agent	NNS	_	21	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug2	drug0	NN	_	21	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	local	local	JJ	_	30	attr	_	_
30	drug3	drug0	NN	_	21	conj	_	_
31	)	-rrb-	-RRB-	_	10	p	_	_
32	have	have	VBP	_	34	aux	_	_
33	been	be	VBN	_	34	aux	_	_
34	observed	observe	VBN	_	0	root	_	_
35	.	.	.	_	34	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	potentiate	potentiate	VB	_	5	comp	_	_
8	the	the	DT	_	10	det	_	_
9	anticoagulant	anticoagulant	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	5	p	_	_
16	resulting	result	VBG	_	5	comp	_	_
17	in	in	IN	_	19	case	_	_
18	a	a	DT	_	19	det	_	_
19	prolongation	prolongation	NN	_	16	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	prothrombin	prothrombin	NN	_	22	com	_	_
22	time	time	NN	_	19	ppmod	_	_
23	.	.	.	_	5	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	interactions	interaction	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	kept	keep	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	mind	mind	NN	_	5	ppmod	_	_
8	when	when	WRB	_	18	adv	_	_
9	drug1	drug0	NN	_	18	dep	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	gel	gel	NN	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	,	,	,	_	9	p	_	_
15	1	0	CD	_	9	appo	_	_
16	%	%	NN	_	15	meta	_	_
17	is	be	VBZ	_	18	aux	_	_
18	prescribed	prescribe	VBN	_	5	comp	_	_
19	for	for	IN	_	20	case	_	_
20	patients	patient	NNS	_	18	ppmod	_	_
21	who	who	WP	_	23	dep	_	_
22	are	be	VBP	_	23	aux	_	_
23	receiving	receive	VBG	_	20	relcl	_	_
24	anticoagulant	anticoagulant	NN	_	25	com	_	_
25	treatment	treatment	NN	_	23	obj	_	_
26	,	,	,	_	23	p	_	_
27	although	although	IN	_	29	mark	_	_
28	they	they	PRP	_	29	dep	_	_
29	are	be	VBP	_	23	comp	_	_
30	less	less	RBR	_	31	adv	_	_
31	likely	likely	JJ	_	29	dep	_	_
32	to	to	TO	_	33	aux	_	_
33	occur	occur	VB	_	29	comp	_	_
34	with	with	IN	_	37	case	_	_
35	topical	topical	JJ	_	37	attr	_	_
36	drug3	drug0	NN	_	37	com	_	_
37	administration	administration	NN	_	33	ppmod	_	_
38	because	because	IN	_	41	case	_	_
39	of	of	IN	_	41	case	_	_
40	low	low	JJ	_	41	attr	_	_
41	absorption	absorption	NN	_	33	ppmod	_	_
42	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	on	on	IN	_	11	case	_	_
10	steroid	steroid	NN	_	11	com	_	_
11	therapy	therapy	NN	_	8	ppmod	_	_
12	because	because	IN	_	15	case	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	potential	potential	NN	_	4	ppmod	_	_
16	for	for	IN	_	17	case	_	_
17	developing	develop	VBG	_	15	ppmod	_	_
18	hypokalemia	hypokalemia	NN	_	17	obj	_	_
19	.	.	.	_	4	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	advised	advise	VBN	_	0	root	_	_
4	for	for	IN	_	5	case	_	_
5	patients	patient	NNS	_	3	ppmod	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	high-dose	high-dose	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	6	obj	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	concomitantly	concomitantly	RB	_	8	adv	_	_
12	,	,	,	_	3	p	_	_
13	as	as	IN	_	25	mark	_	_
14	anorexia	anorexia	NN	_	25	dep	_	_
15	,	,	,	_	14	p	_	_
16	tachypnea	tachypnea	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	lethargy	lethargy	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	coma	coma	NN	_	14	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	death	death	NN	_	14	conj	_	_
23	have	have	VBP	_	25	aux	_	_
24	been	be	VBN	_	25	aux	_	_
25	reported	report	VBN	_	3	comp	_	_
26	with	with	IN	_	28	case	_	_
27	concomitant	concomitant	JJ	_	28	attr	_	_
28	use	use	NN	_	25	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	high-dose	high-dose	JJ	_	31	attr	_	_
31	drug3	drug0	NN	_	28	ppmod	_	_
32	and	and	CC	_	31	cc	_	_
33	drug4	drug0	NN	_	31	conj	_	_
34	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug4	drug0	NNS	_	6	conj	_	_
12	,	,	,	_	6	p	_	_
13	and	and	CC	_	6	cc	_	_
14	with	with	IN	_	16	case	_	_
15	other	other	JJ	_	16	attr	_	_
16	drug5	drug0	NN	_	6	conj	_	_
17	.	.	.	_	4	p	_	_

1	If	if	IN	_	6	mark	_	_
2	signs	sign	NNS	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	folate	folate	NN	_	5	com	_	_
5	deficiency	deficiency	NN	_	2	ppmod	_	_
6	develop	develop	VBP	_	11	advcl	_	_
7	,	,	,	_	11	p	_	_
8	drug1	drug0	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	discontinued	discontinue	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	administered	administer	VBN	_	0	root	_	_
8	until	until	IN	_	12	mark	_	_
9	normal	normal	JJ	_	10	attr	_	_
10	hematopoiesis	hematopoiesis	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	restored	restore	VBN	_	7	comp	_	_
13	.	.	.	_	7	p	_	_

1	Mild	mild	JJ	_	2	attr	_	_
2	hepatotoxicity	hepatotoxicity	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	some	some	DT	_	8	det	_	_
8	patients	patient	NNS	_	5	ppmod	_	_
9	when	when	WRB	_	14	adv	_	_
10	drug1	drug0	NN	_	14	dep	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	were	be	VBD	_	14	aux	_	_
14	administered	administer	VBN	_	5	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	.	.	.	_	5	p	_	_

1	Due	due	IN	_	4	case	_	_
2	to	to	TO	_	4	aux	_	_
3	its	its	PRP$	_	4	poss	_	_
4	effects	effect	NNS	_	14	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	gastric	gastric	JJ	_	7	attr	_	_
7	emptying	emptying	NN	_	4	ppmod	_	_
8	,	,	,	_	14	p	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	therapy	therapy	NN	_	14	dep	_	_
11	should	should	MD	_	14	modal	_	_
12	not	not	RB	_	14	neg	_	_
13	be	be	VB	_	14	aux	_	_
14	considered	consider	VBN	_	0	root	_	_
15	for	for	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	taking	take	VBG	_	16	acl	_	_
18	drugs	drug	NNS	_	17	obj	_	_
19	that	that	WDT	_	20	dep	_	_
20	alter	alter	VBP	_	18	relcl	_	_
21	gastrointestinal	gastrointestinal	JJ	_	22	attr	_	_
22	motility	motility	NN	_	20	obj	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	e.g.	e.g.	FW	_	26	ppmod	_	_
25	,	,	,	_	26	p	_	_
26	drug2	drug0	NNS	_	18	prn	_	_
27	such	such	JJ	_	29	adv	_	_
28	as	as	IN	_	29	case	_	_
29	drug3	drug0	NN	_	26	ppmod	_	_
30	)	-rrb-	-RRB-	_	26	p	_	_
31	and	and	CC	_	18	cc	_	_
32	agents	agent	NNS	_	18	conj	_	_
33	that	that	WDT	_	34	dep	_	_
34	slow	slow	JJ	_	32	relcl	_	_
35	the	the	DT	_	37	det	_	_
36	intestinal	intestinal	JJ	_	37	attr	_	_
37	absorption	absorption	NN	_	34	obj	_	_
38	of	of	IN	_	39	case	_	_
39	nutrients	nutrient	NNS	_	37	ppmod	_	_
40	(	-lrb-	-LRB-	_	43	p	_	_
41	e.g.	e.g.	FW	_	43	ppmod	_	_
42	,	,	,	_	43	p	_	_
43	drug4	drug0	NNS	_	32	prn	_	_
44	)	-rrb-	-RRB-	_	43	p	_	_
45	.	.	.	_	14	p	_	_

1	Patients	patient	NNS	_	8	dep	_	_
2	using	use	VBG	_	1	acl	_	_
3	these	these	DT	_	4	det	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	have	have	VBP	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	studied	study	VBN	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	trials	trial	NNS	_	8	ppmod	_	_
12	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	2	obj	_	_
5	to	to	TO	_	6	aux	_	_
6	delay	delay	VB	_	4	acl	_	_
7	the	the	DT	_	8	det	_	_
8	absorption	absorption	NN	_	6	obj	_	_
9	of	of	IN	_	13	case	_	_
10	concomitantly	concomitantly	RB	_	11	adv	_	_
11	administered	administer	VBN	_	13	attr	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	medications	medication	NNS	_	8	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	When	when	WRB	_	11	adv	_	_
2	the	the	DT	_	4	det	_	_
3	rapid	rapid	JJ	_	4	attr	_	_
4	onset	onset	NN	_	11	dep	_	_
5	of	of	IN	_	10	case	_	_
6	a	a	DT	_	10	det	_	_
7	concomitant	concomitant	JJ	_	10	attr	_	_
8	orally	orally	RB	_	9	adv	_	_
9	administered	administer	VBN	_	10	attr	_	_
10	agent	agent	NN	_	4	ppmod	_	_
11	is	be	VBZ	_	27	advcl	_	_
12	a	a	DT	_	14	det	_	_
13	critical	critical	JJ	_	14	attr	_	_
14	determinant	determinant	NN	_	11	obj	_	_
15	of	of	IN	_	16	case	_	_
16	effectiveness	effectiveness	NN	_	14	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	such	such	JJ	_	11	prn	_	_
19	as	as	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	)	-rrb-	-RRB-	_	18	p	_	_
22	,	,	,	_	27	p	_	_
23	the	the	DT	_	24	det	_	_
24	agent	agent	NN	_	27	dep	_	_
25	should	should	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	administered	administer	VBN	_	0	root	_	_
28	at	at	IN	_	31	case	_	_
29	least	least	JJS	_	30	attr	_	_
30	1	0	CD	_	31	num	_	_
31	hour	hour	NN	_	27	ppmod	_	_
32	prior	prior	RB	_	27	adv	_	_
33	to	to	TO	_	32	ppmod	_	_
34	or	or	CC	_	33	cc	_	_
35	2	0	CD	_	36	num	_	_
36	hours	hour	NNS	_	33	conj	_	_
37	after	after	IN	_	39	case	_	_
38	drug2	drug0	NN	_	39	com	_	_
39	injection	injection	NN	_	36	ppmod	_	_
40	.	.	.	_	27	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	14	ppmod	_	_
4	,	,	,	_	14	p	_	_
5	the	the	DT	_	7	det	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	use	use	NN	_	14	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	did	do	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	alter	alter	VB	_	0	root	_	_
15	the	the	DT	_	18	det	_	_
16	adverse	adverse	JJ	_	18	attr	_	_
17	event	event	NN	_	18	com	_	_
18	profile	profile	NN	_	14	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	No	no	DT	_	4	det	_	_
2	formal	formal	JJ	_	4	attr	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	assess	assess	VB	_	7	comp	_	_
10	the	the	DT	_	11	det	_	_
11	effect	effect	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	on	on	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	kinetics	kinetics	NNS	_	11	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	drug2	drug0	NN	_	16	ppmod	_	_
20	.	.	.	_	7	p	_	_

1	Mixing	mix	VBG	_	2	adv	_	_
2	drug1	drug0	NN	_	11	ppmod	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	The	the	DT	_	7	det	_	_
6	pharmacokinetic	pharmacokinetic	JJ	_	7	attr	_	_
7	parameters	parameter	NNS	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	were	be	VBD	_	11	aux	_	_
11	altered	alter	VBN	_	0	root	_	_
12	when	when	WRB	_	13	adv	_	_
13	mixed	mix	VBN	_	11	comp	_	_
14	with	with	IN	_	22	case	_	_
15	regular	regular	JJ	_	22	attr	_	_
16	,	,	,	_	15	p	_	_
17	NPH	nph	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	70/30	0	NN	_	21	num	_	_
21	premixed	premix	VBN	_	15	conj	_	_
22	formulations	formulation	NNS	_	13	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	recombinant	recombinant	JJ	_	25	attr	_	_
25	drug4	drug0	NNS	_	22	ppmod	_	_
26	immediately	immediately	RB	_	27	adv	_	_
27	prior	prior	JJ	_	25	attr	_	_
28	to	to	TO	_	29	aux	_	_
29	injection	injection	NN	_	27	ppmod	_	_
30	.	.	.	_	11	p	_	_

1	Thus	thus	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	drug1	drug0	NN	_	9	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	should	should	MD	_	9	modal	_	_
7	not	not	RB	_	9	neg	_	_
8	be	be	VB	_	9	aux	_	_
9	mixed	mix	VBN	_	0	root	_	_
10	and	and	CC	_	9	cc	_	_
11	must	must	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	administered	administer	VBN	_	9	conj	_	_
14	separately	separately	RB	_	13	adv	_	_
15	.	.	.	_	9	p	_	_

1	Since	since	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	is	be	VBZ	_	26	advcl	_	_
4	a	a	DT	_	5	det	_	_
5	substrate	substrate	NN	_	3	obj	_	_
6	for	for	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	metabolic	metabolic	JJ	_	9	attr	_	_
9	pathways	pathway	NNS	_	5	ppmod	_	_
10	involving	involve	VBG	_	9	acl	_	_
11	CYP2D6	cyp0d0	NN	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	CYP1A2	cyp0a0	NN	_	11	conj	_	_
14	enzymes	enzyme	NNS	_	10	obj	_	_
15	,	,	,	_	26	p	_	_
16	inhibition	inhibition	NN	_	26	dep	_	_
17	or	or	CC	_	16	cc	_	_
18	induction	induction	NN	_	16	conj	_	_
19	of	of	IN	_	20	case	_	_
20	either	either	DT	_	16	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	these	these	DT	_	23	det	_	_
23	enzymes	enzyme	NNS	_	20	ppmod	_	_
24	would	would	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	expected	expect	VBN	_	0	root	_	_
27	to	to	TO	_	28	aux	_	_
28	alter	alter	VB	_	26	comp	_	_
29	drug2	drug0	NN	_	31	com	_	_
30	plasma	plasma	NN	_	31	com	_	_
31	concentrations	concentration	NNS	_	28	obj	_	_
32	.	.	.	_	26	p	_	_

1	In	in	IN	_	7	case	_	_
2	a	a	DT	_	7	det	_	_
3	formal	formal	JJ	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	single-dose	single-dose	JJ	_	7	attr	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	study	study	NN	_	19	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	n	n	NN	_	7	prn	_	_
10	=	=	JJ	_	9	attr	_	_
11	6	0	CD	_	12	num	_	_
12	males	male	NNS	_	10	advnp	_	_
13	)	-rrb-	-RRB-	_	9	p	_	_
14	the	the	DT	_	15	det	_	_
15	clearance	clearance	NN	_	19	dep	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	was	be	VBD	_	19	aux	_	_
19	decreased	decrease	VBN	_	0	root	_	_
20	by	by	IN	_	21	case	_	_
21	38	0	CD	_	19	ppmod	_	_
22	%	%	NN	_	21	meta	_	_
23	following	follow	VBG	_	25	adv	_	_
24	the	the	DT	_	25	det	_	_
25	coadministration	coadministration	NN	_	19	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	,	,	,	_	27	p	_	_
29	an	an	DT	_	30	det	_	_
30	inhibitor	inhibitor	NN	_	27	appo	_	_
31	of	of	IN	_	32	case	_	_
32	CYP1A2	cyp0a0	NN	_	30	ppmod	_	_
33	.	.	.	_	19	p	_	_

1	In	in	IN	_	4	case	_	_
2	another	another	DT	_	4	det	_	_
3	formal	formal	JJ	_	4	attr	_	_
4	study	study	NN	_	25	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	n	n	NN	_	4	prn	_	_
7	=	=	JJ	_	6	attr	_	_
8	8	0	CD	_	7	num	_	_
9	extensive	extensive	JJ	_	8	attr	_	_
10	and	and	CC	_	8	cc	_	_
11	n	n	NN	_	12	advnp	_	_
12	=	=	JJ	_	15	attr	_	_
13	7	0	CD	_	15	num	_	_
14	poor	poor	JJ	_	15	attr	_	_
15	metabolizers	metabolizers	NNS	_	8	conj	_	_
16	of	of	IN	_	17	case	_	_
17	CYP2D6	cyp0d0	NN	_	8	ppmod	_	_
18	)	-rrb-	-RRB-	_	6	p	_	_
19	,	,	,	_	25	p	_	_
20	coadministration	coadministration	NN	_	25	dep	_	_
21	of	of	IN	_	22	case	_	_
22	drug1	drug0	NN	_	20	ppmod	_	_
23	did	do	VBD	_	25	aux	_	_
24	not	not	RB	_	25	neg	_	_
25	alter	alter	VB	_	0	root	_	_
26	the	the	DT	_	27	det	_	_
27	kinetics	kinetics	NNS	_	25	obj	_	_
28	of	of	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	in	in	IN	_	35	case	_	_
31	the	the	DT	_	35	det	_	_
32	poor	poor	JJ	_	35	attr	_	_
33	CYP2D6	cyp0d0	NN	_	35	com	_	_
34	metabolizer	metabolizer	NN	_	35	com	_	_
35	group	group	NN	_	27	ppmod	_	_
36	.	.	.	_	25	p	_	_

1	However	however	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	the	the	DT	_	5	det	_	_
4	metabolic	metabolic	JJ	_	5	attr	_	_
5	clearance	clearance	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	extensive	extensive	JJ	_	12	attr	_	_
11	metabolizer	metabolizer	NN	_	12	com	_	_
12	phenotype	phenotype	NN	_	5	ppmod	_	_
13	decreased	decrease	VBD	_	0	root	_	_
14	by	by	IN	_	16	case	_	_
15	about	about	RB	_	16	adv	_	_
16	70	0	CD	_	13	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	making	make	VBG	_	13	comp	_	_
19	the	the	DT	_	24	det	_	_
20	poor	poor	JJ	_	24	attr	_	_
21	and	and	CC	_	20	cc	_	_
22	extensive	extensive	JJ	_	20	conj	_	_
23	metabolizer	metabolizer	NN	_	24	com	_	_
24	groups	group	NNS	_	18	comp	_	_
25	indistinguishable	indistinguishable	JJ	_	24	dep	_	_
26	.	.	.	_	13	p	_	_

1	In	in	IN	_	6	case	_	_
2	this	this	DT	_	6	det	_	_
3	crossover	crossover	NN	_	6	attr	_	_
4	steady	steady	JJ	_	6	attr	_	_
5	state	state	NN	_	6	com	_	_
6	study	study	NN	_	13	ppmod	_	_
7	,	,	,	_	13	p	_	_
8	the	the	DT	_	9	det	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	13	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	were	be	VBD	_	13	aux	_	_
13	unaffected	unaffected	VBN	_	0	root	_	_
14	in	in	IN	_	16	case	_	_
15	either	either	DT	_	16	det	_	_
16	phenotype	phenotype	NN	_	13	ppmod	_	_
17	by	by	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	coadministration	coadministration	NN	_	13	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	Addition	addition	NN	_	8	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	lead	lead	VB	_	0	root	_	_
9	to	to	TO	_	13	aux	_	_
10	further	far	JJ	_	13	attr	_	_
11	electrocardiographic	electrocardiographic	JJ	_	13	attr	_	_
12	parameters	parameter	NNS	_	13	com	_	_
13	changes	change	NNS	_	8	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	QRS	qrs	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	QTc	qtc	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	RR	rr	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	PR	pr	NN	_	23	com	_	_
23	intervals	interval	NNS	_	15	conj	_	_
24	than	than	IN	_	25	case	_	_
25	drug3	drug0	NN	_	15	ppmod	_	_
26	alone	alone	RB	_	25	adv	_	_
27	.	.	.	_	8	p	_	_

1	When	when	WRB	_	13	adv	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	13	dep	_	_
4	of	of	IN	_	5	case	_	_
5	either	either	DT	_	3	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	these	these	DT	_	9	det	_	_
8	two	#crd#	CD	_	9	num	_	_
9	drugs	drug	NNS	_	5	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	3	ppmod	_	_
12	is	be	VBZ	_	13	aux	_	_
13	initiated	initiate	VBN	_	22	advcl	_	_
14	,	,	,	_	22	p	_	_
15	the	the	DT	_	16	det	_	_
16	dose	dose	NN	_	22	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	should	should	MD	_	22	modal	_	_
20	be	be	VB	_	22	aux	_	_
21	slowly	slowly	RB	_	22	adv	_	_
22	titrated	titrate	VBN	_	0	root	_	_
23	to	to	TO	_	25	aux	_	_
24	desired	desired	JJ	_	25	attr	_	_
25	effect	effect	NN	_	22	ppmod	_	_
26	.	.	.	_	22	p	_	_

1	In	in	IN	_	6	case	_	_
2	a	a	DT	_	6	det	_	_
3	large	large	JJ	_	6	attr	_	_
4	compassionate	compassionate	JJ	_	6	attr	_	_
5	use	use	NN	_	6	com	_	_
6	program	program	NN	_	10	ppmod	_	_
7	drug1	drug0	NN	_	10	dep	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	used	use	VBN	_	0	root	_	_
11	concurrently	concurrently	RB	_	10	adv	_	_
12	with	with	IN	_	15	case	_	_
13	commonly	commonly	RB	_	14	adv	_	_
14	employed	employ	VBN	_	15	attr	_	_
15	antianginal	antianginal	JJ	_	10	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug3	drug0	NN	_	23	attr	_	_
21	without	without	IN	_	23	case	_	_
22	observed	observe	VBN	_	23	attr	_	_
23	interactions	interaction	NNS	_	15	conj	_	_
24	.	.	.	_	10	p	_	_

1	A	a	DT	_	2	det	_	_
2	variety	variety	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NNS	_	2	ppmod	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	were	be	VBD	_	12	aux	_	_
11	also	also	RB	_	12	adv	_	_
12	added	add	VBN	_	0	root	_	_
13	,	,	,	_	12	p	_	_
14	sometimes	sometimes	RB	_	12	adv	_	_
15	with	with	IN	_	17	case	_	_
16	improved	improved	JJ	_	17	attr	_	_
17	control	control	NN	_	12	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	ventricular	ventricular	JJ	_	20	attr	_	_
20	ectopy	ectopy	NN	_	17	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	When	when	WRB	_	15	adv	_	_
2	drug1	drug0	NN	_	15	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	other	other	JJ	_	7	attr	_	_
5	hepatic	hepatic	JJ	_	7	attr	_	_
6	enzyme	enzyme	NN	_	7	com	_	_
7	inducers	inducer	NNS	_	2	conj	_	_
8	such	such	JJ	_	10	adv	_	_
9	as	as	IN	_	10	case	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	have	have	VBP	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	taken	take	VBN	_	26	advcl	_	_
16	concurrently	concurrently	RB	_	15	adv	_	_
17	with	with	IN	_	18	case	_	_
18	drug4	drug0	NN	_	15	ppmod	_	_
19	,	,	,	_	26	p	_	_
20	lowered	lowered	JJ	_	23	attr	_	_
21	drug5	drug0	NN	_	23	com	_	_
22	plasma	plasma	NN	_	23	com	_	_
23	levels	level	NNS	_	26	dep	_	_
24	have	have	VBP	_	26	aux	_	_
25	been	be	VBN	_	26	aux	_	_
26	reported	report	VBN	_	0	root	_	_
27	.	.	.	_	26	p	_	_

1	Monitoring	monitoring	NN	_	7	dep	_	_
2	of	of	IN	_	5	case	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	levels	level	NNS	_	1	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	during	during	IN	_	11	case	_	_
9	such	such	JJ	_	11	attr	_	_
10	concurrent	concurrent	JJ	_	11	attr	_	_
11	use	use	NN	_	7	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	avoid	avoid	VB	_	11	acl	_	_
14	ineffective	ineffective	JJ	_	15	attr	_	_
15	therapy	therapy	NN	_	13	obj	_	_
16	.	.	.	_	7	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	formal	formal	JJ	_	4	attr	_	_
4	study	study	NN	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	were	be	VBD	_	8	aux	_	_
8	shown	show	VBN	_	0	root	_	_
9	not	not	RB	_	8	neg	_	_
10	to	to	TO	_	11	aux	_	_
11	affect	affect	VB	_	8	comp	_	_
12	drug2	drug0	NN	_	14	com	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	11	obj	_	_
15	.	.	.	_	8	p	_	_

1	ECG	ecg	NN	_	2	com	_	_
2	intervals	interval	NNS	_	13	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	PR	pr	NN	_	2	prn	_	_
5	,	,	,	_	4	p	_	_
6	QRS	qrs	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	QT	qt	NN	_	4	conj	_	_
10	)	-rrb-	-RRB-	_	4	p	_	_
11	were	be	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	affected	affect	VBN	_	0	root	_	_
14	by	by	IN	_	16	case	_	_
15	concurrent	concurrent	JJ	_	16	attr	_	_
16	drug1	drug0	NN	_	13	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	or	or	CC	_	20	cc	_	_
23	drug4	drug0	NN	_	18	conj	_	_
24	.	.	.	_	13	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	has	have	VBZ	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	increase	increase	VB	_	9	comp	_	_
12	,	,	,	_	11	p	_	_
13	decrease	decrease	VB	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	leave	leave	VBP	_	11	conj	_	_
17	unchanged	unchanged	JJ	_	20	attr	_	_
18	drug3	drug0	NN	_	20	com	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	levels	level	NNS	_	16	obj	_	_
21	;	;	:	_	9	p	_	_

1	therefore	therefore	RB	_	5	adv	_	_
2	patients	patient	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	followed	followed	VBN	_	0	root	_	_
6	carefully	carefully	RB	_	5	adv	_	_
7	during	during	IN	_	9	case	_	_
8	concurrent	concurrent	JJ	_	9	attr	_	_
9	therapy	therapy	NN	_	5	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	alter	alter	VB	_	0	root	_	_
5	serum	serum	NN	_	7	com	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	4	obj	_	_
8	but	but	CC	_	4	cc	_	_
9	drug3	drug0	NN	_	23	dep	_	_
10	,	,	,	_	9	p	_	_
11	when	when	WRB	_	12	adv	_	_
12	used	use	VBN	_	9	relcl	_	_
13	to	to	TO	_	14	aux	_	_
14	treat	treat	VB	_	12	comp	_	_
15	gastrointestinal	gastrointestinal	JJ	_	16	attr	_	_
16	symptoms	symptom	NNS	_	14	obj	_	_
17	due	due	JJ	_	19	adv	_	_
18	to	to	TO	_	19	aux	_	_
19	drug4	drug0	NN	_	14	ppmod	_	_
20	,	,	,	_	9	p	_	_
21	has	have	VBZ	_	23	aux	_	_
22	been	be	VBN	_	23	aux	_	_
23	reported	report	VBN	_	4	conj	_	_
24	to	to	TO	_	25	aux	_	_
25	lower	low	JJR	_	23	comp	_	_
26	serum	serum	NN	_	28	com	_	_
27	drug5	drug0	NN	_	28	com	_	_
28	levels	level	NNS	_	25	obj	_	_
29	.	.	.	_	4	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	lead	lead	VB	_	0	root	_	_
9	to	to	TO	_	13	aux	_	_
10	increased	increase	VBN	_	13	attr	_	_
11	plasma	plasma	NN	_	13	com	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	levels	level	NNS	_	8	ppmod	_	_
14	.	.	.	_	8	p	_	_

1	One	#crd#	CD	_	3	num	_	_
2	controlled	controlled	JJ	_	3	attr	_	_
3	study	study	NN	_	8	dep	_	_
4	in	in	IN	_	7	case	_	_
5	eight	#crd#	CD	_	7	num	_	_
6	normal	normal	JJ	_	7	attr	_	_
7	subjects	subject	NNS	_	3	ppmod	_	_
8	showed	show	VBD	_	0	root	_	_
9	a	a	DT	_	13	det	_	_
10	72	0	CD	_	13	num	_	_
11	%	%	NN	_	13	meta	_	_
12	mean	mean	NN	_	13	com	_	_
13	increase	increase	NN	_	8	obj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	range	range	NN	_	13	prn	_	_
16	35-136	0	CD	_	15	num	_	_
17	%	%	NN	_	15	meta	_	_
18	)	-rrb-	-RRB-	_	15	p	_	_
19	in	in	IN	_	22	case	_	_
20	plasma	plasma	NN	_	22	com	_	_
21	drug1	drug0	NN	_	22	com	_	_
22	levels	level	NNS	_	8	ppmod	_	_
23	.	.	.	_	8	p	_	_

1	This	this	DT	_	2	det	_	_
2	increase	increase	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	observed	observe	VBN	_	22	advcl	_	_
5	at	at	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	first	#ord#	JJ	_	9	attr	_	_
8	test	test	NN	_	9	com	_	_
9	point	point	NN	_	4	ppmod	_	_
10	which	which	WDT	_	11	dep	_	_
11	was	be	VBD	_	9	relcl	_	_
12	the	the	DT	_	14	det	_	_
13	second	#ord#	JJ	_	14	attr	_	_
14	day	day	NN	_	11	obj	_	_
15	after	after	IN	_	16	case	_	_
16	starting	start	VBG	_	11	ppmod	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	.	.	.	_	4	p	_	_
19	drug2	drug0	NN	_	21	com	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	levels	level	NNS	_	22	dep	_	_
22	returned	return	VBD	_	0	root	_	_
23	to	to	TO	_	26	aux	_	_
24	pre-	pre-	JJ	_	26	attr	_	_
25	drug3	drug0	NN	_	26	com	_	_
26	values	value	NNS	_	22	ppmod	_	_
27	within	within	IN	_	29	case	_	_
28	48	0	CD	_	29	num	_	_
29	hours	hour	NNS	_	22	ppmod	_	_
30	after	after	IN	_	32	case	_	_
31	discontinuing	discontinuing	NN	_	32	com	_	_
32	drug4	drug0	NN	_	29	ppmod	_	_
33	.	.	.	_	29	p	_	_
34	If	if	IN	_	38	mark	_	_
35	drug5	drug0	NN	_	38	dep	_	_
36	and	and	CC	_	35	cc	_	_
37	drug6	drug0	NN	_	35	conj	_	_
38	are	be	VBP	_	29	acl	_	_
39	to	to	TO	_	41	aux	_	_
40	be	be	VB	_	41	aux	_	_
41	used	use	VBN	_	38	comp	_	_
42	concurrently	concurrently	RB	_	49	adv	_	_
43	,	,	,	_	49	p	_	_
44	drug7	drug0	NN	_	46	com	_	_
45	blood	blood	NN	_	46	com	_	_
46	levels	level	NNS	_	49	dep	_	_
47	should	should	MD	_	49	modal	_	_
48	be	be	VB	_	49	aux	_	_
49	monitored	monitor	VBN	_	41	comp	_	_
50	,	,	,	_	49	p	_	_
51	particularly	particularly	RB	_	52	com	_	_
52	when	when	WRB	_	57	adv	_	_
53	the	the	DT	_	55	det	_	_
54	drug8	drug0	NN	_	55	com	_	_
55	dose	dose	NN	_	57	dep	_	_
56	is	be	VBZ	_	57	aux	_	_
57	changed	change	VBN	_	49	comp	_	_
58	.	.	.	_	22	p	_	_

1	An	an	DT	_	3	det	_	_
2	appropriate	appropriate	JJ	_	3	attr	_	_
3	adjustment	adjustment	NN	_	9	dep	_	_
4	in	in	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	dose	dose	NN	_	3	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	considered	consider	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Additionally	additionally	RB	_	20	adv	_	_
2	,	,	,	_	20	p	_	_
3	in	in	IN	_	6	case	_	_
4	one	#crd#	CD	_	6	num	_	_
5	controlled	controlled	JJ	_	6	attr	_	_
6	study	study	NN	_	20	ppmod	_	_
7	in	in	IN	_	10	case	_	_
8	five	#crd#	CD	_	10	num	_	_
9	normal	normal	JJ	_	10	attr	_	_
10	subjects	subject	NNS	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	seven	#crd#	CD	_	13	num	_	_
13	patients	patient	NNS	_	10	conj	_	_
14	,	,	,	_	20	p	_	_
15	the	the	DT	_	16	det	_	_
16	clearance	clearance	NN	_	20	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	was	be	VBD	_	20	aux	_	_
20	decreased	decrease	VBN	_	0	root	_	_
21	50	0	CD	_	20	obj	_	_
22	%	%	NN	_	21	meta	_	_
23	following	follow	VBG	_	25	adv	_	_
24	the	the	DT	_	25	det	_	_
25	administration	administration	NN	_	20	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	20	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	oral	oral	JJ	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	:	:	:	_	1	p	_	_
6	The	the	DT	_	7	det	_	_
7	activity	activity	NN	_	13	dep	_	_
8	of	of	IN	_	10	case	_	_
9	oral	oral	JJ	_	10	attr	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	potentiated	potentiate	VBN	_	1	acl	_	_
14	by	by	IN	_	16	case	_	_
15	anti-vitamin-K	anti-vitamin-k	NN	_	16	com	_	_
16	activity	activity	NN	_	13	ppmod	_	_
17	attributed	attribute	VBN	_	16	acl	_	_
18	to	to	TO	_	19	aux	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	-	-	CC	_	4	cc	_	_
2	drug1	drug0	NN	_	4	attr	_	_
3	:	:	:	_	4	p	_	_
4	Hyperthyroidism	hyperthyroidism	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	cause	cause	VB	_	0	root	_	_
7	an	an	DT	_	9	det	_	_
8	increased	increase	VBN	_	9	attr	_	_
9	clearance	clearance	NN	_	6	obj	_	_
10	of	of	IN	_	12	case	_	_
11	beta	beta	NN	_	12	com	_	_
12	ratio	ratio	NN	_	9	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	A	a	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	reduction	reduction	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	needed	need	VBN	_	0	root	_	_
9	when	when	WRB	_	13	adv	_	_
10	a	a	DT	_	12	det	_	_
11	hyperthyroid	hyperthyroid	JJ	_	12	attr	_	_
12	patient	patient	NN	_	13	dep	_	_
13	becomes	become	VBZ	_	8	comp	_	_
14	euthyroid	euthyroid	JJ	_	13	dep	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Serum	serum	NN	_	5	com	_	_
4	digitalis	digitalis	NN	_	5	com	_	_
5	levels	level	NNS	_	8	dep	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	increased	increase	VBN	_	1	acl	_	_
9	when	when	WRB	_	17	adv	_	_
10	hyperthyroid	hyperthyroid	JJ	_	11	attr	_	_
11	patients	patient	NNS	_	17	dep	_	_
12	on	on	IN	_	16	case	_	_
13	a	a	DT	_	16	det	_	_
14	stable	stable	JJ	_	16	attr	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	regimen	regimen	NN	_	11	ppmod	_	_
17	become	become	VBP	_	8	comp	_	_
18	euthyroid	euthyroid	JJ	_	17	dep	_	_
19	;	;	:	_	1	p	_	_

1	reduced	reduce	VBN	_	2	attr	_	_
2	dosage	dosage	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	required	require	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	clearance	clearance	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	decrease	decrease	VB	_	1	acl	_	_
7	when	when	WRB	_	15	adv	_	_
8	hyperthyroid	hyperthyroid	JJ	_	9	attr	_	_
9	patients	patient	NNS	_	15	dep	_	_
10	on	on	IN	_	14	case	_	_
11	a	a	DT	_	14	det	_	_
12	stable	stable	JJ	_	14	attr	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	regimen	regimen	NN	_	9	ppmod	_	_
15	become	become	VBP	_	6	comp	_	_
16	euthyroid	euthyroid	JJ	_	15	dep	_	_
17	;	;	:	_	1	p	_	_

1	a	a	DT	_	3	det	_	_
2	reduced	reduce	VBN	_	3	attr	_	_
3	dose	dose	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	needed	need	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	concomitantly	concomitantly	RB	_	6	adv	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	because	because	IN	_	13	mark	_	_
11	they	they	PRP	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	have	have	VB	_	6	comp	_	_
14	additive	additive	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	13	obj	_	_
16	.	.	.	_	6	p	_	_

1	Some	some	DT	_	2	det	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	interact	interact	VB	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	.	.	.	_	4	p	_	_

1	They	they	PRP	_	4	dep	_	_
2	can	can	MD	_	4	modal	_	_
3	either	either	RB	_	4	adv	_	_
4	increase	increase	VB	_	0	root	_	_
5	or	or	CC	_	4	cc	_	_
6	decrease	decrease	VB	_	4	conj	_	_
7	the	the	DT	_	8	det	_	_
8	effect	effect	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	Those	those	DT	_	2	det	_	_
2	drug1	drug0	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	drug2	drug0	NN	_	3	obj	_	_
5	,	,	,	_	4	p	_	_
6	drug3	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	drug4	drug0	NN	_	4	conj	_	_
10	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	affect	affect	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	which	which	WDT	_	12	dep	_	_
12	include	include	VBP	_	9	relcl	_	_
13	some	some	DT	_	31	det	_	_
14	drug2	drug0	NN	_	31	attr	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	certain	certain	JJ	_	20	attr	_	_
19	heart	heart	NN	_	20	com	_	_
20	medicines	medicine	NNS	_	14	conj	_	_
21	,	,	,	_	20	p	_	_
22	birth	birth	NN	_	24	com	_	_
23	control	control	NN	_	24	com	_	_
24	pills	pill	NNS	_	14	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	14	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug5	drug0	NN	_	14	conj	_	_
29	and	and	CC	_	28	cc	_	_
30	drug6	drug0	NN	_	14	conj	_	_
31	Please	please	NN	_	32	dep	_	_
32	note	note	VB	_	12	comp	_	_
33	that	that	IN	_	36	mark	_	_
34	drug7	drug0	NN	_	36	dep	_	_
35	may	may	MD	_	36	modal	_	_
36	interact	interact	VB	_	32	comp	_	_
37	with	with	IN	_	39	case	_	_
38	other	other	JJ	_	39	attr	_	_
39	drugs	drug	NNS	_	36	ppmod	_	_
40	that	that	WDT	_	43	dep	_	_
41	are	be	VBP	_	43	aux	_	_
42	not	not	RB	_	43	neg	_	_
43	listed	list	VBN	_	39	relcl	_	_
44	here	here	RB	_	43	adv	_	_
45	.	.	.	_	4	p	_	_

1	Use	use	NN	_	12	dep	_	_
2	with	with	IN	_	4	case	_	_
3	Other	other	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	:	:	:	_	12	p	_	_
6	The	the	DT	_	8	det	_	_
7	depressant	depressant	NN	_	8	com	_	_
8	effects	effect	NNS	_	12	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	are	be	VBP	_	12	aux	_	_
12	potentiated	potentiate	VBN	_	0	root	_	_
13	by	by	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	presence	presence	NN	_	12	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	other	other	JJ	_	18	attr	_	_
18	drug3	drug0	NNS	_	15	ppmod	_	_
19	such	such	JJ	_	21	adv	_	_
20	as	as	IN	_	21	case	_	_
21	drug4	drug0	NN	_	18	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	drug5	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug6	drug0	NN	_	21	conj	_	_
26	,	,	,	_	25	p	_	_
27	or	or	CC	_	25	cc	_	_
28	drug7	drug0	NN	_	21	conj	_	_
29	.	.	.	_	12	p	_	_

1	Use	use	NN	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	conjunction	conjunction	NN	_	1	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	increase	increase	VB	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	respiratory	respiratory	JJ	_	15	attr	_	_
15	depression	depression	NN	_	12	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	hypotension	hypotension	NN	_	15	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	profound	profound	JJ	_	20	attr	_	_
20	sedation	sedation	NN	_	17	conj	_	_
21	or	or	CC	_	17	cc	_	_
22	coma	coma	NN	_	15	conj	_	_
23	.	.	.	_	10	p	_	_

1	Interaction	interaction	NN	_	21	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	:	:	:	_	1	p	_	_
5	drug2	drug0	NN	_	1	appo	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	i.e.	i.e.	FW	_	9	ppmod	_	_
8	,	,	,	_	9	p	_	_
9	drug3	drug0	NN	_	5	prn	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	drug6	drug0	NN	_	9	conj	_	_
17	)	-rrb-	-RRB-	_	9	p	_	_
18	should	should	MD	_	21	modal	_	_
19	NOT	not	RB	_	21	neg	_	_
20	be	be	VB	_	21	aux	_	_
21	administered	administer	VBN	_	0	root	_	_
22	to	to	TO	_	23	aux	_	_
23	patients	patient	NNS	_	21	ppmod	_	_
24	who	who	WP	_	26	dep	_	_
25	have	have	VBP	_	26	aux	_	_
26	received	receive	VBN	_	23	relcl	_	_
27	or	or	CC	_	26	cc	_	_
28	are	be	VBP	_	29	aux	_	_
29	receiving	receive	VBG	_	26	conj	_	_
30	a	a	DT	_	31	det	_	_
31	course	course	NN	_	29	obj	_	_
32	of	of	IN	_	33	case	_	_
33	therapy	therapy	NN	_	31	ppmod	_	_
34	with	with	IN	_	37	case	_	_
35	a	a	DT	_	37	det	_	_
36	proof	proof	NN	_	37	com	_	_
37	drug7	drug0	NN	_	29	ppmod	_	_
38	.	.	.	_	21	p	_	_

1	In	in	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	patients	patient	NNS	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	the	the	DT	_	7	det	_	_
6	mixed	mixed	JJ	_	7	attr	_	_
7	agonist/antagonist	agonist/antagonist	NN	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	alter	alter	VB	_	0	root	_	_
10	the	the	DT	_	12	det	_	_
11	analgesic	analgesic	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	or	or	CC	_	9	cc	_	_
14	may	may	MD	_	15	modal	_	_
15	precipitate	precipitate	VB	_	9	conj	_	_
16	withdrawal	withdrawal	NN	_	17	com	_	_
17	symptoms	symptom	NNS	_	15	obj	_	_
18	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hypotensive	hypotensive	JJ	_	6	attr	_	_
6	effect	effect	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Use	use	NN	_	2	dep	_	_
2	cautiously	cautiously	RB	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	pressor	pressor	JJ	_	5	attr	_	_
5	agents	agent	NNS	_	2	ppmod	_	_
6	.	.	.	_	2	p	_	_

1	Human	human	JJ	_	3	attr	_	_
2	pharmacologic	pharmacologic	JJ	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	9	mark	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	inhibit	inhibit	VB	_	5	comp	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug4	drug0	NN	_	15	prn	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	17	appo	_	_
20	,	,	,	_	17	p	_	_
21	drug6	drug0	NN	_	17	appo	_	_
22	)	-rrb-	-RRB-	_	17	p	_	_
23	,	,	,	_	15	p	_	_
24	drug7	drug0	NN	_	13	conj	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	drug8	drug0	NN	_	13	conj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	drug9	drug0	NN	_	27	prn	_	_
30	,	,	,	_	29	p	_	_
31	drug10	drug0	NN	_	29	appo	_	_
32	,	,	,	_	29	p	_	_
33	drug11	drug0	NN	_	29	appo	_	_
34	)	-rrb-	-RRB-	_	29	p	_	_
35	.	.	.	_	5	p	_	_

1	Downward	downward	NN	_	3	com	_	_
2	dosage	dosage	NN	_	3	com	_	_
3	adjustments	adjustment	NNS	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	drugs	drug	NNS	_	3	ppmod	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	required	require	VBN	_	0	root	_	_
10	when	when	WRB	_	11	adv	_	_
11	given	give	VBN	_	9	comp	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	11	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	Serious	serious	JJ	_	3	attr	_	_
2	adverse	adverse	JJ	_	3	attr	_	_
3	events	event	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	use	use	NN	_	6	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	6	p	_	_
13	although	although	IN	_	21	mark	_	_
14	no	no	DT	_	15	det	_	_
15	causality	causality	NN	_	21	dep	_	_
16	for	for	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	combination	combination	NN	_	15	ppmod	_	_
19	has	have	VBZ	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	established	establish	VBN	_	6	comp	_	_
22	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	safety	safety	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	using	use	VBG	_	2	ppmod	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	other	other	JJ	_	14	attr	_	_
12	centrally	centrally	RB	_	13	adv	_	_
13	acting	act	VBG	_	14	attr	_	_
14	drug3	drug0	NNS	_	9	conj	_	_
15	has	have	VBZ	_	19	aux	_	_
16	not	not	RB	_	19	neg	_	_
17	been	be	VBN	_	19	aux	_	_
18	systemically	systemically	RB	_	19	adv	_	_
19	evaluated	evaluate	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	Co-administration	co-administration	NN	_	37	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	strong	strong	JJ	_	6	attr	_	_
6	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	CYP3A4	cyp0a0	NN	_	10	com	_	_
10	family	family	NN	_	6	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	e.g.	e.g.	FW	_	14	ppmod	_	_
13	,	,	,	_	14	p	_	_
14	drug2	drug0	NN	_	10	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	appo	_	_
17	,	,	,	_	14	p	_	_
18	drug4	drug0	NN	_	14	appo	_	_
19	,	,	,	_	14	p	_	_
20	drug5	drug0	NN	_	14	appo	_	_
21	,	,	,	_	14	p	_	_
22	drug6	drug0	NN	_	14	appo	_	_
23	,	,	,	_	14	p	_	_
24	drug7	drug0	NN	_	14	appo	_	_
25	,	,	,	_	14	p	_	_
26	drug8	drug0	NN	_	14	appo	_	_
27	,	,	,	_	14	p	_	_
28	drug9	drug0	NN	_	14	appo	_	_
29	,	,	,	_	14	p	_	_
30	drug10	drug0	NN	_	14	appo	_	_
31	,	,	,	_	14	p	_	_
32	drug11	drug0	NN	_	14	appo	_	_
33	,	,	,	_	14	p	_	_
34	drug12	drug0	NN	_	14	appo	_	_
35	)	-rrb-	-RRB-	_	14	p	_	_
36	may	may	MD	_	37	dep	_	_
37	increases	increase	VBZ	_	0	root	_	_
38	drug13	drug0	NN	_	39	com	_	_
39	concentrations	concentration	NNS	_	37	obj	_	_
40	.	.	.	_	37	p	_	_

1	Grapefruit	grapefruit	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	increase	increase	VBP	_	0	root	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	concentrations	concentration	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	Co-administration	co-administration	NN	_	32	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	inducers	inducer	NNS	_	1	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	CYP3A4	cyp0a0	NN	_	9	com	_	_
9	family	family	NN	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	e.g.	e.g.	FW	_	13	ppmod	_	_
12	,	,	,	_	13	p	_	_
13	drug2	drug0	NN	_	9	prn	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	appo	_	_
16	,	,	,	_	13	p	_	_
17	drug4	drug0	NN	_	13	appo	_	_
18	,	,	,	_	13	p	_	_
19	drug5	drug0	NN	_	13	appo	_	_
20	,	,	,	_	13	p	_	_
21	drug6	drug0	NN	_	13	appo	_	_
22	,	,	,	_	13	p	_	_
23	drug7	drug0	NN	_	13	appo	_	_
24	,	,	,	_	13	p	_	_
25	drug8	drug0	NN	_	13	appo	_	_
26	,	,	,	_	13	p	_	_
27	St.	st.	NN	_	13	appo	_	_
28	Johns	johns	NNP	_	29	com	_	_
29	Wort	wort	NNP	_	27	attr	_	_
30	)	-rrb-	-RRB-	_	13	p	_	_
31	may	may	MD	_	32	modal	_	_
32	decrease	decrease	VB	_	0	root	_	_
33	drug9	drug0	NN	_	34	com	_	_
34	concentrations	concentration	NNS	_	32	obj	_	_
35	.	.	.	_	32	p	_	_

1	St.	st.	NN	_	0	root	_	_

1	Johns	johns	NNP	_	2	com	_	_
2	Wort	wort	NNP	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	decrease	decrease	VB	_	0	root	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	4	obj	_	_
8	unpredictably	unpredictably	RB	_	4	adv	_	_
9	.	.	.	_	4	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	should	should	MD	_	6	modal	_	_
5	not	not	RB	_	6	neg	_	_
6	take	take	VB	_	0	root	_	_
7	St.	st.	NN	_	6	obj	_	_

1	Johns	johns	NNP	_	2	com	_	_
2	Wort	wort	NNP	_	0	root	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	.	.	.	_	2	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	dose	dose	NN	_	3	com	_	_
3	modification	modification	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	recommended	recommend	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	using	use	VBG	_	7	acl	_	_
9	concomitant	concomitant	JJ	_	11	attr	_	_
10	CYP3A4	cyp0a0	JJ	_	11	attr	_	_
11	inhibitors	inhibitor	NNS	_	8	obj	_	_
12	or	or	CC	_	11	cc	_	_
13	inducers	inducer	NNS	_	11	conj	_	_
14	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Excessive	excessive	JJ	_	4	attr	_	_
4	reductions	reduction	NNS	_	9	dep	_	_
5	in	in	IN	_	7	case	_	_
6	blood	blood	NN	_	7	com	_	_
7	pressure	pressure	NN	_	4	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	occur	occur	VB	_	1	acl	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	on	on	IN	_	14	case	_	_
13	diuretic	diuretic	JJ	_	14	attr	_	_
14	therapy	therapy	NN	_	11	ppmod	_	_
15	when	when	WRB	_	18	adv	_	_
16	drug2	drug0	NNS	_	18	dep	_	_
17	are	be	VBP	_	18	aux	_	_
18	started	start	VBN	_	9	comp	_	_
19	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	hypotensive	hypotensive	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	can	can	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	minimized	minimize	VBN	_	43	advcl	_	_
11	by	by	IN	_	12	case	_	_
12	discontinuing	discontinue	VBG	_	10	ppmod	_	_
13	diuretic	diuretic	JJ	_	14	attr	_	_
14	therapy	therapy	NN	_	12	obj	_	_
15	for	for	IN	_	17	case	_	_
16	several	several	JJ	_	17	attr	_	_
17	days	day	NNS	_	14	ppmod	_	_
18	or	or	CC	_	12	cc	_	_
19	cautiously	cautiously	RB	_	20	adv	_	_
20	increasing	increase	VBG	_	12	conj	_	_
21	salt	salt	NN	_	22	com	_	_
22	intake	intake	NN	_	20	obj	_	_
23	before	before	IN	_	24	case	_	_
24	initiation	initiation	NN	_	20	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	treatment	treatment	NN	_	24	ppmod	_	_
27	with	with	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	10	p	_	_
30	If	if	IN	_	32	mark	_	_
31	this	this	DT	_	32	dep	_	_
32	is	be	VBZ	_	43	advcl	_	_
33	not	not	RB	_	32	neg	_	_
34	possible	possible	JJ	_	32	dep	_	_
35	,	,	,	_	43	p	_	_
36	the	the	DT	_	38	det	_	_
37	starting	start	VBG	_	38	attr	_	_
38	dose	dose	NN	_	43	dep	_	_
39	of	of	IN	_	40	case	_	_
40	drug3	drug0	NN	_	38	ppmod	_	_
41	should	should	MD	_	43	modal	_	_
42	be	be	VB	_	43	aux	_	_
43	reduced	reduce	VBN	_	0	root	_	_
44	.	.	.	_	43	p	_	_
45	.	.	.	_	43	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Supplements	supplement	NNS	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NNS	_	2	conj	_	_
5	:	:	:	_	2	p	_	_
6	drug3	drug0	NN	_	8	dep	_	_
7	can	can	MD	_	8	modal	_	_
8	increase	increase	VB	_	2	acl	_	_
9	serum	serum	NN	_	10	com	_	_
10	potassium	potassium	NN	_	8	obj	_	_
11	because	because	IN	_	13	mark	_	_
12	it	it	PRP	_	13	dep	_	_
13	decreases	decrease	VBZ	_	8	comp	_	_
14	aldosterone	aldosterone	NN	_	15	com	_	_
15	secretion	secretion	NN	_	13	obj	_	_
16	.	.	.	_	2	p	_	_

1	Use	use	NN	_	18	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	appo	_	_
8	,	,	,	_	5	p	_	_
9	drug4	drug0	NN	_	5	appo	_	_
10	)	-rrb-	-RRB-	_	5	p	_	_
11	or	or	CC	_	3	cc	_	_
12	drug5	drug0	NN	_	13	com	_	_
13	supplements	supplement	NNS	_	3	conj	_	_
14	concomitantly	concomitantly	RB	_	16	adv	_	_
15	with	with	IN	_	16	case	_	_
16	drug6	drug0	NN	_	1	ppmod	_	_
17	can	can	MD	_	18	modal	_	_
18	increase	increase	VB	_	0	root	_	_
19	the	the	DT	_	20	det	_	_
20	risk	risk	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	hyperkalemia	hyperkalemia	NN	_	20	ppmod	_	_
23	.	.	.	_	18	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	if	if	IN	_	10	mark	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	8	case	_	_
7	such	such	JJ	_	8	attr	_	_
8	agents	agent	NNS	_	5	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	indicated	indicate	VBN	_	15	advcl	_	_
11	,	,	,	_	15	p	_	_
12	they	they	PRP	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	given	give	VBN	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	caution	caution	NN	_	15	ppmod	_	_
18	and	and	CC	_	15	cc	_	_
19	the	the	DT	_	20	det	_	_
20	patient	patient	NN	_	23	poss	_	_
21	's	's	POS	_	20	case	_	_
22	serum	serum	NN	_	23	com	_	_
23	potassium	potassium	NN	_	26	dep	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	monitored	monitor	VBN	_	15	conj	_	_
27	.	.	.	_	15	p	_	_

1	Oral	oral	JJ	_	5	attr	_	_
2	drug1	drug0	NN	_	5	attr	_	_
3	:	:	:	_	5	p	_	_
4	Interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	failed	fail	VBD	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	identify	identify	VB	_	8	comp	_	_
11	any	any	DT	_	14	det	_	_
12	clinically	clinically	RB	_	13	adv	_	_
13	important	important	JJ	_	14	attr	_	_
14	effect	effect	NN	_	10	obj	_	_
15	on	on	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	serum	serum	NN	_	18	com	_	_
18	concentrations	concentration	NNS	_	14	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	drug3	drug0	NN	_	18	ppmod	_	_
22	or	or	CC	_	18	cc	_	_
23	on	on	IN	_	26	case	_	_
24	its	its	PRP$	_	26	poss	_	_
25	anticoagulant	anticoagulant	JJ	_	26	attr	_	_
26	effect	effect	NN	_	18	conj	_	_
27	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Increased	increase	VBN	_	6	attr	_	_
4	serum	serum	NN	_	6	com	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	levels	level	NNS	_	14	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	symptoms	symptom	NNS	_	6	conj	_	_
9	of	of	IN	_	11	case	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	toxicity	toxicity	NN	_	6	ppmod	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	1	acl	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	drug4	drug0	NN	_	17	obj	_	_
19	during	during	IN	_	20	case	_	_
20	therapy	therapy	NN	_	17	ppmod	_	_
21	with	with	IN	_	22	case	_	_
22	drug5	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	coadministered	coadministered	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	caution	caution	NN	_	5	ppmod	_	_
8	,	,	,	_	5	p	_	_
9	and	and	CC	_	5	cc	_	_
10	frequent	frequent	JJ	_	11	attr	_	_
11	monitoring	monitoring	NN	_	17	dep	_	_
12	of	of	IN	_	15	case	_	_
13	serum	serum	NN	_	15	com	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	levels	level	NNS	_	11	ppmod	_	_
16	is	be	VBZ	_	17	aux	_	_
17	recommended	recommend	VBN	_	5	conj	_	_
18	.	.	.	_	5	p	_	_

1	If	if	IN	_	6	mark	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	also	also	RB	_	6	adv	_	_
6	used	use	VBN	_	15	advcl	_	_
7	,	,	,	_	15	p	_	_
8	the	the	DT	_	9	det	_	_
9	risk	risk	NN	_	15	dep	_	_
10	of	of	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	toxicity	toxicity	NN	_	9	ppmod	_	_
13	may	may	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	increased	increase	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	Agents	agent	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	No	no	DT	_	8	det	_	_
5	clinically	clinically	RB	_	6	adv	_	_
6	important	important	JJ	_	8	attr	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
8	interactions	interaction	NNS	_	9	dep	_	_
9	occurred	occur	VBD	_	2	acl	_	_
10	when	when	WRB	_	13	adv	_	_
11	drug1	drug0	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	administered	administer	VBN	_	9	comp	_	_
14	concomitantly	concomitantly	RB	_	13	adv	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	or	or	CC	_	18	cc	_	_
21	drug4	drug0	NN	_	16	conj	_	_
22	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	clinical	clinical	JJ	_	7	attr	_	_
7	trials	trial	NNS	_	4	ppmod	_	_
8	concomitantly	concomitantly	RB	_	10	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	drug6	drug0	NN	_	10	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	cholesterol-lowering	cholesterol-lowering	JJ	_	23	attr	_	_
23	agents	agent	NNS	_	10	conj	_	_
24	.	.	.	_	4	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	of	of	IN	_	9	case	_	_
6	clinically	clinically	RB	_	7	adv	_	_
7	important	important	JJ	_	9	attr	_	_
8	adverse	adverse	JJ	_	9	attr	_	_
9	interactions	interaction	NNS	_	4	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	primarily	primarily	RB	_	4	adv	_	_
4	eliminated	eliminate	VBN	_	0	root	_	_
5	unchanged	unchanged	JJ	_	4	dep	_	_
6	renally	renally	RB	_	4	adv	_	_
7	as	as	IN	_	9	case	_	_
8	a	a	DT	_	9	det	_	_
9	result	result	NN	_	4	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	glomerular	glomerular	JJ	_	12	attr	_	_
12	filtration	filtration	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	tubular	tubular	JJ	_	15	attr	_	_
15	secretion	secretion	NN	_	12	conj	_	_
16	.	.	.	_	4	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	nephrotoxic	nephrotoxic	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	2	ppmod	_	_
6	could	could	MD	_	7	modal	_	_
7	result	result	VB	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	delayed	delay	VBN	_	10	attr	_	_
10	clearance	clearance	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	17	dep	_	_
3	of	of	IN	_	4	case	_	_
4	substances	substance	NNS	_	2	ppmod	_	_
5	that	that	WDT	_	9	dep	_	_
6	are	be	VBP	_	9	aux	_	_
7	also	also	RB	_	9	adv	_	_
8	tubularly	tubularly	RB	_	9	adv	_	_
9	secreted	secrete	VBN	_	4	relcl	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	e.g.	e.g.	FW	_	13	adv	_	_
12	,	,	,	_	13	p	_	_
13	drug1	drug0	NN	_	4	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	could	could	MD	_	17	modal	_	_
16	potentially	potentially	RB	_	17	adv	_	_
17	result	result	VB	_	0	root	_	_
18	in	in	IN	_	20	case	_	_
19	delayed	delay	VBN	_	20	attr	_	_
20	clearance	clearance	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	17	p	_	_

1	Although	although	IN	_	10	mark	_	_
2	drug1	drug0	NN	_	10	dep	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	400	0	CD	_	5	num	_	_
5	mg	mg	NN	_	2	prn	_	_
6	qid	qid	JJ	_	5	attr	_	_
7	)	-rrb-	-RRB-	_	5	p	_	_
8	can	can	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	administered	administer	VBN	_	29	advcl	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	10	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	normal	normal	JJ	_	18	attr	_	_
17	renal	renal	JJ	_	18	attr	_	_
18	function	function	NN	_	14	ppmod	_	_
19	(	-lrb-	-LRB-	_	23	p	_	_
20	creatinine	creatinine	NN	_	23	attr	_	_
21	clearance	clearance	NN	_	23	attr	_	_
22	80	0	CD	_	23	num	_	_
23	mL/min	ml/min	NN	_	18	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	29	p	_	_
26	caution	caution	NN	_	29	dep	_	_
27	should	should	MD	_	29	modal	_	_
28	be	be	VB	_	29	aux	_	_
29	used	use	VBN	_	0	root	_	_
30	when	when	WRB	_	31	adv	_	_
31	administering	administer	VBG	_	29	comp	_	_
32	drug3	drug0	NN	_	31	obj	_	_
33	concurrently	concurrently	RB	_	35	adv	_	_
34	with	with	IN	_	35	case	_	_
35	drug4	drug0	NN	_	32	ppmod	_	_
36	to	to	TO	_	37	aux	_	_
37	patients	patient	NNS	_	31	ppmod	_	_
38	with	with	IN	_	43	case	_	_
39	mild	mild	JJ	_	41	adv	_	_
40	to	to	TO	_	41	adv	_	_
41	moderate	moderate	JJ	_	43	attr	_	_
42	renal	renal	JJ	_	43	attr	_	_
43	insufficiency	insufficiency	NN	_	37	ppmod	_	_
44	(	-lrb-	-LRB-	_	46	p	_	_
45	creatinine	creatinine	NN	_	46	com	_	_
46	clearance	clearance	NN	_	43	prn	_	_
47	from	from	IN	_	51	case	_	_
48	45	0	CD	_	51	num	_	_
49	to	to	TO	_	48	cc	_	_
50	79	0	CD	_	48	conj	_	_
51	mL/min	ml/min	NN	_	46	ppmod	_	_
52	)	-rrb-	-RRB-	_	46	p	_	_
53	.	.	.	_	29	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	with	with	IN	_	7	case	_	_
3	mild	mild	JJ	_	5	adv	_	_
4	to	to	TO	_	5	adv	_	_
5	moderate	moderate	JJ	_	7	attr	_	_
6	renal	renal	JJ	_	7	attr	_	_
7	insufficiency	insufficiency	NN	_	1	ppmod	_	_
8	should	should	MD	_	9	modal	_	_
9	avoid	avoid	VB	_	0	root	_	_
10	taking	take	VBG	_	9	comp	_	_
11	drug1	drug0	NN	_	10	obj	_	_
12	with	with	IN	_	15	case	_	_
13	short	short	JJ	_	15	attr	_	_
14	elimination	elimination	NN	_	15	com	_	_
15	half-lives	half-life	NNS	_	11	ppmod	_	_
16	for	for	IN	_	18	case	_	_
17	a	a	DT	_	18	det	_	_
18	period	period	NN	_	15	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	2	0	CD	_	21	num	_	_
21	days	day	NNS	_	18	ppmod	_	_
22	before	before	IN	_	21	case	_	_
23	,	,	,	_	21	p	_	_
24	the	the	DT	_	25	det	_	_
25	day	day	NN	_	21	conj	_	_
26	of	of	IN	_	25	case	_	_
27	,	,	,	_	25	p	_	_
28	and	and	CC	_	25	cc	_	_
29	2	0	CD	_	30	num	_	_
30	days	day	NNS	_	21	conj	_	_
31	following	follow	VBG	_	30	acl	_	_
32	administration	administration	NN	_	31	obj	_	_
33	of	of	IN	_	34	case	_	_
34	drug2	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	9	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	absence	absence	NN	_	23	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	data	datum	NNS	_	3	ppmod	_	_
6	regarding	regard	VBG	_	5	acl	_	_
7	potential	potential	JJ	_	8	attr	_	_
8	interaction	interaction	NN	_	6	obj	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	with	with	IN	_	15	case	_	_
14	longer	long	JJR	_	15	attr	_	_
15	half-lives	half-life	NNS	_	8	ppmod	_	_
16	,	,	,	_	23	p	_	_
17	all	all	DT	_	18	det	_	_
18	patients	patient	NNS	_	23	dep	_	_
19	taking	take	VBG	_	18	acl	_	_
20	these	these	DT	_	21	det	_	_
21	drug3	drug0	NNS	_	19	obj	_	_
22	should	should	MD	_	23	modal	_	_
23	interrupt	interrupt	VB	_	0	root	_	_
24	dosing	dosing	NN	_	23	obj	_	_
25	for	for	IN	_	29	case	_	_
26	at	at	IN	_	28	case	_	_
27	least	least	JJS	_	28	attr	_	_
28	5	0	CD	_	29	num	_	_
29	days	day	NNS	_	23	ppmod	_	_
30	before	before	IN	_	29	case	_	_
31	,	,	,	_	29	p	_	_
32	the	the	DT	_	33	det	_	_
33	day	day	NN	_	29	appo	_	_
34	of	of	IN	_	33	case	_	_
35	,	,	,	_	29	p	_	_
36	and	and	CC	_	29	cc	_	_
37	2	0	CD	_	38	num	_	_
38	days	day	NNS	_	29	conj	_	_
39	following	follow	VBG	_	38	acl	_	_
40	drug4	drug0	NN	_	41	com	_	_
41	administration	administration	NN	_	39	obj	_	_
42	.	.	.	_	23	p	_	_

1	If	if	IN	_	7	mark	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	an	an	DT	_	6	det	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	13	advcl	_	_
8	necessary	necessary	JJ	_	7	dep	_	_
9	,	,	,	_	13	p	_	_
10	patients	patient	NNS	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	monitored	monitor	VBN	_	0	root	_	_
14	closely	closely	RB	_	13	adv	_	_
15	for	for	IN	_	16	case	_	_
16	toxicity	toxicity	NN	_	13	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	especially	especially	RB	_	19	adv	_	_
19	myelosuppression	myelosuppression	NN	_	16	conj	_	_
20	,	,	,	_	19	p	_	_
21	renal	renal	JJ	_	16	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	gastrointestinal	gastrointestinal	JJ	_	25	attr	_	_
25	toxicity	toxicity	NN	_	16	conj	_	_
26	.	.	.	_	13	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	5	dep	_	_
4	None	none	NN	_	5	dep	_	_
5	known	know	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	Prothrombin	prothrombin	NN	_	2	com	_	_
2	time	time	NN	_	10	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	other	other	JJ	_	7	attr	_	_
5	suitable	suitable	JJ	_	7	attr	_	_
6	anticoagulation	anticoagulation	NN	_	7	com	_	_
7	test	test	NN	_	2	conj	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	monitored	monitor	VBN	_	0	root	_	_
11	if	if	IN	_	14	mark	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	administered	administer	VBN	_	10	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	10	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	render	render	VB	_	0	root	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	drug3	drug0	NN	_	9	obj	_	_
12	less	less	RBR	_	13	adv	_	_
13	effective	effective	JJ	_	11	attr	_	_
14	.	.	.	_	9	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	5	dep	_	_
4	There	there	RB	_	5	adv	_	_
5	are	be	VBP	_	0	root	_	_
6	no	no	DT	_	10	det	_	_
7	reported	report	VBN	_	10	attr	_	_
8	drug-laboratory	drug-laboratory	JJ	_	10	attr	_	_
9	test	test	NN	_	10	com	_	_
10	interactions	interaction	NNS	_	5	obj	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	20	case	_	_
5	the	the	DT	_	7	det	_	_
6	following	following	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	20	attr	_	_
8	:	:	:	_	7	p	_	_
9	drug2	drug0	NN	_	7	appo	_	_
10	and	and	CC	_	9	cc	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug3	drug0	NNS	_	9	conj	_	_
13	(	-lrb-	-LRB-	_	12	p	_	_
14	may	may	MD	_	15	modal	_	_
15	lower	low	JJR	_	12	acl	_	_
16	drug4	drug0	NN	_	17	com	_	_
17	levels	level	NNS	_	15	obj	_	_
18	)	-rrb-	-RRB-	_	12	p	_	_
19	,	,	,	_	12	p	_	_
20	drug5	drug0	NN	_	3	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	bioavailability	bioavailability	NN	_	20	prn	_	_
23	of	of	IN	_	25	case	_	_
24	oral	oral	JJ	_	25	attr	_	_
25	drug6	drug0	NN	_	22	ppmod	_	_
26	is	be	VBZ	_	27	aux	_	_
27	increased	increase	VBN	_	25	acl	_	_
28	with	with	IN	_	29	case	_	_
29	coadministration	coadministration	NN	_	27	ppmod	_	_
30	)	-rrb-	-RRB-	_	22	p	_	_
31	,	,	,	_	20	p	_	_
32	drug7	drug0	NN	_	20	conj	_	_
33	(	-lrb-	-LRB-	_	35	p	_	_
34	may	may	MD	_	35	modal	_	_
35	decrease	decrease	VB	_	32	prn	_	_
36	drug8	drug0	NN	_	37	com	_	_
37	levels	level	NNS	_	35	obj	_	_
38	)	-rrb-	-RRB-	_	35	p	_	_
39	,	,	,	_	32	p	_	_
40	drug9	drug0	NN	_	20	conj	_	_
41	(	-lrb-	-LRB-	_	42	p	_	_
42	reports	report	NNS	_	40	prn	_	_
43	of	of	IN	_	45	case	_	_
44	psychotic	psychotic	JJ	_	45	attr	_	_
45	episodes	episode	NNS	_	42	ppmod	_	_
46	when	when	WRB	_	47	adv	_	_
47	coadministered	coadministered	VBN	_	45	relcl	_	_
48	)	-rrb-	-RRB-	_	42	p	_	_
49	,	,	,	_	40	p	_	_
50	drug10	drug0	NN	_	20	conj	_	_
51	(	-lrb-	-LRB-	_	52	p	_	_
52	coadministration	coadministration	NN	_	50	prn	_	_
53	of	of	IN	_	54	case	_	_
54	drug11	drug0	NN	_	52	ppmod	_	_
55	with	with	IN	_	56	case	_	_
56	drug12	drug0	NN	_	52	ppmod	_	_
57	can	can	MD	_	58	modal	_	_
58	inhibit	inhibit	VB	_	52	acl	_	_
59	ovarian	ovarian	JJ	_	60	attr	_	_
60	function	function	NN	_	58	obj	_	_
61	in	in	IN	_	62	case	_	_
62	women	woman	NNS	_	60	ppmod	_	_
63	)	-rrb-	-RRB-	_	52	p	_	_
64	,	,	,	_	50	p	_	_
65	drug13	drug0	NN	_	20	conj	_	_
66	and	and	CC	_	65	cc	_	_
67	other	other	JJ	_	69	attr	_	_
68	sedating	sedating	JJ	_	69	attr	_	_
69	drugs	drug	NNS	_	65	conj	_	_
70	(	-lrb-	-LRB-	_	72	p	_	_
71	may	may	MD	_	72	modal	_	_
72	result	result	VB	_	65	prn	_	_
73	in	in	IN	_	75	case	_	_
74	additive	additive	JJ	_	75	attr	_	_
75	sedation	sedation	NN	_	72	ppmod	_	_
76	and	and	CC	_	75	cc	_	_
77	an	an	DT	_	79	det	_	_
78	increased	increase	VBN	_	79	attr	_	_
79	incidence	incidence	NN	_	75	conj	_	_
80	of	of	IN	_	82	case	_	_
81	adverse	adverse	JJ	_	82	attr	_	_
82	effects	effect	NNS	_	79	ppmod	_	_
83	)	-rrb-	-RRB-	_	72	p	_	_
84	,	,	,	_	65	p	_	_
85	and	and	CC	_	65	cc	_	_
86	drug14	drug0	NN	_	20	conj	_	_
87	(	-lrb-	-LRB-	_	88	p	_	_
88	coadministration	coadministration	NN	_	86	prn	_	_
89	of	of	IN	_	90	case	_	_
90	drug15	drug0	NN	_	88	ppmod	_	_
91	and	and	CC	_	90	cc	_	_
92	drug16	drug0	NN	_	90	conj	_	_
93	may	may	MD	_	94	modal	_	_
94	interfere	interfere	VB	_	90	acl	_	_
95	with	with	IN	_	97	case	_	_
96	the	the	DT	_	97	det	_	_
97	efficacy	efficacy	NN	_	94	ppmod	_	_
98	of	of	IN	_	100	case	_	_
99	the	the	DT	_	100	det	_	_
100	drug17	drug0	NN	_	97	ppmod	_	_
101	)	-rrb-	-RRB-	_	88	p	_	_
102	.	.	.	_	3	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	8	dep	_	_
4	with	with	IN	_	7	case	_	_
5	human	human	JJ	_	7	attr	_	_
6	liver	liver	NN	_	7	com	_	_
7	microsomes	microsome	NNS	_	3	ppmod	_	_
8	showed	show	VBD	_	0	root	_	_
9	that	that	IN	_	13	mark	_	_
10	drug1	drug0	NN	_	13	dep	_	_
11	does	do	VBZ	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	inhibit	inhibit	VB	_	8	comp	_	_
14	the	the	DT	_	15	det	_	_
15	metabolism	metabolism	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	17	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug5	drug0	NN	_	17	conj	_	_
25	.	.	.	_	8	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	also	also	RB	_	6	adv	_	_
6	shown	show	VBN	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	inhibits	inhibit	VBZ	_	6	comp	_	_
10	CYP2D6-mediated	cyp0d0-mediated	JJ	_	11	attr	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	.	.	.	_	6	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	be	be	VB	_	0	root	_	_
4	of	of	IN	_	6	case	_	_
5	clinical	clinical	JJ	_	6	attr	_	_
6	relevance	relevance	NN	_	3	ppmod	_	_
7	for	for	IN	_	8	case	_	_
8	compounds	compound	NNS	_	3	ppmod	_	_
9	predominantly	predominantly	RB	_	10	adv	_	_
10	metabolized	metabolize	VBN	_	8	acl	_	_
11	by	by	IN	_	13	case	_	_
12	this	this	DT	_	13	det	_	_
13	enzyme	enzyme	NN	_	10	ppmod	_	_
14	,	,	,	_	8	p	_	_
15	such	such	JJ	_	17	adv	_	_
16	as	as	IN	_	17	case	_	_
17	drug1	drug0	NN	_	8	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	-blockers	-blockers	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug2	drug0	NN	_	17	conj	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	drug3	drug0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	21	p	_	_
26	and	and	CC	_	21	cc	_	_
27	drug4	drug0	NN	_	17	conj	_	_
28	,	,	,	_	3	p	_	_
29	if	if	IN	_	31	mark	_	_
30	they	they	PRP	_	31	dep	_	_
31	have	have	VBP	_	3	comp	_	_
32	a	a	DT	_	35	det	_	_
33	narrow	narrow	JJ	_	35	attr	_	_
34	therapeutic	therapeutic	JJ	_	35	attr	_	_
35	window	window	NN	_	31	obj	_	_
36	.	.	.	_	3	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vivo	vivo	FW	_	5	attr	_	_
3	drug-drug	drug-drug	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	11	dep	_	_
6	conducted	conduct	VBN	_	5	acl	_	_
7	in	in	IN	_	10	case	_	_
8	normal	normal	JJ	_	10	attr	_	_
9	volunteer	volunteer	NN	_	10	com	_	_
10	subjects	subject	NNS	_	6	ppmod	_	_
11	showed	show	VBD	_	0	root	_	_
12	that	that	IN	_	16	mark	_	_
13	drug1	drug0	NN	_	16	dep	_	_
14	does	do	VBZ	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	affect	affect	VB	_	11	comp	_	_
17	the	the	DT	_	18	det	_	_
18	clearance	clearance	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreases	decrease	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	clearance	clearance	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	by	by	IN	_	8	case	_	_
8	19	0	CD	_	2	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increases	increase	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	clearance	clearance	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	by	by	IN	_	8	case	_	_
8	15	0	CD	_	4	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	.	.	.	_	2	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	36	advcl	_	_
4	spontaneous	spontaneous	JJ	_	5	attr	_	_
5	reports	report	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	increase	increase	NN	_	5	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	decrease	decrease	NN	_	7	conj	_	_
10	in	in	IN	_	12	case	_	_
11	prothrombin	prothrombin	NN	_	12	com	_	_
12	times	time	NNS	_	5	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	concomitantly	concomitantly	RB	_	16	adv	_	_
16	taking	take	VBG	_	14	acl	_	_
17	oral	oral	JJ	_	18	attr	_	_
18	drug1	drug0	NN	_	16	obj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	,	,	,	_	36	p	_	_
22	however	however	RB	_	36	adv	_	_
23	,	,	,	_	36	p	_	_
24	a	a	DT	_	26	det	_	_
25	causal	causal	JJ	_	26	attr	_	_
26	relationship	relationship	NN	_	36	dep	_	_
27	between	between	IN	_	29	case	_	_
28	drug3	drug0	NN	_	29	com	_	_
29	Tablets	tablet	NNS	_	26	ppmod	_	_
30	and	and	CC	_	29	cc	_	_
31	these	these	DT	_	32	det	_	_
32	changes	change	NNS	_	29	conj	_	_
33	has	have	VBZ	_	36	aux	_	_
34	not	not	RB	_	36	neg	_	_
35	been	be	VBN	_	36	aux	_	_
36	established	establish	VBN	_	0	root	_	_
37	.	.	.	_	36	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	clearance	clearance	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	increased	increase	VBN	_	0	root	_	_
5	100	0	CD	_	4	obj	_	_
6	%	%	NN	_	5	meta	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	a	a	DT	_	13	det	_	_
11	CyP450	cyp0	NN	_	13	com	_	_
12	enzyme	enzyme	NN	_	13	com	_	_
13	inducer	inducer	NN	_	8	appo	_	_
14	,	,	,	_	8	p	_	_
15	and	and	CC	_	4	cc	_	_
16	decreased	decrease	VBN	_	4	conj	_	_
17	33	0	CD	_	16	obj	_	_
18	%	%	NN	_	17	meta	_	_
19	by	by	IN	_	20	case	_	_
20	drug3	drug0	NN	_	16	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	a	a	DT	_	25	det	_	_
23	CyP450	cyp0	NN	_	25	com	_	_
24	enzyme	enzyme	NN	_	25	com	_	_
25	inhibitor	inhibitor	NN	_	20	appo	_	_
26	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	clearance	clearance	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	unaffected	unaffected	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	.	.	.	_	4	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	information	information	NN	_	2	obj	_	_
5	available	available	JJ	_	4	attr	_	_
6	from	from	IN	_	10	case	_	_
7	adequate	adequate	JJ	_	10	attr	_	_
8	drug-drug	drug-drug	JJ	_	10	attr	_	_
9	interaction	interaction	NN	_	10	com	_	_
10	studies	study	NNS	_	5	ppmod	_	_
11	with	with	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	following	following	JJ	_	14	attr	_	_
14	classes	class	NNS	_	10	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drugs	drug	NNS	_	14	ppmod	_	_
17	:	:	:	_	14	p	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	drug1	drug0	NN	_	14	appo	_	_
20	,	,	,	_	19	p	_	_
21	hormone	hormone	NN	_	23	com	_	_
22	replacement	replacement	NN	_	23	com	_	_
23	therapies	therapy	NNS	_	19	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug2	drug0	NN	_	19	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug3	drug0	NN	_	19	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug4	drug0	NN	_	19	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug5	drug0	NN	_	19	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug6	drug0	NN	_	19	conj	_	_
34	,	,	,	_	33	p	_	_
35	and	and	CC	_	33	cc	_	_
36	drug7	drug0	NN	_	19	conj	_	_
37	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	demonstrate	demonstrate	VBP	_	0	root	_	_
4	additive	additive	JJ	_	5	attr	_	_
5	toxicity	toxicity	NN	_	3	obj	_	_
6	when	when	WRB	_	7	adv	_	_
7	used	use	VBN	_	3	comp	_	_
8	in	in	IN	_	9	case	_	_
9	combination	combination	NN	_	7	ppmod	_	_
10	with	with	IN	_	13	case	_	_
11	other	other	JJ	_	13	attr	_	_
12	cytotoxic	cytotoxic	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	9	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	prolong	prolong	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	elimination	elimination	NN	_	9	com	_	_
9	half-life	half-life	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	4	cc	_	_
13	may	may	MD	_	14	modal	_	_
14	lead	lead	VB	_	4	conj	_	_
15	to	to	TO	_	19	aux	_	_
16	severe	severe	JJ	_	19	attr	_	_
17	bone	bone	NN	_	19	com	_	_
18	marrow	marrow	NN	_	19	com	_	_
19	suppression	suppression	NN	_	14	ppmod	_	_
20	;	;	:	_	4	p	_	_

1	a	a	DT	_	2	det	_	_
2	reduction	reduction	NN	_	9	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	dosage	dosage	NN	_	2	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	considered	consider	VBN	_	0	root	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	receiving	receive	VBG	_	11	acl	_	_
13	drug2	drug0	NN	_	12	obj	_	_
14	concurrently	concurrently	RB	_	9	adv	_	_
15	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	in	in	IN	_	13	case	_	_
12	one	#crd#	CD	_	13	num	_	_
13	case	case	NN	_	10	ppmod	_	_
14	to	to	TO	_	15	aux	_	_
15	result	result	VB	_	10	comp	_	_
16	in	in	IN	_	19	case	_	_
17	reduced	reduce	VBN	_	19	attr	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	cytotoxicity	cytotoxicity	NN	_	15	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	causes	cause	VBZ	_	1	acl	_	_
5	a	a	DT	_	8	det	_	_
6	60	0	CD	_	8	num	_	_
7	%	%	NN	_	8	meta	_	_
8	reduction	reduction	NN	_	4	obj	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	absorption	absorption	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	enterohepatic	enterohepatic	JJ	_	14	attr	_	_
14	cycling	cycling	NN	_	11	conj	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	11	ppmod	_	_
17	and	and	CC	_	4	cc	_	_
18	should	should	MD	_	21	modal	_	_
19	not	not	RB	_	21	neg	_	_
20	be	be	VB	_	21	aux	_	_
21	coadministered	coadministered	VBN	_	4	conj	_	_
22	with	with	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	coadministration	coadministration	NN	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	has	have	VBZ	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	assessed	assess	VBN	_	1	acl	_	_
13	under	under	IN	_	15	case	_	_
14	chronic	chronic	JJ	_	15	attr	_	_
15	conditions	condition	NNS	_	12	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	However	however	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	10	0	CD	_	5	num	_	_
4	%	%	NN	_	3	meta	_	_
5	decreases	decrease	NNS	_	11	dep	_	_
6	in	in	IN	_	8	case	_	_
7	prothrombin	prothrombin	NN	_	8	com	_	_
8	time	time	NN	_	5	ppmod	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	single-dose	single-dose	JJ	_	14	attr	_	_
14	studies	study	NNS	_	11	ppmod	_	_
15	.	.	.	_	11	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	given	give	VBN	_	13	advcl	_	_
5	concurrently	concurrently	RB	_	4	adv	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	prothrombin	prothrombin	NN	_	10	com	_	_
10	time	time	NN	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	monitored	monitor	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Other	other	JJ	_	4	attr	_	_
2	Highly	highly	RB	_	3	adv	_	_
3	Protein-Bound	protein-bound	JJ	_	4	attr	_	_
4	Drugs	drug	NNS	_	0	root	_	_
5	:	:	:	_	4	p	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	is	be	VBZ	_	4	acl	_	_
8	more	more	JJR	_	10	attr	_	_
9	than	than	IN	_	8	com	_	_
10	95	0	CD	_	7	obj	_	_
11	%	%	NN	_	10	meta	_	_
12	bound	bind	VBD	_	10	acl	_	_
13	to	to	TO	_	15	aux	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	proteins	protein	NNS	_	12	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	7	adv	_	_
3	,	,	,	_	7	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	did	do	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	affect	affect	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	binding	binding	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	drug4	drug0	NN	_	11	conj	_	_
17	.	.	.	_	7	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	coadministered	coadministered	VBN	_	4	comp	_	_
9	with	with	IN	_	13	case	_	_
10	other	other	JJ	_	13	attr	_	_
11	highly	highly	RB	_	12	adv	_	_
12	protein-bound	protein-bound	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	8	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	such	such	JJ	_	17	adv	_	_
16	as	as	IN	_	17	case	_	_
17	drug2	drug0	NN	_	13	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	17	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug5	drug0	NN	_	17	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug6	drug0	NN	_	17	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	drug7	drug0	NN	_	17	conj	_	_
29	.	.	.	_	4	p	_	_

1	See	see	VB	_	0	root	_	_
2	also	also	RB	_	1	adv	_	_
3	CLINICAL	clinical	JJ	_	4	attr	_	_
4	PHARMACOLOGY	pharmacology	NN	_	1	obj	_	_
5	,	,	,	_	1	p	_	_
6	Drug-Drug	drug-drug	JJ	_	7	attr	_	_
7	Interactions	interaction	NNS	_	1	dep	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug4	drug0	NN	_	7	conj	_	_
13	.	.	.	_	3	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	interact	interact	VB	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	increased	increase	VBN	_	9	attr	_	_
9	thrombocytopenia	thrombocytopenia	NN	_	6	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	6	p	_	_
12	drug2	drug0	NN	_	6	appo	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	increased	increase	VBN	_	15	attr	_	_
15	nephrotoxicity	nephrotoxicity	NN	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	6	p	_	_
18	drug3	drug0	NN	_	6	appo	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	increased	increase	VBN	_	22	attr	_	_
21	hypoglycemic	hypoglycemic	JJ	_	22	attr	_	_
22	response	response	NN	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	6	p	_	_
25	drug4	drug0	NN	_	6	appo	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	increased	increase	VBN	_	29	attr	_	_
28	anticoagulant	anticoagulant	NN	_	29	com	_	_
29	effect	effect	NN	_	25	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	,	,	,	_	6	p	_	_
32	drug5	drug0	NN	_	6	appo	_	_
33	(	-lrb-	-LRB-	_	36	p	_	_
34	decreased	decrease	VBN	_	36	attr	_	_
35	renal	renal	JJ	_	36	attr	_	_
36	excretion	excretion	NN	_	32	prn	_	_
37	of	of	IN	_	38	case	_	_
38	drug6	drug0	NN	_	36	ppmod	_	_
39	)	-rrb-	-RRB-	_	36	p	_	_
40	,	,	,	_	6	p	_	_
41	drug7	drug0	NN	_	6	appo	_	_
42	(	-lrb-	-LRB-	_	45	p	_	_
43	decreased	decrease	VBN	_	45	attr	_	_
44	hepatic	hepatic	JJ	_	45	attr	_	_
45	clearance	clearance	NN	_	41	prn	_	_
46	of	of	IN	_	47	case	_	_
47	drug8	drug0	NN	_	45	ppmod	_	_
48	)	-rrb-	-RRB-	_	45	p	_	_
49	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	21	dep	_	_
2	,	,	,	_	1	p	_	_
3	such	such	JJ	_	6	adv	_	_
4	as	as	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug3	drug0	NN	_	6	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	drug5	drug0	NN	_	8	appo	_	_
13	)	-rrb-	-RRB-	_	8	p	_	_
14	or	or	CC	_	6	cc	_	_
15	drug6	drug0	NN	_	6	conj	_	_
16	,	,	,	_	1	p	_	_
17	ordinarily	ordinarily	RB	_	21	adv	_	_
18	should	should	MD	_	21	modal	_	_
19	not	not	RB	_	21	neg	_	_
20	be	be	VB	_	21	aux	_	_
21	administered	administer	VBN	_	0	root	_	_
22	concurrently	concurrently	RB	_	21	adv	_	_
23	with	with	IN	_	24	case	_	_
24	drug7	drug0	NN	_	21	ppmod	_	_
25	(	-lrb-	-LRB-	_	27	p	_	_
26	a	a	DT	_	27	det	_	_
27	drug8	drug0	NN	_	24	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	;	;	:	_	21	p	_	_

1	these	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	diminish	diminish	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	effectiveness	effectiveness	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	is	be	VBZ	_	15	advcl	_	_
4	approximately	approximately	RB	_	5	adv	_	_
5	90	0	CD	_	3	obj	_	_
6	%	%	NN	_	5	meta	_	_
7	bound	bind	VBD	_	5	acl	_	_
8	to	to	TO	_	10	aux	_	_
9	plasma	plasma	NN	_	10	com	_	_
10	proteins	protein	NNS	_	7	ppmod	_	_
11	,	,	,	_	15	p	_	_
12	caution	caution	NN	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	exercised	exercise	VBN	_	0	root	_	_
16	if	if	IN	_	19	mark	_	_
17	drug2	drug0	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	coadministered	coadministered	VBN	_	15	comp	_	_
20	with	with	IN	_	22	case	_	_
21	other	other	JJ	_	22	attr	_	_
22	drugs	drug	NNS	_	19	ppmod	_	_
23	known	know	VBN	_	22	acl	_	_
24	to	to	TO	_	25	aux	_	_
25	affect	affect	VB	_	23	comp	_	_
26	protein	protein	NN	_	27	com	_	_
27	binding	binding	NN	_	25	obj	_	_
28	.	.	.	_	15	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	9	dep	_	_
3	:	:	:	_	2	p	_	_
4	Women	woman	NNS	_	2	appo	_	_
5	on	on	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	have	have	VBP	_	9	aux	_	_
9	shown	show	VBN	_	0	root	_	_
10	a	a	DT	_	12	det	_	_
11	significant	significant	JJ	_	12	attr	_	_
12	increase	increase	NN	_	9	obj	_	_
13	in	in	IN	_	16	case	_	_
14	plasma	plasma	NN	_	16	com	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	levels	level	NNS	_	12	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	gastrointestinal	gastrointestinal	JJ	_	7	attr	_	_
7	motility	motility	NN	_	2	ppmod	_	_
8	are	be	VBP	_	9	aux	_	_
9	antagonized	antagonize	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	.	.	.	_	9	p	_	_

1	Additive	additive	JJ	_	3	attr	_	_
2	sedative	sedative	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	5	dep	_	_
4	can	can	MD	_	5	modal	_	_
5	occur	occur	VB	_	0	root	_	_
6	when	when	WRB	_	9	adv	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	given	give	VBN	_	5	comp	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug4	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug5	drug0	NN	_	11	conj	_	_
18	,	,	,	_	17	p	_	_
19	or	or	CC	_	17	cc	_	_
20	drug6	drug0	NN	_	11	conj	_	_
21	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	finding	finding	NN	_	12	dep	_	_
3	that	that	IN	_	5	mark	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	releases	release	VBZ	_	2	acl	_	_
6	catecholamines	catecholamine	NNS	_	5	obj	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	5	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	essential	essential	JJ	_	11	attr	_	_
11	hypertension	hypertension	NN	_	8	ppmod	_	_
12	suggests	suggest	VBZ	_	0	root	_	_
13	that	that	IN	_	17	mark	_	_
14	it	it	PRP	_	17	dep	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	used	use	VBN	_	12	comp	_	_
18	cautiously	cautiously	RB	_	17	adv	_	_
19	,	,	,	_	17	p	_	_
20	if	if	IN	_	17	adv	_	_
21	at	at	IN	_	22	case	_	_
22	all	all	NN	_	20	ppmod	_	_
23	,	,	,	_	17	p	_	_
24	in	in	IN	_	25	case	_	_
25	patients	patient	NNS	_	17	ppmod	_	_
26	receiving	receive	VBG	_	25	acl	_	_
27	drug2	drug0	NN	_	26	obj	_	_
28	.	.	.	_	12	p	_	_

1	Absorption	absorption	NN	_	9	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drugs	drug	NNS	_	1	ppmod	_	_
4	from	from	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	stomach	stomach	NN	_	1	ppmod	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	diminished	diminish	VBN	_	33	advcl	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	e.g.	e.g.	FW	_	13	ppmod	_	_
12	,	,	,	_	13	p	_	_
13	drug1	drug0	NN	_	9	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	by	by	IN	_	16	case	_	_
16	drug2	drug0	NN	_	9	ppmod	_	_
17	,	,	,	_	33	p	_	_
18	whereas	whereas	IN	_	33	case	_	_
19	the	the	DT	_	20	det	_	_
20	rate	rate	NN	_	33	dep	_	_
21	and/or	and/or	CC	_	20	cc	_	_
22	extent	extent	NN	_	20	conj	_	_
23	of	of	IN	_	24	case	_	_
24	absorption	absorption	NN	_	20	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drugs	drug	NNS	_	24	ppmod	_	_
27	from	from	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	small	small	JJ	_	30	attr	_	_
30	bowel	bowel	NN	_	26	ppmod	_	_
31	may	may	MD	_	33	modal	_	_
32	be	be	VB	_	33	aux	_	_
33	increased	increase	VBN	_	0	root	_	_
34	(	-lrb-	-LRB-	_	37	p	_	_
35	e.g.	e.g.	FW	_	37	ppmod	_	_
36	,	,	,	_	37	p	_	_
37	drug3	drug0	NN	_	33	prn	_	_
38	,	,	,	_	37	p	_	_
39	drug4	drug0	NN	_	37	appo	_	_
40	,	,	,	_	37	p	_	_
41	drug5	drug0	NN	_	37	appo	_	_
42	,	,	,	_	37	p	_	_
43	drug6	drug0	NN	_	37	appo	_	_
44	,	,	,	_	37	p	_	_
45	drug7	drug0	NN	_	37	appo	_	_
46	)	-rrb-	-RRB-	_	37	p	_	_
47	.	.	.	_	33	p	_	_

1	Gastroparesis	gastroparesis	NN	_	7	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	gastric	gastric	JJ	_	4	attr	_	_
4	stasis	stasis	NN	_	1	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	responsible	responsible	JJ	_	7	dep	_	_
9	for	for	IN	_	12	case	_	_
10	poor	poor	JJ	_	12	attr	_	_
11	diabetic	diabetic	JJ	_	12	attr	_	_
12	control	control	NN	_	8	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	some	some	DT	_	15	det	_	_
15	patients	patient	NNS	_	12	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	Exogenously	exogenously	RB	_	2	adv	_	_
2	administered	administer	VBN	_	3	attr	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	begin	begin	VB	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	act	act	VB	_	5	comp	_	_
8	before	before	IN	_	10	mark	_	_
9	food	food	NN	_	10	dep	_	_
10	has	have	VBZ	_	7	comp	_	_
11	left	left	JJ	_	13	attr	_	_
12	the	the	DT	_	13	det	_	_
13	stomach	stomach	NN	_	10	obj	_	_
14	and	and	CC	_	5	cc	_	_
15	lead	lead	VB	_	5	conj	_	_
16	to	to	TO	_	17	aux	_	_
17	hypoglycemia	hypoglycemia	NN	_	15	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	Because	because	IN	_	7	mark	_	_
2	the	the	DT	_	3	det	_	_
3	action	action	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	will	will	MD	_	7	modal	_	_
7	influence	influence	VB	_	29	advcl	_	_
8	the	the	DT	_	9	det	_	_
9	delivery	delivery	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	food	food	NN	_	9	ppmod	_	_
12	to	to	TO	_	14	aux	_	_
13	the	the	DT	_	14	det	_	_
14	intestines	intestine	NNS	_	9	ppmod	_	_
15	and	and	CC	_	7	cc	_	_
16	thus	thus	RB	_	18	adv	7:adv	_
17	the	the	DT	_	18	det	_	_
18	rate	rate	NN	_	7	conj	_	_
19	of	of	IN	_	20	case	_	_
20	absorption	absorption	NN	_	18	ppmod	_	_
21	,	,	,	_	29	p	_	_
22	drug2	drug0	NN	_	23	com	_	_
23	dosage	dosage	NN	_	29	dep	_	_
24	or	or	CC	_	23	cc	_	_
25	timing	timing	NN	_	23	conj	_	_
26	of	of	IN	_	27	case	_	_
27	dosage	dosage	NN	_	23	ppmod	_	_
28	may	may	MD	_	29	modal	_	_
29	require	require	VB	_	0	root	_	_
30	adjustment	adjustment	NN	_	29	obj	_	_
31	.	.	.	_	29	p	_	_

1	The	the	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	listed	list	VBN	_	3	acl	_	_
5	below	below	IN	_	4	case	_	_
6	are	be	VBP	_	0	root	_	_
7	potentially	potentially	RB	_	9	adv	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	important	important	JJ	_	6	dep	_	_
10	.	.	.	_	6	p	_	_

1	Drugs	drug	NNS	_	14	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	induce	induce	VBP	_	1	relcl	_	_
4	hepatic	hepatic	JJ	_	5	attr	_	_
5	enzymes	enzyme	NNS	_	3	obj	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	may	may	MD	_	14	modal	_	_
14	increase	increase	VB	_	0	root	_	_
15	the	the	DT	_	16	det	_	_
16	clearance	clearance	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	14	cc	_	_
20	may	may	MD	_	21	modal	_	_
21	require	require	VB	_	14	conj	_	_
22	increases	increase	NNS	_	21	obj	_	_
23	in	in	IN	_	25	case	_	_
24	drug5	drug0	NN	_	25	com	_	_
25	dose	dose	NN	_	22	ppmod	_	_
26	to	to	TO	_	27	aux	_	_
27	achieve	achieve	VB	_	21	comp	_	_
28	the	the	DT	_	30	det	_	_
29	desired	desired	JJ	_	30	attr	_	_
30	response	response	NN	_	27	obj	_	_
31	.	.	.	_	14	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	such	such	JJ	_	4	adv	_	_
3	as	as	IN	_	4	case	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	inhibit	inhibit	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	metabolism	metabolism	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	8	cc	_	_
14	thus	thus	RB	_	15	adv	_	_
15	decrease	decrease	VB	_	8	conj	_	_
16	their	their	PRP$	_	17	poss	_	_
17	clearance	clearance	NN	_	15	obj	_	_
18	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	the	the	DT	_	4	det	_	_
4	dose	dose	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	titrated	titrate	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	avoid	avoid	VB	_	9	comp	_	_
12	steroid	steroid	NN	_	13	com	_	_
13	toxicity	toxicity	NN	_	11	obj	_	_
14	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	clearance	clearance	NN	_	3	obj	_	_
6	of	of	IN	_	10	case	_	_
7	chronic	chronic	JJ	_	10	attr	_	_
8	high	high	JJ	_	10	attr	_	_
9	dose	dose	NN	_	10	com	_	_
10	drug2	drug0	NN	_	5	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	This	this	DT	_	3	dep	_	_
2	could	could	MD	_	3	modal	_	_
3	lead	lead	VB	_	0	root	_	_
4	to	to	TO	_	8	aux	_	_
5	decreased	decrease	VBN	_	8	attr	_	_
6	drug1	drug0	NN	_	8	com	_	_
7	serum	serum	NN	_	8	com	_	_
8	levels	level	NNS	_	3	ppmod	_	_
9	or	or	CC	_	3	cc	_	_
10	increase	increase	VBP	_	3	conj	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	toxicity	toxicity	NN	_	12	ppmod	_	_
16	when	when	WRB	_	19	adv	_	_
17	drug3	drug0	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	withdrawn	withdraw	VBN	_	10	comp	_	_
20	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	cautiously	cautiously	RB	_	4	adv	_	_
6	in	in	IN	_	7	case	_	_
7	conjunction	conjunction	NN	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	suffering	suffer	VBG	_	11	acl	_	_
13	from	from	IN	_	14	case	_	_
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	12	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug2	drug0	NNS	_	2	ppmod	_	_
8	is	be	VBZ	_	0	root	_	_
9	variable	variable	NN	_	8	obj	_	_
10	.	.	.	_	8	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	reports	report	NNS	_	2	obj	_	_
4	of	of	IN	_	5	case	_	_
5	enhanced	enhance	VBN	_	3	ppmod	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	5	cc	_	_
8	as	as	IN	_	7	com	_	_
9	diminished	diminish	VBN	_	10	attr	_	_
10	effects	effect	NNS	_	5	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	when	when	WRB	_	14	adv	_	_
14	given	give	VBN	_	2	comp	_	_
15	concurrently	concurrently	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	coagulation	coagulation	NN	_	4	com	_	_
4	indices	index	NNS	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	monitored	monitor	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	maintain	maintain	VB	_	7	comp	_	_
10	the	the	DT	_	13	det	_	_
11	desired	desired	JJ	_	13	attr	_	_
12	anticoagulant	anticoagulant	JJ	_	13	attr	_	_
13	effect	effect	NN	_	9	obj	_	_
14	.	.	.	_	7	p	_	_

1	Co-administration	co-administration	NN	_	9	dep	_	_
2	of	of	IN	_	6	case	_	_
3	oral	oral	JJ	_	6	attr	_	_
4	drug1	drug0	NN	_	6	attr	_	_
5	200	0	CD	_	6	num	_	_
6	mg	mg	NN	_	1	ppmod	_	_
7	twice	twice	RB	_	8	com	_	_
8	daily	daily	RB	_	6	adv	_	_
9	increased	increase	VBD	_	0	root	_	_
10	drug2	drug0	NN	_	13	attr	_	_
11	geometric	geometric	JJ	_	13	attr	_	_
12	mean	mean	JJ	_	13	attr	_	_
13	AUC	auc	NN	_	9	obj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	0-24	0	NN	_	13	num	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	and	and	CC	_	13	cc	_	_
18	Cmax	cmax	NN	_	13	conj	_	_
19	by	by	IN	_	20	case	_	_
20	81	0	CD	_	9	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	after	after	IN	_	24	case	_	_
23	topical	topical	JJ	_	24	attr	_	_
24	application	application	NN	_	9	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	drug3	drug0	NN	_	27	com	_	_
27	ointment	ointment	NN	_	24	ppmod	_	_
28	,	,	,	_	27	p	_	_
29	1	0	CD	_	27	appo	_	_
30	%	%	NN	_	29	meta	_	_
31	on	on	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	abraded	abraded	JJ	_	34	attr	_	_
34	skin	skin	NN	_	24	ppmod	_	_
35	of	of	IN	_	38	case	_	_
36	healthy	healthy	JJ	_	38	attr	_	_
37	adult	adult	JJ	_	38	attr	_	_
38	males	male	NNS	_	34	ppmod	_	_
39	.	.	.	_	9	p	_	_

1	Due	due	JJ	_	5	adv	_	_
2	to	to	TO	_	5	aux	_	_
3	low	low	JJ	_	5	attr	_	_
4	systemic	systemic	JJ	_	5	attr	_	_
5	exposure	exposure	NN	_	18	ppmod	_	_
6	to	to	TO	_	7	aux	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	following	follow	VBG	_	10	adv	_	_
9	topical	topical	JJ	_	10	attr	_	_
10	application	application	NN	_	5	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	,	,	,	_	18	p	_	_
14	dosage	dosage	NN	_	15	com	_	_
15	adjustments	adjustment	NNS	_	18	dep	_	_
16	for	for	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	are	be	VBP	_	0	root	_	_
19	unnecessary	unnecessary	JJ	_	18	dep	_	_
20	when	when	WRB	_	21	adv	_	_
21	co-administered	co-administered	VBN	_	18	comp	_	_
22	with	with	IN	_	24	case	_	_
23	CYP3A4	cyp0a0	JJ	_	24	attr	_	_
24	inhibitors	inhibitor	NNS	_	21	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	such	such	JJ	_	28	adv	_	_
27	as	as	IN	_	28	case	_	_
28	drug3	drug0	NN	_	24	ppmod	_	_
29	.	.	.	_	18	p	_	_

1	Based	base	VBN	_	7	adv	_	_
2	on	on	IN	_	7	case	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	7	attr	_	_
5	P450	p0	NN	_	7	com	_	_
6	inhibition	inhibition	NN	_	7	com	_	_
7	studies	study	NNS	_	21	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	the	the	DT	_	12	det	_	_
10	low	low	JJ	_	12	attr	_	_
11	systemic	systemic	JJ	_	12	attr	_	_
12	exposure	exposure	NN	_	7	conj	_	_
13	observed	observe	VBN	_	12	acl	_	_
14	following	follow	VBG	_	16	adv	_	_
15	topical	topical	JJ	_	16	attr	_	_
16	application	application	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	21	p	_	_
20	drug2	drug0	NN	_	21	dep	_	_
21	is	be	VBZ	_	0	root	_	_
22	unlikely	unlikely	JJ	_	21	dep	_	_
23	to	to	TO	_	24	aux	_	_
24	affect	affect	VB	_	22	comp	_	_
25	the	the	DT	_	26	det	_	_
26	metabolism	metabolism	NN	_	24	obj	_	_
27	of	of	IN	_	30	case	_	_
28	other	other	JJ	_	30	attr	_	_
29	P450	p0	NN	_	30	com	_	_
30	substrates	substrate	NNS	_	26	ppmod	_	_
31	.	.	.	_	21	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	21	dep	_	_
3	of	of	IN	_	5	case	_	_
4	concurrent	concurrent	JJ	_	5	attr	_	_
5	application	application	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	other	other	JJ	_	11	attr	_	_
10	topical	topical	JJ	_	11	attr	_	_
11	products	product	NNS	_	7	conj	_	_
12	to	to	TO	_	15	aux	_	_
13	the	the	DT	_	15	det	_	_
14	same	same	JJ	_	15	attr	_	_
15	area	area	NN	_	5	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	skin	skin	NN	_	15	ppmod	_	_
18	has	have	VBZ	_	21	aux	_	_
19	not	not	RB	_	21	neg	_	_
20	been	be	VBN	_	21	aux	_	_
21	studied	study	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	drug3	drug0	NN	_	8	com	_	_
8	type	type	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	5	p	_	_
11	drug4	drug0	NN	_	5	appo	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	e.g.	e.g.	FW	_	15	ppmod	_	_
14	,	,	,	_	15	p	_	_
15	drug5	drug0	NN	_	11	prn	_	_
16	,	,	,	_	15	p	_	_
17	drug6	drug0	NN	_	15	appo	_	_
18	,	,	,	_	15	p	_	_
19	drug7	drug0	NN	_	15	appo	_	_
20	,	,	,	_	15	p	_	_
21	drug8	drug0	NN	_	15	appo	_	_
22	,	,	,	_	15	p	_	_
23	drug9	drug0	NN	_	15	appo	_	_
24	,	,	,	_	15	p	_	_
25	drug10	drug0	NN	_	15	appo	_	_
26	)	-rrb-	-RRB-	_	15	p	_	_
27	,	,	,	_	11	p	_	_
28	drug11	drug0	CD	_	11	appo	_	_
29	,	,	,	_	28	p	_	_
30	drug12	drug0	CD	_	28	appo	_	_
31	,	,	,	_	28	p	_	_
32	drug13	drug0	CD	_	28	appo	_	_
33	(	-lrb-	-LRB-	_	36	p	_	_
34	e.g.	e.g.	FW	_	36	ppmod	_	_
35	,	,	,	_	36	p	_	_
36	drug14	drug0	CD	_	32	num	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	,	,	,	_	28	p	_	_
39	other	other	JJ	_	40	attr	_	_
40	drug15	drug0	NN	_	28	appo	_	_
41	,	,	,	_	28	p	_	_
42	drug16	drug0	CD	_	43	num	_	_
43	supplements	supplement	NNS	_	28	appo	_	_
44	,	,	,	_	28	p	_	_
45	drug17	drug0	CD	_	28	appo	_	_
46	,	,	,	_	28	p	_	_
47	drug18	drug0	CD	_	28	appo	_	_
48	(	-lrb-	-LRB-	_	51	p	_	_
49	e.g.	e.g.	FW	_	51	ppmod	_	_
50	,	,	,	_	51	p	_	_
51	drug19	drug0	CD	_	47	num	_	_
52	-	-	CC	_	51	cc	_	_
53	drug20	drug0	CD	_	51	conj	_	_
54	)	-rrb-	-RRB-	_	51	p	_	_
55	,	,	,	_	28	p	_	_
56	drug21	drug0	CD	_	28	appo	_	_
57	(	-lrb-	-LRB-	_	62	p	_	_
58	e.g.	e.g.	FW	_	60	adv	_	_
59	,	,	,	_	60	p	_	_
60	drug22	drug0	NN	_	62	ppmod	_	_
61	,	,	,	_	62	p	_	_
62	drug23	drug0	CD	_	56	num	_	_
63	)	-rrb-	-RRB-	_	62	p	_	_
64	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	is	be	VBZ	_	5	aux	_	_
3	highly	highly	RB	_	5	adv	_	_
4	protein	protein	NN	_	5	dep	_	_
5	bound	bind	VBN	_	0	root	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	therefore	therefore	RB	_	5	adv	_	_
9	,	,	,	_	5	p	_	_
10	might	might	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	expected	expect	VBN	_	5	conj	_	_
13	to	to	TO	_	14	aux	_	_
14	displace	displace	VB	_	12	comp	_	_
15	other	other	JJ	_	17	attr	_	_
16	protein-bound	protein-bound	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	14	obj	_	_
18	.	.	.	_	5	p	_	_

1	Although	although	IN	_	5	mark	_	_
2	this	this	DT	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	occurred	occur	VBN	_	18	advcl	_	_
6	in	in	IN	_	9	case	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	9	attr	_	_
9	studies	study	NNS	_	5	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	18	p	_	_
13	interactions	interaction	NNS	_	18	dep	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	have	have	VBP	_	18	aux	_	_
17	been	be	VBN	_	18	aux	_	_
18	reported	report	VBN	_	0	root	_	_
19	with	with	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	since	since	IN	_	29	mark	_	_
22	marketing	marketing	JJ	_	29	dep	_	_
23	,	,	,	_	29	p	_	_
24	therefore	therefore	RB	_	29	adv	_	_
25	,	,	,	_	29	p	_	_
26	physicians	physician	NNS	_	29	dep	_	_
27	should	should	MD	_	29	modal	_	_
28	closely	closely	RB	_	29	adv	_	_
29	monitor	monitor	VB	_	18	comp	_	_
30	patients	patient	NNS	_	29	obj	_	_
31	for	for	IN	_	33	case	_	_
32	a	a	DT	_	33	det	_	_
33	change	change	NN	_	30	ppmod	_	_
34	in	in	IN	_	36	case	_	_
35	dosage	dosage	NN	_	36	com	_	_
36	requirements	requirement	NNS	_	33	ppmod	_	_
37	when	when	WRB	_	38	adv	_	_
38	administering	administer	VBG	_	29	comp	_	_
39	drug4	drug0	NN	_	38	obj	_	_
40	to	to	TO	_	41	aux	_	_
41	patients	patient	NNS	_	38	ppmod	_	_
42	on	on	IN	_	43	case	_	_
43	drug5	drug0	NN	_	41	ppmod	_	_
44	and	and	CC	_	43	cc	_	_
45	other	other	JJ	_	48	attr	_	_
46	highly	highly	RB	_	47	adv	_	_
47	protein-bound	protein-bound	JJ	_	48	attr	_	_
48	drugs	drug	NNS	_	43	conj	_	_
49	.	.	.	_	18	p	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	levels	level	NNS	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	are	be	VBP	_	6	aux	_	_
6	depressed	depress	VBN	_	48	comp	_	_
7	to	to	TO	_	9	aux	_	_
8	approximately	approximately	RB	_	9	adv	_	_
9	80	0	CD	_	6	ppmod	_	_
10	%	%	NN	_	9	meta	_	_
11	of	of	IN	_	14	case	_	_
12	their	their	PRP$	_	14	poss	_	_
13	normal	normal	JJ	_	14	attr	_	_
14	values	value	NNS	_	9	ppmod	_	_
15	when	when	WRB	_	18	adv	_	_
16	drug2	drug0	NN	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	administered	administer	VBN	_	6	comp	_	_
19	in	in	IN	_	20	case	_	_
20	conjunction	conjunction	NN	_	18	ppmod	_	_
21	with	with	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	(	-lrb-	-LRB-	_	25	p	_	_
24	3900	0	NN	_	25	num	_	_
25	mg/day	mg/day	NN	_	22	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	6	p	_	_
28	but	but	CC	_	6	cc	_	_
29	concomitant	concomitant	JJ	_	30	attr	_	_
30	administration	administration	NN	_	33	dep	_	_
31	of	of	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	has	have	VBZ	_	6	conj	_	_
34	no	no	DT	_	35	det	_	_
35	effect	effect	NN	_	33	obj	_	_
36	on	on	IN	_	39	case	_	_
37	drug5	drug0	NN	_	39	com	_	_
38	plasma	plasma	NN	_	39	com	_	_
39	levels	level	NNS	_	33	ppmod	_	_
40	.	.	.	_	33	p	_	_
41	drug6	drug0	NN	_	48	dep	_	_
42	,	,	,	_	41	p	_	_
43	including	include	VBG	_	41	acl	_	_
44	drug7	drug0	NN	_	43	obj	_	_
45	,	,	,	_	41	p	_	_
46	have	have	VBP	_	48	aux	_	_
47	been	be	VBN	_	48	aux	_	_
48	reported	report	VBN	_	0	root	_	_
49	to	to	TO	_	50	aux	_	_
50	increase	increase	VB	_	48	comp	_	_
51	steady	steady	JJ	_	55	attr	_	_
52	state	state	NN	_	55	com	_	_
53	plasma	plasma	NN	_	55	com	_	_
54	drug8	drug0	NN	_	55	com	_	_
55	levels	level	NNS	_	50	obj	_	_
56	.	.	.	_	48	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	plasma	plasma	NN	_	7	com	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	9	dep	_	_
8	be	be	VB	_	9	aux	_	_
9	monitored	monitor	VBN	_	3	comp	_	_
10	when	when	WRB	_	11	adv	_	_
11	initiating	initiate	VBG	_	9	comp	_	_
12	,	,	,	_	11	p	_	_
13	adjusting	adjust	VBG	_	11	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	discontinuing	discontinue	VBG	_	11	conj	_	_
16	drug2	drug0	NN	_	15	obj	_	_
17	.	.	.	_	3	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	administered	administer	VBN	_	7	advcl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	,	,	,	_	7	p	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	increase	increase	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	drug2	drug0	NNS	_	9	ppmod	_	_
13	;	;	:	_	7	p	_	_

1	monitor	monitor	VB	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	adjust	adjust	VB	_	1	conj	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	dosage	dosage	NN	_	3	obj	_	_
6	accordingly	accordingly	RB	_	3	adv	_	_
7	.	.	.	_	1	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Physiologic	physiologic	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	result	result	VB	_	3	acl	_	_
11	in	in	IN	_	14	case	_	_
12	decreased	decrease	VBN	_	14	attr	_	_
13	estradiol	estradiol	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	10	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	radioimmunoassays	radioimmunoassay	NNS	_	14	ppmod	_	_
17	for	for	IN	_	18	case	_	_
18	estradiol	estradiol	NN	_	16	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	increased	increase	VBN	_	23	attr	_	_
21	plasma	plasma	NN	_	23	com	_	_
22	calcium	calcium	NN	_	23	com	_	_
23	concentrations	concentration	NNS	_	18	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	increased	increase	VBN	_	29	attr	_	_
27	24-hour	0-hour	JJ	_	29	attr	_	_
28	urinary	urinary	JJ	_	29	attr	_	_
29	excretion	excretion	NN	_	18	conj	_	_
30	of	of	IN	_	31	case	_	_
31	creatine	creatine	NN	_	29	ppmod	_	_
32	and	and	CC	_	31	cc	_	_
33	17-ketosteroids	0-ketosteroids	NN	_	31	conj	_	_
34	.	.	.	_	3	p	_	_

1	Although	although	IN	_	8	mark	_	_
2	a	a	DT	_	4	det	_	_
3	causal	causal	JJ	_	4	attr	_	_
4	relationship	relationship	NN	_	8	dep	_	_
5	has	have	VBZ	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	established	establish	VBN	_	12	advcl	_	_
9	,	,	,	_	12	p	_	_
10	there	there	EX	_	12	dep	_	_
11	have	have	VBP	_	12	aux	_	_
12	been	be	VBN	_	0	root	_	_
13	reports	report	NNS	_	12	obj	_	_
14	of	of	IN	_	19	case	_	_
15	bleeding	bleeding	JJ	_	19	attr	_	_
16	and/or	and/or	CC	_	15	cc	_	_
17	prolonged	prolonged	JJ	_	15	conj	_	_
18	prothrombin	prothrombin	NN	_	19	com	_	_
19	time	time	NN	_	13	ppmod	_	_
20	in	in	IN	_	21	case	_	_
21	patients	patient	NNS	_	13	ppmod	_	_
22	treated	treat	VBN	_	21	acl	_	_
23	with	with	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	with	with	IN	_	22	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	without	without	IN	_	28	case	_	_
28	drug2	drug0	NN	_	25	conj	_	_
29	or	or	CC	_	28	cc	_	_
30	drug3	drug0	NN	_	28	conj	_	_
31	.	.	.	_	12	p	_	_

1	Patients	patient	NNS	_	8	dep	_	_
2	on	on	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	should	should	MD	_	8	modal	_	_
5	have	have	VB	_	8	lv	_	_
6	more	more	RBR	_	7	adv	_	_
7	frequent	frequent	JJ	_	8	attr	_	_
8	monitoring	monitoring	NN	_	0	root	_	_
9	of	of	IN	_	11	case	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	times	time	NNS	_	8	ppmod	_	_
12	,	,	,	_	8	p	_	_
13	while	while	IN	_	32	mark	_	_
14	patients	patient	NNS	_	32	dep	_	_
15	with	with	IN	_	18	case	_	_
16	other	other	JJ	_	18	attr	_	_
17	risk	risk	NN	_	18	com	_	_
18	factors	factor	NNS	_	14	ppmod	_	_
19	complicated	complicate	VBN	_	18	acl	_	_
20	by	by	IN	_	21	case	_	_
21	hemorrhage	hemorrhage	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	29	p	_	_
23	e.g.	e.g.	FW	_	26	adv	_	_
24	,	,	,	_	26	p	_	_
25	recent	recent	JJ	_	26	attr	_	_
26	surgery	surgery	NN	_	29	ppmod	_	_
27	,	,	,	_	29	p	_	_
28	peptic	peptic	JJ	_	29	attr	_	_
29	ulceration	ulceration	NN	_	21	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	should	should	MD	_	32	modal	_	_
32	have	have	VB	_	8	comp	_	_
33	periodic	periodic	JJ	_	34	attr	_	_
34	examinations	examination	NNS	_	32	obj	_	_
35	for	for	IN	_	36	case	_	_
36	bleeding	bleeding	JJ	_	32	ppmod	_	_
37	including	include	VBG	_	38	adv	_	_
38	hematocrit	hematocrit	NN	_	36	ppmod	_	_
39	and/or	and/or	CC	_	38	cc	_	_
40	hemoglobin	hemoglobin	NN	_	38	conj	_	_
41	.	.	.	_	8	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	8	attr	_	_
7	-containing	-containing	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	4	conj	_	_
9	leads	lead	VBZ	_	0	root	_	_
10	to	to	TO	_	13	aux	_	_
11	increased	increase	VBN	_	13	attr	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	levels	level	NNS	_	9	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	16	com	_	_
16	toxicity	toxicity	NN	_	13	conj	_	_
17	in	in	IN	_	19	case	_	_
18	some	some	DT	_	19	det	_	_
19	individuals	individual	NNS	_	13	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	patients	patient	NNS	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	closely	closely	RB	_	6	adv	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	for	for	IN	_	8	case	_	_
8	signs	sign	NNS	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	toxicity	toxicity	NN	_	8	ppmod	_	_
11	and	and	CC	_	6	cc	_	_
12	have	have	VB	_	6	conj	_	_
13	their	their	PRP$	_	15	poss	_	_
14	drug1	drug0	JJ	_	15	attr	_	_
15	dosage	dosage	NN	_	12	obj	_	_
16	adjusted	adjust	VBN	_	15	acl	_	_
17	as	as	IN	_	18	case	_	_
18	necessary	necessary	JJ	_	16	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	concurrently	concurrently	RB	_	4	adv	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	7	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug6	drug0	NN	_	7	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	drug7	drug0	NN	_	7	conj	_	_
19	,	,	,	_	18	p	_	_
20	without	without	IN	_	22	case	_	_
21	observed	observe	VBN	_	22	attr	_	_
22	problems	problem	NNS	_	7	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	Small	small	JJ	_	2	attr	_	_
2	decreases	decrease	NNS	_	8	dep	_	_
3	in	in	IN	_	5	case	_	_
4	blood	blood	NN	_	5	com	_	_
5	pressure	pressure	NN	_	2	ppmod	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	observed	observe	VBN	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	some	some	DT	_	11	det	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	treated	treat	VBN	_	11	acl	_	_
13	with	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	;	;	:	_	8	p	_	_

1	periodic	periodic	JJ	_	5	attr	_	_
2	systemic	systemic	JJ	_	5	attr	_	_
3	blood	blood	NN	_	5	com	_	_
4	pressure	pressure	NN	_	5	com	_	_
5	monitoring	monitoring	NN	_	7	dep	_	_
6	is	be	VBZ	_	7	aux	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	for	for	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	concomitant	concomitant	JJ	_	13	attr	_	_
12	antihypertensive	antihypertensive	JJ	_	13	attr	_	_
13	therapy	therapy	NN	_	10	obj	_	_
14	.	.	.	_	7	p	_	_

1	If	if	IN	_	2	mark	_	_
2	indicated	indicate	VBN	_	10	advcl	_	_
3	,	,	,	_	10	p	_	_
4	dosage	dosage	NN	_	10	dep	_	_
5	of	of	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	reduced	reduce	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	The	the	DT	_	5	det	_	_
5	use	use	NN	_	31	dep	_	_
6	of	of	IN	_	11	case	_	_
7	drug1	drug0	NN	_	11	attr	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	drug2	drug0	NN	_	11	attr	_	_
10	)	-rrb-	-RRB-	_	11	p	_	_
11	Injection	injection	NN	_	5	ppmod	_	_
12	before	before	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	31	p	_	_
15	for	for	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	purpose	purpose	NN	_	31	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	attenuating	attenuate	VBG	_	17	ppmod	_	_
20	some	some	DT	_	19	obj	_	_
21	of	of	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	side	side	JJ	_	24	attr	_	_
24	effects	effect	NNS	_	20	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug4	drug0	NN	_	24	ppmod	_	_
27	,	,	,	_	31	p	_	_
28	has	have	VBZ	_	31	aux	_	_
29	not	not	RB	_	31	neg	_	_
30	been	be	VBN	_	31	aux	_	_
31	studied	study	VBN	_	2	acl	_	_
32	.	.	.	_	2	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	administered	administer	VBN	_	14	advcl	_	_
5	following	follow	VBG	_	6	adv	_	_
6	administration	administration	NN	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	14	p	_	_
10	it	it	PRP	_	14	dep	_	_
11	should	should	MD	_	14	modal	_	_
12	not	not	RB	_	14	neg	_	_
13	be	be	VB	_	14	aux	_	_
14	given	give	VBN	_	0	root	_	_
15	until	until	IN	_	16	case	_	_
16	recovery	recovery	NN	_	14	ppmod	_	_
17	from	from	IN	_	21	mark	_	_
18	drug3	drug0	NN	_	21	dep	_	_
19	has	have	VBZ	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	observed	observe	VBN	_	14	comp	_	_
22	.	.	.	_	14	p	_	_

1	The	the	DT	_	3	det	_	_
2	median	median	JJ	_	3	attr	_	_
3	duration	duration	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	action	action	NN	_	3	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	drug1	drug0	NN	_	9	attr	_	_
8	0.6	0	CD	_	9	num	_	_
9	mg/kg	mg/kg	NN	_	5	ppmod	_	_
10	administered	administer	VBN	_	0	root	_	_
11	after	after	IN	_	15	case	_	_
12	a	a	DT	_	15	det	_	_
13	1	0	CD	_	14	num	_	_
14	mg/kg	mg/kg	NN	_	15	com	_	_
15	dose	dose	NN	_	10	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	when	when	WRB	_	27	adv	_	_
19	T	t	NN	_	27	dep	_	_
20	1	0	CD	_	19	num	_	_
21	returned	return	VBD	_	19	acl	_	_
22	to	to	TO	_	23	aux	_	_
23	75	0	CD	_	21	ppmod	_	_
24	%	%	NN	_	23	meta	_	_
25	of	of	IN	_	26	case	_	_
26	control	control	NN	_	23	ppmod	_	_
27	was	be	VBD	_	10	comp	_	_
28	36	0	CD	_	29	num	_	_
29	minutes	minute	NNS	_	27	obj	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	range	range	NN	_	29	prn	_	_
32	14-57	0	CD	_	31	num	_	_
33	,	,	,	_	31	p	_	_
34	n=12	n=0	NN	_	31	appo	_	_
35	)	-rrb-	-RRB-	_	31	p	_	_
36	vs	vs	CC	_	27	adv	_	_
37	.	.	.	_	10	p	_	_

1	28	0	CD	_	2	num	_	_
2	minutes	minute	NNS	_	0	root	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	17-51	0	NN	_	2	num	_	_
5	,	,	,	_	4	p	_	_
6	n=12	n=0	NN	_	4	appo	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	without	without	IN	_	9	case	_	_
9	drug1	drug0	NN	_	2	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	controlled	controlled	JJ	_	5	attr	_	_
5	studies	study	NNS	_	2	obj	_	_
6	documenting	document	VBG	_	5	acl	_	_
7	the	the	DT	_	8	det	_	_
8	use	use	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	before	before	IN	_	8	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	after	after	IN	_	15	case	_	_
14	other	other	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	11	conj	_	_
16	.	.	.	_	2	p	_	_

1	Interactions	interaction	NNS	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	when	when	WRB	_	10	adv	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug1	drug0	NNS	_	10	dep	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	administered	administer	VBN	_	4	comp	_	_
11	in	in	IN	_	12	case	_	_
12	succession	succession	NN	_	10	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	6	dep	_	_
4	:	:	:	_	6	p	_	_
5	None	none	NN	_	6	dep	_	_
6	known	know	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	10	p	_	_
6	e.g.	e.g.	FW	_	8	adv	_	_
7	,	,	,	_	8	p	_	_
8	drug2	drug0	NN	_	10	ppmod	_	_
9	,	,	,	_	10	p	_	_
10	drug3	drug0	NN	_	4	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	may	may	MD	_	13	modal	_	_
13	diminish	diminish	VB	_	0	root	_	_
14	the	the	DT	_	16	det	_	_
15	bactericidal	bactericidal	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	13	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	by	by	IN	_	20	case	_	_
20	slowing	slow	VBG	_	13	ppmod	_	_
21	the	the	DT	_	22	det	_	_
22	rate	rate	NN	_	20	obj	_	_
23	of	of	IN	_	25	case	_	_
24	bacterial	bacterial	JJ	_	25	attr	_	_
25	growth	growth	NN	_	22	ppmod	_	_
26	.	.	.	_	13	p	_	_

1	Bactericidal	bactericidal	JJ	_	2	attr	_	_
2	agents	agent	NNS	_	3	dep	_	_
3	work	work	VBP	_	0	root	_	_
4	most	most	RBS	_	5	com	_	_
5	effectively	effectively	RB	_	3	adv	_	_
6	against	against	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	immature	immature	JJ	_	10	attr	_	_
9	cell	cell	NN	_	10	com	_	_
10	wall	wall	NN	_	3	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	rapidly	rapidly	RB	_	13	adv	_	_
13	proliferating	proliferate	VBG	_	14	attr	_	_
14	microorganisms	microorganism	NNS	_	10	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	This	this	DT	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	demonstrated	demonstrate	VBN	_	0	root	_	_
5	in	in	FW	_	6	adv	_	_
6	vitro	vitro	FW	_	4	adv	_	_
7	;	;	:	_	4	p	_	_

1	however	however	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	the	the	DT	_	5	det	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	significance	significance	NN	_	12	dep	_	_
6	of	of	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	interaction	interaction	NN	_	5	ppmod	_	_
9	is	be	VBZ	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	well	well	RB	_	12	adv	_	_
12	documented	document	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	few	few	JJ	_	5	attr	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	situations	situation	NNS	_	2	obj	_	_
6	in	in	IN	_	7	case	_	_
7	which	which	WDT	_	22	ppmod	_	_
8	the	the	DT	_	10	det	_	_
9	concurrent	concurrent	JJ	_	10	attr	_	_
10	use	use	NN	_	22	dep	_	_
11	of	of	IN	_	14	case	_	_
12	"	''	JJ	_	14	attr	_	_
13	static	static	JJ	_	14	attr	_	_
14	"	''	NNS	_	10	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	"	''	NN	_	14	conj	_	_
17	cidal	cidal	JJ	_	20	attr	_	_
18	'	'	``	_	20	p	_	_
19	'	'	''	_	20	p	_	_
20	drug1	drug0	NN	_	16	appo	_	_
21	are	be	VBP	_	22	aux	_	_
22	indicated	indicate	VBN	_	5	relcl	_	_
23	.	.	.	_	2	p	_	_

1	However	however	RB	_	26	adv	_	_
2	,	,	,	_	26	p	_	_
3	in	in	IN	_	5	case	_	_
4	selected	select	VBN	_	5	attr	_	_
5	circumstances	circumstance	NNS	_	26	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	which	which	WDT	_	10	ppmod	_	_
8	such	such	JJ	_	9	attr	_	_
9	therapy	therapy	NN	_	10	dep	_	_
10	is	be	VBZ	_	5	relcl	_	_
11	appropriate	appropriate	JJ	_	10	dep	_	_
12	,	,	,	_	10	p	_	_
13	using	use	VBG	_	10	comp	_	_
14	adequate	adequate	JJ	_	15	attr	_	_
15	doses	dose	NNS	_	13	obj	_	_
16	of	of	IN	_	18	case	_	_
17	drug1	drug0	JJ	_	18	attr	_	_
18	agents	agent	NNS	_	15	ppmod	_	_
19	and	and	CC	_	13	cc	_	_
20	beginning	begin	VBG	_	13	conj	_	_
21	penicillin	penicillin	NN	_	22	com	_	_
22	therapy	therapy	NN	_	20	obj	_	_
23	first	#ord#	RB	_	20	adv	_	_
24	,	,	,	_	26	p	_	_
25	should	should	MD	_	26	modal	_	_
26	minimize	minimize	VB	_	0	root	_	_
27	the	the	DT	_	28	det	_	_
28	potential	potential	NN	_	26	obj	_	_
29	for	for	IN	_	30	case	_	_
30	interaction	interaction	NN	_	28	ppmod	_	_
31	.	.	.	_	26	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	blood	blood	NN	_	3	com	_	_
3	levels	level	NNS	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	prolonged	prolong	VBD	_	0	root	_	_
7	by	by	IN	_	9	case	_	_
8	concurrent	concurrent	JJ	_	9	attr	_	_
9	administration	administration	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	which	which	WDT	_	13	dep	_	_
13	blocks	block	VBZ	_	11	relcl	_	_
14	the	the	DT	_	17	det	_	_
15	renal	renal	JJ	_	17	attr	_	_
16	tubular	tubular	JJ	_	17	attr	_	_
17	secretion	secretion	NN	_	13	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	Displacement	displacement	NN	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	from	from	IN	_	8	case	_	_
5	plasma	plasma	NN	_	8	com	_	_
6	protein	protein	NN	_	8	com	_	_
7	binding	binding	NN	_	8	com	_	_
8	sites	site	NNS	_	1	ppmod	_	_
9	will	will	MD	_	10	modal	_	_
10	elevate	elevate	VBP	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	level	level	NN	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	free	free	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	serum	serum	NN	_	12	ppmod	_	_
19	.	.	.	_	10	p	_	_

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	9	dep	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug1	drug0	NN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	may	may	MD	_	9	modal	_	_
9	have	have	VB	_	0	root	_	_
10	an	an	DT	_	12	det	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	when	when	WRB	_	14	adv	_	_
14	given	give	VBN	_	9	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	14	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	plus	plus	CC	_	3	cc	_	_
5	a	a	DT	_	7	det	_	_
6	catecholamine-depleting	catecholamine-depleting	JJ	_	7	attr	_	_
7	agent	agent	NN	_	3	conj	_	_
8	should	should	MD	_	14	modal	_	_
9	,	,	,	_	14	p	_	_
10	therefore	therefore	RB	_	14	adv	_	_
11	,	,	,	_	14	p	_	_
12	be	be	VB	_	14	aux	_	_
13	closely	closely	RB	_	14	adv	_	_
14	observed	observe	VBN	_	0	root	_	_
15	for	for	IN	_	16	case	_	_
16	evidence	evidence	NN	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	hypotension	hypotension	NN	_	16	ppmod	_	_
19	and/or	and/or	CC	_	18	cc	_	_
20	marked	marked	JJ	_	21	attr	_	_
21	bradycardia	bradycardia	NN	_	18	conj	_	_
22	which	which	WDT	_	24	dep	_	_
23	may	may	MD	_	24	modal	_	_
24	produce	produce	VB	_	18	relcl	_	_
25	vertigo	vertigo	NN	_	24	obj	_	_
26	,	,	,	_	25	p	_	_
27	syncope	syncope	NN	_	25	conj	_	_
28	,	,	,	_	27	p	_	_
29	or	or	CC	_	27	cc	_	_
30	postural	postural	JJ	_	31	attr	_	_
31	hypotension	hypotension	NN	_	25	conj	_	_
32	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	variety	variety	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	7	p	_	_
11	including	include	VBG	_	12	adv	_	_
12	drug3	drug0	NN	_	7	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug5	drug0	NN	_	12	conj	_	_
18	without	without	IN	_	21	case	_	_
19	unexpected	unexpected	JJ	_	21	attr	_	_
20	adverse	adverse	JJ	_	21	attr	_	_
21	interactions	interaction	NNS	_	12	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	increase	increase	VB	_	4	comp	_	_
7	serum	serum	NN	_	9	com	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	levels	level	NNS	_	6	obj	_	_
10	when	when	WRB	_	13	adv	_	_
11	both	both	DT	_	12	det	_	_
12	drugs	drug	NNS	_	13	dep	_	_
13	are	be	VBP	_	6	comp	_	_
14	co-administered	co-administered	NN	_	13	obj	_	_
15	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	levels	level	NNS	_	6	dep	_	_
3	may	may	MD	_	6	modal	_	_
4	also	also	RB	_	6	adv	_	_
5	be	be	VB	_	6	aux	_	_
6	increased	increase	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	this	this	DT	_	9	det	_	_
9	combination	combination	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	Risk	risk	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	anaphylactic	anaphylactic	JJ	_	4	attr	_	_
4	reaction	reaction	NN	_	1	ppmod	_	_
5	:	:	:	_	1	p	_	_
6	While	while	IN	_	7	mark	_	_
7	taking	take	VBG	_	24	advcl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	,	,	,	_	24	p	_	_
10	patients	patient	NNS	_	24	dep	_	_
11	with	with	IN	_	13	case	_	_
12	a	a	DT	_	13	det	_	_
13	history	history	NN	_	10	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	severe	severe	JJ	_	17	attr	_	_
16	anaphylactic	anaphylactic	JJ	_	17	attr	_	_
17	reaction	reaction	NN	_	13	ppmod	_	_
18	to	to	TO	_	20	aux	_	_
19	a	a	DT	_	20	det	_	_
20	variety	variety	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	allergens	allergen	NNS	_	20	ppmod	_	_
23	may	may	MD	_	24	modal	_	_
24	be	be	VB	_	1	acl	_	_
25	more	more	RBR	_	26	adv	_	_
26	reactive	reactive	JJ	_	24	dep	_	_
27	to	to	TO	_	29	aux	_	_
28	repeated	repeated	JJ	_	29	attr	_	_
29	challenge	challenge	NN	_	26	ppmod	_	_
30	,	,	,	_	26	p	_	_
31	either	either	CC	_	26	cc	_	_
32	accidental	accidental	JJ	_	26	conj	_	_
33	,	,	,	_	32	p	_	_
34	diagnostic	diagnostic	JJ	_	26	conj	_	_
35	,	,	,	_	34	p	_	_
36	or	or	CC	_	34	cc	_	_
37	therapeutic	therapeutic	JJ	_	26	conj	_	_
38	.	.	.	_	1	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	patients	patient	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	unresponsive	unresponsive	JJ	_	4	dep	_	_
6	to	to	TO	_	9	aux	_	_
7	the	the	DT	_	9	det	_	_
8	usual	usual	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	used	use	VBN	_	9	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	treat	treat	VB	_	12	comp	_	_
15	allergic	allergic	JJ	_	16	attr	_	_
16	reactions	reaction	NNS	_	14	obj	_	_
17	.	.	.	_	4	p	_	_

1	Although	although	IN	_	12	mark	_	_
2	specific	specific	JJ	_	3	attr	_	_
3	drug	drug	NN	_	12	dep	_	_
4	or	or	CC	_	3	cc	_	_
5	food	food	NN	_	6	com	_	_
6	interactions	interaction	NNS	_	3	conj	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	3	ppmod	_	_
9	have	have	VBP	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	studied	study	VBN	_	27	advcl	_	_
13	,	,	,	_	27	p	_	_
14	on	on	IN	_	21	case	_	_
15	the	the	DT	_	21	det	_	_
16	basis	basis	NN	_	21	advnp	_	_
17	of	of	IN	_	21	case	_	_
18	this	this	DT	_	21	det	_	_
19	drug	drug	NN	_	21	com	_	_
20	s	s	NN	_	21	com	_	_
21	metabolism	metabolism	NN	_	27	ppmod	_	_
22	by	by	IN	_	24	case	_	_
23	CYP	cyp	NN	_	24	com	_	_
24	3A4	0a0	NN	_	21	ppmod	_	_
25	,	,	,	_	27	p	_	_
26	it	it	PRP	_	27	dep	_	_
27	is	be	VBZ	_	0	root	_	_
28	possible	possible	JJ	_	27	dep	_	_
29	that	that	IN	_	40	mark	_	_
30	drug2	drug0	NN	_	40	dep	_	_
31	,	,	,	_	30	p	_	_
32	drug3	drug0	NN	_	30	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug4	drug0	NN	_	30	conj	_	_
35	,	,	,	_	34	p	_	_
36	and	and	CC	_	34	cc	_	_
37	grapefruit	grapefruit	NN	_	38	com	_	_
38	juice	juice	NN	_	30	conj	_	_
39	may	may	MD	_	40	modal	_	_
40	inhibit	inhibit	VB	_	27	comp	_	_
41	its	its	PRP$	_	42	poss	_	_
42	metabolism	metabolism	NN	_	40	obj	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	increasing	increase	VBG	_	42	prn	_	_
45	serum	serum	NN	_	46	com	_	_
46	levels	level	NNS	_	44	obj	_	_
47	of	of	IN	_	48	case	_	_
48	drug5	drug0	NN	_	46	ppmod	_	_
49	)	-rrb-	-RRB-	_	44	p	_	_
50	.	.	.	_	27	p	_	_

1	Furthermore	furthermore	RB	_	3	adv	_	_
2	,	,	,	_	3	p	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	,	,	,	_	3	p	_	_
5	drug2	drug0	NN	_	3	appo	_	_
6	,	,	,	_	3	p	_	_
7	St.	st.	NN	_	3	appo	_	_

1	John	john	NNP	_	3	com	_	_
2	s	s	NNP	_	3	com	_	_
3	Wort	wort	NNP	_	16	dep	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	certain	certain	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	3	conj	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug2	drug0	NN	_	7	prn	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	9	appo	_	_
12	,	,	,	_	9	p	_	_
13	drug4	drug0	NN	_	9	appo	_	_
14	)	-rrb-	-RRB-	_	9	p	_	_
15	may	may	MD	_	16	modal	_	_
16	induce	induce	VB	_	0	root	_	_
17	drug5	drug0	NN	_	18	com	_	_
18	metabolism	metabolism	NN	_	16	obj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	lowering	lower	VBG	_	16	prn	_	_
21	serum	serum	NN	_	22	com	_	_
22	levels	level	NNS	_	20	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug6	drug0	NN	_	22	ppmod	_	_
25	)	-rrb-	-RRB-	_	20	p	_	_
26	.	.	.	_	16	p	_	_

1	Based	base	VBN	_	6	adv	_	_
2	on	on	IN	_	6	case	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	6	attr	_	_
5	inhibition	inhibition	NN	_	6	com	_	_
6	information	information	NN	_	12	ppmod	_	_
7	,	,	,	_	12	p	_	_
8	coadministration	coadministration	NN	_	12	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	may	may	MD	_	12	modal	_	_
12	lead	lead	VB	_	0	root	_	_
13	to	to	TO	_	15	aux	_	_
14	an	an	DT	_	15	det	_	_
15	increase	increase	NN	_	12	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	serum	serum	NN	_	18	com	_	_
18	levels	level	NNS	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drugs	drug	NNS	_	18	ppmod	_	_
21	that	that	WDT	_	22	dep	_	_
22	are	be	VBP	_	20	relcl	_	_
23	CYP	cyp	NN	_	25	com	_	_
24	3A4	0a0	NN	_	25	com	_	_
25	substrates	substrate	NNS	_	22	obj	_	_
26	.	.	.	_	12	p	_	_

1	Due	due	IN	_	5	case	_	_
2	to	to	TO	_	5	aux	_	_
3	the	the	DT	_	5	det	_	_
4	slow	slow	JJ	_	5	attr	_	_
5	elimination	elimination	NN	_	16	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	from	from	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	body	body	NN	_	5	ppmod	_	_
11	,	,	,	_	16	p	_	_
12	such	such	JJ	_	13	attr	_	_
13	interaction	interaction	NN	_	16	dep	_	_
14	may	may	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	for	for	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	prolonged	prolonged	JJ	_	20	attr	_	_
20	period	period	NN	_	16	ppmod	_	_
21	after	after	IN	_	23	case	_	_
22	its	its	PRP$	_	23	poss	_	_
23	administration	administration	NN	_	20	ppmod	_	_
24	.	.	.	_	16	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	exercised	exercise	VBN	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	administered	administer	VBN	_	6	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drugs	drug	NNS	_	10	ppmod	_	_
13	that	that	WDT	_	14	dep	_	_
14	are	be	VBP	_	12	relcl	_	_
15	CYP	cyp	NN	_	17	com	_	_
16	3A4	0a0	NN	_	17	com	_	_
17	substrates	substrate	NNS	_	14	obj	_	_
18	and	and	CC	_	14	cc	_	_
19	have	have	VBP	_	14	conj	_	_
20	narrow	narrow	JJ	_	22	attr	_	_
21	therapeutic	therapeutic	JJ	_	22	attr	_	_
22	range	range	NN	_	19	obj	_	_
23	,	,	,	_	12	p	_	_
24	including	include	VBG	_	26	adv	_	_
25	some	some	DT	_	26	det	_	_
26	agents	agent	NNS	_	12	ppmod	_	_
27	used	use	VBN	_	26	acl	_	_
28	during	during	IN	_	30	case	_	_
29	general	general	JJ	_	30	attr	_	_
30	anesthesia	anesthesia	NN	_	27	ppmod	_	_
31	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	has	have	VBZ	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	associated	associate	VBN	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	erythema	erythema	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	histamine-like	histamine-like	JJ	_	14	attr	_	_
14	flushing	flushing	NN	_	11	conj	_	_
15	and	and	CC	_	14	cc	_	_
16	anaphylactoid	anaphylactoid	JJ	_	17	attr	_	_
17	reactions	reaction	NNS	_	14	conj	_	_
18	.	.	.	_	9	p	_	_

1	Concurrent	concurrent	JJ	_	7	attr	_	_
2	and/or	and/or	CC	_	1	cc	_	_
3	sequential	sequential	JJ	_	1	conj	_	_
4	systemic	systemic	JJ	_	7	attr	_	_
5	or	or	CC	_	4	cc	_	_
6	topical	topical	JJ	_	4	conj	_	_
7	use	use	NN	_	36	dep	_	_
8	of	of	IN	_	14	case	_	_
9	other	other	JJ	_	14	attr	_	_
10	potentially	potentially	RB	_	11	adv	_	_
11	neurotoxic	neurotoxic	JJ	_	14	attr	_	_
12	and/or	and/or	CC	_	11	cc	_	_
13	nephrotoxic	nephrotoxic	JJ	_	11	conj	_	_
14	drugs	drug	NNS	_	7	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	such	such	JJ	_	18	adv	_	_
17	as	as	IN	_	18	case	_	_
18	drug1	drug0	NN	_	14	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug3	drug0	NN	_	18	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug4	drug0	NN	_	18	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug5	drug0	NN	_	18	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug6	drug0	NN	_	18	conj	_	_
29	,	,	,	_	28	p	_	_
30	or	or	CC	_	28	cc	_	_
31	drug7	drug0	NN	_	18	conj	_	_
32	,	,	,	_	7	p	_	_
33	when	when	WRB	_	34	adv	_	_
34	indicated	indicate	VBN	_	7	relcl	_	_
35	,	,	,	_	7	p	_	_
36	requires	require	VBZ	_	0	root	_	_
37	careful	careful	JJ	_	38	attr	_	_
38	monitoring	monitoring	NN	_	36	obj	_	_
39	.	.	.	_	36	p	_	_

1	Potential	potential	NN	_	11	dep	_	_
2	for	for	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	Affect	affect	VB	_	1	acl	_	_
6	Other	other	JJ	_	7	attr	_	_
7	Drugs	drug	NNS	_	5	obj	_	_
8	drug2	drug0	VBN	_	7	acl	_	_
9	is	be	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	expected	expect	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	cause	cause	VB	_	11	comp	_	_
14	clinically	clinically	RB	_	15	adv	_	_
15	important	important	JJ	_	17	attr	_	_
16	pharmacokinetic	pharmacokinetic	JJ	_	17	attr	_	_
17	interactions	interaction	NNS	_	13	obj	_	_
18	with	with	IN	_	19	case	_	_
19	drugs	drug	NNS	_	17	ppmod	_	_
20	that	that	WDT	_	22	dep	_	_
21	are	be	VBP	_	22	aux	_	_
22	metabolized	metabolize	VBN	_	19	relcl	_	_
23	by	by	IN	_	26	case	_	_
24	cytochrome	cytochrome	NN	_	25	com	_	_
25	P450	p0	NN	_	26	com	_	_
26	isozymes	isozymes	NNS	_	22	ppmod	_	_
27	.	.	.	_	11	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	8	dep	_	_
4	in	in	IN	_	7	case	_	_
5	human	human	JJ	_	7	attr	_	_
6	liver	liver	NN	_	7	com	_	_
7	microsomes	microsome	NNS	_	3	ppmod	_	_
8	showed	show	VBD	_	0	root	_	_
9	that	that	IN	_	14	mark	_	_
10	drug1	drug0	NN	_	14	dep	_	_
11	does	do	VBZ	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	substantially	substantially	RB	_	14	adv	_	_
14	inhibit	inhibit	VB	_	8	comp	_	_
15	the	the	DT	_	16	det	_	_
16	metabolism	metabolism	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drugs	drug	NNS	_	16	ppmod	_	_
19	metabolized	metabolize	VBN	_	18	acl	_	_
20	by	by	IN	_	23	case	_	_
21	cytochrome	cytochrome	NN	_	23	com	_	_
22	P450	p0	NN	_	23	com	_	_
23	isozymes	isozymes	NNS	_	19	ppmod	_	_
24	,	,	,	_	23	p	_	_
25	including	include	VBG	_	26	adv	_	_
26	CYP1A2	cyp0a0	NN	_	23	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	CYP2A6	cyp0a0	NN	_	26	conj	_	_
29	,	,	,	_	28	p	_	_
30	CYP2C8/9/10	cyp0c0	NN	_	26	conj	_	_
31	,	,	,	_	30	p	_	_
32	CYP2D6	cyp0d0	NN	_	26	conj	_	_
33	,	,	,	_	32	p	_	_
34	CYP2E1	cyp0e0	NN	_	26	conj	_	_
35	,	,	,	_	34	p	_	_
36	CYP3A4	cyp0a0	NN	_	26	conj	_	_
37	,	,	,	_	36	p	_	_
38	and	and	CC	_	36	cc	_	_
39	CYP3A5	cyp0a0	NN	_	26	conj	_	_
40	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	expected	expect	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	inhibit	inhibit	VB	_	6	comp	_	_
9	clearance	clearance	NN	_	8	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drugs	drug	NNS	_	9	ppmod	_	_
12	that	that	WDT	_	14	dep	_	_
13	are	be	VBP	_	14	aux	_	_
14	metabolized	metabolize	VBN	_	11	relcl	_	_
15	by	by	IN	_	18	case	_	_
16	these	these	DT	_	18	det	_	_
17	metabolic	metabolic	JJ	_	18	attr	_	_
18	pathways	pathway	NNS	_	14	ppmod	_	_
19	in	in	IN	_	23	case	_	_
20	a	a	DT	_	23	det	_	_
21	clinically	clinically	RB	_	22	adv	_	_
22	relevant	relevant	JJ	_	23	attr	_	_
23	manner	manner	NN	_	14	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	is	be	VBZ	_	5	aux	_	_
3	also	also	RB	_	5	adv	_	_
4	not	not	RB	_	5	neg	_	_
5	expected	expect	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	have	have	VB	_	5	comp	_	_
8	enzyme	enzyme	NN	_	10	com	_	_
9	inducing	inducing	NN	_	10	com	_	_
10	properties	property	NNS	_	7	obj	_	_
11	.	.	.	_	5	p	_	_

1	At	at	IN	_	3	case	_	_
2	therapeutic	therapeutic	JJ	_	3	attr	_	_
3	concentrations	concentration	NNS	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	inhibit	inhibit	VB	_	0	root	_	_
9	P-glycoprotein	p-glycoprotein	NN	_	8	obj	_	_
10	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	is	be	VBZ	_	5	aux	_	_
3	therefore	therefore	RB	_	5	adv	_	_
4	not	not	RB	_	5	neg	_	_
5	expected	expect	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibit	inhibit	VB	_	5	comp	_	_
8	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	9	attr	_	_
9	transport	transport	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_
13	in	in	IN	_	17	case	_	_
14	a	a	DT	_	17	det	_	_
15	clinically	clinically	RB	_	16	adv	_	_
16	relevant	relevant	JJ	_	17	attr	_	_
17	manner	manner	NN	_	7	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	Given	given	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	primary	primary	JJ	_	5	attr	_	_
4	CNS	cns	NN	_	5	com	_	_
5	effects	effect	NNS	_	12	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	12	p	_	_
9	drug2	drug0	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	used	use	VBN	_	0	root	_	_
13	with	with	IN	_	14	case	_	_
14	caution	caution	NN	_	12	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	combination	combination	NN	_	12	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	other	other	JJ	_	19	attr	_	_
19	drug3	drug0	NN	_	16	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	antagonize	antagonize	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	other	other	JJ	_	10	attr	_	_
10	drug3	drug0	NN	_	7	conj	_	_
11	.	.	.	_	3	p	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	its	its	PRP$	_	4	poss	_	_
4	potential	potential	NN	_	15	ppmod	_	_
5	for	for	IN	_	6	case	_	_
6	inducing	induce	VBG	_	4	ppmod	_	_
7	orthostatic	orthostatic	JJ	_	8	attr	_	_
8	hypotension	hypotension	NN	_	6	obj	_	_
9	,	,	,	_	15	p	_	_
10	an	an	DT	_	12	det	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effect	effect	NN	_	15	dep	_	_
13	may	may	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	observed	observe	VBN	_	0	root	_	_
16	when	when	WRB	_	19	adv	_	_
17	drug1	drug0	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	administered	administer	VBN	_	15	comp	_	_
20	with	with	IN	_	23	case	_	_
21	other	other	JJ	_	23	attr	_	_
22	therapeutic	therapeutic	JJ	_	23	attr	_	_
23	agents	agent	NNS	_	19	ppmod	_	_
24	that	that	WDT	_	25	dep	_	_
25	have	have	VBP	_	23	relcl	_	_
26	this	this	DT	_	27	det	_	_
27	potential	potential	NN	_	25	obj	_	_
28	.	.	.	_	15	p	_	_

1	Potential	potential	NN	_	9	dep	_	_
2	for	for	IN	_	4	case	_	_
3	Other	other	JJ	_	4	attr	_	_
4	Drugs	drug	NNS	_	1	ppmod	_	_
5	to	to	TO	_	8	aux	_	_
6	Affect	affect	NN	_	8	com	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	drug2	drug0	NN	_	1	ppmod	_	_
9	is	be	VBZ	_	0	root	_	_
10	not	not	RB	_	9	neg	_	_
11	a	a	DT	_	12	det	_	_
12	substrate	substrate	NN	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	CYP1A2	cyp0a0	NN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	CYP2A6	cyp0a0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	CYP2C9	cyp0c0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	CYP2C19	cyp0c0	NN	_	14	conj	_	_
22	,	,	,	_	9	p	_	_
23	so	so	RB	_	34	adv	_	_
24	that	that	IN	_	34	mark	_	_
25	an	an	DT	_	26	det	_	_
26	interaction	interaction	NN	_	34	dep	_	_
27	with	with	IN	_	28	case	_	_
28	inhibitors	inhibitor	NNS	_	26	ppmod	_	_
29	or	or	CC	_	28	cc	_	_
30	inducers	inducer	NNS	_	28	conj	_	_
31	of	of	IN	_	33	case	_	_
32	these	these	DT	_	33	det	_	_
33	isozymes	isozymes	NNS	_	26	ppmod	_	_
34	is	be	VBZ	_	9	comp	_	_
35	unlikely	unlikely	JJ	_	34	dep	_	_
36	.	.	.	_	9	p	_	_

1	While	while	IN	_	5	mark	_	_
2	in	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	4	attr	_	_
4	studies	study	NNS	_	5	dep	_	_
5	indicate	indicate	VBP	_	23	advcl	_	_
6	that	that	IN	_	13	mark	_	_
7	CYP2D6	cyp0d0	NN	_	13	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	CYP3A4	cyp0a0	NN	_	7	conj	_	_
10	may	may	MD	_	13	modal	_	_
11	be	be	VB	_	13	aux	_	_
12	minimally	minimally	RB	_	13	adv	_	_
13	involved	involve	VBN	_	5	comp	_	_
14	in	in	IN	_	16	case	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	metabolism	metabolism	NN	_	13	ppmod	_	_
17	,	,	,	_	23	p	_	_
18	in	in	FW	_	19	adv	_	_
19	vivo	vivo	FW	_	20	attr	_	_
20	studies	study	NNS	_	23	dep	_	_
21	do	do	VBP	_	23	aux	_	_
22	not	not	RB	_	23	neg	_	_
23	show	show	VB	_	0	root	_	_
24	decreased	decrease	VBN	_	25	attr	_	_
25	elimination	elimination	NN	_	23	obj	_	_
26	by	by	IN	_	28	case	_	_
27	these	these	DT	_	28	det	_	_
28	isozymes	isozymes	NNS	_	25	ppmod	_	_
29	and	and	CC	_	23	cc	_	_
30	they	they	PRP	_	31	dep	_	_
31	contribute	contribute	VBP	_	23	conj	_	_
32	to	to	TO	_	36	aux	_	_
33	only	only	RB	_	36	adv	_	_
34	a	a	DT	_	36	det	_	_
35	small	small	JJ	_	36	attr	_	_
36	fraction	fraction	NN	_	31	ppmod	_	_
37	of	of	IN	_	40	case	_	_
38	total	total	JJ	_	40	attr	_	_
39	body	body	NN	_	40	com	_	_
40	clearance	clearance	NN	_	36	ppmod	_	_
41	.	.	.	_	23	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	with	with	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	2	ppmod	_	_
11	has	have	VBZ	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	studied	study	VBN	_	0	root	_	_
15	in	in	IN	_	16	case	_	_
16	humans	human	NNS	_	14	ppmod	_	_
17	.	.	.	_	14	p	_	_

1	Patients	patient	NNS	_	19	dep	_	_
2	who	who	WP	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	receiving	receive	VBG	_	1	relcl	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	concurrently	concurrently	RB	_	9	adv	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	4	ppmod	_	_
10	,	,	,	_	1	p	_	_
11	especially	especially	RB	_	1	adv	_	_
12	drugs	drug	NNS	_	1	appo	_	_
13	with	with	IN	_	15	case	_	_
14	CNS	cns	NN	_	15	com	_	_
15	activity	activity	NN	_	12	ppmod	_	_
16	,	,	,	_	1	p	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	monitored	monitor	VBN	_	0	root	_	_
20	carefully	carefully	RB	_	19	adv	_	_
21	.	.	.	_	19	p	_	_

1	Decreased	decrease	VBN	_	3	attr	_	_
2	seizure	seizure	NN	_	3	com	_	_
3	threshold	threshold	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	concomitantly	concomitantly	RB	_	13	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	9	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	CYP	cyp	VBG	_	12	advcl	_	_
2	3A4	0a0	NN	_	3	com	_	_
3	Inhibitors	inhibitor	NNS	_	1	obj	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	e.g.	e.g.	FW	_	6	adv	_	_
6	drug1	drug0	NN	_	3	prn	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	)	-rrb-	-RRB-	_	6	p	_	_
10	There	there	EX	_	12	dep	_	_
11	have	have	VBP	_	12	aux	_	_
12	been	be	VBN	_	0	root	_	_
13	rare	rare	JJ	_	14	attr	_	_
14	reports	report	NNS	_	12	obj	_	_
15	of	of	IN	_	18	case	_	_
16	serious	serious	JJ	_	18	attr	_	_
17	adverse	adverse	JJ	_	18	attr	_	_
18	events	event	NNS	_	14	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	connection	connection	NN	_	18	ppmod	_	_
21	with	with	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	coadministration	coadministration	NN	_	20	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	certain	certain	JJ	_	26	attr	_	_
26	drug3	drug0	NNS	_	23	ppmod	_	_
27	(	-lrb-	-LRB-	_	29	p	_	_
28	e.g.	e.g.	FW	_	29	adv	_	_
29	drug4	drug0	NN	_	26	prn	_	_
30	and	and	CC	_	29	cc	_	_
31	drug5	drug0	NN	_	29	conj	_	_
32	)	-rrb-	-RRB-	_	29	p	_	_
33	and	and	CC	_	26	cc	_	_
34	potent	potent	JJ	_	37	attr	_	_
35	CYP	cyp	NN	_	37	com	_	_
36	3A4	0a0	NN	_	37	com	_	_
37	inhibitors	inhibitor	NNS	_	26	conj	_	_
38	,	,	,	_	12	p	_	_
39	resulting	result	VBG	_	12	comp	_	_
40	in	in	IN	_	41	case	_	_
41	vasospasm	vasospasm	NN	_	39	ppmod	_	_
42	leading	lead	VBG	_	41	acl	_	_
43	to	to	TO	_	45	aux	_	_
44	cerebral	cerebral	JJ	_	45	attr	_	_
45	ischemia	ischemia	NN	_	42	ppmod	_	_
46	and/or	and/or	CC	_	45	cc	_	_
47	ischemia	ischemia	NN	_	45	conj	_	_
48	of	of	IN	_	50	case	_	_
49	the	the	DT	_	50	det	_	_
50	extremities	extremity	NNS	_	45	ppmod	_	_
51	.	.	.	_	12	p	_	_

1	Although	although	IN	_	4	mark	_	_
2	there	there	EX	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	been	be	VBN	_	21	advcl	_	_
5	no	no	DT	_	6	det	_	_
6	reports	report	NNS	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	such	such	JJ	_	9	attr	_	_
9	interactions	interaction	NNS	_	6	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	alone	alone	RB	_	11	adv	_	_
13	,	,	,	_	21	p	_	_
14	potent	potent	JJ	_	17	attr	_	_
15	CYP	cyp	NN	_	17	com	_	_
16	3A4	0a0	NN	_	17	com	_	_
17	inhibitors	inhibitor	NNS	_	21	dep	_	_
18	should	should	MD	_	21	modal	_	_
19	not	not	RB	_	21	neg	_	_
20	be	be	VB	_	21	aux	_	_
21	coadministered	coadministered	VBN	_	0	root	_	_
22	with	with	IN	_	23	case	_	_
23	methylergonovine	methylergonovine	NN	_	21	ppmod	_	_
24	.	.	.	_	21	p	_	_

1	Examples	example	NNS	_	11	dep	_	_
2	of	of	IN	_	3	case	_	_
3	some	some	DT	_	1	ppmod	_	_
4	of	of	IN	_	10	case	_	_
5	the	the	DT	_	10	det	_	_
6	more	more	RBR	_	7	adv	_	_
7	potent	potent	JJ	_	10	attr	_	_
8	CYP	cyp	NN	_	10	com	_	_
9	3A4	0a0	NN	_	10	com	_	_
10	inhibitors	inhibitor	NNS	_	3	ppmod	_	_
11	include	include	VBP	_	0	root	_	_
12	drug1	drug0	NN	_	11	obj	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	e.g.	e.g.	FW	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	drug2	drug0	NN	_	12	prn	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	appo	_	_
19	,	,	,	_	16	p	_	_
20	drug4	drug0	NN	_	16	appo	_	_
21	)	-rrb-	-RRB-	_	16	p	_	_
22	,	,	,	_	12	p	_	_
23	drug5	drug0	NN	_	12	conj	_	_
24	or	or	CC	_	23	cc	_	_
25	drug6	drug0	NN	_	23	conj	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	e.g.	e.g.	FW	_	29	ppmod	_	_
28	,	,	,	_	29	p	_	_
29	drug7	drug0	NN	_	23	prn	_	_
30	,	,	,	_	29	p	_	_
31	drug8	drug0	NN	_	29	appo	_	_
32	,	,	,	_	29	p	_	_
33	drug9	drug0	NN	_	29	appo	_	_
34	,	,	,	_	29	p	_	_
35	drug10	drug0	NN	_	29	appo	_	_
36	)	-rrb-	-RRB-	_	29	p	_	_
37	or	or	CC	_	23	cc	_	_
38	drug11	drug0	NN	_	12	conj	_	_
39	(	-lrb-	-LRB-	_	46	p	_	_
40	e.g.	e.g.	FW	_	46	ppmod	_	_
41	,	,	,	_	46	p	_	_
42	drug12	drug0	CD	_	46	num	_	_
43	,	,	,	_	46	p	_	_
44	drug13	drug0	CD	_	46	num	_	_
45	,	,	,	_	46	p	_	_
46	drug14	drug0	CD	_	38	num	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	.	.	.	_	11	p	_	_

1	Less	less	RBR	_	2	adv	_	_
2	potent	potent	JJ	_	5	attr	_	_
3	CYP	cyp	NN	_	5	com	_	_
4	3A4	0a0	NN	_	5	com	_	_
5	inhibitors	inhibitor	NNS	_	8	dep	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	administered	administer	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	caution	caution	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	Less	less	RBR	_	2	adv	_	_
2	potent	potent	JJ	_	3	attr	_	_
3	inhibitors	inhibitor	NNS	_	4	dep	_	_
4	include	include	VBP	_	0	root	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	grapefruit	grapefruit	NN	_	12	com	_	_
12	juice	juice	NN	_	5	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	5	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	5	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug6	drug0	NN	_	5	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	drug7	drug0	NN	_	5	conj	_	_
22	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	lists	list	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	not	not	RB	_	3	neg	_	_
5	exhaustive	exhaustive	JJ	_	3	dep	_	_
6	,	,	,	_	3	p	_	_
7	and	and	CC	_	3	cc	_	_
8	the	the	DT	_	9	det	_	_
9	prescriber	prescriber	NN	_	11	dep	_	_
10	should	should	MD	_	11	modal	_	_
11	consider	consider	VB	_	3	conj	_	_
12	the	the	DT	_	13	det	_	_
13	effects	effect	NNS	_	21	dep	_	_
14	on	on	IN	_	16	case	_	_
15	CYP	cyp	NN	_	16	com	_	_
16	3A4	0a0	NN	_	13	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	other	other	JJ	_	19	attr	_	_
19	agents	agent	NNS	_	16	ppmod	_	_
20	being	be	VBG	_	21	aux	_	_
21	considered	consider	VBN	_	11	comp	_	_
22	for	for	IN	_	24	case	_	_
23	concomitant	concomitant	JJ	_	24	attr	_	_
24	use	use	NN	_	21	ppmod	_	_
25	with	with	IN	_	26	case	_	_
26	drug1	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	No	no	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	10	dep	_	_
4	involving	involve	VBG	_	3	acl	_	_
5	other	other	JJ	_	8	attr	_	_
6	cytochrome	cytochrome	NN	_	8	com	_	_
7	P450	p0	NN	_	8	com	_	_
8	isoenzymes	isoenzymes	NNS	_	4	obj	_	_
9	are	be	VBP	_	10	aux	_	_
10	known	know	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	11	adv	_	_
6	drug1	drug0	NN	_	11	dep	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug2	drug0	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	is	be	VBZ	_	11	aux	_	_
11	used	use	VBN	_	4	comp	_	_
12	concurrently	concurrently	RB	_	11	adv	_	_
13	with	with	IN	_	15	case	_	_
14	other	other	JJ	_	15	attr	_	_
15	drug3	drug0	NN	_	11	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	.	.	.	_	4	p	_	_

1	To	to	TO	_	2	aux	_	_
2	minimize	minimize	VB	_	20	advcl	_	_
3	CNS	cns	NN	_	4	com	_	_
4	depression	depression	NN	_	2	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	possible	possible	JJ	_	7	attr	_	_
7	potentiation	potentiation	NN	_	4	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug1	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	7	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug4	drug0	NN	_	7	conj	_	_
16	or	or	CC	_	15	cc	_	_
17	drug5	drug0	NN	_	7	conj	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	used	use	VBN	_	0	root	_	_
21	with	with	IN	_	22	case	_	_
22	caution	caution	NN	_	20	ppmod	_	_
23	.	.	.	_	20	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	since	since	IN	_	9	mark	_	_
7	there	there	EX	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	be	be	VB	_	5	comp	_	_
10	an	an	DT	_	16	det	_	_
11	Antabuse	antabuse	NN	_	15	advnp	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	disulfiram	disulfiram	NN	_	15	advnp	_	_
14	)	-rrb-	-RRB-	_	15	p	_	_
15	-like	-like	JJ	_	16	attr	_	_
16	reaction	reaction	NN	_	9	obj	_	_
17	.	.	.	_	5	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	exhibits	exhibit	VBZ	_	45	advcl	_	_
4	some	some	DT	_	8	det	_	_
5	monoamine	monoamine	NN	_	8	attr	_	_
6	oxidase	oxidase	NN	_	8	attr	_	_
7	inhibitory	inhibitory	JJ	_	8	attr	_	_
8	activity	activity	NN	_	3	obj	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	appo	_	_
11	,	,	,	_	45	p	_	_
12	drug3	drug0	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	45	dep	_	_
14	(	-lrb-	-LRB-	_	19	p	_	_
15	e.g.	e.g.	FW	_	17	adv	_	_
16	,	,	,	_	17	p	_	_
17	drug4	drug0	NN	_	19	ppmod	_	_
18	,	,	,	_	19	p	_	_
19	drug5	drug0	NN	_	13	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	and	and	CC	_	13	cc	_	_
22	other	other	JJ	_	23	attr	_	_
23	drugs	drug	NNS	_	13	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	foods	food	NNS	_	23	conj	_	_
26	with	with	IN	_	30	case	_	_
27	known	known	JJ	_	30	attr	_	_
28	high	high	JJ	_	30	attr	_	_
29	drug6	drug0	NN	_	30	com	_	_
30	content	content	NN	_	23	ppmod	_	_
31	,	,	,	_	13	p	_	_
32	such	such	JJ	_	34	adv	_	_
33	as	as	IN	_	34	case	_	_
34	wine	wine	NN	_	13	ppmod	_	_
35	,	,	,	_	34	p	_	_
36	yogurt	yogurt	NN	_	34	conj	_	_
37	,	,	,	_	36	p	_	_
38	ripe	ripe	JJ	_	39	attr	_	_
39	cheese	cheese	NN	_	34	conj	_	_
40	and	and	CC	_	39	cc	_	_
41	bananas	bananas	NN	_	34	conj	_	_
42	,	,	,	_	13	p	_	_
43	should	should	MD	_	45	modal	_	_
44	be	be	VB	_	45	aux	_	_
45	avoided	avoid	VBN	_	0	root	_	_
46	.	.	.	_	45	p	_	_

1	A	a	DT	_	3	det	_	_
2	further	far	JJ	_	3	attr	_	_
3	phenomenon	phenomenon	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	toxicity	toxicity	NN	_	3	ppmod	_	_
6	common	common	JJ	_	5	attr	_	_
7	to	to	TO	_	9	aux	_	_
8	many	many	JJ	_	9	attr	_	_
9	drug1	drug0	NNS	_	6	ppmod	_	_
10	is	be	VBZ	_	0	root	_	_
11	hemolysis	hemolysis	NN	_	10	obj	_	_
12	and	and	CC	_	11	cc	_	_
13	the	the	DT	_	14	det	_	_
14	appearance	appearance	NN	_	11	conj	_	_
15	of	of	IN	_	18	case	_	_
16	Heinz-Ehrlich	heinz-ehrlich	JJ	_	18	attr	_	_
17	inclusion	inclusion	NN	_	18	com	_	_
18	bodies	body	NNS	_	14	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	erythrocytes	erythrocyte	NNS	_	14	ppmod	_	_
21	.	.	.	_	10	p	_	_

1	No	no	DT	_	2	det	_	_
2	cross-resistance	cross-resistance	NN	_	12	dep	_	_
3	with	with	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	radiotherapy	radiotherapy	NN	_	5	conj	_	_
8	or	or	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	5	conj	_	_
10	has	have	VBZ	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	demonstrated	demonstrate	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	capable	capable	JJ	_	2	dep	_	_
4	of	of	IN	_	6	case	_	_
5	potentiating	potentiating	NN	_	6	com	_	_
6	drug2	drug0	NN	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	e.g.	e.g.	FW	_	10	ppmod	_	_
9	,	,	,	_	10	p	_	_
10	drug3	drug0	NN	_	2	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	drug5	drug0	NN	_	10	appo	_	_
15	,	,	,	_	10	p	_	_
16	drug6	drug0	NN	_	10	appo	_	_
17	,	,	,	_	10	p	_	_
18	etc	etc	NN	_	10	appo	_	_
19	.	.	.	_	10	p	_	_
20	)	-rrb-	-RRB-	_	10	p	_	_

1	as	as	RB	_	2	com	_	_
2	well	well	RB	_	0	root	_	_
3	as	as	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	.	.	.	_	2	p	_	_

1	Drugs	drug	NNS	_	15	dep	_	_
2	affecting	affect	VBG	_	1	acl	_	_
3	pituitary	pituitary	NN	_	2	obj	_	_
4	or	or	CC	_	3	cc	_	_
5	adrenocortical	adrenocortical	JJ	_	6	attr	_	_
6	function	function	NN	_	3	conj	_	_
7	,	,	,	_	1	p	_	_
8	including	include	VBG	_	11	adv	_	_
9	all	all	NN	_	11	com	_	_
10	corticosteroid	corticosteroid	NN	_	11	com	_	_
11	therapy	therapy	NN	_	1	ppmod	_	_
12	,	,	,	_	1	p	_	_
13	must	must	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	discontinued	discontinue	VBN	_	0	root	_	_
16	prior	prior	RB	_	15	adv	_	_
17	to	to	TO	_	16	ppmod	_	_
18	and	and	CC	_	16	cc	_	_
19	during	during	IN	_	20	case	_	_
20	testing	testing	NN	_	16	conj	_	_
21	with	with	IN	_	22	case	_	_
22	drug1	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	15	p	_	_

1	The	the	DT	_	2	det	_	_
2	metabolism	metabolism	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	accelerated	accelerate	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	;	;	:	_	6	p	_	_

1	therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	results	result	NNS	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	test	test	NN	_	3	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	be	be	VB	_	0	root	_	_
9	inaccurate	inaccurate	JJ	_	8	dep	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	taking	take	VBG	_	11	acl	_	_
13	drug1	drug0	NN	_	12	obj	_	_
14	within	within	IN	_	16	case	_	_
15	two	#crd#	CD	_	16	num	_	_
16	weeks	week	NNS	_	12	ppmod	_	_
17	before	before	IN	_	16	case	_	_
18	.	.	.	_	8	p	_	_

1	Asubnormal	asubnormal	JJ	_	2	attr	_	_
2	response	response	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	occur	occur	VB	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	estrogen	estrogen	NN	_	9	com	_	_
9	therapy	therapy	NN	_	6	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibits	inhibit	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	glucuronidation	glucuronidation	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	2	cc	_	_
8	could	could	MD	_	10	modal	_	_
9	possibly	possibly	RB	_	10	adv	_	_
10	potentiate	potentiate	VB	_	2	conj	_	_
11	drug3	drug0	NN	_	12	com	_	_
12	toxicity	toxicity	NN	_	10	obj	_	_
13	.	.	.	_	2	p	_	_

1	Preliminary	preliminary	JJ	_	2	attr	_	_
2	evidence	evidence	NN	_	3	dep	_	_
3	suggests	suggest	VBZ	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	inhibits	inhibit	VBZ	_	3	comp	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	metabolism	metabolism	NN	_	6	obj	_	_
9	and	and	CC	_	6	cc	_	_
10	may	may	MD	_	11	modal	_	_
11	result	result	VB	_	6	conj	_	_
12	in	in	IN	_	14	case	_	_
13	an	an	DT	_	14	det	_	_
14	increase	increase	NN	_	11	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	concentrations	concentration	NNS	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	through	through	IN	_	8	case	_	_
5	the	the	DT	_	8	det	_	_
6	cytochrome	cytochrome	NN	_	7	com	_	_
7	P450	p0	NN	_	8	com	_	_
8	system	system	NN	_	3	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	primarily	primarily	RB	_	15	adv	_	_
11	the	the	DT	_	15	det	_	_
12	CYP2C19	cyp0c0	NN	_	15	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	CYP3A4	cyp0a0	NN	_	12	conj	_	_
15	isozymes	isozymes	NNS	_	8	appo	_	_
16	,	,	,	_	3	p	_	_
17	and	and	CC	_	3	cc	_	_
18	subsequently	subsequently	RB	_	19	adv	_	_
19	undergoes	undergo	VBZ	_	3	conj	_	_
20	Phase	phase	NN	_	22	attr	_	_
21	II	ii	CD	_	22	num	_	_
22	conjugation	conjugation	NN	_	19	obj	_	_
23	.	.	.	_	3	p	_	_

1	Based	base	VBN	_	3	adv	_	_
2	on	on	IN	_	3	case	_	_
3	studies	study	NNS	_	17	ppmod	_	_
4	evaluating	evaluate	VBG	_	3	acl	_	_
5	possible	possible	JJ	_	6	attr	_	_
6	interactions	interaction	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drugs	drug	NNS	_	6	ppmod	_	_
12	,	,	,	_	17	p	_	_
13	no	no	DT	_	15	det	_	_
14	dosage	dosage	JJ	_	15	attr	_	_
15	adjustment	adjustment	NN	_	17	dep	_	_
16	is	be	VBZ	_	17	aux	_	_
17	needed	need	VBN	_	0	root	_	_
18	with	with	IN	_	20	case	_	_
19	concomitant	concomitant	JJ	_	20	attr	_	_
20	use	use	NN	_	17	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	following	following	NN	_	20	ppmod	_	_
24	:	:	:	_	23	p	_	_
25	drug2	drug0	CD	_	23	appo	_	_
26	,	,	,	_	25	p	_	_
27	drug3	drug0	NN	_	25	appo	_	_
28	,	,	,	_	27	p	_	_
29	drug4	drug0	NN	_	27	appo	_	_
30	,	,	,	_	27	p	_	_
31	drug5	drug0	NN	_	27	appo	_	_
32	,	,	,	_	27	p	_	_
33	drug6	drug0	NN	_	27	appo	_	_
34	,	,	,	_	27	p	_	_
35	drug7	drug0	NN	_	27	appo	_	_
36	(	-lrb-	-LRB-	_	25	p	_	_
37	and	and	CC	_	25	cc	_	_
38	its	its	PRP$	_	40	poss	_	_
39	active	active	JJ	_	40	attr	_	_
40	metabolite	metabolite	NN	_	25	conj	_	_
41	,	,	,	_	40	p	_	_
42	drug8	drug0	NN	_	40	appo	_	_
43	)	-rrb-	-RRB-	_	40	p	_	_
44	,	,	,	_	25	p	_	_
45	drug9	drug0	NN	_	25	conj	_	_
46	,	,	,	_	45	p	_	_
47	drug10	drug0	CD	_	25	conj	_	_
48	,	,	,	_	47	p	_	_
49	drug11	drug0	CD	_	25	conj	_	_
50	,	,	,	_	49	p	_	_
51	drug12	drug0	CD	_	25	conj	_	_
52	,	,	,	_	51	p	_	_
53	drug13	drug0	CD	_	25	conj	_	_
54	,	,	,	_	53	p	_	_
55	drug14	drug0	CD	_	25	conj	_	_
56	,	,	,	_	55	p	_	_
57	an	an	DT	_	59	det	_	_
58	oral	oral	JJ	_	59	attr	_	_
59	drug15	drug0	NN	_	25	conj	_	_
60	(	-lrb-	-LRB-	_	63	p	_	_
61	drug16	drug0	CD	_	63	num	_	_
62	/	/	:	_	63	p	_	_
63	drug17	drug0	CD	_	59	num	_	_
64	)	-rrb-	-RRB-	_	63	p	_	_
65	,	,	,	_	59	p	_	_
66	drug18	drug0	CD	_	25	conj	_	_
67	,	,	,	_	66	p	_	_
68	drug19	drug0	CD	_	25	conj	_	_
69	,	,	,	_	68	p	_	_
70	drug20	drug0	CD	_	25	conj	_	_
71	,	,	,	_	70	p	_	_
72	drug21	drug0	CD	_	25	conj	_	_
73	,	,	,	_	72	p	_	_
74	drug22	drug0	CD	_	25	conj	_	_
75	,	,	,	_	74	p	_	_
76	drug23	drug0	CD	_	25	conj	_	_
77	,	,	,	_	76	p	_	_
78	drug24	drug0	CD	_	25	conj	_	_
79	,	,	,	_	78	p	_	_
80	or	or	CC	_	78	cc	_	_
81	drug25	drug0	CD	_	25	conj	_	_
82	.	.	.	_	17	p	_	_

1	Clinically	clinically	RB	_	2	adv	_	_
2	relevant	relevant	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	16	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	3	ppmod	_	_
9	with	with	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	same	same	JJ	_	13	attr	_	_
12	metabolic	metabolic	JJ	_	13	attr	_	_
13	pathways	pathway	NNS	_	8	ppmod	_	_
14	are	be	VBP	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	expected	expect	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Therefore	therefore	RB	_	20	adv	_	_
2	,	,	,	_	20	p	_	_
3	when	when	WRB	_	4	adv	_	_
4	coadministered	coadministered	VBN	_	20	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	20	p	_	_
8	adjustment	adjustment	NN	_	20	dep	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	dosage	dosage	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	of	of	IN	_	17	case	_	_
16	such	such	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	13	conj	_	_
18	may	may	MD	_	20	modal	_	_
19	not	not	RB	_	20	neg	_	_
20	be	be	VB	_	0	root	_	_
21	necessary	necessary	JJ	_	20	dep	_	_
22	.	.	.	_	20	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	also	also	RB	_	2	adv	_	_
4	no	no	DT	_	5	det	_	_
5	interaction	interaction	NN	_	2	obj	_	_
6	with	with	IN	_	9	case	_	_
7	concomitantly	concomitantly	RB	_	8	adv	_	_
8	administered	administer	VBN	_	9	attr	_	_
9	drug1	drug0	NN	_	5	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	postmarketing	postmarketing	JJ	_	5	attr	_	_
5	reports	report	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	increased	increase	VBN	_	8	attr	_	_
8	INR	inr	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	time	time	NN	_	8	conj	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	5	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	drug1	drug0	NN	_	14	obj	_	_
16	,	,	,	_	3	p	_	_
17	including	include	VBG	_	3	comp	_	_
18	drug2	drug0	NN	_	17	obj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	drug3	drug0	NN	_	18	conj	_	_
22	concomitantly	concomitantly	RB	_	17	adv	_	_
23	.	.	.	_	3	p	_	_

1	Increases	increase	NNS	_	8	dep	_	_
2	in	in	IN	_	3	case	_	_
3	INR	inr	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	prothrombin	prothrombin	NN	_	6	com	_	_
6	time	time	NN	_	3	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	lead	lead	VB	_	0	root	_	_
9	to	to	TO	_	11	aux	_	_
10	abnormal	abnormal	JJ	_	11	attr	_	_
11	bleeding	bleeding	JJ	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	even	even	JJ	_	14	attr	_	_
14	death	death	NN	_	11	conj	_	_
15	.	.	.	_	8	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	concomitantly	concomitantly	RB	_	2	adv	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	monitored	monitor	VBN	_	0	root	_	_
11	for	for	IN	_	12	case	_	_
12	increases	increase	NNS	_	10	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	INR	inr	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	prothrombin	prothrombin	NN	_	17	com	_	_
17	time	time	NN	_	14	conj	_	_
18	.	.	.	_	10	p	_	_

1	Because	because	IN	_	7	case	_	_
2	of	of	IN	_	7	case	_	_
3	profound	profound	JJ	_	7	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	long	long	JJ	_	6	adv	_	_
6	lasting	lasting	JJ	_	3	conj	_	_
7	inhibition	inhibition	NN	_	15	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	gastric	gastric	JJ	_	11	attr	_	_
10	acid	acid	NN	_	11	com	_	_
11	secretion	secretion	NN	_	7	ppmod	_	_
12	,	,	,	_	15	p	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	interfere	interfere	VB	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	absorption	absorption	NN	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drugs	drug	NNS	_	17	ppmod	_	_
20	where	where	WRB	_	23	adv	_	_
21	gastric	gastric	JJ	_	22	attr	_	_
22	pH	ph	NN	_	23	dep	_	_
23	is	be	VBZ	_	19	relcl	_	_
24	an	an	DT	_	26	det	_	_
25	important	important	JJ	_	26	attr	_	_
26	determinant	determinant	NN	_	23	obj	_	_
27	of	of	IN	_	29	case	_	_
28	their	their	PRP$	_	29	poss	_	_
29	bioavailability	bioavailability	NN	_	26	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	eg	eg	NN	_	29	prn	_	_
32	,	,	,	_	31	p	_	_
33	drug2	drug0	NN	_	31	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug3	drug0	NN	_	36	com	_	_
36	esters	ester	NNS	_	31	conj	_	_
37	,	,	,	_	36	p	_	_
38	and	and	CC	_	36	cc	_	_
39	drug4	drug0	NN	_	40	com	_	_
40	salts	salt	NNS	_	31	conj	_	_
41	)	-rrb-	-RRB-	_	31	p	_	_
42	.	.	.	_	15	p	_	_

1	Laboratory	laboratory	NN	_	2	com	_	_
2	Tests	test	NNS	_	0	root	_	_
3	There	there	EX	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	been	be	VBN	_	2	acl	_	_
6	reports	report	NNS	_	5	obj	_	_
7	of	of	IN	_	11	case	_	_
8	false-positive	false-positive	JJ	_	11	attr	_	_
9	urine	urine	NN	_	11	com	_	_
10	screening	screening	NN	_	11	com	_	_
11	tests	test	NNS	_	6	ppmod	_	_
12	for	for	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug2	drug0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	in	in	IN	_	18	case	_	_
18	patients	patient	NNS	_	13	ppmod	_	_
19	receiving	receive	VBG	_	18	acl	_	_
20	most	most	JJ	_	21	attr	_	_
21	drug3	drug0	NN	_	19	obj	_	_
22	,	,	,	_	11	p	_	_
23	including	include	VBG	_	24	adv	_	_
24	drug4	drug0	NN	_	11	ppmod	_	_
25	.	.	.	_	2	p	_	_

1	An	an	DT	_	4	det	_	_
2	alternative	alternative	JJ	_	4	attr	_	_
3	confirmatory	confirmatory	NN	_	4	com	_	_
4	method	method	NN	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	considered	consider	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	verify	verify	VB	_	7	comp	_	_
10	positive	positive	JJ	_	11	attr	_	_
11	results	result	NNS	_	9	obj	_	_
12	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug4	drug0	NN	_	7	conj	_	_
13	.	.	.	_	3	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	interact	interact	VB	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	increased	increase	VBN	_	9	attr	_	_
9	thrombocytopenia	thrombocytopenia	NN	_	6	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	6	p	_	_
12	drug2	drug0	NN	_	6	appo	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	increased	increase	VBN	_	15	attr	_	_
15	nephrotoxicity	nephrotoxicity	NN	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	6	p	_	_
18	drug3	drug0	NN	_	6	appo	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	increased	increase	VBN	_	22	attr	_	_
21	hypoglycemic	hypoglycemic	JJ	_	22	attr	_	_
22	response	response	NN	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	6	p	_	_
25	drug4	drug0	NN	_	6	appo	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	increased	increase	VBN	_	29	attr	_	_
28	anticoagulant	anticoagulant	NN	_	29	com	_	_
29	effect	effect	NN	_	25	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	,	,	,	_	6	p	_	_
32	drug5	drug0	NN	_	6	appo	_	_
33	(	-lrb-	-LRB-	_	36	p	_	_
34	decreased	decrease	VBN	_	36	attr	_	_
35	renal	renal	JJ	_	36	attr	_	_
36	excretion	excretion	NN	_	32	prn	_	_
37	of	of	IN	_	38	case	_	_
38	drug6	drug0	NN	_	36	ppmod	_	_
39	)	-rrb-	-RRB-	_	36	p	_	_
40	,	,	,	_	6	p	_	_
41	drug7	drug0	NN	_	6	appo	_	_
42	(	-lrb-	-LRB-	_	45	p	_	_
43	decreased	decrease	VBN	_	45	attr	_	_
44	hepatic	hepatic	JJ	_	45	attr	_	_
45	clearance	clearance	NN	_	41	prn	_	_
46	of	of	IN	_	47	case	_	_
47	drug8	drug0	NN	_	45	ppmod	_	_
48	)	-rrb-	-RRB-	_	45	p	_	_
49	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	compete	compete	VB	_	0	root	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	such	such	JJ	_	10	adv	_	_
9	as	as	IN	_	10	case	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	for	for	IN	_	13	case	_	_
13	sites	site	NNS	_	3	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	metabolism	metabolism	NN	_	13	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	liver	liver	NN	_	13	ppmod	_	_
19	,	,	,	_	3	p	_	_
20	thus	thus	RB	_	21	adv	_	_
21	elevating	elevate	VBG	_	3	comp	_	_
22	the	the	DT	_	24	det	_	_
23	serum	serum	NN	_	24	com	_	_
24	levels	level	NNS	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	such	such	JJ	_	27	attr	_	_
27	compounds	compound	NNS	_	24	ppmod	_	_
28	to	to	TO	_	31	aux	_	_
29	potentially	potentially	RB	_	30	adv	_	_
30	toxic	toxic	JJ	_	31	attr	_	_
31	levels	level	NNS	_	21	ppmod	_	_
32	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	when	when	WRB	_	10	adv	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	is	be	VBZ	_	15	advcl	_	_
11	anticipated	anticipated	JJ	_	10	dep	_	_
12	,	,	,	_	15	p	_	_
13	it	it	PRP	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	be	be	VB	_	0	root	_	_
16	necessary	necessary	JJ	_	15	dep	_	_
17	to	to	TO	_	18	aux	_	_
18	monitor	monitor	VB	_	16	comp	_	_
19	blood	blood	NN	_	20	com	_	_
20	levels	level	NNS	_	18	obj	_	_
21	and/or	and/or	CC	_	18	cc	_	_
22	reduce	reduce	VB	_	18	conj	_	_
23	the	the	DT	_	24	det	_	_
24	dosage	dosage	NN	_	22	obj	_	_
25	of	of	IN	_	27	case	_	_
26	such	such	JJ	_	27	attr	_	_
27	compounds	compound	NNS	_	24	ppmod	_	_
28	.	.	.	_	15	p	_	_

1	Such	such	JJ	_	3	attr	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	administered	administer	VBN	_	0	root	_	_
7	under	under	IN	_	10	case	_	_
8	careful	careful	JJ	_	10	attr	_	_
9	medical	medical	JJ	_	10	attr	_	_
10	supervision	supervision	NN	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	Administration	administration	NN	_	4	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	decreases	decrease	VBZ	_	0	root	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	clearance	clearance	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	by	by	IN	_	11	case	_	_
10	about	about	RB	_	11	adv	_	_
11	5	0	CD	_	4	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	implication	implication	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	effect	effect	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	known	know	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	11	dep	_	_
2	with	with	IN	_	8	case	_	_
3	Severe	severe	JJ	_	7	attr	_	_
4	Hepatic	hepatic	JJ	_	7	attr	_	_
5	or	or	CC	_	4	cc	_	_
6	Renal	renal	JJ	_	4	conj	_	_
7	Impairment	impairment	NN	_	8	com	_	_
8	Caution	caution	NN	_	1	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	exercised	exercise	VBN	_	0	root	_	_
12	when	when	WRB	_	16	adv	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	Capsules	capsule	NNS	_	16	dep	_	_
15	are	be	VBP	_	16	aux	_	_
16	administered	administer	VBN	_	11	comp	_	_
17	to	to	TO	_	18	aux	_	_
18	patients	patient	NNS	_	16	ppmod	_	_
19	with	with	IN	_	24	case	_	_
20	severe	severe	JJ	_	24	attr	_	_
21	hepatic	hepatic	JJ	_	24	attr	_	_
22	or	or	CC	_	21	cc	_	_
23	renal	renal	JJ	_	21	conj	_	_
24	impairment	impairment	NN	_	18	ppmod	_	_
25	.	.	.	_	11	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	studies	study	NNS	_	3	dep	_	_
3	show	show	VBP	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	there	there	EX	_	6	dep	_	_
6	are	be	VBP	_	3	comp	_	_
7	no	no	DT	_	9	det	_	_
8	significant	significant	JJ	_	9	attr	_	_
9	alterations	alteration	NNS	_	6	obj	_	_
10	in	in	IN	_	12	case	_	_
11	pharmacokinetic	pharmacokinetic	JJ	_	12	attr	_	_
12	parameters	parameter	NNS	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	to	to	TO	_	18	aux	_	_
18	warrant	warrant	VBP	_	6	comp	_	_
19	dosage	dosage	NN	_	20	com	_	_
20	adjustment	adjustment	NN	_	18	obj	_	_
21	when	when	WRB	_	24	adv	_	_
22	drug3	drug0	NN	_	24	dep	_	_
23	is	be	VBZ	_	24	aux	_	_
24	administered	administer	VBN	_	18	comp	_	_
25	with	with	IN	_	27	case	_	_
26	these	these	DT	_	27	det	_	_
27	drugs	drug	NNS	_	24	ppmod	_	_
28	.	.	.	_	3	p	_	_

1	A	a	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	study	study	NN	_	4	dep	_	_
4	demonstrated	demonstrate	VBD	_	0	root	_	_
5	that	that	IN	_	11	mark	_	_
6	coadministration	coadministration	NN	_	11	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	results	result	VBZ	_	4	comp	_	_
12	in	in	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	significant	significant	JJ	_	15	attr	_	_
15	decrease	decrease	NN	_	11	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	pharmacokinetic	pharmacokinetic	JJ	_	19	attr	_	_
19	parameters	parameter	NNS	_	15	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	~36	~0	CD	_	19	num	_	_
22	%	%	NN	_	21	meta	_	_
23	for	for	IN	_	24	case	_	_
24	Cmax	cmax	NN	_	21	ppmod	_	_
25	and	and	CC	_	21	cc	_	_
26	~28	~0	CD	_	21	conj	_	_
27	%	%	NN	_	26	meta	_	_
28	for	for	IN	_	29	case	_	_
29	AUC	auc	NN	_	26	ppmod	_	_
30	)	-rrb-	-RRB-	_	21	p	_	_
31	of	of	IN	_	32	case	_	_
32	drug3	drug0	NN	_	19	ppmod	_	_
33	.	.	.	_	4	p	_	_

1	Administration	administration	NN	_	10	dep	_	_
2	of	of	IN	_	5	case	_	_
3	a	a	DT	_	5	det	_	_
4	higher	high	JJR	_	5	attr	_	_
5	dose	dose	NN	_	1	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	considered	consider	VBN	_	0	root	_	_
11	when	when	WRB	_	12	adv	_	_
12	coadministering	coadministering	VBG	_	10	comp	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	16	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	or	or	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug4	drug0	NNS	_	11	ppmod	_	_
14	were	be	VBD	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	studied	study	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	particularly	particularly	RB	_	1	adv	_	_
4	drug2	drug0	NN	_	1	appo	_	_
5	,	,	,	_	1	p	_	_
6	may	may	MD	_	7	modal	_	_
7	cause	cause	VB	_	0	root	_	_
8	serious	serious	JJ	_	10	attr	_	_
9	cardiac	cardiac	JJ	_	10	attr	_	_
10	arrhythmias	arrhythmia	NNS	_	7	obj	_	_
11	during	during	IN	_	13	case	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	anesthesia	anesthesia	NN	_	7	ppmod	_	_
14	and	and	CC	_	7	cc	_	_
15	therefore	therefore	RB	_	18	adv	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	used	use	VBN	_	7	conj	_	_
19	only	only	RB	_	22	adv	_	_
20	with	with	IN	_	22	case	_	_
21	great	great	JJ	_	22	attr	_	_
22	caution	caution	NN	_	18	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	not	not	RB	_	26	neg	_	_
25	at	at	IN	_	26	case	_	_
26	all	all	NN	_	22	conj	_	_
27	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	The	the	DT	_	5	det	_	_
4	pressor	pressor	JJ	_	5	attr	_	_
5	effect	effect	NN	_	1	conj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	is	be	VBZ	_	10	aux	_	_
9	markedly	markedly	RB	_	10	adv	_	_
10	potentiated	potentiate	VBN	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	drug3	drug0	NN	_	13	obj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	drug4	drug0	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	.	.	.	_	10	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	when	when	WRB	_	4	adv	_	_
4	initiating	initiate	VBG	_	15	advcl	_	_
5	pressor	pressor	NN	_	6	com	_	_
6	therapy	therapy	NN	_	4	obj	_	_
7	in	in	IN	_	9	case	_	_
8	these	these	DT	_	9	det	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	,	,	,	_	15	p	_	_
11	the	the	DT	_	13	det	_	_
12	initial	initial	JJ	_	13	attr	_	_
13	dose	dose	NN	_	15	dep	_	_
14	should	should	MD	_	15	modal	_	_
15	be	be	VB	_	0	root	_	_
16	small	small	JJ	_	15	dep	_	_
17	and	and	CC	_	15	cc	_	_
18	used	use	VBD	_	15	conj	_	_
19	with	with	IN	_	21	case	_	_
20	due	due	JJ	_	21	attr	_	_
21	caution	caution	NN	_	18	ppmod	_	_
22	.	.	.	_	15	p	_	_

1	The	the	DT	_	3	det	_	_
2	pressor	pressor	JJ	_	3	attr	_	_
3	response	response	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	9	modal	_	_
7	also	also	RB	_	9	adv	_	_
8	be	be	VB	_	9	aux	_	_
9	potentiated	potentiate	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	CNS-depressant	cns-depressant	JJ	_	3	attr	_	_
3	effect	effect	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	0	root	_	_
7	additive	additive	JJ	_	6	dep	_	_
8	with	with	IN	_	9	case	_	_
9	that	that	DT	_	7	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug2	drug0	NNS	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	including	include	VBG	_	15	adv	_	_
15	drug3	drug0	NN	_	12	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	As	as	IN	_	2	mark	_	_
2	is	be	VBZ	_	12	advcl	_	_
3	the	the	DT	_	4	det	_	_
4	case	case	NN	_	2	obj	_	_
5	with	with	IN	_	8	case	_	_
6	many	many	JJ	_	8	attr	_	_
7	medicinal	medicinal	JJ	_	8	attr	_	_
8	agents	agent	NNS	_	4	ppmod	_	_
9	,	,	,	_	12	p	_	_
10	drug1	drug0	NN	_	12	dep	_	_
11	may	may	MD	_	12	modal	_	_
12	slow	slow	JJ	_	0	root	_	_
13	the	the	DT	_	14	det	_	_
14	metabolism	metabolism	NN	_	12	obj	_	_
15	of	of	IN	_	19	case	_	_
16	a	a	DT	_	19	det	_	_
17	concomitantly	concomitantly	RB	_	18	adv	_	_
18	administered	administer	VBN	_	19	attr	_	_
19	drug	drug	NN	_	14	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	Should	should	MD	_	3	modal	_	_
2	this	this	DT	_	3	obj	_	_
3	occur	occur	VB	_	13	comp	_	_
4	,	,	,	_	13	p	_	_
5	the	the	DT	_	8	det	_	_
6	higher	high	JJR	_	8	attr	_	_
7	serum	serum	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	13	dep	_	_
9	of	of	IN	_	11	case	_	_
10	that	that	DT	_	11	det	_	_
11	drug	drug	NN	_	8	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	result	result	VB	_	0	root	_	_
14	in	in	IN	_	19	case	_	_
15	increased	increase	VBN	_	19	attr	_	_
16	pharmacologic	pharmacologic	JJ	_	19	attr	_	_
17	or	or	CC	_	16	cc	_	_
18	adverse	adverse	JJ	_	16	conj	_	_
19	effects	effect	NNS	_	13	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	that	that	DT	_	22	det	_	_
22	drug	drug	NN	_	19	ppmod	_	_
23	.	.	.	_	13	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	occurrences	occurrence	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	when	when	WRB	_	9	adv	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	was	be	VBD	_	9	aux	_	_
9	administered	administer	VBN	_	5	comp	_	_
10	to	to	TO	_	11	aux	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	on	on	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	or	or	CC	_	15	cc	_	_
18	drug4	drug0	JJ	_	20	attr	_	_
19	-like	-like	JJ	_	20	attr	_	_
20	drugs	drug	NNS	_	13	conj	_	_
21	.	.	.	_	5	p	_	_

1	Sever	sever	VB	_	3	attr	_	_
2	neurologic	neurologic	JJ	_	3	attr	_	_
3	signs	sign	NNS	_	9	dep	_	_
4	,	,	,	_	3	p	_	_
5	including	include	VBG	_	6	adv	_	_
6	coma	coma	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	have	have	VBP	_	9	aux	_	_
9	occurred	occur	VBN	_	0	root	_	_
10	with	with	IN	_	12	case	_	_
11	concurrent	concurrent	JJ	_	12	attr	_	_
12	use	use	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	Reduced	reduce	VBN	_	2	attr	_	_
2	absorption	absorption	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	when	when	WRB	_	14	adv	_	_
11	those	those	DT	_	12	det	_	_
12	agents	agent	NNS	_	14	dep	_	_
13	were	be	VBD	_	14	aux	_	_
14	administered	administer	VBN	_	9	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	drug3	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	When	when	WRB	_	16	adv	_	_
2	daily	daily	JJ	_	3	attr	_	_
3	doses	dose	NNS	_	16	dep	_	_
4	of	of	IN	_	7	case	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	2	0	CD	_	7	num	_	_
7	g	g	NN	_	3	ppmod	_	_
8	and	and	CC	_	3	cc	_	_
9	weekly	weekly	JJ	_	10	attr	_	_
10	doses	dose	NNS	_	3	conj	_	_
11	of	of	IN	_	14	case	_	_
12	drug2	drug0	NN	_	14	attr	_	_
13	7.5	0	CD	_	14	num	_	_
14	mg	mg	NN	_	10	ppmod	_	_
15	were	be	VBD	_	16	aux	_	_
16	coadministered	coadministered	VBN	_	36	advcl	_	_
17	to	to	TO	_	21	aux	_	_
18	15	0	CD	_	21	num	_	_
19	rheumatoid	rheumatoid	JJ	_	20	attr	_	_
20	arthritis	arthritis	NN	_	21	com	_	_
21	patients	patient	NNS	_	16	ppmod	_	_
22	in	in	IN	_	26	case	_	_
23	a	a	DT	_	26	det	_	_
24	drug-drug	drug-drug	JJ	_	26	attr	_	_
25	interaction	interaction	NN	_	26	com	_	_
26	study	study	NN	_	21	ppmod	_	_
27	,	,	,	_	36	p	_	_
28	the	the	DT	_	30	det	_	_
29	pharmacokinetic	pharmacokinetic	JJ	_	30	attr	_	_
30	disposition	disposition	NN	_	36	dep	_	_
31	of	of	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	drugs	drug	NNS	_	30	ppmod	_	_
34	was	be	VBD	_	36	aux	_	_
35	not	not	RB	_	36	neg	_	_
36	altered	alter	VBN	_	0	root	_	_
37	.	.	.	_	36	p	_	_

1	Daily	daily	JJ	_	2	attr	_	_
2	doses	dose	NNS	_	25	dep	_	_
3	of	of	IN	_	6	case	_	_
4	drug1	drug0	NN	_	6	attr	_	_
5	2	0	CD	_	6	num	_	_
6	g	g	NN	_	2	ppmod	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	maximum	maximum	NN	_	10	attr	_	_
9	3	0	CD	_	10	num	_	_
10	g	g	NN	_	6	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	and	and	CC	_	2	cc	_	_
13	weekly	weekly	JJ	_	14	attr	_	_
14	doses	dose	NNS	_	2	conj	_	_
15	of	of	IN	_	18	case	_	_
16	drug2	drug0	NN	_	18	attr	_	_
17	7.5	0	CD	_	18	num	_	_
18	mg	mg	NN	_	14	ppmod	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	maximum	maximum	NN	_	22	attr	_	_
21	15	0	CD	_	22	num	_	_
22	mg	mg	NN	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	were	be	VBD	_	25	aux	_	_
25	administered	administer	VBN	_	0	root	_	_
26	alone	alone	RB	_	25	adv	_	_
27	or	or	CC	_	26	cc	_	_
28	in	in	IN	_	29	case	_	_
29	combination	combination	NN	_	26	conj	_	_
30	to	to	TO	_	34	aux	_	_
31	310	0	CD	_	34	num	_	_
32	rheumatoid	rheumatoid	JJ	_	34	attr	_	_
33	arthritis	arthritis	NN	_	34	com	_	_
34	patients	patient	NNS	_	29	ppmod	_	_
35	in	in	IN	_	40	case	_	_
36	two	#crd#	CD	_	40	num	_	_
37	controlled	controlled	JJ	_	40	attr	_	_
38	52-week	0-week	JJ	_	40	attr	_	_
39	clinical	clinical	JJ	_	40	attr	_	_
40	studies	study	NNS	_	34	ppmod	_	_
41	.	.	.	_	25	p	_	_

1	The	the	DT	_	4	det	_	_
2	overall	overall	JJ	_	4	attr	_	_
3	toxicity	toxicity	NN	_	4	com	_	_
4	profile	profile	NN	_	8	dep	_	_
5	of	of	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	combination	combination	NN	_	4	ppmod	_	_
8	revealed	reveal	VBD	_	0	root	_	_
9	an	an	DT	_	11	det	_	_
10	increased	increase	VBN	_	11	attr	_	_
11	incidence	incidence	NN	_	8	obj	_	_
12	of	of	IN	_	15	case	_	_
13	gastrointestinal	gastrointestinal	JJ	_	15	attr	_	_
14	adverse	adverse	JJ	_	15	attr	_	_
15	events	event	NNS	_	11	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	especially	especially	RB	_	18	adv	_	_
18	nausea	nausea	NN	_	15	appo	_	_
19	,	,	,	_	15	p	_	_
20	when	when	WRB	_	21	adv	_	_
21	compared	compare	VBN	_	8	comp	_	_
22	to	to	TO	_	24	aux	_	_
23	the	the	DT	_	24	det	_	_
24	incidence	incidence	NN	_	21	ppmod	_	_
25	associated	associate	VBN	_	24	acl	_	_
26	with	with	IN	_	28	case	_	_
27	either	either	DT	_	28	det	_	_
28	drug	drug	NN	_	25	ppmod	_	_
29	administered	administer	VBN	_	28	acl	_	_
30	alone	alone	RB	_	29	adv	_	_
31	.	.	.	_	8	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	The	the	DT	_	6	det	_	_
6	presence	presence	NN	_	18	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	its	its	PRP$	_	11	poss	_	_
11	metabolites	metabolite	NNS	_	8	conj	_	_
12	in	in	IN	_	14	case	_	_
13	body	body	NN	_	14	com	_	_
14	fluids	fluid	NNS	_	6	ppmod	_	_
15	has	have	VBZ	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	been	be	VBN	_	18	aux	_	_
18	reported	report	VBN	_	3	acl	_	_
19	to	to	TO	_	20	aux	_	_
20	interfere	interfere	VB	_	18	comp	_	_
21	with	with	IN	_	24	case	_	_
22	laboratory	laboratory	JJ	_	24	attr	_	_
23	test	test	NN	_	24	com	_	_
24	procedures	procedure	NNS	_	20	ppmod	_	_
25	.	.	.	_	3	p	_	_

1	REFERENCES	reference	NNS	_	2	dep	_	_
2	7.Farr	#hlink#	VBD	_	0	root	_	_
3	M	m	NN	_	2	obj	_	_
4	,	,	,	_	3	p	_	_
5	et	et	FW	_	6	attr	_	_
6	al	al	FW	_	3	appo	_	_
7	.	.	.	_	2	p	_	_

1	Immunodeficiencies	immunodeficiency	NNS	_	2	dep	_	_
2	associated	associate	VBN	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	therapy	therapy	NN	_	2	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	inflammatory	inflammatory	JJ	_	8	attr	_	_
8	arthritis	arthritis	NN	_	5	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	British	british	NNP	_	2	com	_	_
2	Jnl	jnl	NNP	_	6	dep	_	_
3	Rheum	rheum	FW	_	2	attr	_	_
4	1991	0	CD	_	2	num	_	_
5	;	;	:	_	6	p	_	_
6	30:413-417	0	NN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	4	dep	_	_
4	was	be	VBD	_	1	acl	_	_
5	a	a	DT	_	7	det	_	_
6	slight	slight	JJ	_	7	attr	_	_
7	increase	increase	NN	_	4	obj	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	area	area	NN	_	7	ppmod	_	_
11	under	under	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	curve	curve	NN	_	10	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	AUC	auc	NN	_	13	prn	_	_
16	,	,	,	_	15	p	_	_
17	11	0	CD	_	15	appo	_	_
18	%	%	NN	_	17	meta	_	_
19	)	-rrb-	-RRB-	_	15	p	_	_
20	and	and	CC	_	13	cc	_	_
21	mean	mean	JJ	_	24	attr	_	_
22	peak	peak	JJ	_	24	attr	_	_
23	drug	drug	NN	_	24	com	_	_
24	concentration	concentration	NN	_	13	conj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	Cmax	cmax	NN	_	24	prn	_	_
27	,	,	,	_	26	p	_	_
28	18	0	CD	_	26	appo	_	_
29	%	%	NN	_	28	meta	_	_
30	)	-rrb-	-RRB-	_	26	p	_	_
31	of	of	IN	_	32	case	_	_
32	drug2	drug0	NN	_	10	ppmod	_	_
33	with	with	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	co-administration	co-administration	NN	_	4	ppmod	_	_
36	of	of	IN	_	39	case	_	_
37	100	0	CD	_	38	num	_	_
38	mg	mg	NN	_	39	com	_	_
39	drug3	drug0	NN	_	35	ppmod	_	_
40	for	for	IN	_	42	case	_	_
41	10	0	CD	_	42	num	_	_
42	days	day	NNS	_	35	ppmod	_	_
43	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	appropriately	appropriately	RB	_	6	adv	_	_
8	.	.	.	_	6	p	_	_

1	No	no	DT	_	3	det	_	_
2	dosage	dosage	JJ	_	3	attr	_	_
3	adjustment	adjustment	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	is	be	VBZ	_	9	aux	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	While	while	IN	_	5	mark	_	_
2	co-administration	co-administration	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	appeared	appear	VBD	_	18	advcl	_	_
6	to	to	TO	_	7	aux	_	_
7	increase	increase	VB	_	5	comp	_	_
8	the	the	DT	_	9	det	_	_
9	clearance	clearance	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	by	by	IN	_	13	case	_	_
13	70	0	CD	_	9	ppmod	_	_
14	%	%	NN	_	13	meta	_	_
15	,	,	,	_	18	p	_	_
16	these	these	DT	_	17	det	_	_
17	results	result	NNS	_	18	dep	_	_
18	are	be	VBP	_	0	root	_	_
19	not	not	RB	_	18	neg	_	_
20	conclusive	conclusive	JJ	_	18	dep	_	_
21	because	because	IN	_	25	case	_	_
22	of	of	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	small	small	JJ	_	25	attr	_	_
25	number	number	NN	_	18	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	subjects	subject	NNS	_	25	ppmod	_	_
28	studied	study	VBN	_	27	acl	_	_
29	and	and	CC	_	32	cc	_	_
30	because	because	IN	_	32	mark	_	_
31	patients	patient	NNS	_	32	dep	_	_
32	took	take	VBD	_	18	advcl	_	_
33	variable	variable	JJ	_	34	attr	_	_
34	doses	dose	NNS	_	32	obj	_	_
35	of	of	IN	_	36	case	_	_
36	drug3	drug0	NN	_	34	ppmod	_	_
37	.	.	.	_	18	p	_	_

1	Combination	combination	NN	_	2	com	_	_
2	therapy	therapy	NN	_	12	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	and	and	CC	_	4	cc	_	_
9	drug3	drug0	NN	_	4	conj	_	_
10	is	be	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	indicated	indicate	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	reverse	reverse	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	analgesic	analgesic	JJ	_	6	attr	_	_
6	activity	activity	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	17	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	including	include	VBG	_	6	adv	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	drug4	drug0	NN	_	6	conj	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	e.g.	e.g.	FW	_	14	adv	_	_
14	smoking	smoking	NN	_	11	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	may	may	MD	_	17	modal	_	_
17	result	result	VB	_	0	root	_	_
18	in	in	IN	_	20	case	_	_
19	enhanced	enhance	VBN	_	20	attr	_	_
20	vasoconstriction	vasoconstriction	NN	_	17	ppmod	_	_
21	.	.	.	_	17	p	_	_

1	Interactions	interaction	NNS	_	0	root	_	_
2	for	for	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	:	:	:	_	1	p	_	_
8	drug3	drug0	NN	_	1	appo	_	_
9	,	,	,	_	8	p	_	_
10	Oral	oral	JJ	_	11	attr	_	_
11	drug4	drug0	NN	_	8	appo	_	_
12	,	,	,	_	8	p	_	_
13	drug5	drug0	NN	_	8	appo	_	_
14	,	,	,	_	8	p	_	_
15	drug6	drug0	NN	_	8	appo	_	_

1	Interactions	interaction	NNS	_	0	root	_	_
2	for	for	IN	_	10	mark	_	_
3	drug1	drug0	NN	_	10	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	:	:	:	_	3	p	_	_
8	drug3	drug0	NN	_	3	appo	_	_
9	-	-	:	_	3	p	_	_
10	impairs	impair	VBZ	_	1	acl	_	_
11	the	the	DT	_	13	det	_	_
12	intestinal	intestinal	JJ	_	13	attr	_	_
13	absorption	absorption	NN	_	10	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	concurrent	concurrent	JJ	_	4	attr	_	_
4	use	use	NN	_	1	conj	_	_
5	decreases	decrease	VBZ	_	0	root	_	_
6	gastrointestinal	gastrointestinal	JJ	_	7	attr	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	;	;	:	_	5	p	_	_

1	requirements	requirement	NNS	_	6	dep	_	_
2	for	for	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	increased	increase	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug5	drug0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	drug6	drug0	NN	_	5	conj	_	_
15	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Absorption	absorption	NN	_	11	dep	_	_
4	of	of	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	single	single	JJ	_	7	attr	_	_
7	dose	dose	NN	_	3	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	decreased	decrease	VBN	_	43	advcl	_	_
12	when	when	WRB	_	13	adv	_	_
13	administered	administer	VBN	_	11	comp	_	_
14	to	to	TO	_	19	aux	_	_
15	12	0	CD	_	19	num	_	_
16	stable	stable	JJ	_	19	attr	_	_
17	renal	renal	JJ	_	19	attr	_	_
18	transplant	transplant	NN	_	19	com	_	_
19	patients	patient	NNS	_	13	ppmod	_	_
20	also	also	RB	_	21	adv	_	_
21	taking	take	VBG	_	19	acl	_	_
22	drug3	drug0	NN	_	21	obj	_	_
23	-	-	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	containing	contain	VBG	_	22	acl	_	_
26	drug5	drug0	NN	_	25	obj	_	_
27	(	-lrb-	-LRB-	_	29	p	_	_
28	30	0	CD	_	29	num	_	_
29	mL	ml	NN	_	26	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	:	:	:	_	43	p	_	_
32	the	the	DT	_	34	det	_	_
33	mean	mean	NN	_	34	com	_	_
34	Cmax	cmax	NN	_	43	dep	_	_
35	and	and	CC	_	34	cc	_	_
36	AUC	auc	NN	_	40	attr	_	_
37	(	-lrb-	-LRB-	_	38	p	_	_
38	0-t	0-t	NN	_	40	prn	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	values	value	NNS	_	34	conj	_	_
41	for	for	IN	_	42	case	_	_
42	MPA	mpa	NN	_	34	ppmod	_	_
43	were	be	VBD	_	1	acl	_	_
44	25	0	CD	_	49	num	_	_
45	%	%	NN	_	44	meta	_	_
46	and	and	CC	_	44	cc	_	_
47	37	0	CD	_	44	conj	_	_
48	%	%	NN	_	47	meta	_	_
49	lower	low	JJR	_	43	dep	_	_
50	,	,	,	_	43	p	_	_
51	respectively	respectively	RB	_	43	adv	_	_
52	,	,	,	_	43	p	_	_
53	than	than	IN	_	57	case	_	_
54	when	when	WRB	_	57	adv	_	_
55	drug6	drug0	NN	_	57	dep	_	_
56	was	be	VBD	_	57	aux	_	_
57	administered	administer	VBN	_	43	ppmod	_	_
58	alone	alone	RB	_	57	adv	_	_
59	under	under	IN	_	61	case	_	_
60	fasting	fasting	JJ	_	61	attr	_	_
61	conditions	condition	NNS	_	57	ppmod	_	_
62	.	.	.	_	1	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	drug1	drug0	NN	_	10	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	not	not	RB	_	10	neg	_	_
9	be	be	VB	_	10	aux	_	_
10	administered	administer	VBN	_	3	comp	_	_
11	simultaneously	simultaneously	RB	_	10	adv	_	_
12	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	4	adv	_	_
4	studied	study	VBN	_	19	advcl	_	_
5	in	in	IN	_	9	case	_	_
6	stable	stable	JJ	_	9	attr	_	_
7	renal	renal	JJ	_	9	attr	_	_
8	transplant	transplant	NN	_	9	com	_	_
9	patients	patient	NNS	_	4	ppmod	_	_
10	,	,	,	_	19	p	_	_
11	drug2	drug0	NN	_	17	attr	_	_
12	,	,	,	_	17	p	_	_
13	USP	usp	NN	_	17	attr	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	MODIFIED	modified	JJ	_	17	attr	_	_
16	)	-rrb-	-RRB-	_	17	p	_	_
17	pharmacokinetics	pharmacokinetics	NNS	_	19	dep	_	_
18	were	be	VBD	_	19	aux	_	_
19	unaffected	unaffected	VBN	_	1	acl	_	_
20	by	by	IN	_	23	case	_	_
21	steady	steady	JJ	_	23	attr	_	_
22	state	state	NN	_	23	com	_	_
23	dosing	dosing	NN	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	taken	take	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	;	;	:	_	7	p	_	_

1	however	however	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	during	during	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	period	period	NN	_	11	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	treatment	treatment	NN	_	5	ppmod	_	_
8	,	,	,	_	11	p	_	_
9	physicians	physician	NNS	_	11	dep	_	_
10	should	should	MD	_	11	modal	_	_
11	monitor	monitor	VB	_	0	root	_	_
12	blood	blood	NN	_	14	com	_	_
13	cell	cell	NN	_	14	com	_	_
14	counts	count	NNS	_	11	obj	_	_
15	.	.	.	_	11	p	_	_

1	Both	both	DT	_	2	det	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	/	/	:	_	2	p	_	_
4	drug2	drug0	NN	_	7	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	drug3	drug0	NN	_	4	conj	_	_
7	concentrations	concentration	NNS	_	9	dep	_	_
8	are	be	VBP	_	9	aux	_	_
9	increased	increase	VBN	_	20	advcl	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	presence	presence	NN	_	9	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	renal	renal	JJ	_	15	attr	_	_
15	impairment	impairment	NN	_	12	ppmod	_	_
16	,	,	,	_	20	p	_	_
17	their	their	PRP$	_	18	poss	_	_
18	coexistence	coexistence	NN	_	20	dep	_	_
19	may	may	MD	_	20	modal	_	_
20	compete	compete	VB	_	2	acl	_	_
21	for	for	IN	_	23	case	_	_
22	tubular	tubular	JJ	_	23	attr	_	_
23	secretion	secretion	NN	_	20	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	further	far	JJ	_	26	attr	_	_
26	increase	increase	NN	_	23	conj	_	_
27	in	in	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	concentrations	concentration	NNS	_	20	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	two	#crd#	CD	_	29	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	Given	given	IN	_	10	case	_	_
6	that	that	IN	_	10	mark	_	_
7	drug3	drug0	NN	_	10	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	drug4	drug0	NN	_	7	conj	_	_
10	inhibit	inhibit	VBP	_	16	ppmod	_	_
11	purine	purine	NN	_	12	com	_	_
12	metabolism	metabolism	NN	_	10	obj	_	_
13	,	,	,	_	16	p	_	_
14	it	it	PRP	_	16	dep	_	_
15	is	be	VBZ	_	16	aux	_	_
16	recommended	recommend	VBN	_	1	acl	_	_
17	that	that	IN	_	21	mark	_	_
18	drug5	drug0	NN	_	21	dep	_	_
19	not	not	RB	_	21	neg	_	_
20	be	be	VB	_	21	aux	_	_
21	administered	administer	VBN	_	16	comp	_	_
22	concomitantly	concomitantly	RB	_	21	adv	_	_
23	with	with	IN	_	24	case	_	_
24	drug6	drug0	NN	_	21	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	drug7	drug0	NN	_	24	conj	_	_
27	.	.	.	_	1	p	_	_

1	drug1	drug0	NNS	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	Drugs	drug	NNS	_	1	conj	_	_
4	that	that	WDT	_	5	dep	_	_
5	Bind	bind	VBP	_	1	relcl	_	_
6	Bile	bile	JJ	_	7	attr	_	_
7	Acids	acid	NNS	_	5	obj	_	_
8	:	:	:	_	1	p	_	_
9	These	these	DT	_	10	det	_	_
10	drugs	drug	NNS	_	11	dep	_	_
11	interrupt	interrupt	VBP	_	1	acl	_	_
12	enterohepatic	enterohepatic	JJ	_	13	attr	_	_
13	recirculation	recirculation	NN	_	11	obj	_	_
14	and	and	CC	_	11	cc	_	_
15	reduce	reduce	VBP	_	11	conj	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	exposure	exposure	NN	_	15	obj	_	_
18	when	when	WRB	_	19	adv	_	_
19	coadministered	coadministered	VBN	_	15	comp	_	_
20	with	with	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	do	do	VBP	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	administer	administer	VB	_	0	root	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	other	other	JJ	_	11	attr	_	_
11	agents	agent	NNS	_	8	conj	_	_
12	that	that	WDT	_	14	dep	_	_
13	may	may	MD	_	14	modal	_	_
14	interfere	interfere	VB	_	11	relcl	_	_
15	with	with	IN	_	17	case	_	_
16	enterohepatic	enterohepatic	JJ	_	17	attr	_	_
17	recirculation	recirculation	NN	_	14	ppmod	_	_
18	or	or	CC	_	11	cc	_	_
19	drugs	drug	NNS	_	11	conj	_	_
20	that	that	WDT	_	22	dep	_	_
21	may	may	MD	_	22	modal	_	_
22	bind	bind	VB	_	11	relcl	_	_
23	bile	bile	JJ	_	24	attr	_	_
24	acids	acid	NNS	_	22	obj	_	_
25	,	,	,	_	5	p	_	_
26	for	for	IN	_	27	case	_	_
27	example	example	NN	_	5	ppmod	_	_
28	bile	bile	JJ	_	30	attr	_	_
29	acid	acid	NN	_	30	com	_	_
30	sequestrates	sequestrates	NNS	_	27	attr	_	_
31	or	or	CC	_	27	cc	_	_
32	oral	oral	JJ	_	33	attr	_	_
33	drug3	drug0	NN	_	27	conj	_	_
34	,	,	,	_	5	p	_	_
35	because	because	IN	_	38	case	_	_
36	of	of	IN	_	38	case	_	_
37	the	the	DT	_	38	det	_	_
38	potential	potential	NN	_	5	ppmod	_	_
39	to	to	TO	_	40	aux	_	_
40	reduce	reduce	VB	_	38	acl	_	_
41	the	the	DT	_	42	det	_	_
42	efficacy	efficacy	NN	_	40	obj	_	_
43	of	of	IN	_	44	case	_	_
44	drug4	drug0	NN	_	42	ppmod	_	_
45	.	.	.	_	5	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Given	given	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	different	different	JJ	_	7	attr	_	_
7	metabolism	metabolism	NN	_	24	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	drug3	drug0	NN	_	9	conj	_	_
13	,	,	,	_	24	p	_	_
14	no	no	DT	_	16	det	_	_
15	drug	drug	NN	_	16	com	_	_
16	interaction	interaction	NN	_	24	dep	_	_
17	between	between	IN	_	20	case	_	_
18	these	these	DT	_	20	det	_	_
19	two	#crd#	CD	_	20	num	_	_
20	classes	class	NNS	_	16	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug	drug	NN	_	20	ppmod	_	_
23	is	be	VBZ	_	24	aux	_	_
24	expected	expect	VBN	_	2	acl	_	_
25	.	.	.	_	2	p	_	_

1	However	however	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	in	in	IN	_	7	case	_	_
4	a	a	DT	_	7	det	_	_
5	drug-drug	drug-drug	JJ	_	7	attr	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	study	study	NN	_	13	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	mean	mean	JJ	_	11	attr	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	AUC	auc	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	decreased	decrease	VBN	_	0	root	_	_
14	by	by	IN	_	15	case	_	_
15	15	0	CD	_	13	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	when	when	WRB	_	18	adv	_	_
18	coadministered	coadministered	VBN	_	13	comp	_	_
19	with	with	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	13	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	recommended	recommend	VBN	_	0	root	_	_
6	that	that	IN	_	9	mark	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	are	be	VBP	_	5	comp	_	_
10	co-	co-	NN	_	9	obj	_	_
11	administered	administer	VBN	_	10	acl	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	caution	caution	NN	_	11	ppmod	_	_
16	and	and	CC	_	9	cc	_	_
17	additional	additional	JJ	_	20	attr	_	_
18	birth	birth	NN	_	20	com	_	_
19	control	control	NN	_	20	com	_	_
20	methods	method	NNS	_	22	dep	_	_
21	be	be	VB	_	22	aux	_	_
22	considered	consider	VBN	_	9	conj	_	_
23	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	During	during	IN	_	4	case	_	_
4	treatment	treatment	NN	_	14	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	14	p	_	_
8	the	the	DT	_	9	det	_	_
9	use	use	NN	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	avoided	avoid	VBN	_	1	acl	_	_
15	and	and	CC	_	14	cc	_	_
16	patients	patient	NNS	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	advised	advise	VBN	_	14	conj	_	_
20	that	that	IN	_	23	mark	_	_
21	vaccinations	vaccinations	NN	_	23	dep	_	_
22	may	may	MD	_	23	modal	_	_
23	be	be	VB	_	19	comp	_	_
24	less	less	RBR	_	25	adv	_	_
25	effective	effective	JJ	_	23	dep	_	_
26	.	.	.	_	1	p	_	_

1	Influenza	influenza	NN	_	2	com	_	_
2	vaccination	vaccination	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	of	of	IN	_	6	case	_	_
6	value	value	NN	_	4	ppmod	_	_
7	.	.	.	_	4	p	_	_

1	Prescribers	prescribers	NN	_	3	dep	_	_
2	should	should	MD	_	3	modal	_	_
3	refer	refer	VBP	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	national	national	JJ	_	6	attr	_	_
6	guidelines	guideline	NNS	_	3	ppmod	_	_
7	for	for	IN	_	9	case	_	_
8	influenza	influenza	NN	_	9	com	_	_
9	vaccination	vaccination	NN	_	6	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	alter	alter	VBP	_	1	relcl	_	_
4	the	the	DT	_	6	det	_	_
5	gastrointestinal	gastrointestinal	JJ	_	6	attr	_	_
6	flora	flora	NN	_	3	obj	_	_
7	may	may	MD	_	8	modal	_	_
8	interact	interact	VB	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	by	by	IN	_	12	case	_	_
12	disrupting	disrupt	VBG	_	8	ppmod	_	_
13	enterohepatic	enterohepatic	JJ	_	14	attr	_	_
14	recirculation	recirculation	NN	_	12	obj	_	_
15	.	.	.	_	8	p	_	_

1	Interference	interference	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	hydrolysis	hydrolysis	NN	_	1	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	lead	lead	VB	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	less	less	JJR	_	9	attr	_	_
9	drug2	drug0	NNS	_	6	ppmod	_	_
10	available	available	JJ	_	9	attr	_	_
11	for	for	IN	_	12	case	_	_
12	absorption	absorption	NN	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	concomitantly	concomitantly	RB	_	4	adv	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	4	ppmod	_	_
9	commonly	commonly	RB	_	10	adv	_	_
10	used	use	VBN	_	8	acl	_	_
11	in	in	IN	_	12	case	_	_
12	COPD	copd	NN	_	10	ppmod	_	_
13	without	without	IN	_	14	case	_	_
14	increases	increase	NNS	_	10	ppmod	_	_
15	in	in	IN	_	18	case	_	_
16	adverse	adverse	JJ	_	18	attr	_	_
17	drug	drug	NN	_	18	com	_	_
18	reactions	reaction	NNS	_	14	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	dep	_	_
2	include	include	VBP	_	0	root	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	,	,	,	_	3	p	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	oral	oral	JJ	_	11	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	inhaled	inhaled	JJ	_	8	conj	_	_
11	drug3	drug0	NN	_	3	conj	_	_
12	.	.	.	_	2	p	_	_

1	However	however	RB	_	21	adv	_	_
2	,	,	,	_	21	p	_	_
3	the	the	DT	_	5	det	_	_
4	co	co	NN	_	5	com	_	_
5	administration	administration	NN	_	21	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	12	case	_	_
9	other	other	JJ	_	12	attr	_	_
10	drug2	drug0	NN	_	12	com	_	_
11	containing	containing	NN	_	12	com	_	_
12	drugs	drug	NNS	_	5	ppmod	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	e.g.	e.g.	FW	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	drug3	drug0	NNS	_	12	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	has	have	VBZ	_	21	aux	_	_
19	not	not	RB	_	21	neg	_	_
20	been	be	VBN	_	21	aux	_	_
21	studied	study	VBN	_	0	root	_	_
22	and	and	CC	_	21	cc	_	_
23	is	be	VBZ	_	26	aux	_	_
24	therefore	therefore	RB	_	26	adv	_	_
25	not	not	RB	_	26	neg	_	_
26	recommended	recommend	VBN	_	21	conj	_	_
27	.	.	.	_	21	p	_	_

1	Interaction	interaction	NN	_	9	dep	_	_
2	with	with	IN	_	6	case	_	_
3	Other	other	JJ	_	6	attr	_	_
4	drug1	drug0	NN	_	6	attr	_	_
5	:	:	:	_	6	p	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	SHOULD	should	MD	_	9	modal	_	_
8	BE	be	VB	_	9	aux	_	_
9	USED	use	VBN	_	0	root	_	_
10	WITH	with	IN	_	12	case	_	_
11	GREAT	great	JJ	_	12	attr	_	_
12	CAUTION	caution	NN	_	9	ppmod	_	_
13	AND	and	CC	_	12	cc	_	_
14	IN	in	IN	_	16	case	_	_
15	REDUCED	reduce	VBN	_	16	attr	_	_
16	DOSAGE	dosage	NN	_	12	conj	_	_
17	IN	in	IN	_	18	case	_	_
18	PATIENTS	patient	NNS	_	16	ppmod	_	_
19	WHO	who	WP	_	22	dep	_	_
20	ARE	be	VBP	_	22	aux	_	_
21	CONCURRENTLY	concurrently	RB	_	22	adv	_	_
22	RECEIVING	receive	VBG	_	18	relcl	_	_
23	OTHER	other	JJ	_	24	attr	_	_
24	drug3	drug0	NN	_	22	obj	_	_
25	,	,	,	_	24	p	_	_
26	GENERAL	general	JJ	_	27	attr	_	_
27	drug4	drug0	NN	_	24	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug5	drug0	NN	_	24	conj	_	_
30	,	,	,	_	29	p	_	_
31	OTHER	other	JJ	_	32	attr	_	_
32	drug6	drug0	NN	_	24	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug7	drug0	NN	_	24	conj	_	_
35	(	-lrb-	-LRB-	_	37	p	_	_
36	INCLUDING	include	VBG	_	37	adv	_	_
37	drug8	drug0	NN	_	34	prn	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	,	,	,	_	34	p	_	_
40	drug9	drug0	NN	_	24	conj	_	_
41	AND	and	CC	_	40	cc	_	_
42	OTHER	other	JJ	_	43	attr	_	_
43	drug10	drug0	NN	_	24	conj	_	_
44	(	-lrb-	-LRB-	_	46	p	_	_
45	INCLUDING	include	VBG	_	46	adv	_	_
46	drug11	drug0	NN	_	24	prn	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	.	.	.	_	9	p	_	_

1	RESPIRATORY	respiratory	JJ	_	2	attr	_	_
2	DEPRESSION	depression	NN	_	12	dep	_	_
3	,	,	,	_	2	p	_	_
4	HYPOTENSION	hypotension	NN	_	2	conj	_	_
5	,	,	,	_	4	p	_	_
6	AND	and	CC	_	4	cc	_	_
7	PROFOUND	profound	JJ	_	8	attr	_	_
8	SEDATION	sedation	NN	_	2	conj	_	_
9	OR	or	CC	_	8	cc	_	_
10	COMA	coma	NN	_	8	conj	_	_
11	MAY	may	MD	_	12	modal	_	_
12	RESULT	result	VB	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Drug-Drug	drug-drug	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	The	the	DT	_	8	det	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	pharmacodynamic	pharmacodynamic	JJ	_	5	conj	_	_
8	interactions	interaction	NNS	_	18	dep	_	_
9	between	between	IN	_	11	case	_	_
10	drug1	drug0	JJ	_	11	attr	_	_
11	capsules	capsule	NNS	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug2	drug0	NNS	_	11	conj	_	_
15	have	have	VBP	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	been	be	VBN	_	18	aux	_	_
18	determined	determine	VBN	_	2	acl	_	_
19	.	.	.	_	2	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	expected	expect	VBN	_	0	root	_	_
7	and	and	CC	_	6	cc	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	capsules	capsule	NNS	_	13	dep	_	_
10	should	should	MD	_	13	modal	_	_
11	NOT	not	RB	_	13	neg	_	_
12	be	be	VB	_	13	aux	_	_
13	used	use	VBN	_	6	conj	_	_
14	in	in	IN	_	15	case	_	_
15	combination	combination	NN	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	other	other	JJ	_	18	attr	_	_
18	drug2	drug0	NNS	_	15	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	10	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	capsules	capsule	NNS	_	5	conj	_	_
9	was	be	VBD	_	10	aux	_	_
10	investigated	investigate	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	changes	change	NNS	_	3	obj	_	_
6	in	in	IN	_	8	case	_	_
7	drug1	drug0	JJ	_	8	attr	_	_
8	clearance	clearance	NN	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	26	0	CD	_	12	num	_	_
11	%	%	NN	_	12	meta	_	_
12	decrease	decrease	NN	_	8	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	and	and	CC	_	8	cc	_	_
15	AUC	auc	NN	_	8	conj	_	_
16	(	-lrb-	-LRB-	_	19	p	_	_
17	44	0	CD	_	19	num	_	_
18	%	%	NN	_	19	meta	_	_
19	increase	increase	NN	_	15	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	capsules	capsule	NNS	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	caution	caution	NN	_	7	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	17	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	17	p	_	_
15	particularly	particularly	RB	_	17	adv	_	_
16	at	at	IN	_	17	case	_	_
17	doses	dose	NNS	_	7	ppmod	_	_
18	higher	high	JJR	_	17	attr	_	_
19	than	than	IN	_	21	case	_	_
20	0.4	0	CD	_	21	num	_	_
21	mg	mg	NN	_	18	ppmod	_	_
22	.	.	.	_	7	p	_	_

1	Results	result	NNS	_	16	dep	_	_
2	from	from	IN	_	11	case	_	_
3	limited	limited	JJ	_	11	attr	_	_
4	in	in	FW	_	5	adv	_	_
5	vitro	vitro	FW	_	11	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	in	in	FW	_	8	adv	_	_
8	vivo	vivo	FW	_	5	conj	_	_
9	drug-drug	drug-drug	JJ	_	11	attr	_	_
10	interaction	interaction	NN	_	11	com	_	_
11	studies	study	NNS	_	1	ppmod	_	_
12	between	between	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	are	be	VBP	_	0	root	_	_
17	inconclusive	inconclusive	JJ	_	16	dep	_	_
18	.	.	.	_	16	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	exercised	exercise	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	6	ppmod	_	_
10	of	of	IN	_	14	case	_	_
11	drug1	drug0	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	JJ	_	11	conj	_	_
14	capsules	capsule	NNS	_	9	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	9	dep	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug1	drug0	NN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	may	may	MD	_	9	modal	_	_
9	have	have	VB	_	0	root	_	_
10	an	an	DT	_	12	det	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	when	when	WRB	_	14	adv	_	_
14	given	give	VBN	_	9	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	15	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	with	with	IN	_	6	case	_	_
4	extended	extend	VBN	_	6	attr	_	_
5	release	release	NN	_	6	com	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	plus	plus	CC	_	6	cc	_	_
8	a	a	DT	_	10	det	_	_
9	catecholamine	catecholamine	NN	_	10	com	_	_
10	depletor	depletor	NN	_	6	conj	_	_
11	should	should	MD	_	15	modal	_	_
12	therefore	therefore	RB	_	15	adv	_	_
13	be	be	VB	_	15	aux	_	_
14	closely	closely	RB	_	15	adv	_	_
15	observed	observe	VBN	_	0	root	_	_
16	for	for	IN	_	17	case	_	_
17	evidence	evidence	NN	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	hypotension	hypotension	NN	_	17	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	marked	marked	JJ	_	22	attr	_	_
22	bradycardia	bradycardia	NN	_	19	conj	_	_
23	,	,	,	_	19	p	_	_
24	which	which	WDT	_	26	dep	_	_
25	may	may	MD	_	26	modal	_	_
26	produce	produce	VB	_	19	relcl	_	_
27	vertigo	vertigo	NN	_	26	obj	_	_
28	,	,	,	_	27	p	_	_
29	syncope	syncope	NN	_	27	conj	_	_
30	,	,	,	_	29	p	_	_
31	or	or	CC	_	29	cc	_	_
32	postural	postural	JJ	_	33	attr	_	_
33	hypotension	hypotension	NN	_	27	conj	_	_
34	.	.	.	_	15	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	0	root	_	_
3	contra-indicated	contra-indicated	JJ	_	2	attr	_	_
4	:	:	:	_	2	p	_	_
5	-	-	CC	_	2	cc	_	_
6	Vasoconstrictive	vasoconstrictive	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	2	conj	_	_
8	.	.	.	_	2	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administrations	administration	NNS	_	13	dep	_	_
3	not	not	RB	_	4	neg	_	_
4	recommended	recommend	VBN	_	2	acl	_	_
5	:	:	:	_	2	p	_	_
6	-	-	CC	_	7	cc	_	_
7	drug1	drug0	NN	_	2	appo	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	:	:	:	_	2	p	_	_
11	Certain	certain	JJ	_	12	attr	_	_
12	drug3	drug0	NN	_	2	appo	_	_
13	interact	interact	VBP	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug5	drug0	NN	_	15	conj	_	_
18	leading	lead	VBG	_	15	acl	_	_
19	to	to	TO	_	22	aux	_	_
20	increased	increase	VBN	_	22	attr	_	_
21	serum	serum	NN	_	22	com	_	_
22	concentrations	concentration	NNS	_	18	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	latter	latter	JJ	_	22	ppmod	_	_
26	.	.	.	_	13	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	result	result	VB	_	0	root	_	_
4	in	in	IN	_	7	case	_	_
5	severe	severe	JJ	_	7	attr	_	_
6	ventricular	ventricular	NN	_	7	com	_	_
7	arrhythmia	arrhythmia	NN	_	3	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	typically	typically	RB	_	7	adv	_	_
10	torsades	torsades	NNS	_	12	com	_	_
11	de	de	NN	_	12	com	_	_
12	pointe	pointe	NN	_	7	appo	_	_
13	.	.	.	_	3	p	_	_

1	Although	although	IN	_	8	mark	_	_
2	such	such	PDT	_	4	det	_	_
3	a	a	DT	_	4	det	_	_
4	reaction	reaction	NN	_	8	dep	_	_
5	has	have	VBZ	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	demonstrated	demonstrate	VBN	_	22	advcl	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	22	p	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	administration	administration	NN	_	22	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	with	with	IN	_	17	case	_	_
17	drug3	drug0	NN	_	13	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	drug4	drug0	NN	_	17	conj	_	_
20	is	be	VBZ	_	22	aux	_	_
21	not	not	RB	_	22	neg	_	_
22	recommended	recommend	VBN	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	drug2	drug0	NN	_	2	appo	_	_
5	:	:	:	_	2	p	_	_
6	Other	other	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	23	dep	_	_
8	such	such	JJ	_	10	adv	_	_
9	as	as	IN	_	10	case	_	_
10	drug3	drug0	NN	_	7	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	,	,	,	_	10	p	_	_
14	which	which	WDT	_	16	dep	_	_
15	are	be	VBP	_	16	aux	_	_
16	metabolised	metabolise	VBN	_	10	relcl	_	_
17	by	by	IN	_	20	case	_	_
18	hepatic	hepatic	JJ	_	20	attr	_	_
19	CYP3A	cyp0a	NN	_	20	com	_	_
20	isozymes	isozymes	NNS	_	16	ppmod	_	_
21	have	have	VBP	_	23	aux	_	_
22	been	be	VBN	_	23	aux	_	_
23	associated	associate	VBN	_	2	acl	_	_
24	with	with	IN	_	27	case	_	_
25	QT	qt	NN	_	27	com	_	_
26	interval	interval	NN	_	27	com	_	_
27	prolongation	prolongation	NN	_	23	ppmod	_	_
28	and/or	and/or	CC	_	27	cc	_	_
29	cardiac	cardiac	JJ	_	30	attr	_	_
30	arrythmias	arrythmias	NNS	_	27	conj	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	typically	typically	RB	_	35	adv	_	_
33	torsades	torsades	NNS	_	35	com	_	_
34	de	de	NN	_	35	com	_	_
35	pointe	pointe	NN	_	30	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	as	as	IN	_	39	case	_	_
38	a	a	DT	_	39	det	_	_
39	result	result	NN	_	23	ppmod	_	_
40	of	of	IN	_	41	case	_	_
41	increase	increase	NN	_	39	ppmod	_	_
42	in	in	IN	_	45	case	_	_
43	their	their	PRP$	_	45	poss	_	_
44	serum	serum	NN	_	45	com	_	_
45	level	level	NN	_	41	ppmod	_	_
46	subsequent	subsequent	JJ	_	45	attr	_	_
47	to	to	TO	_	48	aux	_	_
48	interaction	interaction	NN	_	46	ppmod	_	_
49	with	with	IN	_	51	case	_	_
50	significant	significant	JJ	_	51	attr	_	_
51	inhibitors	inhibitor	NNS	_	48	ppmod	_	_
52	of	of	IN	_	54	case	_	_
53	the	the	DT	_	54	det	_	_
54	isozyme	isozyme	NN	_	51	ppmod	_	_
55	,	,	,	_	51	p	_	_
56	including	include	VBG	_	58	adv	_	_
57	some	some	DT	_	58	det	_	_
58	drug5	drug0	NN	_	51	ppmod	_	_
59	.	.	.	_	2	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	such	such	PDT	_	4	det	_	_
3	a	a	DT	_	4	det	_	_
4	risk	risk	NN	_	7	dep	_	_
5	is	be	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	verified	verify	VBN	_	19	advcl	_	_
8	for	for	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	19	p	_	_
11	combination	combination	NN	_	19	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	such	such	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	11	ppmod	_	_
17	is	be	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	recommended	recommend	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	16	dep	_	_
5	of	of	IN	_	8	case	_	_
6	chronic	chronic	JJ	_	8	attr	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	use	use	NN	_	4	ppmod	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	4	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	are	be	VBP	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	known	know	VBN	_	1	acl	_	_
17	.	.	.	_	1	p	_	_

1	When	when	WRB	_	10	adv	_	_
2	a	a	DT	_	6	det	_	_
3	single	single	JJ	_	6	attr	_	_
4	100	0	CD	_	5	num	_	_
5	mg	mg	NN	_	6	com	_	_
6	dose	dose	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	administered	administer	VBN	_	41	advcl	_	_
11	one	#crd#	CD	_	12	num	_	_
12	hour	hour	NN	_	15	dat	_	_
13	after	after	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	initiation	initiation	NN	_	10	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	22	p	_	_
19	300	0	CD	_	22	num	_	_
20	mg	mg	NN	_	22	attr	_	_
21	four	#crd#	CD	_	22	num	_	_
22	times	time	NNS	_	10	prn	_	_
23	a	a	DT	_	24	det	_	_
24	day	day	NN	_	22	appo	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	,	,	,	_	41	p	_	_
27	the	the	DT	_	31	det	_	_
28	apparent	apparent	JJ	_	31	attr	_	_
29	total	total	JJ	_	31	attr	_	_
30	drug3	drug0	NN	_	31	com	_	_
31	clearance	clearance	NN	_	41	dep	_	_
32	of	of	IN	_	35	case	_	_
33	this	this	DT	_	35	det	_	_
34	single	single	JJ	_	35	attr	_	_
35	dose	dose	NN	_	31	ppmod	_	_
36	in	in	IN	_	39	case	_	_
37	normal	normal	JJ	_	39	attr	_	_
38	healthy	healthy	JJ	_	39	attr	_	_
39	adults	adult	NNS	_	31	ppmod	_	_
40	was	be	VBD	_	41	aux	_	_
41	reduced	reduce	VBN	_	0	root	_	_
42	by	by	IN	_	43	case	_	_
43	18	0	CD	_	41	ppmod	_	_
44	%	%	NN	_	43	meta	_	_
45	(	-lrb-	-LRB-	_	52	p	_	_
46	compared	compare	VBN	_	52	adv	_	_
47	to	to	TO	_	52	aux	_	_
48	the	the	DT	_	52	det	_	_
49	apparent	apparent	JJ	_	52	attr	_	_
50	total	total	JJ	_	52	attr	_	_
51	drug4	drug0	NN	_	52	com	_	_
52	clearance	clearance	NN	_	41	prn	_	_
53	in	in	IN	_	56	case	_	_
54	the	the	DT	_	56	det	_	_
55	same	same	JJ	_	56	attr	_	_
56	subjects	subject	NNS	_	52	ppmod	_	_
57	in	in	IN	_	59	case	_	_
58	the	the	DT	_	59	det	_	_
59	absence	absence	NN	_	52	ppmod	_	_
60	of	of	IN	_	61	case	_	_
61	drug5	drug0	NN	_	59	ppmod	_	_
62	)	-rrb-	-RRB-	_	52	p	_	_
63	.	.	.	_	41	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	100	0	CD	_	6	num	_	_
6	mg	mg	NN	_	1	appo	_	_
7	,	,	,	_	1	p	_	_
8	was	be	VBD	_	9	aux	_	_
9	given	give	VBN	_	0	root	_	_
10	twice	twice	RB	_	11	com	_	_
11	daily	daily	RB	_	9	adv	_	_
12	for	for	IN	_	14	case	_	_
13	13	0	CD	_	14	num	_	_
14	days	day	NNS	_	9	ppmod	_	_
15	to	to	TO	_	18	aux	_	_
16	12	0	CD	_	18	num	_	_
17	healthy	healthy	JJ	_	18	attr	_	_
18	volunteers	volunteer	NNS	_	9	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	On	on	IN	_	2	case	_	_
2	day	day	NN	_	14	ppmod	_	_
3	11	0	CD	_	2	num	_	_
4	,	,	,	_	14	p	_	_
5	drug1	drug0	NN	_	14	dep	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	650	0	CD	_	8	num	_	_
8	mg	mg	NN	_	5	prn	_	_
9	four	#crd#	CD	_	10	num	_	_
10	times	time	NNS	_	11	advnp	_	_
11	daily	daily	RB	_	8	adv	_	_
12	)	-rrb-	-RRB-	_	8	p	_	_
13	was	be	VBD	_	14	aux	_	_
14	started	start	VBN	_	0	root	_	_
15	and	and	CC	_	14	cc	_	_
16	continued	continue	VBN	_	14	conj	_	_
17	for	for	IN	_	19	case	_	_
18	8	0	CD	_	19	num	_	_
19	days	day	NNS	_	16	ppmod	_	_
20	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	6	aux	_	_
6	assessed	assess	VBN	_	0	root	_	_
7	on	on	IN	_	8	case	_	_
8	days	day	NNS	_	6	ppmod	_	_
9	11	0	CD	_	8	num	_	_
10	and	and	CC	_	8	cc	_	_
11	13	0	CD	_	8	conj	_	_
12	.	.	.	_	6	p	_	_

1	Coadministration	coadministration	NN	_	4	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	reduced	reduce	VBD	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	peak	peak	NN	_	7	com	_	_
7	concentration	concentration	NN	_	4	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	AUC	auc	NN	_	10	com	_	_
10	values	value	NNS	_	7	conj	_	_
11	for	for	IN	_	12	case	_	_
12	drug2	drug0	NN	_	7	ppmod	_	_
13	by	by	IN	_	15	case	_	_
14	approximately	approximately	RB	_	15	adv	_	_
15	11	0	CD	_	4	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	:	:	:	_	3	p	_	_
3	drug2	drug0	NN	_	9	dep	_	_
4	,	,	,	_	3	p	_	_
5	100	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	appo	_	_
7	,	,	,	_	3	p	_	_
8	was	be	VBD	_	9	aux	_	_
9	given	give	VBN	_	0	root	_	_
10	twice	twice	RB	_	11	adv	_	_
11	daily	daily	JJ	_	14	attr	_	_
12	fro	fro	NN	_	14	attr	_	_
13	13	0	CD	_	14	num	_	_
14	days	day	NNS	_	9	obj	_	_
15	to	to	TO	_	18	aux	_	_
16	12	0	CD	_	18	num	_	_
17	healthy	healthy	JJ	_	18	attr	_	_
18	volunteers	volunteer	NNS	_	9	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	On	on	IN	_	2	case	_	_
2	day	day	NN	_	15	ppmod	_	_
3	11	0	CD	_	2	num	_	_
4	,	,	,	_	15	p	_	_
5	drug1	drug0	NN	_	15	dep	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	650	0	CD	_	8	num	_	_
8	mg	mg	NN	_	5	prn	_	_
9	,	,	,	_	8	p	_	_
10	four	#crd#	CD	_	11	num	_	_
11	times	time	NNS	_	12	advnp	_	_
12	daily	daily	RB	_	8	adv	_	_
13	)	-rrb-	-RRB-	_	8	p	_	_
14	was	be	VBD	_	15	aux	_	_
15	started	start	VBN	_	0	root	_	_
16	and	and	CC	_	15	cc	_	_
17	continued	continue	VBN	_	15	conj	_	_
18	for	for	IN	_	20	case	_	_
19	8	0	CD	_	20	num	_	_
20	days	day	NNS	_	17	ppmod	_	_
21	.	.	.	_	15	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	6	aux	_	_
6	assessed	assess	VBN	_	0	root	_	_
7	on	on	IN	_	8	case	_	_
8	days	day	NNS	_	6	ppmod	_	_
9	11	0	CD	_	8	num	_	_
10	and	and	CC	_	8	cc	_	_
11	13	0	CD	_	8	conj	_	_
12	.	.	.	_	6	p	_	_

1	Peak	peak	NN	_	3	com	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	9	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	AUC	auc	NN	_	3	conj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	were	be	VBD	_	9	aux	_	_
9	reduced	reduce	VBN	_	0	root	_	_
10	approximately	approximately	RB	_	11	adv	_	_
11	10	0	CD	_	9	obj	_	_
12	%	%	NN	_	11	meta	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	presence	presence	NN	_	9	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	Because	because	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	shown	show	VBN	_	19	advcl	_	_
6	to	to	TO	_	7	aux	_	_
7	depress	depress	VB	_	5	comp	_	_
8	plasma	plasma	NN	_	10	com	_	_
9	prothrombin	prothrombin	NN	_	10	com	_	_
10	activity	activity	NN	_	7	obj	_	_
11	,	,	,	_	19	p	_	_
12	patients	patient	NNS	_	19	dep	_	_
13	who	who	WP	_	14	dep	_	_
14	are	be	VBP	_	12	relcl	_	_
15	on	on	IN	_	17	case	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	therapy	therapy	NN	_	14	ppmod	_	_
18	may	may	MD	_	19	modal	_	_
19	require	require	VB	_	0	root	_	_
20	downward	downward	JJ	_	21	attr	_	_
21	adjustment	adjustment	NN	_	19	obj	_	_
22	of	of	IN	_	25	case	_	_
23	their	their	PRP$	_	25	poss	_	_
24	drug3	drug0	NN	_	25	com	_	_
25	dosage	dosage	NN	_	21	ppmod	_	_
26	.	.	.	_	19	p	_	_

1	Since	since	IN	_	5	mark	_	_
2	bacteriostatic	bacteriostatic	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	interfere	interfere	VB	_	14	advcl	_	_
6	with	with	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	bactericidal	bactericidal	JJ	_	9	attr	_	_
9	action	action	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	14	p	_	_
13	it	it	PRP	_	14	dep	_	_
14	is	be	VBZ	_	0	root	_	_
15	advisable	advisable	JJ	_	14	dep	_	_
16	to	to	TO	_	17	aux	_	_
17	avoid	avoid	VB	_	15	comp	_	_
18	giving	giving	NN	_	19	com	_	_
19	drug2	drug0	NN	_	17	obj	_	_
20	in	in	IN	_	21	case	_	_
21	conjunction	conjunction	NN	_	17	ppmod	_	_
22	with	with	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	Absorption	absorption	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	is	be	VBZ	_	5	aux	_	_
5	impaired	impair	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	containing	contain	VBG	_	7	acl	_	_
9	drug3	drug0	NN	_	8	obj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	9	conj	_	_
12	or	or	CC	_	11	cc	_	_
13	drug5	drug0	NN	_	11	conj	_	_
14	,	,	,	_	11	p	_	_
15	and	and	CC	_	11	cc	_	_
16	drug6	drug0	NN	_	18	attr	_	_
17	-containing	-containing	JJ	_	18	attr	_	_
18	preparations	preparation	NNS	_	9	conj	_	_
19	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	result	result	VB	_	10	comp	_	_
13	in	in	IN	_	16	case	_	_
14	fatal	fatal	JJ	_	16	attr	_	_
15	renal	renal	JJ	_	16	attr	_	_
16	toxicity	toxicity	NN	_	12	ppmod	_	_
17	.	.	.	_	10	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	render	render	VB	_	0	root	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	drug3	drug0	NN	_	9	obj	_	_
12	less	less	RBR	_	13	adv	_	_
13	effective	effective	JJ	_	11	attr	_	_
14	.	.	.	_	9	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	no	no	DT	_	8	det	_	_
5	formal	formal	JJ	_	8	attr	_	_
6	drug	drug	NN	_	8	com	_	_
7	interaction	interaction	NN	_	8	com	_	_
8	studies	study	NNS	_	3	obj	_	_
9	performed	performed	VBN	_	8	acl	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	humans	human	NNS	_	9	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	Administration	administration	NN	_	8	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	combination	combination	NN	_	1	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	resulted	result	VBD	_	0	root	_	_
9	in	in	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	two-fold	two-fold	JJ	_	12	attr	_	_
12	decrease	decrease	NN	_	8	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	clearance	clearance	NN	_	12	ppmod	_	_
16	in	in	IN	_	20	case	_	_
17	a	a	DT	_	20	det	_	_
18	non-human	non-human	JJ	_	20	attr	_	_
19	primate	primate	JJ	_	20	attr	_	_
20	study	study	NN	_	15	ppmod	_	_
21	and	and	CC	_	12	cc	_	_
22	in	in	IN	_	25	case	_	_
23	a	a	DT	_	25	det	_	_
24	1.5-fold	0-fold	JJ	_	25	attr	_	_
25	increase	increase	NN	_	12	conj	_	_
26	in	in	IN	_	29	case	_	_
27	drug4	drug0	NN	_	29	com	_	_
28	serum	serum	NN	_	29	com	_	_
29	levels	level	NNS	_	25	ppmod	_	_
30	in	in	IN	_	32	case	_	_
31	clinical	clinical	JJ	_	32	attr	_	_
32	studies	study	NNS	_	29	ppmod	_	_
33	.	.	.	_	8	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	22	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	3	ppmod	_	_
9	that	that	WDT	_	10	dep	_	_
10	produce	produce	VBP	_	8	relcl	_	_
11	dry	dry	JJ	_	12	attr	_	_
12	mouth	mouth	NN	_	10	obj	_	_
13	,	,	,	_	12	p	_	_
14	constipation	constipation	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	other	other	JJ	_	20	attr	_	_
18	anticholinergic	anticholinergic	JJ	_	20	attr	_	_
19	pharmacological	pharmacological	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	12	conj	_	_
21	may	may	MD	_	22	modal	_	_
22	increase	increase	VB	_	0	root	_	_
23	the	the	DT	_	24	det	_	_
24	frequency	frequency	NN	_	22	obj	_	_
25	and/or	and/or	CC	_	24	cc	_	_
26	severity	severity	NN	_	24	conj	_	_
27	of	of	IN	_	29	case	_	_
28	such	such	JJ	_	29	attr	_	_
29	effects	effect	NNS	_	24	ppmod	_	_
30	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	potentially	potentially	RB	_	4	adv	_	_
4	alter	alter	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	absorption	absorption	NN	_	4	obj	_	_
7	of	of	IN	_	11	case	_	_
8	some	some	DT	_	11	det	_	_
9	concomitantly	concomitantly	RB	_	10	adv	_	_
10	administered	administer	VBN	_	11	attr	_	_
11	drugs	drug	NNS	_	6	ppmod	_	_
12	due	due	JJ	_	11	attr	_	_
13	to	to	TO	_	15	aux	_	_
14	anticholinergic	anticholinergic	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	12	ppmod	_	_
16	on	on	IN	_	18	case	_	_
17	gastrointestinal	gastrointestinal	JJ	_	18	attr	_	_
18	motility	motility	NN	_	15	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Eliminated	eliminate	VBN	_	22	advcl	_	_
3	by	by	IN	_	6	case	_	_
4	Active	active	JJ	_	6	attr	_	_
5	Tubular	tubular	JJ	_	6	attr	_	_
6	Secretion	secretion	NN	_	2	ppmod	_	_
7	:	:	:	_	22	p	_	_
8	Although	although	IN	_	19	mark	_	_
9	studies	study	NNS	_	19	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	assess	assess	VB	_	9	acl	_	_
12	drug-drug	drug-drug	JJ	_	13	attr	_	_
13	interactions	interaction	NNS	_	11	obj	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	have	have	VBP	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	been	be	VBN	_	19	aux	_	_
19	conducted	conduct	VBN	_	22	advcl	_	_
20	,	,	,	_	22	p	_	_
21	drug2	drug0	NN	_	22	dep	_	_
22	has	have	VBZ	_	0	root	_	_
23	the	the	DT	_	24	det	_	_
24	potential	potential	NN	_	22	obj	_	_
25	for	for	IN	_	27	case	_	_
26	pharmacokinetic	pharmacokinetic	JJ	_	27	attr	_	_
27	interactions	interaction	NNS	_	24	ppmod	_	_
28	with	with	IN	_	30	case	_	_
29	other	other	JJ	_	30	attr	_	_
30	drugs	drug	NNS	_	27	ppmod	_	_
31	that	that	WDT	_	33	dep	_	_
32	are	be	VBP	_	33	aux	_	_
33	eliminated	eliminate	VBN	_	30	relcl	_	_
34	by	by	IN	_	37	case	_	_
35	active	active	JJ	_	37	attr	_	_
36	tubular	tubular	JJ	_	37	attr	_	_
37	secretion	secretion	NN	_	33	ppmod	_	_
38	(	-lrb-	-LRB-	_	40	p	_	_
39	e.g.	e.g.	FW	_	40	ppmod	_	_
40	drug3	drug0	NN	_	37	prn	_	_
41	,	,	,	_	40	p	_	_
42	drug4	drug0	NN	_	40	conj	_	_
43	,	,	,	_	42	p	_	_
44	drug5	drug0	NN	_	40	conj	_	_
45	,	,	,	_	44	p	_	_
46	drug6	drug0	NN	_	40	conj	_	_
47	,	,	,	_	46	p	_	_
48	drug7	drug0	NN	_	40	conj	_	_
49	,	,	,	_	48	p	_	_
50	drug8	drug0	NN	_	40	conj	_	_
51	and	and	CC	_	50	cc	_	_
52	drug9	drug0	NN	_	40	conj	_	_
53	)	-rrb-	-RRB-	_	40	p	_	_
54	.	.	.	_	22	p	_	_

1	Coadministration	coadministration	NN	_	15	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drugs	drug	NNS	_	1	ppmod	_	_
6	that	that	WDT	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	eliminated	eliminate	VBN	_	5	relcl	_	_
9	by	by	IN	_	13	case	_	_
10	active	active	JJ	_	13	attr	_	_
11	renal	renal	JJ	_	13	attr	_	_
12	tubular	tubular	JJ	_	13	attr	_	_
13	secretion	secretion	NN	_	8	ppmod	_	_
14	may	may	MD	_	15	modal	_	_
15	increase	increase	VB	_	0	root	_	_
16	the	the	DT	_	18	det	_	_
17	serum	serum	NN	_	18	com	_	_
18	concentration	concentration	NN	_	15	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	and/or	and/or	CC	_	20	cc	_	_
22	the	the	DT	_	24	det	_	_
23	coadministered	coadministered	JJ	_	24	attr	_	_
24	drug	drug	NN	_	20	conj	_	_
25	due	due	IN	_	27	case	_	_
26	to	to	TO	_	27	aux	_	_
27	competition	competition	NN	_	15	ppmod	_	_
28	for	for	IN	_	31	case	_	_
29	this	this	DT	_	31	det	_	_
30	elimination	elimination	NN	_	31	com	_	_
31	pathway	pathway	NN	_	27	ppmod	_	_
32	.	.	.	_	15	p	_	_

1	Careful	careful	JJ	_	3	attr	_	_
2	patient	patient	NN	_	3	com	_	_
3	monitoring	monitoring	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	recommended	recommend	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	such	such	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	8	obj	_	_
11	.	.	.	_	5	p	_	_

1	Drug-Laboratory-Test	drug-laboratory-test	JJ	_	3	attr	_	_
2	Interactions	interaction	NNS	_	3	com	_	_
3	Interactions	interaction	NNS	_	12	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	laboratory	laboratory	NN	_	8	com	_	_
8	tests	test	NNS	_	5	conj	_	_
9	have	have	VBP	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	studied	study	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	administering	administer	VBG	_	4	ppmod	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	or	or	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	because	because	IN	_	23	mark	_	_
15	the	the	DT	_	17	det	_	_
16	extrapyramidal	extrapyramidal	JJ	_	17	attr	_	_
17	effects	effect	NNS	_	23	dep	_	_
18	of	of	IN	_	20	case	_	_
19	these	these	DT	_	20	det	_	_
20	drugs	drug	NNS	_	17	ppmod	_	_
21	can	can	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	expected	expect	VBN	_	11	acl	_	_
24	to	to	TO	_	26	aux	_	_
25	be	be	VB	_	26	aux	_	_
26	potentiated	potentiate	VBN	_	23	comp	_	_
27	by	by	IN	_	28	case	_	_
28	inhibition	inhibition	NN	_	26	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	catecholamine	catecholamine	NN	_	31	com	_	_
31	synthesis	synthesis	NN	_	28	ppmod	_	_
32	.	.	.	_	4	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug3	drug0	NN	_	6	conj	_	_
10	can	can	MD	_	11	modal	_	_
11	increase	increase	VB	_	0	root	_	_
12	their	their	PRP$	_	14	poss	_	_
13	sedative	sedative	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	11	obj	_	_
15	.	.	.	_	11	p	_	_

1	You	you	NN	_	3	dep	_	_
2	cannot	cannot	MD	_	3	modal	_	_
3	take	take	VB	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	if	if	IN	_	8	mark	_	_
6	you	you	RB	_	8	adv	_	_
7	have	have	VBP	_	8	aux	_	_
8	taken	take	VBN	_	3	comp	_	_
9	a	a	DT	_	10	det	_	_
10	drug2	drug0	NN	_	8	obj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug3	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	drug4	drug0	NN	_	10	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug5	drug0	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	,	,	,	_	16	p	_	_
21	drug6	drug0	NN	_	16	conj	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	drug7	drug0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	21	p	_	_
26	or	or	CC	_	21	cc	_	_
27	drug8	drug0	NN	_	16	conj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	drug9	drug0	NN	_	27	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	in	in	IN	_	35	case	_	_
32	the	the	DT	_	35	det	_	_
33	last	last	JJ	_	35	attr	_	_
34	14	0	CD	_	35	num	_	_
35	days	day	NNS	_	8	ppmod	_	_
36	.	.	.	_	3	p	_	_

1	Changes	change	NNS	_	10	dep	_	_
2	in	in	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	8	attr	_	_
6	diabetes	diabetes	NN	_	8	com	_	_
7	drug	drug	NN	_	8	com	_	_
8	therapies	therapy	NNS	_	3	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	be	be	VB	_	0	root	_	_
11	necessary	necessary	JJ	_	10	dep	_	_
12	during	during	IN	_	13	case	_	_
13	treatment	treatment	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	reduce	reduce	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug3	drug0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	.	.	.	_	3	p	_	_

1	This	this	DT	_	3	dep	_	_
2	could	could	MD	_	3	modal	_	_
3	lead	lead	VB	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	an	an	DT	_	6	det	_	_
6	increase	increase	NN	_	3	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	blood	blood	NN	_	9	com	_	_
9	pressure	pressure	NN	_	6	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	Tell	tell	NN	_	3	com	_	_
2	your	your	NN	_	3	com	_	_
3	doctor	doctor	NN	_	7	dep	_	_
4	if	if	IN	_	5	case	_	_
5	you	you	NN	_	3	ppmod	_	_
6	are	be	VBP	_	7	aux	_	_
7	taking	take	VBG	_	0	root	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	.	.	.	_	7	p	_	_

1	Before	before	IN	_	4	case	_	_
2	taking	take	VBG	_	4	lv	_	_
3	this	this	DT	_	4	det	_	_
4	medication	medication	NN	_	0	root	_	_
5	,	,	,	_	4	p	_	_
6	tell	tell	NN	_	8	com	_	_
7	your	your	NN	_	8	com	_	_
8	doctor	doctor	NN	_	12	dep	_	_
9	if	if	IN	_	10	case	_	_
10	you	you	NN	_	8	ppmod	_	_
11	are	be	VBP	_	12	aux	_	_
12	taking	take	VBG	_	4	acl	_	_
13	a	a	DT	_	14	det	_	_
14	drug1	drug0	NN	_	12	obj	_	_
15	such	such	JJ	_	14	attr	_	_
16	as	as	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	drug3	drug0	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	,	,	,	_	17	p	_	_
22	drug4	drug0	NN	_	17	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug5	drug0	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	22	p	_	_
27	drug6	drug0	NN	_	17	conj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	drug7	drug0	NN	_	27	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	,	,	,	_	27	p	_	_
32	drug8	drug0	NN	_	17	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	drug9	drug0	NN	_	32	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	,	,	,	_	32	p	_	_
37	drug10	drug0	NN	_	17	conj	_	_
38	(	-lrb-	-LRB-	_	37	p	_	_
39	drug11	drug0	CD	_	37	num	_	_
40	)	-rrb-	-RRB-	_	37	p	_	_
41	,	,	,	_	37	p	_	_
42	drug12	drug0	NN	_	17	conj	_	_
43	(	-lrb-	-LRB-	_	42	p	_	_
44	drug13	drug0	CD	_	42	num	_	_
45	)	-rrb-	-RRB-	_	42	p	_	_
46	,	,	,	_	42	p	_	_
47	drug14	drug0	NN	_	17	conj	_	_
48	(	-lrb-	-LRB-	_	47	p	_	_
49	drug15	drug0	CD	_	47	num	_	_
50	)	-rrb-	-RRB-	_	47	p	_	_
51	,	,	,	_	47	p	_	_
52	or	or	CC	_	47	cc	_	_
53	drug16	drug0	NN	_	17	conj	_	_
54	(	-lrb-	-LRB-	_	53	p	_	_
55	drug17	drug0	CD	_	53	num	_	_
56	)	-rrb-	-RRB-	_	53	p	_	_
57	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	decrease	decrease	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	accelerate	accelerate	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	metabolism	metabolism	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	by	by	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	mechanism	mechanism	NN	_	6	ppmod	_	_
14	of	of	IN	_	18	case	_	_
15	hepatic	hepatic	JJ	_	18	attr	_	_
16	microsomal	microsomal	JJ	_	18	attr	_	_
17	enzyme	enzyme	NN	_	18	com	_	_
18	induction	induction	NN	_	13	ppmod	_	_
19	,	,	,	_	6	p	_	_
20	leading	lead	VBG	_	6	comp	_	_
21	to	to	TO	_	23	aux	_	_
22	an	an	DT	_	23	det	_	_
23	increase	increase	NN	_	20	ppmod	_	_
24	in	in	IN	_	26	case	_	_
25	dosage	dosage	NN	_	26	com	_	_
26	requirements	requirement	NNS	_	23	ppmod	_	_
27	for	for	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	physicians	physician	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	closely	closely	RB	_	6	adv	_	_
6	monitor	monitor	VB	_	0	root	_	_
7	patients	patient	NNS	_	6	obj	_	_
8	for	for	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	change	change	NN	_	7	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	drug1	drug0	NN	_	14	com	_	_
13	dosage	dosage	NN	_	14	com	_	_
14	requirements	requirement	NNS	_	10	ppmod	_	_
15	when	when	WRB	_	16	adv	_	_
16	administering	administer	VBG	_	6	comp	_	_
17	drug2	drug0	NN	_	16	obj	_	_
18	to	to	TO	_	19	aux	_	_
19	patients	patient	NNS	_	16	ppmod	_	_
20	on	on	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	given	give	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	caution	caution	NN	_	7	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	patients	patient	NNS	_	7	ppmod	_	_
12	receiving	receive	VBG	_	11	acl	_	_
13	other	other	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	12	obj	_	_
15	susceptible	susceptible	JJ	_	14	attr	_	_
16	to	to	TO	_	18	aux	_	_
17	the	the	DT	_	18	det	_	_
18	influence	influence	NN	_	15	ppmod	_	_
19	of	of	IN	_	22	case	_	_
20	hepatic	hepatic	JJ	_	22	attr	_	_
21	enzyme	enzyme	NN	_	22	com	_	_
22	induction	induction	NN	_	18	ppmod	_	_
23	.	.	.	_	7	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	-containing	-containing	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	cause	cause	VB	_	6	comp	_	_
9	prolonged	prolonged	JJ	_	11	attr	_	_
10	vasospastic	vasospastic	JJ	_	11	attr	_	_
11	reactions	reaction	NNS	_	8	obj	_	_
12	.	.	.	_	6	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	is	be	VBZ	_	36	advcl	_	_
4	a	a	DT	_	6	det	_	_
5	theoretical	theoretical	JJ	_	6	attr	_	_
6	basis	basis	NN	_	3	obj	_	_
7	that	that	IN	_	11	mark	_	_
8	these	these	DT	_	9	det	_	_
9	effects	effect	NNS	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	be	be	VB	_	6	acl	_	_
12	additive	additive	JJ	_	11	dep	_	_
13	,	,	,	_	36	p	_	_
14	use	use	NN	_	36	dep	_	_
15	of	of	IN	_	19	case	_	_
16	drug1	drug0	JJ	_	17	adv	_	_
17	-containing	-containing	JJ	_	19	attr	_	_
18	or	or	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	14	ppmod	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	like	like	IN	_	22	case	_	_
22	drug3	drug0	NN	_	19	prn	_	_
23	or	or	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	and	and	CC	_	19	cc	_	_
27	drug5	drug0	NN	_	19	conj	_	_
28	within	within	IN	_	30	case	_	_
29	24	0	CD	_	30	num	_	_
30	hours	hour	NNS	_	14	ppmod	_	_
31	of	of	IN	_	33	case	_	_
32	each	each	DT	_	33	det	_	_
33	other	other	JJ	_	30	ppmod	_	_
34	should	should	MD	_	36	modal	_	_
35	be	be	VB	_	36	aux	_	_
36	avoided	avoid	VBN	_	0	root	_	_
37	.	.	.	_	36	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduce	reduce	VBP	_	0	root	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	clearance	clearance	NN	_	2	obj	_	_
5	,	,	,	_	2	p	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	increasing	increase	VBG	_	2	comp	_	_
8	systemic	systemic	JJ	_	9	attr	_	_
9	exposure	exposure	NN	_	7	obj	_	_
10	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	the	the	DT	_	4	det	_	_
4	use	use	NN	_	13	dep	_	_
5	of	of	IN	_	7	case	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	tablets	tablet	NNS	_	4	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	is	be	VBZ	_	13	aux	_	_
13	contraindicated	contraindicate	VBN	_	32	advcl	_	_
14	.	.	.	_	13	p	_	_
15	drug3	drug0	NN	_	32	dep	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug4	drug0	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	e.g.	e.g.	FW	_	22	ppmod	_	_
21	,	,	,	_	22	p	_	_
22	drug5	drug0	NN	_	15	prn	_	_
23	,	,	,	_	22	p	_	_
24	drug6	drug0	NN	_	22	appo	_	_
25	,	,	,	_	22	p	_	_
26	drug7	drug0	NN	_	22	appo	_	_
27	,	,	,	_	22	p	_	_
28	drug8	drug0	NN	_	22	appo	_	_
29	)	-rrb-	-RRB-	_	22	p	_	_
30	have	have	VBP	_	32	aux	_	_
31	been	be	VBN	_	32	aux	_	_
32	reported	report	VBN	_	0	root	_	_
33	,	,	,	_	32	p	_	_
34	rarely	rarely	RB	_	32	adv	_	_
35	,	,	,	_	32	p	_	_
36	to	to	TO	_	37	aux	_	_
37	cause	cause	VB	_	32	comp	_	_
38	weakness	weakness	NN	_	37	obj	_	_
39	,	,	,	_	38	p	_	_
40	hyperreflexia	hyperreflexia	NN	_	38	conj	_	_
41	,	,	,	_	40	p	_	_
42	and	and	CC	_	40	cc	_	_
43	incoordination	incoordination	NN	_	38	conj	_	_
44	when	when	WRB	_	45	adv	_	_
45	coadministered	coadministered	VBN	_	37	comp	_	_
46	with	with	IN	_	47	case	_	_
47	drug9	drug0	NN	_	45	ppmod	_	_
48	.	.	.	_	32	p	_	_

1	If	if	IN	_	11	mark	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	treatment	treatment	NN	_	11	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	an	an	DT	_	8	det	_	_
8	drug2	drug0	NN	_	5	conj	_	_
9	is	be	VBZ	_	11	aux	_	_
10	clinically	clinically	RB	_	11	adv	_	_
11	warranted	warrant	VBN	_	19	advcl	_	_
12	,	,	,	_	19	p	_	_
13	appropriate	appropriate	JJ	_	14	attr	_	_
14	observation	observation	NN	_	19	dep	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	patient	patient	NN	_	14	ppmod	_	_
18	is	be	VBZ	_	19	aux	_	_
19	advised	advise	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	The	the	DT	_	2	det	_	_
2	bioavailability	bioavailability	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	decreased	decrease	VBN	_	0	root	_	_
7	80	0	CD	_	6	obj	_	_
8	%	%	NN	_	7	meta	_	_
9	by	by	IN	_	10	case	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	when	when	WRB	_	17	adv	_	_
13	drug3	drug0	NN	_	17	dep	_	_
14	and	and	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	13	conj	_	_
16	are	be	VBP	_	17	aux	_	_
17	administered	administer	VBN	_	10	relcl	_	_
18	at	at	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	same	same	JJ	_	21	attr	_	_
21	time	time	NN	_	17	ppmod	_	_
22	,	,	,	_	10	p	_	_
23	and	and	CC	_	7	cc	_	_
24	60	0	CD	_	7	conj	_	_
25	%	%	NN	_	24	meta	_	_
26	by	by	IN	_	28	case	_	_
27	some	some	DT	_	28	det	_	_
28	drug5	drug0	NN	_	6	ppmod	_	_
29	-	-	:	_	28	p	_	_
30	or	or	CC	_	28	cc	_	_
31	drug6	drug0	NN	_	33	attr	_	_
32	-containing	-containing	JJ	_	33	attr	_	_
33	drug7	drug0	NN	_	28	conj	_	_
34	,	,	,	_	6	p	_	_
35	when	when	WRB	_	36	adv	_	_
36	administered	administer	VBN	_	6	comp	_	_
37	1	0	CD	_	38	num	_	_
38	hour	hour	NN	_	40	dat	_	_
39	before	before	IN	_	40	case	_	_
40	drug8	drug0	NN	_	36	ppmod	_	_
41	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	bioavailability	bioavailability	NN	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	by	by	IN	_	10	case	_	_
8	up	up	RB	_	10	adv	_	_
9	to	to	TO	_	10	attr	_	_
10	50	0	CD	_	4	ppmod	_	_
11	%	%	NN	_	10	meta	_	_
12	when	when	WRB	_	13	adv	_	_
13	taken	take	VBN	_	3	comp	_	_
14	2	0	CD	_	15	num	_	_
15	hours	hour	NNS	_	17	dat	_	_
16	after	after	IN	_	17	case	_	_
17	drug3	drug0	NN	_	13	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	bioavailability	bioavailability	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	increased	increase	VBN	_	0	root	_	_
7	2-4	0	CD	_	8	num	_	_
8	fold	fold	NN	_	6	obj	_	_
9	by	by	IN	_	10	case	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	but	but	CC	_	6	cc	_	_
12	is	be	VBZ	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	significantly	significantly	RB	_	15	adv	_	_
15	altered	alter	VBN	_	6	conj	_	_
16	by	by	IN	_	17	case	_	_
17	coadministration	coadministration	NN	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	parameters	parameter	NNS	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	are	be	VBP	_	9	aux	_	_
7	not	not	RB	_	9	neg	_	_
8	significantly	significantly	RB	_	9	adv	_	_
9	modified	modify	VBN	_	0	root	_	_
10	by	by	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	coadministration	coadministration	NN	_	9	ppmod	_	_
13	.	.	.	_	9	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	show	show	VBP	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	drug1	drug0	NN	_	9	dep	_	_
7	does	do	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	displace	displace	VB	_	4	comp	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	from	from	IN	_	14	case	_	_
12	its	its	PRP$	_	14	poss	_	_
13	binding	bind	VBG	_	14	attr	_	_
14	site	site	NN	_	9	ppmod	_	_
15	on	on	IN	_	16	case	_	_
16	protein	protein	NN	_	14	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	usually	usually	RB	_	2	adv	_	_
4	complete	complete	JJ	_	5	attr	_	_
5	cross-resistance	cross-resistance	NN	_	2	obj	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug2	drug0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	and	and	CC	_	7	cc	_	_
12	drug3	drug0	NN	_	14	com	_	_
13	brand	brand	NN	_	14	com	_	_
14	drug4	drug0	NNS	_	7	conj	_	_
15	.	.	.	_	2	p	_	_

1	As	as	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	is	be	VBZ	_	27	advcl	_	_
4	in	in	FW	_	5	adv	_	_
5	vitro	vitro	FW	_	6	attr	_	_
6	evidence	evidence	NN	_	3	obj	_	_
7	that	that	IN	_	19	mark	_	_
8	drug1	drug0	NN	_	19	dep	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	e.g.	e.g.	FW	_	12	adv	_	_
11	,	,	,	_	12	p	_	_
12	drug2	drug0	NN	_	8	prn	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	drug4	drug0	NN	_	12	conj	_	_
18	)	-rrb-	-RRB-	_	12	p	_	_
19	inhibit	inhibit	VBP	_	6	acl	_	_
20	the	the	DT	_	22	det	_	_
21	TPMT	tpmt	NN	_	22	com	_	_
22	enzyme	enzyme	NN	_	19	obj	_	_
23	,	,	,	_	27	p	_	_
24	they	they	PRP	_	27	dep	_	_
25	should	should	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	administered	administer	VBN	_	0	root	_	_
28	with	with	IN	_	29	case	_	_
29	caution	caution	NN	_	27	ppmod	_	_
30	to	to	TO	_	31	aux	_	_
31	patients	patient	NNS	_	27	ppmod	_	_
32	receiving	receive	VBG	_	31	acl	_	_
33	concurrent	concurrent	JJ	_	35	attr	_	_
34	drug5	drug0	NN	_	35	com	_	_
35	therapy	therapy	NN	_	32	obj	_	_
36	.	.	.	_	27	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	eye	eye	NN	_	3	com	_	_
3	drops	drops	NN	_	20	dep	_	_
4	or	or	CC	_	3	cc	_	_
5	medications	medication	NNS	_	3	conj	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	3	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug2	drug0	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	and	and	CC	_	8	cc	_	_
13	drug3	drug0	NN	_	8	conj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug4	drug0	NN	_	13	prn	_	_
16	,	,	,	_	15	p	_	_
17	drug5	drug0	NN	_	15	appo	_	_
18	)	-rrb-	-RRB-	_	15	p	_	_
19	may	may	MD	_	20	modal	_	_
20	decrease	decrease	VB	_	0	root	_	_
21	the	the	DT	_	22	det	_	_
22	effects	effect	NNS	_	20	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug6	drug0	NN	_	22	ppmod	_	_
25	ophthalmic	ophthalmic	JJ	_	24	attr	_	_
26	.	.	.	_	20	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	particularly	particularly	RB	_	1	adv	_	_
4	drug2	drug0	NN	_	1	appo	_	_
5	,	,	,	_	1	p	_	_
6	may	may	MD	_	7	modal	_	_
7	cause	cause	VB	_	0	root	_	_
8	serious	serious	JJ	_	10	attr	_	_
9	cardiac	cardiac	JJ	_	10	attr	_	_
10	arrhythmias	arrhythmia	NNS	_	7	obj	_	_
11	during	during	IN	_	13	case	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	anesthesia	anesthesia	NN	_	7	ppmod	_	_
14	and	and	CC	_	7	cc	_	_
15	therefore	therefore	RB	_	18	adv	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	used	use	VBN	_	7	conj	_	_
19	only	only	RB	_	22	adv	_	_
20	with	with	IN	_	22	case	_	_
21	great	great	JJ	_	22	attr	_	_
22	caution	caution	NN	_	18	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	not	not	RB	_	26	neg	_	_
25	at	at	IN	_	26	case	_	_
26	all	all	NN	_	22	conj	_	_
27	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	pressor	pressor	JJ	_	5	attr	_	_
5	effect	effect	NN	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	is	be	VBZ	_	10	aux	_	_
9	markedly	markedly	RB	_	10	adv	_	_
10	potentiated	potentiate	VBN	_	1	acl	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	drug3	drug0	NN	_	13	obj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	drug4	drug0	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	when	when	WRB	_	4	adv	_	_
4	initiating	initiate	VBG	_	15	advcl	_	_
5	pressor	pressor	NN	_	6	com	_	_
6	therapy	therapy	NN	_	4	obj	_	_
7	in	in	IN	_	9	case	_	_
8	these	these	DT	_	9	det	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	,	,	,	_	15	p	_	_
11	the	the	DT	_	13	det	_	_
12	initial	initial	JJ	_	13	attr	_	_
13	dose	dose	NN	_	15	dep	_	_
14	should	should	MD	_	15	modal	_	_
15	be	be	VB	_	0	root	_	_
16	small	small	JJ	_	15	dep	_	_
17	and	and	CC	_	15	cc	_	_
18	used	use	VBD	_	15	conj	_	_
19	with	with	IN	_	21	case	_	_
20	due	due	JJ	_	21	attr	_	_
21	caution	caution	NN	_	18	ppmod	_	_
22	.	.	.	_	15	p	_	_

1	The	the	DT	_	3	det	_	_
2	pressor	pressor	JJ	_	3	attr	_	_
3	response	response	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	9	modal	_	_
7	also	also	RB	_	9	adv	_	_
8	be	be	VB	_	9	aux	_	_
9	potentiated	potentiate	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	expected	expect	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	inhibit	inhibit	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	clearance	clearance	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drugs	drug	NNS	_	8	ppmod	_	_
11	metabolized	metabolize	VBN	_	10	acl	_	_
12	by	by	IN	_	15	case	_	_
13	cytochrome	cytochrome	NN	_	15	com	_	_
14	P450	p0	NN	_	15	com	_	_
15	enzymes	enzyme	NNS	_	11	ppmod	_	_
16	CYP1A2	cyp0a0	NN	_	15	appo	_	_
17	,	,	,	_	16	p	_	_
18	CYP2A6	cyp0a0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	CYP2B6	cyp0b0	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	CYP2C8	cyp0c0	NN	_	16	conj	_	_
23	,	,	,	_	22	p	_	_
24	CYP2C9	cyp0c0	NN	_	16	conj	_	_
25	,	,	,	_	24	p	_	_
26	CYP2C19	cyp0c0	NN	_	16	conj	_	_
27	,	,	,	_	26	p	_	_
28	CYP2D6	cyp0d0	NN	_	29	com	_	_
29	CYP2E1	cyp0e0	NN	_	16	conj	_	_
30	or	or	CC	_	29	cc	_	_
31	CYP3A	cyp0a	NN	_	16	conj	_	_
32	nor	nor	CC	_	6	cc	_	_
33	induce	induce	VB	_	6	conj	_	_
34	the	the	DT	_	35	det	_	_
35	clearance	clearance	NN	_	33	obj	_	_
36	of	of	IN	_	37	case	_	_
37	drugs	drug	NNS	_	35	ppmod	_	_
38	metabolized	metabolize	VBN	_	37	acl	_	_
39	by	by	IN	_	40	case	_	_
40	CYP2B6	cyp0b0	NN	_	38	ppmod	_	_
41	,	,	,	_	40	p	_	_
42	CYP2C9	cyp0c0	NN	_	40	conj	_	_
43	or	or	CC	_	42	cc	_	_
44	CYP3A	cyp0a	NN	_	40	conj	_	_
45	.	.	.	_	4	p	_	_

1	A	a	DT	_	6	det	_	_
2	multiple	multiple	JJ	_	6	attr	_	_
3	dose	dose	NN	_	6	attr	_	_
4	drug-drug	drug-drug	JJ	_	6	attr	_	_
5	interaction	interaction	NN	_	6	com	_	_
6	study	study	NN	_	7	dep	_	_
7	demonstrated	demonstrate	VBD	_	0	root	_	_
8	that	that	IN	_	11	mark	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	approximately	approximately	RB	_	11	adv	_	_
11	doubled	double	VBD	_	7	comp	_	_
12	drug2	drug0	NN	_	11	obj	_	_
13	AUC0-	auc0-	CD	_	12	num	_	_
14	.	.	.	_	11	p	_	_
15	Since	since	IN	_	19	mark	_	_
16	drug3	drug0	NN	_	19	dep	_	_
17	is	be	VBZ	_	19	aux	_	_
18	partially	partially	RB	_	19	adv	_	_
19	metabolized	metabolize	VBN	_	7	advcl	_	_
20	by	by	IN	_	21	case	_	_
21	CYP3A	cyp0a	NN	_	19	ppmod	_	_
22	and	and	CC	_	19	cc	_	_
23	drug4	drug0	NN	_	24	com	_	_
24	le	le	NN	_	26	dep	_	_
25	is	be	VBZ	_	26	aux	_	_
26	known	know	VBN	_	19	conj	_	_
27	to	to	TO	_	28	aux	_	_
28	be	be	VB	_	26	comp	_	_
29	a	a	DT	_	31	det	_	_
30	strong	strong	JJ	_	31	attr	_	_
31	inhibitor	inhibitor	NN	_	28	obj	_	_
32	of	of	IN	_	36	case	_	_
33	cytochrome	cytochrome	NN	_	36	com	_	_
34	P450	p0	NN	_	36	com	_	_
35	3A	0a	NN	_	36	com	_	_
36	enzyme	enzyme	NN	_	31	ppmod	_	_
37	,	,	,	_	36	p	_	_
38	care	care	NN	_	41	dep	_	_
39	should	should	MD	_	41	modal	_	_
40	be	be	VB	_	41	aux	_	_
41	taken	take	VBN	_	36	acl	_	_
42	while	while	IN	_	44	case	_	_
43	dosing	dosing	NN	_	44	com	_	_
44	drug5	drug0	NN	_	41	ppmod	_	_
45	with	with	IN	_	46	case	_	_
46	drug6	drug0	NN	_	44	ppmod	_	_
47	and	and	CC	_	46	cc	_	_
48	other	other	JJ	_	52	attr	_	_
49	strong	strong	JJ	_	52	attr	_	_
50	P450	p0	NN	_	52	com	_	_
51	3A	0a	NN	_	52	com	_	_
52	inhibitors	inhibitor	NNS	_	46	conj	_	_
53	including	include	VBG	_	54	adv	_	_
54	drug7	drug0	NN	_	52	ppmod	_	_
55	,	,	,	_	54	p	_	_
56	drug8	drug0	NN	_	54	appo	_	_
57	,	,	,	_	54	p	_	_
58	drug9	drug0	NN	_	54	appo	_	_
59	,	,	,	_	54	p	_	_
60	drug10	drug0	CD	_	54	num	_	_
61	,	,	,	_	60	p	_	_
62	drug11	drug0	CD	_	60	conj	_	_
63	,	,	,	_	62	p	_	_
64	drug12	drug0	CD	_	60	conj	_	_
65	,	,	,	_	64	p	_	_
66	drug13	drug0	CD	_	60	conj	_	_
67	,	,	,	_	66	p	_	_
68	drug14	drug0	CD	_	60	conj	_	_
69	,	,	,	_	68	p	_	_
70	drug15	drug0	CD	_	60	conj	_	_
71	or	or	CC	_	70	cc	_	_
72	drug16	drug0	CD	_	60	conj	_	_
73	.	.	.	_	7	p	_	_

1	Dose	dose	NN	_	2	com	_	_
2	adjustment	adjustment	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	Capsules	capsule	NNS	_	2	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	required	require	VBN	_	0	root	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	iPTH	ipth	NN	_	19	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	serum	serum	NN	_	15	com	_	_
14	calcium	calcium	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	11	conj	_	_
16	should	should	MD	_	19	modal	_	_
17	be	be	VB	_	19	aux	_	_
18	closely	closely	RB	_	19	adv	_	_
19	monitored	monitor	VBN	_	8	conj	_	_
20	if	if	IN	_	23	mark	_	_
21	a	a	DT	_	22	det	_	_
22	patient	patient	NN	_	23	dep	_	_
23	initiates	initiate	VBZ	_	19	comp	_	_
24	or	or	CC	_	23	cc	_	_
25	discontinues	discontinue	VBZ	_	23	conj	_	_
26	therapy	therapy	NN	_	25	obj	_	_
27	with	with	IN	_	31	case	_	_
28	a	a	DT	_	31	det	_	_
29	strong	strong	JJ	_	31	attr	_	_
30	CYP3A4	cyp0a0	NN	_	31	com	_	_
31	inhibitor	inhibitor	NN	_	26	ppmod	_	_
32	such	such	JJ	_	34	adv	_	_
33	as	as	IN	_	34	case	_	_
34	drug2	drug0	NN	_	31	ppmod	_	_
35	.	.	.	_	8	p	_	_

1	Drugs	drug	NNS	_	14	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	impair	impair	VBP	_	1	relcl	_	_
4	intestinal	intestinal	JJ	_	5	attr	_	_
5	absorption	absorption	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	1	p	_	_
9	such	such	JJ	_	11	adv	_	_
10	as	as	IN	_	11	case	_	_
11	drug2	drug0	NN	_	1	ppmod	_	_
12	,	,	,	_	1	p	_	_
13	may	may	MD	_	14	modal	_	_
14	interfere	interfere	VB	_	0	root	_	_
15	with	with	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	absorption	absorption	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	Capsules	capsule	NNS	_	17	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	competitively	competitively	RB	_	3	adv	_	_
3	inhibits	inhibit	VBZ	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	intracellular	intracellular	JJ	_	6	attr	_	_
6	phosphorylation	phosphorylation	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	use	use	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	3	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	avoided	avoid	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	In	in	FW	_	3	attr	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	data	datum	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	12	mark	_	_
6	the	the	DT	_	7	det	_	_
7	phosphorylation	phosphorylation	NN	_	12	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	12	aux	_	_
11	also	also	RB	_	12	adv	_	_
12	inhibited	inhibit	VBN	_	4	comp	_	_
13	at	at	IN	_	15	case	_	_
14	relevant	relevant	JJ	_	15	attr	_	_
15	concentrations	concentration	NNS	_	12	ppmod	_	_
16	by	by	IN	_	17	case	_	_
17	drug2	drug0	NN	_	12	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	9	dep	_	_
4	of	of	IN	_	8	case	_	_
5	these	these	DT	_	8	det	_	_
6	in	in	FW	_	7	adv	_	_
7	vitro	vitro	FW	_	8	attr	_	_
8	interactions	interaction	NNS	_	3	ppmod	_	_
9	is	be	VBZ	_	0	root	_	_
10	unknown	unknown	JJ	_	9	dep	_	_
11	;	;	:	_	9	p	_	_

1	therefore	therefore	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	either	either	DT	_	4	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	these	these	DT	_	11	det	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	undertaken	undertake	VBN	_	0	root	_	_
15	with	with	IN	_	16	case	_	_
16	caution	caution	NN	_	14	ppmod	_	_
17	.	.	.	_	14	p	_	_

1	No	no	DT	_	7	det	_	_
2	specific	specific	JJ	_	7	attr	_	_
3	cytochrome	cytochrome	NN	_	7	attr	_	_
4	P450-based	p0-based	JJ	_	7	attr	_	_
5	drug	drug	NN	_	7	com	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	10	dep	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	conducted	conduct	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	No	no	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	13	dep	_	_
4	between	between	IN	_	7	case	_	_
5	85	0	CD	_	6	num	_	_
6	mg/m2	mg/m0	NN	_	7	com	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	infusional	infusional	JJ	_	10	attr	_	_
10	drug2	drug0	NN	_	7	conj	_	_
11	has	have	VBZ	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	treated	treat	VBN	_	15	acl	_	_
17	every	every	DT	_	19	det	_	_
18	2	0	CD	_	19	num	_	_
19	weeks	week	NNS	_	16	obj	_	_
20	.	.	.	_	13	p	_	_

1	Increases	increase	NNS	_	12	dep	_	_
2	of	of	IN	_	5	case	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	1	ppmod	_	_
6	by	by	IN	_	8	case	_	_
7	approximately	approximately	RB	_	8	adv	_	_
8	20	0	CD	_	1	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	observed	observe	VBN	_	0	root	_	_
13	with	with	IN	_	19	mark	_	_
14	doses	dose	NNS	_	19	dep	_	_
15	of	of	IN	_	17	case	_	_
16	130	0	CD	_	17	num	_	_
17	mg/m2	mg/m0	NN	_	14	ppmod	_	_
18	drug2	drug0	VBP	_	19	aux	_	_
19	dosed	dose	VBN	_	12	comp	_	_
20	every	every	DT	_	22	det	_	_
21	3	0	CD	_	22	num	_	_
22	weeks	week	NNS	_	19	obj	_	_
23	.	.	.	_	12	p	_	_

1	Since	since	IN	_	6	mark	_	_
2	platinum	platinum	NN	_	4	com	_	_
3	containing	containing	NN	_	4	com	_	_
4	species	species	NNS	_	6	dep	_	_
5	are	be	VBP	_	6	aux	_	_
6	eliminated	eliminate	VBN	_	18	advcl	_	_
7	primarily	primarily	RB	_	6	adv	_	_
8	through	through	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	kidney	kidney	NN	_	6	ppmod	_	_
11	,	,	,	_	18	p	_	_
12	clearance	clearance	NN	_	18	dep	_	_
13	of	of	IN	_	15	case	_	_
14	these	these	DT	_	15	det	_	_
15	products	product	NNS	_	12	ppmod	_	_
16	may	may	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	decreased	decrease	VBN	_	0	root	_	_
19	by	by	IN	_	20	case	_	_
20	coadministration	coadministration	NN	_	18	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	potentially	potentially	RB	_	23	adv	_	_
23	nephrotoxic	nephrotoxic	JJ	_	24	attr	_	_
24	compounds	compound	NNS	_	20	ppmod	_	_
25	;	;	:	_	18	p	_	_

1	although	although	IN	_	8	case	_	_
2	,	,	,	_	8	p	_	_
3	this	this	DT	_	8	dep	_	_
4	has	have	VBZ	_	8	aux	_	_
5	not	not	RB	_	8	neg	_	_
6	been	be	VBN	_	8	aux	_	_
7	specifically	specifically	RB	_	8	adv	_	_
8	studied	study	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	interact	interact	VB	_	4	comp	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	6	ppmod	_	_
10	including	include	VBG	_	12	adv	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	supplements	supplement	NNS	_	9	ppmod	_	_
13	;	;	:	_	4	p	_	_

1	interactions	interaction	NNS	_	6	dep	_	_
2	have	have	VBP	_	6	aux	_	_
3	not	not	RB	_	6	neg	_	_
4	been	be	VBN	_	6	aux	_	_
5	systematically	systematically	RB	_	6	adv	_	_
6	studied	study	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	8	case	_	_
6	other	other	JJ	_	8	attr	_	_
7	chelation	chelation	NN	_	8	com	_	_
8	therapy	therapy	NN	_	2	ppmod	_	_
9	,	,	,	_	2	p	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug2	drug0	NN	_	2	ppmod	_	_
13	is	be	VBZ	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	recommended	recommend	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	2	com	_	_
2	Tests	test	NNS	_	3	com	_	_
3	Interaction	interaction	NN	_	7	comp	_	_
4	:	:	:	_	7	p	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	interfere	interfere	VB	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	serum	serum	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	urinary	urinary	JJ	_	13	attr	_	_
12	laboratory	laboratory	NN	_	13	com	_	_
13	tests	test	NNS	_	9	conj	_	_
14	.	.	.	_	7	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	cause	cause	VB	_	5	comp	_	_
9	false	false	JJ	_	10	adv	_	_
10	positive	positive	JJ	_	11	attr	_	_
11	results	result	NNS	_	8	obj	_	_
12	for	for	IN	_	13	case	_	_
13	ketones	ketone	NNS	_	11	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	urine	urine	NN	_	8	ppmod	_	_
16	using	use	VBG	_	15	acl	_	_
17	nitroprusside	nitroprusside	NN	_	18	com	_	_
18	reagents	reagent	NNS	_	16	obj	_	_
19	such	such	JJ	_	21	adv	_	_
20	as	as	IN	_	21	case	_	_
21	Ketostix	ketostix	NN	_	18	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	falsely	falsely	RB	_	24	adv	_	_
24	decreased	decrease	VBN	_	25	attr	_	_
25	measurements	measurement	NNS	_	21	conj	_	_
26	of	of	IN	_	29	case	_	_
27	serum	serum	NN	_	29	attr	_	_
28	uric	uric	JJ	_	29	attr	_	_
29	acid	acid	NN	_	25	ppmod	_	_
30	and	and	CC	_	29	cc	_	_
31	CPK	cpk	NN	_	29	conj	_	_
32	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	accentuate	accentuate	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	orthostatic	orthostatic	JJ	_	6	attr	_	_
6	hypotension	hypotension	NN	_	3	obj	_	_
7	that	that	WDT	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	occur	occur	VB	_	6	relcl	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	Antihypertensive	antihypertensive	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	10	dep	_	_
3	of	of	IN	_	7	case	_	_
4	drug1	drug0	JJ	_	7	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	related	related	JJ	_	4	conj	_	_
7	compounds	compound	NNS	_	2	ppmod	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	counteracted	counteract	VBN	_	0	root	_	_
11	when	when	WRB	_	14	adv	_	_
12	drug2	drug0	NNS	_	14	dep	_	_
13	are	be	VBP	_	14	aux	_	_
14	used	use	VBN	_	10	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	.	.	.	_	10	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	results	result	VBZ	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	increased	increase	VBN	_	11	attr	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	levels	level	NNS	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	both	both	DT	_	14	det	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	A	a	DT	_	2	det	_	_
2	total	total	NN	_	10	dep	_	_
3	of	of	IN	_	8	case	_	_
4	11	0	CD	_	8	num	_	_
5	clinical	clinical	JJ	_	8	attr	_	_
6	drug-drug	drug-drug	JJ	_	8	attr	_	_
7	interaction	interaction	NN	_	8	com	_	_
8	studies	study	NNS	_	2	ppmod	_	_
9	were	be	VBD	_	10	aux	_	_
10	conducted	conduct	VBN	_	0	root	_	_
11	in	in	IN	_	13	case	_	_
12	healthy	healthy	JJ	_	13	attr	_	_
13	volunteers	volunteer	NNS	_	10	ppmod	_	_
14	to	to	TO	_	15	aux	_	_
15	evaluate	evaluate	VB	_	10	comp	_	_
16	the	the	DT	_	17	det	_	_
17	potential	potential	NN	_	15	obj	_	_
18	for	for	IN	_	19	case	_	_
19	interaction	interaction	NN	_	17	ppmod	_	_
20	between	between	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	drug2	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug3	drug0	NN	_	21	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug4	drug0	NN	_	21	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug5	drug0	NN	_	21	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug6	drug0	NN	_	21	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug7	drug0	NN	_	21	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug8	drug0	NN	_	21	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug9	drug0	NN	_	21	conj	_	_
38	,	,	,	_	37	p	_	_
39	and	and	CC	_	37	cc	_	_
40	drug10	drug0	NN	_	21	conj	_	_
41	.	.	.	_	10	p	_	_

1	In	in	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	studies	study	NNS	_	14	ppmod	_	_
4	,	,	,	_	14	p	_	_
5	no	no	DT	_	6	det	_	_
6	interaction	interaction	NN	_	14	dep	_	_
7	that	that	WDT	_	8	dep	_	_
8	altered	alter	VBD	_	6	relcl	_	_
9	the	the	DT	_	10	det	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	was	be	VBD	_	14	aux	_	_
14	observed	observe	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	of	of	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	single	single	JJ	_	8	attr	_	_
8	dose	dose	NN	_	4	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	multiple	multiple	JJ	_	11	attr	_	_
11	doses	dose	NNS	_	8	conj	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	on	on	IN	_	15	case	_	_
15	drug2	drug0	NN	_	4	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug5	drug0	NN	_	15	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug6	drug0	NN	_	25	com	_	_
25	pharmacokinetics	pharmacokinetics	NNS	_	15	conj	_	_
26	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	AUC	auc	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	increased	increase	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	21	0	CD	_	4	ppmod	_	_
7	%	%	NN	_	6	meta	_	_
8	with	with	IN	_	10	case	_	_
9	no	no	DT	_	10	det	_	_
10	effect	effect	NN	_	6	ppmod	_	_
11	on	on	IN	_	12	case	_	_
12	Cmax	cmax	NN	_	10	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	presence	presence	NN	_	4	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	steady-state	steady-state	JJ	_	18	attr	_	_
18	drug2	drug0	NN	_	15	ppmod	_	_
19	compared	compare	VBN	_	21	adv	_	_
20	with	with	IN	_	21	case	_	_
21	drug3	drug0	NN	_	4	ppmod	_	_
22	alone	alone	RB	_	21	adv	_	_
23	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	AUC	auc	NN	_	6	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	Cmax	cmax	NN	_	2	conj	_	_
5	were	be	VBD	_	6	aux	_	_
6	increased	increase	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	18	0	CD	_	6	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	and	and	CC	_	8	cc	_	_
11	42	0	CD	_	8	conj	_	_
12	%	%	NN	_	11	meta	_	_
13	,	,	,	_	11	p	_	_
14	respectively	respectively	RB	_	8	conj	_	_
15	,	,	,	_	6	p	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	presence	presence	NN	_	6	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	steady-state	steady-state	JJ	_	21	attr	_	_
21	drug2	drug0	NNS	_	18	ppmod	_	_
22	compared	compare	VBN	_	24	adv	_	_
23	with	with	IN	_	24	case	_	_
24	drug3	drug0	NN	_	21	ppmod	_	_
25	alone	alone	RB	_	24	adv	_	_
26	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	12	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	or	or	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	2	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	monitored	monitor	VBN	_	0	root	_	_
13	for	for	IN	_	14	case	_	_
14	drug4	drug0	NN	_	12	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	drug5	drug0	NN	_	17	com	_	_
17	toxicity	toxicity	NN	_	14	conj	_	_
18	and	and	CC	_	14	cc	_	_
19	drug6	drug0	NN	_	14	conj	_	_
20	or	or	CC	_	12	cc	_	_
21	drug7	drug0	NN	_	22	com	_	_
22	dosage	dosage	NN	_	25	dep	_	_
23	should	should	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	reduced	reduce	VBN	_	12	conj	_	_
26	if	if	IN	_	27	mark	_	_
27	necessary	necessary	JJ	_	25	comp	_	_
28	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	an	an	DT	_	5	det	_	_
5	inhibitor	inhibitor	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	P-glycoprotein	p-glycoprotein	NN	_	5	ppmod	_	_
8	and	and	CC	_	2	cc	_	_
9	,	,	,	_	2	p	_	_
10	therefore	therefore	RB	_	2	adv	_	_
11	,	,	,	_	2	p	_	_
12	would	would	MD	_	15	modal	_	_
13	not	not	RB	_	15	neg	_	_
14	be	be	VB	_	15	aux	_	_
15	expected	expect	VBN	_	2	conj	_	_
16	to	to	TO	_	17	aux	_	_
17	alter	alter	VB	_	15	comp	_	_
18	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	21	attr	_	_
19	drug	drug	NN	_	21	com	_	_
20	transport	transport	NN	_	21	com	_	_
21	activity	activity	NN	_	17	obj	_	_
22	.	.	.	_	2	p	_	_

1	Hypokalemia	hypokalemia	NN	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	sensitize	sensitize	VB	_	0	root	_	_
4	or	or	CC	_	3	cc	_	_
5	exaggerate	exaggerate	VB	_	3	conj	_	_
6	the	the	DT	_	7	det	_	_
7	response	response	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	heart	heart	NN	_	7	ppmod	_	_
11	to	to	TO	_	14	aux	_	_
12	the	the	DT	_	14	det	_	_
13	toxic	toxic	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	7	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	(	-lrb-	-LRB-	_	22	p	_	_
18	e.g.	e.g.	FW	_	22	adv	_	_
19	,	,	,	_	22	p	_	_
20	increased	increase	VBN	_	22	attr	_	_
21	ventricular	ventricular	NN	_	22	com	_	_
22	irritability	irritability	NN	_	16	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	.	.	.	_	3	p	_	_

1	Hypokalemia	hypokalemia	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	develop	develop	VB	_	0	root	_	_
4	during	during	IN	_	6	case	_	_
5	concomitant	concomitant	JJ	_	6	attr	_	_
6	use	use	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	requirements	requirement	NNS	_	7	dep	_	_
3	in	in	IN	_	5	case	_	_
4	diabetic	diabetic	JJ	_	5	attr	_	_
5	patients	patient	NNS	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	increased	increase	VBN	_	7	dep	_	_
9	,	,	,	_	8	p	_	_
10	decreased	decrease	VBN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	or	or	CC	_	10	cc	_	_
13	unchanged	unchanged	JJ	_	8	conj	_	_
14	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	arterial	arterial	JJ	_	5	attr	_	_
5	responsiveness	responsiveness	NN	_	3	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	det	_	_
2	diminution	diminution	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	not	not	RB	_	3	neg	_	_
5	sufficient	sufficient	JJ	_	3	dep	_	_
6	to	to	TO	_	7	aux	_	_
7	preclude	preclude	VB	_	5	comp	_	_
8	effectiveness	effectiveness	NN	_	7	obj	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	pressor	pressor	JJ	_	12	attr	_	_
12	agent	agent	NN	_	8	ppmod	_	_
13	for	for	IN	_	15	case	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	use	use	NN	_	12	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	responsiveness	responsiveness	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	renal	renal	JJ	_	3	attr	_	_
3	clearance	clearance	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	reduced	reduce	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	5	p	_	_
9	increasing	increase	VBG	_	5	comp	_	_
10	the	the	DT	_	11	det	_	_
11	risk	risk	NN	_	9	obj	_	_
12	of	of	IN	_	14	case	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	toxicity	toxicity	NN	_	11	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	add	add	VBP	_	0	root	_	_
4	to	to	TO	_	3	ppmod	_	_
5	or	or	CC	_	3	cc	_	_
6	potentiate	potentiate	VB	_	3	conj	_	_
7	the	the	DT	_	8	det	_	_
8	action	action	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug2	drug0	NNS	_	8	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	Potentiation	potentiation	NN	_	2	dep	_	_
2	occurs	occur	VBZ	_	0	root	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	/	/	:	_	1	p	_	_
7	drug4	drug0	NN	_	1	appo	_	_
8	does	do	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	influence	influence	VB	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	pharmacokinetics	pharmacokinetics	NNS	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug5	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	healthy	healthy	JJ	_	17	attr	_	_
17	volunteers	volunteer	NNS	_	12	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	N=	n=	NN	_	17	prn	_	_
20	10	0	CD	_	19	num	_	_
21	)	-rrb-	-RRB-	_	19	p	_	_
22	.	.	.	_	10	p	_	_

1	5	0	CD	_	2	num	_	_
2	hours	hour	NNS	_	0	root	_	_
3	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	:	:	:	_	14	p	_	_
3	In	in	IN	_	5	case	_	_
4	healthy	healthy	JJ	_	5	attr	_	_
5	volunteers	volunteer	NNS	_	14	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	N=	n=	NN	_	5	prn	_	_
8	11	0	CD	_	7	num	_	_
9	)	-rrb-	-RRB-	_	7	p	_	_
10	,	,	,	_	14	p	_	_
11	drug2	drug0	NN	_	14	dep	_	_
12	did	do	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	influence	influence	VB	_	0	root	_	_
15	the	the	DT	_	16	det	_	_
16	pharmacokinetics	pharmacokinetics	NNS	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	5	attr	_	_
2	:	:	:	_	5	p	_	_
3	Population	population	NN	_	5	attr	_	_
4	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
5	analysis	analysis	NN	_	6	dep	_	_
6	suggests	suggest	VBZ	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug2	drug0	NN	_	9	dep	_	_
9	is	be	VBZ	_	6	comp	_	_
10	unlikely	unlikely	JJ	_	9	dep	_	_
11	to	to	TO	_	12	aux	_	_
12	alter	alter	VB	_	10	comp	_	_
13	the	the	DT	_	15	det	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	clearance	clearance	NN	_	12	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	N=	n=	NN	_	17	prn	_	_
20	54	0	CD	_	19	num	_	_
21	)	-rrb-	-RRB-	_	19	p	_	_
22	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	21	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	a	a	DT	_	7	det	_	_
6	known	known	JJ	_	7	attr	_	_
7	inhibitor	inhibitor	NN	_	1	appo	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	tubular	tubular	JJ	_	11	attr	_	_
11	secretion	secretion	NN	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	organic	organic	JJ	_	14	attr	_	_
14	bases	base	NNS	_	11	ppmod	_	_
15	via	via	IN	_	19	case	_	_
16	the	the	DT	_	19	det	_	_
17	cationic	cationic	JJ	_	19	attr	_	_
18	transport	transport	NN	_	19	com	_	_
19	system	system	NN	_	11	ppmod	_	_
20	,	,	,	_	1	p	_	_
21	caused	cause	VBD	_	0	root	_	_
22	a	a	DT	_	25	det	_	_
23	50	0	CD	_	25	num	_	_
24	%	%	NN	_	23	meta	_	_
25	increase	increase	NN	_	21	obj	_	_
26	in	in	IN	_	28	case	_	_
27	drug3	drug0	NN	_	28	com	_	_
28	AUC	auc	NN	_	25	ppmod	_	_
29	and	and	CC	_	25	cc	_	_
30	a	a	DT	_	33	det	_	_
31	40	0	CD	_	33	num	_	_
32	%	%	NN	_	31	meta	_	_
33	increase	increase	NN	_	25	conj	_	_
34	in	in	IN	_	35	case	_	_
35	half-life	half-life	NN	_	33	ppmod	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	N=	n=	NN	_	35	prn	_	_
38	12	0	CD	_	37	num	_	_
39	)	-rrb-	-RRB-	_	37	p	_	_
40	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	23	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	a	a	DT	_	7	det	_	_
6	known	known	JJ	_	7	attr	_	_
7	inhibitor	inhibitor	NN	_	1	appo	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	tubular	tubular	JJ	_	11	attr	_	_
11	secretion	secretion	NN	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	organic	organic	JJ	_	14	attr	_	_
14	acids	acid	NNS	_	11	ppmod	_	_
15	via	via	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	aruonic	aruonic	JJ	_	18	attr	_	_
18	transporter	transporter	NN	_	11	ppmod	_	_
19	,	,	,	_	1	p	_	_
20	did	do	VBD	_	23	aux	_	_
21	not	not	RB	_	23	neg	_	_
22	noticeably	noticeably	RB	_	23	adv	_	_
23	influence	influence	VB	_	0	root	_	_
24	drug3	drug0	NN	_	25	com	_	_
25	pharmacokinetics	pharmacokinetics	NNS	_	23	obj	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	N=	n=	NN	_	25	prn	_	_
28	12	0	CD	_	27	num	_	_
29	)	-rrb-	-RRB-	_	27	p	_	_
30	.	.	.	_	23	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	0	root	_	_
3	eliminated	eliminate	VBN	_	2	acl	_	_
4	via	via	IN	_	6	case	_	_
5	renal	renal	JJ	_	6	attr	_	_
6	secretion	secretion	NN	_	3	ppmod	_	_
7	:	:	:	_	2	p	_	_
8	Population	population	NN	_	10	attr	_	_
9	pharmacokinetic	pharmacokinetic	JJ	_	10	attr	_	_
10	analysis	analysis	NN	_	11	dep	_	_
11	suggests	suggest	VBZ	_	2	acl	_	_
12	that	that	IN	_	42	mark	_	_
13	coadministration	coadministration	NN	_	42	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drugs	drug	NNS	_	13	ppmod	_	_
16	that	that	WDT	_	18	dep	_	_
17	are	be	VBP	_	18	aux	_	_
18	secreted	secrete	VBN	_	15	relcl	_	_
19	by	by	IN	_	23	case	_	_
20	the	the	DT	_	23	det	_	_
21	cationic	cationic	JJ	_	23	attr	_	_
22	transport	transport	NN	_	23	com	_	_
23	system	system	NN	_	18	ppmod	_	_
24	(	-lrb-	-LRB-	_	23	p	_	_
25	e.g.	e.g.	FW	_	27	adv	_	_
26	,	,	,	_	27	p	_	_
27	drug1	drug0	NN	_	23	ppmod	_	_
28	,	,	,	_	27	p	_	_
29	drug2	drug0	NN	_	27	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug3	drug0	NN	_	27	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug4	drug0	NN	_	27	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug5	drug0	NN	_	27	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug6	drug0	NN	_	27	conj	_	_
38	,	,	,	_	37	p	_	_
39	and	and	CC	_	37	cc	_	_
40	drug7	drug0	NN	_	27	conj	_	_
41	)	-rrb-	-RRB-	_	23	p	_	_
42	decreases	decrease	VBZ	_	11	comp	_	_
43	the	the	DT	_	45	det	_	_
44	oral	oral	JJ	_	45	attr	_	_
45	clearance	clearance	NN	_	42	obj	_	_
46	of	of	IN	_	47	case	_	_
47	drug8	drug0	NN	_	45	ppmod	_	_
48	by	by	IN	_	50	case	_	_
49	about	about	RB	_	50	adv	_	_
50	20	0	CD	_	42	ppmod	_	_
51	%	%	NN	_	50	meta	_	_
52	,	,	,	_	42	p	_	_
53	while	while	IN	_	75	mark	_	_
54	those	those	DT	_	55	det	_	_
55	secreted	secrete	VBN	_	75	dep	_	_
56	by	by	IN	_	60	case	_	_
57	the	the	DT	_	60	det	_	_
58	anionic	anionic	JJ	_	60	attr	_	_
59	transport	transport	NN	_	60	com	_	_
60	system	system	NN	_	55	ppmod	_	_
61	(	-lrb-	-LRB-	_	60	p	_	_
62	e.g.	e.g.	FW	_	64	adv	_	_
63	,	,	,	_	64	p	_	_
64	drug9	drug0	NN	_	60	ppmod	_	_
65	,	,	,	_	64	p	_	_
66	drug10	drug0	NN	_	64	conj	_	_
67	,	,	,	_	66	p	_	_
68	drug11	drug0	NN	_	64	conj	_	_
69	,	,	,	_	68	p	_	_
70	drug12	drug0	NN	_	64	conj	_	_
71	,	,	,	_	70	p	_	_
72	and	and	CC	_	70	cc	_	_
73	drug13	drug0	NN	_	64	conj	_	_
74	)	-rrb-	-RRB-	_	60	p	_	_
75	are	be	VBP	_	42	comp	_	_
76	likely	likely	JJ	_	75	dep	_	_
77	to	to	TO	_	78	aux	_	_
78	have	have	VB	_	76	comp	_	_
79	little	little	JJ	_	80	attr	_	_
80	effect	effect	NN	_	78	obj	_	_
81	on	on	IN	_	84	case	_	_
82	the	the	DT	_	84	det	_	_
83	oral	oral	JJ	_	84	attr	_	_
84	clearance	clearance	NN	_	78	ppmod	_	_
85	of	of	IN	_	86	case	_	_
86	drug14	drug0	NN	_	84	ppmod	_	_
87	.	.	.	_	2	p	_	_

1	CYP	cyp	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Inhibitors	inhibitor	NNS	_	12	dep	_	_
5	of	of	IN	_	8	case	_	_
6	cytochrome	cytochrome	NN	_	8	com	_	_
7	P450	p0	NN	_	8	com	_	_
8	enzymes	enzyme	NNS	_	4	ppmod	_	_
9	would	would	MD	_	12	modal	_	_
10	not	not	RB	_	12	neg	_	_
11	be	be	VB	_	12	aux	_	_
12	expected	expect	VBN	_	2	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	affect	affect	VB	_	12	comp	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	elimination	elimination	NN	_	14	obj	_	_
17	because	because	IN	_	22	mark	_	_
18	drug2	drug0	NN	_	22	dep	_	_
19	is	be	VBZ	_	22	aux	_	_
20	not	not	RB	_	22	neg	_	_
21	appreciably	appreciably	RB	_	22	adv	_	_
22	metabolized	metabolize	VBN	_	14	comp	_	_
23	by	by	IN	_	25	case	_	_
24	these	these	DT	_	25	det	_	_
25	enzymes	enzyme	NNS	_	22	ppmod	_	_
26	in	in	FW	_	27	adv	_	_
27	vivo	vivo	FW	_	22	adv	_	_
28	or	or	CC	_	27	cc	_	_
29	in	in	FW	_	30	adv	_	_
30	vitro	vitro	FW	_	27	conj	_	_
31	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	inhibit	inhibit	VB	_	0	root	_	_
5	CYP	cyp	JJ	_	6	attr	_	_
6	enzymes	enzyme	NNS	_	4	obj	_	_
7	CYPIA2	cypia0	NN	_	6	attr	_	_
8	,	,	,	_	7	p	_	_
9	CYP2C9	cyp0c0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	CYP2CI9	cyp0ci0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	CYP2EI	cyp0ei	NN	_	7	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	CYP3A4	cyp0a0	NN	_	7	conj	_	_
17	.	.	.	_	4	p	_	_

1	Inhibition	inhibition	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	CYP2D6	cyp0d0	NN	_	1	ppmod	_	_
4	was	be	VBD	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	with	with	IN	_	9	case	_	_
7	an	an	DT	_	9	det	_	_
8	apparent	apparent	JJ	_	9	attr	_	_
9	Ki	ki	NN	_	5	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	30	0	CD	_	12	num	_	_
12	uM	um	NN	_	9	ppmod	_	_
13	,	,	,	_	5	p	_	_
14	indicating	indicate	VBG	_	5	comp	_	_
15	that	that	IN	_	19	mark	_	_
16	drug1	drug0	NN	_	19	dep	_	_
17	will	will	MD	_	19	modal	_	_
18	not	not	RB	_	19	neg	_	_
19	inhibit	inhibit	VBP	_	14	comp	_	_
20	CYP	cyp	JJ	_	21	attr	_	_
21	enzymes	enzyme	NNS	_	19	obj	_	_
22	at	at	IN	_	24	case	_	_
23	plasma	plasma	NN	_	24	com	_	_
24	concentrations	concentration	NNS	_	19	ppmod	_	_
25	observed	observe	VBN	_	24	acl	_	_
26	following	follow	VBG	_	31	adv	_	_
27	the	the	DT	_	31	det	_	_
28	highest	high	JJS	_	31	attr	_	_
29	recommended	recommend	VBN	_	31	attr	_	_
30	clinical	clinical	JJ	_	31	attr	_	_
31	dose	dose	NN	_	25	ppmod	_	_
32	(	-lrb-	-LRB-	_	34	p	_	_
33	1.5	0	CD	_	34	num	_	_
34	mg	mg	NN	_	31	prn	_	_
35	tid	tid	JJ	_	34	attr	_	_
36	)	-rrb-	-RRB-	_	34	p	_	_
37	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Since	since	IN	_	5	mark	_	_
4	drug2	drug0	NN	_	5	dep	_	_
5	is	be	VBZ	_	10	advcl	_	_
6	a	a	DT	_	7	det	_	_
7	drug3	drug0	NN	_	5	obj	_	_
8	,	,	,	_	10	p	_	_
9	it	it	PRP	_	10	dep	_	_
10	is	be	VBZ	_	1	acl	_	_
11	possible	possible	JJ	_	10	dep	_	_
12	that	that	IN	_	30	mark	_	_
13	drug4	drug0	NNS	_	30	dep	_	_
14	,	,	,	_	13	p	_	_
15	such	such	JJ	_	18	adv	_	_
16	as	as	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	drug5	drug0	NN	_	13	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug6	drug0	NN	_	18	prn	_	_
21	,	,	,	_	20	p	_	_
22	drug7	drug0	NN	_	20	appo	_	_
23	,	,	,	_	20	p	_	_
24	drug8	drug0	NN	_	20	appo	_	_
25	)	-rrb-	-RRB-	_	20	p	_	_
26	or	or	CC	_	18	cc	_	_
27	drug9	drug0	NN	_	18	conj	_	_
28	,	,	,	_	13	p	_	_
29	may	may	MD	_	30	modal	_	_
30	diminish	diminish	VB	_	10	comp	_	_
31	the	the	DT	_	32	det	_	_
32	effectiveness	effectiveness	NN	_	30	obj	_	_
33	of	of	IN	_	34	case	_	_
34	drug10	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	1	p	_	_

1	Drug/	drug/	VBG	_	6	advcl	_	_
2	Laboratory	laboratory	NN	_	4	com	_	_
3	Test	test	NN	_	4	com	_	_
4	Interactions	interaction	NNS	_	1	obj	_	_
5	There	there	EX	_	6	dep	_	_
6	are	be	VBP	_	0	root	_	_
7	no	no	DT	_	9	det	_	_
8	known	known	JJ	_	9	attr	_	_
9	interactions	interaction	NNS	_	6	obj	_	_
10	between	between	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	laboratory	laboratory	NN	_	14	com	_	_
14	tests	test	NNS	_	11	conj	_	_
15	.	.	.	_	6	p	_	_

1	Do	do	VBP	_	3	aux	_	_
2	not	not	RB	_	3	neg	_	_
3	exceed	exceed	VB	_	0	root	_	_
4	a	a	DT	_	8	det	_	_
5	5	0	CD	_	6	num	_	_
6	mg	mg	NN	_	8	attr	_	_
7	daily	daily	JJ	_	8	attr	_	_
8	dose	dose	NN	_	3	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	when	when	WRB	_	12	adv	_	_
12	administered	administer	VBN	_	3	comp	_	_
13	with	with	IN	_	15	case	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	doses	dose	NNS	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	other	other	JJ	_	22	attr	_	_
20	potent	potent	JJ	_	22	attr	_	_
21	CYP3A4	cyp0a0	JJ	_	22	attr	_	_
22	inhibitors	inhibitor	NNS	_	17	conj	_	_
23	.	.	.	_	3	p	_	_

1	Patients	patient	NNS	_	57	dep	_	_
2	with	with	IN	_	7	case	_	_
3	Congenital	congenital	JJ	_	7	attr	_	_
4	or	or	CC	_	3	cc	_	_
5	Acquired	acquired	JJ	_	3	conj	_	_
6	QT	qt	NN	_	7	com	_	_
7	Prolongation	prolongation	NN	_	1	ppmod	_	_
8	In	in	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	study	study	NN	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	effect	effect	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	on	on	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	QT	qt	JJ	_	19	attr	_	_
19	interval	interval	NN	_	13	ppmod	_	_
20	in	in	IN	_	23	case	_	_
21	76	0	CD	_	23	num	_	_
22	healthy	healthy	JJ	_	23	attr	_	_
23	women	woman	NNS	_	19	ppmod	_	_
24	,	,	,	_	13	p	_	_
25	the	the	DT	_	28	det	_	_
26	QT	qt	JJ	_	28	attr	_	_
27	prolonging	prolong	VBG	_	28	attr	_	_
28	effect	effect	NN	_	13	conj	_	_
29	appeared	appear	VBD	_	28	acl	_	_
30	less	less	JJR	_	29	dep	_	_
31	with	with	IN	_	34	case	_	_
32	drug2	drug0	NN	_	34	attr	_	_
33	10	0	CD	_	34	num	_	_
34	mg	mg	NN	_	30	ppmod	_	_
35	than	than	IN	_	38	case	_	_
36	with	with	IN	_	38	case	_	_
37	30	0	CD	_	38	num	_	_
38	mg	mg	NN	_	30	ppmod	_	_
39	(	-lrb-	-LRB-	_	41	p	_	_
40	three	#crd#	CD	_	41	num	_	_
41	times	time	NNS	_	38	prn	_	_
42	the	the	DT	_	45	det	_	_
43	maximum	maximum	JJ	_	45	attr	_	_
44	recommended	recommend	VBN	_	45	attr	_	_
45	dose	dose	NN	_	41	appo	_	_
46	)	-rrb-	-RRB-	_	41	p	_	_
47	,	,	,	_	28	p	_	_
48	and	and	CC	_	28	cc	_	_
49	the	the	DT	_	50	det	_	_
50	effect	effect	NN	_	13	conj	_	_
51	of	of	IN	_	54	case	_	_
52	drug3	drug0	NN	_	54	attr	_	_
53	30	0	CD	_	54	num	_	_
54	mg	mg	NN	_	50	ppmod	_	_
55	did	do	VBD	_	57	aux	_	_
56	not	not	RB	_	57	neg	_	_
57	appear	appear	VB	_	0	root	_	_
58	as	as	IN	_	59	case	_	_
59	large	large	JJ	_	57	ppmod	_	_
60	as	as	IN	_	61	case	_	_
61	that	that	DT	_	59	ppmod	_	_
62	of	of	IN	_	66	case	_	_
63	the	the	DT	_	66	det	_	_
64	positive	positive	JJ	_	66	attr	_	_
65	control	control	NN	_	66	com	_	_
66	drug4	drug0	NN	_	61	ppmod	_	_
67	at	at	IN	_	70	case	_	_
68	its	its	PRP$	_	70	poss	_	_
69	therapeutic	therapeutic	JJ	_	70	attr	_	_
70	dose	dose	NN	_	66	ppmod	_	_
71	.	.	.	_	57	p	_	_

1	This	this	DT	_	2	det	_	_
2	observation	observation	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	considered	consider	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	clinical	clinical	JJ	_	8	attr	_	_
8	decisions	decision	NNS	_	5	ppmod	_	_
9	to	to	TO	_	10	aux	_	_
10	prescribe	prescribe	VB	_	5	comp	_	_
11	drug1	drug0	NN	_	10	obj	_	_
12	for	for	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	with	with	IN	_	17	case	_	_
15	a	a	DT	_	17	det	_	_
16	known	known	JJ	_	17	attr	_	_
17	history	history	NN	_	13	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	QT	qt	NN	_	20	com	_	_
20	prolongation	prolongation	NN	_	17	ppmod	_	_
21	or	or	CC	_	13	cc	_	_
22	patients	patient	NNS	_	13	conj	_	_
23	who	who	WP	_	26	dep	_	_
24	are	be	VBP	_	26	aux	_	_
25	taking	take	VBG	_	26	lv	_	_
26	medications	medication	NNS	_	22	relcl	_	_
27	known	know	VBN	_	26	acl	_	_
28	to	to	TO	_	29	aux	_	_
29	prolong	prolong	VB	_	27	comp	_	_
30	the	the	DT	_	32	det	_	_
31	QT	qt	JJ	_	32	attr	_	_
32	interval	interval	NN	_	29	obj	_	_
33	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	18	dep	_	_
2	at	at	IN	_	4	case	_	_
3	a	a	DT	_	4	det	_	_
4	Dose	dose	NN	_	1	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	10	0	CD	_	7	num	_	_
7	mg	mg	NN	_	4	ppmod	_	_
8	Once	once	RB	_	9	adv	_	_
9	Daily	daily	JJ	_	7	attr	_	_
10	Dosed	dosed	JJ	_	14	adv	_	_
11	to	to	TO	_	14	aux	_	_
12	Pharmacokinetic	pharmacokinetic	JJ	_	14	attr	_	_
13	Steady	steady	JJ	_	14	attr	_	_
14	State	state	NN	_	9	ppmod	_	_
15	-	-	:	_	1	p	_	_
16	did	do	VBD	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	cause	cause	VB	_	0	root	_	_
19	clinically	clinically	RB	_	20	adv	_	_
20	significant	significant	JJ	_	21	attr	_	_
21	changes	change	NNS	_	18	obj	_	_
22	in	in	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	kinetics	kinetics	NNS	_	21	ppmod	_	_
25	of	of	IN	_	29	case	_	_
26	a	a	DT	_	29	det	_	_
27	single	single	JJ	_	29	attr	_	_
28	intravenous	intravenous	JJ	_	29	attr	_	_
29	dose	dose	NN	_	24	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug2	drug0	NN	_	29	ppmod	_	_
32	(	-lrb-	-LRB-	_	38	p	_	_
33	predominantly	predominantly	RB	_	38	adv	_	_
34	a	a	DT	_	38	det	_	_
35	cytochrome	cytochrome	NN	_	38	com	_	_
36	P450	p0	NN	_	38	com	_	_
37	1A2	0a0	NN	_	38	com	_	_
38	substrate	substrate	NN	_	31	prn	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	.	.	.	_	18	p	_	_

1	-	-	CC	_	4	cc	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	21:neg	_
4	change	change	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	pharmacokinetic	pharmacokinetic	JJ	_	7	attr	_	_
7	profile	profile	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	a	a	DT	_	12	det	_	_
12	substrate	substrate	NN	_	9	prn	_	_
13	of	of	IN	_	16	case	_	_
14	cytochromes	cytochromes	NN	_	16	com	_	_
15	P450	p0	NN	_	16	com	_	_
16	2A6	0a0	NN	_	12	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	2C9	0c0	NN	_	16	conj	_	_
19	)	-rrb-	-RRB-	_	12	p	_	_
20	or	or	CC	_	4	cc	_	_
21	influence	influence	VB	_	4	conj	_	_
22	the	the	DT	_	23	det	_	_
23	effect	effect	NN	_	21	obj	_	_
24	of	of	IN	_	29	case	_	_
25	a	a	DT	_	29	det	_	_
26	single	single	JJ	_	29	attr	_	_
27	30-mg	0-mg	NN	_	29	attr	_	_
28	oral	oral	JJ	_	29	attr	_	_
29	dose	dose	NN	_	23	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug2	drug0	NN	_	29	ppmod	_	_
32	on	on	IN	_	34	case	_	_
33	prothrombin	prothrombin	NN	_	34	com	_	_
34	time	time	NN	_	23	ppmod	_	_
35	or	or	CC	_	34	cc	_	_
36	the	the	DT	_	37	det	_	_
37	INR	inr	NN	_	34	conj	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	International	international	NNP	_	4	prn	_	_
40	Normalized	normalize	VBN	_	39	acl	_	_
41	Ratio	ratio	NN	_	40	obj	_	_
42	)	-rrb-	-RRB-	_	39	p	_	_
43	.	.	.	_	4	p	_	_

1	-	-	CC	_	4	cc	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	change	change	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	pharmacokinetic	pharmacokinetic	JJ	_	7	attr	_	_
7	profile	profile	NN	_	4	obj	_	_
8	or	or	CC	_	7	cc	_	_
9	urinary	urinary	JJ	_	10	attr	_	_
10	excretion	excretion	NN	_	7	conj	_	_
11	of	of	IN	_	13	case	_	_
12	immunoreactive	immunoreactive	JJ	_	13	attr	_	_
13	drug1	drug0	NN	_	7	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	-	-	TO	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	change	change	VB	_	0	root	_	_
5	the	the	DT	_	8	det	_	_
6	plasma	plasma	NN	_	8	com	_	_
7	concentration	concentration	NN	_	8	com	_	_
8	profile	profile	NN	_	4	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	a	a	DT	_	13	det	_	_
13	substrate	substrate	NN	_	10	prn	_	_
14	of	of	IN	_	17	case	_	_
15	cytochrome	cytochrome	NN	_	17	com	_	_
16	P450	p0	NN	_	17	com	_	_
17	3A4	0a0	NN	_	13	ppmod	_	_
18	)	-rrb-	-RRB-	_	13	p	_	_
19	or	or	CC	_	10	cc	_	_
20	drug2	drug0	NN	_	10	conj	_	_
21	,	,	,	_	20	p	_	_
22	its	its	PRP$	_	24	poss	_	_
23	carboxylated	carboxylated	JJ	_	24	attr	_	_
24	metabolite	metabolite	NN	_	20	appo	_	_
25	,	,	,	_	20	p	_	_
26	and	and	CC	_	4	cc	_	_
27	did	do	VBD	_	29	aux	_	_
28	not	not	RB	_	29	neg	_	_
29	prolong	prolong	VB	_	4	conj	_	_
30	the	the	DT	_	32	det	_	_
31	QTc	qtc	NN	_	32	com	_	_
32	interval	interval	NN	_	29	obj	_	_
33	following	follow	VBG	_	34	adv	_	_
34	co-administration	co-administration	NN	_	32	ppmod	_	_
35	with	with	IN	_	38	case	_	_
36	drug3	drug0	NN	_	38	attr	_	_
37	60	0	CD	_	38	num	_	_
38	mg	mg	NN	_	34	ppmod	_	_
39	twice	twice	RB	_	40	com	_	_
40	daily	daily	RB	_	38	adv	_	_
41	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	at	at	IN	_	3	case	_	_
3	Doses	dose	NNS	_	1	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	100	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	ppmod	_	_
7	Daily	daily	RB	_	8	adv	_	_
8	Dosed	dose	VBN	_	0	root	_	_
9	to	to	TO	_	12	aux	_	_
10	Pharmacokinetic	pharmacokinetic	JJ	_	12	attr	_	_
11	Steady	steady	JJ	_	12	attr	_	_
12	State	state	NN	_	8	ppmod	_	_
13	:	:	:	_	8	p	_	_
14	-	-	CC	_	8	cc	_	_
15	did	do	VBD	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	significantly	significantly	RB	_	18	adv	_	_
18	alter	alter	VB	_	8	conj	_	_
19	the	the	DT	_	21	det	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	concentrations	concentration	NNS	_	18	obj	_	_
22	of	of	IN	_	24	case	_	_
23	either	either	DT	_	24	det	_	_
24	component	component	NN	_	21	ppmod	_	_
25	of	of	IN	_	28	case	_	_
26	an	an	DT	_	28	det	_	_
27	oral	oral	JJ	_	28	attr	_	_
28	drug2	drug0	NN	_	24	ppmod	_	_
29	containing	contain	VBG	_	28	acl	_	_
30	drug3	drug0	NN	_	35	attr	_	_
31	1	0	CD	_	35	num	_	_
32	mg/ethinyl	mg/ethinyl	NN	_	35	attr	_	_
33	drug4	drug0	NN	_	35	attr	_	_
34	35	0	CD	_	35	num	_	_
35	mcg	mcg	NN	_	29	obj	_	_
36	.	.	.	_	8	p	_	_

1	-	-	CC	_	4	cc	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	cause	cause	VB	_	0	root	_	_
5	any	any	DT	_	8	det	_	_
6	clinically	clinically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	change	change	NN	_	4	obj	_	_
9	in	in	IN	_	11	case	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	profiles	profile	NNS	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	following	follow	VBG	_	17	adv	_	_
17	administration	administration	NN	_	13	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	either	either	CC	_	21	cc	_	_
20	oral	oral	JJ	_	21	attr	_	_
21	drug3	drug0	NN	_	17	ppmod	_	_
22	or	or	CC	_	21	cc	_	_
23	intravenous	intravenous	JJ	_	24	attr	_	_
24	drug4	drug0	NN	_	21	conj	_	_
25	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	which	which	WDT	_	4	dep	_	_
4	induces	induce	VBZ	_	1	relcl	_	_
5	hepatic	hepatic	JJ	_	6	attr	_	_
6	metabolism	metabolism	NN	_	4	obj	_	_
7	,	,	,	_	1	p	_	_
8	decreased	decrease	VBD	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	AUC	auc	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	approximately	approximately	RB	_	14	adv	_	_
14	40	0	CD	_	20	dat	_	_
15	%	%	NN	_	14	meta	_	_
16	following	follow	VBG	_	20	adv	_	_
17	a	a	DT	_	20	det	_	_
18	single	single	JJ	_	20	attr	_	_
19	10-mg	0-mg	JJ	_	20	attr	_	_
20	dose	dose	NN	_	8	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	8	p	_	_

1	No	no	DT	_	3	det	_	_
2	dosage	dosage	JJ	_	3	attr	_	_
3	adjustment	adjustment	NN	_	7	dep	_	_
4	for	for	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	reasonable	reasonable	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	employ	employ	VB	_	3	comp	_	_
6	appropriate	appropriate	JJ	_	8	attr	_	_
7	clinical	clinical	JJ	_	8	attr	_	_
8	monitoring	monitoring	NN	_	5	obj	_	_
9	when	when	WRB	_	23	adv	_	_
10	potent	potent	JJ	_	14	attr	_	_
11	cytochrome	cytochrome	NN	_	14	com	_	_
12	P450	p0	NN	_	14	com	_	_
13	enzyme	enzyme	NN	_	14	com	_	_
14	inducers	inducer	NNS	_	23	dep	_	_
15	,	,	,	_	14	p	_	_
16	such	such	JJ	_	18	adv	_	_
17	as	as	IN	_	18	case	_	_
18	drug1	drug0	NN	_	14	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	,	,	,	_	14	p	_	_
22	are	be	VBP	_	23	aux	_	_
23	co-administered	co-administered	VBN	_	2	comp	_	_
24	with	with	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	therapies	therapy	NNS	_	4	ppmod	_	_
8	routinely	routinely	RB	_	9	adv	_	_
9	used	use	VBN	_	7	acl	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	prophylaxis	prophylaxis	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	chronic	chronic	JJ	_	15	attr	_	_
15	treatment	treatment	NN	_	12	conj	_	_
16	of	of	IN	_	17	case	_	_
17	asthma	asthma	NN	_	12	ppmod	_	_
18	with	with	IN	_	21	case	_	_
19	no	no	DT	_	21	det	_	_
20	apparent	apparent	JJ	_	21	attr	_	_
21	increase	increase	NN	_	9	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	adverse	adverse	JJ	_	24	attr	_	_
24	reactions	reaction	NNS	_	21	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	In	in	IN	_	3	case	_	_
2	drug-interaction	drug-interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	13	ppmod	_	_
4	,	,	,	_	13	p	_	_
5	the	the	DT	_	8	det	_	_
6	recommended	recommend	VBN	_	8	attr	_	_
7	clinical	clinical	JJ	_	8	attr	_	_
8	dose	dose	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	did	do	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	have	have	VB	_	0	root	_	_
14	clinically	clinically	RB	_	15	adv	_	_
15	important	important	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	13	obj	_	_
17	on	on	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	pharmacokinetics	pharmacokinetics	NNS	_	13	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	following	following	JJ	_	23	attr	_	_
23	drugs	drug	NNS	_	19	ppmod	_	_
24	:	:	:	_	23	p	_	_
25	drug2	drug0	NN	_	23	appo	_	_
26	,	,	,	_	25	p	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug4	drug0	NN	_	25	conj	_	_
30	,	,	,	_	29	p	_	_
31	oral	oral	JJ	_	32	attr	_	_
32	drug5	drug0	NN	_	25	conj	_	_
33	(	-lrb-	-LRB-	_	39	p	_	_
34	drug6	drug0	NN	_	39	attr	_	_
35	1	0	CD	_	39	num	_	_
36	mg/	mg/	NN	_	39	attr	_	_
37	drug7	drug0	NN	_	39	attr	_	_
38	35	0	CD	_	39	num	_	_
39	mcg	mcg	NN	_	32	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	,	,	,	_	32	p	_	_
42	drug8	drug0	NN	_	25	conj	_	_
43	,	,	,	_	42	p	_	_
44	drug9	drug0	NN	_	25	conj	_	_
45	,	,	,	_	44	p	_	_
46	and	and	CC	_	44	cc	_	_
47	drug10	drug0	NN	_	25	conj	_	_
48	.	.	.	_	13	p	_	_

1	Although	although	IN	_	8	mark	_	_
2	additional	additional	JJ	_	5	attr	_	_
3	specific	specific	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	were	be	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	performed	performed	VBN	_	12	advcl	_	_
9	,	,	,	_	12	p	_	_
10	drug1	drug0	NN	_	12	dep	_	_
11	was	be	VBD	_	12	aux	_	_
12	used	use	VBN	_	0	root	_	_
13	concomitantly	concomitantly	RB	_	12	adv	_	_
14	with	with	IN	_	17	case	_	_
15	a	a	DT	_	17	det	_	_
16	wide	wide	JJ	_	17	attr	_	_
17	range	range	NN	_	12	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	commonly	commonly	RB	_	20	adv	_	_
20	prescribed	prescribe	VBN	_	21	attr	_	_
21	drugs	drug	NNS	_	17	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	clinical	clinical	JJ	_	24	attr	_	_
24	studies	study	NNS	_	12	ppmod	_	_
25	without	without	IN	_	26	case	_	_
26	evidence	evidence	NN	_	24	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	clinical	clinical	JJ	_	30	attr	_	_
29	adverse	adverse	JJ	_	30	attr	_	_
30	interactions	interaction	NNS	_	26	ppmod	_	_
31	.	.	.	_	12	p	_	_

1	These	these	DT	_	2	det	_	_
2	medications	medication	NNS	_	3	dep	_	_
3	included	include	VBD	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug5	drug0	NN	_	4	conj	_	_
14	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	which	which	WDT	_	4	dep	_	_
4	induces	induce	VBZ	_	1	relcl	_	_
5	hepatic	hepatic	JJ	_	6	attr	_	_
6	metabolism	metabolism	NN	_	4	obj	_	_
7	,	,	,	_	1	p	_	_
8	decreased	decrease	VBD	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	AUC	auc	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	approximately	approximately	RB	_	14	adv	_	_
14	40	0	CD	_	20	dat	_	_
15	%	%	NN	_	14	meta	_	_
16	following	follow	VBG	_	20	adv	_	_
17	a	a	DT	_	20	det	_	_
18	single	single	JJ	_	20	attr	_	_
19	10-mg	0-mg	JJ	_	20	attr	_	_
20	dose	dose	NN	_	8	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	8	p	_	_

1	No	no	DT	_	3	det	_	_
2	dosage	dosage	JJ	_	3	attr	_	_
3	adjustment	adjustment	NN	_	7	dep	_	_
4	for	for	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	reasonable	reasonable	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	employ	employ	VB	_	3	comp	_	_
6	appropriate	appropriate	JJ	_	8	attr	_	_
7	clinical	clinical	JJ	_	8	attr	_	_
8	monitoring	monitoring	NN	_	5	obj	_	_
9	when	when	WRB	_	23	adv	_	_
10	potent	potent	JJ	_	14	attr	_	_
11	cytochrome	cytochrome	NN	_	14	com	_	_
12	P450	p0	NN	_	14	com	_	_
13	enzyme	enzyme	NN	_	14	com	_	_
14	inducers	inducer	NNS	_	23	dep	_	_
15	,	,	,	_	14	p	_	_
16	such	such	JJ	_	18	adv	_	_
17	as	as	IN	_	18	case	_	_
18	drug1	drug0	NN	_	14	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	,	,	,	_	14	p	_	_
22	are	be	VBP	_	23	aux	_	_
23	co-administered	co-administered	VBN	_	2	comp	_	_
24	with	with	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	pharmacokinetic	pharmacokinetic	JJ	_	4	attr	_	_
4	study	study	NN	_	24	ppmod	_	_
5	of	of	IN	_	10	case	_	_
6	18	0	CD	_	10	num	_	_
7	chronic	chronic	JJ	_	10	attr	_	_
8	hepatitis	hepatitis	NN	_	10	com	_	_
9	C	c	NN	_	10	com	_	_
10	patients	patient	NNS	_	4	ppmod	_	_
11	concomitantly	concomitantly	RB	_	12	adv	_	_
12	receiving	receive	VBG	_	10	acl	_	_
13	drug1	drug0	NN	_	12	obj	_	_
14	,	,	,	_	24	p	_	_
15	treatment	treatment	NN	_	24	dep	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	once	once	RB	_	19	com	_	_
19	weekly	weekly	RB	_	22	adv	_	_
20	for	for	IN	_	22	case	_	_
21	4	0	CD	_	22	num	_	_
22	weeks	week	NNS	_	15	ppmod	_	_
23	was	be	VBD	_	24	aux	_	_
24	associated	associate	VBN	_	0	root	_	_
25	with	with	IN	_	28	case	_	_
26	a	a	DT	_	28	det	_	_
27	mean	mean	JJ	_	28	attr	_	_
28	increase	increase	NN	_	24	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	16	0	CD	_	28	ppmod	_	_
31	%	%	NN	_	30	meta	_	_
32	in	in	IN	_	34	case	_	_
33	drug3	drug0	NN	_	34	com	_	_
34	AUC	auc	NN	_	28	ppmod	_	_
35	;	;	:	_	24	p	_	_

1	in	in	IN	_	6	case	_	_
2	2	0	CD	_	5	num	_	_
3	out	out	IN	_	5	case	_	_
4	of	of	IN	_	5	case	_	_
5	18	0	CD	_	6	num	_	_
6	patients	patient	NNS	_	10	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	AUC	auc	NN	_	10	dep	_	_
10	doubled	double	VBD	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	finding	finding	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	;	;	:	_	7	p	_	_

1	however	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	patients	patient	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	for	for	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	signs	sign	NNS	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	symptoms	symptom	NNS	_	9	conj	_	_
12	of	of	IN	_	15	case	_	_
13	increased	increase	VBN	_	15	attr	_	_
14	narcotic	narcotic	JJ	_	15	attr	_	_
15	effect	effect	NN	_	9	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	7	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	the	the	DT	_	7	det	_	_
7	potential	potential	NN	_	0	root	_	_
8	for	for	IN	_	9	case	_	_
9	interaction	interaction	NN	_	7	ppmod	_	_
10	by	by	IN	_	12	case	_	_
11	a	a	DT	_	12	det	_	_
12	variety	variety	NN	_	7	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	mechanisms	mechanism	NNS	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	21	p	_	_
16	e.g.	e.g.	FW	_	21	ppmod	_	_
17	,	,	,	_	21	p	_	_
18	pharmacodynamic	pharmacodynamic	JJ	_	20	adv	_	_
19	,	,	,	_	20	p	_	_
20	pharmacokinetic	pharmacokinetic	JJ	_	21	attr	_	_
21	inhibition	inhibition	NN	_	7	prn	_	_
22	or	or	CC	_	21	cc	_	_
23	enhancement	enhancement	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	etc	etc	NN	_	21	conj	_	_
26	.	.	.	_	25	p	_	_
27	)	-rrb-	-RRB-	_	21	p	_	_

1	is	be	VBZ	_	0	root	_	_
2	a	a	DT	_	3	det	_	_
3	possibility	possibility	NN	_	1	obj	_	_
4	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	19	dep	_	_
2	Affecting	affect	VBG	_	1	acl	_	_
3	Hepatic	hepatic	JJ	_	4	attr	_	_
4	Metabolism	metabolism	NN	_	2	obj	_	_
5	The	the	DT	_	6	det	_	_
6	metabolism	metabolism	NN	_	4	attr	_	_
7	and	and	CC	_	4	cc	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	16	attr	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	Orally	orally	RB	_	15	adv	_	_
15	Disintegrating	disintegrating	JJ	_	16	attr	_	_
16	Tablets	tablet	NNS	_	4	conj	_	_
17	may	may	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	affected	affect	VBN	_	0	root	_	_
20	by	by	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	induction	induction	NN	_	19	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	inhibition	inhibition	NN	_	22	conj	_	_
25	of	of	IN	_	27	case	_	_
26	drug-metab-olizing	drug-metab-olizing	JJ	_	27	attr	_	_
27	enzymes	enzyme	NNS	_	24	ppmod	_	_
28	.	.	.	_	19	p	_	_

1	Drugs	drug	NNS	_	7	dep	_	_
2	that	that	WDT	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	Metabolized	metabolize	VBN	_	1	relcl	_	_
5	by	by	IN	_	6	case	_	_
6	and/or	and/or	CC	_	4	ppmod	_	_
7	Inhibit	inhibit	VBP	_	0	root	_	_
8	Cytochrome	cytochrome	NN	_	10	com	_	_
9	P450	p0	NN	_	10	com	_	_
10	Enzymes	enzyme	NNS	_	7	obj	_	_
11	Many	many	JJ	_	12	attr	_	_
12	drugs	drug	NNS	_	14	dep	_	_
13	are	be	VBP	_	14	aux	_	_
14	metabolized	metabolize	VBN	_	10	acl	_	_
15	by	by	IN	_	14	case	_	_
16	and/or	and/or	CC	_	7	cc	_	_
17	inhibit	inhibit	VBP	_	7	conj	_	_
18	various	various	JJ	_	21	attr	_	_
19	cytochrome	cytochrome	NN	_	21	com	_	_
20	P450	p0	NN	_	21	com	_	_
21	enzymes	enzyme	NNS	_	17	obj	_	_
22	,	,	,	_	21	p	_	_
23	e.g.	e.g.	FW	_	25	adv	_	_
24	,	,	,	_	25	p	_	_
25	2D6	0d0	NN	_	21	ppmod	_	_
26	,	,	,	_	25	p	_	_
27	1A2	0a0	NN	_	25	appo	_	_
28	,	,	,	_	25	p	_	_
29	3A4	0a0	NN	_	25	appo	_	_
30	,	,	,	_	25	p	_	_
31	etc	etc	NN	_	25	appo	_	_
32	.	.	.	_	7	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	8	mark	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	is	be	VBZ	_	5	comp	_	_
9	a	a	DT	_	10	det	_	_
10	substrate	substrate	NN	_	8	obj	_	_
11	for	for	IN	_	12	case	_	_
12	several	several	JJ	_	10	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	these	these	DT	_	15	det	_	_
15	enzymes	enzyme	NNS	_	12	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	including	include	VBG	_	18	adv	_	_
18	2D6	0d0	NN	_	15	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	1A2	0a0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	3A4	0a0	NN	_	18	conj	_	_
24	.	.	.	_	5	p	_	_

1	While	while	IN	_	6	mark	_	_
2	in	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	4	attr	_	_
4	studies	study	NNS	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	shown	show	VBN	_	66	advcl	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	is	be	VBZ	_	6	comp	_	_
10	not	not	RB	_	9	neg	_	_
11	a	a	DT	_	13	det	_	_
12	potent	potent	JJ	_	13	attr	_	_
13	inhibitor	inhibitor	NN	_	9	obj	_	_
14	of	of	IN	_	15	case	_	_
15	any	any	DT	_	13	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	these	these	DT	_	18	det	_	_
18	enzymes	enzyme	NNS	_	15	ppmod	_	_
19	,	,	,	_	13	p	_	_
20	an	an	DT	_	21	det	_	_
21	indication	indication	NN	_	13	appo	_	_
22	that	that	IN	_	28	mark	_	_
23	drug2	drug0	NN	_	28	dep	_	_
24	is	be	VBZ	_	28	aux	_	_
25	not	not	RB	_	28	neg	_	_
26	likely	likely	RB	_	28	adv	_	_
27	to	to	TO	_	28	aux	_	_
28	have	have	VB	_	21	acl	_	_
29	a	a	DT	_	33	det	_	_
30	clinically	clinically	RB	_	31	adv	_	_
31	significant	significant	JJ	_	33	attr	_	_
32	inhibitory	inhibitory	JJ	_	33	attr	_	_
33	effect	effect	NN	_	28	obj	_	_
34	on	on	IN	_	36	case	_	_
35	the	the	DT	_	36	det	_	_
36	metabolism	metabolism	NN	_	33	ppmod	_	_
37	of	of	IN	_	39	case	_	_
38	other	other	JJ	_	39	attr	_	_
39	drugs	drug	NNS	_	36	ppmod	_	_
40	that	that	WDT	_	41	dep	_	_
41	are	be	VBP	_	39	relcl	_	_
42	substrates	substrate	NNS	_	41	obj	_	_
43	for	for	IN	_	47	case	_	_
44	these	these	DT	_	47	det	_	_
45	cytochrome	cytochrome	NN	_	47	com	_	_
46	P450	p0	NN	_	47	com	_	_
47	enzymes	enzyme	NNS	_	42	ppmod	_	_
48	,	,	,	_	66	p	_	_
49	the	the	DT	_	51	det	_	_
50	concomitant	concomitant	JJ	_	51	attr	_	_
51	use	use	NN	_	66	dep	_	_
52	of	of	IN	_	53	case	_	_
53	drug3	drug0	NN	_	51	ppmod	_	_
54	with	with	IN	_	57	case	_	_
55	most	most	JJ	_	57	attr	_	_
56	other	other	JJ	_	57	attr	_	_
57	drugs	drug	NNS	_	51	ppmod	_	_
58	metabolized	metabolize	VBN	_	57	acl	_	_
59	by	by	IN	_	61	case	_	_
60	these	these	DT	_	61	det	_	_
61	enzymes	enzyme	NNS	_	58	ppmod	_	_
62	has	have	VBZ	_	66	aux	_	_
63	not	not	RB	_	66	neg	_	_
64	been	be	VBN	_	66	aux	_	_
65	formally	formally	RB	_	66	adv	_	_
66	studied	study	VBN	_	0	root	_	_
67	.	.	.	_	66	p	_	_

1	Consequently	consequently	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	it	it	PRP	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	not	not	RB	_	4	neg	_	_
6	possible	possible	JJ	_	4	dep	_	_
7	to	to	TO	_	11	aux	_	_
8	make	make	VB	_	11	lv	_	_
9	any	any	DT	_	11	det	_	_
10	definitive	definitive	JJ	_	11	attr	_	_
11	statements	statement	NNS	_	4	comp	_	_
12	about	about	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	risks	risk	NNS	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	coadministration	coadministration	NN	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	with	with	IN	_	21	case	_	_
20	such	such	JJ	_	21	attr	_	_
21	drugs	drug	NNS	_	16	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	13	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	11	p	_	_
8	equivalent	equivalent	JJ	_	10	attr	_	_
9	to	to	TO	_	8	com	_	_
10	60	0	CD	_	11	num	_	_
11	g	g	NN	_	6	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	had	have	VBD	_	1	acl	_	_
14	a	a	DT	_	16	det	_	_
15	minimal	minimal	JJ	_	16	attr	_	_
16	effect	effect	NN	_	13	obj	_	_
17	on	on	IN	_	19	case	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	levels	level	NNS	_	13	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	15	0	CD	_	24	num	_	_
24	mg	mg	NN	_	21	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	in	in	IN	_	30	case	_	_
27	6	0	CD	_	30	num	_	_
28	healthy	healthy	JJ	_	30	attr	_	_
29	male	male	JJ	_	30	attr	_	_
30	subjects	subject	NNS	_	19	ppmod	_	_
31	.	.	.	_	1	p	_	_

1	However	however	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	the	the	DT	_	4	det	_	_
4	impairment	impairment	NN	_	14	dep	_	_
5	of	of	IN	_	9	case	_	_
6	cognitive	cognitive	JJ	_	9	attr	_	_
7	and	and	CC	_	9	cc	_	_
8	motor	motor	NN	_	9	com	_	_
9	skills	skill	NNS	_	4	ppmod	_	_
10	produced	produce	VBN	_	9	acl	_	_
11	by	by	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	were	be	VBD	_	14	aux	_	_
14	shown	show	VBN	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	be	be	VB	_	14	comp	_	_
17	additive	additive	JJ	_	16	dep	_	_
18	with	with	IN	_	19	case	_	_
19	those	those	DT	_	17	ppmod	_	_
20	produced	produce	VBN	_	19	acl	_	_
21	by	by	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	14	p	_	_

1	Accordingly	accordingly	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	patients	patient	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	advised	advise	VBN	_	24	advcl	_	_
7	to	to	TO	_	8	aux	_	_
8	avoid	avoid	VB	_	6	comp	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	while	while	IN	_	11	mark	_	_
11	taking	take	VBG	_	8	comp	_	_
12	drug2	drug0	NN	_	14	attr	_	_
13	.	.	.	_	12	p	_	_
14	drug3	drug0	NN	_	11	obj	_	_
15	:	:	:	_	24	p	_	_
16	Concomitant	concomitant	JJ	_	17	attr	_	_
17	administration	administration	NN	_	24	dep	_	_
18	of	of	IN	_	19	case	_	_
19	drug4	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	15	0	CD	_	22	num	_	_
22	mg	mg	NN	_	19	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	had	have	VBD	_	0	root	_	_
25	a	a	DT	_	27	det	_	_
26	minimal	minimal	JJ	_	27	attr	_	_
27	effect	effect	NN	_	24	obj	_	_
28	on	on	IN	_	30	case	_	_
29	plasma	plasma	NN	_	30	com	_	_
30	levels	level	NNS	_	24	ppmod	_	_
31	of	of	IN	_	32	case	_	_
32	drug5	drug0	NN	_	30	ppmod	_	_
33	(	-lrb-	-LRB-	_	35	p	_	_
34	15	0	CD	_	35	num	_	_
35	mg	mg	NN	_	32	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	in	in	IN	_	40	case	_	_
38	12	0	CD	_	40	num	_	_
39	healthy	healthy	JJ	_	40	attr	_	_
40	subjects	subject	NNS	_	32	ppmod	_	_
41	.	.	.	_	24	p	_	_

1	However	however	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	the	the	DT	_	4	det	_	_
4	impairment	impairment	NN	_	13	dep	_	_
5	of	of	IN	_	7	case	_	_
6	motor	motor	NN	_	7	com	_	_
7	skills	skill	NNS	_	4	ppmod	_	_
8	produced	produce	VBN	_	4	acl	_	_
9	by	by	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	has	have	VBZ	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	shown	show	VBN	_	0	root	_	_
14	to	to	TO	_	15	aux	_	_
15	be	be	VB	_	13	comp	_	_
16	additive	additive	JJ	_	15	dep	_	_
17	with	with	IN	_	18	case	_	_
18	those	those	DT	_	16	ppmod	_	_
19	caused	cause	VBN	_	18	acl	_	_
20	by	by	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	Accordingly	accordingly	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	patients	patient	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	advised	advise	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	avoid	avoid	VB	_	6	comp	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	other	other	JJ	_	13	attr	_	_
12	similar	similar	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	9	conj	_	_
14	while	while	IN	_	15	mark	_	_
15	taking	take	VBG	_	8	comp	_	_
16	drug2	drug0	NN	_	15	obj	_	_
17	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Spontaneous	spontaneous	JJ	_	6	attr	_	_
4	adverse	adverse	JJ	_	6	attr	_	_
5	reaction	reaction	NN	_	6	com	_	_
6	reports	report	NNS	_	17	dep	_	_
7	of	of	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	drug2	drug0	NN	_	9	obj	_	_
12	with	with	IN	_	14	case	_	_
13	recommended	recommend	VBN	_	14	attr	_	_
14	doses	dose	NNS	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	demonstrate	demonstrate	VBP	_	1	acl	_	_
18	QT	qt	NN	_	20	attr	_	_
19	interval	interval	JJ	_	20	attr	_	_
20	prolongation	prolongation	NN	_	17	obj	_	_
21	and	and	CC	_	20	cc	_	_
22	rare	rare	JJ	_	25	attr	_	_
23	serious	serious	JJ	_	25	attr	_	_
24	cardiac	cardiac	JJ	_	25	attr	_	_
25	events	event	NNS	_	20	conj	_	_
26	,	,	,	_	17	p	_	_
27	e.g.	e.g.	FW	_	17	ppmod	_	_

1	death	death	NN	_	9	dep	_	_
2	,	,	,	_	1	p	_	_
3	cardiac	cardiac	JJ	_	4	attr	_	_
4	arrest	arrest	NN	_	1	conj	_	_
5	,	,	,	_	4	p	_	_
6	and	and	CC	_	4	cc	_	_
7	ventricular	ventricular	JJ	_	8	attr	_	_
8	arrhythmia	arrhythmia	NN	_	1	conj	_	_
9	including	include	VBG	_	0	root	_	_
10	torsades	torsades	NNS	_	9	obj	_	_
11	de	de	FW	_	12	adv	_	_
12	pointes	pointes	FW	_	10	attr	_	_
13	.	.	.	_	9	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	data	datum	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	markedly	markedly	RB	_	7	adv	_	_
7	inhibits	inhibit	VBZ	_	3	comp	_	_
8	the	the	DT	_	9	det	_	_
9	metabolism	metabolism	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	7	p	_	_
13	resulting	result	VBG	_	7	comp	_	_
14	in	in	IN	_	18	case	_	_
15	elevated	elevated	JJ	_	18	attr	_	_
16	plasma	plasma	NN	_	18	com	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	levels	level	NNS	_	13	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	Presence	presence	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	unchanged	unchanged	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	associated	associate	VBN	_	0	root	_	_
7	with	with	IN	_	10	case	_	_
8	statistically	statistically	RB	_	9	adv	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	prolongation	prolongation	NN	_	6	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	QT	qt	NN	_	10	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	QTc	qtc	NN	_	16	com	_	_
16	intervals	interval	NNS	_	13	conj	_	_
17	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	is	be	VBZ	_	8	aux	_	_
8	contraindicated	contraindicate	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Torsades	torsades	NNS	_	13	dep	_	_
4	de	de	FW	_	5	adv	_	_
5	pointes	pointes	FW	_	3	attr	_	_
6	and	and	CC	_	3	cc	_	_
7	elevated	elevated	JJ	_	10	attr	_	_
8	parent	parent	NN	_	10	com	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	levels	level	NNS	_	3	conj	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	reported	report	VBN	_	1	acl	_	_
14	during	during	IN	_	16	case	_	_
15	concomitant	concomitant	JJ	_	16	attr	_	_
16	use	use	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	in	in	IN	_	23	case	_	_
22	clinical	clinical	JJ	_	23	attr	_	_
23	trials	trial	NNS	_	16	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug5	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	23	cc	_	_
27	from	from	IN	_	30	case	_	_
28	foreign	foreign	JJ	_	30	attr	_	_
29	post-marketing	post-marketing	JJ	_	30	attr	_	_
30	sources	source	NNS	_	23	conj	_	_
31	.	.	.	_	1	p	_	_

1	One	#crd#	CD	_	2	num	_	_
2	death	death	NN	_	6	dep	_	_
3	has	have	VBZ	_	6	aux	_	_
4	also	also	RB	_	6	adv	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	from	from	IN	_	11	case	_	_
8	foreign	foreign	JJ	_	11	attr	_	_
9	post-	post-	JJ	_	11	attr	_	_
10	marketing	marketing	JJ	_	11	attr	_	_
11	sources	source	NNS	_	6	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	is	be	VBZ	_	8	aux	_	_
8	contraindicated	contraindicate	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Due	due	JJ	_	5	adv	_	_
2	to	to	TO	_	5	aux	_	_
3	the	the	DT	_	5	det	_	_
4	chemical	chemical	JJ	_	5	attr	_	_
5	similarity	similarity	NN	_	33	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	including	include	VBG	_	11	adv	_	_
11	drug2	drug0	NN	_	8	prn	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug4	drug0	NN	_	11	conj	_	_
17	)	-rrb-	-RRB-	_	11	p	_	_
18	to	to	TO	_	19	aux	_	_
19	drug5	drug0	NN	_	5	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	drug6	drug0	NN	_	19	conj	_	_
23	,	,	,	_	33	p	_	_
24	concomitant	concomitant	JJ	_	25	attr	_	_
25	use	use	NN	_	33	dep	_	_
26	of	of	IN	_	28	case	_	_
27	these	these	DT	_	28	det	_	_
28	products	product	NNS	_	25	ppmod	_	_
29	with	with	IN	_	30	case	_	_
30	drug7	drug0	NN	_	25	ppmod	_	_
31	is	be	VBZ	_	33	aux	_	_
32	not	not	RB	_	33	neg	_	_
33	recommended	recommend	VBN	_	0	root	_	_
34	pending	pending	VBG	_	33	comp	_	_
35	full	full	JJ	_	36	attr	_	_
36	examination	examination	NN	_	34	obj	_	_
37	of	of	IN	_	39	case	_	_
38	potential	potential	JJ	_	39	attr	_	_
39	interactions	interaction	NNS	_	36	ppmod	_	_
40	.	.	.	_	33	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Clinical	clinical	JJ	_	6	attr	_	_
4	drug	drug	NN	_	6	com	_	_
5	interaction	interaction	NN	_	6	com	_	_
6	studies	study	NNS	_	7	dep	_	_
7	indicate	indicate	VBP	_	1	acl	_	_
8	that	that	IN	_	13	mark	_	_
9	drug2	drug0	NN	_	13	dep	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	can	can	MD	_	13	modal	_	_
13	exert	exert	VB	_	7	comp	_	_
14	an	an	DT	_	15	det	_	_
15	effect	effect	NN	_	13	obj	_	_
16	on	on	IN	_	18	case	_	_
17	drug4	drug0	NN	_	18	com	_	_
18	metabolism	metabolism	NN	_	13	ppmod	_	_
19	by	by	IN	_	21	case	_	_
20	a	a	DT	_	21	det	_	_
21	mechanism	mechanism	NN	_	13	ppmod	_	_
22	which	which	WDT	_	24	dep	_	_
23	may	may	MD	_	24	modal	_	_
24	be	be	VB	_	21	relcl	_	_
25	similar	similar	JJ	_	24	dep	_	_
26	to	to	TO	_	27	aux	_	_
27	that	that	DT	_	25	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug5	drug0	NN	_	27	ppmod	_	_
30	,	,	,	_	27	p	_	_
31	but	but	CC	_	27	cc	_	_
32	to	to	TO	_	35	aux	_	_
33	a	a	DT	_	35	det	_	_
34	lesser	less	JJR	_	35	attr	_	_
35	extent	extent	NN	_	27	conj	_	_
36	.	.	.	_	1	p	_	_

1	Although	although	IN	_	4	mark	_	_
2	erythromycin	erythromycin	NN	_	4	dep	_	_
3	measurably	measurably	RB	_	4	adv	_	_
4	decreases	decrease	VBZ	_	19	advcl	_	_
5	the	the	DT	_	6	det	_	_
6	clearance	clearance	NN	_	4	obj	_	_
7	of	of	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	drug1	drug0	NN	_	11	com	_	_
10	acid	acid	NN	_	11	com	_	_
11	metabolite	metabolite	NN	_	6	ppmod	_	_
12	,	,	,	_	19	p	_	_
13	its	its	PRP$	_	14	poss	_	_
14	influence	influence	NN	_	19	dep	_	_
15	on	on	IN	_	18	case	_	_
16	terfenadine	terfenadine	NN	_	18	com	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	levels	level	NNS	_	14	ppmod	_	_
19	is	be	VBZ	_	0	root	_	_
20	still	still	RB	_	19	adv	_	_
21	under	under	IN	_	22	case	_	_
22	investigation	investigation	NN	_	19	ppmod	_	_
23	.	.	.	_	19	p	_	_

1	A	a	DT	_	4	det	_	_
2	few	few	JJ	_	4	attr	_	_
3	spontaneous	spontaneous	JJ	_	4	attr	_	_
4	accounts	account	VBZ	_	19	dep	_	_
5	of	of	IN	_	8	case	_	_
6	QT	qt	NN	_	8	attr	_	_
7	interval	interval	JJ	_	8	attr	_	_
8	prolongation	prolongation	NN	_	4	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	ventricular	ventricular	JJ	_	11	attr	_	_
11	arrhythmia	arrhythmia	NN	_	8	ppmod	_	_
12	including	include	VBG	_	13	adv	_	_
13	torsades	torsades	NNS	_	11	ppmod	_	_
14	de	de	FW	_	15	adv	_	_
15	pointes	pointes	FW	_	13	attr	_	_
16	,	,	,	_	13	p	_	_
17	have	have	VBP	_	19	aux	_	_
18	been	be	VBN	_	19	aux	_	_
19	reported	report	VBN	_	0	root	_	_
20	in	in	IN	_	21	case	_	_
21	patients	patient	NNS	_	19	ppmod	_	_
22	receiving	receive	VBG	_	21	acl	_	_
23	drug1	drug0	NN	_	22	obj	_	_
24	or	or	CC	_	23	cc	_	_
25	drug2	drug0	NN	_	23	conj	_	_
26	.	.	.	_	19	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	or	or	CC	_	8	cc	_	_
11	drug4	drug0	NN	_	6	conj	_	_
12	is	be	VBZ	_	13	aux	_	_
13	contraindicated	contraindicate	VBN	_	35	advcl	_	_
14	:	:	:	_	35	p	_	_
15	Pending	pending	VBG	_	35	advcl	_	_
16	full	full	JJ	_	17	attr	_	_
17	characterization	characterization	NN	_	15	obj	_	_
18	of	of	IN	_	20	case	_	_
19	potential	potential	JJ	_	20	attr	_	_
20	interactions	interaction	NNS	_	17	ppmod	_	_
21	,	,	,	_	35	p	_	_
22	concomitant	concomitant	JJ	_	23	attr	_	_
23	administration	administration	NN	_	35	dep	_	_
24	of	of	IN	_	25	case	_	_
25	drug5	drug0	NN	_	23	ppmod	_	_
26	with	with	IN	_	28	case	_	_
27	other	other	JJ	_	28	attr	_	_
28	drug6	drug0	NNS	_	23	ppmod	_	_
29	,	,	,	_	28	p	_	_
30	including	include	VBG	_	31	adv	_	_
31	drug7	drug0	NN	_	28	ppmod	_	_
32	,	,	,	_	28	p	_	_
33	is	be	VBZ	_	35	aux	_	_
34	not	not	RB	_	35	neg	_	_
35	recommended	recommend	VBN	_	0	root	_	_
36	.	.	.	_	35	p	_	_

1	Studies	study	NNS	_	10	dep	_	_
2	to	to	TO	_	3	aux	_	_
3	evaluate	evaluate	VB	_	1	acl	_	_
4	potential	potential	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NNS	_	5	ppmod	_	_
10	are	be	VBP	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	progress	progress	NN	_	10	ppmod	_	_
13	.	.	.	_	10	p	_	_

1	Acromegalic	acromegalic	JJ	_	2	attr	_	_
2	patients	patient	NNS	_	15	dep	_	_
3	with	with	IN	_	5	case	_	_
4	diabetes	diabetes	NN	_	5	com	_	_
5	mellitus	mellitus	NN	_	2	ppmod	_	_
6	being	be	VBG	_	7	aux	_	_
7	treated	treat	VBN	_	5	acl	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and/or	and/or	CC	_	9	cc	_	_
11	oral	oral	JJ	_	13	attr	_	_
12	drug2	drug0	JJ	_	13	attr	_	_
13	agents	agent	NNS	_	9	conj	_	_
14	may	may	MD	_	15	modal	_	_
15	require	require	VB	_	0	root	_	_
16	dose	dose	NN	_	17	com	_	_
17	reductions	reduction	NNS	_	15	obj	_	_
18	of	of	IN	_	21	case	_	_
19	these	these	DT	_	21	det	_	_
20	therapeutic	therapeutic	JJ	_	21	attr	_	_
21	agents	agent	NNS	_	17	ppmod	_	_
22	after	after	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	initiation	initiation	NN	_	15	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	therapy	therapy	NN	_	24	ppmod	_	_
27	with	with	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	15	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	patients	patient	NNS	_	9	dep	_	_
6	on	on	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	often	often	RB	_	9	adv	_	_
9	needed	need	VBD	_	0	root	_	_
10	higher	high	JJR	_	13	attr	_	_
11	serum	serum	NN	_	13	com	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	9	obj	_	_
14	to	to	TO	_	15	aux	_	_
15	achieve	achieve	VB	_	9	comp	_	_
16	appropriate	appropriate	JJ	_	18	attr	_	_
17	IGF-I	igf-i	NN	_	18	com	_	_
18	suppression	suppression	NN	_	15	obj	_	_
19	compared	compare	VBN	_	21	adv	_	_
20	with	with	IN	_	21	case	_	_
21	patients	patient	NNS	_	15	ppmod	_	_
22	not	not	RB	_	23	neg	_	_
23	receiving	receive	VBG	_	21	acl	_	_
24	drug3	drug0	NN	_	23	obj	_	_
25	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanism	mechanism	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	interaction	interaction	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	known	know	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	digitalized	digitalized	JJ	_	9	attr	_	_
9	patients	patient	NNS	_	4	ppmod	_	_
10	,	,	,	_	4	p	_	_
11	since	since	IN	_	19	mark	_	_
12	the	the	DT	_	13	det	_	_
13	combination	combination	NN	_	19	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	may	may	MD	_	19	modal	_	_
19	cause	cause	VB	_	4	comp	_	_
20	ectopic	ectopic	JJ	_	21	attr	_	_
21	arrhythmias	arrhythmias	NN	_	19	obj	_	_
22	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	potentiate	potentiate	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	action	action	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	Therefore	therefore	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	when	when	WRB	_	4	adv	_	_
4	initiating	initiate	VBG	_	17	advcl	_	_
5	pressor	pressor	NN	_	6	com	_	_
6	therapy	therapy	NN	_	4	obj	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	these	these	DT	_	11	det	_	_
11	drugs	drug	NNS	_	9	obj	_	_
12	,	,	,	_	17	p	_	_
13	the	the	DT	_	15	det	_	_
14	initial	initial	JJ	_	15	attr	_	_
15	dose	dose	NN	_	17	dep	_	_
16	should	should	MD	_	17	modal	_	_
17	be	be	VB	_	0	root	_	_
18	small	small	JJ	_	17	dep	_	_
19	and	and	CC	_	17	cc	_	_
20	given	give	VBN	_	17	conj	_	_
21	with	with	IN	_	22	case	_	_
22	caution	caution	NN	_	20	ppmod	_	_
23	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	5	det	_	_
4	bacteriostatic	bacteriostatic	JJ	_	5	attr	_	_
5	drug2	drug0	NN	_	1	appo	_	_
6	,	,	,	_	1	p	_	_
7	may	may	MD	_	8	modal	_	_
8	antagonize	antagonize	VB	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	bactericidal	bactericidal	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	8	cc	_	_
15	concurrent	concurrent	JJ	_	16	attr	_	_
16	use	use	NN	_	22	dep	_	_
17	of	of	IN	_	19	case	_	_
18	these	these	DT	_	19	det	_	_
19	drugs	drug	NNS	_	16	ppmod	_	_
20	should	should	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	avoided	avoid	VBN	_	8	conj	_	_
23	.	.	.	_	8	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	result	result	VB	_	0	root	_	_
9	in	in	IN	_	13	case	_	_
10	an	an	DT	_	13	det	_	_
11	adverse	adverse	JJ	_	13	attr	_	_
12	drug	drug	NN	_	13	com	_	_
13	interaction	interaction	NN	_	8	ppmod	_	_
14	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	studied	study	VBN	_	0	root	_	_
5	on	on	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	background	background	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	15	p	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	15	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	,	,	,	_	15	p	_	_
13	has	have	VBZ	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	associated	associate	VBN	_	0	root	_	_
16	with	with	IN	_	18	case	_	_
17	an	an	DT	_	18	det	_	_
18	increase	increase	NN	_	15	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	bleeding	bleeding	JJ	_	18	ppmod	_	_
21	compared	compare	VBN	_	18	acl	_	_
22	to	to	TO	_	23	aux	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	drug5	drug0	NN	_	23	conj	_	_
26	alone	alone	RB	_	21	adv	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	see	see	VB	_	15	prn	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Inhibitors	inhibitor	NNS	_	2	appo	_	_
5	of	of	IN	_	7	case	_	_
6	CYP3A4	cyp0a0	NN	_	7	com	_	_
7	Isozymes	isozymes	NNS	_	4	ppmod	_	_
8	:	:	:	_	2	p	_	_
9	Caution	caution	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	advised	advise	VBN	_	2	acl	_	_
12	when	when	WRB	_	15	adv	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	is	be	VBZ	_	15	aux	_	_
15	administered	administer	VBN	_	11	comp	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	with	with	IN	_	18	case	_	_
18	drugs	drug	NNS	_	15	ppmod	_	_
19	that	that	WDT	_	21	dep	_	_
20	are	be	VBP	_	21	aux	_	_
21	known	know	VBN	_	18	relcl	_	_
22	to	to	TO	_	23	aux	_	_
23	inhibit	inhibit	VB	_	21	comp	_	_
24	the	the	DT	_	29	det	_	_
25	cytochrome	cytochrome	NN	_	27	com	_	_
26	P450	p0	NN	_	27	com	_	_
27	3A4	0a0	NN	_	29	com	_	_
28	enzyme	enzyme	NN	_	29	com	_	_
29	system	system	NN	_	23	obj	_	_
30	(	-lrb-	-LRB-	_	34	p	_	_
31	ie	ie	FW	_	34	ppmod	_	_
32	,	,	,	_	34	p	_	_
33	some	some	DT	_	34	det	_	_
34	drugs	drug	NNS	_	21	prn	_	_
35	in	in	IN	_	38	case	_	_
36	the	the	DT	_	38	det	_	_
37	drug	drug	NN	_	38	com	_	_
38	classes	class	NNS	_	34	ppmod	_	_
39	of	of	IN	_	40	case	_	_
40	drug2	drug0	NN	_	38	ppmod	_	_
41	,	,	,	_	40	p	_	_
42	drug3	drug0	NN	_	40	conj	_	_
43	,	,	,	_	42	p	_	_
44	drug4	drug0	NN	_	40	conj	_	_
45	,	,	,	_	44	p	_	_
46	and	and	CC	_	44	cc	_	_
47	drug5	drug0	NN	_	40	conj	_	_
48	)	-rrb-	-RRB-	_	34	p	_	_
49	.	.	.	_	2	p	_	_

1	Drugs	drug	NNS	_	16	dep	_	_
2	such	such	JJ	_	4	adv	_	_
3	as	as	IN	_	4	case	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug5	drug0	NN	_	4	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug6	drug0	NN	_	4	conj	_	_
15	were	be	VBD	_	16	aux	_	_
16	shown	show	VBN	_	0	root	_	_
17	to	to	TO	_	19	aux	_	_
18	significantly	significantly	RB	_	19	adv	_	_
19	increase	increase	VB	_	16	comp	_	_
20	the	the	DT	_	22	det	_	_
21	C	c	NN	_	22	com	_	_
22	max	max	NN	_	19	obj	_	_
23	and	and	CC	_	22	cc	_	_
24	AUC	auc	NN	_	22	conj	_	_
25	of	of	IN	_	28	case	_	_
26	orally	orally	RB	_	27	adv	_	_
27	administered	administer	VBN	_	28	attr	_	_
28	drug7	drug0	NN	_	22	ppmod	_	_
29	.	.	.	_	16	p	_	_

1	These	these	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	result	result	VB	_	0	root	_	_
6	in	in	IN	_	10	case	_	_
7	increased	increase	VBN	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	prolonged	prolonged	JJ	_	7	conj	_	_
10	sedation	sedation	NN	_	5	ppmod	_	_
11	due	due	JJ	_	10	attr	_	_
12	to	to	TO	_	14	aux	_	_
13	a	a	DT	_	14	det	_	_
14	decrease	decrease	NN	_	11	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	clearance	clearance	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	not	not	RB	_	3	neg	_	_
3	studied	study	VBN	_	15	advcl	_	_
4	,	,	,	_	15	p	_	_
5	the	the	DT	_	10	det	_	_
6	potent	potent	JJ	_	10	attr	_	_
7	cytochrome	cytochrome	NN	_	9	com	_	_
8	P450	p0	NN	_	9	com	_	_
9	3A4	0a0	NN	_	10	com	_	_
10	inhibitors	inhibitor	NNS	_	15	dep	_	_
11	drug1	drug0	NN	_	10	appo	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	may	may	MD	_	15	modal	_	_
15	cause	cause	VB	_	0	root	_	_
16	intense	intense	JJ	_	19	attr	_	_
17	and	and	CC	_	16	cc	_	_
18	prolonged	prolonged	JJ	_	16	conj	_	_
19	sedation	sedation	NN	_	15	obj	_	_
20	and	and	CC	_	19	cc	_	_
21	respiratory	respiratory	JJ	_	22	attr	_	_
22	depression	depression	NN	_	19	conj	_	_
23	due	due	JJ	_	26	adv	_	_
24	to	to	TO	_	26	aux	_	_
25	a	a	DT	_	26	det	_	_
26	decrease	decrease	NN	_	15	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	plasma	plasma	NN	_	29	com	_	_
29	clearance	clearance	NN	_	26	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug3	drug0	NN	_	29	ppmod	_	_
32	.	.	.	_	15	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	advised	advise	VBN	_	0	root	_	_
4	when	when	WRB	_	7	adv	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	is	be	VBZ	_	7	aux	_	_
7	used	use	VBN	_	3	comp	_	_
8	concomitantly	concomitantly	RB	_	7	adv	_	_
9	with	with	IN	_	11	case	_	_
10	these	these	DT	_	11	det	_	_
11	drugs	drug	NNS	_	7	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	Dose	dose	NN	_	2	com	_	_
2	adjustments	adjustment	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	considered	consider	VBN	_	0	root	_	_
6	and	and	CC	_	5	cc	_	_
7	possible	possible	JJ	_	8	attr	_	_
8	prolongation	prolongation	NN	_	15	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	intensity	intensity	NN	_	8	conj	_	_
11	of	of	IN	_	12	case	_	_
12	effect	effect	NN	_	8	ppmod	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	anticipated	anticipate	VBN	_	5	conj	_	_
16	.	.	.	_	5	p	_	_

1	Inducers	inducer	NNS	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	CYP3A4	cyp0a0	NN	_	4	com	_	_
4	Isozymes	isozymes	NNS	_	1	ppmod	_	_
5	:	:	:	_	1	p	_	_
6	Cytochrome	cytochrome	NN	_	7	com	_	_
7	P450	p0	NN	_	8	com	_	_
8	inducers	inducer	NNS	_	19	dep	_	_
9	,	,	,	_	8	p	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug1	drug0	NN	_	8	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug3	drug0	NN	_	12	conj	_	_
18	,	,	,	_	8	p	_	_
19	induce	induce	VBP	_	1	acl	_	_
20	metabolism	metabolism	NN	_	19	obj	_	_
21	and	and	CC	_	19	cc	_	_
22	caused	cause	VBD	_	19	conj	_	_
23	a	a	DT	_	27	det	_	_
24	markedly	markedly	RB	_	25	adv	_	_
25	decreased	decrease	VBN	_	27	attr	_	_
26	C	c	NN	_	27	com	_	_
27	max	max	NN	_	22	obj	_	_
28	and	and	CC	_	27	cc	_	_
29	AUC	auc	NN	_	27	conj	_	_
30	of	of	IN	_	32	case	_	_
31	oral	oral	JJ	_	32	attr	_	_
32	drug4	drug0	NNS	_	27	ppmod	_	_
33	in	in	IN	_	35	case	_	_
34	adult	adult	JJ	_	35	attr	_	_
35	studies	study	NNS	_	27	ppmod	_	_
36	.	.	.	_	1	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	7	dep	_	_
4	have	have	VBP	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	11	advcl	_	_
8	,	,	,	_	11	p	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	expected	expect	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	have	have	VB	_	11	comp	_	_
14	the	the	DT	_	16	det	_	_
15	same	same	JJ	_	16	attr	_	_
16	effect	effect	NN	_	13	obj	_	_
17	.	.	.	_	11	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	advised	advise	VBN	_	0	root	_	_
4	when	when	WRB	_	5	adv	_	_
5	administering	administer	VBG	_	3	advcl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	patients	patient	NNS	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	these	these	DT	_	11	det	_	_
11	medications	medication	NNS	_	9	obj	_	_
12	and	and	CC	_	5	cc	_	_
13	if	if	IN	_	19	mark	_	_
14	necessary	necessary	JJ	_	16	attr	_	_
15	dose	dose	NN	_	16	com	_	_
16	adjustments	adjustment	NNS	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	considered	consider	VBN	_	5	conj	_	_
20	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	difficulty	difficulty	NN	_	9	dep	_	_
3	in	in	IN	_	4	case	_	_
4	achieving	achieve	VBG	_	2	ppmod	_	_
5	adequate	adequate	JJ	_	6	attr	_	_
6	sedation	sedation	NN	_	4	obj	_	_
7	may	may	MD	_	9	modal	_	_
8	have	have	VBP	_	9	aux	_	_
9	been	be	VBN	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	result	result	NN	_	9	obj	_	_
12	of	of	IN	_	14	case	_	_
13	decreased	decrease	VBN	_	14	attr	_	_
14	absorption	absorption	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	drug1	drug0	NN	_	14	ppmod	_	_
18	due	due	JJ	_	17	attr	_	_
19	to	to	TO	_	23	aux	_	_
20	both	both	CC	_	23	cc	_	_
21	the	the	DT	_	23	det	_	_
22	gastrointestinal	gastrointestinal	JJ	_	23	attr	_	_
23	effects	effect	NNS	_	18	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	stimulant	stimulant	JJ	_	26	attr	_	_
26	effects	effect	NNS	_	23	conj	_	_
27	of	of	IN	_	28	case	_	_
28	drug2	drug0	NN	_	23	ppmod	_	_
29	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	sedative	sedative	JJ	_	3	attr	_	_
3	effect	effect	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	accentuated	accentuate	VBN	_	0	root	_	_
8	by	by	IN	_	12	case	_	_
9	any	any	DT	_	12	det	_	_
10	concomitantly	concomitantly	RB	_	11	adv	_	_
11	administered	administer	VBN	_	12	attr	_	_
12	medication	medication	NN	_	7	ppmod	_	_
13	which	which	WDT	_	14	dep	_	_
14	depresses	depress	VBZ	_	12	relcl	_	_
15	the	the	DT	_	18	det	_	_
16	central	central	JJ	_	18	attr	_	_
17	nervous	nervous	JJ	_	18	attr	_	_
18	system	system	NN	_	14	obj	_	_
19	,	,	,	_	12	p	_	_
20	particularly	particularly	RB	_	12	adv	_	_
21	drug2	drug0	NN	_	12	appo	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	eg	eg	NN	_	21	prn	_	_
24	,	,	,	_	23	p	_	_
25	drug3	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug4	drug0	NN	_	23	conj	_	_
28	and	and	CC	_	27	cc	_	_
29	drug5	drug0	NN	_	23	conj	_	_
30	)	-rrb-	-RRB-	_	23	p	_	_
31	,	,	,	_	21	p	_	_
32	drug6	drug0	NN	_	21	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug7	drug0	NN	_	21	conj	_	_
35	,	,	,	_	34	p	_	_
36	drug8	drug0	NN	_	21	conj	_	_
37	,	,	,	_	36	p	_	_
38	drug9	drug0	NN	_	21	conj	_	_
39	and	and	CC	_	38	cc	_	_
40	drug10	drug0	NN	_	21	conj	_	_
41	.	.	.	_	7	p	_	_

1	Consequently	consequently	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	the	the	DT	_	4	det	_	_
4	dose	dose	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	adjusted	adjust	VBN	_	0	root	_	_
10	according	accord	VBG	_	13	adv	_	_
11	to	to	TO	_	13	aux	_	_
12	the	the	DT	_	13	det	_	_
13	type	type	NN	_	9	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	amount	amount	NN	_	13	conj	_	_
16	of	of	IN	_	18	case	_	_
17	concomitant	concomitant	JJ	_	18	attr	_	_
18	medications	medication	NNS	_	13	ppmod	_	_
19	administered	administer	VBN	_	18	acl	_	_
20	and	and	CC	_	18	cc	_	_
21	the	the	DT	_	24	det	_	_
22	desired	desired	JJ	_	24	attr	_	_
23	clinical	clinical	JJ	_	24	attr	_	_
24	response	response	NN	_	18	conj	_	_
25	.	.	.	_	9	p	_	_

1	No	no	DT	_	4	det	_	_
2	significant	significant	JJ	_	4	attr	_	_
3	adverse	adverse	JJ	_	4	attr	_	_
4	interactions	interaction	NNS	_	30	dep	_	_
5	with	with	IN	_	7	case	_	_
6	common	common	JJ	_	7	attr	_	_
7	premedications	premedications	NNS	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	such	such	JJ	_	7	prn	_	_
10	as	as	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	11	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	11	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	other	other	JJ	_	23	attr	_	_
23	drug6	drug0	NN	_	11	conj	_	_
24	)	-rrb-	-RRB-	_	9	p	_	_
25	or	or	CC	_	7	cc	_	_
26	local	local	JJ	_	27	attr	_	_
27	drug7	drug0	NN	_	7	conj	_	_
28	have	have	VBP	_	30	aux	_	_
29	been	be	VBN	_	30	aux	_	_
30	observed	observe	VBN	_	0	root	_	_
31	.	.	.	_	30	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	29	dep	_	_
4	of	of	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	including	include	VBG	_	8	adv	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	general	general	JJ	_	15	attr	_	_
15	drug5	drug0	NN	_	8	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug6	drug0	NN	_	8	conj	_	_
18	,	,	,	_	17	p	_	_
19	other	other	JJ	_	20	attr	_	_
20	drug7	drug0	NN	_	8	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug8	drug0	NN	_	8	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug9	drug0	NN	_	8	conj	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	drug10	drug0	NN	_	8	conj	_	_
28	may	may	MD	_	29	modal	_	_
29	produce	produce	VB	_	0	root	_	_
30	additive	additive	JJ	_	33	attr	_	_
31	CNS	cns	NN	_	33	com	_	_
32	depressant	depressant	NN	_	33	com	_	_
33	effects	effect	NNS	_	29	obj	_	_
34	.	.	.	_	29	p	_	_

1	When	when	WRB	_	6	adv	_	_
2	such	such	JJ	_	4	attr	_	_
3	combined	combined	JJ	_	4	attr	_	_
4	therapy	therapy	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	contemplated	contemplate	VBN	_	17	advcl	_	_
7	,	,	,	_	17	p	_	_
8	the	the	DT	_	9	det	_	_
9	dose	dose	NN	_	17	dep	_	_
10	of	of	IN	_	11	case	_	_
11	one	#crd#	CD	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	both	both	DT	_	14	attr	_	_
14	agents	agent	NNS	_	11	conj	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	reduced	reduce	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	other	other	JJ	_	4	attr	_	_
4	medications	medication	NNS	_	1	conj	_	_
5	with	with	IN	_	7	case	_	_
6	anticholinergic	anticholinergic	JJ	_	7	attr	_	_
7	activity	activity	NN	_	0	root	_	_
8	when	when	WRB	_	9	adv	_	_
9	used	use	VBN	_	7	comp	_	_
10	concurrently	concurrently	RB	_	9	adv	_	_
11	with	with	IN	_	14	mark	_	_
12	drug2	drug0	NN	_	14	dep	_	_
13	may	may	MD	_	14	modal	_	_
14	result	result	VB	_	9	comp	_	_
15	in	in	IN	_	17	case	_	_
16	increased	increase	VBN	_	17	attr	_	_
17	risk	risk	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	urinary	urinary	JJ	_	20	attr	_	_
20	retention	retention	NN	_	17	ppmod	_	_
21	and/or	and/or	CC	_	20	cc	_	_
22	severe	severe	JJ	_	23	attr	_	_
23	constipation	constipation	NN	_	20	conj	_	_
24	,	,	,	_	17	p	_	_
25	which	which	WDT	_	27	dep	_	_
26	may	may	MD	_	27	modal	_	_
27	lead	lead	VB	_	17	relcl	_	_
28	to	to	TO	_	30	aux	_	_
29	paralytic	paralytic	JJ	_	30	attr	_	_
30	ileus	ileus	NNS	_	27	ppmod	_	_
31	.	.	.	_	7	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	that	that	IN	_	11	mark	_	_
6	the	the	DT	_	7	det	_	_
7	incidence	incidence	NN	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	bradycardia	bradycardia	NN	_	7	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	increased	increase	VBN	_	4	comp	_	_
12	when	when	WRB	_	15	adv	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	combined	combine	VBN	_	11	comp	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	for	for	IN	_	19	case	_	_
19	induction	induction	NN	_	15	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	anesthesia	anesthesia	NN	_	19	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	CNS	cns	NN	_	5	com	_	_
5	toxicity	toxicity	NN	_	8	dep	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	confusion	confusion	NN	_	8	prn	_	_
11	,	,	,	_	10	p	_	_
12	disorientation	disorientation	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	respiratory	respiratory	JJ	_	15	attr	_	_
15	depression	depression	NN	_	10	appo	_	_
16	,	,	,	_	10	p	_	_
17	apnea	apnea	NN	_	10	appo	_	_
18	,	,	,	_	10	p	_	_
19	seizures	seizures	NN	_	10	appo	_	_
20	)	-rrb-	-RRB-	_	10	p	_	_
21	following	follow	VBG	_	22	adv	_	_
22	coadministration	coadministration	NN	_	8	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	with	with	IN	_	26	case	_	_
26	drug2	drug0	NN	_	22	ppmod	_	_
27	;	;	:	_	8	p	_	_

1	no	no	DT	_	6	det	_	_
2	clear-cut	clear-cut	JJ	_	6	attr	_	_
3	cause	cause	NN	_	6	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	effect	effect	NN	_	3	conj	_	_
6	relationship	relationship	NN	_	8	dep	_	_
7	was	be	VBD	_	8	aux	_	_
8	established	establish	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Dosages	dosage	NNS	_	8	dep	_	_
2	of	of	IN	_	5	case	_	_
3	concomitantly	concomitantly	RB	_	4	adv	_	_
4	administered	administer	VBN	_	5	attr	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	reduced	reduce	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	approximately	approximately	RB	_	11	adv	_	_
11	half	half	NN	_	8	ppmod	_	_
12	,	,	,	_	8	p	_	_
13	because	because	IN	_	15	mark	_	_
14	drug2	drug0	NN	_	15	dep	_	_
15	amplifies	amplify	VBZ	_	8	comp	_	_
16	the	the	DT	_	18	det	_	_
17	therapeutic	therapeutic	JJ	_	18	attr	_	_
18	actions	action	NNS	_	15	obj	_	_
19	and	and	CC	_	18	cc	_	_
20	side-effects	side-effect	NNS	_	18	conj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	18	ppmod	_	_
23	.	.	.	_	8	p	_	_

1	Combination	combination	NN	_	8	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	is	be	VBZ	_	8	aux	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	11	case	_	_
10	increased	increase	VBN	_	11	attr	_	_
11	risk	risk	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	seizures	seizure	NNS	_	11	ppmod	_	_
14	.	.	.	_	8	p	_	_

1	Additive	additive	JJ	_	3	attr	_	_
2	sedative	sedative	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	8	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	confusional	confusional	JJ	_	6	attr	_	_
6	states	state	NNS	_	3	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	emerge	emerge	VB	_	0	root	_	_
9	if	if	IN	_	12	mark	_	_
10	drug1	drug0	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	given	give	VBN	_	8	comp	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	.	.	.	_	8	p	_	_

1	This	this	DT	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	avoided	avoid	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	using	use	VBG	_	4	ppmod	_	_
7	the	the	DT	_	9	det	_	_
8	lowest	low	JJS	_	9	attr	_	_
9	dose	dose	NN	_	6	obj	_	_
10	possible	possible	JJ	_	9	attr	_	_
11	with	with	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	substances	substance	NNS	_	10	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	question	question	NN	_	13	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	Exert	exert	VBP	_	20	advcl	_	_
2	particular	particular	JJ	_	3	attr	_	_
3	caution	caution	NN	_	1	obj	_	_
4	in	in	IN	_	5	case	_	_
5	combining	combine	VBG	_	1	ppmod	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug3	drug0	NN	_	9	prn	_	_
12	and	and	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	)	-rrb-	-RRB-	_	11	p	_	_
15	:	:	:	_	20	p	_	_
16	Particularly	particularly	RB	_	18	adv	_	_
17	the	the	DT	_	18	det	_	_
18	elderly	elderly	JJ	_	20	dep	_	_
19	may	may	MD	_	20	modal	_	_
20	develop	develop	VB	_	0	root	_	_
21	delirium	delirium	NN	_	20	obj	_	_
22	,	,	,	_	21	p	_	_
23	high	high	JJ	_	24	attr	_	_
24	fever	fever	NN	_	21	conj	_	_
25	,	,	,	_	24	p	_	_
26	severe	severe	JJ	_	27	attr	_	_
27	obstipation	obstipation	NN	_	21	conj	_	_
28	,	,	,	_	27	p	_	_
29	even	even	JJ	_	30	attr	_	_
30	ileus	ileus	NN	_	21	conj	_	_
31	and	and	CC	_	30	cc	_	_
32	glaucoma	glaucoma	NN	_	21	conj	_	_
33	.	.	.	_	20	p	_	_

1	Reduce	reduce	VBP	_	0	root	_	_
2	both	both	CC	_	4	cc	_	_
3	the	the	DT	_	4	det	_	_
4	dose	dose	NN	_	1	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	4	cc	_	_
8	the	the	DT	_	9	det	_	_
9	dose	dose	NN	_	4	conj	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug	drug	NN	_	9	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	If	if	IN	_	2	mark	_	_
2	possible	possible	JJ	_	4	advcl	_	_
3	,	,	,	_	4	p	_	_
4	avoid	avoid	VB	_	0	root	_	_
5	such	such	JJ	_	6	attr	_	_
6	combinations	combination	NNS	_	4	obj	_	_
7	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	and/or	and/or	CC	_	1	cc	_	_
3	stimulantes	stimulantes	NN	_	1	conj	_	_
4	of	of	IN	_	9	case	_	_
5	the	the	DT	_	9	det	_	_
6	drug2	drug0	NN	_	9	attr	_	_
7	/	/	:	_	9	p	_	_
8	drug3	drug0	NN	_	9	com	_	_
9	type	type	NN	_	1	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	counteract	counteract	VB	_	0	root	_	_
12	the	the	DT	_	14	det	_	_
13	specific	specific	JJ	_	14	attr	_	_
14	actions	action	NNS	_	11	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	substances	substance	NNS	_	2	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	avoided	avoid	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Coffee	coffee	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	black	black	JJ	_	4	attr	_	_
4	tea	tea	NN	_	1	conj	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	avoided	avoid	VBN	_	0	root	_	_
8	because	because	IN	_	10	mark	_	_
9	they	they	PRP	_	10	dep	_	_
10	decrease	decrease	VBP	_	7	comp	_	_
11	the	the	DT	_	12	det	_	_
12	absorption	absorption	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	considerably	considerably	RB	_	10	adv	_	_
16	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	same	same	JJ	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	true	true	JJ	_	3	dep	_	_
5	for	for	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	;	;	:	_	3	p	_	_

1	these	these	DT	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	given	give	VBN	_	0	root	_	_
5	1	0	CD	_	8	num	_	_
6	to	to	TO	_	5	cc	_	_
7	2	0	CD	_	5	conj	_	_
8	hours	hour	NNS	_	4	obj	_	_
9	before	before	IN	_	4	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	after	after	IN	_	13	case	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	administration	administration	NN	_	9	conj	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	Usage	usage	NN	_	0	root	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	:	:	:	_	1	p	_	_
5	Due	due	JJ	_	8	adv	_	_
6	to	to	TO	_	8	aux	_	_
7	the	the	DT	_	8	det	_	_
8	potential	potential	NN	_	18	ppmod	_	_
9	for	for	IN	_	13	case	_	_
10	increased	increase	VBN	_	13	attr	_	_
11	CNS	cns	NN	_	13	com	_	_
12	depressants	depressants	NN	_	13	com	_	_
13	effects	effect	NNS	_	8	ppmod	_	_
14	,	,	,	_	18	p	_	_
15	drug2	drug0	NN	_	18	dep	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	used	use	VBN	_	1	acl	_	_
19	with	with	IN	_	20	case	_	_
20	caution	caution	NN	_	18	ppmod	_	_
21	in	in	IN	_	22	case	_	_
22	patients	patient	NNS	_	20	ppmod	_	_
23	who	who	WP	_	26	dep	_	_
24	are	be	VBP	_	26	aux	_	_
25	currently	currently	RB	_	26	adv	_	_
26	receiving	receive	VBG	_	22	relcl	_	_
27	drug3	drug0	NN	_	26	obj	_	_
28	.	.	.	_	1	p	_	_

1	The	the	DT	_	4	det	_	_
2	CNS	cns	NN	_	4	com	_	_
3	depressant	depressant	NN	_	4	com	_	_
4	effects	effect	NNS	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	be	be	VB	_	0	root	_	_
9	additive	additive	JJ	_	8	dep	_	_
10	with	with	IN	_	11	case	_	_
11	that	that	DT	_	9	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug2	drug0	NNS	_	11	ppmod	_	_
15	.	.	.	_	8	p	_	_
16	.	.	.	_	8	p	_	_

1	Limited	limited	JJ	_	2	attr	_	_
2	evidence	evidence	NN	_	3	dep	_	_
3	suggests	suggest	VBZ	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	influence	influence	VB	_	3	comp	_	_
8	the	the	DT	_	9	det	_	_
9	intensity	intensity	NN	_	7	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	duration	duration	NN	_	9	conj	_	_
12	of	of	IN	_	13	case	_	_
13	action	action	NN	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	multiple-dose	multiple-dose	JJ	_	6	attr	_	_
6	study	study	NN	_	32	ppmod	_	_
7	in	in	IN	_	11	case	_	_
8	30	0	CD	_	11	num	_	_
9	normal	normal	JJ	_	11	attr	_	_
10	weight	weight	NN	_	11	com	_	_
11	subjects	subject	NNS	_	6	ppmod	_	_
12	,	,	,	_	32	p	_	_
13	coadministration	coadministration	NN	_	32	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	40	0	CD	_	18	num	_	_
18	grams	gram	NNS	_	15	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	(	-lrb-	-LRB-	_	26	p	_	_
22	e.g.	e.g.	FW	_	26	ppmod	_	_
23	,	,	,	_	26	p	_	_
24	approximately	approximately	RB	_	25	adv	_	_
25	3	0	CD	_	26	num	_	_
26	glasses	glass	NNS	_	18	prn	_	_
27	of	of	IN	_	28	case	_	_
28	wine	wine	NN	_	26	ppmod	_	_
29	)	-rrb-	-RRB-	_	26	p	_	_
30	did	do	VBD	_	32	aux	_	_
31	not	not	RB	_	32	neg	_	_
32	result	result	VB	_	1	acl	_	_
33	in	in	IN	_	34	case	_	_
34	alteration	alteration	NN	_	32	ppmod	_	_
35	of	of	IN	_	37	case	_	_
36	drug4	drug0	NN	_	37	com	_	_
37	pharmacokinetics	pharmacokinetics	NNS	_	34	ppmod	_	_
38	,	,	,	_	37	p	_	_
39	drug5	drug0	NN	_	40	com	_	_
40	pharmacodynamics	pharmacodynamics	NNS	_	37	conj	_	_
41	(	-lrb-	-LRB-	_	44	p	_	_
42	fecal	fecal	JJ	_	44	attr	_	_
43	fat	fat	JJ	_	44	attr	_	_
44	excretion	excretion	NN	_	40	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	,	,	,	_	40	p	_	_
47	or	or	CC	_	40	cc	_	_
48	systemic	systemic	JJ	_	49	attr	_	_
49	exposure	exposure	NN	_	37	conj	_	_
50	to	to	TO	_	51	aux	_	_
51	drug6	drug0	NN	_	49	ppmod	_	_
52	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Preliminary	preliminary	JJ	_	4	attr	_	_
4	data	datum	NNS	_	13	dep	_	_
5	from	from	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	12	com	_	_
10	drug	drug	NN	_	12	com	_	_
11	interaction	interaction	NN	_	12	com	_	_
12	study	study	NN	_	7	conj	_	_
13	indicate	indicate	VBP	_	1	acl	_	_
14	a	a	DT	_	15	det	_	_
15	reduction	reduction	NN	_	13	obj	_	_
16	in	in	IN	_	19	case	_	_
17	drug4	drug0	NN	_	19	com	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	levels	level	NNS	_	15	ppmod	_	_
20	when	when	WRB	_	23	adv	_	_
21	drug5	drug0	NN	_	23	dep	_	_
22	was	be	VBD	_	23	aux	_	_
23	coadministered	coadministered	VBN	_	15	relcl	_	_
24	with	with	IN	_	25	case	_	_
25	drug6	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	12	0	CD	_	6	num	_	_
5	normal-weight	normal-weight	JJ	_	6	attr	_	_
6	subjects	subject	NNS	_	22	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug2	drug0	NN	_	12	attr	_	_
9	120	0	CD	_	12	num	_	_
10	mg	mg	NN	_	12	attr	_	_
11	three	#crd#	CD	_	12	num	_	_
12	times	time	NNS	_	7	obj	_	_
13	a	a	DT	_	14	det	_	_
14	day	day	NN	_	12	appo	_	_
15	for	for	IN	_	17	case	_	_
16	6	0	CD	_	17	num	_	_
17	days	day	NNS	_	14	ppmod	_	_
18	,	,	,	_	22	p	_	_
19	drug3	drug0	NN	_	22	dep	_	_
20	did	do	VBD	_	22	aux	_	_
21	not	not	RB	_	22	neg	_	_
22	alter	alter	VB	_	1	acl	_	_
23	the	the	DT	_	24	det	_	_
24	pharmacokinetics	pharmacokinetics	NNS	_	22	obj	_	_
25	of	of	IN	_	28	case	_	_
26	a	a	DT	_	28	det	_	_
27	single	single	JJ	_	28	attr	_	_
28	dose	dose	NN	_	24	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug4	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	Analogues	analogue	NNS	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	A	a	DT	_	8	det	_	_
6	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
7	interaction	interaction	NN	_	8	com	_	_
8	study	study	NN	_	9	dep	_	_
9	showed	show	VBD	_	1	acl	_	_
10	a	a	DT	_	13	det	_	_
11	30	0	CD	_	13	num	_	_
12	%	%	NN	_	13	meta	_	_
13	reduction	reduction	NN	_	9	obj	_	_
14	in	in	IN	_	17	case	_	_
15	drug2	drug0	JJ	_	17	attr	_	_
16	supplement	supplement	NN	_	17	com	_	_
17	absorption	absorption	NN	_	13	ppmod	_	_
18	when	when	WRB	_	20	adv	_	_
19	concomitantly	concomitantly	RB	_	20	adv	_	_
20	administered	administer	VBN	_	9	comp	_	_
21	with	with	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibited	inhibit	VBD	_	0	root	_	_
3	absorption	absorption	NN	_	2	obj	_	_
4	of	of	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	supplement	supplement	NN	_	3	ppmod	_	_
8	by	by	IN	_	10	case	_	_
9	approximately	approximately	RB	_	10	adv	_	_
10	60	0	CD	_	2	ppmod	_	_
11	%	%	NN	_	10	meta	_	_
12	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	absorption	absorption	NN	_	2	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	supplemental	supplemental	JJ	_	10	attr	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	nutritionally-derived	nutritionally-derived	JJ	_	16	attr	_	_
16	drug4	drug0	NNS	_	10	conj	_	_
17	is	be	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	known	know	VBN	_	0	root	_	_
20	at	at	IN	_	22	case	_	_
21	this	this	DT	_	22	det	_	_
22	time	time	NN	_	19	ppmod	_	_
23	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	22	dep	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	12	0	CD	_	6	num	_	_
5	normal-weight	normal-weight	JJ	_	6	attr	_	_
6	subjects	subject	NNS	_	1	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	80	0	CD	_	10	num	_	_
10	mg	mg	NN	_	7	obj	_	_
11	three	#crd#	CD	_	12	num	_	_
12	times	time	NNS	_	10	appo	_	_
13	a	a	DT	_	14	det	_	_
14	day	day	NN	_	12	appo	_	_
15	for	for	IN	_	17	case	_	_
16	5	0	CD	_	17	num	_	_
17	days	day	NNS	_	14	ppmod	_	_
18	,	,	,	_	10	p	_	_
19	drug3	drug0	NN	_	10	appo	_	_
20	did	do	VBD	_	22	aux	_	_
21	not	not	RB	_	22	neg	_	_
22	alter	alter	VB	_	0	root	_	_
23	the	the	DT	_	24	det	_	_
24	pharmacokinetics	pharmacokinetics	NNS	_	22	obj	_	_
25	or	or	CC	_	24	cc	_	_
26	pharmacodynamics	pharmacodynamics	NNS	_	24	conj	_	_
27	(	-lrb-	-LRB-	_	29	p	_	_
28	blood	blood	NN	_	29	advnp	_	_
29	glucose-lowering	glucose-lowering	JJ	_	24	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	of	of	IN	_	32	case	_	_
32	drug4	drug0	NN	_	24	ppmod	_	_
33	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	extended-release	extended-release	NN	_	4	com	_	_
4	tablets	tablet	NNS	_	1	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	:	:	:	_	1	p	_	_
7	In	in	IN	_	10	case	_	_
8	17	0	CD	_	10	num	_	_
9	normal-weight	normal-weight	JJ	_	10	attr	_	_
10	subjects	subject	NNS	_	26	ppmod	_	_
11	receiving	receive	VBG	_	10	acl	_	_
12	drug2	drug0	NN	_	16	attr	_	_
13	120	0	CD	_	16	num	_	_
14	mg	mg	NN	_	16	attr	_	_
15	three	#crd#	CD	_	16	num	_	_
16	times	time	NNS	_	11	obj	_	_
17	a	a	DT	_	18	det	_	_
18	day	day	NN	_	16	appo	_	_
19	for	for	IN	_	21	case	_	_
20	6	0	CD	_	21	num	_	_
21	days	day	NNS	_	18	ppmod	_	_
22	,	,	,	_	26	p	_	_
23	drug3	drug0	NN	_	26	dep	_	_
24	did	do	VBD	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	alter	alter	VB	_	1	acl	_	_
27	the	the	DT	_	28	det	_	_
28	bioavailability	bioavailability	NN	_	26	obj	_	_
29	of	of	IN	_	30	case	_	_
30	drug4	drug0	NNS	_	28	ppmod	_	_
31	(	-lrb-	-LRB-	_	33	p	_	_
32	extended-release	extended-release	NN	_	33	com	_	_
33	tablets	tablet	NNS	_	30	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	.	.	.	_	1	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	In	in	IN	_	8	case	_	_
5	20	0	CD	_	8	num	_	_
6	normal-weight	normal-weight	JJ	_	8	attr	_	_
7	female	female	JJ	_	8	attr	_	_
8	subjects	subject	NNS	_	23	ppmod	_	_
9	,	,	,	_	23	p	_	_
10	the	the	DT	_	11	det	_	_
11	treatment	treatment	NN	_	23	dep	_	_
12	of	of	IN	_	17	case	_	_
13	drug2	drug0	NN	_	17	attr	_	_
14	120	0	CD	_	17	num	_	_
15	mg	mg	NN	_	17	attr	_	_
16	three	#crd#	CD	_	17	num	_	_
17	times	time	NNS	_	11	ppmod	_	_
18	a	a	DT	_	19	det	_	_
19	day	day	NN	_	17	appo	_	_
20	for	for	IN	_	22	case	_	_
21	23	0	CD	_	22	num	_	_
22	days	day	NNS	_	19	ppmod	_	_
23	resulted	result	VBD	_	2	acl	_	_
24	in	in	IN	_	26	case	_	_
25	no	no	DT	_	26	det	_	_
26	changes	change	NNS	_	23	ppmod	_	_
27	in	in	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	ovulation-suppressing	ovulation-suppressing	JJ	_	30	attr	_	_
30	action	action	NN	_	26	ppmod	_	_
31	of	of	IN	_	33	case	_	_
32	oral	oral	JJ	_	33	attr	_	_
33	drug3	drug0	NN	_	30	ppmod	_	_
34	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	12	0	CD	_	6	num	_	_
5	normal-weight	normal-weight	JJ	_	6	attr	_	_
6	subjects	subject	NNS	_	22	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug2	drug0	NN	_	12	attr	_	_
9	120	0	CD	_	12	num	_	_
10	mg	mg	NN	_	12	attr	_	_
11	three	#crd#	CD	_	12	num	_	_
12	times	time	NNS	_	7	obj	_	_
13	a	a	DT	_	14	det	_	_
14	day	day	NN	_	12	appo	_	_
15	for	for	IN	_	17	case	_	_
16	7	0	CD	_	17	num	_	_
17	days	day	NNS	_	14	ppmod	_	_
18	,	,	,	_	22	p	_	_
19	drug3	drug0	NN	_	22	dep	_	_
20	did	do	VBD	_	22	aux	_	_
21	not	not	RB	_	22	neg	_	_
22	alter	alter	VB	_	1	acl	_	_
23	the	the	DT	_	24	det	_	_
24	pharmacokinetics	pharmacokinetics	NNS	_	22	obj	_	_
25	of	of	IN	_	29	case	_	_
26	a	a	DT	_	29	det	_	_
27	single	single	JJ	_	29	attr	_	_
28	300-mg	0-mg	NN	_	29	com	_	_
29	dose	dose	NN	_	24	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	7	case	_	_
4	a	a	DT	_	7	det	_	_
5	2-way	0-way	JJ	_	7	attr	_	_
6	crossover	crossover	NN	_	7	com	_	_
7	study	study	NN	_	30	ppmod	_	_
8	of	of	IN	_	14	case	_	_
9	24	0	CD	_	14	num	_	_
10	normal-weight	normal-weight	JJ	_	13	adv	_	_
11	,	,	,	_	13	p	_	_
12	mildly	mildly	RB	_	13	adv	_	_
13	hypercholesterolemic	hypercholesterolemic	JJ	_	14	attr	_	_
14	patients	patient	NNS	_	7	ppmod	_	_
15	receiving	receive	VBG	_	14	acl	_	_
16	drug2	drug0	NN	_	20	attr	_	_
17	120	0	CD	_	20	num	_	_
18	mg	mg	NN	_	20	attr	_	_
19	three	#crd#	CD	_	20	num	_	_
20	times	time	NNS	_	15	obj	_	_
21	a	a	DT	_	22	det	_	_
22	day	day	NN	_	20	appo	_	_
23	for	for	IN	_	25	case	_	_
24	6	0	CD	_	25	num	_	_
25	days	day	NNS	_	22	ppmod	_	_
26	,	,	,	_	30	p	_	_
27	drug3	drug0	NN	_	30	dep	_	_
28	did	do	VBD	_	30	aux	_	_
29	not	not	RB	_	30	neg	_	_
30	affect	affect	VB	_	1	acl	_	_
31	the	the	DT	_	32	det	_	_
32	pharmacokinetics	pharmacokinetics	NNS	_	30	obj	_	_
33	of	of	IN	_	34	case	_	_
34	drug4	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	12	0	CD	_	6	num	_	_
5	normal-weight	normal-weight	JJ	_	6	attr	_	_
6	subjects	subject	NNS	_	22	ppmod	_	_
7	,	,	,	_	22	p	_	_
8	administration	administration	NN	_	22	dep	_	_
9	of	of	IN	_	14	case	_	_
10	drug2	drug0	NN	_	14	attr	_	_
11	120	0	CD	_	14	num	_	_
12	mg	mg	NN	_	14	attr	_	_
13	three	#crd#	CD	_	14	num	_	_
14	times	time	NNS	_	8	ppmod	_	_
15	a	a	DT	_	16	det	_	_
16	day	day	NN	_	14	appo	_	_
17	for	for	IN	_	19	case	_	_
18	16	0	CD	_	19	num	_	_
19	days	day	NNS	_	16	ppmod	_	_
20	did	do	VBD	_	22	aux	_	_
21	not	not	RB	_	22	neg	_	_
22	result	result	VB	_	1	acl	_	_
23	in	in	IN	_	25	case	_	_
24	any	any	DT	_	25	det	_	_
25	change	change	NN	_	22	ppmod	_	_
26	in	in	IN	_	29	case	_	_
27	either	either	CC	_	29	cc	_	_
28	drug3	drug0	NN	_	29	com	_	_
29	pharmacokinetics	pharmacokinetics	NNS	_	25	ppmod	_	_
30	(	-lrb-	-LRB-	_	32	p	_	_
31	both	both	CC	_	32	cc	_	_
32	R-	r-	NN	_	29	prn	_	_
33	and	and	CC	_	32	cc	_	_
34	S-enantiomers	s-enantiomers	NN	_	32	conj	_	_
35	)	-rrb-	-RRB-	_	32	p	_	_
36	or	or	CC	_	29	cc	_	_
37	pharmacodynamics	pharmacodynamics	NNS	_	29	conj	_	_
38	(	-lrb-	-LRB-	_	40	p	_	_
39	prothrombin	prothrombin	NN	_	40	com	_	_
40	time	time	NN	_	37	prn	_	_
41	and	and	CC	_	40	cc	_	_
42	serum	serum	NN	_	44	com	_	_
43	Factor	factor	NN	_	44	com	_	_
44	VII	vii	NN	_	40	conj	_	_
45	)	-rrb-	-RRB-	_	40	p	_	_
46	.	.	.	_	1	p	_	_

1	Although	although	IN	_	13	mark	_	_
2	undercarboxylated	undercarboxylated	JJ	_	3	attr	_	_
3	osteocalcin	osteocalcin	NN	_	13	dep	_	_
4	,	,	,	_	3	p	_	_
5	a	a	DT	_	6	det	_	_
6	marker	marker	NN	_	3	appo	_	_
7	of	of	IN	_	11	case	_	_
8	vitamin	vitamin	NN	_	11	attr	_	_
9	K	k	NN	_	11	attr	_	_
10	nutritional	nutritional	JJ	_	11	attr	_	_
11	status	status	NN	_	6	ppmod	_	_
12	,	,	,	_	3	p	_	_
13	was	be	VBD	_	22	advcl	_	_
14	unaltered	unaltered	JJ	_	13	dep	_	_
15	with	with	IN	_	17	case	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	administration	administration	NN	_	13	ppmod	_	_
18	,	,	,	_	22	p	_	_
19	vitamin	vitamin	NN	_	21	com	_	_
20	K	k	NN	_	21	com	_	_
21	levels	level	NNS	_	22	dep	_	_
22	tended	tend	VBD	_	0	root	_	_
23	to	to	TO	_	24	aux	_	_
24	decline	decline	NN	_	22	ppmod	_	_
25	in	in	IN	_	26	case	_	_
26	subjects	subject	NNS	_	22	ppmod	_	_
27	taking	take	VBG	_	26	acl	_	_
28	drug2	drug0	NN	_	27	obj	_	_
29	.	.	.	_	22	p	_	_

1	Therefore	therefore	RB	_	25	adv	_	_
2	,	,	,	_	25	p	_	_
3	as	as	IN	_	8	mark	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	absorption	absorption	NN	_	8	dep	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	decreased	decrease	VBN	_	25	advcl	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	25	p	_	_
12	patients	patient	NNS	_	25	dep	_	_
13	on	on	IN	_	16	case	_	_
14	chronic	chronic	JJ	_	16	attr	_	_
15	stable	stable	JJ	_	16	attr	_	_
16	doses	dose	NNS	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	who	who	WP	_	21	dep	_	_
20	are	be	VBP	_	21	aux	_	_
21	prescribed	prescribe	VBN	_	12	relcl	_	_
22	drug4	drug0	NN	_	21	obj	_	_
23	should	should	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	monitored	monitor	VBN	_	0	root	_	_
26	closely	closely	RB	_	25	adv	_	_
27	for	for	IN	_	28	case	_	_
28	changes	change	NNS	_	25	ppmod	_	_
29	in	in	IN	_	31	case	_	_
30	coagulation	coagulation	NN	_	31	com	_	_
31	parameters	parameter	NNS	_	28	ppmod	_	_
32	.	.	.	_	25	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	competes	compete	VBZ	_	0	root	_	_
3	with	with	IN	_	4	case	_	_
4	drug2	drug0	NN	_	2	ppmod	_	_
5	for	for	IN	_	8	case	_	_
6	active	active	JJ	_	8	attr	_	_
7	tubular	tubular	JJ	_	8	attr	_	_
8	secretion	secretion	NN	_	2	ppmod	_	_
9	and	and	CC	_	2	cc	_	_
10	thus	thus	RB	_	11	adv	_	_
11	inhibits	inhibit	VBZ	_	2	conj	_	_
12	the	the	DT	_	14	det	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	excretion	excretion	NN	_	11	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	This	this	DT	_	2	dep	_	_
2	led	lead	VBD	_	0	root	_	_
3	to	to	TO	_	6	aux	_	_
4	statistically	statistically	RB	_	5	adv	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	increases	increase	NNS	_	2	ppmod	_	_
7	in	in	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	elimination	elimination	NN	_	10	com	_	_
10	half-life	half-life	NN	_	6	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	38	0	CD	_	10	num	_	_
13	%	%	NN	_	12	meta	_	_
14	)	-rrb-	-RRB-	_	12	p	_	_
15	and	and	CC	_	10	cc	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	extent	extent	NN	_	10	conj	_	_
19	of	of	IN	_	21	case	_	_
20	systemic	systemic	JJ	_	21	attr	_	_
21	exposure	exposure	NN	_	18	ppmod	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	56	0	CD	_	21	num	_	_
24	%	%	NN	_	23	meta	_	_
25	)	-rrb-	-RRB-	_	23	p	_	_
26	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	4	det	_	_
4	coadministration	coadministration	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	is	be	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	recommended	recommend	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	evidence	evidence	NN	_	2	obj	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	reduce	reduce	VB	_	3	acl	_	_
8	serum	serum	NN	_	9	com	_	_
9	levels	level	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	to	to	TO	_	14	aux	_	_
13	subtherapeutic	subtherapeutic	JJ	_	14	attr	_	_
14	levels	level	NNS	_	7	ppmod	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	therapeutic	therapeutic	JJ	_	17	attr	_	_
17	range	range	NN	_	14	prn	_	_
18	considered	consider	VBN	_	17	acl	_	_
19	to	to	TO	_	20	aux	_	_
20	be	be	VB	_	18	comp	_	_
21	50	0	CD	_	26	num	_	_
22	to	to	TO	_	21	cc	_	_
23	100	0	CD	_	21	conj	_	_
24	g/mL	g/ml	NN	_	26	attr	_	_
25	total	total	JJ	_	26	attr	_	_
26	drug3	drug0	NN	_	20	obj	_	_
27	)	-rrb-	-RRB-	_	17	p	_	_
28	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	does	do	VBZ	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	itself	itself	PRP	_	2	obj	_	_
5	appear	appear	VBP	_	4	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	induce	induce	VB	_	5	comp	_	_
8	or	or	CC	_	7	cc	_	_
9	inhibit	inhibit	VB	_	7	conj	_	_
10	the	the	DT	_	15	det	_	_
11	cytochrome	cytochrome	NN	_	12	com	_	_
12	P-450	p-0	NN	_	15	com	_	_
13	drug-metabolizing	drug-metabolizing	NN	_	15	com	_	_
14	enzyme	enzyme	NN	_	15	com	_	_
15	system	system	NN	_	9	obj	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	liver	liver	NN	_	15	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	metabolized	metabolize	VBN	_	26	advcl	_	_
5	by	by	IN	_	10	case	_	_
6	hepatic	hepatic	JJ	_	10	attr	_	_
7	cytochrome	cytochrome	NN	_	10	attr	_	_
8	P-450	p-0	NN	_	10	attr	_	_
9	drug-metabolizing	drug-metabolizing	JJ	_	10	attr	_	_
10	enzymes	enzyme	NNS	_	4	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	CYP3A4	cyp0a0	NN	_	10	prn	_	_
13	,	,	,	_	12	p	_	_
14	CYP2D6	cyp0d0	NN	_	12	appo	_	_
15	,	,	,	_	12	p	_	_
16	CYP1A2	cyp0a0	NN	_	12	appo	_	_
17	)	-rrb-	-RRB-	_	12	p	_	_
18	,	,	,	_	26	p	_	_
19	inducers	inducer	NNS	_	26	dep	_	_
20	or	or	CC	_	19	cc	_	_
21	inhibitors	inhibitor	NNS	_	19	conj	_	_
22	of	of	IN	_	24	case	_	_
23	these	these	DT	_	24	det	_	_
24	enzymes	enzyme	NNS	_	19	ppmod	_	_
25	may	may	MD	_	26	modal	_	_
26	change	change	VB	_	0	root	_	_
27	the	the	DT	_	28	det	_	_
28	clearance	clearance	NN	_	26	obj	_	_
29	and	and	CC	_	28	cc	_	_
30	,	,	,	_	28	p	_	_
31	hence	hence	RB	_	28	adv	_	_
32	,	,	,	_	28	p	_	_
33	the	the	DT	_	34	det	_	_
34	half-life	half-life	NN	_	28	conj	_	_
35	of	of	IN	_	36	case	_	_
36	drug2	drug0	NN	_	34	ppmod	_	_
37	.	.	.	_	26	p	_	_

1	On	on	IN	_	7	case	_	_
2	the	the	DT	_	7	det	_	_
3	basis	basis	NN	_	7	advnp	_	_
4	of	of	IN	_	7	case	_	_
5	limited	limited	JJ	_	7	attr	_	_
6	available	available	JJ	_	7	attr	_	_
7	data	datum	NNS	_	13	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	no	no	DT	_	11	det	_	_
10	dosage	dosage	JJ	_	11	attr	_	_
11	adjustment	adjustment	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	recommended	recommend	VBN	_	0	root	_	_
14	for	for	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	on	on	IN	_	18	case	_	_
17	these	these	DT	_	18	det	_	_
18	drugs	drug	NNS	_	15	ppmod	_	_
19	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	:	:	:	_	1	p	_	_
8	In	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	33	ppmod	_	_
10	treated	treat	VBN	_	9	acl	_	_
11	with	with	IN	_	13	case	_	_
12	potent	potent	JJ	_	13	attr	_	_
13	inducers	inducer	NNS	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	CYP3A4	cyp0a0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	19	p	_	_
17	i.e.	i.e.	FW	_	19	adv	_	_
18	,	,	,	_	19	p	_	_
19	drug4	drug0	NN	_	9	prn	_	_
20	,	,	,	_	19	p	_	_
21	drug5	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug6	drug0	NN	_	19	conj	_	_
25	)	-rrb-	-RRB-	_	19	p	_	_
26	,	,	,	_	33	p	_	_
27	the	the	DT	_	28	det	_	_
28	clearance	clearance	NN	_	33	dep	_	_
29	of	of	IN	_	30	case	_	_
30	drug7	drug0	NN	_	28	ppmod	_	_
31	was	be	VBD	_	33	aux	_	_
32	significantly	significantly	RB	_	33	adv	_	_
33	increased	increase	VBN	_	1	acl	_	_
34	and	and	CC	_	33	cc	_	_
35	drug8	drug0	NN	_	37	com	_	_
36	blood	blood	NN	_	37	com	_	_
37	concentrations	concentration	NNS	_	39	dep	_	_
38	were	be	VBD	_	39	aux	_	_
39	decreased	decrease	VBN	_	33	conj	_	_
40	.	.	.	_	1	p	_	_

1	However	however	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	on	on	IN	_	8	case	_	_
4	the	the	DT	_	8	det	_	_
5	basis	basis	NN	_	8	advnp	_	_
6	of	of	IN	_	8	case	_	_
7	available	available	JJ	_	8	attr	_	_
8	data	datum	NNS	_	16	ppmod	_	_
9	,	,	,	_	16	p	_	_
10	no	no	DT	_	12	det	_	_
11	dosage	dosage	JJ	_	12	attr	_	_
12	adjustment	adjustment	NN	_	16	dep	_	_
13	for	for	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	is	be	VBZ	_	16	aux	_	_
16	recommended	recommend	VBN	_	75	advcl	_	_
17	for	for	IN	_	18	case	_	_
18	patients	patient	NNS	_	16	ppmod	_	_
19	on	on	IN	_	22	case	_	_
20	these	these	DT	_	22	det	_	_
21	drugs.1,3	drugs.0	JJ	_	22	attr	_	_
22	drug2	drug0	NNS	_	18	ppmod	_	_
23	:	:	:	_	75	p	_	_
24	Although	although	IN	_	35	mark	_	_
25	no	no	DT	_	28	det	_	_
26	pharmacokinetic	pharmacokinetic	JJ	_	28	attr	_	_
27	drug	drug	NN	_	28	com	_	_
28	interaction	interaction	NN	_	35	dep	_	_
29	between	between	IN	_	30	case	_	_
30	drug3	drug0	NN	_	28	ppmod	_	_
31	and	and	CC	_	30	cc	_	_
32	drug4	drug0	NN	_	30	conj	_	_
33	has	have	VBZ	_	35	aux	_	_
34	been	be	VBN	_	35	aux	_	_
35	observed	observe	VBN	_	42	advcl	_	_
36	,	,	,	_	42	p	_	_
37	data	datum	NNS	_	42	dep	_	_
38	from	from	IN	_	41	case	_	_
39	2	0	CD	_	41	num	_	_
40	small	small	JJ	_	41	attr	_	_
41	studies	study	NNS	_	37	ppmod	_	_
42	indicate	indicate	VBP	_	75	advcl	_	_
43	that	that	IN	_	47	mark	_	_
44	drug5	drug0	NN	_	47	dep	_	_
45	may	may	MD	_	47	modal	_	_
46	be	be	VB	_	47	aux	_	_
47	associated	associate	VBN	_	42	comp	_	_
48	with	with	IN	_	50	case	_	_
49	an	an	DT	_	50	det	_	_
50	increase	increase	NN	_	47	ppmod	_	_
51	in	in	IN	_	54	case	_	_
52	patient	patient	NN	_	53	advnp	_	_
53	controlled	controlled	JJ	_	54	attr	_	_
54	administration	administration	NN	_	50	ppmod	_	_
55	of	of	IN	_	60	case	_	_
56	drug6	drug0	NN	_	60	attr	_	_
57	.4	0	CD	_	60	num	_	_
58	,	,	,	_	60	p	_	_
59	5	0	CD	_	60	num	_	_
60	Chemotherapy	chemotherapy	NN	_	54	ppmod	_	_
61	:	:	:	_	75	p	_	_
62	Tumor	tumor	NN	_	63	com	_	_
63	response	response	NN	_	75	dep	_	_
64	to	to	TO	_	65	aux	_	_
65	chemotherapy	chemotherapy	NN	_	63	ppmod	_	_
66	in	in	IN	_	72	case	_	_
67	the	the	DT	_	72	det	_	_
68	P	p	NN	_	72	attr	_	_
69	388	0	CD	_	72	num	_	_
70	mouse	mouse	NN	_	72	com	_	_
71	leukemia	leukemia	NN	_	72	com	_	_
72	model	model	NN	_	63	ppmod	_	_
73	is	be	VBZ	_	75	aux	_	_
74	not	not	RB	_	75	neg	_	_
75	affected	affect	VBN	_	0	root	_	_
76	by	by	IN	_	77	case	_	_
77	drug7	drug0	NN	_	75	ppmod	_	_
78	.	.	.	_	75	p	_	_

1	In	in	IN	_	2	case	_	_
2	humans	human	NNS	_	12	ppmod	_	_
3	,	,	,	_	12	p	_	_
4	drug1	drug0	NN	_	12	dep	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	drug3	drug0	NN	_	4	conj	_	_
10	do	do	VBP	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	affect	affect	VB	_	0	root	_	_
13	the	the	DT	_	14	det	_	_
14	pharmacokinetics	pharmacokinetics	NNS	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	12	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	crossover	crossover	JJ	_	4	attr	_	_
4	study	study	NN	_	10	ppmod	_	_
5	in	in	IN	_	8	case	_	_
6	76	0	CD	_	8	num	_	_
7	pediatric	pediatric	JJ	_	8	attr	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	,	,	,	_	10	p	_	_
10	I.V.	i.v.	NN	_	0	root	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	increase	increase	VB	_	0	root	_	_
5	blood	blood	NN	_	6	com	_	_
6	levels	level	NNS	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	high-dose	high-dose	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	CYP3A4	cyp0a0	JJ	_	2	attr	_	_
2	Inhibitors	inhibitor	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug1	drug0	NN	_	16	dep	_	_
5	,	,	,	_	4	p	_	_
6	an	an	DT	_	7	det	_	_
7	inhibitor	inhibitor	NN	_	4	appo	_	_
8	of	of	IN	_	13	case	_	_
9	the	the	DT	_	13	det	_	_
10	drug	drug	NN	_	13	com	_	_
11	metabolizing	metabolizing	NN	_	13	com	_	_
12	enzyme	enzyme	NN	_	13	com	_	_
13	CYP3A4	cyp0a0	NN	_	7	ppmod	_	_
14	,	,	,	_	4	p	_	_
15	significantly	significantly	RB	_	16	adv	_	_
16	increased	increase	VBD	_	2	acl	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	concentrations	concentration	NNS	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	when	when	WRB	_	22	adv	_	_
22	coadministered	coadministered	VBN	_	16	comp	_	_
23	to	to	TO	_	24	aux	_	_
24	subjects	subject	NNS	_	22	ppmod	_	_
25	who	who	WP	_	26	dep	_	_
26	were	be	VBD	_	24	relcl	_	_
27	poor	poor	JJ	_	28	attr	_	_
28	metabolizers	metabolizers	NNS	_	26	obj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	see	see	VB	_	26	prn	_	_
31	CLINICAL	clinical	JJ	_	32	attr	_	_
32	PHARMACOLOGY	pharmacology	NN	_	30	obj	_	_
33	,	,	,	_	32	p	_	_
34	Variability	variability	NN	_	32	conj	_	_
35	in	in	IN	_	36	case	_	_
36	Metabolism	metabolism	NN	_	34	ppmod	_	_
37	and	and	CC	_	34	cc	_	_
38	Drug-Drug	drug-drug	JJ	_	39	attr	_	_
39	Interactions	interaction	NNS	_	32	conj	_	_
40	)	-rrb-	-RRB-	_	30	p	_	_
41	.	.	.	_	2	p	_	_

1	For	for	IN	_	2	case	_	_
2	patients	patient	NNS	_	40	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	or	or	CC	_	4	cc	_	_
6	other	other	JJ	_	9	attr	_	_
7	potent	potent	JJ	_	9	attr	_	_
8	CYP3A4	cyp0a0	JJ	_	9	attr	_	_
9	inhibitors	inhibitor	NNS	_	4	conj	_	_
10	such	such	JJ	_	13	adv	_	_
11	as	as	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	9	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	eg	eg	NN	_	13	prn	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	appo	_	_
18	,	,	,	_	15	p	_	_
19	drug4	drug0	NN	_	15	appo	_	_
20	)	-rrb-	-RRB-	_	15	p	_	_
21	or	or	CC	_	13	cc	_	_
22	drug5	drug0	NN	_	13	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	eg	eg	NN	_	22	prn	_	_
25	,	,	,	_	24	p	_	_
26	drug6	drug0	NN	_	24	appo	_	_
27	,	,	,	_	24	p	_	_
28	drug7	drug0	NN	_	24	appo	_	_
29	)	-rrb-	-RRB-	_	24	p	_	_
30	or	or	CC	_	13	cc	_	_
31	drug8	drug0	NN	_	13	conj	_	_
32	or	or	CC	_	31	cc	_	_
33	drug9	drug0	NN	_	31	conj	_	_
34	,	,	,	_	40	p	_	_
35	the	the	DT	_	37	det	_	_
36	recommended	recommend	VBN	_	37	attr	_	_
37	dose	dose	NN	_	40	dep	_	_
38	of	of	IN	_	39	case	_	_
39	drug10	drug0	NN	_	37	ppmod	_	_
40	is	be	VBZ	_	0	root	_	_
41	2	0	CD	_	42	num	_	_
42	mg	mg	NN	_	40	obj	_	_
43	daily	daily	RB	_	42	adv	_	_
44	.	.	.	_	40	p	_	_

1	Drug-Laboratory-Test	drug-laboratory-test	JJ	_	3	attr	_	_
2	Interactions	interaction	NNS	_	3	com	_	_
3	Interactions	interaction	NNS	_	12	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	laboratory	laboratory	NN	_	8	com	_	_
8	tests	test	NNS	_	5	conj	_	_
9	have	have	VBP	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	studied	study	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Since	since	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	metabolized	metabolize	VBN	_	22	advcl	_	_
5	by	by	IN	_	9	case	_	_
6	a	a	DT	_	9	det	_	_
7	P450	p0	NN	_	9	com	_	_
8	enzyme	enzyme	NN	_	9	com	_	_
9	system	system	NN	_	4	ppmod	_	_
10	,	,	,	_	22	p	_	_
11	drugs	drug	NNS	_	22	dep	_	_
12	that	that	WDT	_	13	dep	_	_
13	induce	induce	VBP	_	11	relcl	_	_
14	or	or	CC	_	13	cc	_	_
15	inhibit	inhibit	VBP	_	13	conj	_	_
16	this	this	DT	_	20	det	_	_
17	drug	drug	NN	_	20	com	_	_
18	metabolizing	metabolizing	NN	_	20	com	_	_
19	enzyme	enzyme	NN	_	20	com	_	_
20	system	system	NN	_	15	obj	_	_
21	may	may	MD	_	22	modal	_	_
22	elicit	elicit	VB	_	0	root	_	_
23	important	important	JJ	_	25	attr	_	_
24	drug-drug	drug-drug	JJ	_	25	attr	_	_
25	interactions	interaction	NNS	_	22	obj	_	_
26	that	that	WDT	_	28	dep	_	_
27	may	may	MD	_	28	modal	_	_
28	alter	alter	VB	_	25	relcl	_	_
29	drug2	drug0	NN	_	31	com	_	_
30	plasma	plasma	NN	_	31	com	_	_
31	concentrations	concentration	NNS	_	28	obj	_	_
32	.	.	.	_	22	p	_	_

1	Agents	agent	NNS	_	19	dep	_	_
2	that	that	WDT	_	5	dep	_	_
3	might	might	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	coadministered	coadministered	VBN	_	1	relcl	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	AIDS	aids	NN	_	10	com	_	_
10	patients	patient	NNS	_	7	ppmod	_	_
11	for	for	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	indications	indication	NNS	_	7	ppmod	_	_
14	that	that	WDT	_	16	dep	_	_
15	could	could	MD	_	16	modal	_	_
16	elicit	elicit	VB	_	13	relcl	_	_
17	this	this	DT	_	18	det	_	_
18	activity	activity	NN	_	16	obj	_	_
19	include	include	VBP	_	0	root	_	_
20	drug2	drug0	NN	_	19	obj	_	_
21	,	,	,	_	20	p	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug4	drug0	NN	_	20	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug5	drug0	NN	_	20	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	drug6	drug0	NN	_	20	conj	_	_
30	.	.	.	_	19	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	perfusion	perfusion	NN	_	9	dep	_	_
4	of	of	IN	_	7	case	_	_
5	isolated	isolate	VBN	_	7	attr	_	_
6	rat	rat	NN	_	7	com	_	_
7	liver	liver	NN	_	3	ppmod	_	_
8	has	have	VBZ	_	9	aux	_	_
9	shown	show	VBN	_	0	root	_	_
10	that	that	IN	_	12	mark	_	_
11	drug1	drug0	NN	_	12	dep	_	_
12	caused	cause	VBD	_	9	advcl	_	_
13	a	a	DT	_	15	det	_	_
14	significant	significant	JJ	_	15	attr	_	_
15	reduction	reduction	NN	_	12	obj	_	_
16	in	in	IN	_	18	case	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	metabolism	metabolism	NN	_	15	ppmod	_	_
19	and	and	CC	_	12	cc	_	_
20	that	that	IN	_	22	mark	_	_
21	drug3	drug0	NN	_	22	dep	_	_
22	altered	alter	VBD	_	12	conj	_	_
23	the	the	DT	_	25	det	_	_
24	relative	relative	JJ	_	25	attr	_	_
25	concentration	concentration	NN	_	22	obj	_	_
26	of	of	IN	_	28	case	_	_
27	trimetrexate	trimetrexate	NN	_	28	com	_	_
28	metabolites	metabolite	NNS	_	25	ppmod	_	_
29	possibly	possibly	RB	_	31	adv	_	_
30	by	by	IN	_	31	case	_	_
31	competing	compete	VBG	_	22	ppmod	_	_
32	for	for	IN	_	34	case	_	_
33	sulfate	sulfate	NN	_	34	com	_	_
34	metabolites	metabolite	NNS	_	31	ppmod	_	_
35	.	.	.	_	9	p	_	_

1	Based	base	VBN	_	8	adv	_	_
2	on	on	IN	_	8	case	_	_
3	an	an	DT	_	8	det	_	_
4	in	in	FW	_	5	adv	_	_
5	vitro	vitro	FW	_	8	attr	_	_
6	rat	rat	NN	_	8	com	_	_
7	liver	liver	NN	_	8	com	_	_
8	model	model	NN	_	20	ppmod	_	_
9	,	,	,	_	20	p	_	_
10	nitrogen	nitrogen	NN	_	12	attr	_	_
11	substituted	substitute	VBN	_	12	attr	_	_
12	drug1	drug0	NN	_	20	dep	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug2	drug0	NN	_	12	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	appo	_	_
17	,	,	,	_	14	p	_	_
18	drug4	drug0	NN	_	14	appo	_	_
19	)	-rrb-	-RRB-	_	14	p	_	_
20	were	be	VBD	_	0	root	_	_
21	potent	potent	JJ	_	23	adv	_	_
22	,	,	,	_	23	p	_	_
23	non-competitive	non-competitive	JJ	_	24	attr	_	_
24	inhibitors	inhibitor	NNS	_	20	obj	_	_
25	of	of	IN	_	27	case	_	_
26	drug5	drug0	NN	_	27	com	_	_
27	metabolism	metabolism	NN	_	24	ppmod	_	_
28	.	.	.	_	20	p	_	_

1	Patients	patient	NNS	_	11	dep	_	_
2	medicated	medicate	VBN	_	1	acl	_	_
3	with	with	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	drugs	drug	NNS	_	2	ppmod	_	_
6	and	and	CC	_	1	cc	_	_
7	drug1	drug0	NN	_	1	conj	_	_
8	should	should	MD	_	11	modal	_	_
9	be	be	VB	_	11	aux	_	_
10	carefully	carefully	RB	_	11	adv	_	_
11	monitored	monitor	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Prolongation	prolongation	NN	_	18	dep	_	_
4	of	of	IN	_	6	case	_	_
5	prothrombin	prothrombin	NN	_	6	com	_	_
6	time	time	NN	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	PT	pt	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	and	and	CC	_	6	cc	_	_
11	International	international	NNP	_	13	attr	_	_
12	Normalized	normalize	VBN	_	13	attr	_	_
13	Ratio	ratio	NN	_	6	conj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	INR	inr	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	were	be	VBD	_	18	aux	_	_
18	observed	observe	VBN	_	1	acl	_	_
19	in	in	IN	_	20	case	_	_
20	patients	patient	NNS	_	18	ppmod	_	_
21	receiving	receive	VBG	_	20	acl	_	_
22	drug2	drug0	NN	_	21	obj	_	_
23	concomitantly	concomitantly	RB	_	25	adv	_	_
24	with	with	IN	_	25	case	_	_
25	drug3	drug0	NN	_	21	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	Physicians	physician	NNS	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	carefully	carefully	RB	_	4	adv	_	_
4	monitor	monitor	VB	_	0	root	_	_
5	PT	pt	NN	_	4	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	INR	inr	NN	_	5	conj	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	5	ppmod	_	_
10	concurrently	concurrently	RB	_	11	adv	_	_
11	administered	administer	VBN	_	9	acl	_	_
12	drug1	drug0	NN	_	11	comp	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	.	.	.	_	4	p	_	_

1	Other	other	JJ	_	4	attr	_	_
2	drug1	drug0	NN	_	4	attr	_	_
3	Severe	severe	JJ	_	4	attr	_	_
4	thrombocytopenia	thrombocytopenia	NN	_	10	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	gastrointestinal	gastrointestinal	JJ	_	7	attr	_	_
7	bleeding	bleeding	JJ	_	4	conj	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	with	with	IN	_	13	case	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	use	use	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	other	other	JJ	_	18	attr	_	_
18	drug3	drug0	NNS	_	15	conj	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	e.g.	e.g.	FW	_	22	ppmod	_	_
21	,	,	,	_	22	p	_	_
22	drug4	drug0	NNS	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	.	.	.	_	10	p	_	_

1	Monitor	monitor	NN	_	3	com	_	_
2	platelet	platelet	NN	_	3	com	_	_
3	count	count	NN	_	6	dep	_	_
4	every	every	DT	_	6	det	_	_
5	2	0	CD	_	6	num	_	_
6	weeks	week	NNS	_	0	root	_	_
7	for	for	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	first	#ord#	JJ	_	11	attr	_	_
10	2	0	CD	_	11	num	_	_
11	months	month	NNS	_	6	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	Nasal	nasal	JJ	_	5	attr	_	_
2	Spray	spray	NN	_	5	attr	_	_
3	:	:	:	_	5	p	_	_
4	Formal	formal	JJ	_	5	attr	_	_
5	studies	study	NNS	_	16	dep	_	_
6	designed	design	VBN	_	5	acl	_	_
7	to	to	TO	_	8	aux	_	_
8	evaluate	evaluate	VB	_	6	comp	_	_
9	drug	drug	NN	_	10	com	_	_
10	interactions	interaction	NNS	_	8	obj	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	have	have	VBP	_	16	aux	_	_
14	not	not	RB	_	16	neg	_	_
15	been	be	VBN	_	16	aux	_	_
16	done	do	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	No	no	DT	_	4	det	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	0	root	_	_
8	with	with	IN	_	12	case	_	_
9	drug1	drug0	NN	_	12	attr	_	_
10	nasal	nasal	JJ	_	12	attr	_	_
11	spray	spray	NN	_	12	com	_	_
12	ingredients	ingredient	NNS	_	7	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	Currently	currently	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	no	no	DT	_	5	det	_	_
4	drug	drug	NN	_	5	com	_	_
5	interactions	interaction	NNS	_	10	dep	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	observed	observe	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	15	dep	_	_
3	of	of	IN	_	5	case	_	_
4	prior	prior	JJ	_	5	attr	_	_
5	use	use	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	11	case	_	_
9	postmenopausal	postmenopausal	JJ	_	11	attr	_	_
10	osteoporosis	osteoporosis	NN	_	11	com	_	_
11	patients	patient	NNS	_	5	ppmod	_	_
12	have	have	VBP	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	assessed	assess	VBN	_	0	root	_	_
16	;	;	:	_	15	p	_	_

1	however	however	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	in	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	12	ppmod	_	_
5	with	with	IN	_	8	case	_	_
6	Paget	paget	NN	_	8	attr	_	_
7	's	's	POS	_	8	case	_	_
8	Disease	disease	NN	_	4	ppmod	_	_
9	prior	prior	JJ	_	11	attr	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	use	use	NN	_	12	dep	_	_
12	appears	appear	VBZ	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	reduce	reduce	VB	_	12	comp	_	_
15	the	the	DT	_	17	det	_	_
16	anti-resorptive	anti-resorptive	JJ	_	17	attr	_	_
17	response	response	NN	_	14	obj	_	_
18	to	to	TO	_	21	aux	_	_
19	drug2	drug0	NN	_	21	attr	_	_
20	nasal	nasal	JJ	_	21	attr	_	_
21	spray	spray	NN	_	17	ppmod	_	_
22	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	absorption	absorption	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	medications	medication	NNS	_	2	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	decreased	decrease	VBN	_	0	root	_	_
9	during	during	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	concurrent	concurrent	JJ	_	12	attr	_	_
12	use	use	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	because	because	IN	_	19	case	_	_
16	of	of	IN	_	19	case	_	_
17	decreased	decrease	VBN	_	19	attr	_	_
18	gastric	gastric	JJ	_	19	attr	_	_
19	motility	motility	NN	_	12	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	delayed	delay	VBN	_	23	attr	_	_
22	gastric	gastric	JJ	_	23	attr	_	_
23	emptying	emptying	NN	_	19	conj	_	_
24	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	care	care	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	other	other	JJ	_	11	attr	_	_
11	drugs	drug	NNS	_	9	obj	_	_
12	that	that	WDT	_	13	dep	_	_
13	are	be	VBP	_	11	relcl	_	_
14	capable	capable	JJ	_	13	dep	_	_
15	of	of	IN	_	16	case	_	_
16	causing	cause	VBG	_	14	ppmod	_	_
17	CNS	cns	NN	_	18	com	_	_
18	effects	effect	NNS	_	16	obj	_	_
19	such	such	JJ	_	21	adv	_	_
20	as	as	IN	_	21	case	_	_
21	drug2	drug0	NN	_	18	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	drug3	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	or	or	CC	_	23	cc	_	_
26	drug4	drug0	NN	_	21	conj	_	_
27	.	.	.	_	4	p	_	_

1	Special	special	JJ	_	2	attr	_	_
2	attention	attention	NN	_	4	dep	_	_
3	should	should	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	paid	paid	JJ	_	4	dep	_	_
6	to	to	TO	_	8	aux	_	_
7	potential	potential	JJ	_	8	attr	_	_
8	interactions	interaction	NNS	_	5	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drugs	drug	NNS	_	8	ppmod	_	_
11	having	have	VBG	_	10	acl	_	_
12	anticholinergic	anticholinergic	JJ	_	13	attr	_	_
13	properties	property	NNS	_	11	obj	_	_
14	;	;	:	_	4	p	_	_

1	e.g.	e.g.	FW	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	0	root	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	including	include	VBG	_	9	adv	_	_
9	drug3	drug0	NN	_	6	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	6	p	_	_
12	drug4	drug0	NN	_	4	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	drug5	drug0	NN	_	4	conj	_	_
16	.	.	.	_	4	p	_	_

1	Laboratory	laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	6	dep	_	_
4	drug1	drug0	NN	_	3	attr	_	_
5	will	will	MD	_	6	modal	_	_
6	interfere	interfere	VB	_	0	root	_	_
7	with	with	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	gastric	gastric	JJ	_	11	attr	_	_
10	secretion	secretion	NN	_	11	com	_	_
11	test	test	NN	_	6	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	Formal	formal	JJ	_	3	attr	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	3	ppmod	_	_
9	have	have	VBP	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	performed	performed	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	studied	study	VBN	_	1	acl	_	_
3	in	in	IN	_	5	case	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	trials	trial	NNS	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	were	be	VBD	_	10	aux	_	_
9	routinely	routinely	RB	_	10	adv	_	_
10	treated	treat	VBN	_	0	root	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	28	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	such	such	JJ	_	1	prn	_	_
4	as	as	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	)	-rrb-	-RRB-	_	3	p	_	_
9	and	and	CC	_	1	cc	_	_
10	drugs	drug	NNS	_	1	conj	_	_
11	that	that	WDT	_	12	dep	_	_
12	alter	alter	VBP	_	10	relcl	_	_
13	platelet	platelet	NN	_	14	com	_	_
14	function	function	NN	_	12	obj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	such	such	JJ	_	10	prn	_	_
17	as	as	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	GP	gp	NN	_	25	com	_	_
24	IIb/IIIa	iib/iiia	NN	_	25	com	_	_
25	inhibitors	inhibitor	NNS	_	18	conj	_	_
26	)	-rrb-	-RRB-	_	16	p	_	_
27	may	may	MD	_	28	modal	_	_
28	increase	increase	VB	_	0	root	_	_
29	the	the	DT	_	30	det	_	_
30	risk	risk	NN	_	28	obj	_	_
31	of	of	IN	_	32	case	_	_
32	bleeding	bleeding	JJ	_	30	ppmod	_	_
33	if	if	IN	_	34	mark	_	_
34	administered	administer	VBN	_	32	acl	_	_
35	prior	prior	RB	_	34	adv	_	_
36	to	to	TO	_	35	ppmod	_	_
37	,	,	,	_	28	p	_	_
38	during	during	IN	_	28	ppmod	_	_
39	,	,	,	_	38	p	_	_
40	or	or	CC	_	38	cc	_	_
41	after	after	IN	_	43	case	_	_
42	drug6	drug0	NN	_	43	com	_	_
43	therapy	therapy	NN	_	38	conj	_	_
44	.	.	.	_	28	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	18	dep	_	_
4	During	during	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	therapy	therapy	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	results	result	NNS	_	3	conj	_	_
9	of	of	IN	_	11	case	_	_
10	coagulation	coagulation	NN	_	11	com	_	_
11	tests	test	NNS	_	8	ppmod	_	_
12	and/or	and/or	CC	_	8	cc	_	_
13	measures	measure	NNS	_	3	conj	_	_
14	of	of	IN	_	16	case	_	_
15	fibrinolytic	fibrinolytic	JJ	_	16	attr	_	_
16	activity	activity	NN	_	13	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	0	root	_	_
19	unreliable	unreliable	JJ	_	18	dep	_	_
20	unless	unless	IN	_	24	mark	_	_
21	specific	specific	JJ	_	22	attr	_	_
22	precautions	precaution	NNS	_	24	dep	_	_
23	are	be	VBP	_	24	aux	_	_
24	taken	take	VBN	_	18	comp	_	_
25	to	to	TO	_	26	aux	_	_
26	prevent	prevent	VB	_	24	comp	_	_
27	in	in	FW	_	28	adv	_	_
28	vitro	vitro	FW	_	29	attr	_	_
29	artifacts	artifact	NNS	_	26	obj	_	_
30	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	an	an	DT	_	4	det	_	_
4	enzyme	enzyme	NN	_	2	obj	_	_
5	that	that	WDT	_	15	dep	_	_
6	,	,	,	_	15	p	_	_
7	when	when	WRB	_	8	adv	_	_
8	present	present	JJ	_	15	advcl	_	_
9	in	in	IN	_	10	case	_	_
10	blood	blood	NN	_	8	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	pharmacologic	pharmacologic	JJ	_	13	attr	_	_
13	concentrations	concentration	NNS	_	10	ppmod	_	_
14	,	,	,	_	15	p	_	_
15	remains	remain	VBZ	_	4	relcl	_	_
16	active	active	JJ	_	15	dep	_	_
17	under	under	IN	_	20	case	_	_
18	in	in	FW	_	19	adv	_	_
19	vitro	vitro	FW	_	20	attr	_	_
20	conditions	condition	NNS	_	15	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	This	this	DT	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	lead	lead	VB	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	degradation	degradation	NN	_	3	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	fibrinogen	fibrinogen	NN	_	5	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	blood	blood	NN	_	10	com	_	_
10	samples	sample	NNS	_	5	ppmod	_	_
11	removed	remove	VBN	_	10	acl	_	_
12	for	for	IN	_	13	case	_	_
13	analysis	analysis	NN	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	(	-lrb-	-LRB-	_	5	p	_	_
9	causing	cause	VBG	_	5	acl	_	_
10	too	too	RB	_	13	adv	_	_
11	great	great	JJ	_	13	attr	_	_
12	a	a	DT	_	13	det	_	_
13	decrease	decrease	NN	_	9	obj	_	_
14	in	in	IN	_	16	case	_	_
15	adrenal	adrenal	JJ	_	16	attr	_	_
16	function	function	NN	_	13	ppmod	_	_
17	)	-rrb-	-RRB-	_	5	p	_	_
18	.	.	.	_	3	p	_	_

1	Although	although	IN	_	12	mark	_	_
2	drug1	drug0	NN	_	12	dep	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	a	a	DT	_	5	det	_	_
5	mixture	mixture	NN	_	2	prn	_	_
6	of	of	IN	_	8	case	_	_
7	three	#crd#	CD	_	8	num	_	_
8	stereoisomers	stereoisomers	NNS	_	5	ppmod	_	_
9	)	-rrb-	-RRB-	_	5	p	_	_
10	has	have	VBZ	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	administered	administer	VBN	_	29	advcl	_	_
13	safely	safely	RB	_	12	adv	_	_
14	following	follow	VBG	_	12	comp	_	_
15	succinylcholine-facilitated	succinylcholine-facilitated	JJ	_	17	attr	_	_
16	tracheal	tracheal	NN	_	17	com	_	_
17	intubation	intubation	NN	_	14	obj	_	_
18	,	,	,	_	29	p	_	_
19	the	the	DT	_	20	det	_	_
20	interaction	interaction	NN	_	29	dep	_	_
21	between	between	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	has	have	VBZ	_	29	aux	_	_
26	not	not	RB	_	29	neg	_	_
27	been	be	VBN	_	29	aux	_	_
28	systematically	systematically	RB	_	29	adv	_	_
29	studied	study	VBN	_	0	root	_	_
30	.	.	.	_	29	p	_	_

1	Prior	prior	JJ	_	2	attr	_	_
2	administration	administration	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	can	can	MD	_	6	modal	_	_
6	potentiate	potentiate	VB	_	0	root	_	_
7	the	the	DT	_	10	det	_	_
8	neuromuscular	neuromuscular	JJ	_	10	attr	_	_
9	blocking	blocking	NN	_	10	com	_	_
10	effects	effect	NNS	_	6	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	Evidence	evidence	NN	_	9	dep	_	_
2	of	of	IN	_	4	case	_	_
3	spontaneous	spontaneous	JJ	_	4	attr	_	_
4	recovery	recovery	NN	_	1	ppmod	_	_
5	from	from	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	before	before	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	administration	administration	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	before	before	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	attenuate	attenuate	VB	_	2	acl	_	_
9	some	some	DT	_	8	obj	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	side	side	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NNS	_	13	ppmod	_	_
16	has	have	VBZ	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	been	be	VBN	_	19	aux	_	_
19	studied	study	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	data	datum	NNS	_	2	obj	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	use	use	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NNS	_	8	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	1	p	_	_
5	administered	administer	VBN	_	1	acl	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	5	ppmod	_	_
8	/	/	:	_	1	p	_	_
9	drug4	drug0	NN	_	1	appo	_	_
10	to	to	TO	_	11	aux	_	_
11	achieve	achieve	VB	_	9	acl	_	_
12	1.25	0	CD	_	13	num	_	_
13	M.C.	m.c.	NNP	_	11	obj	_	_

1	decrease	decrease	VBP	_	0	root	_	_
2	the	the	DT	_	3	det	_	_
3	ED50	ed0	NN	_	1	obj	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	by	by	IN	_	10	case	_	_
7	as	as	RB	_	10	adv	_	_
8	much	much	JJ	_	10	attr	_	_
9	as	as	IN	_	10	case	_	_
10	25	0	CD	_	1	ppmod	_	_
11	%	%	NN	_	10	meta	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	see	see	VB	_	1	prn	_	_
14	CLINICAL	clinical	JJ	_	15	attr	_	_
15	PHARMACOLOGY	pharmacology	NN	_	13	obj	_	_
16	:	:	:	_	15	p	_	_
17	Pharmacodynamics	pharmacodynamics	NNS	_	15	appo	_	_
18	and	and	CC	_	17	cc	_	_
19	Individualization	individualization	NN	_	17	conj	_	_
20	of	of	IN	_	21	case	_	_
21	Dosages	dosage	NNS	_	17	ppmod	_	_
22	)	-rrb-	-RRB-	_	13	p	_	_
23	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	also	also	RB	_	5	adv	_	_
5	prolong	prolong	VB	_	0	root	_	_
6	the	the	DT	_	9	det	_	_
7	clinically	clinically	RB	_	8	adv	_	_
8	effective	effective	JJ	_	9	attr	_	_
9	duration	duration	NN	_	5	obj	_	_
10	of	of	IN	_	11	case	_	_
11	action	action	NN	_	9	ppmod	_	_
12	and	and	CC	_	5	cc	_	_
13	decrease	decrease	VB	_	5	conj	_	_
14	the	the	DT	_	17	det	_	_
15	average	average	JJ	_	17	attr	_	_
16	infusion	infusion	NN	_	17	com	_	_
17	requirement	requirement	NN	_	13	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	by	by	IN	_	24	case	_	_
21	as	as	RB	_	24	adv	_	_
22	much	much	JJ	_	24	attr	_	_
23	as	as	IN	_	24	case	_	_
24	35	0	CD	_	13	ppmod	_	_
25	%	%	NN	_	24	meta	_	_
26	to	to	TO	_	27	aux	_	_
27	40	0	CD	_	13	ppmod	_	_
28	%	%	NN	_	27	meta	_	_
29	.	.	.	_	5	p	_	_

1	A	a	DT	_	3	det	_	_
2	greater	great	JJR	_	3	attr	_	_
3	potentiation	potentiation	NN	_	13	dep	_	_
4	of	of	IN	_	8	case	_	_
5	the	the	DT	_	8	det	_	_
6	neuromuscular	neuromuscular	JJ	_	8	attr	_	_
7	blocking	blocking	NN	_	8	com	_	_
8	effects	effect	NNS	_	3	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	expected	expect	VBN	_	0	root	_	_
14	with	with	IN	_	16	case	_	_
15	higher	high	JJR	_	16	attr	_	_
16	concentrations	concentration	NNS	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	little	little	JJ	_	2	obj	_	_
4	or	or	CC	_	3	cc	_	_
5	no	no	DT	_	6	attr	_	_
6	effect	effect	NN	_	3	conj	_	_
7	on	on	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	ED50	ed0	NN	_	2	ppmod	_	_
10	,	,	,	_	2	p	_	_
11	but	but	CC	_	2	cc	_	_
12	may	may	MD	_	13	modal	_	_
13	prolong	prolong	VB	_	2	conj	_	_
14	the	the	DT	_	15	det	_	_
15	duration	duration	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	action	action	NN	_	15	ppmod	_	_
18	and	and	CC	_	13	cc	_	_
19	decrease	decrease	VB	_	13	conj	_	_
20	the	the	DT	_	23	det	_	_
21	average	average	JJ	_	23	attr	_	_
22	infusion	infusion	NN	_	23	com	_	_
23	requirement	requirement	NN	_	19	obj	_	_
24	by	by	IN	_	28	case	_	_
25	as	as	RB	_	28	adv	_	_
26	much	much	JJ	_	28	attr	_	_
27	as	as	IN	_	28	case	_	_
28	20	0	CD	_	23	ppmod	_	_
29	%	%	NN	_	28	meta	_	_
30	.	.	.	_	2	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	15	dep	_	_
3	which	which	WDT	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	enhance	enhance	VB	_	2	relcl	_	_
6	the	the	DT	_	9	det	_	_
7	neuromuscular	neuromuscular	JJ	_	9	attr	_	_
8	blocking	block	VBG	_	9	attr	_	_
9	action	action	NN	_	5	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	include	include	VBP	_	0	root	_	_
16	certain	certain	JJ	_	17	attr	_	_
17	drug3	drug0	NN	_	15	obj	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	e.g.	e.g.	FW	_	21	adv	_	_
20	,	,	,	_	21	p	_	_
21	drug4	drug0	NN	_	17	prn	_	_
22	,	,	,	_	21	p	_	_
23	drug5	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug6	drug0	NN	_	21	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug7	drug0	NN	_	21	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug8	drug0	NN	_	21	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug9	drug0	NN	_	21	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug10	drug0	NN	_	21	conj	_	_
34	,	,	,	_	33	p	_	_
35	and	and	CC	_	33	cc	_	_
36	drug11	drug0	NN	_	21	conj	_	_
37	)	-rrb-	-RRB-	_	21	p	_	_
38	,	,	,	_	17	p	_	_
39	drug12	drug0	NN	_	40	com	_	_
40	salts	salt	NNS	_	17	conj	_	_
41	,	,	,	_	40	p	_	_
42	drug13	drug0	NN	_	17	conj	_	_
43	,	,	,	_	42	p	_	_
44	local	local	JJ	_	45	attr	_	_
45	drug14	drug0	NN	_	17	conj	_	_
46	,	,	,	_	45	p	_	_
47	drug15	drug0	NN	_	17	conj	_	_
48	,	,	,	_	47	p	_	_
49	and	and	CC	_	47	cc	_	_
50	drug16	drug0	NN	_	17	conj	_	_
51	.	.	.	_	15	p	_	_

1	The	the	DT	_	4	det	_	_
2	neuromuscular	neuromuscular	JJ	_	4	attr	_	_
3	blocking	blocking	NN	_	4	com	_	_
4	effect	effect	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	enhanced	enhance	VBN	_	51	advcl	_	_
10	by	by	IN	_	11	case	_	_
11	drugs	drug	NNS	_	9	ppmod	_	_
12	that	that	WDT	_	13	dep	_	_
13	reduce	reduce	VBP	_	11	relcl	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	cholinesterase	cholinesterase	NN	_	16	com	_	_
16	activity	activity	NN	_	13	obj	_	_
17	(	-lrb-	-LRB-	_	23	p	_	_
18	e.g.	e.g.	FW	_	23	adv	_	_
19	,	,	,	_	23	p	_	_
20	chronically	chronically	RB	_	21	adv	_	_
21	administered	administer	VBN	_	23	attr	_	_
22	oral	oral	JJ	_	23	attr	_	_
23	drug2	drug0	NN	_	16	prn	_	_
24	,	,	,	_	23	p	_	_
25	drug3	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	or	or	CC	_	25	cc	_	_
28	certain	certain	JJ	_	29	attr	_	_
29	drug4	drug0	NNS	_	23	conj	_	_
30	)	-rrb-	-RRB-	_	23	p	_	_
31	or	or	CC	_	11	cc	_	_
32	by	by	IN	_	33	case	_	_
33	drugs	drug	NNS	_	11	conj	_	_
34	that	that	WDT	_	36	dep	_	_
35	irreversibly	irreversibly	RB	_	36	adv	_	_
36	inhibit	inhibit	VBP	_	33	relcl	_	_
37	plasma	plasma	NN	_	38	com	_	_
38	cholinesterase	cholinesterase	NN	_	36	obj	_	_
39	.	.	.	_	9	p	_	_
40	Resistance	resistance	NN	_	51	dep	_	_
41	to	to	TO	_	45	aux	_	_
42	the	the	DT	_	45	det	_	_
43	neuromuscular	neuromuscular	JJ	_	45	attr	_	_
44	blocking	block	VBG	_	45	attr	_	_
45	action	action	NN	_	40	ppmod	_	_
46	of	of	IN	_	48	case	_	_
47	nondepolarizing	nondepolarizing	JJ	_	48	attr	_	_
48	drug5	drug0	NN	_	45	ppmod	_	_
49	has	have	VBZ	_	51	aux	_	_
50	been	be	VBN	_	51	aux	_	_
51	demonstrated	demonstrate	VBN	_	0	root	_	_
52	in	in	IN	_	53	case	_	_
53	patients	patient	NNS	_	51	ppmod	_	_
54	chronically	chronically	RB	_	55	adv	_	_
55	administered	administer	VBN	_	53	acl	_	_
56	drug6	drug0	NN	_	55	obj	_	_
57	or	or	CC	_	56	cc	_	_
58	drug7	drug0	NN	_	56	conj	_	_
59	.	.	.	_	51	p	_	_

1	While	while	IN	_	15	mark	_	_
2	the	the	DT	_	3	det	_	_
3	effects	effect	NNS	_	15	dep	_	_
4	of	of	IN	_	6	case	_	_
5	chronic	chronic	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug2	drug0	JJ	_	9	attr	_	_
9	therapy	therapy	NN	_	6	conj	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	action	action	NN	_	3	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	are	be	VBP	_	26	advcl	_	_
16	unknown	unknown	JJ	_	15	dep	_	_
17	,	,	,	_	26	p	_	_
18	slightly	slightly	RB	_	19	adv	_	_
19	shorter	short	JJR	_	20	attr	_	_
20	durations	duration	NNS	_	26	dep	_	_
21	of	of	IN	_	23	case	_	_
22	neuromuscular	neuromuscular	JJ	_	23	attr	_	_
23	block	block	NN	_	20	ppmod	_	_
24	may	may	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	anticipated	anticipate	VBN	_	0	root	_	_
27	and	and	CC	_	26	cc	_	_
28	infusion	infusion	NN	_	30	com	_	_
29	rate	rate	NN	_	30	com	_	_
30	requirements	requirement	NNS	_	32	dep	_	_
31	may	may	MD	_	32	modal	_	_
32	be	be	VB	_	26	conj	_	_
33	higher	high	JJR	_	32	dep	_	_
34	.	.	.	_	26	p	_	_

1	Some	some	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	:	:	:	_	4	p	_	_
6	-	-	CC	_	9	cc	_	_
7	birth	birth	NN	_	9	com	_	_
8	control	control	NN	_	9	com	_	_
9	pills	pill	NNS	_	4	obj	_	_
10	-	-	CC	_	9	cc	_	_
11	drug1	drug0	NN	_	9	conj	_	_
12	-	-	:	_	4	p	_	_
13	medicines	medicine	NNS	_	4	dep	_	_
14	for	for	IN	_	15	case	_	_
15	angina	angina	NN	_	13	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	high	high	JJ	_	19	attr	_	_
18	blood	blood	NN	_	19	com	_	_
19	pressure	pressure	NN	_	15	conj	_	_
20	-	-	CC	_	13	cc	_	_
21	medicines	medicine	NNS	_	13	conj	_	_
22	for	for	IN	_	23	case	_	_
23	pain	pain	NN	_	13	ppmod	_	_
24	-	-	CC	_	23	cc	_	_
25	medicines	medicine	NNS	_	23	conj	_	_
26	to	to	TO	_	28	aux	_	_
27	control	control	NN	_	28	com	_	_
28	seizures	seizure	NNS	_	23	ppmod	_	_
29	such	such	JJ	_	31	adv	_	_
30	as	as	IN	_	31	case	_	_
31	drug2	drug0	NN	_	28	ppmod	_	_
32	or	or	CC	_	31	cc	_	_
33	drug3	drug0	NN	_	31	conj	_	_
34	-	-	CC	_	31	cc	_	_
35	certain	certain	JJ	_	36	attr	_	_
36	drug4	drug0	NN	_	31	conj	_	_
37	given	give	VBN	_	31	acl	_	_
38	by	by	IN	_	39	case	_	_
39	injection	injection	NN	_	37	ppmod	_	_
40	-	-	CC	_	39	cc	_	_
41	drug5	drug0	NN	_	39	conj	_	_
42	-	-	CC	_	39	cc	_	_
43	drug6	drug0	NN	_	39	conj	_	_
44	-	-	CC	_	43	cc	_	_
45	drug7	drug0	NN	_	43	conj	_	_
46	-	-	CC	_	23	cc	_	_
47	drug8	drug0	NN	_	23	conj	_	_
48	or	or	CC	_	23	cc	_	_
49	drug9	drug0	NN	_	23	conj	_	_
50	-	-	CC	_	13	cc	_	_
51	local	local	JJ	_	52	attr	_	_
52	drug10	drug0	NN	_	13	conj	_	_
53	such	such	JJ	_	13	attr	_	_
54	as	as	IN	_	55	case	_	_
55	drug11	drug0	NN	_	53	ppmod	_	_
56	-	-	CC	_	55	cc	_	_
57	general	general	JJ	_	58	attr	_	_
58	drug12	drug0	NN	_	55	conj	_	_
59	-	-	:	_	4	p	_	_
60	drug13	drug0	NN	_	4	dep	_	_
61	or	or	CC	_	60	cc	_	_
62	other	other	JJ	_	63	attr	_	_
63	drug14	drug0	NN	_	60	conj	_	_

1	Clinically	clinically	RB	_	4	adv	_	_
2	or	or	CC	_	4	cc	_	_
3	potentially	potentially	RB	_	4	adv	_	_
4	significant	significant	JJ	_	6	attr	_	_
5	drug	drug	NN	_	6	com	_	_
6	interactions	interaction	NNS	_	15	dep	_	_
7	between	between	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	the	the	DT	_	12	det	_	_
11	following	following	JJ	_	12	attr	_	_
12	agents/classes	agents/classes	NNS	_	8	conj	_	_
13	have	have	VBP	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	observed	observe	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	These	these	DT	_	3	dep	_	_
2	are	be	VBP	_	3	aux	_	_
3	described	describe	VBN	_	0	root	_	_
4	in	in	IN	_	6	case	_	_
5	greater	great	JJR	_	6	attr	_	_
6	detail	detail	NN	_	3	ppmod	_	_
7	below	below	IN	_	9	case	_	_
8	:	:	:	_	9	p	_	_
9	drug1	drug0	NN	_	3	ppmod	_	_
10	and	and	CC	_	3	cc	_	_
11	the	the	DT	_	13	det	_	_
12	following	following	JJ	_	13	attr	_	_
13	agents/classes	agents/classes	NNS	_	16	dep	_	_
14	have	have	VBP	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	observed	observe	VBN	_	3	conj	_	_
17	.	.	.	_	3	p	_	_

1	These	these	DT	_	3	dep	_	_
2	are	be	VBP	_	3	aux	_	_
3	described	describe	VBN	_	41	advcl	_	_
4	in	in	IN	_	6	case	_	_
5	greater	great	JJR	_	6	attr	_	_
6	detail	detail	NN	_	3	ppmod	_	_
7	below	below	IN	_	10	case	_	_
8	:	:	:	_	10	p	_	_
9	Oral	oral	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	3	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	drug3	drug0	NN	_	10	appo	_	_
15	,	,	,	_	10	p	_	_
16	drug4	drug0	NN	_	10	appo	_	_
17	,	,	,	_	10	p	_	_
18	drug5	drug0	NN	_	10	appo	_	_
19	,	,	,	_	10	p	_	_
20	drug6	drug0	NN	_	10	appo	_	_
21	,	,	,	_	10	p	_	_
22	drug7	drug0	NN	_	10	appo	_	_
23	,	,	,	_	10	p	_	_
24	drug8	drug0	NN	_	10	appo	_	_
25	,	,	,	_	10	p	_	_
26	drug9	drug0	NN	_	10	appo	_	_
27	,	,	,	_	10	p	_	_
28	drug10	drug0	NN	_	10	appo	_	_
29	,	,	,	_	10	p	_	_
30	drug11	drug0	NN	_	10	appo	_	_
31	,	,	,	_	10	p	_	_
32	drug12	drug0	NN	_	10	appo	_	_
33	,	,	,	_	10	p	_	_
34	Oral	oral	JJ	_	35	attr	_	_
35	drug13	drug0	NN	_	10	appo	_	_
36	:	:	:	_	41	p	_	_
37	Clinically	clinically	RB	_	38	adv	_	_
38	significant	significant	JJ	_	39	attr	_	_
39	hypoglycemia	hypoglycemia	NN	_	41	dep	_	_
40	may	may	MD	_	41	modal	_	_
41	be	be	VB	_	0	root	_	_
42	precipitated	precipitated	JJ	_	41	dep	_	_
43	by	by	IN	_	45	case	_	_
44	the	the	DT	_	45	det	_	_
45	use	use	NN	_	42	ppmod	_	_
46	of	of	IN	_	47	case	_	_
47	drug14	drug0	NN	_	45	ppmod	_	_
48	with	with	IN	_	50	case	_	_
49	oral	oral	JJ	_	50	attr	_	_
50	drug15	drug0	NN	_	45	ppmod	_	_
51	;	;	:	_	41	p	_	_

1	one	#crd#	NN	_	5	dep	_	_
2	fatality	fatality	CD	_	1	num	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	from	from	IN	_	7	case	_	_
7	hypoglycemia	hypoglycemia	NN	_	5	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	association	association	NN	_	5	ppmod	_	_
10	with	with	IN	_	12	case	_	_
11	combined	combined	JJ	_	12	attr	_	_
12	drug1	drug0	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	use	use	NN	_	12	conj	_	_
16	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduces	reduce	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	metabolism	metabolism	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	drug4	drug0	NN	_	6	conj	_	_
12	and	and	CC	_	2	cc	_	_
13	increases	increase	VBZ	_	2	conj	_	_
14	the	the	DT	_	16	det	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentration	concentration	NN	_	13	obj	_	_
17	of	of	IN	_	19	case	_	_
18	these	these	DT	_	19	det	_	_
19	agents	agent	NNS	_	16	ppmod	_	_
20	.	.	.	_	2	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	used	use	VBN	_	18	advcl	_	_
5	concomitantly	concomitantly	RB	_	4	adv	_	_
6	with	with	IN	_	7	case	_	_
7	these	these	DT	_	4	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	other	other	JJ	_	10	attr	_	_
10	drug2	drug0	NNS	_	7	conj	_	_
11	,	,	,	_	18	p	_	_
12	blood	blood	NN	_	14	com	_	_
13	glucose	glucose	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	18	dep	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	carefully	carefully	RB	_	18	adv	_	_
18	monitored	monitor	VBN	_	0	root	_	_
19	and	and	CC	_	18	cc	_	_
20	the	the	DT	_	21	det	_	_
21	dose	dose	NN	_	27	dep	_	_
22	of	of	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	drug3	drug0	NN	_	21	ppmod	_	_
25	should	should	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	adjusted	adjust	VBN	_	18	conj	_	_
28	as	as	IN	_	29	case	_	_
29	necessary	necessary	JJ	_	27	ppmod	_	_
30	.	.	.	_	27	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	:	:	:	_	1	p	_	_
3	Prothrombin	prothrombin	NN	_	4	com	_	_
4	time	time	NN	_	1	appo	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	increased	increase	VBN	_	0	root	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	10	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	.	.	.	_	7	p	_	_

1	In	in	IN	_	3	case	_	_
2	post-marketing	post-marketing	JJ	_	3	attr	_	_
3	experience	experience	VBP	_	27	ppmod	_	_
4	,	,	,	_	27	p	_	_
5	as	as	IN	_	8	case	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	27	ppmod	_	_
9	,	,	,	_	27	p	_	_
10	bleeding	bleeding	JJ	_	11	attr	_	_
11	events	event	NNS	_	27	dep	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	bruising	bruising	NN	_	11	prn	_	_
14	,	,	,	_	13	p	_	_
15	epistaxis	epistaxis	NNS	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	gastrointestinal	gastrointestinal	JJ	_	18	attr	_	_
18	bleeding	bleeding	JJ	_	13	conj	_	_
19	,	,	,	_	18	p	_	_
20	hematuria	hematuria	NN	_	13	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	melena	melena	NN	_	13	conj	_	_
24	)	-rrb-	-RRB-	_	13	p	_	_
25	have	have	VBP	_	27	aux	_	_
26	been	be	VBN	_	27	aux	_	_
27	reported	report	VBN	_	0	root	_	_
28	in	in	IN	_	29	case	_	_
29	association	association	NN	_	27	ppmod	_	_
30	with	with	IN	_	31	case	_	_
31	increases	increase	NNS	_	29	ppmod	_	_
32	in	in	IN	_	34	case	_	_
33	prothrombin	prothrombin	NN	_	34	com	_	_
34	time	time	NN	_	31	ppmod	_	_
35	in	in	IN	_	36	case	_	_
36	patients	patient	NNS	_	34	ppmod	_	_
37	receiving	receive	VBG	_	36	acl	_	_
38	drug2	drug0	NN	_	37	obj	_	_
39	concurrently	concurrently	RB	_	41	adv	_	_
40	with	with	IN	_	41	case	_	_
41	drug3	drug0	NN	_	37	ppmod	_	_
42	.	.	.	_	27	p	_	_

1	Careful	careful	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	13	dep	_	_
3	of	of	IN	_	5	case	_	_
4	prothrombin	prothrombin	NN	_	5	com	_	_
5	time	time	NN	_	2	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	2	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	is	be	VBZ	_	13	aux	_	_
13	recommended	recommend	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	See	see	VB	_	0	root	_	_
3	&lt	&lt	NN	_	2	obj	_	_
4	;	;	:	_	3	p	_	_
5	a	a	DT	_	7	det	_	_
6	href=	href=	JJ	_	7	attr	_	_
7	&quot	&quot	NN	_	3	appo	_	_
8	;	;	:	_	3	p	_	_
9	flucon_cp.htm	#hlink#	NN	_	11	com	_	_
10	#	#	NN	_	11	com	_	_
11	CP&quot	cp&quot	NN	_	3	appo	_	_
12	;	;	:	_	3	p	_	_
13	>CLINICAL	>clinical	NN	_	14	com	_	_
14	PHARMACOLOGY	pharmacology	NN	_	3	appo	_	_
15	:	:	:	_	3	p	_	_
16	Drug	drug	NN	_	18	com	_	_
17	Interaction	interaction	NN	_	18	com	_	_
18	Studies	study	NNS	_	3	appo	_	_
19	.	.	.	_	3	p	_	_
20	)	-rrb-	-RRB-	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	increases	increase	VBZ	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	Careful	careful	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	13	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	2	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	2	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	drug2	drug0	NN	_	8	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	is	be	VBZ	_	13	aux	_	_
13	recommended	recommend	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	See	see	VB	_	0	root	_	_
3	&lt	&lt	NN	_	2	obj	_	_
4	;	;	:	_	3	p	_	_
5	a	a	DT	_	7	det	_	_
6	href=	href=	JJ	_	7	attr	_	_
7	&quot	&quot	NN	_	3	appo	_	_
8	;	;	:	_	3	p	_	_
9	flucon_cp.htm	#hlink#	NN	_	11	com	_	_
10	#	#	NN	_	11	com	_	_
11	CP&quot	cp&quot	NN	_	3	appo	_	_
12	;	;	:	_	3	p	_	_
13	>CLINICAL	>clinical	NN	_	14	com	_	_
14	PHARMACOLOGY	pharmacology	NN	_	3	appo	_	_
15	:	:	:	_	3	p	_	_
16	Drug	drug	NN	_	18	com	_	_
17	Interaction	interaction	NN	_	18	com	_	_
18	Studies	study	NNS	_	3	appo	_	_
19	.	.	.	_	3	p	_	_
20	)	-rrb-	-RRB-	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	significantly	significantly	RB	_	6	adv	_	_
6	increase	increase	VB	_	1	acl	_	_
7	drug3	drug0	NN	_	8	com	_	_
8	levels	level	NNS	_	6	obj	_	_
9	in	in	IN	_	12	case	_	_
10	renal	renal	JJ	_	12	attr	_	_
11	transplant	transplant	NN	_	12	com	_	_
12	patients	patient	NNS	_	6	ppmod	_	_
13	with	with	IN	_	12	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	without	without	IN	_	17	case	_	_
16	renal	renal	JJ	_	17	attr	_	_
17	impairment	impairment	NN	_	13	conj	_	_
18	.	.	.	_	1	p	_	_

1	Careful	careful	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	serum	serum	NN	_	8	com	_	_
8	creatinine	creatinine	NN	_	5	conj	_	_
9	is	be	VBZ	_	10	aux	_	_
10	recommended	recommend	VBN	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	drug2	drug0	NN	_	13	obj	_	_
15	and	and	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	.	.	.	_	10	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	See	see	VB	_	0	root	_	_
3	CLINICAL	clinical	JJ	_	4	attr	_	_
4	PHARMACOLOGY	pharmacology	NN	_	2	obj	_	_
5	:	:	:	_	2	p	_	_
6	Drug	drug	NN	_	8	com	_	_
7	Interaction	interaction	NN	_	8	com	_	_
8	Studies	study	NNS	_	2	dep	_	_
9	.	.	.	_	2	p	_	_
10	)	-rrb-	-RRB-	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	enhances	enhance	VBZ	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	metabolism	metabolism	NN	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	concurrently	concurrently	RB	_	9	adv	_	_
9	administered	administer	VBN	_	10	attr	_	_
10	drug3	drug0	NN	_	6	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	Depending	depend	VBG	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	circumstances	circumstance	NNS	_	9	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	consideration	consideration	NN	_	9	dep	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	given	give	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	increasing	increase	VBG	_	9	ppmod	_	_
12	the	the	DT	_	13	det	_	_
13	dose	dose	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	when	when	WRB	_	19	adv	_	_
17	it	it	PRP	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	administered	administer	VBN	_	15	relcl	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	increases	increase	VBZ	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	serum	serum	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	Careful	careful	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	14	dep	_	_
3	of	of	IN	_	6	case	_	_
4	serum	serum	NN	_	6	com	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	concentrations	concentration	NNS	_	2	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	2	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	is	be	VBZ	_	14	aux	_	_
14	recommended	recommend	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Because	because	IN	_	6	case	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	occurrence	occurrence	NN	_	31	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	serious	serious	JJ	_	10	attr	_	_
9	cardiac	cardiac	JJ	_	10	attr	_	_
10	dysrhythmias	dysrhythmia	NNS	_	6	ppmod	_	_
11	secondary	secondary	JJ	_	10	attr	_	_
12	to	to	TO	_	13	aux	_	_
13	prolongation	prolongation	NN	_	11	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	QTc	qtc	NN	_	17	com	_	_
17	interval	interval	NN	_	13	ppmod	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	13	ppmod	_	_
20	receiving	receive	VBG	_	19	acl	_	_
21	drug2	drug0	NN	_	20	obj	_	_
22	in	in	IN	_	23	case	_	_
23	conjunction	conjunction	NN	_	20	ppmod	_	_
24	with	with	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	,	,	,	_	31	p	_	_
27	interaction	interaction	NN	_	28	com	_	_
28	studies	study	NNS	_	31	dep	_	_
29	have	have	VBP	_	31	aux	_	_
30	been	be	VBN	_	31	aux	_	_
31	performed	performed	VBN	_	1	acl	_	_
32	.	.	.	_	1	p	_	_

1	One	#crd#	CD	_	2	num	_	_
2	study	study	NN	_	10	dep	_	_
3	at	at	IN	_	7	case	_	_
4	a	a	DT	_	7	det	_	_
5	200-mg	0-mg	JJ	_	7	attr	_	_
6	daily	daily	JJ	_	7	attr	_	_
7	dose	dose	NN	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	failed	fail	VBD	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	demonstrate	demonstrate	VB	_	10	comp	_	_
13	a	a	DT	_	14	det	_	_
14	prolongation	prolongation	NN	_	12	obj	_	_
15	in	in	IN	_	17	case	_	_
16	QTc	qtc	NN	_	17	com	_	_
17	interval	interval	NN	_	14	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	Another	another	DT	_	2	det	_	_
2	study	study	NN	_	12	dep	_	_
3	at	at	IN	_	9	case	_	_
4	a	a	DT	_	9	det	_	_
5	400-mg	0-mg	JJ	_	9	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	800-mg	0-mg	JJ	_	5	conj	_	_
8	daily	daily	JJ	_	9	attr	_	_
9	dose	dose	NN	_	2	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	demonstrated	demonstrate	VBD	_	0	root	_	_
13	that	that	IN	_	26	mark	_	_
14	drug2	drug0	NN	_	26	dep	_	_
15	taken	take	VBN	_	14	acl	_	_
16	in	in	IN	_	17	case	_	_
17	doses	dose	NNS	_	15	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	400	0	CD	_	20	num	_	_
20	mg	mg	NN	_	17	ppmod	_	_
21	per	per	IN	_	22	case	_	_
22	day	day	NN	_	20	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	greater	great	JJR	_	22	conj	_	_
25	significantly	significantly	RB	_	26	adv	_	_
26	increases	increase	VBZ	_	12	comp	_	_
27	plasma	plasma	NN	_	28	com	_	_
28	levels	level	NNS	_	26	obj	_	_
29	of	of	IN	_	30	case	_	_
30	drug3	drug0	NN	_	28	ppmod	_	_
31	when	when	WRB	_	32	adv	_	_
32	taken	take	VBN	_	26	comp	_	_
33	concomitantly	concomitantly	RB	_	32	adv	_	_
34	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	combined	combined	JJ	_	3	attr	_	_
3	use	use	NN	_	16	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	at	at	IN	_	7	case	_	_
7	doses	dose	NNS	_	3	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	400	0	CD	_	10	num	_	_
10	mg	mg	NN	_	7	ppmod	_	_
11	or	or	CC	_	12	cc	_	_
12	greater	great	JJR	_	10	num	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	10	ppmod	_	_
15	is	be	VBZ	_	16	aux	_	_
16	contraindicated	contraindicate	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	The	the	DT	_	2	det	_	_
2	coadministration	coadministration	NN	_	16	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	at	at	IN	_	6	case	_	_
6	doses	dose	NNS	_	4	ppmod	_	_
7	lower	low	JJR	_	6	attr	_	_
8	than	than	IN	_	10	case	_	_
9	400	0	CD	_	10	num	_	_
10	mg/day	mg/day	NN	_	7	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	should	should	MD	_	16	modal	_	_
14	be	be	VB	_	16	aux	_	_
15	carefully	carefully	RB	_	16	adv	_	_
16	monitored	monitor	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	been	be	VBN	_	1	acl	_	_
6	reports	report	NNS	_	5	obj	_	_
7	of	of	IN	_	9	case	_	_
8	cardiac	cardiac	JJ	_	9	attr	_	_
9	events	event	NNS	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	including	include	VBG	_	14	adv	_	_
12	torsade	torsade	NN	_	14	com	_	_
13	de	de	NN	_	14	com	_	_
14	pointes	point	NNS	_	9	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	to	to	TO	_	18	aux	_	_
18	whom	whom	WP	_	23	ppmod	_	_
19	drug2	drug0	NN	_	23	dep	_	_
20	and	and	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	were	be	VBD	_	23	aux	_	_
23	coadministered	coadministered	VBN	_	16	relcl	_	_
24	.	.	.	_	1	p	_	_

1	A	a	DT	_	3	det	_	_
2	controlled	controlled	JJ	_	3	attr	_	_
3	study	study	NN	_	4	dep	_	_
4	found	find	VBD	_	0	root	_	_
5	that	that	IN	_	20	mark	_	_
6	concomitant	concomitant	JJ	_	9	attr	_	_
7	drug1	drug0	NN	_	9	attr	_	_
8	200	0	CD	_	9	num	_	_
9	mg	mg	NN	_	20	dep	_	_
10	once	once	RB	_	11	com	_	_
11	daily	daily	RB	_	9	adv	_	_
12	and	and	CC	_	9	cc	_	_
13	drug2	drug0	NN	_	15	attr	_	_
14	20	0	CD	_	15	num	_	_
15	mg	mg	NN	_	9	conj	_	_
16	four	#crd#	CD	_	17	num	_	_
17	times	time	NNS	_	15	appo	_	_
18	a	a	DT	_	19	det	_	_
19	day	day	NN	_	17	attr	_	_
20	yielded	yield	VBD	_	4	comp	_	_
21	a	a	DT	_	23	det	_	_
22	significant	significant	JJ	_	23	attr	_	_
23	increase	increase	NN	_	20	obj	_	_
24	in	in	IN	_	27	case	_	_
25	drug3	drug0	NN	_	27	com	_	_
26	plasma	plasma	NN	_	27	com	_	_
27	levels	level	NNS	_	23	ppmod	_	_
28	and	and	CC	_	23	cc	_	_
29	prolongation	prolongation	NN	_	23	conj	_	_
30	of	of	IN	_	32	case	_	_
31	QTc	qtc	NN	_	32	com	_	_
32	interval	interval	NN	_	29	ppmod	_	_
33	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	combined	combined	JJ	_	3	attr	_	_
3	use	use	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	contraindicated	contraindicate	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	use	use	NN	_	23	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	concurrently	concurrently	RB	_	10	adv	_	_
10	taking	take	VBG	_	8	acl	_	_
11	drug3	drug0	NN	_	10	obj	_	_
12	or	or	CC	_	11	cc	_	_
13	other	other	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	11	conj	_	_
15	metabolized	metabolize	VBN	_	11	acl	_	_
16	by	by	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	cytochrome	cytochrome	NN	_	20	com	_	_
19	P450	p0	NN	_	20	com	_	_
20	system	system	NN	_	15	ppmod	_	_
21	may	may	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	associated	associate	VBN	_	1	acl	_	_
24	with	with	IN	_	25	case	_	_
25	elevations	elevation	NNS	_	23	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	serum	serum	NN	_	28	com	_	_
28	levels	level	NNS	_	25	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	these	these	DT	_	31	det	_	_
31	drugs	drug	NNS	_	28	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	absence	absence	NN	_	11	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	definitive	definitive	JJ	_	6	attr	_	_
6	information	information	NN	_	3	ppmod	_	_
7	,	,	,	_	11	p	_	_
8	caution	caution	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	used	use	VBN	_	0	root	_	_
12	when	when	WRB	_	13	adv	_	_
13	coadministering	coadministering	VBG	_	11	comp	_	_
14	drug1	drug0	NN	_	13	obj	_	_
15	.	.	.	_	11	p	_	_

1	Patients	patient	NNS	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	be	be	VB	_	5	aux	_	_
4	carefully	carefully	RB	_	5	adv	_	_
5	monitored	monitor	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	been	be	VBN	_	1	acl	_	_
6	reports	report	NNS	_	5	obj	_	_
7	of	of	IN	_	8	case	_	_
8	uveitis	uveitis	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	5	ppmod	_	_
11	to	to	TO	_	12	aux	_	_
12	whom	whom	WP	_	17	ppmod	_	_
13	drug2	drug0	NN	_	17	dep	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	were	be	VBD	_	17	aux	_	_
17	coadministered	coadministered	VBN	_	10	relcl	_	_
18	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	concomitantly	concomitantly	RB	_	10	adv	_	_
7	should	should	MD	_	10	modal	_	_
8	be	be	VB	_	10	aux	_	_
9	carefully	carefully	RB	_	10	adv	_	_
10	monitored	monitor	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	been	be	VBN	_	1	acl	_	_
6	reports	report	NNS	_	5	obj	_	_
7	of	of	IN	_	8	case	_	_
8	nephrotoxicity	nephrotoxicity	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	5	ppmod	_	_
11	to	to	TO	_	12	aux	_	_
12	whom	whom	WP	_	17	ppmod	_	_
13	drug2	drug0	NN	_	17	dep	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	were	be	VBD	_	17	aux	_	_
17	coadministered	coadministered	VBN	_	10	relcl	_	_
18	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	concomitantly	concomitantly	RB	_	10	adv	_	_
7	should	should	MD	_	10	modal	_	_
8	be	be	VB	_	10	aux	_	_
9	carefully	carefully	RB	_	10	adv	_	_
10	monitored	monitor	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Following	following	JJ	_	5	attr	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	administration	administration	NN	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	appo	_	_
10	resulted	result	VBD	_	1	acl	_	_
11	in	in	IN	_	13	case	_	_
12	substantial	substantial	JJ	_	13	attr	_	_
13	increases	increase	NNS	_	10	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	drug4	drug0	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	13	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	psychomotor	psychomotor	NN	_	19	com	_	_
19	effects	effect	NNS	_	16	conj	_	_
20	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	5	dep	_	_
3	on	on	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	appears	appear	VBZ	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	be	be	VB	_	5	comp	_	_
8	more	more	RBR	_	9	adv	_	_
9	pronounced	pronounced	JJ	_	7	dep	_	_
10	following	follow	VBG	_	12	adv	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	administration	administration	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	than	than	IN	_	17	case	_	_
16	with	with	IN	_	17	case	_	_
17	drug3	drug0	NN	_	12	ppmod	_	_
18	administered	administer	VBN	_	17	acl	_	_
19	intravenously	intravenously	RB	_	18	adv	_	_
20	.	.	.	_	5	p	_	_

1	If	if	IN	_	15	mark	_	_
2	drug1	drug0	NN	_	15	dep	_	_
3	,	,	,	_	2	p	_	_
4	which	which	WDT	_	6	dep	_	_
5	are	be	VBP	_	6	aux	_	_
6	metabolized	metabolize	VBN	_	2	relcl	_	_
7	by	by	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	cytochrome	cytochrome	NN	_	11	com	_	_
10	P450	p0	NN	_	11	com	_	_
11	system	system	NN	_	6	ppmod	_	_
12	,	,	,	_	2	p	_	_
13	are	be	VBP	_	15	aux	_	_
14	concomitantly	concomitantly	RB	_	15	adv	_	_
15	administered	administer	VBN	_	22	advcl	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	22	p	_	_
19	consideration	consideration	NN	_	22	dep	_	_
20	should	should	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	given	give	VBN	_	0	root	_	_
23	to	to	TO	_	24	aux	_	_
24	decreasing	decrease	VBG	_	22	ppmod	_	_
25	the	the	DT	_	27	det	_	_
26	drug3	drug0	NN	_	27	com	_	_
27	dosage	dosage	NN	_	24	obj	_	_
28	,	,	,	_	22	p	_	_
29	and	and	CC	_	22	cc	_	_
30	the	the	DT	_	31	det	_	_
31	patients	patient	NNS	_	35	dep	_	_
32	should	should	MD	_	35	modal	_	_
33	be	be	VB	_	35	aux	_	_
34	appropriately	appropriately	RB	_	35	adv	_	_
35	monitored	monitor	VBN	_	22	conj	_	_
36	.	.	.	_	35	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	tablets	tablet	NNS	_	12	dep	_	_
3	coadministered	coadministered	VBN	_	2	acl	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	-	-	:	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	drug3	drug0	NN	_	11	attr	_	_
9	-containing	-containing	JJ	_	11	attr	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	drug4	drug0	NNS	_	5	conj	_	_
12	produced	produce	VBD	_	0	root	_	_
13	an	an	DT	_	16	det	_	_
14	overall	overall	JJ	_	16	attr	_	_
15	mean	mean	NN	_	16	com	_	_
16	increase	increase	NN	_	12	obj	_	_
17	in	in	IN	_	18	case	_	_
18	drug5	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug6	drug0	NN	_	21	com	_	_
21	levels	level	NNS	_	18	conj	_	_
22	;	;	:	_	12	p	_	_

1	however	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	in	in	IN	_	5	case	_	_
4	some	some	DT	_	5	det	_	_
5	patients	patient	NNS	_	7	ppmod	_	_
6	there	there	EX	_	7	dep	_	_
7	were	be	VBD	_	0	root	_	_
8	decreases	decrease	NNS	_	7	obj	_	_
9	up	up	RP	_	11	prt	_	_
10	to	to	TO	_	11	aux	_	_
11	47	0	CD	_	8	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	and	and	CC	_	11	cc	_	_
14	33	0	CD	_	11	conj	_	_
15	%	%	NN	_	14	meta	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	11	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	levels	level	NNS	_	17	conj	_	_
21	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	data	datum	NNS	_	5	dep	_	_
3	presently	presently	RB	_	4	adv	_	_
4	available	available	JJ	_	2	attr	_	_
5	indicate	indicate	VBP	_	0	root	_	_
6	that	that	IN	_	20	mark	_	_
7	the	the	DT	_	8	det	_	_
8	decreases	decrease	NNS	_	20	dep	_	_
9	in	in	IN	_	12	case	_	_
10	some	some	DT	_	12	det	_	_
11	individual	individual	JJ	_	12	attr	_	_
12	drug1	drug0	NN	_	8	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	16	com	_	_
15	AUC	auc	NN	_	16	com	_	_
16	values	value	NNS	_	12	conj	_	_
17	with	with	IN	_	19	case	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	treatment	treatment	NN	_	12	ppmod	_	_
20	are	be	VBP	_	5	comp	_	_
21	likely	likely	RB	_	20	adv	_	_
22	the	the	DT	_	23	det	_	_
23	result	result	NN	_	20	obj	_	_
24	of	of	IN	_	26	case	_	_
25	random	random	JJ	_	26	attr	_	_
26	variation	variation	NN	_	23	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	While	while	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	is	be	VBZ	_	17	advcl	_	_
4	evidence	evidence	NN	_	3	obj	_	_
5	that	that	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	can	can	MD	_	8	modal	_	_
8	inhibit	inhibit	VB	_	4	acl	_	_
9	the	the	DT	_	10	det	_	_
10	metabolism	metabolism	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	17	p	_	_
16	there	there	EX	_	17	dep	_	_
17	is	be	VBZ	_	0	root	_	_
18	no	no	DT	_	19	det	_	_
19	evidence	evidence	NN	_	17	obj	_	_
20	that	that	IN	_	22	mark	_	_
21	drug4	drug0	NN	_	22	dep	_	_
22	is	be	VBZ	_	19	acl	_	_
23	a	a	DT	_	25	det	_	_
24	net	net	JJ	_	25	attr	_	_
25	inducer	inducer	NN	_	22	obj	_	_
26	of	of	IN	_	27	case	_	_
27	drug5	drug0	NN	_	25	ppmod	_	_
28	or	or	CC	_	27	cc	_	_
29	drug6	drug0	NN	_	30	com	_	_
30	metabolism	metabolism	NN	_	27	conj	_	_
31	.	.	.	_	17	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	effects	effect	NNS	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	presently	presently	RB	_	7	adv	_	_
9	unknown	unknown	JJ	_	7	dep	_	_
10	.	.	.	_	7	p	_	_

1	Physicians	physician	NNS	_	3	dep	_	_
2	should	should	MD	_	3	modal	_	_
3	be	be	VB	_	0	root	_	_
4	aware	aware	NN	_	3	obj	_	_
5	that	that	IN	_	34	mark	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	34	dep	_	_
8	with	with	IN	_	9	case	_	_
9	medications	medication	NNS	_	7	ppmod	_	_
10	other	other	JJ	_	9	attr	_	_
11	than	than	IN	_	12	case	_	_
12	those	those	DT	_	10	ppmod	_	_
13	listed	list	VBN	_	12	acl	_	_
14	in	in	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	&lt	&lt	NN	_	13	ppmod	_	_
17	;	;	:	_	16	p	_	_
18	a	a	DT	_	20	det	_	_
19	href=	href=	NN	_	20	com	_	_
20	&quot	&quot	NN	_	16	appo	_	_
21	;	;	:	_	16	p	_	_
22	flucon_cp.htm	#hlink#	NN	_	24	com	_	_
23	#	#	NN	_	24	com	_	_
24	CP&quot	cp&quot	NN	_	16	appo	_	_
25	;	;	:	_	16	p	_	_
26	&gt	&gt	NN	_	16	appo	_	_
27	;	;	:	_	16	p	_	_
28	CLINICAL	clinical	JJ	_	30	attr	_	_
29	PHARMACOLOGY	pharmacology	NN	_	30	com	_	_
30	section	section	NN	_	16	appo	_	_
31	have	have	VBP	_	34	aux	_	_
32	not	not	RB	_	34	neg	_	_
33	been	be	VBN	_	34	aux	_	_
34	conducted	conduct	VBN	_	3	comp	_	_
35	,	,	,	_	34	p	_	_
36	but	but	CC	_	34	cc	_	_
37	such	such	JJ	_	38	attr	_	_
38	interactions	interaction	NNS	_	40	dep	_	_
39	may	may	MD	_	40	modal	_	_
40	occur	occur	VB	_	34	conj	_	_
41	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	appo	_	_
7	,	,	,	_	4	p	_	_
8	with	with	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	2	ppmod	_	_
11	has	have	VBZ	_	15	aux	_	_
12	not	not	RB	_	15	neg	_	_
13	been	be	VBN	_	15	aux	_	_
14	well	well	RB	_	15	adv	_	_
15	studied	study	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Use	use	NN	_	21	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	--	--	:	_	1	p	_	_
7	drug3	drug0	NN	_	1	appo	_	_
8	,	,	,	_	1	p	_	_
9	drug4	drug0	NN	_	1	appo	_	_
10	,	,	,	_	1	p	_	_
11	alone	alone	RB	_	1	adv	_	_
12	or	or	CC	_	11	cc	_	_
13	in	in	IN	_	14	case	_	_
14	combination	combination	NN	_	11	conj	_	_
15	with	with	IN	_	16	case	_	_
16	drug5	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug6	drug0	NN	_	16	conj	_	_
19	,	,	,	_	14	p	_	_
20	may	may	MD	_	21	modal	_	_
21	cause	cause	VB	_	0	root	_	_
22	bleeding	bleeding	JJ	_	23	attr	_	_
23	complications	complication	NNS	_	21	obj	_	_
24	.	.	.	_	21	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	careful	careful	JJ	_	4	attr	_	_
4	monitoring	monitoring	NN	_	5	dep	_	_
5	is	be	VBZ	_	0	root	_	_
6	advised	advised	JJ	_	5	dep	_	_
7	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	treatment	treatment	NN	_	17	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	acute	acute	JJ	_	6	attr	_	_
6	MI	mus	NNS	_	3	ppmod	_	_
7	,	,	,	_	17	p	_	_
8	drug1	drug0	NN	_	17	dep	_	_
9	,	,	,	_	17	p	_	_
10	when	when	WRB	_	13	adv	_	_
11	not	not	RB	_	13	neg	_	_
12	otherwise	otherwise	RB	_	13	adv	_	_
13	contraindicated	contraindicate	VBN	_	17	advcl	_	_
14	,	,	,	_	17	p	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	administered	administer	VBN	_	0	root	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	see	see	VB	_	19	prn	_	_
22	below	below	IN	_	21	case	_	_
23	)	-rrb-	-RRB-	_	21	p	_	_
24	.	.	.	_	17	p	_	_

1	Anticoagulation	anticoagulation	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug1	drug0	NN	_	1	conj	_	_
4	After	after	IN	_	5	case	_	_
5	Treatment	treatment	NN	_	1	ppmod	_	_
6	for	for	IN	_	8	case	_	_
7	Myocardial	myocardial	JJ	_	8	attr	_	_
8	Infarction	infarction	NN	_	1	ppmod	_	_
9	--	--	:	_	1	p	_	_
10	In	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	treatment	treatment	NN	_	24	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	acute	acute	JJ	_	16	attr	_	_
15	myocardial	myocardial	JJ	_	16	attr	_	_
16	infarction	infarction	NN	_	12	ppmod	_	_
17	,	,	,	_	24	p	_	_
18	the	the	DT	_	19	det	_	_
19	use	use	NN	_	24	dep	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	has	have	VBZ	_	24	aux	_	_
23	been	be	VBN	_	24	aux	_	_
24	shown	show	VBN	_	1	acl	_	_
25	to	to	TO	_	26	aux	_	_
26	reduce	reduce	VB	_	24	comp	_	_
27	the	the	DT	_	28	det	_	_
28	incidence	incidence	NN	_	26	obj	_	_
29	of	of	IN	_	30	case	_	_
30	reinfarction	reinfarction	NN	_	28	ppmod	_	_
31	and	and	CC	_	30	cc	_	_
32	stroke	stroke	NN	_	30	conj	_	_
33	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	addition	addition	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	causes	cause	VBZ	_	0	root	_	_
8	a	a	DT	_	10	det	_	_
9	minimal	minimal	JJ	_	10	attr	_	_
10	increase	increase	NN	_	7	obj	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	risk	risk	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	minor	minor	JJ	_	16	attr	_	_
16	bleeding	bleeding	JJ	_	13	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	3.9	0	CD	_	16	num	_	_
19	%	%	NN	_	18	meta	_	_
20	vs.	vs.	CC	_	18	cc	_	_
21	3.1	0	CD	_	18	conj	_	_
22	%	%	NN	_	21	meta	_	_
23	)	-rrb-	-RRB-	_	18	p	_	_
24	,	,	,	_	7	p	_	_
25	but	but	CC	_	7	cc	_	_
26	does	do	VBZ	_	28	aux	_	_
27	not	not	RB	_	28	neg	_	_
28	appear	appear	VB	_	7	conj	_	_
29	to	to	TO	_	30	aux	_	_
30	increase	increase	VB	_	28	comp	_	_
31	the	the	DT	_	32	det	_	_
32	incidence	incidence	NN	_	30	obj	_	_
33	of	of	IN	_	35	case	_	_
34	major	major	JJ	_	35	attr	_	_
35	bleeding	bleeding	JJ	_	32	ppmod	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	see	see	VB	_	30	prn	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	used	use	VBN	_	14	advcl	_	_
5	with	with	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	,	,	,	_	14	p	_	_
9	potentiation	potentiation	NN	_	14	dep	_	_
10	of	of	IN	_	12	case	_	_
11	antihypertensive	antihypertensive	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	occur	occur	VB	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Patients	patient	NNS	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	followed	followed	VBN	_	0	root	_	_
5	carefully	carefully	RB	_	4	adv	_	_
6	to	to	TO	_	7	aux	_	_
7	detect	detect	VB	_	4	comp	_	_
8	side	side	JJ	_	9	attr	_	_
9	reactions	reaction	NNS	_	7	obj	_	_
10	or	or	CC	_	9	cc	_	_
11	unusual	unusual	JJ	_	12	attr	_	_
12	manifestations	manifestation	NNS	_	9	conj	_	_
13	of	of	IN	_	15	case	_	_
14	drug	drug	NN	_	15	com	_	_
15	idiosyncrasy	idiosyncrasy	NN	_	9	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	Patients	patient	NNS	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	require	require	VB	_	0	root	_	_
4	reduced	reduce	VBN	_	5	attr	_	_
5	doses	dose	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	when	when	WRB	_	3	adv	_	_
9	on	on	IN	_	10	case	_	_
10	drug2	drug0	NN	_	3	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	If	if	IN	_	4	mark	_	_
2	hypotension	hypotension	NN	_	4	dep	_	_
3	does	do	VBZ	_	4	aux	_	_
4	occur	occur	VB	_	12	advcl	_	_
5	during	during	IN	_	6	case	_	_
6	anesthesia	anesthesia	NN	_	4	ppmod	_	_
7	,	,	,	_	12	p	_	_
8	it	it	PRP	_	12	dep	_	_
9	usually	usually	RB	_	12	adv	_	_
10	can	can	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	controlled	control	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	adrenergic	adrenergic	JJ	_	3	attr	_	_
3	receptors	receptor	NNS	_	4	dep	_	_
4	remain	remain	VBP	_	0	root	_	_
5	sensitive	sensitive	JJ	_	4	dep	_	_
6	during	during	IN	_	7	case	_	_
7	treatment	treatment	NN	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	When	when	WRB	_	6	adv	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	are	be	VBP	_	6	aux	_	_
6	given	give	VBN	_	13	advcl	_	_
7	concomitantly	concomitantly	RB	_	6	adv	_	_
8	the	the	DT	_	9	det	_	_
9	patient	patient	NN	_	13	dep	_	_
10	should	should	MD	_	13	modal	_	_
11	be	be	VB	_	13	aux	_	_
12	carefully	carefully	RB	_	13	adv	_	_
13	monitored	monitor	VBN	_	0	root	_	_
14	for	for	IN	_	15	case	_	_
15	symptoms	symptom	NNS	_	13	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	toxicity	toxicity	NN	_	15	ppmod	_	_
19	.	.	.	_	13	p	_	_

1	Read	read	VBN	_	0	root	_	_
2	the	the	DT	_	3	det	_	_
3	circular	circular	JJ	_	1	obj	_	_
4	for	for	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	preparations	preparation	NNS	_	3	ppmod	_	_
7	.	.	.	_	1	p	_	_

1	Several	several	JJ	_	2	attr	_	_
2	studies	study	NNS	_	3	dep	_	_
3	demonstrate	demonstrate	VBP	_	0	root	_	_
4	a	a	DT	_	5	det	_	_
5	decrease	decrease	NN	_	3	obj	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	bioavailability	bioavailability	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	when	when	WRB	_	14	adv	_	_
12	it	it	PRP	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	ingested	ingest	VBN	_	3	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	.	.	.	_	3	p	_	_

1	This	this	DT	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	adversely	adversely	RB	_	4	adv	_	_
4	affect	affect	VBP	_	0	root	_	_
5	blood	blood	NN	_	7	com	_	_
6	pressure	pressure	NN	_	7	com	_	_
7	control	control	NN	_	4	obj	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	4	ppmod	_	_
10	treated	treat	VBN	_	9	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	is	be	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	recommended	recommend	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	See	see	VB	_	1	acl	_	_
4	CONTRAINDICATIONS	contraindication	NNS	_	3	obj	_	_
5	.	.	.	_	1	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	6	dep	_	_
4	drug1	drug0	RB	_	6	adv	_	_
5	may	may	MD	_	6	modal	_	_
6	interfere	interfere	VB	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	measurement	measurement	NN	_	6	ppmod	_	_
9	of	of	IN	_	13	case	_	_
10	:	:	:	_	13	p	_	_
11	urinary	urinary	JJ	_	13	attr	_	_
12	uric	uric	JJ	_	13	attr	_	_
13	acid	acid	NN	_	8	ppmod	_	_
14	by	by	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	phosphotungstate	phosphotungstate	NN	_	17	com	_	_
17	method	method	NN	_	13	ppmod	_	_
18	,	,	,	_	13	p	_	_
19	serum	serum	NN	_	20	com	_	_
20	creatinine	creatinine	NN	_	13	conj	_	_
21	by	by	IN	_	25	case	_	_
22	the	the	DT	_	25	det	_	_
23	alkaline	alkaline	NN	_	25	com	_	_
24	picrate	picrate	NN	_	25	com	_	_
25	method	method	NN	_	20	ppmod	_	_
26	,	,	,	_	20	p	_	_
27	and	and	CC	_	20	cc	_	_
28	SGOT	sgot	NN	_	13	conj	_	_
29	by	by	IN	_	31	case	_	_
30	colorimetric	colorimetric	JJ	_	31	attr	_	_
31	methods	method	NNS	_	28	ppmod	_	_
32	.	.	.	_	6	p	_	_

1	Interference	interference	NN	_	11	dep	_	_
2	with	with	IN	_	4	case	_	_
3	spectrophotometric	spectrophotometric	JJ	_	4	attr	_	_
4	methods	method	NNS	_	1	ppmod	_	_
5	for	for	IN	_	7	case	_	_
6	SGOT	sgot	NN	_	7	com	_	_
7	analysis	analysis	NN	_	1	ppmod	_	_
8	has	have	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	reported	report	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Since	since	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	causes	cause	VBZ	_	24	advcl	_	_
4	fluorescence	fluorescence	NN	_	3	obj	_	_
5	in	in	IN	_	7	case	_	_
6	urine	urine	NN	_	7	com	_	_
7	samples	sample	NNS	_	4	ppmod	_	_
8	at	at	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	same	same	JJ	_	12	attr	_	_
11	wave	wave	NN	_	12	com	_	_
12	lengths	length	NNS	_	4	ppmod	_	_
13	as	as	IN	_	14	case	_	_
14	catecholamines	catecholamine	NNS	_	3	ppmod	_	_
15	,	,	,	_	24	p	_	_
16	falsely	falsely	RB	_	17	adv	_	_
17	high	high	JJ	_	18	attr	_	_
18	levels	level	NNS	_	24	dep	_	_
19	of	of	IN	_	21	case	_	_
20	urinary	urinary	JJ	_	21	attr	_	_
21	catecholamines	catecholamine	NNS	_	18	ppmod	_	_
22	may	may	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	reported	report	VBN	_	0	root	_	_
25	.	.	.	_	24	p	_	_

1	This	this	DT	_	3	dep	_	_
2	will	will	MD	_	3	modal	_	_
3	interfere	interfere	VB	_	0	root	_	_
4	with	with	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	diagnosis	diagnosis	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	pheochromocytoma	pheochromocytoma	NN	_	6	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	important	important	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	recognize	recognize	VB	_	2	comp	_	_
6	this	this	DT	_	7	det	_	_
7	phenomenon	phenomenon	NN	_	5	obj	_	_
8	before	before	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	patient	patient	NN	_	5	ppmod	_	_
11	with	with	IN	_	14	case	_	_
12	a	a	DT	_	14	det	_	_
13	possible	possible	JJ	_	14	attr	_	_
14	pheochromocytoma	pheochromocytoma	NN	_	10	ppmod	_	_
15	is	be	VBZ	_	16	aux	_	_
16	subjected	subject	VBN	_	14	acl	_	_
17	to	to	TO	_	18	aux	_	_
18	surgery	surgery	NN	_	16	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	interfere	interfere	VB	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	measurement	measurement	NN	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug3	drug0	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	,	,	,	_	8	p	_	_
13	a	a	DT	_	14	det	_	_
14	test	test	NN	_	8	appo	_	_
15	for	for	IN	_	16	case	_	_
16	pheochromocytoma	pheochromocytoma	NN	_	14	ppmod	_	_
17	,	,	,	_	8	p	_	_
18	by	by	IN	_	20	case	_	_
19	those	those	DT	_	20	det	_	_
20	methods	method	NNS	_	4	ppmod	_	_
21	which	which	WDT	_	22	dep	_	_
22	convert	convert	VBP	_	20	relcl	_	_
23	drug4	drug0	NN	_	22	obj	_	_
24	to	to	TO	_	25	aux	_	_
25	drug5	drug0	NN	_	22	ppmod	_	_
26	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	recommended	recommend	VBN	_	0	root	_	_
5	for	for	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	treatment	treatment	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	pheochromocytoma	pheochromocytoma	NN	_	9	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	Rarely	rarely	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	when	when	WRB	_	6	adv	_	_
4	urine	urine	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	exposed	expose	VBN	_	14	advcl	_	_
7	to	to	TO	_	8	aux	_	_
8	air	air	NN	_	6	ppmod	_	_
9	after	after	IN	_	10	case	_	_
10	voiding	voiding	NN	_	6	ppmod	_	_
11	,	,	,	_	14	p	_	_
12	it	it	PRP	_	14	dep	_	_
13	may	may	MD	_	14	modal	_	_
14	darken	darken	VB	_	0	root	_	_
15	because	because	IN	_	17	case	_	_
16	of	of	IN	_	17	case	_	_
17	breakdown	breakdown	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	its	its	PRP$	_	22	poss	_	_
22	metabolites	metabolite	NNS	_	19	conj	_	_
23	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concurrent	concurrent	JJ	_	4	attr	_	_
4	use	use	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	result	result	VB	_	1	acl	_	_
11	in	in	IN	_	14	case	_	_
12	increased	increase	VBN	_	14	attr	_	_
13	systemic	systemic	JJ	_	14	attr	_	_
14	toxicity	toxicity	NN	_	10	ppmod	_	_
15	since	since	IN	_	17	mark	_	_
16	drug4	drug0	NNS	_	17	dep	_	_
17	inhibit	inhibit	VBP	_	10	comp	_	_
18	the	the	DT	_	19	det	_	_
19	breakdown	breakdown	NN	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug5	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	Antimyasthenics	antimyasthenics	NN	_	3	attr	_	_
2	Concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	antimyasthenics	antimyasthenics	NN	_	5	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	result	result	VB	_	0	root	_	_
10	in	in	IN	_	11	case	_	_
11	loss	loss	NN	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	control	control	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	symptoms	symptom	NNS	_	13	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	myasthenia	myasthenia	JJ	_	18	attr	_	_
18	gravis	gravis	NNS	_	15	ppmod	_	_
19	due	due	JJ	_	18	attr	_	_
20	to	to	TO	_	21	aux	_	_
21	antagonism	antagonism	NN	_	19	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	effects	effect	NNS	_	21	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	antimyasthenics	antimyasthenics	NNS	_	24	ppmod	_	_
27	on	on	IN	_	29	case	_	_
28	skeletal	skeletal	JJ	_	29	attr	_	_
29	muscle	muscle	NN	_	24	ppmod	_	_
30	.	.	.	_	9	p	_	_

1	Temporary	temporary	JJ	_	3	attr	_	_
2	dosage	dosage	NN	_	3	com	_	_
3	adjustment	adjustment	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	antimyasthenics	antimyasthenics	NNS	_	3	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	required	require	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Also	also	RB	_	6	adv	_	_
2	antimyasthenics	antimyasthenics	NN	_	6	dep	_	_
3	may	may	MD	_	6	modal	_	_
4	have	have	VB	_	6	lv	_	_
5	anticholinesterase	anticholinesterase	NN	_	6	com	_	_
6	activity	activity	NN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	medications	medication	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Concurrent	concurrent	JJ	_	5	attr	_	_
5	use	use	NN	_	11	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	may	may	MD	_	11	modal	_	_
11	result	result	VB	_	2	acl	_	_
12	in	in	IN	_	15	case	_	_
13	additive	additive	JJ	_	15	attr	_	_
14	depressant	depressant	NN	_	15	com	_	_
15	effects	effect	NNS	_	11	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	diffusion	diffusion	NN	_	8	com	_	_
8	rate	rate	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	5	p	_	_
12	resulting	result	VBG	_	5	comp	_	_
13	in	in	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	decreased	decrease	VBN	_	16	attr	_	_
16	time	time	NN	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	onset	onset	NN	_	16	ppmod	_	_
19	,	,	,	_	16	p	_	_
20	but	but	CC	_	16	cc	_	_
21	an	an	DT	_	22	det	_	_
22	increase	increase	NN	_	16	conj	_	_
23	in	in	IN	_	25	case	_	_
24	systemic	systemic	JJ	_	25	attr	_	_
25	toxicity	toxicity	NN	_	22	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	such	such	JJ	_	4	com	_	_
4	as	as	IN	_	5	cc	_	_
5	drug2	drug0	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	:	:	:	_	1	p	_	_
8	Concurrent	concurrent	JJ	_	9	attr	_	_
9	use	use	NN	_	15	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	may	may	MD	_	15	modal	_	_
15	result	result	VB	_	1	acl	_	_
16	in	in	IN	_	17	case	_	_
17	prolongation	prolongation	NN	_	15	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	enhancement	enhancement	NN	_	17	conj	_	_
20	of	of	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	neuromuscular	neuromuscular	JJ	_	23	attr	_	_
23	blockade	blockade	NN	_	17	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concurrent	concurrent	JJ	_	4	attr	_	_
4	use	use	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	result	result	VB	_	1	acl	_	_
11	in	in	IN	_	13	case	_	_
12	a	a	DT	_	13	det	_	_
13	reduction	reduction	NN	_	10	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	antibacterial	antibacterial	JJ	_	17	attr	_	_
17	action	action	NN	_	13	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	drug4	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concurrent	concurrent	JJ	_	4	attr	_	_
4	use	use	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	extend	extend	VB	_	1	acl	_	_
11	the	the	DT	_	13	det	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	half-life	half-life	NN	_	10	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Patients	patient	NNS	_	15	dep	_	_
4	on	on	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	and	and	CC	_	3	cc	_	_
8	especially	especially	RB	_	7	com	_	_
9	those	those	DT	_	3	conj	_	_
10	started	start	VBN	_	9	acl	_	_
11	recently	recently	RB	_	10	adv	_	_
12	,	,	,	_	9	p	_	_
13	may	may	MD	_	15	modal	_	_
14	occasionally	occasionally	RB	_	15	adv	_	_
15	experience	experience	VBP	_	1	acl	_	_
16	an	an	DT	_	18	det	_	_
17	excessive	excessive	JJ	_	18	attr	_	_
18	reduction	reduction	NN	_	15	obj	_	_
19	of	of	IN	_	21	case	_	_
20	blood	blood	NN	_	21	com	_	_
21	pressure	pressure	NN	_	18	ppmod	_	_
22	after	after	IN	_	23	case	_	_
23	initiation	initiation	NN	_	18	ppmod	_	_
24	of	of	IN	_	27	case	_	_
25	drug3	drug0	CD	_	27	num	_	_
26	Tablets	tablet	NNS	_	27	com	_	_
27	therapy	therapy	NN	_	23	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	hypotensive	hypotensive	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	ppmod	_	_
6	can	can	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	minimized	minimize	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	either	either	CC	_	11	cc	_	_
11	discontinuing	discontinue	VBG	_	8	ppmod	_	_
12	the	the	DT	_	13	det	_	_
13	drug1	drug0	NN	_	11	obj	_	_
14	or	or	CC	_	11	cc	_	_
15	increasing	increase	VBG	_	11	conj	_	_
16	the	the	DT	_	18	det	_	_
17	salt	salt	NN	_	18	com	_	_
18	intake	intake	NN	_	15	obj	_	_
19	prior	prior	JJ	_	18	attr	_	_
20	to	to	TO	_	21	aux	_	_
21	initiation	initiation	NN	_	19	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	treatment	treatment	NN	_	21	ppmod	_	_
24	with	with	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	8	p	_	_

1	If	if	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	cannot	cannot	NNS	_	5	dep	_	_
4	be	be	VB	_	5	aux	_	_
5	interrupted	interrupt	VBN	_	12	advcl	_	_
6	,	,	,	_	12	p	_	_
7	close	close	JJ	_	9	attr	_	_
8	medical	medical	JJ	_	9	attr	_	_
9	supervision	supervision	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	provided	provided	VBN	_	0	root	_	_
13	with	with	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	first	#ord#	JJ	_	16	attr	_	_
16	dose	dose	NN	_	12	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	Tablets	tablet	NNS	_	16	ppmod	_	_
20	,	,	,	_	12	p	_	_
21	for	for	IN	_	25	case	_	_
22	at	at	IN	_	24	case	_	_
23	least	least	JJS	_	24	attr	_	_
24	two	#crd#	CD	_	25	num	_	_
25	hours	hour	NNS	_	12	ppmod	_	_
26	and	and	CC	_	12	cc	_	_
27	until	until	IN	_	29	case	_	_
28	blood	blood	NN	_	29	com	_	_
29	pressure	pressure	NN	_	31	ppmod	_	_
30	has	have	VBZ	_	31	aux	_	_
31	stabilized	stabilize	VBN	_	12	conj	_	_
32	for	for	IN	_	34	case	_	_
33	another	another	DT	_	34	det	_	_
34	hour	hour	NN	_	31	ppmod	_	_
35	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	rate	rate	NN	_	12	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	extent	extent	NN	_	2	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	absorption	absorption	NN	_	6	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	elimination	elimination	NN	_	7	conj	_	_
10	are	be	VBP	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	affected	affect	VBN	_	0	root	_	_
13	by	by	IN	_	15	case	_	_
14	concomitant	concomitant	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	bioavailability	bioavailability	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	reduced	reduce	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	6	p	_	_
10	however	however	RB	_	6	adv	_	_
11	,	,	,	_	6	p	_	_
12	and	and	CC	_	6	cc	_	_
13	this	this	DT	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	associated	associate	VBN	_	6	conj	_	_
16	with	with	IN	_	18	case	_	_
17	a	a	DT	_	18	det	_	_
18	decrease	decrease	NN	_	15	ppmod	_	_
19	in	in	IN	_	22	case	_	_
20	plasma	plasma	NN	_	22	com	_	_
21	ACE	ace	NN	_	22	com	_	_
22	inhibition	inhibition	NN	_	18	ppmod	_	_
23	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Supplements	supplement	NNS	_	9	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	7	attr	_	_
5	:	:	:	_	7	p	_	_
6	drug3	drug0	NN	_	7	com	_	_
7	Tablets	tablet	NNS	_	2	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	increase	increase	VB	_	0	root	_	_
10	serum	serum	NN	_	11	com	_	_
11	potassium	potassium	NN	_	9	obj	_	_
12	because	because	IN	_	15	case	_	_
13	of	of	IN	_	15	case	_	_
14	its	its	PRP$	_	15	poss	_	_
15	potential	potential	NN	_	9	ppmod	_	_
16	to	to	TO	_	17	aux	_	_
17	decrease	decrease	VB	_	15	acl	_	_
18	aldosterone	aldosterone	NN	_	19	com	_	_
19	production	production	NN	_	17	obj	_	_
20	.	.	.	_	9	p	_	_

1	Use	use	NN	_	34	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	and	and	CC	_	9	cc	_	_
11	others	other	NNS	_	5	conj	_	_
12	)	-rrb-	-RRB-	_	5	p	_	_
13	,	,	,	_	3	p	_	_
14	drug5	drug0	NN	_	15	com	_	_
15	supplements	supplement	NNS	_	3	conj	_	_
16	or	or	CC	_	15	cc	_	_
17	other	other	JJ	_	18	attr	_	_
18	drugs	drug	NNS	_	3	conj	_	_
19	capable	capable	JJ	_	18	attr	_	_
20	of	of	IN	_	21	case	_	_
21	increasing	increase	VBG	_	19	ppmod	_	_
22	serum	serum	NN	_	23	com	_	_
23	potassium	potassium	NN	_	21	obj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	drug6	drug0	NN	_	23	prn	_	_
26	,	,	,	_	25	p	_	_
27	drug7	drug0	NN	_	25	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug8	drug0	NN	_	25	conj	_	_
30	and	and	CC	_	29	cc	_	_
31	others	other	NNS	_	25	conj	_	_
32	)	-rrb-	-RRB-	_	25	p	_	_
33	can	can	MD	_	34	modal	_	_
34	increase	increase	VB	_	0	root	_	_
35	the	the	DT	_	36	det	_	_
36	risk	risk	NN	_	34	obj	_	_
37	of	of	IN	_	38	case	_	_
38	hyperkalemia	hyperkalemia	NN	_	36	ppmod	_	_
39	.	.	.	_	34	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	if	if	IN	_	10	mark	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	8	case	_	_
7	such	such	JJ	_	8	attr	_	_
8	agents	agent	NNS	_	5	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	indicated	indicate	VBN	_	15	advcl	_	_
11	,	,	,	_	15	p	_	_
12	they	they	PRP	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	given	give	VBN	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	caution	caution	NN	_	15	ppmod	_	_
18	and	and	CC	_	15	cc	_	_
19	the	the	DT	_	20	det	_	_
20	patient	patient	NN	_	23	poss	_	_
21	's	's	POS	_	20	case	_	_
22	serum	serum	NN	_	23	com	_	_
23	potassium	potassium	NN	_	26	dep	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	monitored	monitor	VBN	_	15	conj	_	_
27	frequently	frequently	RB	_	26	adv	_	_
28	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Increased	increase	VBN	_	5	attr	_	_
4	serum	serum	NN	_	5	com	_	_
5	drug2	drug0	NN	_	13	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	symptoms	symptom	NNS	_	5	conj	_	_
8	of	of	IN	_	10	case	_	_
9	drug3	drug0	NN	_	10	com	_	_
10	toxicity	toxicity	NN	_	7	ppmod	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	reported	report	VBN	_	1	acl	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	receiving	receive	VBG	_	15	acl	_	_
17	concomitant	concomitant	JJ	_	18	attr	_	_
18	drug4	drug0	NN	_	16	obj	_	_
19	and	and	CC	_	18	cc	_	_
20	ACE	ace	NN	_	22	com	_	_
21	inhibitor	inhibitor	NN	_	22	com	_	_
22	therapy	therapy	NN	_	18	conj	_	_
23	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	coadministered	coadministered	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	caution	caution	NN	_	5	ppmod	_	_
8	and	and	CC	_	5	cc	_	_
9	frequent	frequent	JJ	_	10	attr	_	_
10	monitoring	monitoring	NN	_	16	dep	_	_
11	of	of	IN	_	14	case	_	_
12	serum	serum	NN	_	14	com	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	concentration	concentration	NN	_	10	ppmod	_	_
15	is	be	VBZ	_	16	aux	_	_
16	recommended	recommend	VBN	_	5	conj	_	_
17	.	.	.	_	5	p	_	_

1	Use	use	NN	_	7	dep	_	_
2	of	of	IN	_	4	case	_	_
3	a	a	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	further	far	RB	_	7	adv	_	_
7	increase	increase	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	risk	risk	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	toxicity	toxicity	NN	_	9	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	6	det	_	_
4	controlled	controlled	JJ	_	6	attr	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	6	attr	_	_
6	study	study	NN	_	8	dep	_	_
7	has	have	VBZ	_	8	aux	_	_
8	shown	show	VBN	_	1	acl	_	_
9	no	no	DT	_	10	det	_	_
10	effect	effect	NN	_	8	obj	_	_
11	on	on	IN	_	14	case	_	_
12	plasma	plasma	NN	_	14	com	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	10	ppmod	_	_
15	when	when	WRB	_	16	adv	_	_
16	coadministered	coadministered	VBN	_	14	relcl	_	_
17	with	with	IN	_	19	case	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	Tablets	tablet	NNS	_	16	ppmod	_	_
20	,	,	,	_	8	p	_	_
21	but	but	CC	_	8	cc	_	_
22	an	an	DT	_	23	det	_	_
23	effect	effect	NN	_	37	dep	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	on	on	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	plasma	plasma	NN	_	29	com	_	_
29	concentration	concentration	NN	_	23	ppmod	_	_
30	of	of	IN	_	33	case	_	_
31	drug5	drug0	NN	_	33	attr	_	_
32	/	/	:	_	33	p	_	_
33	drug6	drug0	NN	_	29	ppmod	_	_
34	has	have	VBZ	_	37	aux	_	_
35	not	not	RB	_	37	neg	_	_
36	been	be	VBN	_	37	aux	_	_
37	excluded	exclude	VBN	_	8	conj	_	_
38	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Animal	animal	NN	_	4	com	_	_
4	data	datum	NNS	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	suggested	suggest	VBN	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	possibility	possibility	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	interaction	interaction	NN	_	8	ppmod	_	_
11	between	between	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	.	.	.	_	6	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	this	this	DT	_	7	dep	_	_
4	has	have	VBZ	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	investigated	investigate	VBN	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	human	human	JJ	_	10	attr	_	_
10	studies	study	NNS	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	Coadministration	coadministration	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	both	both	DT	_	4	det	_	_
4	drugs	drug	NNS	_	1	ppmod	_	_
5	should	should	MD	_	6	modal	_	_
6	proceed	proceed	VB	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	caution	caution	NN	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_

1	Food	food	NN	_	2	com	_	_
2	Interaction	interaction	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Oral	oral	JJ	_	5	attr	_	_
5	administration	administration	NN	_	11	dep	_	_
6	of	of	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	Tablets	tablet	NNS	_	5	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	food	food	NN	_	5	ppmod	_	_
11	does	do	VBZ	_	2	acl	_	_
12	not	not	RB	_	11	neg	_	_
13	significantly	significantly	RB	_	14	adv	_	_
14	lower	low	JJR	_	16	attr	_	_
15	the	the	DT	_	16	det	_	_
16	rate	rate	NN	_	11	obj	_	_
17	or	or	CC	_	16	cc	_	_
18	extent	extent	NN	_	16	conj	_	_
19	of	of	IN	_	21	case	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	absorption	absorption	NN	_	16	ppmod	_	_
22	relative	relative	JJ	_	21	attr	_	_
23	to	to	TO	_	26	aux	_	_
24	the	the	DT	_	26	det	_	_
25	fasted	fasted	JJ	_	26	attr	_	_
26	state	state	NN	_	22	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	However	however	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	the	the	DT	_	4	det	_	_
4	extent	extent	NN	_	17	dep	_	_
5	of	of	IN	_	6	case	_	_
6	biotransformation	biotransformation	NN	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	to	to	TO	_	12	aux	_	_
10	the	the	DT	_	12	det	_	_
11	active	active	JJ	_	12	attr	_	_
12	metabolite	metabolite	NN	_	6	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug2	drug0	NN	_	12	appo	_	_
15	,	,	,	_	12	p	_	_
16	is	be	VBZ	_	17	aux	_	_
17	reduced	reduce	VBN	_	0	root	_	_
18	approximately	approximately	RB	_	19	adv	_	_
19	43	0	CD	_	17	obj	_	_
20	%	%	NN	_	19	meta	_	_
21	,	,	,	_	19	p	_	_
22	resulting	result	VBG	_	19	acl	_	_
23	in	in	IN	_	25	case	_	_
24	a	a	DT	_	25	det	_	_
25	reduction	reduction	NN	_	22	ppmod	_	_
26	in	in	IN	_	31	case	_	_
27	the	the	DT	_	31	det	_	_
28	plasma	plasma	NN	_	31	com	_	_
29	ACE	ace	NN	_	31	com	_	_
30	inhibition	inhibition	NN	_	31	com	_	_
31	curve	curve	NN	_	25	ppmod	_	_
32	of	of	IN	_	34	case	_	_
33	approximately	approximately	RB	_	34	adv	_	_
34	20	0	CD	_	31	ppmod	_	_
35	%	%	NN	_	34	meta	_	_
36	,	,	,	_	22	p	_	_
37	probably	probably	RB	_	22	adv	_	_
38	clinically	clinically	RB	_	39	adv	_	_
39	insignificant	insignificant	JJ	_	22	dep	_	_
40	.	.	.	_	17	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	was	be	VBD	_	8	aux	_	_
7	generally	generally	RB	_	8	adv	_	_
8	administered	administer	VBN	_	0	root	_	_
9	in	in	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	non-fasting	non-fasting	JJ	_	12	attr	_	_
12	state	state	NN	_	8	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	interact	interact	VB	_	97	advcl	_	_
4	with	with	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	drugs	drug	NNS	_	3	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	following	following	JJ	_	10	attr	_	_
10	categories	category	NNS	_	6	ppmod	_	_
11	:	:	:	_	6	p	_	_
12	-	-	:	_	6	p	_	_
13	Blood	blood	NN	_	14	com	_	_
14	dyscrasia	dyscrasia	NN	_	6	appo	_	_
15	:	:	:	_	14	p	_	_
16	can	can	MD	_	17	modal	_	_
17	cause	cause	VB	_	14	acl	_	_
18	unpredictable	unpredictable	JJ	_	19	attr	_	_
19	myelotoxicity	myelotoxicity	NN	_	17	obj	_	_
20	-	-	:	_	14	p	_	_
21	Bone	bone	NN	_	23	com	_	_
22	marrow	marrow	NN	_	23	com	_	_
23	depressants	depressant	NNS	_	14	appo	_	_
24	:	:	:	_	14	p	_	_
25	can	can	MD	_	26	modal	_	_
26	cause	cause	VB	_	14	acl	_	_
27	a	a	DT	_	30	det	_	_
28	predictable	predictable	JJ	_	30	attr	_	_
29	dose-related	dose-related	JJ	_	30	attr	_	_
30	myelotoxicity	myelotoxicity	NN	_	26	obj	_	_
31	-	-	:	_	14	p	_	_
32	Radiation	radiation	NN	_	33	com	_	_
33	therapy	therapy	NN	_	14	appo	_	_
34	:	:	:	_	14	p	_	_
35	may	may	MD	_	36	modal	_	_
36	cause	cause	VB	_	14	acl	_	_
37	marrow	marrow	NN	_	38	com	_	_
38	depression	depression	NN	_	36	obj	_	_
39	-	-	:	_	14	p	_	_
40	Neurotoxic	neurotoxic	JJ	_	41	attr	_	_
41	medications	medication	NNS	_	14	appo	_	_
42	:	:	:	_	14	p	_	_
43	can	can	MD	_	44	modal	_	_
44	cause	cause	VB	_	14	acl	_	_
45	neurologic	neurologic	JJ	_	46	attr	_	_
46	toxicity	toxicity	NN	_	44	obj	_	_
47	-	-	:	_	14	p	_	_
48	drug2	drug0	NN	_	14	appo	_	_
49	:	:	:	_	14	p	_	_
50	can	can	MD	_	51	modal	_	_
51	increase	increase	VB	_	14	acl	_	_
52	seizure	seizure	JJ	_	53	attr	_	_
53	activity	activity	NN	_	51	obj	_	_
54	-	-	:	_	14	p	_	_
55	drug3	drug0	NN	_	14	appo	_	_
56	:	:	:	_	3	p	_	_
57	may	may	MD	_	58	modal	_	_
58	potentiate	potentiate	VB	_	3	conj	_	_
59	the	the	DT	_	60	det	_	_
60	replication	replication	NN	_	58	obj	_	_
61	of	of	IN	_	64	case	_	_
62	the	the	DT	_	64	det	_	_
63	drug4	drug0	NN	_	64	com	_	_
64	virus	virus	NN	_	58	ppmod	_	_
65	,	,	,	_	58	p	_	_
66	may	may	MD	_	67	modal	_	_
67	increase	increase	VB	_	3	conj	_	_
68	the	the	DT	_	70	det	_	_
69	side	side	JJ	_	70	attr	_	_
70	effects	effect	NNS	_	67	obj	_	_
71	of	of	IN	_	73	case	_	_
72	the	the	DT	_	73	det	_	_
73	vaccination	vaccination	NN	_	67	ppmod	_	_
74	,	,	,	_	67	p	_	_
75	and	and	CC	_	67	cc	_	_
76	decrease	decrease	VB	_	3	conj	_	_
77	patient	patient	NN	_	79	attr	_	_
78	's	's	POS	_	79	case	_	_
79	response	response	NN	_	76	obj	_	_
80	to	to	TO	_	82	aux	_	_
81	the	the	DT	_	82	det	_	_
82	vaccine	vaccine	NN	_	79	ppmod	_	_
83	-	-	:	_	97	p	_	_
84	drug5	drug0	NN	_	97	dep	_	_
85	:	:	:	_	84	p	_	_
86	may	may	MD	_	87	modal	_	_
87	cause	cause	VB	_	84	acl	_	_
88	shortness	shortness	NN	_	87	obj	_	_
89	of	of	IN	_	90	case	_	_
90	breath	breath	NN	_	87	ppmod	_	_
91	and	and	CC	_	90	cc	_	_
92	bronchospasm	bronchospasm	NN	_	90	conj	_	_
93	-	-	:	_	84	p	_	_
94	drug6	drug0	NN	_	84	appo	_	_
95	:	:	:	_	84	p	_	_
96	may	may	MD	_	97	modal	_	_
97	decrease	decrease	VB	_	0	root	_	_
98	patient	patient	NN	_	100	attr	_	_
99	's	's	POS	_	100	case	_	_
100	response	response	NN	_	97	obj	_	_
101	to	to	TO	_	103	aux	_	_
102	the	the	DT	_	103	det	_	_
103	drug7	drug0	NN	_	97	ppmod	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibits	inhibit	VBZ	_	0	root	_	_
3	some	some	DT	_	2	obj	_	_
4	of	of	IN	_	8	case	_	_
5	the	the	DT	_	8	det	_	_
6	liver	liver	NN	_	8	attr	_	_
7	's	's	POS	_	8	case	_	_
8	ability	ability	NN	_	3	ppmod	_	_
9	to	to	TO	_	10	aux	_	_
10	metabolize	metabolize	VB	_	8	acl	_	_
11	some	some	DT	_	13	det	_	_
12	other	other	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	10	obj	_	_
14	-	-	:	_	3	p	_	_
15	drug2	drug0	NN	_	3	appo	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug5	drug0	NN	_	15	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug6	drug0	NN	_	15	conj	_	_
25	.	.	.	_	2	p	_	_

1	Thus	thus	RB	_	8	adv	_	_
2	the	the	DT	_	3	det	_	_
3	concentrations	concentration	NNS	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	drugs	drug	NNS	_	3	ppmod	_	_
7	would	would	MD	_	8	modal	_	_
8	increase	increase	VB	_	14	advcl	_	_
9	meaning	meaning	NN	_	8	obj	_	_
10	side	side	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	14	dep	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	seen	see	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	A	a	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	adjustment	adjustment	NN	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	required	require	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	30	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	3	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	with	with	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	agents	agent	NNS	_	8	conj	_	_
13	which	which	WDT	_	14	dep	_	_
14	produce	produce	VBP	_	12	relcl	_	_
15	dry	dry	JJ	_	16	attr	_	_
16	mouth	mouth	NN	_	14	obj	_	_
17	,	,	,	_	16	p	_	_
18	constipation	constipation	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	somnolence	somnolence	NN	_	16	conj	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drowsiness	drowsiness	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	20	p	_	_
25	and/or	and/or	CC	_	20	cc	_	_
26	other	other	JJ	_	28	attr	_	_
27	anticholinergic-like	anticholinergic-like	JJ	_	28	attr	_	_
28	effects	effect	NNS	_	16	conj	_	_
29	may	may	MD	_	30	modal	_	_
30	increase	increase	VB	_	0	root	_	_
31	the	the	DT	_	32	det	_	_
32	frequency	frequency	NN	_	30	obj	_	_
33	and/or	and/or	CC	_	32	cc	_	_
34	severity	severity	NN	_	32	conj	_	_
35	of	of	IN	_	37	case	_	_
36	such	such	JJ	_	37	attr	_	_
37	effects	effect	NNS	_	32	ppmod	_	_
38	.	.	.	_	30	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	potentially	potentially	RB	_	4	adv	_	_
4	alter	alter	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	absorption	absorption	NN	_	4	obj	_	_
7	of	of	IN	_	11	case	_	_
8	some	some	DT	_	11	det	_	_
9	concomitantly	concomitantly	RB	_	10	adv	_	_
10	administered	administer	VBN	_	11	attr	_	_
11	drugs	drug	NNS	_	6	ppmod	_	_
12	due	due	JJ	_	11	attr	_	_
13	to	to	TO	_	15	aux	_	_
14	anticholinergic	anticholinergic	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	12	ppmod	_	_
16	on	on	IN	_	18	case	_	_
17	gastrointestinal	gastrointestinal	JJ	_	18	attr	_	_
18	motility	motility	NN	_	15	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	be	be	VB	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	concern	concern	NN	_	3	ppmod	_	_
6	for	for	IN	_	7	case	_	_
7	drugs	drug	NNS	_	3	ppmod	_	_
8	with	with	IN	_	12	case	_	_
9	a	a	DT	_	12	det	_	_
10	narrow	narrow	JJ	_	12	attr	_	_
11	therapeutic	therapeutic	JJ	_	12	attr	_	_
12	index	index	NN	_	7	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Mean	mean	JJ	_	4	attr	_	_
2	drug1	drug0	NN	_	4	com	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	5	dep	_	_
5	were	be	VBD	_	0	root	_	_
6	approximately	approximately	RB	_	7	adv	_	_
7	2	0	CD	_	8	num	_	_
8	fold	fold	NN	_	9	advnp	_	_
9	higher	high	JJR	_	5	dep	_	_
10	when	when	WRB	_	13	adv	_	_
11	drug2	drug0	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	administered	administer	VBN	_	5	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	a	a	DT	_	20	det	_	_
18	potent	potent	JJ	_	20	attr	_	_
19	CYP3A4	cyp0a0	NN	_	20	com	_	_
20	inhibitor	inhibitor	NN	_	15	appo	_	_
21	.	.	.	_	5	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	inhibitors	inhibitor	NNS	_	32	dep	_	_
3	of	of	IN	_	9	case	_	_
4	the	the	DT	_	9	det	_	_
5	cytochrome	cytochrome	NN	_	7	com	_	_
6	P450	p0	NN	_	7	com	_	_
7	3A4	0a0	NN	_	9	com	_	_
8	enzyme	enzyme	NN	_	9	com	_	_
9	system	system	NN	_	2	ppmod	_	_
10	,	,	,	_	2	p	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	drug1	drug0	NN	_	2	ppmod	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	e.g.	e.g.	FW	_	17	adv	_	_
16	,	,	,	_	17	p	_	_
17	drug2	drug0	NN	_	13	prn	_	_
18	and	and	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	or	or	CC	_	13	cc	_	_
22	drug4	drug0	NN	_	13	conj	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	e.g.	e.g.	FW	_	26	adv	_	_
25	,	,	,	_	26	p	_	_
26	drug5	drug0	NN	_	22	prn	_	_
27	and	and	CC	_	26	cc	_	_
28	drug6	drug0	NN	_	26	conj	_	_
29	)	-rrb-	-RRB-	_	26	p	_	_
30	,	,	,	_	2	p	_	_
31	may	may	MD	_	32	modal	_	_
32	alter	alter	VB	_	0	root	_	_
33	drug7	drug0	NN	_	36	attr	_	_
34	mean	mean	NN	_	36	attr	_	_
35	pharmacokinetic	pharmacokinetic	JJ	_	36	attr	_	_
36	parameters	parameter	NNS	_	32	obj	_	_
37	(	-lrb-	-LRB-	_	40	p	_	_
38	i.e.	i.e.	FW	_	40	ppmod	_	_
39	,	,	,	_	40	p	_	_
40	Cmax	cmax	NN	_	36	prn	_	_
41	and	and	CC	_	40	cc	_	_
42	AUC	auc	NN	_	40	conj	_	_
43	)	-rrb-	-RRB-	_	40	p	_	_
44	.	.	.	_	32	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	relevance	relevance	NN	_	10	dep	_	_
4	of	of	IN	_	7	case	_	_
5	such	such	JJ	_	7	attr	_	_
6	potential	potential	JJ	_	7	attr	_	_
7	interactions	interaction	NNS	_	3	ppmod	_	_
8	is	be	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	known	know	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	such	such	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	8	dep	_	_
8	are	be	VBP	_	4	comp	_	_
9	co-administered	co-administered	NN	_	8	obj	_	_
10	.	.	.	_	4	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	ingestion	ingestion	NN	_	21	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	20	0	CD	_	7	num	_	_
7	mL	ml	NN	_	4	prn	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NNS	_	7	ppmod	_	_
10	containing	contain	VBG	_	9	acl	_	_
11	drug3	drug0	NN	_	10	obj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug5	drug0	NN	_	11	conj	_	_
17	)	-rrb-	-RRB-	_	7	p	_	_
18	did	do	VBD	_	21	aux	_	_
19	not	not	RB	_	21	neg	_	_
20	significantly	significantly	RB	_	21	adv	_	_
21	affect	affect	VB	_	0	root	_	_
22	the	the	DT	_	23	det	_	_
23	exposure	exposure	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug6	drug0	NN	_	23	ppmod	_	_
26	or	or	CC	_	25	cc	_	_
27	drug7	drug0	NN	_	25	conj	_	_
28	.	.	.	_	21	p	_	_

1	-LSB-Interaction	-lsb-interaction	NN	_	0	root	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	]	-rsb-	-RRB-	_	1	p	_	_
7	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interaction	interaction	NN	_	9	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	has	have	VBZ	_	9	aux	_	_
9	been	be	VBN	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	subject	subject	NN	_	9	obj	_	_
12	of	of	IN	_	14	case	_	_
13	much	much	JJ	_	14	attr	_	_
14	study	study	NN	_	11	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	recent	recent	JJ	_	17	attr	_	_
17	years	year	NNS	_	11	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	Contradictory	contradictory	JJ	_	2	attr	_	_
2	results	result	NNS	_	21	dep	_	_
3	regarding	regard	VBG	_	2	acl	_	_
4	the	the	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	on	on	IN	_	10	case	_	_
9	platelet	platelet	NN	_	10	com	_	_
10	reactivity	reactivity	NN	_	5	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	on	on	IN	_	14	case	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	outcome	outcome	NN	_	10	conj	_	_
15	in	in	IN	_	18	case	_	_
16	drug2	drug0	CD	_	18	num	_	_
17	-treated	-treated	JJ	_	18	attr	_	_
18	patients	patient	NNS	_	14	ppmod	_	_
19	have	have	VBP	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	reported	report	VBN	_	0	root	_	_
22	in	in	IN	_	23	case	_	_
23	literature	literature	NN	_	21	ppmod	_	_
24	.	.	.	_	21	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	was	be	VBD	_	8	aux	_	_
8	found	find	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	decrease	decrease	VB	_	8	comp	_	_
11	the	the	DT	_	12	det	_	_
12	exposure	exposure	NN	_	10	obj	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	AUC	auc	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	to	to	TO	_	20	aux	_	_
17	clopidogrel	clopidogrel	NN	_	20	attr	_	_
18	's	's	POS	_	20	case	_	_
19	active	active	JJ	_	20	attr	_	_
20	metabolite	metabolite	NN	_	12	ppmod	_	_
21	by	by	IN	_	22	case	_	_
22	50	0	CD	_	10	ppmod	_	_
23	%	%	NN	_	22	meta	_	_
24	and	and	CC	_	10	cc	_	_
25	to	to	TO	_	27	aux	_	_
26	sharply	sharply	RB	_	27	adv	_	_
27	increase	increase	VB	_	10	conj	_	_
28	platelet	platelet	NN	_	29	com	_	_
29	reactivity	reactivity	NN	_	27	obj	_	_
30	,	,	,	_	27	p	_	_
31	as	as	IN	_	33	case	_	_
32	a	a	DT	_	33	det	_	_
33	result	result	NN	_	27	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	inhibition	inhibition	NN	_	33	ppmod	_	_
36	by	by	IN	_	37	case	_	_
37	drug3	drug0	NN	_	35	ppmod	_	_
38	of	of	IN	_	39	case	_	_
39	CYP2C19	cyp0c0	NN	_	37	ppmod	_	_
40	,	,	,	_	39	p	_	_
41	a	a	DT	_	47	det	_	_
42	cytochrome	cytochrome	NN	_	43	com	_	_
43	P450	p0	NN	_	47	attr	_	_
44	(	-lrb-	-LRB-	_	45	p	_	_
45	CYP	cyp	NN	_	43	prn	_	_
46	)	-rrb-	-RRB-	_	45	p	_	_
47	enzyme	enzyme	NN	_	39	appo	_	_
48	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	much	much	RB	_	5	adv	_	_
5	weaker	weak	JJR	_	6	attr	_	_
6	effect	effect	NN	_	2	obj	_	_
7	on	on	IN	_	10	case	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	's	's	POS	_	10	case	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	on	on	IN	_	14	case	_	_
13	platelet	platelet	NN	_	14	com	_	_
14	reactivity	reactivity	NN	_	10	conj	_	_
15	during	during	IN	_	17	case	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	use	use	NN	_	14	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	influence	influence	NN	_	16	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	when	when	WRB	_	8	adv	_	_
8	used	use	VBN	_	6	relcl	_	_
9	simultaneously	simultaneously	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	has	have	VBZ	_	16	aux	_	_
13	not	not	RB	_	16	neg	_	_
14	yet	yet	RB	_	16	adv	_	_
15	been	be	VBN	_	16	aux	_	_
16	investigated	investigate	VBN	_	0	root	_	_
17	in	in	IN	_	20	case	_	_
18	adequately	adequately	RB	_	19	adv	_	_
19	randomized	randomized	JJ	_	20	attr	_	_
20	studies	study	NNS	_	16	ppmod	_	_
21	.	.	.	_	16	p	_	_

1	Regulatory	regulatory	JJ	_	2	attr	_	_
2	agencies	agency	NNS	_	3	com	_	_
3	state	state	NN	_	0	root	_	_
4	that	that	IN	_	18	mark	_	_
5	the	the	DT	_	6	det	_	_
6	combination	combination	NN	_	18	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	6	cc	_	_
10	the	the	DT	_	12	det	_	_
11	CYP2C19	cyp0c0	NN	_	12	com	_	_
12	inhibitors	inhibitor	NNS	_	6	conj	_	_
13	drug2	drug0	NN	_	12	appo	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	avoided	avoid	VBN	_	3	comp	_	_
19	.	.	.	_	3	p	_	_

1	To	to	TO	_	2	aux	_	_
2	date	date	NN	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	there	there	EX	_	5	dep	_	_
5	is	be	VBZ	_	0	root	_	_
6	no	no	DT	_	8	det	_	_
7	conclusive	conclusive	JJ	_	8	attr	_	_
8	evidence	evidence	NN	_	5	obj	_	_
9	of	of	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	clinically-relevant	clinically-relevant	JJ	_	12	attr	_	_
12	interaction	interaction	NN	_	8	ppmod	_	_
13	between	between	IN	_	14	case	_	_
14	any	any	DT	_	12	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	drug1	drug0	NN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	.	.	.	_	5	p	_	_

1	Interaction	interaction	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	,	,	,	_	3	p	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	3	adv	_	_
9	and	and	CC	_	8	cc	_	_
10	in	in	FW	_	11	adv	_	_
11	vivo	vivo	FW	_	8	conj	_	_
12	,	,	,	_	3	p	_	_
13	in	in	IN	_	17	case	_	_
14	human	human	JJ	_	17	attr	_	_
15	A375	a0	NN	_	17	com	_	_
16	melanoma	melanoma	NN	_	17	com	_	_
17	cells	cell	NNS	_	3	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	evaluated	evaluate	VBD	_	0	root	_	_
3	mechanisms	mechanism	NNS	_	2	obj	_	_
4	of	of	IN	_	5	case	_	_
5	interaction	interaction	NN	_	3	ppmod	_	_
6	between	between	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	alkyating	alkyating	JJ	_	10	attr	_	_
9	agent	agent	NN	_	10	com	_	_
10	drug1	drug0	NN	_	5	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	and	and	CC	_	10	cc	_	_
15	the	the	DT	_	16	det	_	_
16	pro-oxidant	pro-oxidant	JJ	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	appo	_	_
19	,	,	,	_	16	p	_	_
20	in	in	IN	_	26	case	_	_
21	the	the	DT	_	26	det	_	_
22	human	human	JJ	_	26	attr	_	_
23	A375	a0	NN	_	26	com	_	_
24	melanoma	melanoma	NN	_	26	com	_	_
25	cell	cell	NN	_	26	com	_	_
26	line	line	NN	_	3	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	2	p	_	_
8	alone	alone	RB	_	2	adv	_	_
9	and	and	CC	_	8	cc	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	8	conj	_	_
12	,	,	,	_	2	p	_	_
13	was	be	VBD	_	14	aux	_	_
14	evaluated	evaluate	VBN	_	0	root	_	_
15	for	for	IN	_	17	case	_	_
16	growth	growth	NN	_	17	com	_	_
17	inhibition	inhibition	NN	_	14	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	MTT	mtt	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	,	,	,	_	17	p	_	_
22	radiolabeled	radiolabeled	VBN	_	24	attr	_	_
23	drug	drug	NN	_	24	com	_	_
24	uptake	uptake	NN	_	17	conj	_	_
25	,	,	,	_	24	p	_	_
26	cellular	cellular	JJ	_	28	attr	_	_
27	thiol	thiol	NN	_	28	com	_	_
28	content	content	NN	_	17	conj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	HPLC	hplc	NN	_	28	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	,	,	,	_	28	p	_	_
33	and	and	CC	_	28	cc	_	_
34	DNA	dna	NN	_	36	com	_	_
35	strand	strand	NN	_	36	com	_	_
36	breaks	break	NNS	_	17	conj	_	_
37	(	-lrb-	-LRB-	_	39	p	_	_
38	Comet	comet	NN	_	39	com	_	_
39	assay	assay	NN	_	36	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	.	.	.	_	14	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	antitumor	antitumor	JJ	_	1	conj	_	_
4	effects	effect	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	evaluated	evaluate	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	mice	mouse	NNS	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_

1	Growth	growth	NN	_	2	com	_	_
2	inhibition	inhibition	NN	_	5	dep	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	2	adv	_	_
5	was	be	VBD	_	0	root	_	_
6	additive	additive	JJ	_	5	dep	_	_
7	with	with	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	two	#crd#	CD	_	10	num	_	_
10	drugs	drug	NNS	_	6	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	drug	drug	NN	_	7	com	_	_
7	uptake	uptake	NN	_	4	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	number	number	NN	_	7	conj	_	_
12	of	of	IN	_	15	case	_	_
13	DNA	dna	NN	_	15	com	_	_
14	strand	strand	NN	_	15	com	_	_
15	breaks	break	NNS	_	11	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	>75	>0	CD	_	6	num	_	_
5	%	%	NN	_	6	meta	_	_
6	reduction	reduction	NN	_	2	obj	_	_
7	in	in	IN	_	9	case	_	_
8	cellular	cellular	JJ	_	9	attr	_	_
9	glutathione	glutathione	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	cysteine	cysteine	NN	_	9	conj	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	6	ppmod	_	_
14	but	but	CC	_	13	cc	_	_
15	not	not	RB	_	14	com	_	_
16	drug2	drug0	NN	_	13	conj	_	_
17	.	.	.	_	2	p	_	_

1	Co-administration	co-administration	NN	_	8	dep	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	two	#crd#	CD	_	5	num	_	_
5	drugs	drug	NNS	_	1	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	mice	mouse	NNS	_	1	ppmod	_	_
8	caused	cause	VBD	_	0	root	_	_
9	an	an	DT	_	10	det	_	_
10	increase	increase	NN	_	8	obj	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	area	area	NN	_	10	ppmod	_	_
14	under	under	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	curve	curve	NN	_	13	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	both	both	DT	_	19	det	_	_
19	drugs	drug	NNS	_	16	ppmod	_	_
20	,	,	,	_	8	p	_	_
21	but	but	CC	_	8	cc	_	_
22	the	the	DT	_	23	det	_	_
23	combination	combination	NN	_	24	dep	_	_
24	was	be	VBD	_	8	conj	_	_
25	not	not	RB	_	24	neg	_	_
26	effective	effective	JJ	_	24	dep	_	_
27	in	in	IN	_	28	case	_	_
28	reducing	reduce	VBG	_	26	ppmod	_	_
29	human	human	JJ	_	32	attr	_	_
30	A375	a0	NN	_	32	com	_	_
31	melanoma	melanoma	NN	_	32	com	_	_
32	tumors	tumor	NNS	_	28	obj	_	_
33	in	in	FW	_	34	adv	_	_
34	vivo	vivo	FW	_	28	adv	_	_
35	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	show	show	VBP	_	0	root	_	_
5	additive	additive	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	in	in	FW	_	12	adv	_	_
8	vitro	vitro	FW	_	12	adv	_	_
9	but	but	CC	_	12	cc	_	_
10	not	not	RB	_	9	com	_	_
11	in	in	FW	_	12	adv	_	_
12	vivo	vivo	FW	_	4	adv	_	_
13	in	in	IN	_	17	case	_	_
14	human	human	JJ	_	17	attr	_	_
15	A375	a0	NN	_	17	com	_	_
16	melanoma	melanoma	NN	_	17	com	_	_
17	cells	cell	NNS	_	4	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Enhancement	enhancement	NN	_	7	dep	_	_
2	of	of	IN	_	5	case	_	_
3	humoral	humoral	JJ	_	5	attr	_	_
4	immune	immune	JJ	_	5	attr	_	_
5	responses	response	NNS	_	1	ppmod	_	_
6	to	to	TO	_	5	ppmod	_	_
7	inactivated	inactivate	VBD	_	0	root	_	_
8	Newcastle	newcastle	JJ	_	9	attr	_	_
9	disease	disease	NN	_	7	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug1	drug0	NN	_	9	conj	_	_
12	by	by	IN	_	14	case	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	administration	administration	NN	_	7	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	chickens	chicken	NNS	_	16	ppmod	_	_
19	.	.	.	_	7	p	_	_

1	Newcastle	newcastle	JJ	_	2	attr	_	_
2	disease	disease	NN	_	12	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	ND	nd	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	and	and	CC	_	2	cc	_	_
7	avian	avian	JJ	_	8	attr	_	_
8	influenza	influenza	NN	_	2	conj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	AI	ai	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	are	be	VBP	_	0	root	_	_
13	common	common	JJ	_	12	dep	_	_
14	in	in	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	poultry	poultry	NN	_	17	com	_	_
17	industry	industry	NN	_	13	ppmod	_	_
18	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	objective	objective	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	evaluate	evaluate	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	effect	effect	NN	_	8	obj	_	_
11	of	of	IN	_	13	case	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	administration	administration	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug2	drug0	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	on	on	IN	_	23	case	_	_
20	the	the	DT	_	23	det	_	_
21	humoral	humoral	JJ	_	23	attr	_	_
22	immune	immune	JJ	_	23	attr	_	_
23	responses	response	NNS	_	10	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	chickens	chicken	NNS	_	23	ppmod	_	_
26	to	to	TO	_	27	aux	_	_
27	drug3	drug0	NN	_	23	ppmod	_	_
28	and	and	CC	_	27	cc	_	_
29	drug4	drug0	NN	_	30	com	_	_
30	drug4	drug0	NN	_	27	conj	_	_
31	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	experiment	experiment	NN	_	31	ppmod	_	_
3	1	0	CD	_	2	num	_	_
4	,	,	,	_	31	p	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	administration	administration	NN	_	31	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	at	at	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	dose	dose	NN	_	6	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	5	0	CD	_	14	num	_	_
14	mg/kg	mg/kg	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	BW	bw	NN	_	14	ppmod	_	_
17	for	for	IN	_	19	case	_	_
18	7	0	CD	_	19	num	_	_
19	d	d	NN	_	14	ppmod	_	_
20	on	on	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	immune	immune	JJ	_	23	attr	_	_
23	response	response	NN	_	14	ppmod	_	_
24	in	in	IN	_	25	case	_	_
25	chickens	chicken	NNS	_	23	ppmod	_	_
26	intramuscularly	intramuscularly	RB	_	27	adv	_	_
27	injected	inject	VBN	_	25	acl	_	_
28	with	with	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	was	be	VBD	_	31	aux	_	_
31	evaluated	evaluate	VBN	_	0	root	_	_
32	.	.	.	_	31	p	_	_

1	Results	result	NNS	_	2	dep	_	_
2	showed	show	VBD	_	0	root	_	_
3	that	that	IN	_	6	mark	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	significantly	significantly	RB	_	6	adv	_	_
6	increased	increase	VBD	_	2	comp	_	_
7	the	the	DT	_	9	det	_	_
8	antibody	antibody	NN	_	9	com	_	_
9	level	level	NN	_	6	obj	_	_
10	against	against	IN	_	11	case	_	_
11	ND	nd	NN	_	9	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	serum	serum	NN	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	chickens	chicken	NNS	_	14	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	experiment	experiment	NN	_	11	ppmod	_	_
3	2	0	CD	_	2	num	_	_
4	,	,	,	_	11	p	_	_
5	the	the	DT	_	7	det	_	_
6	same	same	JJ	_	7	attr	_	_
7	regimen	regimen	NN	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	chickens	chicken	NNS	_	11	ppmod	_	_
14	inoculated	inoculate	VBN	_	13	acl	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	11	p	_	_
18	and	and	CC	_	11	cc	_	_
19	an	an	DT	_	23	det	_	_
20	enhanced	enhance	VBN	_	23	attr	_	_
21	serum	serum	NN	_	23	com	_	_
22	antibody	antibody	NN	_	23	com	_	_
23	response	response	NN	_	29	dep	_	_
24	to	to	TO	_	26	aux	_	_
25	AI	ai	NN	_	26	com	_	_
26	vaccination	vaccination	NN	_	23	ppmod	_	_
27	was	be	VBD	_	29	aux	_	_
28	also	also	RB	_	29	adv	_	_
29	observed	observe	VBN	_	11	conj	_	_
30	.	.	.	_	11	p	_	_

1	Considering	consider	VBG	_	19	advcl	_	_
2	the	the	DT	_	3	det	_	_
3	safety	safety	NN	_	1	obj	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	19	p	_	_
7	because	because	IN	_	12	mark	_	_
8	no	no	DT	_	10	det	_	_
9	adverse	adverse	JJ	_	10	attr	_	_
10	effect	effect	NN	_	12	dep	_	_
11	was	be	VBD	_	12	aux	_	_
12	found	find	VBN	_	19	advcl	_	_
13	throughout	throughout	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	experiments	experiment	NNS	_	12	ppmod	_	_
16	,	,	,	_	19	p	_	_
17	drug2	drug0	NN	_	19	dep	_	_
18	may	may	MD	_	19	modal	_	_
19	be	be	VB	_	0	root	_	_
20	a	a	DT	_	23	det	_	_
21	promising	promising	JJ	_	23	attr	_	_
22	oral	oral	JJ	_	23	attr	_	_
23	adjuvant	adjuvant	JJ	_	19	obj	_	_
24	to	to	TO	_	25	aux	_	_
25	improve	improve	VB	_	23	acl	_	_
26	immunization	immunization	NN	_	25	obj	_	_
27	in	in	IN	_	28	case	_	_
28	poultry	poultry	NN	_	25	ppmod	_	_
29	.	.	.	_	19	p	_	_

1	Protective	protective	JJ	_	2	attr	_	_
2	effect	effect	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	against	against	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	acute	acute	JJ	_	10	attr	_	_
10	toxicity	toxicity	NN	_	2	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	diepoxybutane	diepoxybutane	NN	_	10	ppmod	_	_
13	to	to	TO	_	15	aux	_	_
14	human	human	JJ	_	15	attr	_	_
15	lymphocytes	lymphocyte	NNS	_	12	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	biotransformation	biotransformation	NN	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	oxidative	oxidative	JJ	_	5	attr	_	_
5	stress	stress	NN	_	2	conj	_	_
6	may	may	MD	_	7	modal	_	_
7	contribute	contribute	VB	_	0	root	_	_
8	to	to	TO	_	14	aux	_	_
9	1,2:3,4-diepoxybutane	0-diepoxybutane	NN	_	13	advnp	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	DEB	deb	NN	_	13	advnp	_	_
12	)	-rrb-	-RRB-	_	13	p	_	_
13	-induced	-induced	JJ	_	14	attr	_	_
14	toxicity	toxicity	NN	_	7	ppmod	_	_
15	to	to	TO	_	17	aux	_	_
16	human	human	JJ	_	17	attr	_	_
17	lymphocytes	lymphocyte	NNS	_	7	ppmod	_	_
18	of	of	IN	_	24	case	_	_
19	Fanconi	fanconi	NNP	_	20	com	_	_
20	Anemia	anemia	NN	_	24	attr	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	FA	fa	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	patients	patient	NNS	_	17	ppmod	_	_
25	.	.	.	_	7	p	_	_

1	Thus	thus	RB	_	29	adv	_	_
2	,	,	,	_	29	p	_	_
3	the	the	DT	_	4	det	_	_
4	identification	identification	NN	_	29	dep	_	_
5	of	of	IN	_	7	case	_	_
6	putative	putative	JJ	_	7	attr	_	_
7	inhibitors	inhibitor	NNS	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	bioactivation	bioactivation	NN	_	7	ppmod	_	_
10	,	,	,	_	4	p	_	_
11	as	as	RB	_	12	com	_	_
12	well	well	RB	_	4	cc	_	_
13	as	as	IN	_	12	com	_	_
14	the	the	DT	_	15	det	_	_
15	determination	determination	NN	_	4	conj	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	protective	protective	JJ	_	19	attr	_	_
19	role	role	NN	_	15	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	oxidant	oxidant	JJ	_	22	attr	_	_
22	defenses	defense	NNS	_	19	ppmod	_	_
23	,	,	,	_	15	p	_	_
24	on	on	IN	_	26	case	_	_
25	DEB-induced	deb-induced	JJ	_	26	attr	_	_
26	toxicity	toxicity	NN	_	15	ppmod	_	_
27	,	,	,	_	15	p	_	_
28	can	can	MD	_	29	modal	_	_
29	help	help	VB	_	0	root	_	_
30	to	to	TO	_	31	aux	_	_
31	understand	understand	VB	_	29	comp	_	_
32	what	what	WP	_	34	dep	_	_
33	is	be	VBZ	_	34	aux	_	_
34	failing	fail	VBG	_	31	comp	_	_
35	in	in	IN	_	37	case	_	_
36	FA	fa	NN	_	37	com	_	_
37	cells	cell	NNS	_	34	ppmod	_	_
38	.	.	.	_	29	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	work	work	NN	_	6	ppmod	_	_
5	we	we	PRP	_	6	dep	_	_
6	studied	study	VBD	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	contribution	contribution	NN	_	6	obj	_	_
9	of	of	IN	_	12	case	_	_
10	several	several	JJ	_	12	attr	_	_
11	biochemical	biochemical	JJ	_	12	attr	_	_
12	pathways	pathway	NNS	_	8	ppmod	_	_
13	for	for	IN	_	16	case	_	_
14	DEB-induced	deb-induced	JJ	_	16	attr	_	_
15	acute	acute	JJ	_	16	attr	_	_
16	toxicity	toxicity	NN	_	8	ppmod	_	_
17	in	in	IN	_	20	case	_	_
18	human	human	JJ	_	20	attr	_	_
19	lymphocyte	lymphocyte	NN	_	20	com	_	_
20	suspensions	suspension	NNS	_	16	ppmod	_	_
21	,	,	,	_	6	p	_	_
22	by	by	IN	_	23	case	_	_
23	using	use	VBG	_	6	ppmod	_	_
24	inhibitors	inhibitor	NNS	_	23	obj	_	_
25	of	of	IN	_	27	case	_	_
26	epoxide	epoxide	NN	_	27	com	_	_
27	hydrolases	hydrolases	NNS	_	24	ppmod	_	_
28	,	,	,	_	24	p	_	_
29	inhibitors	inhibitor	NNS	_	24	conj	_	_
30	of	of	IN	_	32	case	_	_
31	protective	protective	JJ	_	32	attr	_	_
32	enzymes	enzyme	NNS	_	29	ppmod	_	_
33	as	as	IN	_	35	case	_	_
34	glutathione	glutathione	NN	_	35	com	_	_
35	S-transferase	s-transferase	NN	_	32	ppmod	_	_
36	and	and	CC	_	35	cc	_	_
37	catalase	catalase	NN	_	35	conj	_	_
38	,	,	,	_	29	p	_	_
39	the	the	DT	_	40	det	_	_
40	depletion	depletion	NN	_	24	conj	_	_
41	of	of	IN	_	42	case	_	_
42	glutathione	glutathione	NN	_	40	ppmod	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	GSH	gsh	NN	_	42	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	,	,	,	_	40	p	_	_
47	and	and	CC	_	40	cc	_	_
48	the	the	DT	_	49	det	_	_
49	inhibition	inhibition	NN	_	24	conj	_	_
50	of	of	IN	_	52	case	_	_
51	protein	protein	NN	_	52	com	_	_
52	synthesis	synthesis	NN	_	49	ppmod	_	_
53	;	;	:	_	6	p	_	_

1	and	and	CC	_	3	cc	_	_
2	a	a	DT	_	3	det	_	_
3	variety	variety	NN	_	0	root	_	_
4	of	of	IN	_	7	case	_	_
5	putative	putative	JJ	_	7	attr	_	_
6	protective	protective	JJ	_	7	attr	_	_
7	compounds	compound	NNS	_	3	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	including	include	VBG	_	10	adv	_	_
10	antioxidants	antioxidant	NNS	_	7	ppmod	_	_
11	,	,	,	_	7	p	_	_
12	and	and	CC	_	3	cc	_	_
13	mitochondrial	mitochondrial	JJ	_	15	attr	_	_
14	protective	protective	JJ	_	15	attr	_	_
15	agents	agent	NNS	_	3	conj	_	_
16	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	present	present	JJ	_	3	attr	_	_
3	study	study	NN	_	4	dep	_	_
4	reports	report	VBZ	_	15	advcl	_	_
5	two	#crd#	CD	_	7	num	_	_
6	novel	novel	JJ	_	7	attr	_	_
7	findings	finding	NNS	_	4	obj	_	_
8	:	:	:	_	15	p	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	i	i	LS	_	15	meta	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	it	it	PRP	_	15	dep	_	_
13	was	be	VBD	_	15	aux	_	_
14	clearly	clearly	RB	_	15	adv	_	_
15	evidenced	evidence	VBN	_	0	root	_	_
16	,	,	,	_	15	p	_	_
17	for	for	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	first	#ord#	JJ	_	20	attr	_	_
20	time	time	NN	_	15	ppmod	_	_
21	,	,	,	_	15	p	_	_
22	that	that	IN	_	33	mark	_	_
23	the	the	DT	_	25	det	_	_
24	acute	acute	JJ	_	25	attr	_	_
25	exposure	exposure	NN	_	33	dep	_	_
26	of	of	IN	_	30	case	_	_
27	freshly	freshly	RB	_	28	adv	_	_
28	isolated	isolate	VBN	_	30	attr	_	_
29	human	human	JJ	_	30	attr	_	_
30	lymphocytes	lymphocyte	NNS	_	25	ppmod	_	_
31	to	to	TO	_	32	aux	_	_
32	DEB	deb	NN	_	25	ppmod	_	_
33	results	result	VBZ	_	15	comp	_	_
34	in	in	IN	_	37	case	_	_
35	severe	severe	JJ	_	37	attr	_	_
36	GSH	gsh	NN	_	37	com	_	_
37	depletion	depletion	NN	_	33	ppmod	_	_
38	and	and	CC	_	37	cc	_	_
39	loss	loss	NN	_	37	conj	_	_
40	of	of	IN	_	41	case	_	_
41	ATP	atp	NN	_	39	ppmod	_	_
42	,	,	,	_	33	p	_	_
43	followed	followed	VBN	_	33	comp	_	_
44	by	by	IN	_	46	case	_	_
45	cell	cell	NN	_	46	com	_	_
46	death	death	NN	_	43	ppmod	_	_
47	;	;	:	_	15	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	ii	ii	LS	_	4	meta	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	elicits	elicit	VBZ	_	0	root	_	_
6	a	a	DT	_	9	det	_	_
7	significant	significant	JJ	_	9	attr	_	_
8	protective	protective	JJ	_	9	attr	_	_
9	effect	effect	NN	_	5	obj	_	_
10	on	on	IN	_	13	case	_	_
11	DEB	deb	NN	_	13	attr	_	_
12	induced	induced	JJ	_	13	attr	_	_
13	toxicity	toxicity	NN	_	9	ppmod	_	_
14	,	,	,	_	9	p	_	_
15	which	which	WDT	_	17	dep	_	_
16	was	be	VBD	_	17	aux	_	_
17	potentiated	potentiate	VBN	_	9	relcl	_	_
18	by	by	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	Collectively	collectively	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	these	these	DT	_	4	det	_	_
4	findings	finding	NNS	_	5	dep	_	_
5	contribute	contribute	VBP	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	increase	increase	VB	_	5	comp	_	_
8	our	our	PRP$	_	9	poss	_	_
9	knowledge	knowledge	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	DEB-induce	deb-induce	JJ	_	12	attr	_	_
12	toxicity	toxicity	NN	_	9	ppmod	_	_
13	and	and	CC	_	5	cc	_	_
14	will	will	MD	_	15	modal	_	_
15	be	be	VB	_	5	conj	_	_
16	very	very	RB	_	17	adv	_	_
17	useful	useful	JJ	_	15	dep	_	_
18	when	when	WRB	_	19	adv	_	_
19	applied	apply	VBN	_	17	comp	_	_
20	in	in	IN	_	21	case	_	_
21	studies	study	NNS	_	19	ppmod	_	_
22	with	with	IN	_	23	case	_	_
23	lymphocytes	lymphocyte	NNS	_	21	ppmod	_	_
24	from	from	IN	_	26	case	_	_
25	FA	fa	JJ	_	26	attr	_	_
26	patients	patient	NNS	_	23	ppmod	_	_
27	,	,	,	_	15	p	_	_
28	in	in	IN	_	31	mark	_	_
29	order	order	NN	_	31	dep	_	_
30	to	to	TO	_	31	aux	_	_
31	find	find	VB	_	15	comp	_	_
32	out	out	RP	_	31	prt	_	_
33	a	a	DT	_	35	det	_	_
34	protective	protective	JJ	_	35	attr	_	_
35	agent	agent	NN	_	31	obj	_	_
36	against	against	IN	_	41	case	_	_
37	spontaneous	spontaneous	JJ	_	41	attr	_	_
38	and	and	CC	_	37	cc	_	_
39	DEB-induced	deb-induced	JJ	_	37	conj	_	_
40	chromosome	chromosome	NN	_	41	com	_	_
41	instability	instability	NN	_	35	ppmod	_	_
42	.	.	.	_	5	p	_	_

1	Metabotropic	metabotropic	JJ	_	3	attr	_	_
2	glutamate	glutamate	NN	_	3	com	_	_
3	receptor	receptor	NN	_	5	attr	_	_
4	5	0	CD	_	3	num	_	_
5	antagonist	antagonist	NN	_	6	dep	_	_
6	protects	protect	VBZ	_	0	root	_	_
7	dopaminergic	dopaminergic	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	noradrenergic	noradrenergic	JJ	_	7	conj	_	_
10	neurons	neuron	NNS	_	6	obj	_	_
11	from	from	IN	_	12	case	_	_
12	degeneration	degeneration	NN	_	6	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	drug1	drug0	JJ	_	16	attr	_	_
15	-treated	-treated	JJ	_	16	attr	_	_
16	monkeys	monkey	NNS	_	12	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	Degeneration	degeneration	NN	_	15	dep	_	_
2	of	of	IN	_	6	case	_	_
3	the	the	DT	_	6	det	_	_
4	dopaminergic	dopaminergic	JJ	_	6	attr	_	_
5	nigrostriatal	nigrostriatal	JJ	_	6	attr	_	_
6	system	system	NN	_	1	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	of	of	IN	_	10	case	_	_
9	noradrenergic	noradrenergic	JJ	_	10	attr	_	_
10	neurons	neuron	NNS	_	6	conj	_	_
11	in	in	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	locus	locus	NN	_	14	com	_	_
14	coeruleus	coeruleus	NN	_	10	ppmod	_	_
15	are	be	VBP	_	0	root	_	_
16	important	important	JJ	_	18	attr	_	_
17	pathological	pathological	JJ	_	18	attr	_	_
18	features	feature	NNS	_	15	obj	_	_
19	of	of	IN	_	22	case	_	_
20	Parkinson	parkinson	NN	_	22	poss	_	_
21	's	's	POS	_	20	case	_	_
22	disease	disease	NN	_	18	ppmod	_	_
23	.	.	.	_	15	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	an	an	DT	_	5	det	_	_
4	urgent	urgent	JJ	_	5	attr	_	_
5	need	need	NN	_	2	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	develop	develop	VB	_	5	acl	_	_
8	therapies	therapy	NNS	_	7	obj	_	_
9	that	that	IN	_	13	case	_	_
10	slow	slow	JJ	_	13	attr	_	_
11	down	down	JJ	_	13	attr	_	_
12	the	the	DT	_	13	det	_	_
13	progression	progression	NN	_	8	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	neurodegeneration	neurodegeneration	NN	_	13	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	Parkinson	parkinson	NN	_	19	poss	_	_
18	's	's	POS	_	17	case	_	_
19	disease	disease	NN	_	13	ppmod	_	_
20	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	7	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	we	we	PRP	_	7	dep	_	_
7	tested	test	VBD	_	0	root	_	_
8	whether	whether	IN	_	20	mark	_	_
9	the	the	DT	_	16	det	_	_
10	highly	highly	RB	_	11	adv	_	_
11	specific	specific	JJ	_	16	attr	_	_
12	metabotropic	metabotropic	JJ	_	14	attr	_	_
13	glutamate	glutamate	NN	_	14	com	_	_
14	receptor	receptor	NN	_	16	attr	_	_
15	5	0	CD	_	14	num	_	_
16	antagonist	antagonist	NN	_	20	dep	_	_
17	,	,	,	_	16	p	_	_
18	drug1	drug0	NN	_	16	appo	_	_
19	,	,	,	_	16	p	_	_
20	reduces	reduce	VBZ	_	7	comp	_	_
21	dopaminergic	dopaminergic	JJ	_	25	attr	_	_
22	and	and	CC	_	21	cc	_	_
23	noradrenergic	noradrenergic	JJ	_	21	conj	_	_
24	neuronal	neuronal	JJ	_	25	attr	_	_
25	loss	loss	NN	_	20	obj	_	_
26	in	in	IN	_	27	case	_	_
27	monkeys	monkey	NNS	_	20	ppmod	_	_
28	rendered	render	VBN	_	27	acl	_	_
29	parkinsonian	parkinsonian	NN	_	28	obj	_	_
30	by	by	IN	_	32	case	_	_
31	chronic	chronic	JJ	_	32	attr	_	_
32	treatment	treatment	NN	_	28	ppmod	_	_
33	with	with	IN	_	35	case	_	_
34	low	low	JJ	_	35	attr	_	_
35	doses	dose	NNS	_	32	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	drug2	drug0	NN	_	35	ppmod	_	_
38	.	.	.	_	7	p	_	_

1	Weekly	weekly	JJ	_	4	attr	_	_
2	intramuscular	intramuscular	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	injections	injection	NNS	_	23	dep	_	_
5	(	-lrb-	-LRB-	_	9	p	_	_
6	0.2-0.5	0	CD	_	9	num	_	_
7	mg/kg	mg/kg	NN	_	9	com	_	_
8	body	body	NN	_	9	com	_	_
9	weight	weight	NN	_	4	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	23	p	_	_
12	in	in	IN	_	13	case	_	_
13	combination	combination	NN	_	23	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	daily	daily	JJ	_	16	attr	_	_
16	administration	administration	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	vehicle	vehicle	NN	_	18	conj	_	_
21	,	,	,	_	23	p	_	_
22	were	be	VBD	_	23	aux	_	_
23	performed	performed	VBN	_	0	root	_	_
24	until	until	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	development	development	NN	_	23	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	parkinsonian	parkinsonian	JJ	_	30	attr	_	_
29	motor	motor	NN	_	30	com	_	_
30	symptoms	symptom	NNS	_	26	ppmod	_	_
31	in	in	IN	_	32	case	_	_
32	either	either	DT	_	30	ppmod	_	_
33	of	of	IN	_	37	case	_	_
34	the	the	DT	_	37	det	_	_
35	two	#crd#	CD	_	37	num	_	_
36	experimental	experimental	JJ	_	37	attr	_	_
37	groups	group	NNS	_	32	ppmod	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	drug3	drug0	NN	_	37	prn	_	_
40	/	/	:	_	39	p	_	_
41	drug4	drug0	NN	_	39	conj	_	_
42	versus	versus	CC	_	41	cc	_	_
43	drug5	drug0	NN	_	44	com	_	_
44	/vehicle	/vehicle	NN	_	39	conj	_	_
45	)	-rrb-	-RRB-	_	39	p	_	_
46	.	.	.	_	23	p	_	_

1	After	after	IN	_	3	case	_	_
2	21	0	CD	_	3	num	_	_
3	weeks	week	NNS	_	12	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	treatment	treatment	NN	_	3	ppmod	_	_
7	,	,	,	_	12	p	_	_
8	all	all	DT	_	11	det	_	_
9	drug2	drug0	NN	_	11	attr	_	_
10	/vehicle-treated	/vehicle-treated	JJ	_	11	attr	_	_
11	animals	animal	NNS	_	12	dep	_	_
12	displayed	display	VBD	_	27	advcl	_	_
13	parkinsonian	parkinsonian	JJ	_	14	attr	_	_
14	symptoms	symptom	NNS	_	12	obj	_	_
15	,	,	,	_	27	p	_	_
16	whereas	whereas	IN	_	27	case	_	_
17	none	none	NN	_	27	dep	_	_
18	of	of	IN	_	24	case	_	_
19	the	the	DT	_	24	det	_	_
20	drug3	drug0	NN	_	24	attr	_	_
21	/	/	:	_	24	p	_	_
22	drug4	drug0	NN	_	24	attr	_	_
23	-treated	-treated	JJ	_	24	attr	_	_
24	monkeys	monkey	NNS	_	17	ppmod	_	_
25	were	be	VBD	_	27	aux	_	_
26	significantly	significantly	RB	_	27	adv	_	_
27	affected	affect	VBN	_	0	root	_	_
28	.	.	.	_	27	p	_	_

1	These	these	DT	_	3	det	_	_
2	behavioural	behavioural	JJ	_	3	attr	_	_
3	observations	observation	NNS	_	4	dep	_	_
4	were	be	VBD	_	0	root	_	_
5	consistent	consistent	JJ	_	4	dep	_	_
6	with	with	IN	_	13	case	_	_
7	in	in	FW	_	8	adv	_	_
8	vivo	vivo	FW	_	11	attr	_	_
9	positron	positron	NN	_	11	com	_	_
10	emission	emission	NN	_	11	com	_	_
11	tomography	tomography	NN	_	13	com	_	_
12	dopamine	dopamine	NN	_	13	com	_	_
13	transporter	transporter	NN	_	5	ppmod	_	_
14	imaging	image	VBG	_	13	acl	_	_
15	data	datum	NNS	_	14	obj	_	_
16	,	,	,	_	13	p	_	_
17	and	and	CC	_	13	cc	_	_
18	with	with	IN	_	21	case	_	_
19	post-mortem	post-mortem	JJ	_	21	attr	_	_
20	stereological	stereological	JJ	_	21	attr	_	_
21	counts	count	NNS	_	13	conj	_	_
22	of	of	IN	_	25	case	_	_
23	midbrain	midbrain	JJ	_	25	attr	_	_
24	dopaminergic	dopaminergic	JJ	_	25	attr	_	_
25	neurons	neuron	NNS	_	21	ppmod	_	_
26	,	,	,	_	4	p	_	_
27	as	as	RB	_	28	com	_	_
28	well	well	RB	_	4	cc	_	_
29	as	as	IN	_	28	com	_	_
30	striatal	striatal	JJ	_	32	attr	_	_
31	intensity	intensity	NN	_	32	com	_	_
32	measurements	measurement	NNS	_	4	conj	_	_
33	of	of	IN	_	35	case	_	_
34	dopamine	dopamine	NN	_	35	com	_	_
35	transporter	transporter	NN	_	32	ppmod	_	_
36	and	and	CC	_	35	cc	_	_
37	tyrosine	tyrosine	NN	_	38	com	_	_
38	hydroxylase	hydroxylase	NN	_	39	com	_	_
39	immunoreactivity	immunoreactivity	NN	_	35	conj	_	_
40	,	,	,	_	35	p	_	_
41	which	which	WDT	_	42	dep	_	_
42	were	be	VBD	_	35	relcl	_	_
43	all	all	RB	_	42	adv	_	_
44	significantly	significantly	RB	_	45	adv	_	_
45	higher	high	JJR	_	42	dep	_	_
46	in	in	IN	_	51	case	_	_
47	drug1	drug0	NN	_	51	attr	_	_
48	/	/	:	_	51	p	_	_
49	drug2	drug0	NN	_	51	attr	_	_
50	-treated	-treated	JJ	_	51	attr	_	_
51	animals	animal	NNS	_	45	ppmod	_	_
52	than	than	IN	_	56	case	_	_
53	in	in	IN	_	56	case	_	_
54	drug3	drug0	CD	_	56	num	_	_
55	/vehicle-treated	/vehicle-treated	JJ	_	56	attr	_	_
56	monkeys	monkey	NNS	_	45	ppmod	_	_
57	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	treatment	treatment	NN	_	5	dep	_	_
4	also	also	RB	_	5	adv	_	_
5	had	have	VBD	_	0	root	_	_
6	a	a	DT	_	8	det	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	on	on	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	drug2	drug0	NN	_	12	advnp	_	_
12	-induced	-induced	JJ	_	13	attr	_	_
13	loss	loss	NN	_	5	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	norepinephrine	norepinephrine	NN	_	16	com	_	_
16	neurons	neuron	NNS	_	13	ppmod	_	_
17	in	in	IN	_	28	case	_	_
18	the	the	DT	_	20	det	_	_
19	locus	locus	NN	_	20	com	_	_
20	coeruleus	coeruleus	NN	_	28	attr	_	_
21	and	and	CC	_	20	cc	_	_
22	adjoining	adjoining	JJ	_	23	attr	_	_
23	A5	a0	NN	_	20	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	A7	a0	NN	_	26	com	_	_
26	noradrenaline	noradrenaline	NN	_	23	conj	_	_
27	cell	cell	NN	_	28	com	_	_
28	groups	group	NNS	_	16	ppmod	_	_
29	.	.	.	_	5	p	_	_

1	In	in	IN	_	4	case	_	_
2	drug1	drug0	NN	_	4	attr	_	_
3	/vehicle-treated	/vehicle-treated	JJ	_	4	attr	_	_
4	animals	animal	NNS	_	16	ppmod	_	_
5	,	,	,	_	16	p	_	_
6	almost	almost	RB	_	7	adv	_	_
7	40	0	CD	_	9	num	_	_
8	%	%	NN	_	7	meta	_	_
9	loss	loss	NN	_	16	dep	_	_
10	of	of	IN	_	14	case	_	_
11	tyrosine	tyrosine	NN	_	12	advnp	_	_
12	hydroxylase-positive	hydroxylase-positive	JJ	_	14	attr	_	_
13	norepinephrine	norepinephrine	NN	_	14	com	_	_
14	neurons	neuron	NNS	_	9	ppmod	_	_
15	was	be	VBD	_	16	aux	_	_
16	found	find	VBN	_	0	root	_	_
17	in	in	IN	_	22	case	_	_
18	locus	locus	NN	_	22	com	_	_
19	coeruleus/A5/A7	coeruleus/a0/a0	NN	_	22	com	_	_
20	noradrenaline	noradrenaline	NN	_	22	com	_	_
21	cell	cell	NN	_	22	com	_	_
22	groups	group	NNS	_	16	ppmod	_	_
23	,	,	,	_	16	p	_	_
24	whereas	whereas	IN	_	30	mark	_	_
25	the	the	DT	_	26	det	_	_
26	extent	extent	NN	_	30	dep	_	_
27	of	of	IN	_	29	case	_	_
28	neuronal	neuronal	JJ	_	29	attr	_	_
29	loss	loss	NN	_	26	ppmod	_	_
30	was	be	VBD	_	16	comp	_	_
31	lower	low	JJR	_	33	attr	_	_
32	than	than	IN	_	31	com	_	_
33	15	0	CD	_	30	obj	_	_
34	%	%	NN	_	33	meta	_	_
35	of	of	IN	_	37	case	_	_
36	control	control	NN	_	37	com	_	_
37	values	value	NNS	_	33	ppmod	_	_
38	in	in	IN	_	43	case	_	_
39	drug2	drug0	NN	_	43	attr	_	_
40	/	/	:	_	43	p	_	_
41	drug3	drug0	NN	_	43	attr	_	_
42	-treated	-treated	JJ	_	43	attr	_	_
43	monkeys	monkey	NNS	_	30	ppmod	_	_
44	.	.	.	_	16	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	data	datum	NNS	_	3	dep	_	_
3	demonstrate	demonstrate	VBP	_	0	root	_	_
4	that	that	IN	_	18	mark	_	_
5	chronic	chronic	JJ	_	6	attr	_	_
6	treatment	treatment	NN	_	18	dep	_	_
7	with	with	IN	_	13	case	_	_
8	the	the	DT	_	11	det	_	_
9	metabotropic	metabotropic	JJ	_	11	attr	_	_
10	glutamate	glutamate	NN	_	11	com	_	_
11	receptor	receptor	NN	_	13	attr	_	_
12	5	0	CD	_	11	num	_	_
13	antagonist	antagonist	NN	_	6	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug1	drug0	NN	_	13	appo	_	_
16	,	,	,	_	13	p	_	_
17	significantly	significantly	RB	_	18	adv	_	_
18	reduces	reduce	VBZ	_	3	comp	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	toxicity	toxicity	NN	_	18	obj	_	_
21	towards	towards	IN	_	26	case	_	_
22	dopaminergic	dopaminergic	JJ	_	26	attr	_	_
23	and	and	CC	_	22	cc	_	_
24	noradrenergic	noradrenergic	JJ	_	22	conj	_	_
25	cell	cell	NN	_	26	com	_	_
26	groups	group	NNS	_	20	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	non-human	non-human	JJ	_	29	attr	_	_
29	primates	primate	NNS	_	20	ppmod	_	_
30	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	dep	_	_
2	suggests	suggest	VBZ	_	0	root	_	_
3	that	that	IN	_	13	mark	_	_
4	the	the	DT	_	5	det	_	_
5	use	use	NN	_	13	dep	_	_
6	of	of	IN	_	11	case	_	_
7	metabotropic	metabotropic	JJ	_	11	attr	_	_
8	glutamate	glutamate	NN	_	11	attr	_	_
9	receptor	receptor	NN	_	11	attr	_	_
10	5	0	CD	_	11	num	_	_
11	antagonists	antagonist	NNS	_	5	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	be	be	VB	_	2	comp	_	_
14	a	a	DT	_	16	det	_	_
15	useful	useful	JJ	_	16	attr	_	_
16	strategy	strategy	NN	_	13	obj	_	_
17	to	to	TO	_	18	aux	_	_
18	reduce	reduce	VB	_	16	acl	_	_
19	degeneration	degeneration	NN	_	18	obj	_	_
20	of	of	IN	_	22	case	_	_
21	catecholaminergic	catecholaminergic	JJ	_	22	attr	_	_
22	neurons	neuron	NNS	_	19	ppmod	_	_
23	in	in	IN	_	26	case	_	_
24	Parkinson	parkinson	NN	_	26	poss	_	_
25	's	's	POS	_	24	case	_	_
26	disease	disease	NN	_	19	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	activity	activity	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	combined	combine	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	against	against	IN	_	11	case	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	isolates	isolate	NNS	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	-resistant	-resistant	JJ	_	13	attr	_	_
15	Staphylococcus	staphylococcus	FW	_	16	adv	_	_
16	aureus	aureus	FW	_	14	adv	_	_
17	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	aimed	aim	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	evaluate	evaluate	VB	_	3	comp	_	_
6	the	the	DT	_	9	det	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	9	attr	_	_
9	activity	activity	NN	_	5	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	combined	combine	VBN	_	11	acl	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	against	against	IN	_	16	case	_	_
16	isolates	isolate	NNS	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	CD	_	16	ppmod	_	_
19	-resistant	-resistant	JJ	_	18	attr	_	_
20	Staphylococcus	staphylococcus	FW	_	21	attr	_	_
21	aureus	aureus	FW	_	18	attr	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	MRSA	mrsa	NN	_	18	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	.	.	.	_	3	p	_	_

1	A	a	DT	_	2	det	_	_
2	total	total	NN	_	15	dep	_	_
3	of	of	IN	_	6	case	_	_
4	87	0	CD	_	6	num	_	_
5	clinical	clinical	JJ	_	6	attr	_	_
6	isolates	isolate	NNS	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	MRSA	mrsa	NN	_	6	ppmod	_	_
9	collected	collect	VBN	_	6	acl	_	_
10	from	from	IN	_	13	case	_	_
11	three	#crd#	CD	_	13	num	_	_
12	Chinese	chinese	JJ	_	13	attr	_	_
13	hospitals	hospital	NNS	_	9	ppmod	_	_
14	were	be	VBD	_	15	aux	_	_
15	included	include	VBN	_	0	root	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	study	study	NN	_	15	ppmod	_	_
19	.	.	.	_	15	p	_	_

1	The	the	DT	_	3	det	_	_
2	checkerboard	checkerboard	JJ	_	3	attr	_	_
3	method	method	NN	_	15	dep	_	_
4	with	with	IN	_	5	case	_	_
5	determination	determination	NN	_	3	ppmod	_	_
6	of	of	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	fractional	fractional	JJ	_	10	attr	_	_
9	IC	ic	NN	_	10	com	_	_
10	index	index	NN	_	5	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	FICI	fici	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	was	be	VBD	_	15	aux	_	_
15	used	use	VBN	_	0	root	_	_
16	to	to	TO	_	17	aux	_	_
17	determine	determine	VB	_	15	comp	_	_
18	whether	whether	IN	_	21	mark	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	combinations	combination	NNS	_	21	dep	_	_
21	act	act	VBP	_	17	comp	_	_
22	synergistically	synergistically	RB	_	21	adv	_	_
23	against	against	IN	_	25	case	_	_
24	these	these	DT	_	25	det	_	_
25	isolates	isolate	NNS	_	21	ppmod	_	_
26	.	.	.	_	15	p	_	_

1	The	the	DT	_	3	det	_	_
2	susceptibility	susceptibility	NN	_	3	com	_	_
3	results	result	NNS	_	9	dep	_	_
4	for	for	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	were	be	VBD	_	9	aux	_	_
9	interpreted	interpret	VBN	_	0	root	_	_
10	according	accord	VBG	_	15	adv	_	_
11	to	to	TO	_	15	aux	_	_
12	the	the	DT	_	15	det	_	_
13	most	most	RBS	_	14	adv	_	_
14	relevant	relevant	JJ	_	15	attr	_	_
15	criteria	criterion	NNS	_	9	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	demonstrated	demonstrate	VBD	_	28	advcl	_	_
4	the	the	DT	_	6	det	_	_
5	following	following	JJ	_	6	attr	_	_
6	interactions	interaction	NNS	_	3	obj	_	_
7	:	:	:	_	28	p	_	_
8	76	0	CD	_	9	num	_	_
9	isolates	isolate	NNS	_	28	dep	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	87.4	0	CD	_	9	num	_	_
12	%	%	NN	_	11	meta	_	_
13	)	-rrb-	-RRB-	_	11	p	_	_
14	showed	show	VBD	_	28	aux	_	_
15	synergistic	synergistic	JJ	_	16	attr	_	_
16	interactions	interaction	NNS	_	28	obj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	FICI	fici	NNP	_	16	prn	_	_
19	0.5	0	CD	_	18	num	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	and	and	CC	_	16	cc	_	_
22	11	0	CD	_	23	num	_	_
23	isolates	isolate	NNS	_	16	conj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	12.6	0	CD	_	23	num	_	_
26	%	%	NN	_	25	meta	_	_
27	)	-rrb-	-RRB-	_	25	p	_	_
28	showed	show	VBD	_	0	root	_	_
29	indifferent	indifferent	JJ	_	30	attr	_	_
30	interactions	interaction	NNS	_	28	obj	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	0.5&amp	0&amp	NN	_	30	prn	_	_
33	;	;	:	_	32	p	_	_
34	lt	lt	NN	_	32	appo	_	_
35	;	;	:	_	32	p	_	_
36	FICI&amp	fici&amp	NN	_	32	appo	_	_
37	;	;	:	_	32	p	_	_
38	lt	lt	NN	_	32	appo	_	_
39	;	;	:	_	32	p	_	_
40	4	0	CD	_	32	appo	_	_
41	)	-rrb-	-RRB-	_	32	p	_	_
42	.	.	.	_	28	p	_	_

1	No	no	DT	_	3	det	_	_
2	antagonistic	antagonistic	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	9	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	FICI	fici	NNP	_	3	prn	_	_
6	4	0	CD	_	5	num	_	_
7	)	-rrb-	-RRB-	_	5	p	_	_
8	were	be	VBD	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	combination	combination	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	can	can	MD	_	8	modal	_	_
8	be	be	VB	_	0	root	_	_
9	synergistic	synergistic	JJ	_	8	dep	_	_
10	against	against	IN	_	11	case	_	_
11	MRSA	mrsa	NN	_	9	ppmod	_	_
12	.	.	.	_	8	p	_	_

1	Further	far	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	required	require	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	determine	determine	VB	_	4	comp	_	_
7	the	the	DT	_	10	det	_	_
8	potential	potential	JJ	_	9	adv	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	role	role	NN	_	6	obj	_	_
11	of	of	IN	_	14	case	_	_
12	this	this	DT	_	14	det	_	_
13	combination	combination	NN	_	14	com	_	_
14	regimen	regimen	NN	_	10	ppmod	_	_
15	as	as	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	therapeutic	therapeutic	JJ	_	18	attr	_	_
18	alternative	alternative	NN	_	10	ppmod	_	_
19	for	for	IN	_	21	case	_	_
20	certain	certain	JJ	_	21	attr	_	_
21	types	type	NNS	_	18	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	MRSA	mrsa	NN	_	24	com	_	_
24	infections	infection	NNS	_	21	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	enhances	enhance	VBZ	_	0	root	_	_
3	drug2	drug0	NN	_	4	advnp	_	_
4	-mediated	-mediated	JJ	_	7	attr	_	_
5	antibody-dependent	antibody-dependent	JJ	_	7	attr	_	_
6	cellular	cellular	JJ	_	7	attr	_	_
7	cytotoxicity	cytotoxicity	NN	_	2	obj	_	_
8	by	by	IN	_	9	case	_	_
9	up-regulation	up-regulation	NN	_	2	ppmod	_	_
10	of	of	IN	_	14	case	_	_
11	cell	cell	NN	_	14	com	_	_
12	surface	surface	NN	_	14	com	_	_
13	HER2	her0	NN	_	14	com	_	_
14	expression	expression	NN	_	9	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	Although	although	IN	_	5	mark	_	_
2	it	it	PRP	_	5	dep	_	_
3	was	be	VBD	_	5	aux	_	_
4	previously	previously	RB	_	5	adv	_	_
5	reported	report	VBN	_	33	advcl	_	_
6	that	that	IN	_	11	mark	_	_
7	drug1	drug0	NN	_	11	dep	_	_
8	combined	combine	VBN	_	7	acl	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	improved	improve	VBD	_	5	comp	_	_
12	the	the	DT	_	15	det	_	_
13	progression-free	progression-free	JJ	_	15	attr	_	_
14	survival	survival	NN	_	15	com	_	_
15	rate	rate	NN	_	11	obj	_	_
16	compared	compare	VBN	_	18	adv	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	11	ppmod	_	_
19	alone	alone	RB	_	18	adv	_	_
20	for	for	IN	_	21	case	_	_
21	patients	patient	NNS	_	11	ppmod	_	_
22	with	with	IN	_	28	case	_	_
23	drug4	drug0	NN	_	28	attr	_	_
24	-refractory	-refractory	JJ	_	28	attr	_	_
25	HER2-positive	her0-positive	JJ	_	28	attr	_	_
26	metastatic	metastatic	JJ	_	28	attr	_	_
27	breast	breast	NN	_	28	com	_	_
28	cancer	cancer	NN	_	21	ppmod	_	_
29	,	,	,	_	33	p	_	_
30	the	the	DT	_	31	det	_	_
31	mechanism	mechanism	NN	_	33	dep	_	_
32	is	be	VBZ	_	33	aux	_	_
33	purported	purport	VBN	_	0	root	_	_
34	to	to	TO	_	35	aux	_	_
35	be	be	VB	_	33	comp	_	_
36	an	an	DT	_	38	det	_	_
37	antiproliferative	antiproliferative	JJ	_	38	attr	_	_
38	effect	effect	NN	_	35	obj	_	_
39	relating	relate	VBG	_	38	acl	_	_
40	to	to	TO	_	42	aux	_	_
41	the	the	DT	_	42	det	_	_
42	synergism	synergism	NN	_	39	ppmod	_	_
43	of	of	IN	_	46	case	_	_
44	these	these	DT	_	46	det	_	_
45	two	#crd#	CD	_	46	num	_	_
46	agents	agent	NNS	_	42	ppmod	_	_
47	.	.	.	_	33	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	evaluated	evaluate	VBD	_	0	root	_	_
3	how	how	WRB	_	5	adv	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	interacts	interact	VBZ	_	2	comp	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	11	case	_	_
9	HER2-positive	her0-positive	JJ	_	11	attr	_	_
10	breast	breast	NN	_	11	com	_	_
11	cancer	cancer	NN	_	7	ppmod	_	_
12	,	,	,	_	5	p	_	_
13	with	with	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	particular	particular	JJ	_	16	attr	_	_
16	focus	focus	NN	_	5	ppmod	_	_
17	on	on	IN	_	22	case	_	_
18	drug3	drug0	NN	_	22	attr	_	_
19	-mediated	-mediated	JJ	_	22	attr	_	_
20	antibody-dependent	antibody-dependent	JJ	_	22	attr	_	_
21	cellular	cellular	JJ	_	22	attr	_	_
22	cytotoxicity	cytotoxicity	NN	_	16	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	ADCC	adcc	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	.	.	.	_	2	p	_	_

1	In	in	IN	_	5	case	_	_
2	an	an	DT	_	5	det	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	assay	assay	NN	_	8	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	induced	induce	VBD	_	0	root	_	_
9	HER2	her0	NN	_	10	com	_	_
10	expression	expression	NN	_	8	obj	_	_
11	at	at	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	cell	cell	NN	_	14	com	_	_
14	surface	surface	NN	_	8	ppmod	_	_
15	of	of	IN	_	20	case	_	_
16	HER2-positive	her0-positive	JJ	_	20	attr	_	_
17	breast	breast	NN	_	20	com	_	_
18	cancer	cancer	NN	_	20	com	_	_
19	cell	cell	NN	_	20	com	_	_
20	lines	line	NNS	_	14	ppmod	_	_
21	,	,	,	_	8	p	_	_
22	leading	lead	VBG	_	8	comp	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	enhancement	enhancement	NN	_	22	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	drug2	drug0	NN	_	29	attr	_	_
28	-mediated	-mediated	JJ	_	29	attr	_	_
29	ADCC	adcc	NN	_	25	ppmod	_	_
30	.	.	.	_	8	p	_	_

1	Furthermore	furthermore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	present	present	VBP	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	case	case	NN	_	7	com	_	_
7	report	report	NN	_	4	obj	_	_
8	in	in	IN	_	9	case	_	_
9	which	which	WDT	_	16	ppmod	_	_
10	a	a	DT	_	13	det	_	_
11	second	#ord#	JJ	_	13	attr	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	treatment	treatment	NN	_	16	dep	_	_
14	following	follow	VBG	_	15	adv	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	resulted	result	VBD	_	7	relcl	_	_
17	in	in	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	marked	marked	JJ	_	20	attr	_	_
20	shrinkage	shrinkage	NN	_	16	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	multiple	multiple	JJ	_	24	attr	_	_
23	metastatic	metastatic	JJ	_	24	attr	_	_
24	tumors	tumor	NNS	_	20	ppmod	_	_
25	in	in	IN	_	28	case	_	_
26	HER2-positive	her0-positive	JJ	_	28	attr	_	_
27	breast	breast	NN	_	28	com	_	_
28	cancer	cancer	NN	_	24	ppmod	_	_
29	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	have	have	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	potential	potential	NN	_	3	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	convert	convert	VBP	_	5	acl	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	-refractory	-refractory	NN	_	7	obj	_	_
10	to	to	TO	_	13	aux	_	_
11	drug3	drug0	NN	_	13	attr	_	_
12	-sensitive	-sensitive	JJ	_	13	attr	_	_
13	tumors	tumor	NNS	_	7	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	HER2-positive	her0-positive	JJ	_	17	attr	_	_
16	breast	breast	NN	_	17	com	_	_
17	cancer	cancer	NN	_	13	ppmod	_	_
18	by	by	IN	_	19	case	_	_
19	up-regulation	up-regulation	NN	_	3	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	the	the	DT	_	24	det	_	_
22	cell	cell	NN	_	24	com	_	_
23	surface	surface	NN	_	24	com	_	_
24	expression	expression	NN	_	19	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	HER2	her0	NN	_	24	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	Improved	improved	JJ	_	4	attr	_	_
2	parathyroid	parathyroid	JJ	_	3	attr	_	_
3	hormone	hormone	NN	_	4	com	_	_
4	control	control	NN	_	8	dep	_	_
5	by	by	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	reduction	reduction	NN	_	8	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	requirement	requirement	NN	_	10	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	with	with	IN	_	19	case	_	_
17	end-stage	end-stage	JJ	_	19	attr	_	_
18	renal	renal	JJ	_	19	attr	_	_
19	disease	disease	NN	_	15	ppmod	_	_
20	.	.	.	_	8	p	_	_

1	Uncontrolled	uncontrolled	JJ	_	2	attr	_	_
2	hy-per-parathyroidism	hy-per-parathyroidism	NN	_	3	dep	_	_
3	causes	cause	VBZ	_	0	root	_	_
4	bone	bone	NN	_	5	com	_	_
5	marrow	marrow	NN	_	6	com	_	_
6	fibrosis	fibrosis	NN	_	3	obj	_	_
7	,	,	,	_	3	p	_	_
8	leading	lead	VBG	_	3	comp	_	_
9	to	to	TO	_	14	aux	_	_
10	drug1	drug0	NN	_	14	attr	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	drug2	drug0	NN	_	14	attr	_	_
13	)	-rrb-	-RRB-	_	14	p	_	_
14	resistance	resistance	NN	_	8	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Medical	medical	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	5	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	0	root	_	_
6	effective	effective	JJ	_	5	dep	_	_
7	in	in	IN	_	8	case	_	_
8	reducing	reduce	VBG	_	6	ppmod	_	_
9	plasma	plasma	NN	_	11	attr	_	_
10	parathyroid	parathyroid	JJ	_	11	attr	_	_
11	hormone	hormone	NN	_	15	attr	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	PTH	pth	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	levels	level	NNS	_	8	obj	_	_
16	,	,	,	_	5	p	_	_
17	but	but	CC	_	5	cc	_	_
18	its	its	PRP$	_	19	poss	_	_
19	effect	effect	NN	_	23	dep	_	_
20	on	on	IN	_	22	case	_	_
21	drug2	drug0	NN	_	22	com	_	_
22	dosing	dosing	NN	_	19	ppmod	_	_
23	is	be	VBZ	_	5	conj	_	_
24	unknown	unknown	JJ	_	23	dep	_	_
25	.	.	.	_	5	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	AND	and	CC	_	1	cc	_	_
3	AIMS	aim	NNS	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	We	we	PRP	_	6	dep	_	_
6	conducted	conduct	VBN	_	1	acl	_	_
7	a	a	DT	_	10	det	_	_
8	retrospective	retrospective	JJ	_	10	attr	_	_
9	cohort	cohort	NN	_	10	com	_	_
10	study	study	NN	_	6	obj	_	_
11	of	of	IN	_	19	case	_	_
12	40	0	CD	_	19	num	_	_
13	end-stage	end-stage	JJ	_	15	attr	_	_
14	renal	renal	JJ	_	15	attr	_	_
15	disease	disease	NN	_	19	attr	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	ESRD	esrd	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	patients	patient	NNS	_	10	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	age	age	NN	_	19	prn	_	_
22	:	:	:	_	21	p	_	_
23	55	0	CD	_	27	num	_	_
24	14	0	CD	_	27	num	_	_
25	;	;	:	_	27	p	_	_
26	mean	mean	NN	_	27	com	_	_
27	SD	sd	NN	_	21	appo	_	_
28	;	;	:	_	21	p	_	_
29	21	0	CD	_	21	appo	_	_
30	:	:	:	_	21	p	_	_
31	male	male	NN	_	21	appo	_	_
32	)	-rrb-	-RRB-	_	21	p	_	_
33	who	who	WP	_	34	dep	_	_
34	had	have	VBD	_	19	relcl	_	_
35	at	at	IN	_	37	case	_	_
36	least	least	JJS	_	37	attr	_	_
37	12	0	CD	_	38	num	_	_
38	months	month	NNS	_	34	obj	_	_
39	of	of	IN	_	41	case	_	_
40	drug1	drug0	NN	_	41	com	_	_
41	therapy	therapy	NN	_	38	ppmod	_	_
42	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	distribution	distribution	NN	_	7	dep	_	_
3	of	of	IN	_	6	case	_	_
4	renal	renal	JJ	_	6	attr	_	_
5	replacement	replacement	NN	_	6	com	_	_
6	therapies	therapy	NNS	_	2	ppmod	_	_
7	were	be	VBD	_	0	root	_	_
8	:	:	:	_	7	p	_	_
9	14	0	CD	_	11	num	_	_
10	peritoneal	peritoneal	JJ	_	11	attr	_	_
11	dialysis	dialysis	NNS	_	7	obj	_	_
12	,	,	,	_	11	p	_	_
13	18	0	CD	_	15	num	_	_
14	conventional	conventional	JJ	_	15	attr	_	_
15	hemodialysis	hemodialysis	NN	_	11	appo	_	_
16	and	and	CC	_	15	cc	_	_
17	8	0	CD	_	19	num	_	_
18	nocturnal	nocturnal	JJ	_	19	attr	_	_
19	hemodialysis	hemodialysis	NN	_	15	conj	_	_
20	.	.	.	_	7	p	_	_

1	Standard	standard	JJ	_	5	attr	_	_
2	dialysis	dialysis	NN	_	5	attr	_	_
3	related	related	JJ	_	5	attr	_	_
4	biochemical	biochemical	JJ	_	5	attr	_	_
5	indices	index	NNS	_	10	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	medications	medication	NNS	_	5	conj	_	_
8	used	use	VBN	_	5	acl	_	_
9	were	be	VBD	_	10	aux	_	_
10	recorded	record	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	The	the	DT	_	3	det	_	_
2	primary	primary	JJ	_	3	attr	_	_
3	objective	objective	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	study	study	NN	_	3	ppmod	_	_
7	was	be	VBD	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	ascertain	ascertain	VB	_	7	comp	_	_
10	the	the	DT	_	11	det	_	_
11	difference	difference	NN	_	9	obj	_	_
12	in	in	IN	_	14	case	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	responsiveness	responsiveness	NN	_	11	ppmod	_	_
15	before	before	IN	_	11	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	after	after	IN	_	19	case	_	_
18	12	0	CD	_	19	num	_	_
19	months	month	NNS	_	15	conj	_	_
20	of	of	IN	_	22	case	_	_
21	drug2	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	19	ppmod	_	_
23	.	.	.	_	7	p	_	_

1	Our	our	PRP$	_	3	poss	_	_
2	secondary	secondary	JJ	_	3	attr	_	_
3	objective	objective	NN	_	4	dep	_	_
4	was	be	VBD	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	determine	determine	VB	_	4	comp	_	_
7	if	if	IN	_	9	mark	_	_
8	there	there	EX	_	9	dep	_	_
9	was	be	VBD	_	6	comp	_	_
10	a	a	DT	_	11	det	_	_
11	relationship	relationship	NN	_	9	obj	_	_
12	between	between	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	changes	change	NNS	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	PTH	pth	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug1	drug0	NN	_	19	com	_	_
19	requirement	requirement	NN	_	16	conj	_	_
20	.	.	.	_	4	p	_	_

1	Overall	overall	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	PTH	pth	NN	_	4	com	_	_
4	levels	level	NNS	_	5	dep	_	_
5	decreased	decrease	VBD	_	0	root	_	_
6	from	from	IN	_	29	case	_	_
7	197.5	0	CD	_	29	num	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	151.8	0	CD	_	11	num	_	_
10	;	;	:	_	11	p	_	_
11	249.2	0	CD	_	7	num	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	to	to	TO	_	7	attr	_	_
14	66.1	0	CD	_	7	appo	_	_
15	(	-lrb-	-LRB-	_	18	p	_	_
16	41.2	0	CD	_	18	num	_	_
17	;	;	:	_	18	p	_	_
18	136.5	0	CD	_	7	num	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	median	median	NN	_	7	prn	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	25th	#ord#	NN	_	21	prn	_	_
24	;	;	:	_	23	p	_	_
25	75th	#ord#	NN	_	26	com	_	_
26	percentile	percentile	NN	_	23	appo	_	_
27	)	-rrb-	-RRB-	_	23	p	_	_
28	)	-rrb-	-RRB-	_	21	p	_	_
29	pmol/l	pmol/l	NN	_	5	ppmod	_	_
30	;	;	:	_	5	p	_	_

1	p	p	NN	_	2	com	_	_
2	&amp	&amp	NN	_	0	root	_	_
3	;	;	:	_	2	p	_	_
4	lt	lt	NN	_	2	appo	_	_
5	;	;	:	_	2	p	_	_

1	0.001	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	dose	dose	NN	_	3	dep	_	_
3	increased	increase	VBD	_	0	root	_	_
4	from	from	IN	_	13	case	_	_
5	30.0	0	CD	_	13	num	_	_
6	6	0	CD	_	13	num	_	_
7	to	to	TO	_	6	cc	_	_
8	63	0	CD	_	6	conj	_	_
9	25	0	CD	_	10	num	_	_
10	mg/day	mg/day	NN	_	13	attr	_	_
11	,	,	,	_	13	p	_	_
12	p	p	NN	_	13	com	_	_
13	&lt	&lt	NN	_	3	ppmod	_	_
14	;	;	:	_	3	p	_	_

1	0.05	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Hemoglobin	hemoglobin	NN	_	2	dep	_	_
2	remained	remain	VBD	_	0	root	_	_
3	unchanged	unchanged	JJ	_	2	dep	_	_
4	(	-lrb-	-LRB-	_	10	p	_	_
5	116	0	CD	_	10	num	_	_
6	13	0	CD	_	10	num	_	_
7	to	to	TO	_	6	cc	_	_
8	116	0	CD	_	6	conj	_	_
9	13	0	CD	_	10	num	_	_
10	g/l	g/l	NN	_	3	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	,	,	,	_	2	p	_	_
13	while	while	IN	_	16	mark	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	requirement	requirement	NN	_	16	dep	_	_
16	decreased	decrease	VBD	_	2	comp	_	_
17	from	from	IN	_	22	case	_	_
18	40	0	CD	_	22	num	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	20	0	CD	_	22	num	_	_
21	;	;	:	_	22	p	_	_
22	60	0	CD	_	16	ppmod	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	to	to	TO	_	31	aux	_	_
25	24	0	CD	_	31	num	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	19	0	CD	_	29	num	_	_
28	;	;	:	_	29	p	_	_
29	59	0	CD	_	25	num	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	g/week	g/week	NN	_	16	ppmod	_	_
32	,	,	,	_	31	p	_	_
33	p	p	NN	_	31	appo	_	_
34	=	=	JJ	_	33	attr	_	_
35	0.02	0	CD	_	34	num	_	_
36	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	remainder	remainder	NN	_	21	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	dialysis-related	dialysis-related	JJ	_	6	attr	_	_
6	biochemistry	biochemistry	NN	_	2	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	electrolytes	electrolyte	NNS	_	6	prn	_	_
9	,	,	,	_	8	p	_	_
10	calcium	calcium	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	phosphate	phosphate	NN	_	8	appo	_	_
13	,	,	,	_	8	p	_	_
14	iron	iron	NN	_	15	com	_	_
15	status	status	NN	_	8	appo	_	_
16	)	-rrb-	-RRB-	_	8	p	_	_
17	and	and	CC	_	6	cc	_	_
18	vitamin	vitamin	NN	_	20	com	_	_
19	D	d	NN	_	20	com	_	_
20	use	use	NN	_	6	conj	_	_
21	remained	remain	VBD	_	0	root	_	_
22	unchanged	unchanged	JJ	_	21	dep	_	_
23	.	.	.	_	21	p	_	_

1	A	a	DT	_	2	det	_	_
2	reduction	reduction	NN	_	12	dep	_	_
3	in	in	IN	_	5	case	_	_
4	PTH	pth	NN	_	5	com	_	_
5	level	level	NN	_	2	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	greater	great	JJR	_	9	attr	_	_
8	than	than	IN	_	7	com	_	_
9	30	0	CD	_	5	ppmod	_	_
10	%	%	NN	_	9	meta	_	_
11	was	be	VBD	_	12	aux	_	_
12	experienced	experience	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	82.5	0	CD	_	12	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	33/40	0	NN	_	14	num	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	of	of	IN	_	21	case	_	_
20	our	our	PRP$	_	21	poss	_	_
21	cohort	cohort	NN	_	14	ppmod	_	_
22	.	.	.	_	12	p	_	_

1	Among	among	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	responders	responder	NNS	_	14	ppmod	_	_
4	,	,	,	_	14	p	_	_
5	the	the	DT	_	14	dep	_	_
6	fall	fall	VBP	_	5	acl	_	_
7	in	in	IN	_	8	case	_	_
8	PTH	pth	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	reduction	reduction	NN	_	12	com	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	requirement	requirement	NN	_	8	conj	_	_
13	were	be	VBD	_	14	aux	_	_
14	related	related	JJ	_	0	root	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	R	r	NN	_	14	prn	_	_
17	=	=	JJ	_	16	attr	_	_
18	-0.48	0	CD	_	17	num	_	_
19	,	,	,	_	16	p	_	_
20	p	p	NN	_	21	dep	_	_
21	=	=	JJ	_	16	advcl	_	_
22	0.004	0	CD	_	21	obj	_	_
23	)	-rrb-	-RRB-	_	16	p	_	_
24	.	.	.	_	14	p	_	_

1	Reduction	reduction	NN	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	PTH	pth	NN	_	1	ppmod	_	_
4	by	by	IN	_	5	case	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	decrease	decrease	NN	_	7	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	requirement	requirement	NN	_	10	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	interface	interface	NN	_	10	dep	_	_
3	between	between	IN	_	4	case	_	_
4	bone	bone	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	bone	bone	NN	_	7	com	_	_
7	marrow	marrow	NN	_	4	conj	_	_
8	in	in	IN	_	9	case	_	_
9	uremia	uremia	NN	_	2	ppmod	_	_
10	represents	represent	VBZ	_	0	root	_	_
11	a	a	DT	_	13	det	_	_
12	critical	critical	JJ	_	13	attr	_	_
13	step	step	NN	_	10	obj	_	_
14	in	in	IN	_	18	case	_	_
15	red	red	JJ	_	18	attr	_	_
16	blood	blood	NN	_	18	com	_	_
17	cell	cell	NN	_	18	com	_	_
18	production	production	NN	_	13	ppmod	_	_
19	which	which	WDT	_	20	dep	_	_
20	merits	merit	NNS	_	13	relcl	_	_
21	further	far	JJ	_	22	attr	_	_
22	investigation	investigation	NN	_	20	obj	_	_
23	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	inhibit	inhibit	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	absorption	absorption	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	5	0	CD	_	9	num	_	_
9	milligrams	milligram	NNS	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	at	at	IN	_	15	case	_	_
15	doses	dose	NNS	_	6	ppmod	_	_
16	less	less	JJR	_	15	attr	_	_
17	than	than	IN	_	19	case	_	_
18	800	0	CD	_	19	num	_	_
19	milligrams	milligram	NNS	_	16	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	nonpregnant	nonpregnant	JJ	_	22	attr	_	_
22	women	woman	NNS	_	19	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	the	the	DT	_	6	det	_	_
4	only	only	RB	_	5	adv	_	_
5	known	known	JJ	_	6	attr	_	_
6	component	component	NN	_	2	obj	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	diet	diet	NN	_	6	ppmod	_	_
10	that	that	WDT	_	12	dep	_	_
11	may	may	MD	_	12	modal	_	_
12	affect	affect	VB	_	6	relcl	_	_
13	absorption	absorption	NN	_	12	obj	_	_
14	of	of	IN	_	16	case	_	_
15	both	both	CC	_	16	cc	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	.	.	.	_	2	p	_	_

1	However	however	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	the	the	DT	_	4	det	_	_
4	evidence	evidence	NN	_	13	dep	_	_
5	for	for	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	drug1	drug0	JJ	_	8	attr	_	_
8	effect	effect	NN	_	4	ppmod	_	_
9	on	on	IN	_	11	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	absorption	absorption	NN	_	8	ppmod	_	_
12	mainly	mainly	RB	_	13	adv	_	_
13	comes	come	VBZ	_	0	root	_	_
14	from	from	IN	_	15	case	_	_
15	studies	study	NNS	_	13	ppmod	_	_
16	that	that	WDT	_	19	dep	_	_
17	did	do	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	isolate	isolate	VB	_	15	relcl	_	_
20	the	the	DT	_	21	det	_	_
21	effect	effect	NN	_	19	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	from	from	IN	_	25	case	_	_
25	that	that	DT	_	19	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	other	other	JJ	_	29	attr	_	_
28	dietary	dietary	JJ	_	29	attr	_	_
29	components	component	NNS	_	25	ppmod	_	_
30	,	,	,	_	19	p	_	_
31	because	because	IN	_	34	mark	_	_
32	it	it	PRP	_	34	dep	_	_
33	was	be	VBD	_	34	aux	_	_
34	detected	detect	VBN	_	19	comp	_	_
35	in	in	IN	_	37	case	_	_
36	single-meal	single-meal	JJ	_	37	attr	_	_
37	studies	study	NNS	_	34	ppmod	_	_
38	.	.	.	_	13	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	objective	objective	NN	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	establish	establish	VB	_	3	comp	_	_
6	potential	potential	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	on	on	IN	_	11	case	_	_
11	absorption	absorption	NN	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	and	and	CC	_	11	cc	_	_
17	the	the	DT	_	19	det	_	_
18	dose	dose	NN	_	19	com	_	_
19	response	response	NN	_	11	conj	_	_
20	for	for	IN	_	22	case	_	_
21	this	this	DT	_	22	det	_	_
22	effect	effect	NN	_	19	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	absence	absence	NN	_	5	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	a	a	DT	_	28	det	_	_
28	meal	meal	NN	_	25	ppmod	_	_
29	.	.	.	_	3	p	_	_

1	Fifty-four	fifty-four	JJ	_	5	attr	_	_
2	healthy	healthy	JJ	_	4	adv	_	_
3	,	,	,	_	4	p	_	_
4	nonpregnant	nonpregnant	JJ	_	5	attr	_	_
5	women	woman	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	selected	select	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	participate	participate	VB	_	7	comp	_	_
10	in	in	IN	_	14	case	_	_
11	4	0	CD	_	14	num	_	_
12	drug1	drug0	JJ	_	14	attr	_	_
13	absorption	absorption	NN	_	14	com	_	_
14	studies	study	NNS	_	9	ppmod	_	_
15	using	use	VBG	_	14	acl	_	_
16	iron	iron	NN	_	18	attr	_	_
17	radioactive	radioactive	JJ	_	18	attr	_	_
18	tracers	tracer	NNS	_	15	obj	_	_
19	.	.	.	_	7	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	evaluated	evaluate	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	drug1	drug0	JJ	_	7	attr	_	_
7	doses	dose	NNS	_	4	ppmod	_	_
8	between	between	IN	_	12	case	_	_
9	200	0	CD	_	12	num	_	_
10	and	and	CC	_	9	cc	_	_
11	1500	0	CD	_	9	conj	_	_
12	mg	mg	NN	_	7	ppmod	_	_
13	on	on	IN	_	14	case	_	_
14	absorption	absorption	NN	_	4	ppmod	_	_
15	of	of	IN	_	18	case	_	_
16	5	0	CD	_	17	num	_	_
17	mg	mg	NN	_	18	com	_	_
18	drug2	drug0	NN	_	14	ppmod	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	as	as	IN	_	21	case	_	_
21	drug3	drug0	NN	_	18	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	.	.	.	_	2	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	evaluated	evaluate	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	drug1	drug0	JJ	_	8	attr	_	_
8	doses	dose	NNS	_	5	ppmod	_	_
9	between	between	IN	_	13	case	_	_
10	200	0	CD	_	13	num	_	_
11	and	and	CC	_	10	cc	_	_
12	800	0	CD	_	10	conj	_	_
13	mg	mg	NN	_	8	ppmod	_	_
14	on	on	IN	_	15	case	_	_
15	absorption	absorption	NN	_	5	ppmod	_	_
16	of	of	IN	_	22	case	_	_
17	5	0	CD	_	18	num	_	_
18	mg	mg	NN	_	22	attr	_	_
19	drug2	drug0	NN	_	22	attr	_	_
20	-LSB-as	-lsb-as	NN	_	22	attr	_	_
21	concentrated	concentrated	JJ	_	22	attr	_	_
22	RBC	rbc	NNS	_	15	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	CRBC	crbc	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	]	-rsb-	-RRB-	_	5	p	_	_
27	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	administered	administer	VBN	_	0	root	_	_
4	as	as	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	all	all	DT	_	8	det	_	_
8	studies	study	NNS	_	3	ppmod	_	_
9	and	and	CC	_	3	cc	_	_
10	drug3	drug0	NN	_	12	dep	_	_
11	were	be	VBD	_	12	aux	_	_
12	ingested	ingest	VBN	_	3	conj	_	_
13	on	on	IN	_	16	case	_	_
14	an	an	DT	_	16	det	_	_
15	empty	empty	JJ	_	16	attr	_	_
16	stomach	stomach	NN	_	12	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	doses	dose	NNS	_	5	dep	_	_
3	1000	0	CD	_	4	num	_	_
4	mg	mg	NN	_	2	appo	_	_
5	diminished	diminish	VBD	_	0	root	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	by	by	IN	_	10	case	_	_
9	an	an	DT	_	10	det	_	_
10	average	average	NN	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	49.6	0	CD	_	10	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	.	.	.	_	5	p	_	_

1	A	a	DT	_	3	det	_	_
2	drug1	drug0	JJ	_	3	attr	_	_
3	dose	dose	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	800	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	ppmod	_	_
7	diminished	diminish	VBD	_	0	root	_	_
8	absorption	absorption	NN	_	7	obj	_	_
9	of	of	IN	_	12	case	_	_
10	5	0	CD	_	11	num	_	_
11	mg	mg	NN	_	12	com	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	by	by	IN	_	14	case	_	_
14	37.7	0	CD	_	8	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	conclusion	conclusion	NN	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	we	we	PRP	_	5	dep	_	_
5	demonstrated	demonstrate	VBD	_	0	root	_	_
6	an	an	DT	_	8	det	_	_
7	isolated	isolate	VBN	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	as	as	IN	_	13	case	_	_
13	chloride	chloride	NN	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	on	on	IN	_	16	case	_	_
16	absorption	absorption	NN	_	8	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	5	0	CD	_	19	num	_	_
19	mg	mg	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	iron	iron	NN	_	19	ppmod	_	_
22	provided	provided	VBN	_	21	acl	_	_
23	as	as	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	27	p	_	_
26	as	as	IN	_	27	case	_	_
27	sulfate	sulfate	NN	_	24	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	and	and	CC	_	24	cc	_	_
30	drug3	drug0	NN	_	35	attr	_	_
31	(	-lrb-	-LRB-	_	33	p	_	_
32	as	as	IN	_	33	case	_	_
33	CRBC	crbc	NN	_	30	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	drug3	drug0	NN	_	24	conj	_	_
36	.	.	.	_	5	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	at	at	IN	_	6	case	_	_
6	doses	dose	NNS	_	4	ppmod	_	_
7	higher	high	JJR	_	6	attr	_	_
8	than	than	IN	_	10	mark	_	_
9	previously	previously	RB	_	10	adv	_	_
10	reported	report	VBN	_	7	comp	_	_
11	from	from	IN	_	13	case	_	_
12	single-meal	single-meal	JJ	_	13	attr	_	_
13	studies	study	NNS	_	10	ppmod	_	_
14	,	,	,	_	4	p	_	_
15	starting	start	VBG	_	4	comp	_	_
16	at	at	IN	_	18	case	_	_
17	~800	~0	CD	_	18	num	_	_
18	mg	mg	NN	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Synergistic	synergistic	JJ	_	2	attr	_	_
2	interaction	interaction	NN	_	7	dep	_	_
3	between	between	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	is	be	VBZ	_	0	root	_	_
8	sequence	sequence	NN	_	9	advnp	_	_
9	dependent	dependent	JJ	_	7	dep	_	_
10	in	in	IN	_	14	case	_	_
11	human	human	JJ	_	14	attr	_	_
12	non-small	non-small	NN	_	14	com	_	_
13	lung	lung	NN	_	14	com	_	_
14	cancer	cancer	NN	_	7	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	EGFR	egfr	NN	_	18	attr	_	_
17	TKIs-resistant	tkis-resistant	JJ	_	18	attr	_	_
18	mutation	mutation	NN	_	14	ppmod	_	_
19	.	.	.	_	7	p	_	_

1	Previous	previous	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	demonstrated	demonstrate	VBN	_	0	root	_	_
5	that	that	IN	_	10	mark	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	has	have	VBZ	_	10	lv	_	_
8	the	the	DT	_	10	det	_	_
9	anti-tumor	anti-tumor	JJ	_	10	attr	_	_
10	activity	activity	NN	_	4	comp	_	_
11	in	in	IN	_	16	case	_	_
12	human	human	JJ	_	16	attr	_	_
13	non-small	non-small	JJ	_	16	attr	_	_
14	cell	cell	NN	_	16	com	_	_
15	lung	lung	NN	_	16	com	_	_
16	cancer	cancer	NN	_	10	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	NSCLC	nsclc	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	aimed	aim	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	investigate	investigate	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	efficacy	efficacy	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	single	single	JJ	_	11	attr	_	_
11	use	use	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	that	that	DT	_	13	conj	_	_
16	of	of	IN	_	20	case	_	_
17	concurrent	concurrent	JJ	_	20	attr	_	_
18	or	or	CC	_	17	cc	_	_
19	sequential	sequential	JJ	_	17	conj	_	_
20	administration	administration	NN	_	15	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	in	in	IN	_	28	case	_	_
26	NSCLC	nsclc	NN	_	28	com	_	_
27	cell	cell	NN	_	28	com	_	_
28	lines	line	NNS	_	8	ppmod	_	_
29	that	that	WDT	_	30	dep	_	_
30	are	be	VBP	_	28	relcl	_	_
31	resistant	resistant	JJ	_	30	dep	_	_
32	to	to	TO	_	34	aux	_	_
33	EGFR	egfr	NN	_	34	com	_	_
34	TKIs	tkis	NN	_	31	ppmod	_	_
35	.	.	.	_	4	p	_	_

1	NSCLC	nsclc	NN	_	3	com	_	_
2	cell	cell	NN	_	3	com	_	_
3	lines	line	NNS	_	12	dep	_	_
4	with	with	IN	_	7	case	_	_
5	EGFR	egfr	NN	_	7	com	_	_
6	T790M	t0m	NN	_	7	com	_	_
7	mutation	mutation	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	K-ras	k-ras	NN	_	10	com	_	_
10	mutation	mutation	NN	_	7	conj	_	_
11	were	be	VBD	_	12	aux	_	_
12	exposed	expose	VBN	_	0	root	_	_
13	to	to	TO	_	15	aux	_	_
14	either	either	CC	_	15	cc	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	or	or	CC	_	15	cc	_	_
19	both	both	DT	_	15	conj	_	_
20	based	base	VBN	_	19	acl	_	_
21	on	on	IN	_	24	case	_	_
22	various	various	JJ	_	24	attr	_	_
23	sequential	sequential	JJ	_	24	attr	_	_
24	administrations	administration	NNS	_	20	ppmod	_	_
25	.	.	.	_	12	p	_	_

1	After	after	IN	_	2	case	_	_
2	exposure	exposure	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	the	the	DT	_	6	det	_	_
5	cell	cell	NN	_	6	com	_	_
6	viability	viability	NN	_	8	dep	_	_
7	was	be	VBD	_	8	aux	_	_
8	measured	measure	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	MTT	mtt	NN	_	11	com	_	_
11	assay	assay	NN	_	8	ppmod	_	_
12	,	,	,	_	8	p	_	_
13	cell	cell	NN	_	15	com	_	_
14	cycle	cycle	NN	_	15	com	_	_
15	distribution	distribution	NN	_	17	dep	_	_
16	was	be	VBD	_	17	aux	_	_
17	analyzed	analyze	VBN	_	8	conj	_	_
18	by	by	IN	_	20	case	_	_
19	flow	flow	NN	_	20	com	_	_
20	cytometry	cytometry	NN	_	17	ppmod	_	_
21	,	,	,	_	17	p	_	_
22	and	and	CC	_	17	cc	_	_
23	alterations	alteration	NNS	_	28	dep	_	_
24	in	in	IN	_	26	case	_	_
25	signaling	signaling	NN	_	26	com	_	_
26	pathway	pathway	NN	_	23	ppmod	_	_
27	were	be	VBD	_	28	aux	_	_
28	determined	determine	VBN	_	8	conj	_	_
29	by	by	IN	_	30	case	_	_
30	immunoblotting	immunoblotting	NN	_	28	ppmod	_	_
31	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	exhibited	exhibit	VBD	_	20	advcl	_	_
3	dose-dependent	dose-dependent	JJ	_	5	attr	_	_
4	growth	growth	NN	_	5	com	_	_
5	inhibition	inhibition	NN	_	2	obj	_	_
6	in	in	IN	_	9	case	_	_
7	NSCLC	nsclc	NN	_	9	com	_	_
8	cell	cell	NN	_	9	com	_	_
9	lines	line	NNS	_	2	ppmod	_	_
10	and	and	CC	_	2	cc	_	_
11	arrested	arrest	VBD	_	2	conj	_	_
12	cell	cell	NN	_	13	com	_	_
13	cycle	cycle	NN	_	11	obj	_	_
14	at	at	IN	_	16	case	_	_
15	G1	g0	NN	_	16	com	_	_
16	phase	phase	NN	_	11	ppmod	_	_
17	,	,	,	_	20	p	_	_
18	whereas	whereas	IN	_	20	case	_	_
19	drug2	drug0	NN	_	20	dep	_	_
20	arrested	arrest	VBD	_	0	root	_	_
21	at	at	IN	_	23	case	_	_
22	S	s	NN	_	23	com	_	_
23	phase	phase	NN	_	20	ppmod	_	_
24	.	.	.	_	20	p	_	_

1	Although	although	IN	_	10	mark	_	_
2	single	single	JJ	_	5	attr	_	_
3	or	or	CC	_	2	cc	_	_
4	concurrent	concurrent	JJ	_	2	conj	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	has	have	VBZ	_	22	advcl	_	_
11	some	some	DT	_	13	det	_	_
12	anti-proliferative	anti-proliferative	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	10	obj	_	_
14	,	,	,	_	22	p	_	_
15	the	the	DT	_	17	det	_	_
16	sequential	sequential	JJ	_	17	attr	_	_
17	administrations	administration	NNS	_	22	dep	_	_
18	of	of	IN	_	20	case	_	_
19	both	both	DT	_	20	det	_	_
20	drugs	drug	NNS	_	17	ppmod	_	_
21	remarkably	remarkably	RB	_	22	adv	_	_
22	enhanced	enhance	VBD	_	0	root	_	_
23	anti-tumor	anti-tumor	JJ	_	24	attr	_	_
24	activity	activity	NN	_	22	obj	_	_
25	.	.	.	_	22	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	cells	cell	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	exposed	expose	VBN	_	13	advcl	_	_
5	to	to	TO	_	6	aux	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	followed	followed	VBN	_	4	comp	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	13	p	_	_
11	synergism	synergism	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	The	the	DT	_	3	det	_	_
2	molecular	molecular	JJ	_	3	attr	_	_
3	basis	basis	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	synergism	synergism	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	that	that	IN	_	21	mark	_	_
9	the	the	DT	_	11	det	_	_
10	signaling	signaling	NN	_	11	com	_	_
11	pathways	pathway	NNS	_	21	dep	_	_
12	that	that	WDT	_	15	dep	_	_
13	were	be	VBD	_	15	aux	_	_
14	initially	initially	RB	_	15	adv	_	_
15	activated	activate	VBN	_	11	relcl	_	_
16	by	by	IN	_	18	case	_	_
17	drug1	drug0	NN	_	18	com	_	_
18	exposure	exposure	NN	_	15	ppmod	_	_
19	were	be	VBD	_	21	aux	_	_
20	efficiently	efficiently	RB	_	21	adv	_	_
21	suppressed	suppress	VBN	_	7	comp	_	_
22	by	by	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	subsequent	subsequent	JJ	_	25	attr	_	_
25	exposure	exposure	NN	_	21	ppmod	_	_
26	to	to	TO	_	27	aux	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	contrast	contrast	NN	_	10	ppmod	_	_
3	,	,	,	_	10	p	_	_
4	the	the	DT	_	5	det	_	_
5	reverse	reverse	NN	_	10	dep	_	_
6	of	of	IN	_	9	case	_	_
7	this	this	DT	_	9	det	_	_
8	sequential	sequential	JJ	_	9	attr	_	_
9	administration	administration	NN	_	5	ppmod	_	_
10	resulted	result	VBD	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	antagonism	antagonism	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	which	which	WDT	_	16	dep	_	_
15	may	may	MD	_	16	modal	_	_
16	be	be	VB	_	12	relcl	_	_
17	due	due	JJ	_	16	dep	_	_
18	to	to	TO	_	20	aux	_	_
19	differential	differential	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	17	ppmod	_	_
21	on	on	IN	_	24	case	_	_
22	cell	cell	NN	_	24	com	_	_
23	cycle	cycle	NN	_	24	com	_	_
24	arrest	arrest	NN	_	20	ppmod	_	_
25	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	as	as	IN	_	5	case	_	_
3	a	a	DT	_	5	det	_	_
4	single	single	JJ	_	5	attr	_	_
5	agent	agent	NN	_	1	ppmod	_	_
6	exhibits	exhibit	VBZ	_	0	root	_	_
7	anti-proliferative	anti-proliferative	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	6	obj	_	_
9	in	in	FW	_	10	adv	_	_
10	vitro	vitro	FW	_	6	adv	_	_
11	in	in	IN	_	14	case	_	_
12	NSCLC	nsclc	NN	_	14	com	_	_
13	cell	cell	NN	_	14	com	_	_
14	lines	line	NNS	_	6	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	EGFR	egfr	NN	_	17	com	_	_
17	T790M	t0m	NN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	K-ras	k-ras	NN	_	20	com	_	_
20	mutations	mutation	NNS	_	17	conj	_	_
21	but	but	CC	_	6	cc	_	_
22	the	the	DT	_	24	det	_	_
23	sequential	sequential	JJ	_	24	attr	_	_
24	administration	administration	NN	_	30	dep	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	followed	followed	VBN	_	26	acl	_	_
28	by	by	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	is	be	VBZ	_	6	conj	_	_
31	superior	superior	JJ	_	30	dep	_	_
32	to	to	TO	_	33	aux	_	_
33	drug4	drug0	NN	_	31	ppmod	_	_
34	followed	followed	VBN	_	33	acl	_	_
35	by	by	IN	_	36	case	_	_
36	drug5	drug0	NN	_	34	ppmod	_	_
37	and	and	CC	_	36	cc	_	_
38	concurrent	concurrent	JJ	_	39	attr	_	_
39	administration	administration	NN	_	36	conj	_	_
40	.	.	.	_	6	p	_	_

1	Determinants	determinant	NNS	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	sensitivity	sensitivity	NN	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	induced	induce	VBD	_	0	root	_	_
7	apoptosis	apoptosis	NN	_	6	obj	_	_
8	in	in	IN	_	11	case	_	_
9	multiple	multiple	JJ	_	11	attr	_	_
10	myeloma	myeloma	NN	_	11	com	_	_
11	cells	cell	NNS	_	6	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	drug1	drug0	NN	_	17	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug2	drug0	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	,	,	,	_	2	p	_	_
7	one	#crd#	CD	_	2	appo	_	_
8	of	of	IN	_	14	case	_	_
9	S-adenosylhomocysteine	s-adenosylhomocysteine	NN	_	14	attr	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	AdoHcy	adohcy	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	hydrolase	hydrolase	NN	_	14	com	_	_
14	inhibitors	inhibitor	NNS	_	7	ppmod	_	_
15	,	,	,	_	2	p	_	_
16	has	have	VBZ	_	17	aux	_	_
17	shown	show	VBN	_	0	root	_	_
18	antitumor	antitumor	JJ	_	19	attr	_	_
19	activities	activity	NNS	_	17	obj	_	_
20	in	in	IN	_	23	case	_	_
21	a	a	DT	_	23	det	_	_
22	broad	broad	JJ	_	23	attr	_	_
23	range	range	NN	_	17	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	solid	solid	JJ	_	26	attr	_	_
26	tumors	tumor	NNS	_	23	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	acute	acute	JJ	_	30	attr	_	_
29	myeloid	myeloid	JJ	_	30	attr	_	_
30	leukemia	leukemia	NN	_	26	conj	_	_
31	.	.	.	_	17	p	_	_

1	Here	here	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	examined	examine	VBD	_	0	root	_	_
5	its	its	PRP$	_	6	poss	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	on	on	IN	_	13	case	_	_
8	multiple	multiple	JJ	_	9	attr	_	_
9	myeloma	myeloma	NN	_	13	attr	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	MM	mm	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	cells	cell	NNS	_	6	ppmod	_	_
14	and	and	CC	_	4	cc	_	_
15	found	find	VBD	_	4	conj	_	_
16	that	that	IN	_	24	mark	_	_
17	,	,	,	_	24	p	_	_
18	at	at	IN	_	20	case	_	_
19	500	0	CD	_	20	num	_	_
20	nM	nm	NN	_	24	ppmod	_	_
21	,	,	,	_	24	p	_	_
22	it	it	PRP	_	24	dep	_	_
23	potently	potently	RB	_	24	adv	_	_
24	inhibited	inhibit	VBD	_	15	comp	_	_
25	growth	growth	NN	_	24	obj	_	_
26	and	and	CC	_	24	cc	_	_
27	induced	induce	VBD	_	24	conj	_	_
28	apoptosis	apoptosis	NN	_	27	obj	_	_
29	in	in	IN	_	35	case	_	_
30	2	0	CD	_	32	num	_	_
31	of	of	IN	_	32	case	_	_
32	8	0	CD	_	35	num	_	_
33	MM	mm	NN	_	35	com	_	_
34	cell	cell	NN	_	35	com	_	_
35	lines	line	NNS	_	28	ppmod	_	_
36	.	.	.	_	4	p	_	_

1	RNA	rna	NN	_	9	dep	_	_
2	from	from	IN	_	7	case	_	_
3	un-treated	un-treated	JJ	_	7	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	drug1	drug0	JJ	_	3	conj	_	_
6	treated	treated	JJ	_	7	attr	_	_
7	cells	cell	NNS	_	1	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	profiled	profile	VBN	_	0	root	_	_
10	by	by	IN	_	15	case	_	_
11	Affymetrix	affymetrix	NN	_	15	attr	_	_
12	HG-U133	hg-u0	NN	_	15	attr	_	_
13	Plus	plus	NN	_	15	attr	_	_
14	2.0	0	CD	_	15	num	_	_
15	microarray	microarray	NN	_	9	ppmod	_	_
16	and	and	CC	_	9	cc	_	_
17	genes	gene	NNS	_	26	dep	_	_
18	with	with	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	significant	significant	JJ	_	21	attr	_	_
21	change	change	NN	_	17	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	gene	gene	NN	_	24	com	_	_
24	expression	expression	NN	_	21	ppmod	_	_
25	were	be	VBD	_	26	aux	_	_
26	determined	determine	VBN	_	9	conj	_	_
27	by	by	IN	_	29	case	_	_
28	significance	significance	NN	_	29	com	_	_
29	analysis	analysis	NN	_	26	ppmod	_	_
30	of	of	IN	_	35	case	_	_
31	microarray	microarray	NN	_	35	attr	_	_
32	(	-lrb-	-LRB-	_	35	p	_	_
33	SAM	sam	NN	_	35	attr	_	_
34	)	-rrb-	-RRB-	_	35	p	_	_
35	testing	testing	NN	_	29	ppmod	_	_
36	.	.	.	_	9	p	_	_

1	ALOX5	alox0	NN	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	the	the	DT	_	6	det	_	_
4	most	most	RBS	_	5	adv	_	_
5	down-regulated	down-regulated	VBN	_	6	attr	_	_
6	gene	gene	NN	_	2	obj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	5.8-fold	0-fold	RB	_	2	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	in	in	IN	_	12	case	_	_
11	sensitive	sensitive	JJ	_	12	attr	_	_
12	cells	cell	NNS	_	2	ppmod	_	_
13	and	and	CC	_	2	cc	_	_
14	was	be	VBD	_	15	aux	_	_
15	expressed	express	VBN	_	2	conj	_	_
16	at	at	IN	_	18	case	_	_
17	low	low	JJ	_	18	attr	_	_
18	level	level	NN	_	15	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	resistant	resistant	JJ	_	21	attr	_	_
21	cells	cell	NNS	_	15	ppmod	_	_
22	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	corroborated	corroborate	VBN	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	quantitative	quantitative	JJ	_	7	attr	_	_
7	RT-PCR	rt-pcr	NN	_	4	ppmod	_	_
8	.	.	.	_	4	p	_	_

1	Western-blot	western-blot	JJ	_	2	attr	_	_
2	analysis	analysis	NN	_	7	dep	_	_
3	indicated	indicate	VBD	_	7	aux	_	_
4	ALOX5	alox0	NN	_	7	obj	_	_
5	was	be	VBD	_	7	aux	_	_
6	highly	highly	RB	_	7	adv	_	_
7	expressed	express	VBN	_	0	root	_	_
8	only	only	RB	_	7	adv	_	_
9	in	in	IN	_	12	case	_	_
10	sensitive	sensitive	JJ	_	12	attr	_	_
11	cell	cell	NN	_	12	com	_	_
12	line	line	NN	_	7	ppmod	_	_
13	H929	h0	CD	_	12	num	_	_
14	and	and	CC	_	7	cc	_	_
15	greatly	greatly	RB	_	16	adv	_	_
16	decreased	decrease	VBD	_	7	conj	_	_
17	upon	upon	IN	_	19	case	_	_
18	drug1	drug0	NN	_	19	com	_	_
19	treatment	treatment	NN	_	16	ppmod	_	_
20	.	.	.	_	7	p	_	_

1	Ectopic	ectopic	JJ	_	2	attr	_	_
2	expression	expression	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	ALOX5	alox0	NN	_	2	ppmod	_	_
5	reduced	reduce	VBD	_	0	root	_	_
6	sensitivity	sensitivity	NN	_	5	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	H929	h0	NN	_	11	com	_	_
11	cells	cell	NNS	_	5	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	Furthermore	furthermore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	down-regulation	down-regulation	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	ALOX5	alox0	NN	_	3	ppmod	_	_
6	by	by	IN	_	8	case	_	_
7	RNA	rna	NN	_	8	com	_	_
8	interference	interference	NN	_	3	ppmod	_	_
9	could	could	MD	_	11	modal	_	_
10	also	also	RB	_	11	adv	_	_
11	induce	induce	VB	_	0	root	_	_
12	apoptosis	apoptosis	NN	_	11	obj	_	_
13	in	in	IN	_	14	case	_	_
14	H929	h0	NN	_	11	ppmod	_	_
15	.	.	.	_	11	p	_	_

1	Gene	gene	NN	_	3	com	_	_
2	expression	expression	NN	_	3	com	_	_
3	analysis	analysis	NN	_	11	dep	_	_
4	on	on	IN	_	7	case	_	_
5	MM	mm	NN	_	7	com	_	_
6	patient	patient	NN	_	7	com	_	_
7	dataset	dataset	NN	_	3	ppmod	_	_
8	indicated	indicate	VBD	_	11	aux	_	_
9	ALOX5	alox0	NN	_	10	com	_	_
10	expression	expression	NN	_	11	obj	_	_
11	was	be	VBD	_	0	root	_	_
12	significantly	significantly	RB	_	13	adv	_	_
13	higher	high	JJR	_	11	dep	_	_
14	in	in	IN	_	16	case	_	_
15	MM	mm	NN	_	16	com	_	_
16	patients	patient	NNS	_	11	ppmod	_	_
17	compared	compare	VBN	_	21	adv	_	_
18	to	to	TO	_	21	aux	_	_
19	normal	normal	JJ	_	21	attr	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	cells	cell	NNS	_	11	ppmod	_	_
22	.	.	.	_	11	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	found	find	VBD	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	Bcl-2	bcl-0	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	overexpressed	overexpressed	VBN	_	3	comp	_	_
8	in	in	IN	_	11	case	_	_
9	drug1	drug0	NN	_	11	attr	_	_
10	insensitive	insensitive	JJ	_	11	attr	_	_
11	cells	cell	NNS	_	7	ppmod	_	_
12	,	,	,	_	7	p	_	_
13	and	and	CC	_	7	cc	_	_
14	cotreatment	cotreatment	NN	_	26	dep	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	16	p	_	_
20	a	a	DT	_	23	det	_	_
21	Bcl-2	bcl-0	NN	_	23	com	_	_
22	family	family	NN	_	23	com	_	_
23	inhibitor	inhibitor	NN	_	16	appo	_	_
24	,	,	,	_	16	p	_	_
25	synergistically	synergistically	RB	_	26	adv	_	_
26	inhibited	inhibit	VBD	_	7	conj	_	_
27	growth	growth	NN	_	26	obj	_	_
28	and	and	CC	_	26	cc	_	_
29	induced	induce	VBD	_	26	conj	_	_
30	apoptosis	apoptosis	NN	_	29	obj	_	_
31	of	of	IN	_	35	case	_	_
32	drug4	drug0	NN	_	35	attr	_	_
33	insensitive	insensitive	JJ	_	35	attr	_	_
34	MM	mm	NN	_	35	com	_	_
35	cells	cell	NNS	_	30	ppmod	_	_
36	.	.	.	_	3	p	_	_

1	Taken	take	VBN	_	6	advcl	_	_
2	together	together	RB	_	1	adv	_	_
3	,	,	,	_	6	p	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	6	dep	_	_
6	shows	show	VBZ	_	0	root	_	_
7	one	#crd#	CD	_	6	obj	_	_
8	of	of	IN	_	9	case	_	_
9	mechanisms	mechanism	NNS	_	7	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	efficacy	efficacy	NN	_	9	ppmod	_	_
14	on	on	IN	_	16	case	_	_
15	MM	mm	JJ	_	16	attr	_	_
16	correlates	correlate	NNS	_	6	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	its	its	PRP$	_	19	poss	_	_
19	ability	ability	NN	_	16	ppmod	_	_
20	to	to	TO	_	21	aux	_	_
21	down-regulate	down-regulate	VB	_	19	acl	_	_
22	the	the	DT	_	24	det	_	_
23	ALOX5	alox0	NN	_	24	com	_	_
24	levels	level	NNS	_	21	obj	_	_
25	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	insensitivity	insensitivity	NN	_	8	dep	_	_
6	might	might	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	overexpression	overexpression	NN	_	8	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	Bcl-2	bcl-0	NN	_	10	ppmod	_	_
13	,	,	,	_	8	p	_	_
14	and	and	CC	_	8	cc	_	_
15	the	the	DT	_	16	det	_	_
16	combination	combination	NN	_	23	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	could	could	MD	_	23	modal	_	_
22	synergistically	synergistically	RB	_	23	adv	_	_
23	induced	induce	VBD	_	8	conj	_	_
24	apoptosis	apoptosis	NN	_	23	obj	_	_
25	.	.	.	_	8	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	exploited	exploit	VBN	_	3	comp	_	_
9	therapeutically	therapeutically	RB	_	8	adv	_	_
10	for	for	IN	_	12	case	_	_
11	a	a	DT	_	12	det	_	_
12	subset	subset	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	MM	mm	NN	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	interaction	interaction	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	8	case	_	_
6	infant	infant	NN	_	8	com	_	_
7	colic	colic	NN	_	8	com	_	_
8	drops	drops	NN	_	2	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	Forest	forest	NNP	_	1	prn	_	_
4	Laboratories	laboratory	NNS	_	3	appo	_	_
5	UK	uk	NNP	_	9	attr	_	_
6	,	,	,	_	9	p	_	_
7	Kent	kent	NNP	_	9	attr	_	_
8	,	,	,	_	9	p	_	_
9	UK	uk	NNP	_	3	appo	_	_
10	)	-rrb-	-RRB-	_	3	p	_	_
11	is	be	VBZ	_	0	root	_	_
12	a	a	DT	_	16	det	_	_
13	widely	widely	RB	_	14	adv	_	_
14	available	available	JJ	_	16	attr	_	_
15	over-the-counter	over-the-counter	NN	_	16	com	_	_
16	preparation	preparation	NN	_	11	obj	_	_
17	used	use	VBN	_	16	acl	_	_
18	to	to	TO	_	19	aux	_	_
19	relieve	relieve	VBP	_	17	comp	_	_
20	colic	colic	NN	_	21	com	_	_
21	symptoms	symptom	NNS	_	19	obj	_	_
22	in	in	IN	_	23	case	_	_
23	neonates	neonate	NNS	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	infants	infant	NNS	_	23	conj	_	_
26	.	.	.	_	11	p	_	_

1	The	the	DT	_	3	det	_	_
2	active	active	JJ	_	3	attr	_	_
3	ingredient	ingredient	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	.	.	.	_	4	p	_	_

1	No	no	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	7	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	are	be	VBP	_	7	aux	_	_
7	documented	document	VBN	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	current	current	JJ	_	11	attr	_	_
11	summary	summary	NN	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	product	product	NN	_	14	com	_	_
14	characteristics	characteristic	NNS	_	11	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	authors	author	NNS	_	3	dep	_	_
3	report	report	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	case	case	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	an	an	DT	_	8	det	_	_
8	infant	infant	NN	_	5	ppmod	_	_
9	with	with	IN	_	12	case	_	_
10	confirmed	confirm	VBN	_	12	attr	_	_
11	congenital	congenital	JJ	_	12	attr	_	_
12	hypothyroidism	hypothyroidism	NN	_	8	ppmod	_	_
13	on	on	IN	_	14	case	_	_
14	drug1	drug0	NN	_	8	ppmod	_	_
15	who	who	WP	_	16	dep	_	_
16	experienced	experience	VBN	_	14	relcl	_	_
17	a	a	DT	_	20	det	_	_
18	possible	possible	JJ	_	20	attr	_	_
19	drug	drug	NN	_	20	com	_	_
20	interaction	interaction	NN	_	16	obj	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	Despite	despite	IN	_	4	case	_	_
2	adequate	adequate	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dosage	dosage	NN	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	thyroid	thyroid	NN	_	8	com	_	_
7	stimulating	stimulating	NN	_	8	com	_	_
8	hormone	hormone	NN	_	12	dep	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	TSH	tsh	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	was	be	VBD	_	0	root	_	_
13	high	high	JJ	_	12	dep	_	_
14	,	,	,	_	12	p	_	_
15	suggesting	suggest	VBG	_	12	comp	_	_
16	undertreatment	undertreatment	NN	_	15	obj	_	_
17	.	.	.	_	12	p	_	_

1	Questioning	questioning	NN	_	2	dep	_	_
2	revealed	reveal	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	child	child	NN	_	2	obj	_	_
5	was	be	VBD	_	4	acl	_	_
6	taking	take	VBG	_	8	adv	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	drops	drops	NN	_	5	ppmod	_	_
9	before	before	IN	_	10	mark	_	_
10	feeds	feed	VBZ	_	5	comp	_	_
11	while	while	IN	_	13	case	_	_
12	on	on	IN	_	13	case	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	colic	colic	NN	_	3	com	_	_
3	drops	drops	NN	_	6	dep	_	_
4	were	be	VBD	_	6	aux	_	_
5	immediately	immediately	RB	_	6	adv	_	_
6	discontinued	discontinue	VBN	_	0	root	_	_
7	and	and	CC	_	6	cc	_	_
8	TSH	tsh	NN	_	10	dep	_	_
9	promptly	promptly	RB	_	10	adv	_	_
10	normalised	normalise	VBD	_	6	conj	_	_
11	with	with	IN	_	13	case	_	_
12	a	a	DT	_	13	det	_	_
13	reduction	reduction	NN	_	10	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	thyroxine	thyroxine	NN	_	16	com	_	_
16	requirement	requirement	NN	_	13	ppmod	_	_
17	to	to	TO	_	21	aux	_	_
18	an	an	DT	_	21	det	_	_
19	age	age	NN	_	21	attr	_	_
20	appropriate	appropriate	JJ	_	21	attr	_	_
21	dosage	dosage	NN	_	13	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	interaction	interaction	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	has	have	VBZ	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	previously	previously	RB	_	10	adv	_	_
12	and	and	CC	_	10	cc	_	_
13	is	be	VBZ	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	listed	list	VBN	_	10	conj	_	_
16	in	in	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	British	british	NNP	_	20	com	_	_
19	National	national	NNP	_	20	com	_	_
20	Formulary	formulary	NN	_	15	ppmod	_	_
21	for	for	IN	_	22	case	_	_
22	Children	child	NNS	_	20	ppmod	_	_
23	.	.	.	_	10	p	_	_

1	Clinicians	clinician	NNS	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	parents	parent	NNS	_	1	conj	_	_
4	need	need	VBP	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	be	be	VB	_	4	comp	_	_
7	aware	aware	NN	_	6	obj	_	_
8	of	of	IN	_	10	case	_	_
9	this	this	DT	_	10	det	_	_
10	interaction	interaction	NN	_	7	ppmod	_	_
11	to	to	TO	_	12	aux	_	_
12	avoid	avoid	VB	_	7	acl	_	_
13	unnecessary	unnecessary	JJ	_	14	attr	_	_
14	undertreatment	undertreatment	NN	_	12	obj	_	_
15	and	and	CC	_	12	cc	_	_
16	prevent	prevent	VB	_	12	conj	_	_
17	potential	potential	JJ	_	20	attr	_	_
18	long-term	long-term	JJ	_	20	attr	_	_
19	neurological	neurological	JJ	_	20	attr	_	_
20	sequelae	sequelae	NN	_	16	obj	_	_
21	.	.	.	_	4	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	locomotor	locomotor	NN	_	3	com	_	_
3	sensitization	sensitization	NN	_	15	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	conditioned	conditioned	JJ	_	7	attr	_	_
6	place	place	NN	_	7	com	_	_
7	preference	preference	NN	_	3	conj	_	_
8	in	in	IN	_	13	case	_	_
9	adolescent	adolescent	JJ	_	13	attr	_	_
10	male	male	JJ	_	13	attr	_	_
11	and	and	CC	_	10	cc	_	_
12	female	female	JJ	_	10	conj	_	_
13	rats	rat	NNS	_	3	ppmod	_	_
14	neonatally	neonatally	RB	_	15	adv	_	_
15	treated	treat	VBN	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	15	p	_	_

1	Neonatal	neonatal	JJ	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	treatment	treatment	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	shown	show	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	produce	produce	VB	_	6	comp	_	_
9	an	an	DT	_	10	det	_	_
10	increase	increase	NN	_	8	obj	_	_
11	in	in	IN	_	15	case	_	_
12	dopamine	dopamine	NN	_	14	attr	_	_
13	D2-like	d0-like	JJ	_	14	attr	_	_
14	receptor	receptor	NN	_	15	com	_	_
15	sensitivity	sensitivity	NN	_	10	ppmod	_	_
16	that	that	WDT	_	17	dep	_	_
17	persists	persist	VBZ	_	10	relcl	_	_
18	throughout	throughout	IN	_	22	case	_	_
19	the	the	DT	_	20	det	_	_
20	subject	subject	NN	_	22	poss	_	_
21	's	's	POS	_	20	case	_	_
22	lifetime	lifetime	NN	_	17	ppmod	_	_
23	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	objective	objective	NN	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	analyze	analyze	VB	_	3	comp	_	_
6	the	the	DT	_	7	det	_	_
7	effects	effect	NNS	_	5	obj	_	_
8	of	of	IN	_	11	case	_	_
9	neonatal	neonatal	JJ	_	11	attr	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	treatment	treatment	NN	_	7	ppmod	_	_
12	on	on	IN	_	13	case	_	_
13	effects	effect	NNS	_	7	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	adolescent	adolescent	JJ	_	18	attr	_	_
18	rats	rat	NNS	_	13	ppmod	_	_
19	using	use	VBG	_	18	acl	_	_
20	locomotor	locomotor	NN	_	21	com	_	_
21	sensitization	sensitization	NN	_	26	attr	_	_
22	and	and	CC	_	21	cc	_	_
23	conditioned	conditioned	JJ	_	25	attr	_	_
24	place	place	NN	_	25	com	_	_
25	preference	preference	NN	_	21	conj	_	_
26	procedures	procedure	NNS	_	19	obj	_	_
27	.	.	.	_	3	p	_	_

1	Sprague-Dawley	sprague-dawley	NN	_	2	com	_	_
2	rats	rat	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	treated	treat	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	1	0	CD	_	9	num	_	_
9	mg/kg	mg/kg	NN	_	6	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	or	or	CC	_	6	cc	_	_
12	saline	saline	NN	_	6	conj	_	_
13	from	from	IN	_	15	case	_	_
14	postnatal	postnatal	JJ	_	15	attr	_	_
15	days	day	NNS	_	4	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	P	p	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	1	0	CD	_	15	num	_	_
20	to	to	TO	_	19	cc	_	_
21	P11	p0	CD	_	19	conj	_	_
22	and	and	CC	_	4	cc	_	_
23	raised	raise	VBN	_	4	conj	_	_
24	to	to	TO	_	25	aux	_	_
25	adolescence	adolescence	NN	_	23	ppmod	_	_
26	.	.	.	_	4	p	_	_

1	For	for	IN	_	3	case	_	_
2	locomotor	locomotor	NN	_	3	com	_	_
3	sensitization	sensitization	NN	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	subjects	subject	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	given	give	VBN	_	0	root	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	1	0	CD	_	11	num	_	_
11	mg/kg	mg/kg	NN	_	8	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	or	or	CC	_	8	cc	_	_
14	saline	saline	NN	_	17	attr	_	_
15	every	every	DT	_	17	det	_	_
16	second	#ord#	JJ	_	17	attr	_	_
17	day	day	NN	_	8	conj	_	_
18	from	from	IN	_	19	case	_	_
19	P35	p0	NN	_	7	ppmod	_	_
20	to	to	TO	_	21	aux	_	_
21	P47	p0	NN	_	7	ppmod	_	_
22	and	and	CC	_	7	cc	_	_
23	were	be	VBD	_	24	aux	_	_
24	placed	place	VBN	_	7	conj	_	_
25	into	into	IN	_	28	case	_	_
26	a	a	DT	_	28	det	_	_
27	locomotor	locomotor	JJ	_	28	attr	_	_
28	arena	arena	NN	_	24	ppmod	_	_
29	.	.	.	_	7	p	_	_

1	In	in	IN	_	3	case	_	_
2	female	female	JJ	_	3	attr	_	_
3	rats	rat	NNS	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	neonatal	neonatal	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	treatment	treatment	NN	_	8	dep	_	_
8	enhanced	enhance	VBD	_	0	root	_	_
9	drug2	drug0	NN	_	11	com	_	_
10	locomotor	locomotor	NN	_	11	com	_	_
11	sensitization	sensitization	NN	_	8	obj	_	_
12	compared	compare	VBN	_	16	adv	_	_
13	with	with	IN	_	16	case	_	_
14	drug3	drug0	CD	_	16	num	_	_
15	-free	-free	JJ	_	16	attr	_	_
16	controls	control	NNS	_	8	ppmod	_	_
17	sensitized	sensitize	VBN	_	16	acl	_	_
18	to	to	TO	_	19	aux	_	_
19	drug4	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	8	p	_	_

1	Male	male	JJ	_	2	attr	_	_
2	rats	rat	NNS	_	3	dep	_	_
3	demonstrated	demonstrate	VBD	_	0	root	_	_
4	sensitization	sensitization	NN	_	3	obj	_	_
5	to	to	TO	_	6	aux	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	although	although	IN	_	11	mark	_	_
9	this	this	DT	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	muted	mute	VBN	_	3	comp	_	_
12	compared	compare	VBN	_	15	adv	_	_
13	with	with	IN	_	15	case	_	_
14	female	female	JJ	_	15	attr	_	_
15	rats	rat	NNS	_	11	ppmod	_	_
16	,	,	,	_	11	p	_	_
17	and	and	CC	_	11	cc	_	_
18	were	be	VBD	_	19	aux	_	_
19	unaffected	unaffected	VBN	_	11	conj	_	_
20	by	by	IN	_	22	case	_	_
21	neonatal	neonatal	JJ	_	22	attr	_	_
22	drug2	drug0	NN	_	19	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	For	for	IN	_	4	case	_	_
2	conditioned	conditioned	JJ	_	4	attr	_	_
3	place	place	NN	_	4	com	_	_
4	preference	preference	NN	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	subjects	subject	NNS	_	8	dep	_	_
7	were	be	VBD	_	8	aux	_	_
8	conditioned	condition	VBN	_	0	root	_	_
9	for	for	IN	_	12	case	_	_
10	8	0	CD	_	12	num	_	_
11	consecutive	consecutive	JJ	_	12	attr	_	_
12	days	day	NNS	_	8	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	P32-39	p0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	with	with	IN	_	17	case	_	_
17	drug1	drug0	NN	_	12	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	1	0	CD	_	20	num	_	_
20	mg/kg	mg/kg	NN	_	17	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	or	or	CC	_	17	cc	_	_
23	saline	saline	NN	_	17	conj	_	_
24	and	and	CC	_	8	cc	_	_
25	a	a	DT	_	28	det	_	_
26	drug-free	drug-free	JJ	_	28	attr	_	_
27	preference	preference	NN	_	28	com	_	_
28	test	test	NN	_	30	dep	_	_
29	was	be	VBD	_	30	aux	_	_
30	conducted	conduct	VBN	_	8	conj	_	_
31	at	at	IN	_	32	case	_	_
32	P40	p0	NN	_	30	ppmod	_	_
33	.	.	.	_	8	p	_	_

1	Rats	rat	NNS	_	30	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	with	with	IN	_	8	case	_	_
4	neonatal	neonatal	JJ	_	8	attr	_	_
5	drug1	drug0	JJ	_	8	attr	_	_
6	enhanced	enhance	VBN	_	8	attr	_	_
7	time	time	NN	_	8	com	_	_
8	spent	spent	NN	_	2	ppmod	_	_
9	in	in	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	drug2	drug0	JJ	_	13	attr	_	_
12	-paired	-paired	JJ	_	13	attr	_	_
13	context	context	NN	_	8	ppmod	_	_
14	compared	compare	VBN	_	18	adv	_	_
15	with	with	IN	_	18	case	_	_
16	drug3	drug0	CD	_	18	num	_	_
17	-free	-free	JJ	_	18	attr	_	_
18	controls	control	NNS	_	2	ppmod	_	_
19	conditioned	condition	VBN	_	18	acl	_	_
20	with	with	IN	_	21	case	_	_
21	drug4	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	1	p	_	_
23	but	but	CC	_	1	cc	_	_
24	only	only	RB	_	23	com	_	_
25	female	female	JJ	_	26	attr	_	_
26	controls	control	NNS	_	1	conj	_	_
27	conditioned	condition	VBN	_	1	acl	_	_
28	with	with	IN	_	29	case	_	_
29	drug5	drug0	NN	_	27	ppmod	_	_
30	spent	spend	VBP	_	0	root	_	_
31	more	more	JJR	_	32	attr	_	_
32	time	time	NN	_	30	obj	_	_
33	in	in	IN	_	36	case	_	_
34	the	the	DT	_	36	det	_	_
35	drug-paired	drug-paired	JJ	_	36	attr	_	_
36	context	context	NN	_	30	ppmod	_	_
37	compared	compare	VBN	_	40	adv	_	_
38	with	with	IN	_	40	case	_	_
39	saline-treated	saline-treated	JJ	_	40	attr	_	_
40	controls	control	NNS	_	30	ppmod	_	_
41	.	.	.	_	30	p	_	_

1	Increased	increase	VBN	_	5	attr	_	_
2	D	d	NN	_	4	attr	_	_
3	-like	-like	JJ	_	4	attr	_	_
4	receptor	receptor	NN	_	5	com	_	_
5	sensitivity	sensitivity	NN	_	6	dep	_	_
6	appears	appear	VBZ	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	have	have	VB	_	9	aux	_	_
9	enhanced	enhance	VBD	_	6	comp	_	_
10	the	the	DT	_	12	det	_	_
11	behavioral	behavioral	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	6	p	_	_
16	but	but	CC	_	6	cc	_	_
17	these	these	DT	_	18	det	_	_
18	effects	effect	NNS	_	19	dep	_	_
19	were	be	VBD	_	6	conj	_	_
20	more	more	RBR	_	21	adv	_	_
21	prevalent	prevalent	JJ	_	19	dep	_	_
22	in	in	IN	_	25	case	_	_
23	adolescent	adolescent	JJ	_	25	attr	_	_
24	female	female	JJ	_	25	attr	_	_
25	rats	rat	NNS	_	19	ppmod	_	_
26	compared	compare	VBN	_	29	adv	_	_
27	with	with	IN	_	29	case	_	_
28	male	male	JJ	_	29	attr	_	_
29	rats	rat	NNS	_	19	ppmod	_	_
30	.	.	.	_	6	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	6	case	_	_
3	drug1	drug0	NN	_	6	attr	_	_
4	-mediated	-mediated	JJ	_	6	attr	_	_
5	CYP3A4	cyp0a0	NN	_	6	com	_	_
6	inhibition	inhibition	NN	_	1	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	1	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug3	drug0	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	,	,	,	_	11	p	_	_
16	an	an	DT	_	19	det	_	_
17	orally	orally	RB	_	18	adv	_	_
18	active	active	JJ	_	19	attr	_	_
19	drug4	drug0	NN	_	11	appo	_	_
20	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	partly	partly	RB	_	4	adv	_	_
4	metabolized	metabolize	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	CYP3A4	cyp0a0	NN	_	4	ppmod	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	4	adv	_	_
9	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	evaluated	evaluate	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	of	of	IN	_	10	case	_	_
7	a	a	DT	_	10	det	_	_
8	potent	potent	JJ	_	10	attr	_	_
9	CYP3A	cyp0a	NN	_	10	com	_	_
10	inhibitor	inhibitor	NN	_	5	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug1	drug0	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	on	on	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	pharmacokinetics	pharmacokinetics	NNS	_	5	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	safety	safety	NN	_	16	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	16	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	Patients	patient	NNS	_	2	dep	_	_
2	received	receive	VBD	_	0	root	_	_
3	a	a	DT	_	7	det	_	_
4	single	single	JJ	_	7	attr	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	dose	dose	NN	_	2	obj	_	_
8	on	on	IN	_	9	case	_	_
9	day	day	NN	_	7	ppmod	_	_
10	1	0	CD	_	9	num	_	_
11	,	,	,	_	7	p	_	_
12	followed	followed	VBN	_	7	acl	_	_
13	by	by	IN	_	17	case	_	_
14	4	0	CD	_	17	num	_	_
15	days	day	NNS	_	17	com	_	_
16	wash-out	wash-out	NN	_	17	com	_	_
17	period	period	NN	_	12	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	On	on	IN	_	2	case	_	_
2	days	day	NNS	_	7	ppmod	_	_
3	5-9	0	CD	_	2	num	_	_
4	,	,	,	_	7	p	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	administered	administer	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	On	on	IN	_	2	case	_	_
2	day	day	NN	_	10	ppmod	_	_
3	8	0	CD	_	2	num	_	_
4	,	,	,	_	10	p	_	_
5	a	a	DT	_	8	det	_	_
6	single	single	JJ	_	8	attr	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	dose	dose	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	co-administered	co-administered	VBN	_	0	root	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	administered	administer	VBN	_	0	root	_	_
4	as	as	IN	_	6	case	_	_
5	single	single	JJ	_	6	attr	_	_
6	agent	agent	NN	_	3	ppmod	_	_
7	three	#crd#	CD	_	8	num	_	_
8	times	time	NNS	_	6	appo	_	_
9	a	a	DT	_	10	det	_	_
10	week	week	NN	_	8	appo	_	_
11	on	on	IN	_	12	case	_	_
12	day	day	NN	_	10	ppmod	_	_
13	15	0	CD	_	12	num	_	_
14	and	and	CC	_	12	cc	_	_
15	onward	onward	CD	_	12	conj	_	_
16	.	.	.	_	3	p	_	_

1	In	in	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	presence	presence	NN	_	5	advnp	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	8	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	there	there	EX	_	8	dep	_	_
8	was	be	VBD	_	0	root	_	_
9	1.6-	0-	NN	_	8	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	1.8-fold	0-fold	JJ	_	12	attr	_	_
12	increase	increase	NN	_	9	conj	_	_
13	in	in	IN	_	14	case	_	_
14	C	c	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	max	max	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	and	and	CC	_	14	cc	_	_
19	AUC	auc	NN	_	14	conj	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	12	p	_	_
23	respectively	respectively	RB	_	9	conj	_	_
24	.	.	.	_	8	p	_	_

1	No	no	DT	_	3	det	_	_
2	substantial	substantial	JJ	_	3	attr	_	_
3	change	change	NN	_	12	dep	_	_
4	in	in	IN	_	5	case	_	_
5	T	t	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	max	max	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	or	or	CC	_	5	cc	_	_
10	half-life	half-life	NN	_	5	conj	_	_
11	was	be	VBD	_	12	aux	_	_
12	observed	observe	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	No	no	DT	_	2	det	_	_
2	difference	difference	NN	_	22	dep	_	_
3	in	in	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	-pharmacokinetics	-pharmacokinetics	NNS	_	2	ppmod	_	_
6	between	between	IN	_	7	case	_	_
7	patients	patient	NNS	_	2	ppmod	_	_
8	carrying	carry	VBG	_	7	acl	_	_
9	CYP3A5	cyp0a0	NN	_	12	com	_	_
10	*	*	NN	_	12	com	_	_
11	1/	0/	NN	_	12	com	_	_
12	*	*	NN	_	20	attr	_	_
13	3	0	CD	_	12	num	_	_
14	and	and	CC	_	12	cc	_	_
15	CYP3A5	cyp0a0	NN	_	18	com	_	_
16	*	*	NN	_	18	com	_	_
17	3/	0/	NN	_	18	com	_	_
18	*	*	NN	_	12	conj	_	_
19	3	0	CD	_	18	num	_	_
20	alleles	allele	NNS	_	8	obj	_	_
21	was	be	VBD	_	22	aux	_	_
22	observed	observe	VBN	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	Most	most	RBS	_	2	com	_	_
2	frequently	frequently	RB	_	3	adv	_	_
3	reported	report	VBN	_	5	attr	_	_
4	adverse	adverse	JJ	_	5	attr	_	_
5	events	event	NNS	_	6	dep	_	_
6	were	be	VBD	_	0	root	_	_
7	gastrointestinal	gastrointestinal	JJ	_	8	adv	_	_
8	related	related	JJ	_	6	dep	_	_
9	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	asymptomatic	asymptomatic	JJ	_	4	attr	_	_
4	hypophosphatemia	hypophosphatemia	NN	_	2	obj	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	64	0	CD	_	4	num	_	_
7	%	%	NN	_	6	meta	_	_
8	)	-rrb-	-RRB-	_	6	p	_	_
9	,	,	,	_	2	p	_	_
10	and	and	CC	_	2	cc	_	_
11	urine	urine	NN	_	12	com	_	_
12	analysis	analysis	NN	_	13	dep	_	_
13	suggested	suggest	VBD	_	2	conj	_	_
14	renal	renal	JJ	_	16	attr	_	_
15	phosphate	phosphate	NN	_	16	com	_	_
16	wasting	wasting	NN	_	13	obj	_	_
17	.	.	.	_	2	p	_	_

1	Co-administration	co-administration	NN	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	CYP3A	cyp0a	NN	_	6	com	_	_
6	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	feasible	feasible	JJ	_	7	dep	_	_
9	as	as	IN	_	19	mark	_	_
10	the	the	DT	_	12	det	_	_
11	observed	observe	VBN	_	12	attr	_	_
12	increase	increase	NN	_	19	dep	_	_
13	in	in	IN	_	16	case	_	_
14	drug2	drug0	NN	_	16	com	_	_
15	PK	pk	NN	_	16	com	_	_
16	parameters	parameter	NNS	_	12	ppmod	_	_
17	was	be	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	considered	consider	VBD	_	7	comp	_	_
20	clinically	clinically	RB	_	21	adv	_	_
21	relevant	relevant	JJ	_	19	dep	_	_
22	.	.	.	_	7	p	_	_

1	Considering	consider	VBG	_	31	advcl	_	_
2	the	the	DT	_	3	det	_	_
3	variability	variability	NN	_	1	obj	_	_
4	in	in	IN	_	5	case	_	_
5	exposure	exposure	NN	_	3	ppmod	_	_
6	following	follow	VBG	_	8	adv	_	_
7	enzyme	enzyme	NN	_	8	com	_	_
8	inhibition	inhibition	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	the	the	DT	_	11	det	_	_
11	fact	fact	NN	_	8	conj	_	_
12	that	that	IN	_	19	mark	_	_
13	chronic	chronic	JJ	_	14	attr	_	_
14	dosing	dosing	NN	_	19	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	was	be	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	studied	study	VBN	_	11	acl	_	_
20	with	with	IN	_	22	case	_	_
21	CYP3A	cyp0a	NN	_	22	com	_	_
22	inhibitors	inhibitor	NNS	_	19	ppmod	_	_
23	,	,	,	_	31	p	_	_
24	close	close	JJ	_	25	attr	_	_
25	monitoring	monitoring	NN	_	31	dep	_	_
26	of	of	IN	_	30	case	_	_
27	drug2	drug0	NN	_	28	advnp	_	_
28	-related	-related	JJ	_	30	attr	_	_
29	adverse	adverse	JJ	_	30	attr	_	_
30	events	event	NNS	_	25	ppmod	_	_
31	is	be	VBZ	_	0	root	_	_
32	necessary	necessary	JJ	_	31	dep	_	_
33	.	.	.	_	31	p	_	_

1	Effects	effect	NNS	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	CYP	cyp	NN	_	4	com	_	_
4	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	metabolism	metabolism	NN	_	1	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	toxicity	toxicity	NN	_	7	conj	_	_
10	in	in	IN	_	13	case	_	_
11	rat	rat	NN	_	13	com	_	_
12	liver	liver	NN	_	13	com	_	_
13	slices	slice	NNS	_	7	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	present	present	VBP	_	0	root	_	_
3	a	a	DT	_	7	det	_	_
4	comprehensive	comprehensive	JJ	_	7	attr	_	_
5	in	in	FW	_	6	adv	_	_
6	vitro	vitro	FW	_	7	attr	_	_
7	approach	approach	NN	_	2	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	assessing	assess	VBG	_	7	ppmod	_	_
10	metabolism-mediated	metabolism-mediated	JJ	_	11	attr	_	_
11	hepatotoxicity	hepatotoxicity	NN	_	9	obj	_	_
12	using	use	VBG	_	11	acl	_	_
13	male	male	JJ	_	17	attr	_	_
14	Sprague-Dawley	sprague-dawley	NN	_	17	com	_	_
15	rat	rat	NN	_	17	com	_	_
16	liver	liver	NN	_	17	com	_	_
17	slices	slice	NNS	_	12	obj	_	_
18	incubated	incubate	VBN	_	17	acl	_	_
19	with	with	IN	_	23	case	_	_
20	the	the	DT	_	23	det	_	_
21	well	well	RB	_	22	adv	_	_
22	characterized	characterize	VBN	_	23	attr	_	_
23	hepatotoxicant	hepatotoxicant	NN	_	18	ppmod	_	_
24	,	,	,	_	23	p	_	_
25	drug1	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	inhibitors	inhibitor	NNS	_	23	conj	_	_
29	of	of	IN	_	35	case	_	_
30	cytochrome	cytochrome	NN	_	31	com	_	_
31	P450	p0	NN	_	35	attr	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	CYP	cyp	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	enzymes	enzyme	NNS	_	28	ppmod	_	_
36	.	.	.	_	2	p	_	_

1	This	this	DT	_	2	det	_	_
2	approach	approach	NN	_	3	dep	_	_
3	combines	combine	VBZ	_	0	root	_	_
4	liquid	liquid	JJ	_	7	attr	_	_
5	chromatography	chromatography	NN	_	7	com	_	_
6	mass	mass	NN	_	7	com	_	_
7	spectrometry	spectrometry	NN	_	13	attr	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	LC	lc	CD	_	10	num	_	_
10	MS	ms	NN	_	7	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	detection	detection	NN	_	13	com	_	_
13	methods	method	NNS	_	3	obj	_	_
14	with	with	IN	_	17	case	_	_
15	multiple	multiple	JJ	_	17	attr	_	_
16	toxicity	toxicity	NN	_	17	com	_	_
17	endpoints	endpoint	NNS	_	3	ppmod	_	_
18	to	to	TO	_	19	aux	_	_
19	enable	enable	VB	_	3	comp	_	_
20	identification	identification	NN	_	19	obj	_	_
21	of	of	IN	_	24	case	_	_
22	critical	critical	JJ	_	24	attr	_	_
23	metabolic	metabolic	JJ	_	24	attr	_	_
24	pathways	pathway	NNS	_	20	ppmod	_	_
25	for	for	IN	_	26	case	_	_
26	hepatotoxicity	hepatotoxicity	NN	_	24	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	incubations	incubation	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	performed	performed	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	absence	absence	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	presence	presence	NN	_	7	conj	_	_
10	of	of	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	non-specific	non-specific	JJ	_	14	attr	_	_
13	CYP	cyp	NN	_	14	com	_	_
14	inhibitor	inhibitor	NN	_	7	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug1	drug0	NN	_	14	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug2	drug0	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	and	and	CC	_	16	cc	_	_
21	isoform-specific	isoform-specific	JJ	_	22	attr	_	_
22	inhibitors	inhibitor	NNS	_	14	conj	_	_
23	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	metabolite	metabolite	NN	_	3	com	_	_
3	profile	profile	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	9	case	_	_
7	rat	rat	NN	_	9	com	_	_
8	liver	liver	NN	_	9	com	_	_
9	slices	slice	NNS	_	3	ppmod	_	_
10	shares	share	VBZ	_	0	root	_	_
11	some	some	DT	_	12	det	_	_
12	features	feature	NNS	_	10	obj	_	_
13	of	of	IN	_	17	case	_	_
14	the	the	DT	_	17	det	_	_
15	in	in	FW	_	16	adv	_	_
16	vivo	vivo	FW	_	17	attr	_	_
17	profile	profile	NN	_	12	ppmod	_	_
18	,	,	,	_	10	p	_	_
19	but	but	CC	_	10	cc	_	_
20	also	also	RB	_	24	adv	_	_
21	had	have	VBD	_	24	lv	_	_
22	a	a	DT	_	24	det	_	_
23	major	major	JJ	_	24	attr	_	_
24	difference	difference	NN	_	10	conj	_	_
25	in	in	IN	_	26	case	_	_
26	that	that	WDT	_	33	ppmod	_	_
27	epoxide	epoxide	NN	_	30	com	_	_
28	dihydrodiol	dihydrodiol	NN	_	30	com	_	_
29	hydrolysis	hydrolysis	NN	_	30	com	_	_
30	products	product	NNS	_	33	dep	_	_
31	were	be	VBD	_	33	aux	_	_
32	not	not	RB	_	33	neg	_	_
33	observed	observe	VBN	_	24	relcl	_	_
34	to	to	TO	_	37	aux	_	_
35	a	a	DT	_	37	det	_	_
36	measurable	measurable	JJ	_	37	attr	_	_
37	extent	extent	NN	_	33	ppmod	_	_
38	.	.	.	_	10	p	_	_

1	As	as	IN	_	2	case	_	_
2	examples	example	NNS	_	25	ppmod	_	_
3	of	of	IN	_	9	case	_	_
4	our	our	PRP$	_	9	poss	_	_
5	liver	liver	NN	_	9	com	_	_
6	slice	slice	NN	_	9	com	_	_
7	metabolite	metabolite	NN	_	9	com	_	_
8	identification	identification	NN	_	9	com	_	_
9	procedure	procedure	NN	_	2	ppmod	_	_
10	,	,	,	_	25	p	_	_
11	a	a	DT	_	14	det	_	_
12	minor	minor	JJ	_	14	attr	_	_
13	glutathione	glutathione	NN	_	14	com	_	_
14	adduct	adduct	NN	_	25	dep	_	_
15	and	and	CC	_	14	cc	_	_
16	previously	previously	RB	_	17	adv	_	_
17	unreported	unreported	VBN	_	21	attr	_	_
18	7-O-desmethyl	0-o-desmethyl	JJ	_	21	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	glucuronidated	glucuronidated	JJ	_	18	conj	_	_
21	metabolites	metabolite	NNS	_	14	conj	_	_
22	of	of	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	are	be	VBP	_	25	aux	_	_
25	reported	report	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	induced	induce	VBD	_	0	root	_	_
3	hepatocellular	hepatocellular	JJ	_	4	attr	_	_
4	necrosis	necrosis	NN	_	2	obj	_	_
5	in	in	IN	_	10	case	_	_
6	a	a	DT	_	10	det	_	_
7	dose-	dose-	NN	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	time-dependent	time-dependent	JJ	_	7	conj	_	_
10	manner	manner	NN	_	2	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreased	decrease	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	toxicity	toxicity	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	2	p	_	_
8	increased	increase	VBD	_	2	conj	_	_
9	exposure	exposure	NN	_	8	obj	_	_
10	to	to	TO	_	12	aux	_	_
11	parent	parent	NN	_	12	com	_	_
12	compound	compound	NN	_	9	ppmod	_	_
13	,	,	,	_	8	p	_	_
14	and	and	CC	_	8	cc	_	_
15	decreased	decrease	VBD	_	2	conj	_	_
16	metabolite	metabolite	NN	_	17	com	_	_
17	levels	level	NNS	_	15	obj	_	_
18	in	in	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	dose-dependent	dose-dependent	JJ	_	21	attr	_	_
21	manner	manner	NN	_	15	ppmod	_	_
22	.	.	.	_	2	p	_	_

1	Of	of	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	isoform-specific	isoform-specific	JJ	_	5	attr	_	_
4	CYP	cyp	NN	_	5	com	_	_
5	inhibitors	inhibitor	NNS	_	18	ppmod	_	_
6	tested	test	VBN	_	5	acl	_	_
7	for	for	IN	_	9	case	_	_
8	an	an	DT	_	9	det	_	_
9	effect	effect	NN	_	6	ppmod	_	_
10	on	on	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	drug1	drug0	NN	_	14	com	_	_
13	metabolite	metabolite	NN	_	14	com	_	_
14	profile	profile	NN	_	9	ppmod	_	_
15	,	,	,	_	18	p	_	_
16	only	only	RB	_	17	adv	_	_
17	drug2	drug0	NN	_	18	dep	_	_
18	was	be	VBD	_	0	root	_	_
19	noticeably	noticeably	RB	_	18	adv	_	_
20	effective	effective	JJ	_	18	dep	_	_
21	,	,	,	_	18	p	_	_
22	indicating	indicate	VBG	_	18	comp	_	_
23	a	a	DT	_	24	det	_	_
24	role	role	NN	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	CYPs	cyps	NNS	_	24	ppmod	_	_
27	2A6	0a0	NN	_	26	attr	_	_
28	,	,	,	_	27	p	_	_
29	2C9	0c0	NN	_	27	conj	_	_
30	,	,	,	_	29	p	_	_
31	2Cl9	0cl0	NN	_	27	conj	_	_
32	,	,	,	_	31	p	_	_
33	and	and	CC	_	31	cc	_	_
34	2E1	0e0	NN	_	27	conj	_	_
35	.	.	.	_	18	p	_	_

1	With	with	IN	_	4	case	_	_
2	respect	respect	NN	_	4	advnp	_	_
3	to	to	TO	_	4	aux	_	_
4	toxicity	toxicity	NN	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	the	the	DT	_	7	det	_	_
7	order	order	NN	_	12	dep	_	_
8	of	of	IN	_	11	case	_	_
9	CYP	cyp	NN	_	11	com	_	_
10	inhibitor	inhibitor	NN	_	11	com	_	_
11	effectiveness	effectiveness	NN	_	7	ppmod	_	_
12	was	be	VBD	_	0	root	_	_
13	drug1	drug0	NN	_	19	com	_	_
14	>	>	NN	_	19	com	_	_
15	drug2	drug0	NN	_	19	com	_	_
16	~	~	NN	_	19	com	_	_
17	drug3	drug0	NN	_	19	com	_	_
18	>	>	NN	_	19	com	_	_
19	drug4	drug0	NN	_	12	obj	_	_
20	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	had	have	VBD	_	0	root	_	_
5	no	no	DT	_	6	det	_	_
6	effect	effect	NN	_	4	obj	_	_
7	,	,	,	_	4	p	_	_
8	while	while	IN	_	10	mark	_	_
9	drug3	drug0	NN	_	10	dep	_	_
10	appeared	appear	VBD	_	4	comp	_	_
11	to	to	TO	_	12	aux	_	_
12	augment	augment	VB	_	10	comp	_	_
13	drug4	drug0	NN	_	14	com	_	_
14	toxicity	toxicity	NN	_	12	obj	_	_
15	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	rat	rat	NN	_	7	com	_	_
6	liver	liver	NN	_	7	com	_	_
7	slices	slice	NNS	_	10	dep	_	_
8	do	do	VBP	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	reproduce	reproduce	VB	_	3	comp	_	_
11	the	the	DT	_	15	det	_	_
12	reported	report	VBN	_	15	attr	_	_
13	in	in	FW	_	14	adv	_	_
14	vivo	vivo	FW	_	15	attr	_	_
15	biotransformation	biotransformation	NN	_	10	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	10	cc	_	_
19	therefore	therefore	RB	_	22	adv	_	_
20	may	may	MD	_	22	modal	_	_
21	not	not	RB	_	22	neg	_	_
22	be	be	VB	_	10	conj	_	_
23	an	an	DT	_	25	det	_	_
24	appropriate	appropriate	JJ	_	25	attr	_	_
25	model	model	NN	_	22	obj	_	_
26	for	for	IN	_	28	case	_	_
27	drug2	drug0	NN	_	28	com	_	_
28	metabolism	metabolism	NN	_	25	ppmod	_	_
29	.	.	.	_	3	p	_	_

1	However	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	these	these	DT	_	4	det	_	_
4	results	result	NNS	_	5	dep	_	_
5	provide	provide	VBP	_	0	root	_	_
6	an	an	DT	_	7	det	_	_
7	example	example	NN	_	5	obj	_	_
8	of	of	IN	_	23	case	_	_
9	how	how	WRB	_	23	adv	_	_
10	small	small	JJ	_	12	attr	_	_
11	molecule	molecule	NN	_	12	com	_	_
12	manipulation	manipulation	NN	_	23	dep	_	_
13	of	of	IN	_	15	case	_	_
14	CYP	cyp	NN	_	15	com	_	_
15	activity	activity	NN	_	12	ppmod	_	_
16	in	in	IN	_	20	case	_	_
17	an	an	DT	_	20	det	_	_
18	in	in	FW	_	19	adv	_	_
19	vitro	vitro	FW	_	20	attr	_	_
20	model	model	NN	_	12	ppmod	_	_
21	can	can	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	used	use	VBN	_	7	ppmod	_	_
24	to	to	TO	_	25	aux	_	_
25	confirm	confirm	VB	_	23	comp	_	_
26	metabolism-mediated	metabolism-mediated	JJ	_	27	attr	_	_
27	toxicity	toxicity	NN	_	25	obj	_	_
28	.	.	.	_	5	p	_	_

1	Glycosidic	glycosidic	JJ	_	2	attr	_	_
2	enzymes	enzyme	NNS	_	3	dep	_	_
3	enhance	enhance	VBP	_	0	root	_	_
4	retinal	retinal	NN	_	5	com	_	_
5	transduction	transduction	NN	_	3	obj	_	_
6	following	follow	VBG	_	8	adv	_	_
7	intravitreal	intravitreal	JJ	_	8	attr	_	_
8	delivery	delivery	NN	_	3	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	To	to	TO	_	2	aux	_	_
2	determine	determine	VB	_	0	root	_	_
3	whether	whether	IN	_	11	mark	_	_
4	the	the	DT	_	5	det	_	_
5	co-injection	co-injection	NN	_	11	dep	_	_
6	of	of	IN	_	10	case	_	_
7	extracellular	extracellular	JJ	_	10	attr	_	_
8	matrix	matrix	NN	_	10	com	_	_
9	degrading	degrading	NN	_	10	com	_	_
10	enzymes	enzyme	NNS	_	5	ppmod	_	_
11	improves	improve	VBZ	_	2	comp	_	_
12	retinal	retinal	NN	_	13	com	_	_
13	transduction	transduction	NN	_	11	obj	_	_
14	following	follow	VBG	_	16	adv	_	_
15	intravitreal	intravitreal	JJ	_	16	attr	_	_
16	delivery	delivery	NN	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug2	drug0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	23	dep	_	_
2	containing	contain	VBG	_	1	acl	_	_
3	cDNA	cdna	NN	_	2	obj	_	_
4	encoding	encode	VBG	_	3	acl	_	_
5	enhanced	enhance	VBN	_	8	attr	_	_
6	green	green	JJ	_	8	attr	_	_
7	fluorescent	fluorescent	JJ	_	8	attr	_	_
8	protein	protein	NN	_	4	obj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	GFP	gfp	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	,	,	,	_	4	p	_	_
13	under	under	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	control	control	NN	_	4	ppmod	_	_
16	of	of	IN	_	20	case	_	_
17	a	a	DT	_	20	det	_	_
18	chicken	chicken	NN	_	20	com	_	_
19	-actin	-actin	NN	_	20	com	_	_
20	promoter	promoter	NN	_	15	ppmod	_	_
21	,	,	,	_	4	p	_	_
22	was	be	VBD	_	23	aux	_	_
23	delivered	deliver	VBN	_	0	root	_	_
24	by	by	IN	_	26	case	_	_
25	intravitreal	intravitreal	JJ	_	26	attr	_	_
26	injection	injection	NN	_	23	ppmod	_	_
27	to	to	TO	_	29	aux	_	_
28	adult	adult	JJ	_	29	attr	_	_
29	mice	mouse	NNS	_	26	ppmod	_	_
30	in	in	IN	_	31	case	_	_
31	conjunction	conjunction	NN	_	26	ppmod	_	_
32	with	with	IN	_	33	case	_	_
33	enzymes	enzyme	NNS	_	31	ppmod	_	_
34	including	include	VBG	_	35	adv	_	_
35	drug2	drug0	NN	_	33	ppmod	_	_
36	,	,	,	_	35	p	_	_
37	drug3	drug0	NN	_	35	conj	_	_
38	,	,	,	_	37	p	_	_
39	drug4	drug0	NN	_	35	conj	_	_
40	,	,	,	_	39	p	_	_
41	or	or	CC	_	39	cc	_	_
42	drug5	drug0	NN	_	35	conj	_	_
43	.	.	.	_	23	p	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	weeks	week	NNS	_	3	advnp	_	_
3	later	later	RB	_	8	adv	_	_
4	,	,	,	_	8	p	_	_
5	retinal	retinal	JJ	_	6	attr	_	_
6	flatmounts	flatmounts	NNS	_	8	dep	_	_
7	were	be	VBD	_	8	aux	_	_
8	examined	examine	VBN	_	0	root	_	_
9	for	for	IN	_	11	case	_	_
10	GFP	gfp	NN	_	11	com	_	_
11	expression	expression	NN	_	8	ppmod	_	_
12	using	use	VBG	_	11	acl	_	_
13	confocal	confocal	JJ	_	14	attr	_	_
14	microscopy	microscopy	NN	_	12	obj	_	_
15	.	.	.	_	8	p	_	_

1	Without	without	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	addition	addition	NN	_	9	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	enzymes	enzyme	NNS	_	3	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	transduction	transduction	NN	_	9	dep	_	_
8	was	be	VBD	_	9	aux	_	_
9	limited	limit	VBN	_	0	root	_	_
10	to	to	TO	_	12	aux	_	_
11	occasional	occasional	JJ	_	12	attr	_	_
12	cells	cell	NNS	_	9	ppmod	_	_
13	in	in	IN	_	18	case	_	_
14	the	the	DT	_	18	det	_	_
15	retinal	retinal	JJ	_	18	attr	_	_
16	ganglion	ganglion	NN	_	18	com	_	_
17	cell	cell	NN	_	18	com	_	_
18	layer	layer	NN	_	12	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	addition	addition	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	greatly	greatly	RB	_	8	adv	_	_
8	enhanced	enhance	VBD	_	0	root	_	_
9	transduction	transduction	NN	_	8	obj	_	_
10	of	of	IN	_	15	case	_	_
11	the	the	DT	_	15	det	_	_
12	retinal	retinal	JJ	_	15	attr	_	_
13	ganglion	ganglion	NN	_	15	com	_	_
14	cell	cell	NN	_	15	com	_	_
15	layer	layer	NN	_	9	ppmod	_	_
16	and	and	CC	_	8	cc	_	_
17	increased	increase	VBD	_	8	conj	_	_
18	the	the	DT	_	19	det	_	_
19	depth	depth	NN	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	transduction	transduction	NN	_	19	ppmod	_	_
22	into	into	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	outer	outer	JJ	_	25	attr	_	_
25	retina	retina	NN	_	19	ppmod	_	_
26	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	limited	limited	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	and	and	CC	_	2	cc	_	_
7	drug2	drug0	NN	_	8	dep	_	_
8	was	be	VBD	_	2	conj	_	_
9	ineffective	ineffective	JJ	_	8	dep	_	_
10	.	.	.	_	2	p	_	_

1	Electroretinograms	electroretinogram	NNS	_	2	dep	_	_
2	survived	survive	VBD	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	higher	high	JJR	_	5	attr	_	_
5	concentrations	concentration	NNS	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	than	than	IN	_	12	mark	_	_
11	were	be	VBD	_	12	aux	_	_
12	required	require	VBN	_	2	comp	_	_
13	for	for	IN	_	16	case	_	_
14	optimal	optimal	JJ	_	16	attr	_	_
15	retinal	retinal	JJ	_	16	attr	_	_
16	transduction	transduction	NN	_	12	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	-mediated	-mediated	JJ	_	4	attr	_	_
3	retinal	retinal	NN	_	4	com	_	_
4	transduction	transduction	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	improved	improve	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	co-injection	co-injection	NN	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	.	.	.	_	6	p	_	_

1	Improved	improved	JJ	_	3	attr	_	_
2	transduction	transduction	NN	_	3	com	_	_
3	efficiency	efficiency	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	allow	allow	VB	_	0	root	_	_
6	intravitreal	intravitreal	JJ	_	7	attr	_	_
7	injection	injection	NN	_	5	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	become	become	VB	_	5	comp	_	_
10	the	the	DT	_	12	det	_	_
11	preferred	preferred	JJ	_	12	attr	_	_
12	route	route	NN	_	9	obj	_	_
13	for	for	IN	_	14	case	_	_
14	delivering	deliver	VBG	_	12	ppmod	_	_
15	gene	gene	NN	_	16	com	_	_
16	therapy	therapy	NN	_	14	obj	_	_
17	to	to	TO	_	23	aux	_	_
18	both	both	CC	_	23	cc	_	_
19	the	the	DT	_	23	det	_	_
20	inner	inner	JJ	_	23	attr	_	_
21	and	and	CC	_	20	cc	_	_
22	outer	outer	JJ	_	20	conj	_	_
23	retina	retina	NNS	_	14	ppmod	_	_
24	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	advnp	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	drug2	drug0	NN	_	5	advnp	_	_
4	)	-rrb-	-RRB-	_	5	p	_	_
5	--better	--better	JJ	_	0	root	_	_
6	than	than	IN	_	7	case	_	_
7	drug3	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug4	drug0	NN	_	5	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	FDA	fda	NN	_	3	dep	_	_
3	has	have	VBZ	_	0	root	_	_
4	approved	approved	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	-AstraZeneca	-astrazeneca	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	5	p	_	_
11	an	an	DT	_	13	det	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	drug3	drug0	NN	_	5	appo	_	_
14	,	,	,	_	5	p	_	_
15	for	for	IN	_	16	case	_	_
16	use	use	NN	_	3	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	low-dose	low-dose	JJ	_	19	attr	_	_
19	drug4	drug0	NN	_	16	ppmod	_	_
20	to	to	TO	_	21	aux	_	_
21	reduce	reduce	VB	_	16	acl	_	_
22	the	the	DT	_	23	det	_	_
23	rate	rate	NN	_	21	obj	_	_
24	of	of	IN	_	27	case	_	_
25	thrombotic	thrombotic	JJ	_	27	attr	_	_
26	cardiovascular	cardiovascular	JJ	_	27	attr	_	_
27	events	event	NNS	_	23	ppmod	_	_
28	in	in	IN	_	29	case	_	_
29	patients	patient	NNS	_	27	ppmod	_	_
30	with	with	IN	_	33	case	_	_
31	acute	acute	JJ	_	33	attr	_	_
32	coronary	coronary	JJ	_	33	attr	_	_
33	syndrome	syndrome	NN	_	29	ppmod	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	ACS	acs	NN	_	33	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	.	.	.	_	3	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	will	will	MD	_	3	modal	_	_
3	compete	compete	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug2	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	and	and	CC	_	5	cc	_	_
10	drug3	drug0	NN	_	5	conj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug4	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	for	for	IN	_	16	case	_	_
15	such	such	JJ	_	16	attr	_	_
16	use	use	NN	_	3	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	expected	expect	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	become	become	VB	_	3	comp	_	_
6	available	available	JJ	_	5	dep	_	_
7	generically	generically	RB	_	6	adv	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	US	us	PRP	_	5	ppmod	_	_
11	within	within	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	next	next	JJ	_	15	attr	_	_
14	few	few	JJ	_	15	attr	_	_
15	months	month	NNS	_	5	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	role	role	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	p27	p0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	Kip1	kip0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	in	in	IN	_	12	case	_	_
9	drug1	drug0	JJ	_	12	attr	_	_
10	-enhanced	-enhanced	JJ	_	12	attr	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	cytotoxicity	cytotoxicity	NN	_	2	ppmod	_	_
13	in	in	IN	_	17	case	_	_
14	human	human	JJ	_	17	attr	_	_
15	ovarian	ovarian	JJ	_	17	attr	_	_
16	cancer	cancer	NN	_	17	com	_	_
17	cells	cell	NNS	_	12	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	Less	less	JJR	_	3	attr	_	_
2	than	than	IN	_	1	com	_	_
3	50	0	CD	_	8	num	_	_
4	%	%	NN	_	3	meta	_	_
5	of	of	IN	_	7	case	_	_
6	ovarian	ovarian	JJ	_	7	attr	_	_
7	cancers	cancer	NNS	_	3	ppmod	_	_
8	respond	respond	VBP	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	Effective	effective	JJ	_	2	attr	_	_
2	strategies	strategy	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	needed	need	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	enhance	enhance	VB	_	4	comp	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	sensitivity	sensitivity	NN	_	6	obj	_	_
9	.	.	.	_	4	p	_	_

1	A	a	DT	_	2	det	_	_
2	library	library	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	silencing	silencing	JJ	_	5	attr	_	_
5	RNAs	rna	NNS	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	siRNAs	sirnas	NNS	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	was	be	VBD	_	10	aux	_	_
10	used	use	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	identify	identify	VB	_	10	comp	_	_
13	kinases	kinase	NNS	_	12	obj	_	_
14	that	that	WDT	_	15	dep	_	_
15	regulate	regulate	VBP	_	13	relcl	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	sensitivity	sensitivity	NN	_	15	obj	_	_
18	in	in	IN	_	23	case	_	_
19	human	human	JJ	_	23	attr	_	_
20	ovarian	ovarian	JJ	_	23	attr	_	_
21	cancer	cancer	NN	_	23	attr	_	_
22	SKOv3	skov0	JJ	_	23	attr	_	_
23	cells	cell	NNS	_	15	ppmod	_	_
24	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	18	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	an	an	DT	_	7	det	_	_
7	inhibitor	inhibitor	NN	_	4	appo	_	_
8	of	of	IN	_	9	case	_	_
9	Src	src	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	Abl	abl	NN	_	12	com	_	_
12	kinases	kinase	NNS	_	9	conj	_	_
13	,	,	,	_	4	p	_	_
14	on	on	IN	_	16	case	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	sensitivity	sensitivity	NN	_	2	ppmod	_	_
17	was	be	VBD	_	18	aux	_	_
18	measured	measure	VBN	_	0	root	_	_
19	in	in	IN	_	22	case	_	_
20	ovarian	ovarian	JJ	_	22	attr	_	_
21	cancer	cancer	NN	_	22	com	_	_
22	cells	cell	NNS	_	18	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	HEY	hey	NN	_	25	com	_	_
25	xenografts	xenograft	NNS	_	22	conj	_	_
26	.	.	.	_	18	p	_	_

1	The	the	DT	_	2	det	_	_
2	roles	role	NNS	_	21	dep	_	_
3	of	of	IN	_	4	case	_	_
4	p27	p0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	Kip1	kip0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	,	,	,	_	4	p	_	_
9	Bcl-2	bcl-0	NN	_	4	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	Cdk1	cdk0	NN	_	4	conj	_	_
13	in	in	IN	_	14	case	_	_
14	apoptosis	apoptosis	NN	_	2	ppmod	_	_
15	induced	induce	VBN	_	14	acl	_	_
16	by	by	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	were	be	VBD	_	21	aux	_	_
21	assessed	assess	VBN	_	0	root	_	_
22	using	use	VBG	_	21	comp	_	_
23	a	a	DT	_	29	det	_	_
24	terminal	terminal	JJ	_	29	attr	_	_
25	deoxynucleotidyl	deoxynucleotidyl	NN	_	29	attr	_	_
26	transferase-mediated	transferase-mediated	JJ	_	29	attr	_	_
27	dUTP	dutp	NN	_	29	com	_	_
28	nick-end	nick-end	NN	_	29	com	_	_
29	labeling	labeling	NN	_	33	attr	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	TUNEL	tunel	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	assay	assay	NN	_	22	obj	_	_
34	,	,	,	_	33	p	_	_
35	siRNA	sirna	NN	_	36	com	_	_
36	knockdown	knockdown	NN	_	33	conj	_	_
37	of	of	IN	_	39	case	_	_
38	gene	gene	NN	_	39	com	_	_
39	expression	expression	NN	_	36	ppmod	_	_
40	,	,	,	_	36	p	_	_
41	transfection	transfection	NN	_	33	conj	_	_
42	with	with	IN	_	43	case	_	_
43	Bcl-2	bcl-0	NN	_	41	ppmod	_	_
44	and	and	CC	_	43	cc	_	_
45	Cdk1	cdk0	NN	_	47	com	_	_
46	expression	expression	NN	_	47	com	_	_
47	vectors	vector	NNS	_	43	conj	_	_
48	,	,	,	_	41	p	_	_
49	and	and	CC	_	41	cc	_	_
50	flow	flow	NN	_	51	com	_	_
51	cytometry	cytometry	NN	_	33	conj	_	_
52	.	.	.	_	21	p	_	_

1	All	all	DT	_	3	det	_	_
2	statistical	statistical	JJ	_	3	attr	_	_
3	tests	test	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	two-sided	two-sided	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	Src	src	NN	_	2	com	_	_
2	family	family	NN	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	Abl	abl	NN	_	5	com	_	_
5	kinases	kinase	NNS	_	2	conj	_	_
6	were	be	VBD	_	7	aux	_	_
7	identified	identify	VBN	_	0	root	_	_
8	as	as	IN	_	9	case	_	_
9	modulators	modulator	NNS	_	7	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	sensitivity	sensitivity	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	SKOv3	skov0	JJ	_	15	attr	_	_
15	cells	cell	NNS	_	9	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	siRNA	sirna	NN	_	3	com	_	_
3	knockdown	knockdown	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	Src	src	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	Fyn	fyn	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	or	or	CC	_	7	cc	_	_
10	Abl1	abl0	NN	_	5	conj	_	_
11	enhanced	enhance	VBD	_	0	root	_	_
12	drug1	drug0	NN	_	13	advnp	_	_
13	-mediated	-mediated	JJ	_	15	attr	_	_
14	growth	growth	NN	_	15	com	_	_
15	inhibition	inhibition	NN	_	11	obj	_	_
16	in	in	IN	_	19	case	_	_
17	ovarian	ovarian	JJ	_	19	attr	_	_
18	cancer	cancer	NN	_	19	com	_	_
19	cells	cell	NNS	_	11	ppmod	_	_
20	compared	compare	VBN	_	24	adv	_	_
21	with	with	IN	_	24	case	_	_
22	a	a	DT	_	24	det	_	_
23	control	control	NN	_	24	com	_	_
24	siRNA	sirna	NN	_	11	ppmod	_	_
25	.	.	.	_	11	p	_	_

1	HEY	hey	NN	_	2	com	_	_
2	cells	cell	NNS	_	8	dep	_	_
3	treated	treat	VBN	_	2	acl	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	plus	plus	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	formed	form	VBD	_	0	root	_	_
9	fewer	few	JJR	_	10	attr	_	_
10	colonies	colony	NNS	_	8	obj	_	_
11	than	than	IN	_	12	mark	_	_
12	did	do	VBD	_	8	comp	_	_
13	cells	cell	NNS	_	12	obj	_	_
14	treated	treat	VBN	_	13	acl	_	_
15	with	with	IN	_	17	case	_	_
16	either	either	DT	_	17	det	_	_
17	agent	agent	NN	_	14	ppmod	_	_
18	alone	alone	RB	_	17	adv	_	_
19	.	.	.	_	8	p	_	_

1	Treatment	treatment	NN	_	10	dep	_	_
2	of	of	IN	_	5	case	_	_
3	HEY	hey	NN	_	5	attr	_	_
4	xenograft-bearing	xenograft-bearing	JJ	_	5	attr	_	_
5	mice	mouse	NNS	_	1	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	1	ppmod	_	_
8	plus	plus	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	inhibited	inhibit	VBD	_	0	root	_	_
11	tumor	tumor	NN	_	12	com	_	_
12	growth	growth	NN	_	10	obj	_	_
13	more	more	JJR	_	12	attr	_	_
14	than	than	IN	_	15	case	_	_
15	treatment	treatment	NN	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	either	either	DT	_	18	det	_	_
18	agent	agent	NN	_	15	ppmod	_	_
19	alone	alone	RB	_	18	adv	_	_
20	(	-lrb-	-LRB-	_	55	p	_	_
21	average	average	JJ	_	23	attr	_	_
22	tumor	tumor	NN	_	23	com	_	_
23	volume	volume	NN	_	55	dep	_	_
24	per	per	IN	_	25	case	_	_
25	mouse	mouse	NN	_	23	ppmod	_	_
26	,	,	,	_	25	p	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	+	+	CC	_	27	cc	_	_
29	drug4	drug0	NN	_	25	conj	_	_
30	vs	vs	CC	_	23	cc	_	_
31	drug5	drug0	NN	_	23	conj	_	_
32	:	:	:	_	47	p	_	_
33	0.28	0	CD	_	36	num	_	_
34	vs.	vs.	CC	_	36	cc	_	_
35	0.81	0	CD	_	36	num	_	_
36	cm3	cm0	NN	_	47	dep	_	_
37	,	,	,	_	36	p	_	_
38	difference	difference	NN	_	41	attr	_	_
39	=	=	JJ	_	41	attr	_	_
40	0.53	0	CD	_	41	num	_	_
41	cm3	cm0	NN	_	36	conj	_	_
42	,	,	,	_	47	p	_	_
43	95	0	CD	_	47	num	_	_
44	%	%	NN	_	47	meta	_	_
45	confidence	confidence	NN	_	47	com	_	_
46	interval	interval	NN	_	47	com	_	_
47	-LSB-CI	-lsb-ci	NN	_	23	prn	_	_
48	]	-rsb-	-RRB-	_	47	p	_	_
49	=	=	JJ	_	23	attr	_	_
50	0.44	0	CD	_	53	num	_	_
51	to	to	TO	_	50	cc	_	_
52	0.62	0	CD	_	50	conj	_	_
53	cm3	cm0	NN	_	49	advnp	_	_
54	,	,	,	_	55	p	_	_
55	P	p	NN	_	10	prn	_	_
56	=	=	JJ	_	55	attr	_	_
57	.014	0	CD	_	55	num	_	_
58	)	-rrb-	-RRB-	_	55	p	_	_
59	;	;	:	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	+	+	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	vs	vs	CC	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	:	:	:	_	3	p	_	_
3	0.28	0	CD	_	0	root	_	_
4	vs	vs	CC	_	3	cc	_	_
5	.	.	.	_	3	p	_	_

1	0.55	0	CD	_	2	num	_	_
2	cm3	cm0	NN	_	5	dep	_	_
3	,	,	,	_	5	p	_	_
4	difference	difference	NN	_	5	dep	_	_
5	=	=	JJ	_	0	root	_	_
6	0.27	0	CD	_	5	obj	_	_
7	cm3	cm0	CD	_	6	num	_	_
8	,	,	,	_	11	p	_	_
9	95	0	CD	_	11	num	_	_
10	%	%	NN	_	9	meta	_	_
11	CI	ci	NN	_	6	prn	_	_
12	=	=	JJ	_	11	attr	_	_
13	0.21	0	CD	_	16	num	_	_
14	to	to	TO	_	13	cc	_	_
15	0.33	0	CD	_	13	conj	_	_
16	cm3	cm0	NN	_	12	advnp	_	_
17	,	,	,	_	11	p	_	_
18	P	p	NN	_	19	dep	_	_
19	=	=	JJ	_	11	advcl	_	_
20	.035	0	CD	_	19	obj	_	_
21	)	-rrb-	-RRB-	_	11	p	_	_
22	.	.	.	_	5	p	_	_

1	Combined	combined	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	3	dep	_	_
3	induced	induce	VBD	_	0	root	_	_
4	more	more	RBR	_	5	adv	_	_
5	TUNEL-positive	tunel-positive	JJ	_	7	attr	_	_
6	apoptotic	apoptotic	JJ	_	7	attr	_	_
7	cells	cell	NNS	_	3	obj	_	_
8	than	than	IN	_	9	mark	_	_
9	did	do	VBD	_	3	comp	_	_
10	either	either	DT	_	11	det	_	_
11	agent	agent	NN	_	9	obj	_	_
12	alone	alone	RB	_	11	adv	_	_
13	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	siRNA	sirna	NN	_	3	com	_	_
3	knockdown	knockdown	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	p27	p0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	Kip1	kip0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	decreased	decrease	VBD	_	0	root	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	-	-	:	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug2	drug0	NN	_	14	advnp	_	_
14	-induced	-induced	JJ	_	15	attr	_	_
15	apoptosis	apoptosis	NN	_	10	conj	_	_
16	compared	compare	VBN	_	21	adv	_	_
17	with	with	IN	_	21	case	_	_
18	a	a	DT	_	21	det	_	_
19	negative	negative	JJ	_	21	attr	_	_
20	control	control	NN	_	21	com	_	_
21	siRNA	sirna	NN	_	9	ppmod	_	_
22	(	-lrb-	-LRB-	_	58	p	_	_
23	sub-G1	sub-g0	NN	_	24	com	_	_
24	fraction	fraction	NN	_	58	dep	_	_
25	,	,	,	_	24	p	_	_
26	control	control	NN	_	27	com	_	_
27	siRNA	sirna	NN	_	24	conj	_	_
28	vs.	vs.	CC	_	27	cc	_	_
29	p27	p0	NN	_	33	attr	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	Kip1	kip0	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	siRNA	sirna	NN	_	24	conj	_	_
34	:	:	:	_	58	p	_	_
35	42.5	0	CD	_	58	num	_	_
36	%	%	NN	_	35	meta	_	_
37	vs.	vs.	CC	_	35	cc	_	_
38	20.1	0	CD	_	35	conj	_	_
39	%	%	NN	_	38	meta	_	_
40	,	,	,	_	58	p	_	_
41	difference	difference	NN	_	48	attr	_	_
42	=	=	JJ	_	48	attr	_	_
43	22.4	0	CD	_	48	num	_	_
44	%	%	NN	_	48	meta	_	_
45	,	,	,	_	48	p	_	_
46	95	0	CD	_	48	num	_	_
47	%	%	NN	_	48	meta	_	_
48	CI	ci	NN	_	58	dep	_	_
49	=	=	JJ	_	48	attr	_	_
50	20.1	0	CD	_	48	num	_	_
51	%	%	NN	_	48	meta	_	_
52	to	to	TO	_	48	attr	_	_
53	24.7	0	CD	_	48	num	_	_
54	%	%	NN	_	48	meta	_	_
55	,	,	,	_	58	p	_	_
56	P	p	NN	_	58	attr	_	_
57	=	=	JJ	_	58	attr	_	_
58	.017	0	NN	_	21	num	_	_
59	)	-rrb-	-RRB-	_	58	p	_	_
60	.	.	.	_	9	p	_	_

1	Studies	study	NNS	_	12	dep	_	_
2	with	with	IN	_	4	case	_	_
3	forced	force	VBN	_	4	attr	_	_
4	expression	expression	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	siRNA	sirna	NN	_	7	com	_	_
7	knockdown	knockdown	NN	_	4	conj	_	_
8	of	of	IN	_	9	case	_	_
9	Bcl-2	bcl-0	NN	_	4	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	Cdk1	cdk0	NN	_	9	conj	_	_
12	suggest	suggest	VBP	_	0	root	_	_
13	that	that	IN	_	22	mark	_	_
14	drug1	drug0	NN	_	16	attr	_	_
15	-mediated	-mediated	JJ	_	16	attr	_	_
16	induction	induction	NN	_	22	dep	_	_
17	of	of	IN	_	18	case	_	_
18	p27	p0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	Kip1	kip0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	enhanced	enhance	VBD	_	12	comp	_	_
23	drug2	drug0	NN	_	25	attr	_	_
24	-induced	-induced	JJ	_	25	attr	_	_
25	apoptosis	apoptosis	NN	_	22	obj	_	_
26	by	by	IN	_	28	case	_	_
27	negatively	negatively	RB	_	28	adv	_	_
28	regulating	regulate	VBG	_	22	ppmod	_	_
29	Bcl-2	bcl-0	NN	_	28	obj	_	_
30	and	and	CC	_	29	cc	_	_
31	Cdk1	cdk0	NN	_	32	com	_	_
32	expression	expression	NN	_	29	conj	_	_
33	.	.	.	_	12	p	_	_

1	Inhibition	inhibition	NN	_	13	dep	_	_
2	of	of	IN	_	4	case	_	_
3	Src	src	NN	_	4	com	_	_
4	family	family	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	Abl	abl	NN	_	7	com	_	_
7	kinases	kinase	NNS	_	4	conj	_	_
8	with	with	IN	_	10	case	_	_
9	either	either	CC	_	10	cc	_	_
10	siRNAs	sirnas	NN	_	1	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug1	drug0	NN	_	10	conj	_	_
13	enhances	enhance	VBZ	_	0	root	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	sensitivity	sensitivity	NN	_	13	obj	_	_
16	of	of	IN	_	19	case	_	_
17	ovarian	ovarian	JJ	_	19	attr	_	_
18	cancer	cancer	NN	_	19	com	_	_
19	cells	cell	NNS	_	15	ppmod	_	_
20	through	through	IN	_	26	case	_	_
21	p27	p0	NN	_	25	advnp	_	_
22	(	-lrb-	-LRB-	_	25	p	_	_
23	Kip1	kip0	NN	_	25	advnp	_	_
24	)	-rrb-	-RRB-	_	25	p	_	_
25	-mediated	-mediated	JJ	_	26	attr	_	_
26	suppression	suppression	NN	_	13	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	Bcl-2	bcl-0	NN	_	26	ppmod	_	_
29	and	and	CC	_	28	cc	_	_
30	Cdk1	cdk0	NN	_	31	com	_	_
31	expression	expression	NN	_	28	conj	_	_
32	.	.	.	_	13	p	_	_

1	Influence	influence	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	induced	induce	VBD	_	0	root	_	_
7	antinociception	antinociception	NN	_	6	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	its	its	PRP$	_	10	poss	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	7	conj	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	CAS	cas	NN	_	4	com	_	_
4	94-62-2	0	NN	_	1	num	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	,	,	,	_	8	p	_	_
7	an	an	DT	_	8	det	_	_
8	alkaloid	alkaloid	NN	_	0	root	_	_
9	obtained	obtain	VBN	_	8	acl	_	_
10	from	from	IN	_	12	case	_	_
11	Piper	piper	NN	_	12	com	_	_
12	nigrum	nigrum	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	P	p	NN	_	12	conj	_	_
15	.	.	.	_	8	p	_	_

1	longum	longum	FW	_	3	dep	_	_
2	,	,	,	_	1	p	_	_
3	is	be	VBZ	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	known	known	JJ	_	6	attr	_	_
6	inhibitor	inhibitor	NN	_	3	obj	_	_
7	of	of	IN	_	9	case	_	_
8	various	various	JJ	_	9	attr	_	_
9	enzymes	enzyme	NNS	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	CYP	cyp	NN	_	12	com	_	_
12	isozymes	isozymes	NNS	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	responsible	responsible	JJ	_	9	attr	_	_
15	for	for	IN	_	16	case	_	_
16	biotransformation	biotransformation	NN	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drugs	drug	NNS	_	16	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	By	by	IN	_	2	case	_	_
2	inhibiting	inhibit	VBG	_	9	ppmod	_	_
3	the	the	DT	_	4	det	_	_
4	metabolism	metabolism	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drugs	drug	NNS	_	4	ppmod	_	_
7	,	,	,	_	9	p	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	improves	improve	VBZ	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	bioavailability	bioavailability	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drugs	drug	NNS	_	11	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	11	ppmod	_	_
5	drug1	drug0	NN	_	11	dep	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	10	0	CD	_	8	num	_	_
8	mg/kg	mg/kg	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	significantly	significantly	RB	_	11	adv	_	_
11	increased	increase	VBD	_	0	root	_	_
12	the	the	DT	_	15	det	_	_
13	dose-dependent	dose-dependent	JJ	_	15	attr	_	_
14	antinociceptive	antinociceptive	JJ	_	15	attr	_	_
15	activity	activity	NN	_	11	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NNS	_	15	ppmod	_	_
18	evaluated	evaluate	VBN	_	17	acl	_	_
19	by	by	IN	_	22	case	_	_
20	both	both	CC	_	22	cc	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	writhing	writhing	NN	_	18	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	formalin	formalin	NN	_	25	com	_	_
25	test	test	NN	_	22	conj	_	_
26	,	,	,	_	11	p	_	_
27	when	when	WRB	_	30	adv	_	_
28	it	it	PRP	_	30	dep	_	_
29	was	be	VBD	_	30	aux	_	_
30	administered	administer	VBN	_	11	comp	_	_
31	with	with	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentration	concentration	NN	_	6	dep	_	_
4	was	be	VBD	_	6	aux	_	_
5	also	also	RB	_	6	adv	_	_
6	increased	increase	VBN	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	it	it	PRP	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	administered	administer	VBN	_	6	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	The	the	DT	_	4	det	_	_
2	synergistic	synergistic	JJ	_	4	attr	_	_
3	antinociception	antinociception	NN	_	4	com	_	_
4	activity	activity	NN	_	13	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	when	when	WRB	_	8	adv	_	_
8	administered	administer	VBN	_	4	relcl	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	can	can	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	attributed	attribute	VBN	_	0	root	_	_
14	to	to	TO	_	17	aux	_	_
15	increased	increase	VBN	_	17	attr	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	concentration	concentration	NN	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	13	p	_	_

1	From	from	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	study	study	NN	_	7	ppmod	_	_
4	it	it	PRP	_	7	dep	_	_
5	can	can	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	concluded	conclude	VBN	_	0	root	_	_
8	that	that	IN	_	12	mark	_	_
9	drug1	drug0	NN	_	12	dep	_	_
10	can	can	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	used	use	VBN	_	7	comp	_	_
13	as	as	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	bioenhancer	bioenhancer	NN	_	12	ppmod	_	_
16	along	along	IN	_	18	case	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	15	ppmod	_	_
19	.	.	.	_	7	p	_	_

1	Prevention	prevention	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	emergence	emergence	NN	_	4	com	_	_
4	agitation	agitation	NN	_	1	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	seven	#crd#	CD	_	7	num	_	_
7	children	child	NNS	_	1	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	low-dose	low-dose	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	8	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	15	attr	_	_
13	total	total	JJ	_	15	attr	_	_
14	intravenous	intravenous	JJ	_	15	attr	_	_
15	anesthesia	anesthesia	NN	_	10	conj	_	_
16	.	.	.	_	1	p	_	_

1	Emergence	emergence	NN	_	2	com	_	_
2	agitation	agitation	NN	_	7	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	EA	ea	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	can	can	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	a	a	DT	_	11	det	_	_
9	distressing	distressing	JJ	_	11	attr	_	_
10	side	side	JJ	_	11	attr	_	_
11	effect	effect	NN	_	7	obj	_	_
12	of	of	IN	_	14	case	_	_
13	pediatric	pediatric	JJ	_	14	attr	_	_
14	anesthesia	anesthesia	NNS	_	11	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	retrospectively	retrospectively	VBP	_	3	aux	_	_
3	reviewed	review	VBN	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	records	record	NNS	_	3	obj	_	_
6	of	of	IN	_	10	case	_	_
7	7	0	CD	_	10	num	_	_
8	pediatric	pediatric	JJ	_	10	attr	_	_
9	oncology	oncology	NN	_	10	com	_	_
10	patients	patient	NNS	_	5	ppmod	_	_
11	who	who	WP	_	12	dep	_	_
12	received	receive	VBD	_	10	relcl	_	_
13	low-dose	low-dose	JJ	_	14	attr	_	_
14	drug1	drug0	NN	_	12	obj	_	_
15	in	in	IN	_	16	case	_	_
16	conjunction	conjunction	NN	_	14	ppmod	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	for	for	IN	_	22	case	_	_
20	total	total	JJ	_	22	attr	_	_
21	intravenous	intravenous	JJ	_	22	attr	_	_
22	anesthesia	anesthesia	NN	_	14	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	TIVA	tiva	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	repeatedly	repeatedly	RB	_	12	adv	_	_
27	for	for	IN	_	29	case	_	_
28	radiation	radiation	NN	_	29	com	_	_
29	therapy	therapy	NN	_	12	ppmod	_	_
30	.	.	.	_	3	p	_	_

1	EA	ea	NN	_	2	com	_	_
2	signs	sign	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	in	in	IN	_	8	case	_	_
6	all	all	DT	_	8	det	_	_
7	7	0	CD	_	8	num	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	association	association	NN	_	4	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	TIVA	tiva	NN	_	10	ppmod	_	_
14	but	but	CC	_	4	cc	_	_
15	did	do	VBD	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	recur	recur	VB	_	4	conj	_	_
18	in	in	IN	_	19	case	_	_
19	any	any	DT	_	17	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	123	0	CD	_	24	num	_	_
22	subsequent	subsequent	JJ	_	24	attr	_	_
23	anesthetics	anesthetics	NN	_	24	com	_	_
24	sessions	session	NNS	_	19	ppmod	_	_
25	during	during	IN	_	26	case	_	_
26	which	which	WDT	_	30	ppmod	_	_
27	low-dose	low-dose	JJ	_	28	attr	_	_
28	drug2	drug0	NN	_	30	dep	_	_
29	was	be	VBD	_	30	aux	_	_
30	added	add	VBN	_	24	relcl	_	_
31	to	to	TO	_	32	aux	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	4	p	_	_

1	Based	base	VBN	_	3	adv	_	_
2	on	on	IN	_	3	case	_	_
3	this	this	DT	_	7	ppmod	_	_
4	experience	experience	VBP	_	3	acl	_	_
5	,	,	,	_	7	p	_	_
6	we	we	PRP	_	7	dep	_	_
7	suggest	suggest	VBP	_	0	root	_	_
8	that	that	IN	_	16	mark	_	_
9	low-dose	low-dose	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	16	dep	_	_
11	added	add	VBN	_	10	acl	_	_
12	to	to	TO	_	13	aux	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	may	may	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	associated	associate	VBN	_	7	comp	_	_
17	with	with	IN	_	18	case	_	_
18	prevention	prevention	NN	_	16	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	EA	ea	NN	_	18	ppmod	_	_
21	in	in	IN	_	22	case	_	_
22	children	child	NNS	_	18	ppmod	_	_
23	with	with	IN	_	25	case	_	_
24	a	a	DT	_	25	det	_	_
25	history	history	NN	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	EA	ea	NN	_	25	ppmod	_	_
28	with	with	IN	_	30	case	_	_
29	drug3	drug0	NN	_	30	com	_	_
30	TIVA	tiva	NN	_	27	ppmod	_	_
31	.	.	.	_	7	p	_	_

1	-LSB-Efficacy	-lsb-efficacy	NN	_	0	root	_	_
2	of	of	IN	_	7	case	_	_
3	fixed	fixed	JJ	_	7	attr	_	_
4	combination	combination	NN	_	7	attr	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	/	/	:	_	7	p	_	_
7	drug2	drug0	NN	_	1	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	hospitalized	hospitalized	JJ	_	10	attr	_	_
10	patients	patient	NNS	_	1	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	hypertensive	hypertensive	JJ	_	13	attr	_	_
13	disease	disease	NN	_	10	ppmod	_	_
14	]	-rsb-	-RRB-	_	1	p	_	_

1	Efficacy	efficacy	NN	_	11	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	tolerability	tolerability	NN	_	1	conj	_	_
4	of	of	IN	_	9	case	_	_
5	fixed	fixed	JJ	_	9	attr	_	_
6	drug1	drug0	NN	_	9	attr	_	_
7	/	/	:	_	9	p	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	combination	combination	NN	_	1	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	studied	study	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	86	0	CD	_	14	num	_	_
14	patients	patient	NNS	_	11	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	hypertensive	hypertensive	JJ	_	17	attr	_	_
17	disease	disease	NN	_	14	ppmod	_	_
18	hospitalized	hospitalize	VBN	_	14	acl	_	_
19	in	in	IN	_	20	case	_	_
20	departments	department	NNS	_	18	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	general	general	JJ	_	24	attr	_	_
23	internal	internal	JJ	_	24	attr	_	_
24	medicine	medicine	NN	_	20	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	cardiology	cardiology	NN	_	24	conj	_	_
27	.	.	.	_	11	p	_	_

1	All	all	DT	_	2	det	_	_
2	patients	patient	NNS	_	4	dep	_	_
3	had	have	VBD	_	4	lv	_	_
4	indications	indication	NNS	_	0	root	_	_
5	for	for	IN	_	7	case	_	_
6	antihypertensive	antihypertensive	JJ	_	7	attr	_	_
7	therapy	therapy	NN	_	4	ppmod	_	_
8	and	and	CC	_	4	cc	_	_
9	were	be	VBD	_	10	aux	_	_
10	randomized	randomize	VBN	_	4	conj	_	_
11	either	either	CC	_	15	cc	_	_
12	to	to	TO	_	15	aux	_	_
13	fixed	fixed	JJ	_	15	attr	_	_
14	combination	combination	NN	_	15	com	_	_
15	drug1	drug0	NN	_	10	ppmod	_	_
16	/	/	:	_	15	p	_	_
17	drug2	drug0	NN	_	15	appo	_	_
18	(	-lrb-	-LRB-	_	17	p	_	_
19	n=43	n=0	CD	_	17	num	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	or	or	CC	_	15	cc	_	_
22	to	to	TO	_	23	aux	_	_
23	therapy	therapy	NN	_	15	conj	_	_
24	which	which	WDT	_	25	dep	_	_
25	corresponded	correspond	VBD	_	23	relcl	_	_
26	to	to	TO	_	29	aux	_	_
27	the	the	DT	_	29	det	_	_
28	hospital	hospital	NN	_	29	com	_	_
29	formulary	formulary	NN	_	25	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	n=43	n=0	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	.	.	.	_	4	p	_	_

1	Correction	correction	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	therapy	therapy	NN	_	1	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	performed	performed	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	treating	treat	VBG	_	6	ppmod	_	_
9	physician	physician	NN	_	8	obj	_	_
10	at	at	IN	_	12	case	_	_
11	daily	daily	JJ	_	12	attr	_	_
12	rounds	round	NNS	_	8	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	Self-control	self-control	NN	_	9	dep	_	_
2	of	of	IN	_	4	case	_	_
3	blood	blood	NN	_	4	com	_	_
4	pressure	pressure	NN	_	1	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	BP	bp	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	was	be	VBD	_	9	aux	_	_
9	performed	performed	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	with	with	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	use	use	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	UA767PC	ua0pc	NN	_	17	com	_	_
17	apparatus	apparatus	NN	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	Results	result	NNS	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	BP	bp	NN	_	4	com	_	_
4	self-control	self-control	NN	_	1	ppmod	_	_
5	were	be	VBD	_	6	aux	_	_
6	compared	compare	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	measurements	measurement	NNS	_	6	ppmod	_	_
10	in	in	IN	_	13	mark	_	_
11	order	order	NN	_	13	dep	_	_
12	to	to	TO	_	13	aux	_	_
13	detect	detect	VB	_	6	comp	_	_
14	concealed	conceal	VBN	_	15	attr	_	_
15	inefficacy	inefficacy	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	treatment	treatment	NN	_	15	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	Results	result	NNS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Rate	rate	NN	_	17	dep	_	_
2	of	of	IN	_	3	case	_	_
3	achievement	achievement	NN	_	1	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	target	target	NN	_	6	com	_	_
6	BP	bp	NN	_	3	ppmod	_	_
7	with	with	IN	_	10	case	_	_
8	fixed	fixed	JJ	_	10	attr	_	_
9	combination	combination	NN	_	10	com	_	_
10	drug1	drug0	NN	_	3	ppmod	_	_
11	/	/	:	_	10	p	_	_
12	drug2	drug0	NN	_	10	appo	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	93	0	CD	_	12	num	_	_
15	%	%	NN	_	14	meta	_	_
16	)	-rrb-	-RRB-	_	14	p	_	_
17	was	be	VBD	_	0	root	_	_
18	comparable	comparable	JJ	_	17	dep	_	_
19	with	with	IN	_	20	case	_	_
20	that	that	DT	_	18	ppmod	_	_
21	on	on	IN	_	23	case	_	_
22	traditional	traditional	JJ	_	23	attr	_	_
23	therapy	therapy	NN	_	20	ppmod	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	90	0	CD	_	23	num	_	_
26	%	%	NN	_	25	meta	_	_
27	)	-rrb-	-RRB-	_	25	p	_	_
28	.	.	.	_	17	p	_	_

1	But	but	CC	_	15	cc	_	_
2	the	the	DT	_	3	det	_	_
3	use	use	NN	_	15	dep	_	_
4	of	of	IN	_	7	case	_	_
5	fixed	fixed	JJ	_	7	attr	_	_
6	combination	combination	NN	_	7	com	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	/	/	:	_	7	p	_	_
9	drug2	drug0	NN	_	7	appo	_	_
10	compared	compare	VBN	_	9	acl	_	_
11	with	with	IN	_	13	case	_	_
12	traditional	traditional	JJ	_	13	attr	_	_
13	therapy	therapy	NN	_	10	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	associated	associate	VBN	_	0	root	_	_
16	with	with	IN	_	22	case	_	_
17	lower	low	RBR	_	18	adv	_	_
18	clinical	clinical	JJ	_	22	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	self	self	NN	_	21	advnp	_	_
21	measured	measure	VBD	_	18	conj	_	_
22	BP	bp	NN	_	15	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	quicker	quicker	JJ	_	25	attr	_	_
25	achievement	achievement	NN	_	22	appo	_	_
26	of	of	IN	_	28	case	_	_
27	target	target	NN	_	28	com	_	_
28	BP	bp	NN	_	25	ppmod	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	5.8+/-2.3	0+/-0	CD	_	28	num	_	_
31	and	and	CC	_	30	cc	_	_
32	9.2+/-1.8	0+/-0	CD	_	33	num	_	_
33	days	day	NNS	_	30	conj	_	_
34	,	,	,	_	30	p	_	_
35	respectively	respectively	RB	_	30	adv	_	_
36	,	,	,	_	30	p	_	_
37	0.05	0	CD	_	30	appo	_	_
38	)	-rrb-	-RRB-	_	30	p	_	_
39	,	,	,	_	22	p	_	_
40	lesser	less	JJR	_	41	attr	_	_
41	number	number	NN	_	22	appo	_	_
42	of	of	IN	_	43	case	_	_
43	drug3	drug0	NN	_	41	ppmod	_	_
44	(	-lrb-	-LRB-	_	48	p	_	_
45	2.5+/-0.6	0+/-0	CD	_	48	num	_	_
46	and	and	CC	_	45	cc	_	_
47	3.0+/-0.9	0+/-0	CD	_	45	conj	_	_
48	days	day	NNS	_	43	prn	_	_
49	,	,	,	_	48	p	_	_
50	respectively	respectively	RB	_	48	adv	_	_
51	)	-rrb-	-RRB-	_	48	p	_	_
52	,	,	,	_	22	p	_	_
53	lower	low	JJR	_	54	attr	_	_
54	rate	rate	NN	_	22	appo	_	_
55	of	of	IN	_	57	case	_	_
56	concealed	conceal	VBN	_	57	attr	_	_
57	inefficacy	inefficacy	NN	_	54	ppmod	_	_
58	of	of	IN	_	59	case	_	_
59	treatment	treatment	NN	_	57	ppmod	_	_
60	(	-lrb-	-LRB-	_	61	p	_	_
61	12	0	CD	_	59	num	_	_
62	and	and	CC	_	61	cc	_	_
63	31	0	CD	_	61	conj	_	_
64	%	%	NN	_	61	meta	_	_
65	,	,	,	_	61	p	_	_
66	respectively	respectively	RB	_	61	adv	_	_
67	,	,	,	_	61	p	_	_
68	0.05	0	CD	_	61	appo	_	_
69	)	-rrb-	-RRB-	_	61	p	_	_
70	.	.	.	_	15	p	_	_

1	Conclusions	conclusion	NNS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	demonstrated	demonstrate	VBN	_	0	root	_	_
4	appropriateness	appropriateness	NN	_	3	obj	_	_
5	of	of	IN	_	7	case	_	_
6	inhospital	inhospital	JJ	_	7	attr	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	of	of	IN	_	13	case	_	_
9	fixed	fixed	JJ	_	13	attr	_	_
10	drug1	drug0	NN	_	13	attr	_	_
11	/	/	:	_	13	p	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	combination	combination	NN	_	7	ppmod	_	_
14	as	as	IN	_	16	case	_	_
15	an	an	DT	_	16	det	_	_
16	approach	approach	NN	_	3	ppmod	_	_
17	allowing	allow	VBG	_	16	acl	_	_
18	to	to	TO	_	19	aux	_	_
19	achieve	achieve	VB	_	17	comp	_	_
20	target	target	NN	_	21	com	_	_
21	BP	bp	NN	_	19	obj	_	_
22	in	in	IN	_	24	case	_	_
23	shorter	short	JJR	_	24	attr	_	_
24	time	time	NN	_	19	ppmod	_	_
25	,	,	,	_	19	p	_	_
26	with	with	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	use	use	NN	_	19	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	fewer	few	JJR	_	31	attr	_	_
31	drug3	drug0	NNS	_	28	ppmod	_	_
32	,	,	,	_	17	p	_	_
33	and	and	CC	_	17	cc	_	_
34	diminishing	diminish	VBG	_	17	conj	_	_
35	concealed	conceal	VBN	_	36	attr	_	_
36	inefficacy	inefficacy	NN	_	34	obj	_	_
37	of	of	IN	_	38	case	_	_
38	treatment	treatment	NN	_	36	ppmod	_	_
39	.	.	.	_	3	p	_	_

1	Antitumor	antitumor	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	a	a	DT	_	8	det	_	_
7	specific	specific	JJ	_	8	attr	_	_
8	inhibitor	inhibitor	NN	_	4	appo	_	_
9	of	of	IN	_	10	case	_	_
10	HB-EGF	hb-egf	NN	_	8	ppmod	_	_
11	,	,	,	_	4	p	_	_
12	in	in	IN	_	16	case	_	_
13	T-cell	t-cell	NN	_	16	attr	_	_
14	acute	acute	JJ	_	16	attr	_	_
15	lymphoblastic	lymphoblastic	JJ	_	16	attr	_	_
16	leukemia	leukemia	NN	_	2	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	therapeutic	therapeutic	JJ	_	3	attr	_	_
3	outcome	outcome	NN	_	12	dep	_	_
4	for	for	IN	_	8	case	_	_
5	T-cell	t-cell	NN	_	8	attr	_	_
6	acute	acute	JJ	_	8	attr	_	_
7	lymphoblastic	lymphoblastic	JJ	_	8	attr	_	_
8	leukemia	leukemia	NN	_	3	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	T-ALL	t-all	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	remains	remain	VBZ	_	0	root	_	_
13	poor	poor	JJ	_	12	dep	_	_
14	;	;	:	_	12	p	_	_

1	thus	thus	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	novel	novel	JJ	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	targeted	targeted	JJ	_	6	attr	_	_
6	therapies	therapy	NNS	_	9	dep	_	_
7	are	be	VBP	_	9	aux	_	_
8	urgently	urgently	RB	_	9	adv	_	_
9	needed	need	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Recently	recently	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	showed	show	VBD	_	0	root	_	_
5	that	that	IN	_	23	mark	_	_
6	heparin-binding	heparin-binding	JJ	_	11	attr	_	_
7	epidermal	epidermal	JJ	_	11	attr	_	_
8	growth	growth	NN	_	11	attr	_	_
9	factor-like	factor-like	JJ	_	11	attr	_	_
10	growth	growth	NN	_	11	com	_	_
11	factor	factor	NN	_	23	dep	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	HB-EGF	hb-egf	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	,	,	,	_	11	p	_	_
16	a	a	DT	_	17	det	_	_
17	member	member	NN	_	11	appo	_	_
18	of	of	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	EGF	egf	NN	_	21	com	_	_
21	family	family	NN	_	17	ppmod	_	_
22	,	,	,	_	11	p	_	_
23	is	be	VBZ	_	4	comp	_	_
24	a	a	DT	_	26	det	_	_
25	promising	promising	JJ	_	26	attr	_	_
26	target	target	NN	_	23	obj	_	_
27	for	for	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	treatment	treatment	NN	_	26	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	various	various	JJ	_	32	attr	_	_
32	types	type	NNS	_	29	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	cancer	cancer	NN	_	32	ppmod	_	_
35	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	aim	aim	NN	_	7	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	present	present	JJ	_	6	attr	_	_
6	study	study	NN	_	2	ppmod	_	_
7	was	be	VBD	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	investigate	investigate	VB	_	7	comp	_	_
10	whether	whether	IN	_	12	mark	_	_
11	HB-EGF	hb-egf	NN	_	12	dep	_	_
12	is	be	VBZ	_	9	comp	_	_
13	a	a	DT	_	15	det	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	target	target	NN	_	12	obj	_	_
16	for	for	IN	_	17	case	_	_
17	T-ALL	t-all	NN	_	15	ppmod	_	_
18	,	,	,	_	9	p	_	_
19	and	and	CC	_	9	cc	_	_
20	to	to	TO	_	22	aux	_	_
21	further	far	RB	_	22	adv	_	_
22	elucidate	elucidate	VB	_	9	conj	_	_
23	the	the	DT	_	25	det	_	_
24	antitumor	antitumor	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	22	obj	_	_
26	of	of	IN	_	29	case	_	_
27	a	a	DT	_	29	det	_	_
28	specific	specific	JJ	_	29	attr	_	_
29	inhibitor	inhibitor	NN	_	25	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	HB-EGF	hb-egf	NN	_	29	ppmod	_	_
32	,	,	,	_	29	p	_	_
33	drug1	drug0	NN	_	29	appo	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	drug2	drug0	NN	_	33	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	.	.	.	_	7	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	elucidated	elucidate	VBN	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	expression	expression	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	HB-EGF	hb-egf	NN	_	4	ppmod	_	_
7	in	in	IN	_	10	case	_	_
8	T-ALL	t-all	NN	_	10	com	_	_
9	cell	cell	NN	_	10	com	_	_
10	lines	line	NNS	_	4	ppmod	_	_
11	,	,	,	_	2	p	_	_
12	and	and	CC	_	2	cc	_	_
13	evaluated	evaluate	VBD	_	2	conj	_	_
14	the	the	DT	_	15	det	_	_
15	effect	effect	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	on	on	IN	_	20	case	_	_
19	these	these	DT	_	20	det	_	_
20	cells	cell	NNS	_	15	ppmod	_	_
21	alone	alone	RB	_	15	adv	_	_
22	or	or	CC	_	21	cc	_	_
23	in	in	IN	_	24	case	_	_
24	combination	combination	NN	_	21	conj	_	_
25	with	with	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	expression	expression	NN	_	9	dep	_	_
3	of	of	IN	_	7	case	_	_
4	EGFR	egfr	NN	_	7	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	EGFR	egfr	NN	_	4	conj	_	_
7	ligands	ligand	NNS	_	2	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	determined	determine	VBN	_	0	root	_	_
10	by	by	IN	_	12	case	_	_
11	flow	flow	NN	_	12	com	_	_
12	cytometry	cytometry	NN	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	RT-PCR	rt-pcr	NN	_	12	conj	_	_
15	and	and	CC	_	14	cc	_	_
16	real-time	real-time	JJ	_	18	attr	_	_
17	quantitative	quantitative	JJ	_	18	attr	_	_
18	PCR	pcr	NN	_	12	conj	_	_
19	.	.	.	_	9	p	_	_

1	Induction	induction	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	apoptosis	apoptosis	NN	_	1	ppmod	_	_
4	was	be	VBD	_	5	aux	_	_
5	assessed	assess	VBN	_	0	root	_	_
6	by	by	IN	_	8	case	_	_
7	TUNEL	tunel	NN	_	8	com	_	_
8	assay	assay	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	HB-EGF	hb-egf	NN	_	4	dep	_	_
2	was	be	VBD	_	4	aux	_	_
3	strongly	strongly	RB	_	4	adv	_	_
4	expressed	express	VBN	_	0	root	_	_
5	by	by	IN	_	8	case	_	_
6	T-ALL	t-all	NN	_	8	com	_	_
7	cell	cell	NN	_	8	com	_	_
8	lines	line	NNS	_	4	ppmod	_	_
9	,	,	,	_	4	p	_	_
10	and	and	CC	_	4	cc	_	_
11	the	the	DT	_	12	det	_	_
12	expression	expression	NN	_	19	dep	_	_
13	of	of	IN	_	15	case	_	_
14	both	both	CC	_	15	cc	_	_
15	HB-EGF	hb-egf	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	EGFR	egfr	NN	_	15	conj	_	_
18	was	be	VBD	_	19	aux	_	_
19	enhanced	enhance	VBN	_	4	conj	_	_
20	by	by	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	induced	induce	VBD	_	0	root	_	_
3	apoptosis	apoptosis	NN	_	2	obj	_	_
4	,	,	,	_	2	p	_	_
5	and	and	CC	_	2	cc	_	_
6	furthermore	furthermore	RB	_	14	adv	_	_
7	,	,	,	_	14	p	_	_
8	the	the	DT	_	9	det	_	_
9	combination	combination	NN	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	plus	plus	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	enhanced	enhance	VBD	_	2	conj	_	_
15	cytotoxicity	cytotoxicity	NN	_	14	obj	_	_
16	in	in	IN	_	20	case	_	_
17	a	a	DT	_	20	det	_	_
18	T-ALL	t-all	NN	_	20	com	_	_
19	cell	cell	NN	_	20	com	_	_
20	line	line	NN	_	14	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	HB-EGF	hb-egf	NN	_	6	dep	_	_
6	is	be	VBZ	_	3	comp	_	_
7	a	a	DT	_	10	det	_	_
8	promising	promising	JJ	_	10	attr	_	_
9	therapeutic	therapeutic	JJ	_	10	attr	_	_
10	target	target	NN	_	6	obj	_	_
11	for	for	IN	_	12	case	_	_
12	T-ALL	t-all	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Distinct	distinct	JJ	_	3	attr	_	_
2	synergistic	synergistic	JJ	_	3	attr	_	_
3	action	action	NN	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	against	against	IN	_	10	case	_	_
9	Pseudomonas	pseudomonas	FW	_	10	attr	_	_
10	aeruginosa	aeruginosa	FW	_	3	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	The	the	DT	_	4	det	_	_
2	dicarbonyl	dicarbonyl	NN	_	4	com	_	_
3	compound	compound	NN	_	4	com	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	is	be	VBZ	_	0	root	_	_
6	a	a	DT	_	8	det	_	_
7	natural	natural	JJ	_	8	attr	_	_
8	constituent	constituent	NN	_	5	obj	_	_
9	of	of	IN	_	11	case	_	_
10	Manuka	manuka	NN	_	11	com	_	_
11	honey	honey	NN	_	8	ppmod	_	_
12	produced	produce	VBN	_	11	acl	_	_
13	from	from	IN	_	15	case	_	_
14	Manuka	manuka	NN	_	15	com	_	_
15	flowers	flower	NNS	_	12	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	New	new	JJ	_	18	attr	_	_
18	Zealand	zealand	NN	_	15	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	possess	possess	VB	_	3	comp	_	_
6	both	both	CC	_	7	cc	_	_
7	anticancer	anticancer	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	antibacterial	antibacterial	JJ	_	7	conj	_	_
10	activity	activity	NN	_	5	obj	_	_
11	.	.	.	_	3	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	observations	observation	NNS	_	3	dep	_	_
3	prompted	prompt	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	investigate	investigate	VB	_	3	comp	_	_
6	the	the	DT	_	7	det	_	_
7	ability	ability	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	as	as	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	potent	potent	JJ	_	13	attr	_	_
13	drug	drug	NN	_	5	ppmod	_	_
14	against	against	IN	_	18	case	_	_
15	multidrug	multidrug	JJ	_	18	attr	_	_
16	resistant	resistant	JJ	_	18	attr	_	_
17	Pseudomonas	pseudomonas	FW	_	18	attr	_	_
18	aeruginosa	aeruginosa	FW	_	13	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	A	a	DT	_	2	det	_	_
2	total	total	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	12	0	CD	_	2	ppmod	_	_
5	test	test	VB	_	0	root	_	_
6	P	p	NN	_	5	obj	_	_
7	.	.	.	_	5	p	_	_

1	aeruginosa	aeruginosa	FW	_	2	attr	_	_
2	strains	strain	NNS	_	8	dep	_	_
3	isolated	isolate	VBN	_	2	acl	_	_
4	from	from	IN	_	6	case	_	_
5	various	various	JJ	_	6	attr	_	_
6	hospitals	hospital	NNS	_	3	ppmod	_	_
7	were	be	VBD	_	8	aux	_	_
8	tested	test	VBN	_	0	root	_	_
9	for	for	IN	_	11	case	_	_
10	their	their	PRP$	_	11	poss	_	_
11	resistances	resistance	NNS	_	8	ppmod	_	_
12	against	against	IN	_	14	case	_	_
13	many	many	JJ	_	14	attr	_	_
14	drug1	drug0	NNS	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	most	most	JJS	_	20	dep	_	_
17	of	of	IN	_	18	case	_	_
18	which	which	WDT	_	16	ppmod	_	_
19	are	be	VBP	_	20	aux	_	_
20	applied	apply	VBN	_	14	relcl	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	treatment	treatment	NN	_	20	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	P	p	NN	_	23	ppmod	_	_
26	.	.	.	_	8	p	_	_

1	aeruginosa	aeruginosa	FW	_	2	attr	_	_
2	infections	infection	NNS	_	0	root	_	_
3	.	.	.	_	2	p	_	_

1	Results	result	NNS	_	2	dep	_	_
2	revealed	reveal	VBD	_	23	advcl	_	_
3	that	that	IN	_	6	mark	_	_
4	the	the	DT	_	5	det	_	_
5	strains	strain	NNS	_	6	dep	_	_
6	were	be	VBD	_	2	comp	_	_
7	resistant	resistant	JJ	_	6	dep	_	_
8	to	to	TO	_	10	aux	_	_
9	many	many	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	at	at	IN	_	13	case	_	_
12	high	high	JJ	_	13	attr	_	_
13	levels	level	NNS	_	6	ppmod	_	_
14	,	,	,	_	6	p	_	_
15	only	only	RB	_	6	adv	_	_
16	drug1	drug0	NN	_	23	dep	_	_
17	,	,	,	_	16	p	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug3	drug0	NN	_	16	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	drug4	drug0	NN	_	16	conj	_	_
23	showed	show	VBD	_	0	root	_	_
24	resistances	resistance	NNS	_	23	obj	_	_
25	at	at	IN	_	28	case	_	_
26	comparatively	comparatively	RB	_	27	adv	_	_
27	lower	low	JJR	_	28	attr	_	_
28	levels	level	NNS	_	23	ppmod	_	_
29	.	.	.	_	23	p	_	_

1	Following	follow	VBG	_	3	adv	_	_
2	multiple	multiple	JJ	_	3	attr	_	_
3	experimentations	experimentation	NNS	_	6	ppmod	_	_
4	it	it	PRP	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	was	be	VBD	_	6	comp	_	_
10	also	also	RB	_	9	adv	_	_
11	antimicrobic	antimicrobic	JJ	_	9	dep	_	_
12	against	against	IN	_	15	case	_	_
13	all	all	PDT	_	15	det	_	_
14	the	the	DT	_	15	det	_	_
15	strains	strain	NNS	_	11	ppmod	_	_
16	at	at	IN	_	18	case	_	_
17	comparable	comparable	JJ	_	18	attr	_	_
18	levels	level	NNS	_	15	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	Distinct	distinct	JJ	_	5	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	statistically	statistically	RB	_	4	adv	_	_
4	significant	significant	JJ	_	1	conj	_	_
5	synergism	synergism	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	observed	observe	VBN	_	0	root	_	_
8	between	between	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	by	by	IN	_	15	case	_	_
13	disc	disc	NN	_	15	com	_	_
14	diffusion	diffusion	NN	_	15	com	_	_
15	tests	test	NNS	_	7	ppmod	_	_
16	when	when	WRB	_	17	adv	_	_
17	compared	compare	VBN	_	7	comp	_	_
18	with	with	IN	_	21	case	_	_
19	their	their	PRP$	_	21	poss	_	_
20	individual	individual	JJ	_	21	attr	_	_
21	effects	effect	NNS	_	17	ppmod	_	_
22	.	.	.	_	7	p	_	_

1	The	the	DT	_	5	det	_	_
2	fractional	fractional	JJ	_	5	attr	_	_
3	inhibitory	inhibitory	JJ	_	5	attr	_	_
4	concentration	concentration	NN	_	5	com	_	_
5	index	index	NN	_	14	dep	_	_
6	of	of	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	combination	combination	NN	_	5	ppmod	_	_
9	evaluated	evaluate	VBN	_	5	acl	_	_
10	by	by	IN	_	12	case	_	_
11	checkerboard	checkerboard	NN	_	12	com	_	_
12	analysis	analysis	NN	_	9	ppmod	_	_
13	,	,	,	_	5	p	_	_
14	was	be	VBD	_	0	root	_	_
15	0.5	0	CD	_	14	obj	_	_
16	,	,	,	_	15	p	_	_
17	which	which	WDT	_	18	dep	_	_
18	confirmed	confirm	VBD	_	15	relcl	_	_
19	synergism	synergism	NN	_	18	obj	_	_
20	between	between	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	pair	pair	NN	_	19	ppmod	_	_
23	.	.	.	_	14	p	_	_

1	Synergism	synergism	NN	_	4	dep	_	_
2	was	be	VBD	_	4	aux	_	_
3	also	also	RB	_	4	adv	_	_
4	noted	note	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	was	be	VBD	_	8	aux	_	_
8	combined	combine	VBN	_	4	comp	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	failure	failure	NN	_	10	dep	_	_
3	in	in	IN	_	6	case	_	_
4	an	an	DT	_	6	det	_	_
5	HIV-positive	hiv-positive	JJ	_	6	attr	_	_
6	woman	woman	NN	_	2	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	therapy	therapy	NN	_	6	ppmod	_	_
10	resulting	result	VBG	_	0	root	_	_
11	in	in	IN	_	14	case	_	_
12	two	#crd#	CD	_	14	num	_	_
13	ectopic	ectopic	JJ	_	14	attr	_	_
14	pregnancies	pregnancy	NNS	_	10	ppmod	_	_
15	.	.	.	_	10	p	_	_

1	Since	since	IN	_	3	case	_	_
2	its	its	PRP$	_	3	poss	_	_
3	introduction	introduction	NN	_	8	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	1999	0	CD	_	3	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	remains	remain	VBZ	_	0	root	_	_
9	one	#crd#	CD	_	8	obj	_	_
10	of	of	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	preferred	preferred	JJ	_	14	attr	_	_
13	contraceptive	contraceptive	JJ	_	14	attr	_	_
14	choices	choice	NNS	_	9	ppmod	_	_
15	for	for	IN	_	17	case	_	_
16	many	many	JJ	_	17	attr	_	_
17	women	woman	NNS	_	14	ppmod	_	_
18	as	as	IN	_	20	mark	_	_
19	it	it	PRP	_	20	dep	_	_
20	offers	offer	VBZ	_	8	comp	_	_
21	a	a	DT	_	24	det	_	_
22	highly	highly	RB	_	23	adv	_	_
23	effective	effective	JJ	_	24	attr	_	_
24	means	means	NN	_	20	obj	_	_
25	of	of	IN	_	27	case	_	_
26	long-term	long-term	JJ	_	27	attr	_	_
27	contraception	contraception	NN	_	24	ppmod	_	_
28	for	for	IN	_	30	case	_	_
29	three	#crd#	CD	_	30	num	_	_
30	years	year	NNS	_	24	ppmod	_	_
31	that	that	WDT	_	34	dep	_	_
32	does	do	VBZ	_	34	aux	_	_
33	not	not	RB	_	34	neg	_	_
34	rely	rely	VB	_	24	relcl	_	_
35	on	on	IN	_	36	case	_	_
36	adherence	adherence	NN	_	34	ppmod	_	_
37	.	.	.	_	8	p	_	_

1	Like	like	IN	_	3	case	_	_
2	all	all	DT	_	3	det	_	_
3	drug1	drug0	NN	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	certain	certain	JJ	_	8	attr	_	_
6	hepatic	hepatic	JJ	_	8	attr	_	_
7	enzyme-inducing	enzyme-inducing	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	reduce	reduce	VB	_	0	root	_	_
11	its	its	PRP$	_	12	poss	_	_
12	efficacy	efficacy	NN	_	10	obj	_	_
13	.	.	.	_	10	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	present	present	VBP	_	0	root	_	_
3	an	an	DT	_	5	det	_	_
4	interesting	interesting	JJ	_	5	attr	_	_
5	case	case	NN	_	2	obj	_	_
6	of	of	IN	_	9	case	_	_
7	an	an	DT	_	9	det	_	_
8	HIV-positive	hiv-positive	JJ	_	9	attr	_	_
9	woman	woman	NN	_	5	ppmod	_	_
10	on	on	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	9	ppmod	_	_
13	having	have	VBG	_	15	lv	_	_
14	tubal	tubal	JJ	_	15	attr	_	_
15	pregnancies	pregnancy	NNS	_	12	acl	_	_
16	on	on	IN	_	19	case	_	_
17	two	#crd#	CD	_	19	num	_	_
18	separate	separate	JJ	_	19	attr	_	_
19	occasions	occasion	NNS	_	15	ppmod	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	in	in	IN	_	23	case	_	_
23	place	place	NN	_	21	ppmod	_	_
24	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	5	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	CYP	cyp	NN	_	4	com	_	_
4	2D6	0d0	NN	_	1	conj	_	_
5	inhibitors	inhibitor	NNS	_	7	dep	_	_
6	:	:	:	_	7	p	_	_
7	caution	caution	NN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	,	,	,	_	1	p	_	_
3	an	an	DT	_	4	det	_	_
4	drug2	drug0	NN	_	1	appo	_	_
5	,	,	,	_	1	p	_	_
6	is	be	VBZ	_	0	root	_	_
7	the	the	DT	_	10	det	_	_
8	standard	standard	JJ	_	10	attr	_	_
9	hormone	hormone	NN	_	10	com	_	_
10	treatment	treatment	NN	_	6	obj	_	_
11	for	for	IN	_	13	case	_	_
12	breast	breast	NN	_	13	com	_	_
13	cancer	cancer	NN	_	10	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	extensively	extensively	RB	_	4	adv	_	_
4	transformed	transform	VBN	_	0	root	_	_
5	into	into	IN	_	8	case	_	_
6	its	its	PRP$	_	8	poss	_	_
7	active	active	JJ	_	8	attr	_	_
8	metabolites	metabolite	NNS	_	4	ppmod	_	_
9	by	by	IN	_	14	case	_	_
10	the	the	DT	_	14	det	_	_
11	cytochrome	cytochrome	NN	_	12	com	_	_
12	P450	p0	NN	_	14	com	_	_
13	enzyme	enzyme	NN	_	14	com	_	_
14	system	system	NN	_	4	ppmod	_	_
15	,	,	,	_	4	p	_	_
16	especially	especially	RB	_	4	adv	_	_
17	into	into	IN	_	18	case	_	_
18	drug1	drug0	NN	_	4	ppmod	_	_
19	by	by	IN	_	22	case	_	_
20	isoenzyme	isoenzyme	NN	_	22	com	_	_
21	CYP	cyp	NN	_	22	com	_	_
22	2D6	0d0	NN	_	4	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	Co-administration	co-administration	NN	_	9	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	8	case	_	_
5	isoenzyme	isoenzyme	JJ	_	8	attr	_	_
6	CYP	cyp	NN	_	8	com	_	_
7	2D6	0d0	NN	_	8	com	_	_
8	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
9	reduces	reduce	VBZ	_	0	root	_	_
10	this	this	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibit	inhibit	VBP	_	0	root	_	_
3	isoenzyme	isoenzyme	NN	_	5	com	_	_
4	CYP	cyp	NN	_	5	com	_	_
5	2D6	0d0	NN	_	2	obj	_	_
6	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	reduce	reduce	VBP	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentration	concentration	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	by	by	IN	_	12	case	_	_
11	about	about	RB	_	12	adv	_	_
12	50	0	CD	_	4	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	.	.	.	_	4	p	_	_

1	Two	#crd#	CD	_	3	num	_	_
2	epidemiological	epidemiological	JJ	_	3	attr	_	_
3	studies	study	NNS	_	9	dep	_	_
4	involving	involve	VBG	_	3	acl	_	_
5	about	about	RB	_	6	adv	_	_
6	3700	0	CD	_	7	num	_	_
7	women	woman	NNS	_	4	obj	_	_
8	have	have	VBP	_	9	aux	_	_
9	shown	show	VBN	_	0	root	_	_
10	a	a	DT	_	11	det	_	_
11	link	link	NN	_	9	obj	_	_
12	between	between	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	use	use	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	14	cc	_	_
18	an	an	DT	_	20	det	_	_
19	increased	increase	VBN	_	20	attr	_	_
20	frequency	frequency	NN	_	14	conj	_	_
21	of	of	IN	_	24	case	_	_
22	breast	breast	NN	_	24	com	_	_
23	cancer	cancer	NN	_	24	com	_	_
24	recurrence	recurrence	NN	_	20	ppmod	_	_
25	.	.	.	_	9	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	studies	study	NNS	_	11	dep	_	_
3	,	,	,	_	2	p	_	_
4	with	with	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	lower	low	JJR	_	7	attr	_	_
7	level	level	NN	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	evidence	evidence	NN	_	7	ppmod	_	_
10	,	,	,	_	2	p	_	_
11	were	be	VBD	_	0	root	_	_
12	less	less	RBR	_	13	adv	_	_
13	convincing	convincing	JJ	_	11	dep	_	_
14	.	.	.	_	11	p	_	_

1	Studies	study	NNS	_	8	dep	_	_
2	of	of	IN	_	7	case	_	_
3	other	other	JJ	_	7	attr	_	_
4	isoenzyme	isoenzyme	JJ	_	7	attr	_	_
5	CYP	cyp	NN	_	7	com	_	_
6	2D6	0d0	NN	_	7	com	_	_
7	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
8	showed	show	VBD	_	0	root	_	_
9	no	no	DT	_	10	det	_	_
10	increase	increase	NN	_	8	obj	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	risk	risk	NN	_	10	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	breast	breast	NN	_	17	com	_	_
16	cancer	cancer	NN	_	17	com	_	_
17	recurrence	recurrence	NN	_	13	ppmod	_	_
18	,	,	,	_	8	p	_	_
19	but	but	CC	_	8	cc	_	_
20	they	they	PRP	_	21	dep	_	_
21	lacked	lack	VBD	_	8	conj	_	_
22	statistical	statistical	JJ	_	23	attr	_	_
23	power	power	NN	_	21	obj	_	_
24	.	.	.	_	8	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	better	well	RB	_	2	adv	_	_
4	to	to	TO	_	5	aux	_	_
5	avoid	avoid	VB	_	2	comp	_	_
6	prescribing	prescribing	JJ	_	10	attr	_	_
7	isoenzyme	isoenzyme	JJ	_	10	attr	_	_
8	CYP	cyp	NN	_	10	com	_	_
9	2D6	0d0	NN	_	10	com	_	_
10	inhibitors	inhibitor	NNS	_	5	obj	_	_
11	to	to	TO	_	12	aux	_	_
12	women	woman	NNS	_	5	ppmod	_	_
13	treated	treat	VBN	_	12	acl	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	for	for	IN	_	18	case	_	_
17	breast	breast	NN	_	18	com	_	_
18	cancer	cancer	NN	_	15	ppmod	_	_
19	,	,	,	_	12	p	_	_
20	especially	especially	RB	_	12	adv	_	_
21	drug2	drug0	NNS	_	12	appo	_	_
22	such	such	JJ	_	24	adv	_	_
23	as	as	IN	_	24	case	_	_
24	drug3	drug0	NN	_	21	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	drug4	drug0	NN	_	24	conj	_	_
27	.	.	.	_	2	p	_	_

1	Depression	depression	NN	_	5	dep	_	_
2	does	do	VBZ	_	5	aux	_	_
3	not	not	RB	_	5	neg	_	_
4	always	always	RB	_	5	adv	_	_
5	require	require	VB	_	0	root	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	therapy	therapy	NN	_	5	obj	_	_
8	,	,	,	_	5	p	_	_
9	and	and	CC	_	5	cc	_	_
10	drug2	drug0	NNS	_	11	dep	_	_
11	have	have	VBP	_	5	conj	_	_
12	no	no	DT	_	15	det	_	_
13	proven	proven	JJ	_	15	attr	_	_
14	preventive	preventive	JJ	_	15	attr	_	_
15	impact	impact	NN	_	11	obj	_	_
16	on	on	IN	_	18	case	_	_
17	hot	hot	JJ	_	18	attr	_	_
18	flushes	flush	NNS	_	11	ppmod	_	_
19	linked	link	VBN	_	18	acl	_	_
20	to	to	TO	_	22	aux	_	_
21	the	the	DT	_	22	det	_	_
22	menopause	menopause	NN	_	19	ppmod	_	_
23	.	.	.	_	5	p	_	_

1	If	if	IN	_	9	mark	_	_
2	in	in	IN	_	4	case	_	_
3	certain	certain	JJ	_	4	attr	_	_
4	cases	case	NNS	_	9	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	an	an	DT	_	7	det	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	considered	consider	VBN	_	14	advcl	_	_
10	necessary	necessary	JJ	_	9	dep	_	_
11	,	,	,	_	14	p	_	_
12	it	it	PRP	_	14	dep	_	_
13	may	may	MD	_	14	modal	_	_
14	be	be	VB	_	0	root	_	_
15	advisable	advisable	JJ	_	14	dep	_	_
16	to	to	TO	_	17	aux	_	_
17	replace	replace	VB	_	15	comp	_	_
18	drug2	drug0	NN	_	17	obj	_	_
19	with	with	IN	_	20	case	_	_
20	drug3	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	Phase	phase	NN	_	3	com	_	_
2	I	i	NN	_	3	com	_	_
3	trial	trial	NN	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	3	ppmod	_	_
10	with	with	IN	_	13	case	_	_
11	relapsed	relapsed	JJ	_	13	attr	_	_
12	multiple	multiple	JJ	_	13	attr	_	_
13	myeloma	myeloma	NN	_	9	ppmod	_	_
14	:	:	:	_	3	p	_	_
15	evidence	evidence	NN	_	3	appo	_	_
16	for	for	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	-	-	:	_	3	p	_	_
19	drug4	drug0	NN	_	20	com	_	_
20	interaction	interaction	NN	_	3	appo	_	_
21	via	via	IN	_	22	case	_	_
22	P-glycoprotein	p-glycoprotein	NN	_	20	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	Multiple	multiple	JJ	_	2	attr	_	_
2	myeloma	myeloma	NN	_	6	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	MM	mm	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	is	be	VBZ	_	0	root	_	_
7	an	an	DT	_	10	det	_	_
8	incurable	incurable	JJ	_	10	attr	_	_
9	plasma-cell	plasma-cell	NN	_	10	com	_	_
10	neoplasm	neoplasm	NN	_	6	obj	_	_
11	for	for	IN	_	12	case	_	_
12	which	which	WDT	_	15	ppmod	_	_
13	most	most	JJS	_	14	attr	_	_
14	treatments	treatment	NNS	_	15	dep	_	_
15	involve	involve	VBP	_	10	relcl	_	_
16	a	a	DT	_	18	det	_	_
17	therapeutic	therapeutic	JJ	_	18	attr	_	_
18	agent	agent	NN	_	15	obj	_	_
19	combined	combine	VBN	_	18	acl	_	_
20	with	with	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	preclinical	preclinical	JJ	_	3	attr	_	_
3	combination	combination	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	mTOR	mtor	NN	_	10	com	_	_
9	inhibitor	inhibitor	NN	_	10	com	_	_
10	drug2	drug0	NN	_	3	ppmod	_	_
11	has	have	VBZ	_	12	aux	_	_
12	displayed	display	VBD	_	0	root	_	_
13	synergy	synergy	NN	_	12	obj	_	_
14	in	in	FW	_	15	adv	_	_
15	vitro	vitro	FW	_	12	adv	_	_
16	and	and	CC	_	12	cc	_	_
17	represents	represent	VBZ	_	12	conj	_	_
18	a	a	DT	_	20	det	_	_
19	novel	novel	JJ	_	20	attr	_	_
20	combination	combination	NN	_	17	obj	_	_
21	in	in	IN	_	22	case	_	_
22	MM	mm	NN	_	17	ppmod	_	_
23	.	.	.	_	12	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vivo	vivo	FW	_	4	attr	_	_
3	CYP3A	cyp0a	NN	_	4	com	_	_
4	activity	activity	NN	_	5	dep	_	_
5	is	be	VBZ	_	0	root	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	lower	low	JJR	_	5	dep	_	_
8	in	in	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	-treated	-treated	JJ	_	9	attr	_	_
11	as	as	IN	_	12	mark	_	_
12	compared	compare	VBN	_	5	comp	_	_
13	with	with	IN	_	18	case	_	_
14	drug2	drug0	NN	_	18	attr	_	_
15	-treated	-treated	JJ	_	18	attr	_	_
16	renal	renal	JJ	_	18	attr	_	_
17	allograft	allograft	NN	_	18	com	_	_
18	recipients	recipient	NNS	_	12	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	identified	identify	VBN	_	0	root	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	as	as	IN	_	11	case	_	_
10	CYP3A	cyp0a	NN	_	11	com	_	_
11	inhibitors	inhibitor	NNS	_	5	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	current	current	JJ	_	4	attr	_	_
4	study	study	NN	_	11	ppmod	_	_
5	in	in	IN	_	8	case	_	_
6	renal	renal	JJ	_	8	attr	_	_
7	allograft	allograft	NN	_	8	com	_	_
8	recipients	recipient	NNS	_	4	ppmod	_	_
9	,	,	,	_	11	p	_	_
10	we	we	PRP	_	11	dep	_	_
11	used	use	VBD	_	0	root	_	_
12	intravenously	intravenously	RB	_	15	adv	_	_
13	and	and	CC	_	12	cc	_	_
14	orally	orally	RB	_	12	conj	_	_
15	administered	administer	VBN	_	16	attr	_	_
16	drug1	drug0	NN	_	11	obj	_	_
17	as	as	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	drug	drug	NN	_	20	com	_	_
20	probe	probe	NN	_	11	ppmod	_	_
21	to	to	TO	_	22	aux	_	_
22	assess	assess	VB	_	11	comp	_	_
23	whether	whether	IN	_	36	mark	_	_
24	the	the	DT	_	26	det	_	_
25	study	study	NN	_	26	com	_	_
26	drugs	drug	NNS	_	36	dep	_	_
27	at	at	IN	_	28	case	_	_
28	doses	dose	NNS	_	26	ppmod	_	_
29	that	that	WDT	_	32	dep	_	_
30	are	be	VBP	_	32	aux	_	_
31	generally	generally	RB	_	32	adv	_	_
32	used	use	VBN	_	28	relcl	_	_
33	in	in	IN	_	35	case	_	_
34	clinical	clinical	JJ	_	35	attr	_	_
35	practice	practice	NN	_	32	ppmod	_	_
36	have	have	VBP	_	22	comp	_	_
37	differential	differential	JJ	_	38	attr	_	_
38	effects	effect	NNS	_	36	obj	_	_
39	on	on	IN	_	46	case	_	_
40	in	in	FW	_	41	adv	_	_
41	vivo	vivo	FW	_	46	attr	_	_
42	hepatic	hepatic	JJ	_	46	attr	_	_
43	and	and	CC	_	42	cc	_	_
44	first-pass	first-pass	JJ	_	42	conj	_	_
45	CYP3A	cyp0a	NN	_	46	com	_	_
46	activities	activity	NNS	_	36	ppmod	_	_
47	.	.	.	_	11	p	_	_

1	Systemic	systemic	JJ	_	6	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	apparent	apparent	JJ	_	4	adv	_	_
4	oral	oral	JJ	_	1	conj	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	clearance	clearance	NN	_	7	dep	_	_
7	were	be	VBD	_	0	root	_	_
8	24	0	CD	_	7	obj	_	_
9	%	%	NN	_	8	meta	_	_
10	(	-lrb-	-LRB-	_	20	p	_	_
11	269	0	CD	_	16	num	_	_
12	73	0	CD	_	16	num	_	_
13	vs.	vs.	CC	_	12	cc	_	_
14	354	0	CD	_	15	com	_	_
15	102	0	CD	_	12	conj	_	_
16	ml/min	ml/min	NN	_	20	dep	_	_
17	,	,	,	_	20	p	_	_
18	P	p	NN	_	20	attr	_	_
19	=	=	JJ	_	20	attr	_	_
20	0.022	0	NN	_	8	num	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	and	and	CC	_	8	cc	_	_
23	31	0	CD	_	8	conj	_	_
24	%	%	NN	_	23	meta	_	_
25	(	-lrb-	-LRB-	_	35	p	_	_
26	479	0	CD	_	31	num	_	_
27	190	0	CD	_	31	num	_	_
28	vs.	vs.	CC	_	27	cc	_	_
29	688	0	CD	_	30	com	_	_
30	265	0	CD	_	27	conj	_	_
31	ml/min	ml/min	NN	_	35	dep	_	_
32	,	,	,	_	35	p	_	_
33	P	p	NN	_	35	attr	_	_
34	=	=	JJ	_	35	attr	_	_
35	0.013	0	NN	_	23	num	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	,	,	,	_	23	p	_	_
38	respectively	respectively	RB	_	23	adv	_	_
39	,	,	,	_	23	p	_	_
40	lower	low	JJR	_	8	conj	_	_
41	in	in	IN	_	44	case	_	_
42	drug2	drug0	JJ	_	44	attr	_	_
43	-treated	-treated	JJ	_	44	attr	_	_
44	patients	patient	NNS	_	40	ppmod	_	_
45	(	-lrb-	-LRB-	_	46	p	_	_
46	n	n	NN	_	44	prn	_	_
47	=	=	JJ	_	46	attr	_	_
48	20	0	CD	_	46	num	_	_
49	)	-rrb-	-RRB-	_	46	p	_	_
50	than	than	IN	_	55	case	_	_
51	in	in	IN	_	55	case	_	_
52	matched	matched	JJ	_	55	attr	_	_
53	drug3	drug0	NN	_	55	attr	_	_
54	-treated	-treated	JJ	_	55	attr	_	_
55	patients	patient	NNS	_	40	ppmod	_	_
56	(	-lrb-	-LRB-	_	57	p	_	_
57	n	n	NN	_	55	prn	_	_
58	=	=	JJ	_	57	attr	_	_
59	20	0	CD	_	57	num	_	_
60	)	-rrb-	-RRB-	_	57	p	_	_
61	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	latter	latter	JJ	_	3	dep	_	_
3	displayed	display	VBD	_	0	root	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	clearances	clearance	NNS	_	3	obj	_	_
6	similar	similar	JJ	_	5	attr	_	_
7	to	to	TO	_	8	aux	_	_
8	those	those	DT	_	6	ppmod	_	_
9	in	in	IN	_	12	case	_	_
10	two	#crd#	CD	_	12	num	_	_
11	larger	large	JJR	_	12	attr	_	_
12	cohorts	cohort	NNS	_	8	ppmod	_	_
13	of	of	IN	_	17	case	_	_
14	nonmatched	nonmatched	JJ	_	17	attr	_	_
15	drug2	drug0	NN	_	17	attr	_	_
16	-treated	-treated	JJ	_	17	attr	_	_
17	patients	patient	NNS	_	12	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	n	n	NN	_	17	prn	_	_
20	=	=	JJ	_	19	attr	_	_
21	58	0	CD	_	19	num	_	_
22	and	and	CC	_	19	cc	_	_
23	n	n	NN	_	19	conj	_	_
24	=	=	JJ	_	23	attr	_	_
25	80	0	CD	_	23	num	_	_
26	)	-rrb-	-RRB-	_	23	p	_	_
27	and	and	CC	_	8	cc	_	_
28	to	to	TO	_	29	aux	_	_
29	those	those	DT	_	8	conj	_	_
30	receiving	receive	VBG	_	29	acl	_	_
31	a	a	DT	_	34	det	_	_
32	drug3	drug0	NN	_	33	advnp	_	_
33	-free	-free	JJ	_	34	attr	_	_
34	regimen	regimen	NN	_	30	obj	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	n	n	NN	_	34	prn	_	_
37	=	=	JJ	_	36	attr	_	_
38	6	0	CD	_	36	num	_	_
39	)	-rrb-	-RRB-	_	36	p	_	_
40	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	dep	_	_
2	implies	imply	VBZ	_	0	root	_	_
3	that	that	IN	_	11	mark	_	_
4	in	in	FW	_	5	adv	_	_
5	vivo	vivo	FW	_	10	attr	_	_
6	hepatic	hepatic	JJ	_	10	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	first-pass	first-pass	JJ	_	6	conj	_	_
9	CYP3A	cyp0a	NN	_	10	com	_	_
10	activities	activity	NNS	_	11	dep	_	_
11	are	be	VBP	_	2	comp	_	_
12	significantly	significantly	RB	_	13	adv	_	_
13	lower	low	JJR	_	11	dep	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	receiving	receive	VBG	_	15	acl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	than	than	IN	_	20	case	_	_
19	in	in	IN	_	20	case	_	_
20	those	those	DT	_	13	ppmod	_	_
21	receiving	receive	VBG	_	20	acl	_	_
22	drug2	drug0	NN	_	21	obj	_	_
23	,	,	,	_	11	p	_	_
24	indicating	indicate	VBG	_	11	comp	_	_
25	that	that	IN	_	37	mark	_	_
26	,	,	,	_	37	p	_	_
27	at	at	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	doses	dose	NNS	_	37	ppmod	_	_
30	generally	generally	RB	_	31	adv	_	_
31	used	use	VBN	_	29	acl	_	_
32	in	in	IN	_	34	case	_	_
33	clinical	clinical	JJ	_	34	attr	_	_
34	practice	practice	NN	_	31	ppmod	_	_
35	,	,	,	_	37	p	_	_
36	drug3	drug0	NN	_	37	dep	_	_
37	is	be	VBZ	_	24	comp	_	_
38	the	the	DT	_	39	det	_	_
39	stronger	strong	JJR	_	37	obj	_	_
40	of	of	IN	_	42	case	_	_
41	the	the	DT	_	42	det	_	_
42	two	#crd#	CD	_	39	ppmod	_	_
43	with	with	IN	_	44	case	_	_
44	respect	respect	NN	_	39	ppmod	_	_
45	to	to	TO	_	47	aux	_	_
46	CYP3A	cyp0a	NN	_	47	com	_	_
47	inhibition	inhibition	NN	_	44	ppmod	_	_
48	.	.	.	_	2	p	_	_

1	This	this	DT	_	2	det	_	_
2	observation	observation	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	lv	_	_
4	important	important	JJ	_	5	attr	_	_
5	implications	implication	NNS	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	context	context	NN	_	5	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	drug-drug	drug-drug	JJ	_	11	attr	_	_
11	interactions	interaction	NNS	_	8	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	transplant	transplant	NN	_	14	com	_	_
14	recipients	recipient	NNS	_	11	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	-LSB-Influence	-lsb-influence	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	on	on	IN	_	9	case	_	_
7	MPTP-evoked	mptp-evoked	JJ	_	9	attr	_	_
8	behavior	behavior	NN	_	9	com	_	_
9	violations	violation	NNS	_	1	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	C57BL/6	c0bl/0	NN	_	12	com	_	_
12	mice	mouse	NNS	_	9	ppmod	_	_
13	]	-rsb-	-RRB-	_	1	p	_	_
14	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	0	root	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	JJ	_	5	attr	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	[	-lsb-	-LRB-	_	7	p	_	_
7	drug3	drug0	NN	_	5	prn	_	_
8	]	-rsb-	-RRB-	_	7	p	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	10	0	CD	_	11	num	_	_
11	mg/kg	mg/kg	NN	_	5	prn	_	_
12	,	,	,	_	11	p	_	_
13	p.	p.	FW	_	14	attr	_	_
14	o	o	NN	_	11	appo	_	_
15	.	.	.	_	14	p	_	_
16	)	-rrb-	-RRB-	_	11	p	_	_

1	and/or	and/or	CC	_	3	cc	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	drug2	drug0	NN	_	0	root	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	100	0	CD	_	6	num	_	_
6	mg/kg	mg/kg	NN	_	3	prn	_	_
7	,	,	,	_	6	p	_	_
8	p.	p.	NNP	_	9	com	_	_
9	o.	o.	NNP	_	6	appo	_	_
10	)	-rrb-	-RRB-	_	6	p	_	_
11	,	,	,	_	3	p	_	_
12	as	as	RB	_	13	com	_	_
13	well	well	RB	_	3	cc	_	_
14	as	as	IN	_	13	com	_	_
15	that	that	DT	_	3	conj	_	_
16	of	of	IN	_	18	case	_	_
17	neurotoxin	neurotoxin	NN	_	18	com	_	_
18	drug3	drug0	NN	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug4	drug0	NN	_	3	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	(	-lrb-	-LRB-	_	26	p	_	_
23	4	0	CD	_	26	num	_	_
24	x	x	CC	_	23	cc	_	_
25	20	0	CD	_	23	conj	_	_
26	mg/kg	mg/kg	NN	_	3	prn	_	_
27	,	,	,	_	26	p	_	_
28	i.	i.	NN	_	29	com	_	_
29	p	p	NN	_	26	appo	_	_
30	.	.	.	_	26	p	_	_
31	)	-rrb-	-RRB-	_	26	p	_	_

1	were	be	VBD	_	2	aux	_	_
2	studied	study	VBN	_	0	root	_	_
3	in	in	IN	_	7	case	_	_
4	elevated	elevated	JJ	_	7	attr	_	_
5	plus	plus	CC	_	4	cc	_	_
6	maze	maze	JJ	_	4	conj	_	_
7	test	test	NN	_	2	ppmod	_	_
8	on	on	IN	_	10	case	_	_
9	C57BL/6	c0bl/0	NN	_	10	com	_	_
10	mice	mouse	NNS	_	7	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	On	on	IN	_	3	case	_	_
2	second	#ord#	JJ	_	3	attr	_	_
3	day	day	NN	_	8	ppmod	_	_
4	after	after	IN	_	5	case	_	_
5	injection	injection	NN	_	3	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	decreased	decrease	VBD	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	locomot	locomot	NN	_	8	obj	_	_
11	or	or	CC	_	10	cc	_	_
12	activity	activity	NN	_	10	conj	_	_
13	in	in	IN	_	14	case	_	_
14	comparison	comparison	NN	_	10	ppmod	_	_
15	to	to	TO	_	16	aux	_	_
16	saline	saline	NN	_	14	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	Acute	acute	JJ	_	2	attr	_	_
2	administration	administration	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	failed	fail	VBD	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	influence	influence	VB	_	7	comp	_	_
10	locomotion	locomotion	NN	_	9	obj	_	_
11	in	in	IN	_	12	case	_	_
12	mice	mouse	NNS	_	10	ppmod	_	_
13	,	,	,	_	7	p	_	_
14	while	while	IN	_	17	mark	_	_
15	their	their	PRP$	_	16	poss	_	_
16	combination	combination	NN	_	17	dep	_	_
17	normalized	normalize	VBN	_	7	comp	_	_
18	motor	motor	NN	_	19	com	_	_
19	activity	activity	NN	_	17	obj	_	_
20	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	4	dep	_	_
3	obtained	obtain	VBN	_	2	acl	_	_
4	confirm	confirm	VBP	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	role	role	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	inflammatory	inflammatory	JJ	_	9	attr	_	_
9	processes	process	NNS	_	6	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	parkinsonism	parkinsonism	NN	_	6	ppmod	_	_
12	and	and	CC	_	4	cc	_	_
13	suggest	suggest	VBP	_	4	conj	_	_
14	expediency	expediency	NN	_	13	obj	_	_
15	of	of	IN	_	17	case	_	_
16	combined	combined	JJ	_	17	attr	_	_
17	pharmacotherapy	pharmacotherapy	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	neurodegenerative	neurodegenerative	JJ	_	20	attr	_	_
20	diseases	disease	NNS	_	17	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Exposure	exposure	NN	_	5	dep	_	_
2	to	to	TO	_	4	aux	_	_
3	oral	oral	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	is	be	VBZ	_	0	root	_	_
6	unaffected	unaffected	JJ	_	5	dep	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	but	but	CC	_	6	cc	_	_
10	greatly	greatly	RB	_	11	adv	_	_
11	increased	increase	VBN	_	6	conj	_	_
12	by	by	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	examined	examine	VBD	_	0	root	_	_
4	drug-drug	drug-drug	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	with	with	IN	_	18	case	_	_
10	the	the	DT	_	18	det	_	_
11	cytochrome	cytochrome	NN	_	12	com	_	_
12	P450	p0	NN	_	18	attr	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	CYP	cyp	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	2B6	0b0	NN	_	18	com	_	_
17	inhibitor	inhibitor	NN	_	18	com	_	_
18	drug2	drug0	NN	_	5	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	the	the	DT	_	23	det	_	_
21	CYP3A	cyp0a	NN	_	23	com	_	_
22	inhibitor	inhibitor	NN	_	23	com	_	_
23	drug3	drug0	NN	_	18	conj	_	_
24	.	.	.	_	3	p	_	_

1	In	in	IN	_	8	case	_	_
2	this	this	DT	_	8	det	_	_
3	randomized	randomized	JJ	_	7	adv	_	_
4	,	,	,	_	7	p	_	_
5	blinded	blinded	JJ	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	crossover	crossover	JJ	_	8	attr	_	_
8	study	study	NN	_	13	ppmod	_	_
9	,	,	,	_	13	p	_	_
10	11	0	CD	_	12	num	_	_
11	healthy	healthy	JJ	_	12	attr	_	_
12	volunteers	volunteer	NNS	_	13	dep	_	_
13	ingested	ingest	VBN	_	0	root	_	_
14	0.2	0	CD	_	15	num	_	_
15	mg/kg	mg/kg	NN	_	16	com	_	_
16	drug1	drug0	NN	_	13	obj	_	_
17	after	after	IN	_	18	case	_	_
18	pretreatments	pretreatment	NNS	_	16	ppmod	_	_
19	with	with	IN	_	21	case	_	_
20	oral	oral	JJ	_	21	attr	_	_
21	drug2	drug0	NN	_	18	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	250	0	CD	_	24	num	_	_
24	mg	mg	NN	_	21	prn	_	_
25	twice	twice	RB	_	26	com	_	_
26	daily	daily	RB	_	24	adv	_	_
27	)	-rrb-	-RRB-	_	24	p	_	_
28	,	,	,	_	21	p	_	_
29	drug3	drug0	NN	_	21	conj	_	_
30	(	-lrb-	-LRB-	_	32	p	_	_
31	200	0	CD	_	32	num	_	_
32	mg	mg	NN	_	29	prn	_	_
33	once	once	RB	_	34	adv	_	_
34	daily	daily	JJ	_	32	attr	_	_
35	)	-rrb-	-RRB-	_	32	p	_	_
36	,	,	,	_	29	p	_	_
37	or	or	CC	_	29	cc	_	_
38	placebo	placebo	NN	_	21	conj	_	_
39	in	in	IN	_	42	case	_	_
40	6-day	0-day	JJ	_	42	attr	_	_
41	treatment	treatment	NN	_	42	com	_	_
42	periods	period	NNS	_	16	ppmod	_	_
43	at	at	IN	_	44	case	_	_
44	intervals	interval	NNS	_	13	ppmod	_	_
45	of	of	IN	_	47	case	_	_
46	4	0	CD	_	47	num	_	_
47	weeks	week	NNS	_	44	ppmod	_	_
48	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	treatment	treatment	NN	_	3	dep	_	_
3	increased	increase	VBD	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	mean	mean	JJ	_	6	attr	_	_
6	area	area	NN	_	3	obj	_	_
7	under	under	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	concentration-time	concentration-time	NN	_	11	com	_	_
11	curve	curve	NN	_	6	ppmod	_	_
12	extrapolated	extrapolate	VBN	_	11	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	infinity	infinity	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	AUC	auc	NN	_	6	prn	_	_
17	(	-lrb-	-LRB-	_	16	p	_	_
18	0-	0-	CD	_	16	num	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	)	-rrb-	-RRB-	_	16	p	_	_
21	of	of	IN	_	23	case	_	_
22	oral	oral	JJ	_	23	attr	_	_
23	drug2	drug0	NN	_	6	ppmod	_	_
24	by	by	IN	_	25	case	_	_
25	2.4-fold	0-fold	RB	_	3	ppmod	_	_
26	,	,	,	_	3	p	_	_
27	whereas	whereas	IN	_	32	mark	_	_
28	drug3	drug0	NN	_	29	com	_	_
29	treatment	treatment	NN	_	32	dep	_	_
30	did	do	VBD	_	32	aux	_	_
31	not	not	RB	_	32	neg	_	_
32	increase	increase	VB	_	3	comp	_	_
33	the	the	DT	_	34	det	_	_
34	exposure	exposure	NN	_	32	obj	_	_
35	to	to	TO	_	36	aux	_	_
36	drug4	drug0	NN	_	34	ppmod	_	_
37	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	ratio	ratio	NN	_	17	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	AUC	auc	NN	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	0-	0-	CD	_	5	num	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	to	to	TO	_	11	aux	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	AUC	auc	NN	_	2	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	0-	0-	CD	_	11	num	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	was	be	VBD	_	17	aux	_	_
16	significantly	significantly	RB	_	17	adv	_	_
17	decreased	decrease	VBN	_	0	root	_	_
18	in	in	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	drug3	drug0	NN	_	17	ppmod	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	P	p	NN	_	23	com	_	_
23	&amp	&amp	NN	_	17	prn	_	_
24	;	;	:	_	23	p	_	_
25	lt	lt	NN	_	23	appo	_	_
26	;	;	:	_	23	p	_	_
27	0.001	0	CD	_	23	appo	_	_
28	)	-rrb-	-RRB-	_	23	p	_	_
29	drug4	drug0	IN	_	31	case	_	_
30	zole	zole	JJ	_	31	attr	_	_
31	phases	phase	NNS	_	17	ppmod	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	P	p	NN	_	31	prn	_	_
34	=	=	JJ	_	33	attr	_	_
35	0.006	0	CD	_	33	num	_	_
36	)	-rrb-	-RRB-	_	33	p	_	_
37	as	as	IN	_	38	mark	_	_
38	compared	compare	VBN	_	17	comp	_	_
39	to	to	TO	_	40	aux	_	_
40	placebo	placebo	NN	_	38	ppmod	_	_
41	.	.	.	_	17	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	drug1	drug0	NN	_	20	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	phases	phase	NNS	_	3	conj	_	_
7	,	,	,	_	20	p	_	_
8	the	the	DT	_	9	det	_	_
9	areas	area	NNS	_	20	dep	_	_
10	under	under	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	effect-time	effect-time	JJ	_	13	attr	_	_
13	curves	curve	NNS	_	9	ppmod	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	self-reported	self-reported	JJ	_	16	attr	_	_
16	drowsiness	drowsiness	NN	_	13	prn	_	_
17	and	and	CC	_	16	cc	_	_
18	performance	performance	NN	_	16	conj	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	were	be	VBD	_	0	root	_	_
21	significantly	significantly	RB	_	22	adv	_	_
22	higher	high	JJR	_	20	dep	_	_
23	than	than	IN	_	24	case	_	_
24	those	those	DT	_	22	ppmod	_	_
25	in	in	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	placebo	placebo	NN	_	28	com	_	_
28	phase	phase	NN	_	24	ppmod	_	_
29	(	-lrb-	-LRB-	_	33	p	_	_
30	P	p	NN	_	33	attr	_	_
31	&lt	&lt	CD	_	33	num	_	_
32	;	;	:	_	33	p	_	_
33	0.05	0	CD	_	24	num	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	.	.	.	_	20	p	_	_

1	The	the	DT	_	2	det	_	_
2	findings	finding	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	11	mark	_	_
5	the	the	DT	_	6	det	_	_
6	dosage	dosage	NN	_	11	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	reduced	reduce	VBN	_	3	comp	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	drug2	drug0	NN	_	14	obj	_	_
16	.	.	.	_	3	p	_	_

1	Interaction	interaction	NN	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	different	different	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	1	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	antagonistic	antagonistic	JJ	_	7	dep	_	_
9	in	in	IN	_	10	case	_	_
10	breast	breast	NN	_	8	ppmod	_	_
11	but	but	CC	_	10	cc	_	_
12	not	not	RB	_	16	neg	_	_
13	in	in	IN	_	16	case	_	_
14	other	other	JJ	_	16	attr	_	_
15	cancer	cancer	NN	_	16	com	_	_
16	cells	cell	NNS	_	10	conj	_	_
17	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	,	,	,	_	1	p	_	_
3	an	an	DT	_	4	det	_	_
4	inhibitor	inhibitor	NN	_	1	appo	_	_
5	of	of	IN	_	6	case	_	_
6	cyclooxygenase-2	cyclooxygenase-0	NN	_	4	ppmod	_	_
7	,	,	,	_	1	p	_	_
8	is	be	VBZ	_	10	aux	_	_
9	being	be	VBG	_	10	aux	_	_
10	investigated	investigate	VBN	_	0	root	_	_
11	for	for	IN	_	12	case	_	_
12	enhancement	enhancement	NN	_	10	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	chemotherapy	chemotherapy	NN	_	15	com	_	_
15	efficacy	efficacy	NN	_	12	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	cancer	cancer	NN	_	19	attr	_	_
18	clinical	clinical	JJ	_	19	attr	_	_
19	trials	trial	NNS	_	12	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	investigates	investigate	VBZ	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	ability	ability	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	sensitize	sensitize	VB	_	5	acl	_	_
10	cells	cell	NNS	_	9	obj	_	_
11	from	from	IN	_	13	case	_	_
12	different	different	JJ	_	13	attr	_	_
13	origins	origin	NNS	_	10	ppmod	_	_
14	to	to	TO	_	16	aux	_	_
15	several	several	JJ	_	16	attr	_	_
16	drug2	drug0	NNS	_	9	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	16	dep	_	_
3	of	of	IN	_	7	case	_	_
4	the	the	DT	_	5	det	_	_
5	drug	drug	NN	_	7	poss	_	_
6	's	's	POS	_	5	case	_	_
7	mechanism	mechanism	NN	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	action	action	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	sequence	sequence	NN	_	9	conj	_	_
12	of	of	IN	_	13	case	_	_
13	administration	administration	NN	_	9	ppmod	_	_
14	are	be	VBP	_	16	aux	_	_
15	also	also	RB	_	16	adv	_	_
16	investigated	investigate	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	The	the	DT	_	2	det	_	_
2	sensitivity	sensitivity	NN	_	42	dep	_	_
3	,	,	,	_	2	p	_	_
4	cell	cell	NN	_	5	com	_	_
5	cycle	cycle	NN	_	2	conj	_	_
6	,	,	,	_	5	p	_	_
7	apoptosis	apoptosis	NN	_	2	conj	_	_
8	and	and	CC	_	7	cc	_	_
9	DNA	dna	NN	_	10	com	_	_
10	damage	damage	NN	_	2	conj	_	_
11	of	of	IN	_	16	case	_	_
12	five	#crd#	CD	_	16	num	_	_
13	different	different	JJ	_	16	attr	_	_
14	cancer	cancer	NN	_	16	com	_	_
15	cell	cell	NN	_	16	com	_	_
16	lines	line	NNS	_	2	ppmod	_	_
17	(	-lrb-	-LRB-	_	16	p	_	_
18	HeLa	hela	NN	_	16	appo	_	_
19	,	,	,	_	18	p	_	_
20	HCT116	hct0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	HepG2	hepg0	NN	_	18	conj	_	_
23	,	,	,	_	22	p	_	_
24	MCF7	mcf0	NN	_	18	conj	_	_
25	and	and	CC	_	24	cc	_	_
26	U251	u0	NN	_	18	conj	_	_
27	)	-rrb-	-RRB-	_	16	p	_	_
28	to	to	TO	_	29	aux	_	_
29	drug1	drug0	NN	_	2	ppmod	_	_
30	,	,	,	_	29	p	_	_
31	drug2	drug0	NN	_	29	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug3	drug0	NN	_	29	conj	_	_
34	and	and	CC	_	33	cc	_	_
35	drug4	drug0	NN	_	40	attr	_	_
36	drug5	drug0	NN	_	40	attr	_	_
37	following	following	JJ	_	40	attr	_	_
38	different	different	JJ	_	40	attr	_	_
39	incubation	incubation	NN	_	40	com	_	_
40	schedules	schedule	NNS	_	29	conj	_	_
41	were	be	VBD	_	42	aux	_	_
42	analyzed	analyze	VBN	_	0	root	_	_
43	.	.	.	_	42	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	found	find	VBD	_	0	root	_	_
3	antagonism	antagonism	NN	_	2	obj	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	the	the	DT	_	9	det	_	_
8	four	#crd#	CD	_	9	num	_	_
9	drugs	drug	NNS	_	5	conj	_	_
10	in	in	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	breast	breast	NN	_	14	com	_	_
13	cancer	cancer	NN	_	14	com	_	_
14	cells	cell	NNS	_	5	ppmod	_	_
15	MCF7	mcf0	RB	_	16	adv	_	_
16	following	follow	VBG	_	14	acl	_	_
17	all	all	DT	_	19	det	_	_
18	incubation	incubation	NN	_	19	com	_	_
19	schedules	schedule	NNS	_	16	obj	_	_
20	and	and	CC	_	5	cc	_	_
21	between	between	IN	_	22	case	_	_
22	drug2	drug0	NN	_	5	conj	_	_
23	and	and	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	in	in	IN	_	28	case	_	_
26	all	all	DT	_	28	det	_	_
27	cell	cell	NN	_	28	com	_	_
28	lines	line	NNS	_	2	ppmod	_	_
29	except	except	IN	_	32	case	_	_
30	for	for	IN	_	32	case	_	_
31	two	#crd#	CD	_	32	num	_	_
32	combinations	combination	NNS	_	2	ppmod	_	_
33	in	in	IN	_	35	case	_	_
34	HCT116	hct0	NN	_	35	com	_	_
35	cells	cell	NNS	_	32	ppmod	_	_
36	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	with	with	IN	_	6	case	_	_
3	the	the	DT	_	6	det	_	_
4	other	other	JJ	_	6	attr	_	_
5	three	#crd#	CD	_	6	num	_	_
6	drugs	drug	NNS	_	1	ppmod	_	_
7	in	in	IN	_	12	case	_	_
8	the	the	DT	_	12	det	_	_
9	remaining	remain	VBG	_	12	attr	_	_
10	four	#crd#	CD	_	12	num	_	_
11	cell	cell	NN	_	12	com	_	_
12	lines	line	NNS	_	1	ppmod	_	_
13	resulted	result	VBD	_	0	root	_	_
14	in	in	IN	_	16	case	_	_
15	variable	variable	JJ	_	16	attr	_	_
16	interactions	interaction	NNS	_	13	ppmod	_	_
17	.	.	.	_	13	p	_	_

1	Mechanistic	mechanistic	JJ	_	2	attr	_	_
2	investigations	investigation	NNS	_	3	dep	_	_
3	revealed	reveal	VBD	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	exerts	exert	VBZ	_	3	comp	_	_
7	different	different	JJ	_	9	attr	_	_
8	molecular	molecular	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	6	obj	_	_
10	in	in	IN	_	12	case	_	_
11	different	different	JJ	_	12	attr	_	_
12	cells	cell	NNS	_	6	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	lines	line	NNS	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	it	it	PRP	_	6	dep	_	_
6	abrogates	abrogate	VBZ	_	0	root	_	_
7	the	the	DT	_	10	det	_	_
8	drug-induced	drug-induced	JJ	_	10	attr	_	_
9	G2/M	g0/m	NN	_	10	com	_	_
10	arrest	arrest	NN	_	6	obj	_	_
11	enhancing	enhance	VBG	_	10	acl	_	_
12	pre-mature	pre-mature	NN	_	13	com	_	_
13	entry	entry	NN	_	11	obj	_	_
14	into	into	IN	_	15	case	_	_
15	mitosis	mitosis	NN	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	damaged	damaged	JJ	_	18	attr	_	_
18	DNA	dna	NN	_	13	ppmod	_	_
19	thus	thus	RB	_	20	adv	_	_
20	increasing	increase	VBG	_	6	comp	_	_
21	apoptosis	apoptosis	NN	_	20	obj	_	_
22	and	and	CC	_	20	cc	_	_
23	resulting	result	VBG	_	20	conj	_	_
24	in	in	IN	_	25	case	_	_
25	synergism	synergism	NN	_	23	ppmod	_	_
26	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	other	other	JJ	_	3	attr	_	_
3	cells	cell	NNS	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	it	it	PRP	_	6	dep	_	_
6	enhances	enhance	VBZ	_	0	root	_	_
7	drug-induced	drug-induced	JJ	_	9	attr	_	_
8	G2/M	g0/m	NN	_	9	com	_	_
9	arrest	arrest	NN	_	6	obj	_	_
10	allowing	allow	VBG	_	9	acl	_	_
11	time	time	NN	_	10	obj	_	_
12	to	to	TO	_	16	aux	_	_
13	repair	repair	NN	_	16	attr	_	_
14	drug-induced	drug-induced	JJ	_	16	attr	_	_
15	DNA	dna	NN	_	16	com	_	_
16	damage	damage	NN	_	11	ppmod	_	_
17	before	before	IN	_	18	case	_	_
18	entry	entry	NN	_	11	ppmod	_	_
19	into	into	IN	_	20	case	_	_
20	mitosis	mitosis	NN	_	18	ppmod	_	_
21	and	and	CC	_	10	cc	_	_
22	decreasing	decrease	VBG	_	10	conj	_	_
23	cell	cell	NN	_	24	com	_	_
24	death	death	NN	_	22	obj	_	_
25	resulting	result	VBG	_	24	acl	_	_
26	in	in	IN	_	27	case	_	_
27	antagonism	antagonism	NN	_	25	ppmod	_	_
28	.	.	.	_	6	p	_	_

1	In	in	IN	_	4	case	_	_
2	some	some	DT	_	4	det	_	_
3	synergistic	synergistic	JJ	_	4	attr	_	_
4	combinations	combination	NNS	_	13	ppmod	_	_
5	,	,	,	_	13	p	_	_
6	celecoxib-induced	celecoxib-induced	JJ	_	7	attr	_	_
7	abrogation	abrogation	NN	_	13	dep	_	_
8	of	of	IN	_	10	case	_	_
9	G2/M	g0/m	NN	_	10	com	_	_
10	arrest	arrest	NN	_	7	ppmod	_	_
11	was	be	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	associated	associate	VBN	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	apoptosis	apoptosis	NN	_	13	ppmod	_	_
16	but	but	CC	_	15	cc	_	_
17	permanent	permanent	JJ	_	18	attr	_	_
18	arrest	arrest	NN	_	15	conj	_	_
19	in	in	IN	_	21	case	_	_
20	G1	g0	NN	_	21	com	_	_
21	phase	phase	NN	_	15	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	8	dep	_	_
3	,	,	,	_	8	p	_	_
4	if	if	IN	_	5	mark	_	_
5	confirmed	confirm	VBN	_	8	advcl	_	_
6	in-vivo	in-vivo	NN	_	5	obj	_	_
7	,	,	,	_	8	p	_	_
8	indicate	indicate	VBP	_	0	root	_	_
9	that	that	IN	_	11	mark	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	is	be	VBZ	_	8	comp	_	_
12	not	not	RB	_	11	neg	_	_
13	a	a	DT	_	15	det	_	_
14	suitable	suitable	JJ	_	15	attr	_	_
15	chemosensitizer	chemosensitizer	NN	_	11	obj	_	_
16	for	for	IN	_	18	case	_	_
17	breast	breast	NN	_	18	com	_	_
18	cancer	cancer	NN	_	15	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	18	conj	_	_
22	for	for	IN	_	24	case	_	_
23	other	other	JJ	_	24	attr	_	_
24	cancers	cancer	NNS	_	21	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	Moreover	moreover	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	combination	combination	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	3	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	tailored	tailor	VBN	_	0	root	_	_
12	to	to	TO	_	15	aux	_	_
13	the	the	DT	_	15	det	_	_
14	tumor	tumor	NN	_	15	com	_	_
15	type	type	NN	_	11	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug	drug	NN	_	15	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	administration	administration	NN	_	20	com	_	_
20	schedule	schedule	NN	_	15	conj	_	_
21	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	interaction	interaction	NN	_	1	conj	_	_
5	and	and	CC	_	1	cc	_	_
6	associated	associate	VBD	_	1	conj	_	_
7	gastrointestinal	gastrointestinal	JJ	_	9	attr	_	_
8	bleeding	bleeding	JJ	_	9	attr	_	_
9	risk	risk	NN	_	6	obj	_	_
10	in	in	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	case-control	case-control	JJ	_	13	attr	_	_
13	study	study	NN	_	6	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	Bleeding	bleeding	JJ	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	the	the	DT	_	9	det	_	_
4	most	most	RBS	_	5	adv	_	_
5	common	common	JJ	_	9	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	worrisome	worrisome	NN	_	8	advnp	_	_
8	adverse	adverse	JJ	_	5	conj	_	_
9	effect	effect	NN	_	2	obj	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	9	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	One	#crd#	CD	_	10	num	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	factors	factor	NNS	_	1	ppmod	_	_
5	that	that	WDT	_	7	dep	_	_
6	might	might	MD	_	7	modal	_	_
7	increase	increase	VB	_	4	relcl	_	_
8	bleeding	bleeding	JJ	_	9	attr	_	_
9	risk	risk	NN	_	7	obj	_	_
10	is	be	VBZ	_	0	root	_	_
11	initiation	initiation	NN	_	10	obj	_	_
12	of	of	IN	_	14	case	_	_
13	interacting	interacting	NN	_	14	com	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	that	that	WDT	_	16	dep	_	_
16	potentiate	potentiate	VB	_	11	relcl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	.	.	.	_	10	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	sought	seek	VBD	_	0	root	_	_
3	to	to	TO	_	4	aux	_	_
4	evaluate	evaluate	VB	_	2	comp	_	_
5	whether	whether	IN	_	10	mark	_	_
6	initiation	initiation	NN	_	10	dep	_	_
7	of	of	IN	_	9	case	_	_
8	an	an	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	increases	increase	VBZ	_	4	comp	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	hospitalization	hospitalization	NN	_	12	ppmod	_	_
15	for	for	IN	_	17	case	_	_
16	gastrointestinal	gastrointestinal	JJ	_	17	attr	_	_
17	bleeding	bleeding	JJ	_	12	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	users	user	NNS	_	17	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	Medicaid	medicaid	NN	_	3	com	_	_
2	claims	claims	NN	_	3	com	_	_
3	data	datum	NNS	_	8	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	1999-2005	0	NN	_	3	num	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	were	be	VBD	_	8	aux	_	_
8	used	use	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	perform	perform	VB	_	8	comp	_	_
11	an	an	DT	_	14	det	_	_
12	observational	observational	JJ	_	14	attr	_	_
13	case-control	case-control	JJ	_	14	attr	_	_
14	study	study	NN	_	10	obj	_	_
15	nested	nest	VBN	_	14	acl	_	_
16	within	within	IN	_	17	case	_	_
17	person-time	person-time	NN	_	15	ppmod	_	_
18	exposed	expose	VBN	_	17	acl	_	_
19	to	to	TO	_	20	aux	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	in	in	IN	_	24	case	_	_
22	those	those	DT	_	24	det	_	_
23	18	0	CD	_	24	num	_	_
24	years	year	NNS	_	18	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	In	in	IN	_	2	case	_	_
2	total	total	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	430,455	0	NN	_	6	num	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	users	user	NNS	_	7	dep	_	_
7	contributed	contribute	VBD	_	0	root	_	_
8	407,370	0	CD	_	9	num	_	_
9	person-years	person-years	NNS	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	use	use	NN	_	9	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	incidence	incidence	NN	_	3	com	_	_
3	rate	rate	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	hospitalization	hospitalization	NN	_	3	ppmod	_	_
6	for	for	IN	_	8	case	_	_
7	GI	gi	JJ	_	8	attr	_	_
8	bleeding	bleeding	JJ	_	5	ppmod	_	_
9	among	among	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	users	user	NNS	_	5	ppmod	_	_
12	was	be	VBD	_	0	root	_	_
13	4.48	0	CD	_	15	num	_	_
14	per	per	IN	_	15	case	_	_
15	100	0	CD	_	16	num	_	_
16	person-years	person-years	NNS	_	12	obj	_	_
17	(	-lrb-	-LRB-	_	22	p	_	_
18	95	0	CD	_	20	num	_	_
19	%	%	NN	_	20	meta	_	_
20	CI	ci	CD	_	22	num	_	_
21	,	,	,	_	22	p	_	_
22	4.42-4.55	0	CD	_	12	num	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	.	.	.	_	12	p	_	_

1	Each	each	DT	_	4	det	_	_
2	gastrointestinal	gastrointestinal	JJ	_	4	attr	_	_
3	bleeding	bleeding	JJ	_	4	attr	_	_
4	cases	case	NNS	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	matched	match	VBN	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	50	0	CD	_	9	num	_	_
9	controls	control	NNS	_	6	ppmod	_	_
10	based	base	VBN	_	9	acl	_	_
11	on	on	IN	_	13	case	_	_
12	index	index	NN	_	13	com	_	_
13	date	date	NN	_	10	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	state	state	NN	_	13	conj	_	_
16	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	users	user	NNS	_	3	dep	_	_
3	had	have	VBD	_	0	root	_	_
4	an	an	DT	_	7	det	_	_
5	increased	increase	VBN	_	7	attr	_	_
6	odds	odds	NNS	_	7	com	_	_
7	ratio	ratio	NN	_	3	obj	_	_
8	of	of	IN	_	10	case	_	_
9	gastrointestinal	gastrointestinal	JJ	_	10	attr	_	_
10	bleeding	bleeding	JJ	_	7	ppmod	_	_
11	upon	upon	IN	_	12	case	_	_
12	initiation	initiation	NN	_	3	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	21	p	_	_
16	OR	or	CC	_	21	cc	_	_
17	=	=	JJ	_	21	attr	_	_
18	1.73	0	CD	_	17	num	_	_
19	-LSB-95	-lsb-0	CD	_	21	num	_	_
20	%	%	NN	_	19	meta	_	_
21	CI	ci	NN	_	14	prn	_	_
22	,	,	,	_	21	p	_	_
23	1.25-2.38	0	CD	_	21	appo	_	_
24	]	-rsb-	-RRB-	_	23	p	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	,	,	,	_	14	p	_	_
27	drug3	drug0	NN	_	14	appo	_	_
28	(	-lrb-	-LRB-	_	34	p	_	_
29	OR	or	CC	_	34	cc	_	_
30	=	=	JJ	_	34	attr	_	_
31	1.63	0	CD	_	30	num	_	_
32	-LSB-95	-lsb-0	CD	_	34	num	_	_
33	%	%	NN	_	32	meta	_	_
34	CI	ci	NN	_	27	prn	_	_
35	,	,	,	_	34	p	_	_
36	1.11-2.38	0	CD	_	34	appo	_	_
37	]	-rsb-	-RRB-	_	36	p	_	_
38	)	-rrb-	-RRB-	_	34	p	_	_
39	,	,	,	_	14	p	_	_
40	drug4	drug0	NN	_	14	appo	_	_
41	(	-lrb-	-LRB-	_	47	p	_	_
42	OR	or	CC	_	47	cc	_	_
43	=	=	JJ	_	47	attr	_	_
44	1.64	0	CD	_	43	num	_	_
45	-LSB-95	-lsb-0	CD	_	47	num	_	_
46	%	%	NN	_	45	meta	_	_
47	CI	ci	NN	_	40	prn	_	_
48	,	,	,	_	47	p	_	_
49	1.27-2.12	0	CD	_	47	appo	_	_
50	]	-rsb-	-RRB-	_	49	p	_	_
51	)	-rrb-	-RRB-	_	47	p	_	_
52	,	,	,	_	14	p	_	_
53	drug5	drug0	NN	_	14	appo	_	_
54	(	-lrb-	-LRB-	_	62	p	_	_
55	OR	or	CC	_	62	cc	_	_
56	=	=	JJ	_	62	attr	_	_
57	1.47	0	NN	_	62	num	_	_
58	-LSB-95	-lsb-0	CD	_	57	num	_	_
59	%	%	NN	_	57	meta	_	_
60	CI	ci	CD	_	62	num	_	_
61	,	,	,	_	62	p	_	_
62	1.02-2.11	0	CD	_	53	num	_	_
63	]	-rsb-	-RRB-	_	62	p	_	_
64	)	-rrb-	-RRB-	_	62	p	_	_
65	.	.	.	_	3	p	_	_

1	Also	also	RB	_	13	adv	_	_
2	drug1	drug0	NN	_	13	dep	_	_
3	,	,	,	_	2	p	_	_
4	which	which	WDT	_	7	dep	_	_
5	is	be	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	believed	believe	VBN	_	2	relcl	_	_
8	to	to	TO	_	9	aux	_	_
9	interact	interact	VB	_	7	comp	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NNS	_	9	ppmod	_	_
12	,	,	,	_	2	p	_	_
13	increased	increase	VBD	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	risk	risk	NN	_	13	obj	_	_
16	of	of	IN	_	18	case	_	_
17	GI	gi	JJ	_	18	attr	_	_
18	bleeding	bleeding	JJ	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	25	p	_	_
20	OR	or	CC	_	25	cc	_	_
21	=	=	JJ	_	25	attr	_	_
22	1.75	0	CD	_	23	com	_	_
23	-LSB-95	-lsb-0	CD	_	21	num	_	_
24	%	%	NN	_	23	meta	_	_
25	CI	ci	NN	_	15	prn	_	_
26	,	,	,	_	25	p	_	_
27	1.30-2.35	0	CD	_	25	appo	_	_
28	]	-rsb-	-RRB-	_	27	p	_	_
29	)	-rrb-	-RRB-	_	25	p	_	_
30	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	users	user	NNS	_	18	dep	_	_
3	who	who	WP	_	4	dep	_	_
4	initiated	initiate	VBD	_	2	relcl	_	_
5	drug2	drug0	NN	_	4	obj	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug5	drug0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	or	or	CC	_	11	cc	_	_
14	drug6	drug0	NN	_	5	conj	_	_
15	had	have	VBD	_	18	lv	_	_
16	an	an	DT	_	18	det	_	_
17	increased	increase	VBN	_	18	attr	_	_
18	risk	risk	NN	_	0	root	_	_
19	of	of	IN	_	20	case	_	_
20	hospitalization	hospitalization	NN	_	18	ppmod	_	_
21	for	for	IN	_	23	case	_	_
22	gastrointestinal	gastrointestinal	JJ	_	23	attr	_	_
23	bleeding	bleeding	JJ	_	18	ppmod	_	_
24	.	.	.	_	18	p	_	_

1	However	however	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	the	the	DT	_	5	det	_	_
4	elevated	elevated	JJ	_	5	attr	_	_
5	risk	risk	NN	_	8	dep	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	suggests	suggest	VBZ	_	0	root	_	_
9	that	that	IN	_	16	mark	_	_
10	a	a	DT	_	12	det	_	_
11	drug-drug	drug-drug	JJ	_	12	attr	_	_
12	interaction	interaction	NN	_	16	dep	_	_
13	may	may	MD	_	16	modal	_	_
14	not	not	RB	_	16	neg	_	_
15	have	have	VBP	_	16	aux	_	_
16	been	be	VBN	_	8	comp	_	_
17	responsible	responsible	JJ	_	16	dep	_	_
18	for	for	IN	_	19	case	_	_
19	all	all	DT	_	17	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	the	the	DT	_	24	det	_	_
22	observed	observe	VBN	_	24	attr	_	_
23	increased	increase	VBN	_	24	attr	_	_
24	risk	risk	NN	_	19	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	enhances	enhance	VBZ	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	antinociceptive	antinociceptive	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	mice	mouse	NNS	_	5	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	7	det	_	_
4	highly	highly	RB	_	5	adv	_	_
5	selective	selective	JJ	_	7	attr	_	_
6	alpha-2-adrenoceptor	alpha-0-adrenoceptor	NN	_	7	com	_	_
7	agonist	agonist	NN	_	1	appo	_	_
8	,	,	,	_	1	p	_	_
9	was	be	VBD	_	11	aux	_	_
10	recently	recently	RB	_	11	adv	_	_
11	introduced	introduce	VBN	_	0	root	_	_
12	into	into	IN	_	14	case	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	practice	practice	NN	_	11	ppmod	_	_
15	for	for	IN	_	20	case	_	_
16	its	its	PRP$	_	20	poss	_	_
17	sedative	sedative	JJ	_	20	attr	_	_
18	and	and	CC	_	17	cc	_	_
19	analgesic	analgesic	JJ	_	17	conj	_	_
20	properties	property	NNS	_	14	ppmod	_	_
21	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	purpose	purpose	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	evaluate	evaluate	VB	_	6	comp	_	_
9	whether	whether	IN	_	14	mark	_	_
10	the	the	DT	_	13	det	_	_
11	psychostimulant	psychostimulant	JJ	_	13	attr	_	_
12	drug	drug	NN	_	13	com	_	_
13	drug1	drug0	NN	_	14	dep	_	_
14	has	have	VBZ	_	8	comp	_	_
15	any	any	DT	_	16	det	_	_
16	effect	effect	NN	_	14	obj	_	_
17	on	on	IN	_	20	case	_	_
18	drug2	drug0	JJ	_	20	attr	_	_
19	-induced	-induced	JJ	_	20	attr	_	_
20	antinociception	antinociception	NN	_	16	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	locomotor	locomotor	NN	_	24	com	_	_
23	inhibitor	inhibitor	NN	_	24	com	_	_
24	activity	activity	NN	_	20	conj	_	_
25	in	in	IN	_	26	case	_	_
26	mice	mouse	NNS	_	16	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	acute	acute	JJ	_	29	attr	_	_
29	application	application	NN	_	14	ppmod	_	_
30	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	both	both	DT	_	3	det	_	_
3	sexes	sex	NNS	_	0	root	_	_
4	of	of	IN	_	7	case	_	_
5	swiss	swiss	NN	_	7	com	_	_
6	albino	albino	NN	_	7	com	_	_
7	mice	mouse	NNS	_	3	ppmod	_	_
8	;	;	:	_	3	p	_	_

1	antinociception	antinociception	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	assessed	assess	VBN	_	0	root	_	_
4	with	with	IN	_	6	case	_	_
5	hot-plate	hot-plate	JJ	_	6	attr	_	_
6	test	test	NN	_	3	ppmod	_	_
7	and	and	CC	_	3	cc	_	_
8	the	the	DT	_	12	det	_	_
9	locomotor	locomotor	JJ	_	11	adv	_	_
10	,	,	,	_	11	p	_	_
11	exploratory	exploratory	JJ	_	12	attr	_	_
12	activities	activity	NNS	_	14	dep	_	_
13	were	be	VBD	_	14	aux	_	_
14	assessed	assess	VBN	_	3	conj	_	_
15	with	with	IN	_	19	case	_	_
16	holed	holed	JJ	_	19	attr	_	_
17	open	open	JJ	_	19	attr	_	_
18	field	field	NN	_	19	com	_	_
19	test	test	NN	_	14	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	animals	animal	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	received	receive	VBN	_	0	root	_	_
5	;	;	:	_	4	p	_	_

1	saline	saline	NN	_	0	root	_	_
2	+	+	CC	_	1	cc	_	_
3	saline	saline	NN	_	1	conj	_	_
4	,	,	,	_	1	p	_	_
5	drug1	drug0	NN	_	1	conj	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	10	0	CD	_	8	num	_	_
8	mg/kg	mg/kg	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	+	+	CC	_	5	cc	_	_
11	saline	saline	NN	_	1	conj	_	_
12	,	,	,	_	11	p	_	_
13	saline	saline	NN	_	11	conj	_	_
14	+	+	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	11	conj	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	15	0	CD	_	18	num	_	_
18	g/kg	g/kg	NN	_	11	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	and	and	CC	_	11	cc	_	_
21	drug3	drug0	NN	_	11	conj	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	10	0	CD	_	24	num	_	_
24	mg/kg	mg/kg	NN	_	11	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	+	+	CC	_	11	cc	_	_
27	drug4	drug0	NN	_	11	conj	_	_
28	(	-lrb-	-LRB-	_	30	p	_	_
29	15	0	CD	_	30	num	_	_
30	g/kg	g/kg	NN	_	11	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	,	,	,	_	1	p	_	_
33	intraperitoneally	intraperitoneally	RB	_	1	adv	_	_
34	,	,	,	_	1	p	_	_
35	30	0	CD	_	36	num	_	_
36	min	min	NN	_	1	appo	_	_
37	before	before	IN	_	39	case	_	_
38	hot	hot	JJ	_	39	attr	_	_
39	plate	plate	NN	_	36	ppmod	_	_
40	or	or	CC	_	39	cc	_	_
41	holed	holed	JJ	_	44	attr	_	_
42	open	open	JJ	_	44	attr	_	_
43	field	field	NN	_	44	com	_	_
44	tests	test	NNS	_	39	conj	_	_
45	.	.	.	_	1	p	_	_

1	In	in	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	hot	hot	JJ	_	5	attr	_	_
4	plate	plate	NN	_	5	com	_	_
5	test	test	NN	_	21	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	mice	mouse	NNS	_	5	ppmod	_	_
8	,	,	,	_	21	p	_	_
9	co-administration	co-administration	NN	_	21	dep	_	_
10	of	of	IN	_	13	case	_	_
11	15	0	CD	_	13	num	_	_
12	g/kg	g/kg	NN	_	13	com	_	_
13	drug1	drug0	NN	_	9	ppmod	_	_
14	with	with	IN	_	17	case	_	_
15	10	0	CD	_	16	num	_	_
16	mg/kg	mg/kg	NN	_	17	com	_	_
17	drug2	drug0	NN	_	9	ppmod	_	_
18	intraperitoneally	intraperitoneally	RB	_	20	com	_	_
19	not	not	RB	_	20	com	_	_
20	only	only	RB	_	21	cc	_	_
21	enhanced	enhance	VBD	_	0	root	_	_
22	,	,	,	_	21	p	_	_
23	but	but	CC	_	21	cc	_	_
24	also	also	RB	_	23	com	_	_
25	prolonged	prolong	VBD	_	21	conj	_	_
26	the	the	DT	_	27	det	_	_
27	duration	duration	NN	_	25	obj	_	_
28	of	of	IN	_	29	case	_	_
29	antinociception	antinociception	NN	_	27	ppmod	_	_
30	induced	induce	VBN	_	29	acl	_	_
31	by	by	IN	_	32	case	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	21	p	_	_

1	At	at	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	same	same	JJ	_	4	attr	_	_
4	time	time	NN	_	13	ppmod	_	_
5	,	,	,	_	13	p	_	_
6	the	the	DT	_	9	det	_	_
7	locomotor	locomotor	JJ	_	9	attr	_	_
8	inhibitory	inhibitory	JJ	_	9	attr	_	_
9	effect	effect	NN	_	13	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	was	be	VBD	_	13	aux	_	_
13	counteracted	counteract	VBN	_	0	root	_	_
14	by	by	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	13	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	concluded	conclude	VBD	_	0	root	_	_
3	that	that	IN	_	12	mark	_	_
4	the	the	DT	_	6	det	_	_
5	combined	combined	JJ	_	6	attr	_	_
6	administration	administration	NN	_	12	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	may	may	MD	_	12	modal	_	_
12	have	have	VB	_	2	comp	_	_
13	beneficial	beneficial	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	12	obj	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	treatment	treatment	NN	_	12	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	pain	pain	NN	_	17	ppmod	_	_
20	without	without	IN	_	21	case	_	_
21	causing	cause	VBG	_	12	ppmod	_	_
22	sedation	sedation	NN	_	21	obj	_	_
23	,	,	,	_	22	p	_	_
24	which	which	WDT	_	25	dep	_	_
25	limits	limit	VBZ	_	22	relcl	_	_
26	the	the	DT	_	27	det	_	_
27	use	use	NN	_	25	obj	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	as	as	IN	_	32	case	_	_
31	an	an	DT	_	32	det	_	_
32	drug4	drug0	NN	_	25	ppmod	_	_
33	in	in	IN	_	34	case	_	_
34	humans	human	NNS	_	32	ppmod	_	_
35	.	.	.	_	2	p	_	_

1	Interaction	interaction	NN	_	2	com	_	_
2	study	study	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	with	with	IN	_	9	case	_	_
8	co-administered	co-administered	VBN	_	9	attr	_	_
9	drugs	drug	NNS	_	2	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	are	be	VBP	_	6	aux	_	_
5	drug3	drug0	RB	_	6	adv	_	_
6	used	use	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	treating	treat	VBG	_	6	ppmod	_	_
9	urinary	urinary	JJ	_	13	attr	_	_
10	and	and	CC	_	9	cc	_	_
11	respiratory	respiratory	JJ	_	9	conj	_	_
12	tract	tract	NN	_	13	com	_	_
13	infections	infection	NNS	_	8	obj	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	are	be	VBP	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	have	have	VB	_	6	lv	_	_
6	interactions	interaction	NNS	_	3	comp	_	_
7	with	with	IN	_	8	case	_	_
8	drugs	drug	NNS	_	6	ppmod	_	_
9	that	that	WDT	_	10	dep	_	_
10	are	be	VBP	_	8	relcl	_	_
11	active	active	JJ	_	10	dep	_	_
12	in	in	IN	_	15	case	_	_
13	gastro	gastro	NN	_	15	attr	_	_
14	intestinal	intestinal	JJ	_	15	attr	_	_
15	tract	tract	NN	_	10	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Being	be	VBG	_	2	adv	_	_
2	drug1	drug0	NN	_	11	ppmod	_	_
3	and	and	CC	_	2	cc	_	_
4	lomefloxacin	lomefloxacin	NN	_	5	com	_	_
5	drug2	drug0	NN	_	2	conj	_	_
6	the	the	DT	_	8	det	_	_
7	interaction	interaction	NN	_	8	com	_	_
8	study	study	NN	_	11	dep	_	_
9	of	of	IN	_	8	case	_	_
10	was	be	VBD	_	11	aux	_	_
11	carried	carry	VBN	_	0	root	_	_
12	out	out	RP	_	11	prt	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug5	drug0	NN	_	14	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug6	drug0	NN	_	14	conj	_	_
21	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	studied	study	VBN	_	0	root	_	_
5	at	at	IN	_	11	case	_	_
6	neutral	neutral	JJ	_	11	attr	_	_
7	,	,	,	_	6	p	_	_
8	acidic	acidic	JJ	_	6	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	basic	basic	JJ	_	6	conj	_	_
11	conditions	condition	NNS	_	4	ppmod	_	_
12	both	both	CC	_	11	cc	_	_
13	at	at	IN	_	15	case	_	_
14	room	room	JJ	_	15	attr	_	_
15	temperature	temperature	NN	_	11	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	37	0	CD	_	18	num	_	_
18	C	c	NN	_	15	conj	_	_
19	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	16	dep	_	_
3	of	of	IN	_	5	case	_	_
4	dissolution	dissolution	NN	_	5	com	_	_
5	medium	medium	NN	_	2	ppmod	_	_
6	simulating	simulate	VBG	_	5	acl	_	_
7	various	various	JJ	_	9	attr	_	_
8	body	body	NN	_	9	com	_	_
9	environments	environment	NNS	_	6	obj	_	_
10	with	with	IN	_	11	case	_	_
11	response	response	NN	_	6	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	pH	ph	NN	_	11	ppmod	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	examined	examine	VBN	_	0	root	_	_
17	in	in	IN	_	20	mark	_	_
18	order	order	NN	_	20	dep	_	_
19	to	to	TO	_	20	aux	_	_
20	elucidate	elucidate	VB	_	16	comp	_	_
21	the	the	DT	_	22	det	_	_
22	interactions	interaction	NNS	_	20	obj	_	_
23	.	.	.	_	16	p	_	_

1	The	the	DT	_	2	det	_	_
2	response	response	NN	_	18	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	after	after	IN	_	8	case	_	_
8	interaction	interaction	NN	_	2	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	co-administered	co-administered	NN	_	11	com	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	at	at	IN	_	14	case	_	_
13	different	different	JJ	_	14	attr	_	_
14	conditions	condition	NNS	_	8	ppmod	_	_
15	and	and	CC	_	8	cc	_	_
16	temperature	temperature	NN	_	8	conj	_	_
17	were	be	VBD	_	18	aux	_	_
18	noted	note	VBN	_	0	root	_	_
19	using	use	VBG	_	18	comp	_	_
20	a	a	DT	_	23	det	_	_
21	Shimadzu	shimadzu	NN	_	23	com	_	_
22	HPLC	hplc	NN	_	23	com	_	_
23	system	system	NN	_	19	obj	_	_
24	with	with	IN	_	26	case	_	_
25	PDA	pda	NN	_	26	com	_	_
26	detector	detector	NN	_	23	ppmod	_	_
27	.	.	.	_	18	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	seen	see	VBN	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	interaction	interaction	NN	_	9	dep	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	drug1	drug0	NNS	_	5	ppmod	_	_
9	was	be	VBD	_	3	comp	_	_
10	more	more	RBR	_	9	adv	_	_
11	at	at	IN	_	13	case	_	_
12	37	0	CD	_	13	num	_	_
13	C	c	NN	_	9	ppmod	_	_
14	than	than	IN	_	17	case	_	_
15	at	at	IN	_	17	case	_	_
16	room	room	JJ	_	17	attr	_	_
17	temperature	temperature	NN	_	9	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	reacts	react	VBZ	_	0	root	_	_
5	faster	fast	JJR	_	4	adv	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug4	drug0	NN	_	7	conj	_	_
10	in	in	IN	_	12	case	_	_
11	acidic	acidic	JJ	_	12	attr	_	_
12	media	medium	NNS	_	7	ppmod	_	_
13	whereas	whereas	IN	_	14	com	_	_
14	with	with	IN	_	12	cc	_	_
15	drug5	drug0	NN	_	12	conj	_	_
16	in	in	IN	_	18	case	_	_
17	basic	basic	JJ	_	18	attr	_	_
18	media	medium	NNS	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug6	drug0	NN	_	18	conj	_	_
21	in	in	IN	_	23	case	_	_
22	neutral	neutral	JJ	_	23	attr	_	_
23	media	medium	NNS	_	15	ppmod	_	_
24	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	ensures	ensure	VBZ	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	interaction	interaction	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	10	case	_	_
9	selected	select	VBN	_	10	attr	_	_
10	class	class	NN	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drugs	drug	NNS	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	achieve	achieve	VB	_	16	advcl	_	_
5	the	the	DT	_	11	det	_	_
6	effective	effective	JJ	_	7	adv	_	_
7	therapeutic	therapeutic	JJ	_	11	attr	_	_
8	effect	effect	NN	_	11	attr	_	_
9	appropriate	appropriate	JJ	_	11	attr	_	_
10	time	time	NN	_	11	com	_	_
11	intervals	interval	NNS	_	4	obj	_	_
12	between	between	IN	_	13	case	_	_
13	administrations	administration	NNS	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drugs	drug	NNS	_	13	ppmod	_	_
16	is	be	VBZ	_	0	root	_	_
17	essential	essential	JJ	_	16	dep	_	_
18	.	.	.	_	16	p	_	_

